1 0 0 8675707 -DOCSTART- -X- -X- O

1 0 9 8675707 Increased VBN B-NP O
2 10 18 8675707 coronary JJ I-NP B-Disease
3 19 24 8675707 heart NN I-NP I-Disease
4 25 32 8675707 disease NN I-NP I-Disease
5 33 35 8675707 in IN B-PP O
6 36 44 8675707 Japanese JJ B-NP O
7 44 45 8675707 - HYPH I-NP O
8 45 53 8675707 American JJ I-NP O
9 54 57 8675707 men NNS I-NP O
10 58 62 8675707 with IN B-PP O
11 63 71 8675707 mutation NN B-NP O
12 72 74 8675707 in IN B-PP O
13 75 78 8675707 the DT B-NP O
14 79 90 8675707 cholesteryl NN I-NP O
15 91 96 8675707 ester NN I-NP O
16 97 105 8675707 transfer NN I-NP O
17 106 113 8675707 protein NN I-NP O
18 114 118 8675707 gene NN I-NP O
19 119 126 8675707 despite IN B-PP O
20 127 136 8675707 increased VBN B-NP O
21 137 140 8675707 HDL NN I-NP O
22 141 147 8675707 levels NNS I-NP O
23 147 148 8675707 . . O O
24 149 155 8675707 Plasma NN B-NP O
25 156 160 8675707 high JJ I-NP O
26 161 168 8675707 density NN I-NP O
27 169 180 8675707 lipoprotein NN I-NP O
28 181 182 8675707 ( ( O O
29 182 185 8675707 HDL NN B-NP O
30 185 186 8675707 ) ) O O
31 187 193 8675707 levels NNS B-NP O
32 194 197 8675707 are VBP B-VP O
33 198 206 8675707 strongly RB I-VP O
34 207 218 8675707 genetically RB I-VP O
35 219 229 8675707 determined VBN I-VP O
36 230 233 8675707 and CC O O
37 234 238 8675707 show VBP B-VP O
38 239 240 8675707 a DT B-NP O
39 241 248 8675707 general JJ I-NP O
40 249 256 8675707 inverse JJ I-NP O
41 257 269 8675707 relationship NN I-NP O
42 270 274 8675707 with IN B-PP O
43 275 283 8675707 coronary JJ B-NP B-Disease
44 284 289 8675707 heart NN I-NP I-Disease
45 290 297 8675707 disease NN I-NP I-Disease
46 298 299 8675707 ( ( O O
47 299 302 8675707 CHD NN B-NP B-Disease
48 302 303 8675707 ) ) O O
49 303 304 8675707 . . O O

1 305 308 8675707 The DT B-NP O
2 309 320 8675707 cholesteryl NN I-NP O
3 321 326 8675707 ester NN I-NP O
4 327 335 8675707 transfer NN I-NP O
5 336 343 8675707 protein NN I-NP O
6 344 345 8675707 ( ( O O
7 345 349 8675707 CETP NN B-NP O
8 349 350 8675707 ) ) O O
9 351 359 8675707 mediates VBZ B-VP O
10 360 363 8675707 the DT B-NP O
11 364 372 8675707 transfer NN I-NP O
12 373 375 8675707 of IN B-PP O
13 376 387 8675707 cholesteryl NN B-NP O
14 388 394 8675707 esters NNS I-NP O
15 395 399 8675707 from IN B-PP O
16 400 403 8675707 HDL NN B-NP O
17 404 406 8675707 to TO B-PP O
18 407 412 8675707 other JJ B-NP O
19 413 425 8675707 lipoproteins NNS I-NP O
20 426 429 8675707 and CC O O
21 430 432 8675707 is VBZ B-VP O
22 433 434 8675707 a DT B-NP O
23 435 438 8675707 key JJ I-NP O
24 439 450 8675707 participant NN I-NP O
25 451 453 8675707 in IN B-PP O
26 454 457 8675707 the DT B-NP O
27 458 465 8675707 reverse JJ I-NP O
28 466 475 8675707 transport NN I-NP O
29 476 478 8675707 of IN B-PP O
30 479 490 8675707 cholesterol NN B-NP O
31 491 495 8675707 from IN B-PP O
32 496 499 8675707 the DT B-NP O
33 500 509 8675707 periphery NN I-NP O
34 510 512 8675707 to TO B-PP O
35 513 516 8675707 the DT B-NP O
36 517 522 8675707 liver NN I-NP O
37 522 523 8675707 . . O O

1 524 525 8675707 A DT B-NP O
2 526 530 8675707 high JJ I-NP O
3 531 541 8675707 prevalence NN I-NP O
4 542 544 8675707 of IN B-PP O
5 545 548 8675707 two CD B-NP O
6 549 558 8675707 different JJ I-NP O
7 559 563 8675707 CETP NN I-NP O
8 564 568 8675707 gene NN I-NP O
9 569 578 8675707 mutations NNS I-NP O
10 579 580 8675707 ( ( O O
11 580 585 8675707 D442G NN B-NP O
12 585 586 8675707 , , O O
13 587 588 8675707 5 CD B-NP O
14 588 589 8675707 . . I-NP O
15 590 592 8675707 1% CD I-NP O
16 592 593 8675707 ; : O O
17 594 600 8675707 intron NN B-NP O
18 601 604 8675707 14G NN I-NP O
19 606 607 8675707 A NN I-NP O
20 607 608 8675707 , , O O
21 609 610 8675707 0 CD B-NP O
22 610 611 8675707 . . O O

1 612 614 8675707 5% LS B-LST O
2 614 615 8675707 ) ) O O
3 615 616 8675707 , , O O
4 617 620 8675707 was VBD B-VP O
5 621 626 8675707 found VBN I-VP O
6 627 629 8675707 in IN B-PP O
7 630 631 8675707 3 CD B-NP O
8 631 632 8675707 , , O O
9 633 636 8675707 469 CD B-NP O
10 637 640 8675707 men NNS I-NP O
11 641 643 8675707 of IN B-PP O
12 644 652 8675707 Japanese JJ B-NP O
13 653 661 8675707 ancestry NN I-NP O
14 662 664 8675707 in IN B-PP O
15 665 668 8675707 the DT B-NP O
16 669 677 8675707 Honolulu NNP I-NP O
17 678 683 8675707 Heart NNP I-NP O
18 684 691 8675707 Program NNP I-NP O
19 692 695 8675707 and CC O O
20 696 705 8675707 mutations NNS B-NP O
21 706 710 8675707 were VBD B-VP O
22 711 721 8675707 associated VBN I-VP O
23 722 726 8675707 with IN B-PP O
24 727 736 8675707 decreased VBN B-NP O
25 737 741 8675707 CETP NN I-NP O
26 742 743 8675707 ( ( O O
27 743 744 8675707 - SYM B-NP O
28 744 747 8675707 35% CD I-NP O
29 747 748 8675707 ) ) O O
30 749 752 8675707 and CC O O
31 753 762 8675707 increased VBD B-VP O
32 763 766 8675707 HDL NN B-NP O
33 767 771 8675707 chol NN I-NP O
34 772 778 8675707 levels NNS I-NP O
35 779 780 8675707 ( ( O O
36 780 781 8675707 + SYM B-NP O
37 782 785 8675707 10% CD B-NP O
38 786 789 8675707 for IN B-PP O
39 790 795 8675707 D442G NN B-NP O
40 795 796 8675707 ) ) O O
41 796 797 8675707 . . O O

1 798 805 8675707 However RB B-ADVP O
2 805 806 8675707 , , O O
3 807 810 8675707 the DT B-NP O
4 811 818 8675707 overall JJ I-NP O
5 819 829 8675707 prevalence NN I-NP O
6 830 832 8675707 of IN B-PP O
7 833 841 8675707 definite JJ B-NP O
8 842 845 8675707 CHD NN I-NP B-Disease
9 846 849 8675707 was VBD B-VP O
10 850 853 8675707 21% CD B-NP O
11 854 856 8675707 in IN B-PP O
12 857 860 8675707 men NNS B-NP O
13 861 865 8675707 with IN B-PP O
14 866 875 8675707 mutations NNS B-NP O
15 876 879 8675707 and CC I-NP O
16 880 883 8675707 16% NN I-NP O
17 884 886 8675707 in IN B-PP O
18 887 890 8675707 men NNS B-NP O
19 891 898 8675707 without IN B-PP O
20 899 908 8675707 mutations NNS B-NP O
21 908 909 8675707 . . O O

1 910 913 8675707 The DT B-NP O
2 914 922 8675707 relative JJ I-NP O
3 923 927 8675707 risk NN I-NP O
4 928 929 8675707 ( ( O O
5 929 931 8675707 RR NN B-NP O
6 931 932 8675707 ) ) O O
7 933 935 8675707 of IN B-PP O
8 936 939 8675707 CHD NN B-NP B-Disease
9 940 943 8675707 was VBD B-VP O
10 944 945 8675707 1 CD B-NP O
11 945 946 8675707 . . O O

1 947 949 8675707 43 CD B-NP O
2 950 952 8675707 in IN B-PP O
3 953 956 8675707 men NNS B-NP O
4 957 961 8675707 with IN B-PP O
5 962 971 8675707 mutations NNS B-NP O
6 972 973 8675707 ( ( O O
7 973 974 8675707 P NN B-NP O
8 975 976 8675707 < SYM B-ADJP O
9 976 977 8675707 . . O O

1 978 980 8675707 05 CD B-NP O
2 980 981 8675707 ) ) O O
3 981 982 8675707 ; : O O
4 983 988 8675707 after IN B-PP O
5 989 999 8675707 adjustment NN B-NP O
6 1000 1003 8675707 for IN B-PP O
7 1004 1007 8675707 CHD NN B-NP B-Disease
8 1008 1012 8675707 risk NN I-NP O
9 1013 1020 8675707 factors NNS I-NP O
10 1020 1021 8675707 , , O O
11 1022 1025 8675707 the DT B-NP O
12 1026 1028 8675707 RR NN I-NP O
13 1029 1032 8675707 was VBD B-VP O
14 1033 1034 8675707 1 CD B-NP O
15 1034 1035 8675707 . . O O

1 1036 1038 8675707 55 CD B-NP O
2 1039 1040 8675707 ( ( O O
3 1040 1041 8675707 P NN B-NP O
4 1042 1043 8675707 = SYM B-VP O
5 1043 1044 8675707 . . O O

1 1045 1047 8675707 02 CD B-NP O
2 1047 1048 8675707 ) ) O O
3 1048 1049 8675707 ; : O O
4 1050 1055 8675707 after IN B-PP O
5 1056 1066 8675707 additional JJ B-NP O
6 1067 1077 8675707 adjustment NN I-NP O
7 1078 1081 8675707 for IN B-PP O
8 1082 1085 8675707 HDL NN B-NP O
9 1086 1092 8675707 levels NNS I-NP O
10 1092 1093 8675707 , , O O
11 1094 1097 8675707 the DT B-NP O
12 1098 1100 8675707 RR NN I-NP O
13 1101 1104 8675707 was VBD B-VP O
14 1105 1106 8675707 1 CD B-NP O
15 1106 1107 8675707 . . O O

1 1108 1110 8675707 68 CD B-NP O
2 1111 1112 8675707 ( ( O O
3 1112 1113 8675707 P NN B-NP O
4 1114 1115 8675707 = SYM B-VP O
5 1115 1116 8675707 . . O O

1 1117 1120 8675707 008 CD B-NP O
2 1120 1121 8675707 ) ) O O
3 1121 1122 8675707 . . O O

1 1123 1130 8675707 Similar JJ B-NP O
2 1131 1133 8675707 RR NN I-NP O
3 1134 1140 8675707 values NNS I-NP O
4 1141 1145 8675707 were VBD B-VP O
5 1146 1154 8675707 obtained VBN I-VP O
6 1155 1158 8675707 for IN B-PP O
7 1159 1162 8675707 the DT B-NP O
8 1163 1168 8675707 D442G NN I-NP O
9 1169 1177 8675707 mutation NN I-NP O
10 1178 1183 8675707 alone RB B-ADVP O
11 1183 1184 8675707 . . O O

1 1185 1194 8675707 Increased VBN B-NP O
2 1195 1198 8675707 CHD NN I-NP B-Disease
3 1199 1201 8675707 in IN B-PP O
4 1202 1205 8675707 men NNS B-NP O
5 1206 1210 8675707 with IN B-PP O
6 1211 1220 8675707 mutations NNS B-NP O
7 1221 1224 8675707 was VBD B-VP O
8 1225 1234 8675707 primarily RB I-VP O
9 1235 1243 8675707 observed VBN I-VP O
10 1244 1247 8675707 for IN B-PP O
11 1248 1251 8675707 HDL NN B-NP O
12 1252 1256 8675707 chol NN I-NP O
13 1257 1259 8675707 41 CD I-NP O
14 1259 1260 8675707 - HYPH I-NP O
15 1260 1262 8675707 60 CD I-NP O
16 1263 1265 8675707 mg NN I-NP O
17 1265 1266 8675707 / SYM B-NP O
18 1266 1268 8675707 dl NN I-NP O
19 1268 1269 8675707 ; : O O
20 1270 1273 8675707 for IN B-PP O
21 1274 1277 8675707 HDL NN B-NP O
22 1278 1282 8675707 chol NN I-NP O
23 1283 1284 8675707 > SYM B-NP O
24 1285 1287 8675707 60 CD B-NP O
25 1288 1290 8675707 mg NN I-NP O
26 1290 1291 8675707 / SYM B-NP O
27 1291 1293 8675707 dl NN B-NP O
28 1294 1297 8675707 men NNS I-NP O
29 1298 1302 8675707 with IN B-PP O
30 1303 1306 8675707 and CC I-PP O
31 1307 1314 8675707 without IN I-PP O
32 1315 1324 8675707 mutations NNS B-NP O
33 1325 1328 8675707 had VBD B-VP O
34 1329 1332 8675707 low JJ B-NP O
35 1333 1336 8675707 CHD NN I-NP B-Disease
36 1337 1347 8675707 prevalence NN I-NP O
37 1347 1348 8675707 . . O O

1 1349 1353 8675707 Thus RB B-ADVP O
2 1353 1354 8675707 , , O O
3 1355 1362 8675707 genetic JJ B-NP O
4 1363 1367 8675707 CETP NN I-NP B-Disease
5 1368 1378 8675707 deficiency NN I-NP I-Disease
6 1379 1386 8675707 appears VBZ B-VP O
7 1387 1389 8675707 to TO I-VP O
8 1390 1392 8675707 be VB I-VP O
9 1393 1395 8675707 an DT B-NP O
10 1396 1407 8675707 independent JJ I-NP O
11 1408 1412 8675707 risk NN I-NP O
12 1413 1419 8675707 factor NN I-NP O
13 1420 1423 8675707 for IN B-PP O
14 1424 1427 8675707 CHD NN B-NP B-Disease
15 1427 1428 8675707 , , O O
16 1429 1438 8675707 primarily RB B-ADVP O
17 1439 1442 8675707 due JJ B-PP O
18 1443 1445 8675707 to TO B-PP O
19 1446 1455 8675707 increased VBN B-NP O
20 1456 1459 8675707 CHD NN I-NP B-Disease
21 1460 1470 8675707 prevalence NN I-NP O
22 1471 1473 8675707 in IN B-PP O
23 1474 1477 8675707 men NNS B-NP O
24 1478 1482 8675707 with IN B-PP O
25 1483 1486 8675707 the DT B-NP O
26 1487 1492 8675707 D442G NN I-NP O
27 1493 1501 8675707 mutation NN I-NP O
28 1502 1505 8675707 and CC O O
29 1506 1509 8675707 HDL NN B-NP O
30 1510 1521 8675707 cholesterol NN I-NP O
31 1522 1529 8675707 between IN B-PP O
32 1530 1532 8675707 41 CD B-NP O
33 1533 1536 8675707 and CC I-NP O
34 1537 1539 8675707 60 CD I-NP O
35 1540 1542 8675707 mg NN I-NP O
36 1542 1543 8675707 / SYM B-NP O
37 1543 1545 8675707 dl NN I-NP O
38 1545 1546 8675707 . . O O

1 1547 1550 8675707 The DT B-NP O
2 1551 1559 8675707 findings NNS I-NP O
3 1560 1567 8675707 suggest VBP B-VP O
4 1568 1572 8675707 that IN B-SBAR O
5 1573 1577 8675707 both CC O O
6 1578 1581 8675707 HDL NN B-NP O
7 1582 1595 8675707 concentration NN I-NP O
8 1596 1599 8675707 and CC O O
9 1600 1603 8675707 the DT B-NP O
10 1604 1612 8675707 dynamics NNS I-NP O
11 1613 1615 8675707 of IN B-PP O
12 1616 1627 8675707 cholesterol NN B-NP O
13 1628 1637 8675707 transport NN I-NP O
14 1638 1645 8675707 through IN B-PP O
15 1646 1649 8675707 HDL NN B-NP O
16 1650 1651 8675707 ( ( O O
17 1651 1652 8675707 i NN B-NP O
18 1652 1653 8675707 . . O O

1 1654 1655 8675707 e NN B-NP O
2 1655 1656 8675707 . NN I-NP O
3 1656 1657 8675707 , , O O
4 1658 1665 8675707 reverse JJ B-NP O
5 1666 1677 8675707 cholesterol NN I-NP O
6 1678 1687 8675707 transport NN I-NP O
7 1687 1688 8675707 ) ) O O
8 1689 1698 8675707 determine VBP B-VP O
9 1699 1702 8675707 the DT B-NP O
10 1703 1707 8675707 anti AFX I-NP O
11 1707 1708 8675707 - HYPH I-NP O
12 1708 1722 8675707 atherogenicity NN I-NP O
13 1723 1725 8675707 of IN B-PP O
14 1726 1729 8675707 the DT B-NP O
15 1730 1733 8675707 HDL NN I-NP O
16 1734 1742 8675707 fraction NN I-NP O
17 1742 1743 8675707 . . O O

1 0 0 8812423 -DOCSTART- -X- -X- O

1 0 3 8812423 LPP NN B-NP O
2 3 4 8812423 , , O O
3 5 8 8812423 the DT B-NP O
4 9 18 8812423 preferred JJ I-NP O
5 19 25 8812423 fusion NN I-NP O
6 26 33 8812423 partner NN I-NP O
7 34 38 8812423 gene NN I-NP O
8 39 41 8812423 of IN B-PP O
9 42 47 8812423 HMGIC NN B-NP O
10 48 50 8812423 in IN B-PP O
11 51 58 8812423 lipomas NNS B-NP B-Disease
12 58 59 8812423 , , O O
13 60 62 8812423 is VBZ B-VP O
14 63 64 8812423 a DT B-NP O
15 65 70 8812423 novel JJ I-NP O
16 71 77 8812423 member NN I-NP O
17 78 80 8812423 of IN B-PP O
18 81 84 8812423 the DT B-NP O
19 85 88 8812423 LIM NN I-NP O
20 89 96 8812423 protein NN I-NP O
21 97 101 8812423 gene NN I-NP O
22 102 108 8812423 family NN I-NP O
23 108 109 8812423 . . O O
24 110 111 8812423 A DT B-NP O
25 112 117 8812423 major JJ I-NP O
26 118 129 8812423 cytogenetic JJ I-NP O
27 130 138 8812423 subgroup NN I-NP O
28 139 141 8812423 of IN B-PP O
29 142 149 8812423 lipomas NNS B-NP B-Disease
30 150 152 8812423 is VBZ B-VP O
31 153 166 8812423 characterized VBN I-VP O
32 167 169 8812423 by IN B-PP O
33 170 179 8812423 recurrent JJ B-NP O
34 180 190 8812423 chromosome NN I-NP O
35 191 202 8812423 aberrations NNS I-NP O
36 202 203 8812423 , , O O
37 204 210 8812423 mainly RB B-NP O
38 211 225 8812423 translocations NNS I-NP O
39 225 226 8812423 , , O O
40 227 231 8812423 that WDT B-NP O
41 232 239 8812423 involve VBP B-VP O
42 240 250 8812423 chromosome NN B-NP O
43 251 258 8812423 segment NN I-NP O
44 259 264 8812423 12q13 CD I-NP O
45 264 265 8812423 - HYPH I-NP O
46 265 268 8812423 q15 NN I-NP O
47 268 269 8812423 . . O O

1 270 278 8812423 Multiple JJ B-NP O
2 279 290 8812423 chromosomes NNS I-NP O
3 291 295 8812423 have VBP B-VP O
4 296 300 8812423 been VBN I-VP O
5 301 306 8812423 found VBN I-VP O
6 307 309 8812423 as IN B-PP O
7 310 313 8812423 the DT B-NP O
8 314 327 8812423 translocation NN I-NP O
9 328 336 8812423 partners NNS I-NP O
10 337 339 8812423 of IN B-PP O
11 340 350 8812423 chromosome NN B-NP O
12 351 353 8812423 12 CD I-NP O
13 354 357 8812423 but CC I-NP O
14 358 362 8812423 3q27 CD I-NP O
15 362 363 8812423 - HYPH I-NP O
16 363 366 8812423 q28 NN I-NP O
17 367 369 8812423 is VBZ B-VP O
18 370 384 8812423 preferentially RB I-VP O
19 385 393 8812423 involved VBN I-VP O
20 393 394 8812423 . . O O

1 395 397 8812423 In IN B-PP O
2 398 406 8812423 previous JJ B-NP O
3 407 414 8812423 studies NNS I-NP O
4 414 415 8812423 , , O O
5 416 418 8812423 it PRP B-NP O
6 419 422 8812423 has VBZ B-VP O
7 423 427 8812423 been VBN I-VP O
8 428 433 8812423 shown VBN I-VP O
9 434 438 8812423 that IN B-SBAR O
10 439 442 8812423 the DT B-NP O
11 443 447 8812423 high JJ I-NP O
12 448 456 8812423 mobility NN I-NP O
13 457 462 8812423 group NN I-NP O
14 463 464 8812423 ( ( O O
15 464 467 8812423 HMG NN B-NP O
16 467 468 8812423 ) ) O O
17 469 476 8812423 protein NN B-NP O
18 477 481 8812423 gene NN I-NP O
19 482 487 8812423 HMGIC NN I-NP O
20 488 490 8812423 at IN B-PP O
21 491 496 8812423 12q15 CD B-NP O
22 497 499 8812423 is VBZ B-VP O
23 500 512 8812423 consistently RB I-VP O
24 513 523 8812423 rearranged VBN I-VP O
25 524 526 8812423 as IN B-PP O
26 527 528 8812423 a DT B-NP O
27 529 540 8812423 consequence NN I-NP O
28 541 543 8812423 of IN B-PP O
29 544 549 8812423 these DT B-NP O
30 550 564 8812423 translocations NNS I-NP O
31 564 565 8812423 . . O O

1 566 570 8812423 Here RB B-ADVP O
2 570 571 8812423 , , O O
3 572 574 8812423 we PRP B-NP O
4 575 581 8812423 report VBP B-VP O
5 582 585 8812423 the DT B-NP O
6 586 600 8812423 identification NN I-NP O
7 601 604 8812423 and CC I-NP O
8 605 621 8812423 characterization NN I-NP O
9 622 624 8812423 of IN B-PP O
10 625 628 8812423 the DT B-NP O
11 629 639 8812423 chromosome NN I-NP O
12 640 641 8812423 3 CD I-NP O
13 641 642 8812423 - HYPH I-NP O
14 642 649 8812423 derived VBN I-NP O
15 650 663 8812423 translocation NN I-NP O
16 664 671 8812423 partner NN I-NP O
17 672 676 8812423 gene NN I-NP O
18 676 677 8812423 , , O O
19 678 683 8812423 which WDT B-NP O
20 684 686 8812423 we PRP B-NP O
21 687 691 8812423 have VBP B-VP O
22 692 702 8812423 designated VBN I-VP O
23 703 706 8812423 LPP NN B-NP O
24 707 708 8812423 ( ( O O
25 708 714 8812423 lipoma NN B-NP B-Disease
26 715 724 8812423 preferred VBN I-NP O
27 725 732 8812423 partner NN I-NP O
28 733 737 8812423 gene NN I-NP O
29 737 738 8812423 ) ) O O
30 738 739 8812423 . . O O

1 740 745 8812423 Using VBG B-VP O
2 746 747 8812423 3 CD B-NP O
3 747 748 8812423 - HYPH I-NP O
4 748 752 8812423 RACE NN I-NP O
5 753 761 8812423 analysis NN I-NP O
6 762 764 8812423 of IN B-PP O
7 765 770 8812423 HMGIC NN B-NP O
8 771 777 8812423 fusion NN I-NP O
9 778 789 8812423 transcripts NNS I-NP O
10 790 792 8812423 in IN B-PP O
11 793 799 8812423 lipoma NN B-NP B-Disease
12 800 804 8812423 cell NN I-NP O
13 805 809 8812423 line NN I-NP O
14 810 812 8812423 Li AFX O O
15 812 813 8812423 - HYPH O O
16 813 816 8812423 501 CD B-NP O
17 816 817 8812423 / SYM I-NP O
18 817 821 8812423 SV40 NN I-NP O
19 821 822 8812423 , , O O
20 823 830 8812423 ectopic JJ B-NP O
21 831 838 8812423 genetic JJ I-NP O
22 839 848 8812423 sequences NNS I-NP O
23 849 853 8812423 were VBD B-VP O
24 854 862 8812423 obtained VBN I-VP O
25 862 863 8812423 , , O O
26 864 869 8812423 which WDT B-NP O
27 870 872 8812423 by IN B-PP O
28 873 877 8812423 CASH NN B-NP O
29 878 879 8812423 ( ( O O
30 879 889 8812423 chromosome NN B-NP O
31 890 900 8812423 assignment NN I-NP O
32 901 906 8812423 using VBG B-VP O
33 907 914 8812423 somatic JJ B-NP O
34 915 919 8812423 cell NN I-NP O
35 920 927 8812423 hybrids NNS I-NP O
36 927 928 8812423 ) ) O O
37 929 932 8812423 and CC O O
38 933 937 8812423 FISH NN B-NP O
39 938 939 8812423 ( ( O O
40 939 951 8812423 fluorescence NN B-NP O
41 952 954 8812423 in FW B-NP O
42 955 959 8812423 situ FW I-NP O
43 960 973 8812423 hybridization NN I-NP O
44 973 974 8812423 ) ) O O
45 975 983 8812423 analysis NN B-NP O
46 984 988 8812423 were VBD B-VP O
47 989 994 8812423 found VBN I-VP O
48 995 997 8812423 to TO I-VP O
49 998 1007 8812423 originate VB I-VP O
50 1008 1012 8812423 from IN B-PP O
51 1013 1023 8812423 chromosome NN B-NP O
52 1024 1031 8812423 segment NN I-NP O
53 1032 1036 8812423 3q27 CD I-NP O
54 1036 1037 8812423 - HYPH I-NP O
55 1037 1040 8812423 q28 NN I-NP O
56 1040 1041 8812423 . . O O

1 1042 1044 8812423 In IN B-PP O
2 1045 1053 8812423 Northern JJ B-NP O
3 1054 1058 8812423 blot NN I-NP O
4 1059 1067 8812423 analysis NN I-NP O
5 1067 1068 8812423 , , O O
6 1069 1071 8812423 an DT B-NP O
7 1072 1076 8812423 mRNA NN I-NP O
8 1077 1079 8812423 of IN B-PP O
9 1080 1084 8812423 over IN B-NP O
10 1085 1087 8812423 10 CD I-NP O
11 1088 1090 8812423 kb NN I-NP O
12 1091 1094 8812423 was VBD B-VP O
13 1095 1103 8812423 detected VBN I-VP O
14 1104 1106 8812423 by IN B-PP O
15 1107 1112 8812423 these DT B-NP O
16 1113 1120 8812423 ectopic JJ I-NP O
17 1121 1130 8812423 sequences NNS I-NP O
18 1131 1133 8812423 in IN B-PP O
19 1134 1135 8812423 a DT B-NP O
20 1136 1143 8812423 variety NN I-NP O
21 1144 1146 8812423 of IN B-PP O
22 1147 1152 8812423 human JJ B-NP O
23 1153 1160 8812423 tissues NNS I-NP O
24 1161 1164 8812423 but CC B-PP O
25 1165 1168 8812423 not RB B-PP O
26 1169 1171 8812423 in IN I-PP O
27 1172 1177 8812423 brain NN B-NP O
28 1178 1181 8812423 and CC O O
29 1182 1192 8812423 peripheral JJ B-NP O
30 1193 1198 8812423 blood NN I-NP O
31 1199 1209 8812423 leukocytes NNS I-NP O
32 1209 1210 8812423 . . O O

1 1211 1215 8812423 Upon IN B-PP O
2 1216 1223 8812423 partial JJ B-NP O
3 1224 1228 8812423 cDNA NN I-NP O
4 1229 1236 8812423 cloning NN I-NP O
5 1236 1237 8812423 , , O O
6 1238 1246 8812423 features NNS B-NP O
7 1247 1249 8812423 of IN B-PP O
8 1250 1253 8812423 the DT B-NP O
9 1254 1261 8812423 genetic JJ I-NP O
10 1262 1274 8812423 organization NN I-NP O
11 1275 1277 8812423 of IN B-PP O
12 1278 1281 8812423 LPP NN B-NP O
13 1282 1286 8812423 were VBD B-VP O
14 1287 1298 8812423 established VBN I-VP O
15 1298 1299 8812423 . . O O

1 1300 1303 8812423 The DT B-NP O
2 1304 1308 8812423 gene NN I-NP O
3 1309 1312 8812423 was VBD B-VP O
4 1313 1318 8812423 found VBN I-VP O
5 1319 1321 8812423 to TO I-VP O
6 1322 1326 8812423 span VB I-VP O
7 1327 1328 8812423 a DT B-NP O
8 1329 1336 8812423 genomic JJ I-NP O
9 1337 1343 8812423 region NN I-NP O
10 1344 1346 8812423 of IN B-PP O
11 1347 1351 8812423 over IN B-NP O
12 1352 1355 8812423 400 CD I-NP O
13 1356 1358 8812423 kb NN I-NP O
14 1358 1359 8812423 . . O O

1 1360 1370 8812423 Nucleotide NN B-NP O
2 1371 1379 8812423 sequence NN I-NP O
3 1380 1388 8812423 analysis NN I-NP O
4 1389 1391 8812423 of IN B-PP O
5 1392 1393 8812423 a DT B-NP O
6 1394 1403 8812423 composite JJ I-NP O
7 1404 1408 8812423 cDNA NN I-NP O
8 1409 1411 8812423 of IN B-PP O
9 1412 1415 8812423 LPP NN B-NP O
10 1416 1424 8812423 revealed VBD B-VP O
11 1425 1427 8812423 an DT B-NP O
12 1428 1432 8812423 open JJ I-NP O
13 1433 1440 8812423 reading NN I-NP O
14 1441 1446 8812423 frame NN I-NP O
15 1447 1449 8812423 of IN B-PP O
16 1450 1454 8812423 1836 CD B-NP O
17 1455 1466 8812423 nucleotides NNS I-NP O
18 1467 1475 8812423 encoding VBG B-VP O
19 1476 1477 8812423 a DT B-NP O
20 1478 1485 8812423 proline NN I-NP O
21 1485 1486 8812423 - HYPH B-NP O
22 1486 1490 8812423 rich JJ I-NP O
23 1491 1498 8812423 protein NN I-NP O
24 1499 1509 8812423 containing VBG B-VP O
25 1510 1511 8812423 a DT B-NP O
26 1512 1519 8812423 leucine NN I-NP O
27 1519 1520 8812423 - HYPH I-NP O
28 1520 1526 8812423 zipper NN I-NP O
29 1527 1532 8812423 motif NN I-NP O
30 1533 1535 8812423 in IN B-PP O
31 1536 1539 8812423 its PRP$ B-NP O
32 1540 1545 8812423 amino JJ I-NP O
33 1545 1546 8812423 - HYPH I-NP O
34 1546 1554 8812423 terminal JJ I-NP O
35 1555 1561 8812423 region NN I-NP O
36 1562 1565 8812423 and CC O O
37 1566 1571 8812423 three CD B-NP O
38 1572 1575 8812423 LIM NN I-NP O
39 1576 1583 8812423 domains NNS I-NP O
40 1584 1586 8812423 in IN B-PP O
41 1587 1590 8812423 its PRP$ B-NP O
42 1591 1598 8812423 carboxy NN I-NP O
43 1598 1599 8812423 - HYPH I-NP O
44 1599 1607 8812423 terminal JJ I-NP O
45 1608 1614 8812423 region NN I-NP O
46 1614 1615 8812423 . . O O

1 1616 1619 8812423 The DT B-NP O
2 1620 1623 8812423 LPP NN I-NP O
3 1623 1624 8812423 - HYPH B-VP O
4 1624 1631 8812423 encoded VBN B-NP O
5 1632 1639 8812423 protein NN I-NP O
6 1640 1646 8812423 should MD B-VP O
7 1647 1649 8812423 be VB I-VP O
8 1650 1660 8812423 classified VBN I-VP O
9 1661 1663 8812423 as IN B-PP O
10 1664 1665 8812423 a DT B-NP O
11 1666 1671 8812423 novel JJ I-NP O
12 1672 1678 8812423 member NN I-NP O
13 1679 1681 8812423 of IN B-PP O
14 1682 1685 8812423 the DT B-NP O
15 1686 1691 8812423 group NN I-NP O
16 1692 1693 8812423 3 CD B-NP O
17 1694 1702 8812423 proteins NNS I-NP O
18 1703 1705 8812423 of IN B-PP O
19 1706 1709 8812423 the DT B-NP O
20 1710 1713 8812423 LIM NN I-NP O
21 1714 1721 8812423 protein NN I-NP O
22 1722 1726 8812423 gene NN I-NP O
23 1727 1733 8812423 family NN I-NP O
24 1733 1734 8812423 . . O O

1 1735 1740 8812423 Using VBG B-VP O
2 1741 1748 8812423 reverse JJ B-NP O
3 1749 1762 8812423 transcriptase NN I-NP O
4 1763 1771 8812423 combined VBN B-VP O
5 1772 1776 8812423 with IN B-PP O
6 1777 1787 8812423 polymerase NN B-NP O
7 1788 1793 8812423 chain NN I-NP O
8 1794 1803 8812423 reactions NNS I-NP O
9 1804 1806 8812423 in IN B-PP O
10 1807 1810 8812423 the DT B-NP O
11 1811 1819 8812423 analysis NN I-NP O
12 1820 1822 8812423 of IN B-PP O
13 1823 1824 8812423 a DT B-NP O
14 1825 1831 8812423 number NN I-NP O
15 1832 1834 8812423 of IN B-PP O
16 1835 1841 8812423 lipoma NN B-NP B-Disease
17 1842 1846 8812423 cell NN I-NP O
18 1847 1852 8812423 lines NNS I-NP O
19 1853 1856 8812423 and CC O O
20 1857 1864 8812423 primary JJ B-NP B-Disease
21 1865 1872 8812423 lipomas NNS I-NP I-Disease
22 1872 1873 8812423 , , O O
23 1874 1876 8812423 it PRP B-NP O
24 1877 1885 8812423 appeared VBD B-VP O
25 1886 1890 8812423 that IN B-SBAR O
26 1891 1894 8812423 LPP NN B-NP O
27 1895 1897 8812423 is VBZ B-VP O
28 1898 1908 8812423 frequently RB I-VP O
29 1909 1919 8812423 rearranged VBN I-VP O
30 1920 1924 8812423 also RB B-ADVP O
31 1925 1927 8812423 in IN B-PP O
32 1928 1933 8812423 cases NNS B-NP O
33 1934 1941 8812423 without IN B-PP O
34 1942 1943 8812423 a DT B-NP O
35 1944 1959 8812423 cytogenetically RB I-NP O
36 1960 1970 8812423 detectable JJ I-NP O
37 1971 1982 8812423 involvement NN I-NP O
38 1983 1985 8812423 of IN B-PP O
39 1986 1990 8812423 3q27 CD B-NP O
40 1990 1991 8812423 - HYPH I-NP O
41 1991 1994 8812423 q28 NN I-NP O
42 1994 1995 8812423 . . O O

1 1996 1999 8812423 Two CD B-NP O
2 2000 2011 8812423 alternative JJ I-NP O
3 2012 2017 8812423 HMGIC NN I-NP O
4 2017 2018 8812423 / SYM B-NP O
5 2018 2021 8812423 LPP NN I-NP O
6 2022 2028 8812423 hybrid NN I-NP O
7 2029 2040 8812423 transcripts NNS I-NP O
8 2041 2045 8812423 have VBP B-VP O
9 2046 2050 8812423 been VBN I-VP O
10 2051 2059 8812423 detected VBN I-VP O
11 2059 2060 8812423 ; : O O
12 2061 2064 8812423 the DT B-NP O
13 2065 2075 8812423 difference NN I-NP O
14 2076 2083 8812423 between IN B-PP O
15 2084 2088 8812423 them PRP B-NP O
16 2089 2091 8812423 is VBZ B-VP O
17 2092 2098 8812423 mainly RB B-ADVP O
18 2099 2102 8812423 the DT B-NP O
19 2103 2111 8812423 presence NN I-NP O
20 2112 2114 8812423 of IN B-PP O
21 2115 2121 8812423 either CC B-NP O
22 2122 2125 8812423 two CD I-NP O
23 2126 2128 8812423 or CC I-NP O
24 2129 2134 8812423 three CD I-NP O
25 2135 2138 8812423 LIM NN I-NP O
26 2139 2146 8812423 domains NNS I-NP O
27 2147 2149 8812423 in IN B-PP O
28 2150 2153 8812423 the DT B-NP O
29 2154 2163 8812423 predicted VBN I-NP O
30 2164 2168 8812423 HMGI NN I-NP O
31 2168 2169 8812423 - HYPH I-NP O
32 2169 2170 8812423 C NN I-NP O
33 2170 2171 8812423 / SYM I-NP O
34 2171 2174 8812423 LPP NN I-NP O
35 2175 2181 8812423 fusion NN I-NP O
36 2182 2190 8812423 proteins NNS I-NP O
37 2190 2191 8812423 . . O O
38 2191 2192 8812423 . . O O

1 0 0 8692963 -DOCSTART- -X- -X- O

1 0 11 8692963 Heterodimer NN B-NP O
2 12 21 8692963 formation NN I-NP O
3 22 25 8692963 and CC I-NP O
4 26 34 8692963 activity NN I-NP O
5 35 37 8692963 in IN B-PP O
6 38 41 8692963 the DT B-NP O
7 42 47 8692963 human JJ I-NP O
8 48 54 8692963 enzyme NN I-NP O
9 55 64 8692963 galactose NN I-NP O
10 64 65 8692963 - HYPH B-NP O
11 65 66 8692963 1 CD I-NP O
12 66 67 8692963 - HYPH I-NP O
13 67 76 8692963 phosphate NN I-NP O
14 77 96 8692963 uridylyltransferase NN I-NP O
15 96 97 8692963 . . O O
16 98 101 8692963 One CD B-NP O
17 102 104 8692963 of IN B-PP O
18 105 108 8692963 the DT B-NP O
19 109 120 8692963 fundamental JJ I-NP O
20 121 130 8692963 questions NNS I-NP O
21 131 141 8692963 concerning VBG B-VP O
22 142 152 8692963 expression NN B-NP O
23 153 156 8692963 and CC O O
24 157 165 8692963 function NN B-NP O
25 166 168 8692963 of IN B-PP O
26 169 176 8692963 dimeric JJ B-NP O
27 177 184 8692963 enzymes NNS I-NP O
28 185 193 8692963 involves VBZ B-VP O
29 194 197 8692963 the DT B-NP O
30 198 204 8692963 impact NN I-NP O
31 205 207 8692963 of IN B-PP O
32 208 217 8692963 naturally RB B-VP O
33 218 227 8692963 occurring VBG I-VP O
34 228 237 8692963 mutations NNS B-NP O
35 238 240 8692963 on IN B-PP O
36 241 248 8692963 subunit NN B-NP O
37 249 257 8692963 assembly NN I-NP O
38 258 261 8692963 and CC O O
39 262 273 8692963 heterodimer NN B-NP O
40 274 282 8692963 activity NN I-NP O
41 282 283 8692963 . . O O

1 284 288 8692963 This DT B-NP O
2 289 297 8692963 question NN I-NP O
3 298 300 8692963 is VBZ B-VP O
4 301 303 8692963 of IN B-PP O
5 304 314 8692963 particular JJ B-NP O
6 315 323 8692963 interest NN I-NP O
7 324 327 8692963 for IN B-PP O
8 328 331 8692963 the DT B-NP O
9 332 337 8692963 human JJ I-NP O
10 338 344 8692963 enzyme NN I-NP O
11 345 354 8692963 galactose NN I-NP O
12 354 355 8692963 - HYPH B-NP O
13 355 356 8692963 l NN I-NP O
14 356 357 8692963 - HYPH O O
15 357 366 8692963 phosphate NN B-NP O
16 367 375 8692963 uridylyl NN I-NP O
17 375 376 8692963 - HYPH O O
18 376 387 8692963 transferase NN B-NP O
19 388 389 8692963 ( ( O O
20 389 393 8692963 GALT NN B-NP O
21 393 394 8692963 ) ) O O
22 394 395 8692963 , , O O
23 396 406 8692963 impairment NN B-NP O
24 407 409 8692963 of IN B-PP O
25 410 415 8692963 which WDT B-NP O
26 416 423 8692963 results VBZ B-VP O
27 424 426 8692963 in IN B-PP O
28 427 430 8692963 the DT B-NP O
29 431 440 8692963 inherited VBN I-NP B-Disease
30 441 450 8692963 metabolic JJ I-NP I-Disease
31 451 459 8692963 disorder NN I-NP I-Disease
32 460 472 8692963 galactosemia NN I-NP B-Disease
33 472 473 8692963 , , O O
34 474 481 8692963 because IN B-SBAR O
35 482 486 8692963 many JJ B-NP O
36 487 489 8692963 if IN B-SBAR O
37 490 493 8692963 not RB O O
38 494 498 8692963 most JJS B-NP O
39 499 507 8692963 patients NNS I-NP O
40 508 515 8692963 studied VBN B-VP O
41 516 518 8692963 to TO B-PP O
42 519 523 8692963 date NN B-NP O
43 524 527 8692963 are VBP B-VP O
44 528 536 8692963 compound NN B-NP O
45 537 550 8692963 heterozygotes NNS I-NP O
46 551 557 8692963 rather RB B-PP O
47 558 562 8692963 than IN I-PP O
48 563 567 8692963 true JJ B-NP O
49 568 577 8692963 molecular JJ I-NP O
50 578 589 8692963 homozygotes NNS I-NP O
51 589 590 8692963 . . O O

1 591 602 8692963 Furthermore RB B-ADVP O
2 602 603 8692963 , , O O
3 604 607 8692963 the DT B-NP O
4 608 613 8692963 broad JJ I-NP O
5 614 619 8692963 range NN I-NP O
6 620 622 8692963 of IN B-PP O
7 623 633 8692963 phenotypic JJ B-NP O
8 634 642 8692963 severity NN I-NP O
9 643 651 8692963 observed VBN B-VP O
10 652 654 8692963 in IN B-PP O
11 655 660 8692963 these DT B-NP O
12 661 669 8692963 patients NNS I-NP O
13 670 676 8692963 raises VBZ B-VP O
14 677 680 8692963 the DT B-NP O
15 681 692 8692963 possibility NN I-NP O
16 693 697 8692963 that IN B-SBAR O
17 698 705 8692963 allelic JJ B-NP O
18 706 717 8692963 combination NN I-NP O
19 717 718 8692963 , , O O
20 719 722 8692963 not RB O O
21 723 727 8692963 just RB B-NP O
22 728 735 8692963 allelic JJ I-NP O
23 736 748 8692963 constitution NN I-NP O
24 748 749 8692963 , , O O
25 750 753 8692963 may MD B-VP O
26 754 758 8692963 play VB I-VP O
27 759 763 8692963 some DT B-NP O
28 764 768 8692963 role NN I-NP O
29 769 771 8692963 in IN B-PP O
30 772 783 8692963 determining VBG B-VP O
31 784 791 8692963 outcome NN B-NP O
32 791 792 8692963 . . O O

1 793 795 8692963 In IN B-PP O
2 796 799 8692963 the DT B-NP O
3 800 804 8692963 work NN I-NP O
4 805 814 8692963 described VBN B-VP O
5 815 821 8692963 herein RB B-ADVP O
6 821 822 8692963 , , O O
7 823 825 8692963 we PRP B-NP O
8 826 830 8692963 have VBP B-VP O
9 831 839 8692963 selected VBN I-VP O
10 840 843 8692963 two CD B-NP O
11 844 852 8692963 distinct JJ I-NP O
12 853 862 8692963 naturally RB B-VP O
13 863 872 8692963 occurring VBG I-VP O
14 873 877 8692963 null JJ B-NP O
15 878 887 8692963 mutations NNS I-NP O
16 888 890 8692963 of IN B-PP O
17 891 895 8692963 GALT NN B-NP O
18 895 896 8692963 , , I-NP O
19 897 902 8692963 Q188R NN I-NP O
20 903 906 8692963 and CC I-NP O
21 907 912 8692963 R333W NN I-NP O
22 912 913 8692963 , , O O
23 914 917 8692963 and CC O O
24 918 923 8692963 asked VBD B-VP O
25 924 927 8692963 the DT B-NP O
26 928 937 8692963 questions NNS I-NP O
27 938 941 8692963 (i) LS B-LST O
28 942 946 8692963 what WP B-NP O
29 947 950 8692963 are VBP B-VP O
30 951 954 8692963 the DT B-NP O
31 955 962 8692963 impacts NNS I-NP O
32 963 965 8692963 of IN B-PP O
33 966 971 8692963 these DT B-NP O
34 972 981 8692963 mutations NNS I-NP O
35 982 984 8692963 on IN B-PP O
36 985 992 8692963 subunit NN B-NP O
37 993 1001 8692963 assembly NN I-NP O
38 1001 1002 8692963 , , O O
39 1003 1006 8692963 and CC O O
40 1007 1011 8692963 (ii) LS B-LST O
41 1012 1014 8692963 if IN B-SBAR O
42 1015 1027 8692963 heterodimers NNS B-NP O
43 1028 1030 8692963 do VBP B-VP O
44 1031 1035 8692963 form VB I-VP O
45 1035 1036 8692963 , , O O
46 1037 1040 8692963 are VBP B-VP O
47 1041 1045 8692963 they PRP B-NP O
48 1046 1052 8692963 active JJ B-ADJP O
49 1053 1054 8692963 ? . O O
50 1055 1057 8692963 To TO B-VP O
51 1058 1064 8692963 answer VB I-VP O
52 1065 1070 8692963 these DT B-NP O
53 1071 1080 8692963 questions NNS I-NP O
54 1080 1081 8692963 , , O O
55 1082 1084 8692963 we PRP B-NP O
56 1085 1089 8692963 have VBP B-VP O
57 1090 1101 8692963 established VBN I-VP O
58 1102 1103 8692963 a DT B-NP O
59 1104 1109 8692963 yeast NN I-NP O
60 1110 1116 8692963 system NN I-NP O
61 1117 1120 8692963 for IN B-PP O
62 1121 1124 8692963 the DT B-NP O
63 1125 1137 8692963 coexpression NN I-NP O
64 1138 1140 8692963 of IN B-PP O
65 1141 1148 8692963 epitope NN B-NP O
66 1148 1149 8692963 - HYPH B-NP O
67 1149 1155 8692963 tagged VBN I-NP O
68 1156 1163 8692963 alleles NNS I-NP O
69 1164 1166 8692963 of IN B-PP O
70 1167 1172 8692963 human JJ B-NP O
71 1173 1177 8692963 GALT NN I-NP O
72 1178 1181 8692963 and CC O O
73 1182 1194 8692963 investigated VBD B-VP O
74 1195 1199 8692963 both CC O O
75 1200 1203 8692963 the DT B-NP O
76 1204 1210 8692963 extent NN I-NP O
77 1211 1213 8692963 of IN B-PP O
78 1214 1222 8692963 specific JJ B-NP O
79 1223 1227 8692963 GALT NN I-NP O
80 1228 1235 8692963 subunit NN I-NP O
81 1236 1248 8692963 interactions NNS I-NP O
82 1249 1252 8692963 and CC O O
83 1253 1256 8692963 the DT B-NP O
84 1257 1265 8692963 activity NN I-NP O
85 1266 1268 8692963 of IN B-PP O
86 1269 1276 8692963 defined VBN B-NP O
87 1277 1288 8692963 heterodimer NN I-NP O
88 1289 1294 8692963 pools NNS I-NP O
89 1294 1295 8692963 . . O O

1 1296 1298 8692963 We PRP B-NP O
2 1299 1303 8692963 have VBP B-VP O
3 1304 1309 8692963 found VBN I-VP O
4 1310 1314 8692963 that IN B-SBAR O
5 1315 1319 8692963 both CC O O
6 1320 1330 8692963 homodimers NNS B-NP O
7 1331 1334 8692963 and CC I-NP O
8 1335 1347 8692963 heterodimers NNS I-NP O
9 1348 1350 8692963 do VBP B-VP O
10 1351 1355 8692963 form VB I-VP O
11 1356 1365 8692963 involving VBG I-VP O
12 1366 1370 8692963 each DT B-NP O
13 1371 1373 8692963 of IN B-PP O
14 1374 1377 8692963 the DT B-NP O
15 1378 1384 8692963 mutant JJ I-NP O
16 1385 1393 8692963 subunits NNS I-NP O
17 1394 1400 8692963 tested VBN B-VP O
18 1401 1404 8692963 and CC O O
19 1405 1409 8692963 that IN B-SBAR O
20 1410 1414 8692963 both CC O O
21 1415 1426 8692963 heterodimer NN B-NP O
22 1427 1432 8692963 pools NNS I-NP O
23 1433 1439 8692963 retain VBP B-VP O
24 1440 1451 8692963 substantial JJ B-NP O
25 1452 1461 8692963 enzymatic JJ I-NP O
26 1462 1470 8692963 activity NN I-NP O
27 1470 1471 8692963 . . O O

1 1472 1477 8692963 These DT B-NP O
2 1478 1485 8692963 results NNS I-NP O
3 1486 1489 8692963 are VBP B-VP O
4 1490 1501 8692963 significant JJ B-ADJP O
5 1502 1505 8692963 not RB B-CONJP O
6 1506 1510 8692963 only RB I-CONJP O
7 1511 1513 8692963 in IN B-PP O
8 1514 1519 8692963 terms NNS B-NP O
9 1520 1522 8692963 of IN B-PP O
10 1523 1528 8692963 their PRP$ B-NP O
11 1529 1541 8692963 implications NNS I-NP O
12 1542 1545 8692963 for IN B-PP O
13 1546 1556 8692963 furthering VBG B-VP O
14 1557 1560 8692963 our PRP$ B-NP O
15 1561 1574 8692963 understanding NN I-NP O
16 1575 1577 8692963 of IN B-PP O
17 1578 1590 8692963 galactosemia NN B-NP B-Disease
18 1591 1594 8692963 and CC I-NP O
19 1595 1599 8692963 GALT NN I-NP O
20 1600 1610 8692963 holoenzyme NN I-NP O
21 1611 1620 8692963 structure NN I-NP O
22 1620 1621 8692963 - HYPH B-NP O
23 1621 1629 8692963 function NN I-NP O
24 1630 1643 8692963 relationships NNS I-NP O
25 1644 1647 8692963 but CC O O
26 1648 1652 8692963 also RB B-ADVP O
27 1653 1660 8692963 because IN B-SBAR O
28 1661 1664 8692963 the DT B-NP O
29 1665 1671 8692963 system NN I-NP O
30 1672 1681 8692963 described VBN B-VP O
31 1682 1685 8692963 may MD B-VP O
32 1686 1691 8692963 serve VB I-VP O
33 1692 1694 8692963 as IN B-PP O
34 1695 1696 8692963 a DT B-NP O
35 1697 1702 8692963 model NN I-NP O
36 1703 1706 8692963 for IN B-PP O
37 1707 1714 8692963 similar JJ B-NP O
38 1715 1722 8692963 studies NNS I-NP O
39 1723 1725 8692963 of IN B-PP O
40 1726 1731 8692963 other JJ B-NP O
41 1732 1741 8692963 complexes NNS I-NP O
42 1742 1750 8692963 composed VBN B-VP O
43 1751 1753 8692963 of IN B-PP O
44 1754 1762 8692963 multiple JJ B-NP O
45 1763 1771 8692963 subunits NNS I-NP O
46 1771 1772 8692963 . . O O
47 1772 1773 8692963 . . O O

1 0 0 9020847 -DOCSTART- -X- -X- O

1 0 8 9020847 Moderate JJ B-NP O
2 9 26 9020847 intergenerational JJ I-NP O
3 27 30 9020847 and CC I-NP O
4 31 38 9020847 somatic JJ I-NP O
5 39 50 9020847 instability NN I-NP O
6 51 53 9020847 of IN B-PP O
7 54 55 9020847 a DT B-NP O
8 56 58 9020847 55 CD I-NP O
9 58 59 9020847 - HYPH I-NP O
10 59 62 9020847 CTG NN I-NP O
11 63 69 9020847 repeat NN I-NP O
12 70 72 9020847 in IN B-PP O
13 73 83 9020847 transgenic JJ B-NP O
14 84 88 9020847 mice NNS I-NP O
15 88 89 9020847 . . O O
16 90 98 9020847 Myotonic JJ B-NP B-Disease
17 99 108 9020847 dystrophy NN I-NP I-Disease
18 109 110 9020847 ( ( O O
19 110 112 9020847 DM NN B-NP B-Disease
20 112 113 9020847 ) ) O O
21 114 116 9020847 is VBZ B-VP O
22 117 127 9020847 associated VBN I-VP O
23 128 132 9020847 with IN B-PP O
24 133 136 9020847 the DT B-NP O
25 137 146 9020847 expansion NN I-NP O
26 147 149 9020847 of IN B-PP O
27 150 151 9020847 a DT B-NP O
28 152 153 9020847 ( ( O O
29 153 156 9020847 CTG NN O O
30 156 157 9020847 ) ) O O
31 158 159 9020847 n NN B-NP O
32 160 173 9020847 trinucleotide NN I-NP O
33 174 180 9020847 repeat NN I-NP O
34 181 183 9020847 in IN B-PP O
35 184 187 9020847 the DT B-NP O
36 188 189 9020847 3 CD I-NP O
37 190 202 9020847 untranslated JJ I-NP O
38 203 209 9020847 region NN I-NP O
39 210 211 9020847 ( ( O O
40 211 214 9020847 UTR NN B-NP O
41 214 215 9020847 ) ) O O
42 216 218 9020847 of IN B-PP O
43 219 222 9020847 the DT B-NP O
44 223 225 9020847 DM NN I-NP B-Disease
45 226 233 9020847 protein NN I-NP O
46 234 240 9020847 kinase NN I-NP O
47 241 245 9020847 gene NN I-NP O
48 246 247 9020847 ( ( O O
49 247 251 9020847 DMPK NN B-NP O
50 251 252 9020847 ) ) O O
51 252 253 9020847 . . O O

1 254 257 9020847 The DT B-NP O
2 258 259 9020847 ( ( O O
3 259 262 9020847 CTG NN O O
4 262 263 9020847 ) ) O O
5 264 265 9020847 n NN B-NP O
6 266 272 9020847 repeat NN I-NP O
7 273 275 9020847 is VBZ B-VP O
8 276 287 9020847 polymorphic JJ B-ADJP O
9 288 291 9020847 and CC O O
10 292 298 9020847 varies VBZ B-VP O
11 299 301 9020847 in IN B-PP O
12 302 306 9020847 size NN B-NP O
13 307 314 9020847 between IN B-PP O
14 315 316 9020847 5 CD B-NP O
15 317 320 9020847 and CC I-NP O
16 321 323 9020847 37 CD I-NP O
17 324 331 9020847 repeats NNS I-NP O
18 332 334 9020847 in IN B-PP O
19 335 345 9020847 unaffected JJ B-NP O
20 346 357 9020847 individuals NNS I-NP O
21 358 365 9020847 whereas IN B-ADVP O
22 366 368 9020847 in IN B-PP O
23 369 377 9020847 affected VBN B-NP O
24 378 386 9020847 patients NNS I-NP O
25 387 392 9020847 there RB B-ADVP O
26 393 396 9020847 are VBP B-VP O
27 397 404 9020847 between IN B-PP O
28 405 407 9020847 50 CD B-NP O
29 408 411 9020847 and CC I-NP O
30 412 413 9020847 4 CD I-NP O
31 413 414 9020847 , , I-NP O
32 415 418 9020847 000 CD I-NP O
33 419 423 9020847 CTGs NNS I-NP O
34 423 424 9020847 . . O O

1 425 428 9020847 The DT B-NP O
2 429 433 9020847 size NN I-NP O
3 434 436 9020847 of IN B-PP O
4 437 440 9020847 the DT B-NP O
5 441 442 9020847 ( ( O O
6 442 445 9020847 CTG NN O O
7 445 446 9020847 ) ) O O
8 447 448 9020847 n NN B-NP O
9 449 455 9020847 repeat NN I-NP O
10 455 456 9020847 , , O O
11 457 462 9020847 which WDT B-NP O
12 463 472 9020847 increases VBZ B-VP O
13 473 480 9020847 through IN B-PP O
14 481 492 9020847 generations NNS B-NP O
15 492 493 9020847 , , O O
16 494 503 9020847 generally RB B-ADVP O
17 504 514 9020847 correlates VBZ B-VP O
18 515 519 9020847 with IN B-PP O
19 520 528 9020847 clinical JJ B-NP O
20 529 537 9020847 severity NN I-NP O
21 538 541 9020847 and CC I-NP O
22 542 545 9020847 age NN I-NP O
23 546 548 9020847 of IN B-PP O
24 549 554 9020847 onset NN B-NP O
25 554 555 9020847 . . O O

1 556 559 9020847 The DT B-NP O
2 560 571 9020847 instability NN I-NP O
3 572 574 9020847 of IN B-PP O
4 575 578 9020847 the DT B-NP O
5 579 582 9020847 CTG NN I-NP O
6 583 589 9020847 repeat NN I-NP O
7 590 597 9020847 appears VBZ B-VP O
8 598 600 9020847 to TO I-VP O
9 601 607 9020847 depend VB I-VP O
10 608 610 9020847 on IN B-PP O
11 611 614 9020847 its PRP$ B-NP O
12 615 619 9020847 size NN I-NP O
13 620 622 9020847 as RB B-CONJP O
14 623 627 9020847 well RB I-CONJP O
15 628 630 9020847 as IN I-CONJP O
16 631 633 9020847 on IN B-PP O
17 634 637 9020847 the DT B-NP O
18 638 641 9020847 sex NN I-NP O
19 642 644 9020847 of IN B-PP O
20 645 648 9020847 the DT B-NP O
21 649 661 9020847 transmitting JJ I-NP O
22 662 668 9020847 parent NN I-NP O
23 668 669 9020847 . . O O

1 670 678 9020847 Moreover RB B-ADVP O
2 678 679 9020847 , , O O
3 680 687 9020847 mitotic JJ B-NP O
4 688 699 9020847 instability NN I-NP O
5 700 708 9020847 analysis NN I-NP O
6 709 711 9020847 of IN B-PP O
7 712 721 9020847 different JJ B-NP O
8 722 727 9020847 human JJ I-NP O
9 728 730 9020847 DM NN I-NP B-Disease
10 731 738 9020847 tissues NNS I-NP O
11 739 744 9020847 shows VBZ B-VP O
12 745 751 9020847 length NN B-NP O
13 752 761 9020847 mosaicism NN I-NP O
14 762 769 9020847 between IN B-PP O
15 770 779 9020847 different JJ B-NP O
16 780 784 9020847 cell NN I-NP O
17 785 793 9020847 lineages NNS I-NP O
18 793 794 9020847 . . O O

1 795 798 9020847 The DT B-NP O
2 799 808 9020847 molecular JJ I-NP O
3 809 819 9020847 mechanisms NNS I-NP O
4 820 822 9020847 of IN B-PP O
5 823 830 9020847 triplet JJ B-NP O
6 831 842 9020847 instability NN I-NP O
7 843 849 9020847 remain VBP B-VP O
8 850 857 9020847 elusive JJ B-ADJP O
9 857 858 9020847 . . O O

1 859 861 9020847 To TO B-VP O
2 862 873 9020847 investigate VB I-VP O
3 874 877 9020847 the DT B-NP O
4 878 882 9020847 role NN I-NP O
5 883 885 9020847 of IN B-PP O
6 886 893 9020847 genomic JJ B-NP O
7 894 903 9020847 sequences NNS I-NP O
8 904 906 9020847 in IN B-PP O
9 907 918 9020847 instability NN B-NP O
10 918 919 9020847 , , O O
11 920 922 9020847 we PRP B-NP O
12 923 931 9020847 produced VBD B-VP O
13 932 942 9020847 transgenic JJ B-NP O
14 943 947 9020847 mice NNS I-NP O
15 948 958 9020847 containing VBG B-VP O
16 959 960 9020847 a DT B-NP O
17 961 963 9020847 45 CD I-NP O
18 963 964 9020847 - HYPH I-NP O
19 964 966 9020847 kb NN I-NP O
20 967 974 9020847 genomic JJ I-NP O
21 975 982 9020847 segment NN I-NP O
22 983 987 9020847 with IN B-PP O
23 988 989 9020847 a DT B-NP O
24 990 992 9020847 55 CD I-NP O
25 992 993 9020847 - HYPH I-NP O
26 993 996 9020847 CTG NN I-NP O
27 997 1003 9020847 repeat NN I-NP O
28 1004 1010 9020847 cloned VBN B-VP O
29 1011 1015 9020847 from IN B-PP O
30 1016 1017 9020847 a DT B-NP O
31 1018 1024 9020847 mildly RB I-NP O
32 1025 1033 9020847 affected VBN I-NP O
33 1034 1041 9020847 patient NN I-NP O
34 1041 1042 9020847 . . O O

1 1043 1045 9020847 In IN B-PP O
2 1046 1054 9020847 contrast NN B-NP O
3 1055 1057 9020847 to TO B-PP O
4 1058 1063 9020847 other JJ B-NP O
5 1064 1069 9020847 mouse NN I-NP O
6 1070 1076 9020847 models NNS I-NP O
7 1077 1087 9020847 containing VBG B-VP O
8 1088 1091 9020847 CAG NN B-NP O
9 1092 1099 9020847 repeats NNS I-NP O
10 1100 1106 9020847 within IN B-PP O
11 1107 1112 9020847 cDNAs NNS B-NP O
12 1112 1113 9020847 , , O O
13 1114 1119 9020847 these DT B-NP O
14 1120 1124 9020847 mice NNS I-NP O
15 1125 1131 9020847 showed VBD B-VP O
16 1132 1136 9020847 both CC O O
17 1137 1154 9020847 intergenerational JJ B-NP O
18 1155 1158 9020847 and CC I-NP O
19 1159 1166 9020847 somatic JJ I-NP O
20 1167 1173 9020847 repeat NN I-NP O
21 1174 1185 9020847 instability NN I-NP O
22 1185 1186 9020847 . . O O
23 1186 1187 9020847 . . O O

1 0 0 8622978 -DOCSTART- -X- -X- O

1 0 9 8622978 Defective JJ B-NP O
2 10 22 8622978 dimerization NN I-NP O
3 23 25 8622978 of IN B-PP O
4 26 29 8622978 von NN B-NP B-Disease
5 30 40 8622978 Willebrand NN I-NP I-Disease
6 41 47 8622978 factor NN I-NP O
7 48 56 8622978 subunits NNS I-NP O
8 57 60 8622978 due JJ B-ADJP O
9 61 63 8622978 to TO B-PP O
10 64 65 8622978 a DT B-NP O
11 66 69 8622978 Cys NN I-NP O
12 69 70 8622978 - HYPH O O
13 70 71 8622978 > SYM B-NP O
14 72 75 8622978 Arg NN I-NP O
15 76 84 8622978 mutation NN I-NP O
16 85 87 8622978 in IN B-PP O
17 88 92 8622978 type NN B-NP B-Disease
18 93 96 8622978 IID NN I-NP I-Disease
19 97 100 8622978 von NN I-NP I-Disease
20 101 111 8622978 Willebrand NN I-NP I-Disease
21 112 119 8622978 disease NN I-NP I-Disease
22 119 120 8622978 . . O O
23 121 124 8622978 The DT B-NP O
24 125 129 8622978 same JJ I-NP O
25 130 142 8622978 heterozygous JJ I-NP O
26 143 144 8622978 T NN I-NP O
27 145 146 8622978 - HYPH B-NP O
28 147 148 8622978 > SYM I-NP O
29 149 150 8622978 C NN I-NP O
30 151 161 8622978 transition NN I-NP O
31 162 164 8622978 at IN B-PP O
32 165 167 8622978 nt NN B-NP O
33 168 172 8622978 8567 CD I-NP O
34 173 175 8622978 of IN B-PP O
35 176 179 8622978 the DT B-NP O
36 180 183 8622978 von NN I-NP B-Disease
37 184 194 8622978 Willebrand NN I-NP I-Disease
38 195 201 8622978 factor NN I-NP O
39 202 203 8622978 ( ( O O
40 203 206 8622978 vWF NN B-NP O
41 206 207 8622978 ) ) O O
42 208 218 8622978 transcript NN B-NP O
43 219 222 8622978 was VBD B-VP O
44 223 228 8622978 found VBN I-VP O
45 229 231 8622978 in IN B-PP O
46 232 235 8622978 two CD B-NP O
47 236 245 8622978 unrelated JJ I-NP O
48 246 254 8622978 patients NNS I-NP O
49 255 259 8622978 with IN B-PP O
50 260 264 8622978 type NN B-NP B-Disease
51 265 268 8622978 IID NN I-NP I-Disease
52 269 272 8622978 von NN I-NP I-Disease
53 273 283 8622978 Willebrand NN I-NP I-Disease
54 284 291 8622978 disease NN I-NP I-Disease
55 291 292 8622978 , , O O
56 293 297 8622978 with IN B-PP O
57 298 300 8622978 no DT B-NP O
58 301 306 8622978 other JJ I-NP O
59 307 315 8622978 apparent JJ I-NP O
60 316 327 8622978 abnormality NN I-NP O
61 327 328 8622978 . . O O

1 329 331 8622978 In IN B-PP O
2 332 335 8622978 one CD B-NP O
3 336 342 8622978 family NN I-NP O
4 342 343 8622978 , , O O
5 344 348 8622978 both DT B-NP O
6 349 356 8622978 alleles NNS I-NP O
7 357 361 8622978 were VBD B-VP O
8 362 368 8622978 normal JJ B-ADJP O
9 369 371 8622978 in IN B-PP O
10 372 375 8622978 the DT B-NP O
11 376 383 8622978 parents NNS I-NP O
12 384 387 8622978 and CC O O
13 388 391 8622978 one CD B-NP O
14 392 398 8622978 sister NN I-NP O
15 398 399 8622978 ; : O O
16 400 404 8622978 thus RB B-ADVP O
17 404 405 8622978 , , O O
18 406 409 8622978 the DT B-NP O
19 410 418 8622978 mutation NN I-NP O
20 419 429 8622978 originated VBD B-VP O
21 430 432 8622978 de FW B-NP O
22 433 437 8622978 novo FW I-NP O
23 438 440 8622978 in IN B-PP O
24 441 444 8622978 the DT B-NP O
25 445 454 8622978 proposita NN I-NP O
26 454 455 8622978 . . O O

1 456 459 8622978 The DT B-NP O
2 460 466 8622978 second JJ I-NP O
3 467 474 8622978 patient NN I-NP O
4 475 479 8622978 also RB B-ADVP O
5 480 483 8622978 had VBD B-VP O
6 484 496 8622978 asymptomatic JJ B-NP O
7 497 504 8622978 parents NNS I-NP O
8 505 508 8622978 who WP B-NP O
9 508 509 8622978 , , O O
10 510 517 8622978 however RB B-ADVP O
11 517 518 8622978 , , O O
12 519 523 8622978 were VBD B-VP O
13 524 527 8622978 not RB O O
14 528 537 8622978 available JJ B-ADJP O
15 538 541 8622978 for IN B-PP O
16 542 547 8622978 study NN B-NP O
17 547 548 8622978 . . O O

1 549 552 8622978 The DT B-NP O
2 553 563 8622978 structural JJ I-NP O
3 564 576 8622978 consequences NNS I-NP O
4 577 579 8622978 of IN B-PP O
5 580 583 8622978 the DT B-NP O
6 584 594 8622978 identified VBN I-NP O
7 595 603 8622978 mutation NN I-NP O
8 603 604 8622978 , , O O
9 605 614 8622978 resulting VBG B-VP O
10 615 617 8622978 in IN B-PP O
11 618 621 8622978 the DT B-NP O
12 622 629 8622978 CyS2010 NN I-NP O
13 630 631 8622978 - HYPH O O
14 632 633 8622978 > SYM B-NP O
15 634 637 8622978 Arg NN I-NP O
16 638 650 8622978 substitution NN I-NP O
17 650 651 8622978 , , O O
18 652 656 8622978 were VBD B-VP O
19 657 666 8622978 evaluated VBN I-VP O
20 667 669 8622978 by IN B-PP O
21 670 680 8622978 expression NN B-NP O
22 681 683 8622978 of IN B-PP O
23 684 687 8622978 the DT B-NP O
24 688 691 8622978 vWF NN I-NP O
25 692 700 8622978 carboxyl NN I-NP O
26 700 701 8622978 - HYPH B-NP O
27 701 709 8622978 terminal JJ I-NP O
28 710 716 8622978 domain NN I-NP O
29 717 727 8622978 containing VBG B-VP O
30 728 736 8622978 residues NNS B-NP O
31 737 741 8622978 1366 CD B-NP O
32 741 742 8622978 - HYPH I-NP O
33 742 746 8622978 2050 CD I-NP O
34 746 747 8622978 . . O O

1 748 754 8622978 Insect NN B-NP O
2 755 760 8622978 cells NNS I-NP O
3 761 769 8622978 infected VBN B-VP O
4 770 774 8622978 with IN B-PP O
5 775 786 8622978 recombinant JJ B-NP O
6 787 798 8622978 baculovirus NN I-NP O
7 799 809 8622978 expressing VBG B-VP O
8 810 816 8622978 normal JJ B-NP O
9 817 820 8622978 vWF NN I-NP O
10 821 829 8622978 sequence NN I-NP O
11 830 838 8622978 secreted VBD B-VP O
12 839 840 8622978 a DT B-NP O
13 841 850 8622978 disulfide NN I-NP O
14 851 857 8622978 linked VBD B-VP O
15 858 865 8622978 dimeric JJ B-NP O
16 866 874 8622978 molecule NN I-NP O
17 875 879 8622978 with IN B-PP O
18 880 882 8622978 an DT B-NP O
19 883 891 8622978 apparent JJ I-NP O
20 892 901 8622978 molecular JJ I-NP O
21 902 906 8622978 mass NN I-NP O
22 907 909 8622978 of IN B-PP O
23 910 913 8622978 150 CD B-NP O
24 914 917 8622978 kDa NN I-NP O
25 918 924 8622978 before IN B-PP O
26 925 934 8622978 reduction NN B-NP O
27 934 935 8622978 , , O O
28 936 944 8622978 yielding VBG B-VP O
29 945 946 8622978 a DT B-NP O
30 947 953 8622978 single JJ I-NP O
31 954 958 8622978 band NN I-NP O
32 959 961 8622978 of IN B-PP O
33 962 964 8622978 80 CD B-NP O
34 965 968 8622978 kDa NN I-NP O
35 969 974 8622978 after IN B-PP O
36 975 984 8622978 disulfide NN B-NP O
37 985 989 8622978 bond NN I-NP O
38 990 999 8622978 reduction NN I-NP O
39 999 1000 8622978 . . O O

1 1001 1003 8622978 In IN B-PP O
2 1004 1012 8622978 contrast NN B-NP O
3 1012 1013 8622978 , , O O
4 1014 1019 8622978 cells NNS B-NP O
5 1020 1030 8622978 expressing VBG B-VP O
6 1031 1034 8622978 the DT B-NP O
7 1035 1041 8622978 mutant JJ I-NP O
8 1042 1050 8622978 fragment NN I-NP O
9 1051 1059 8622978 secreted VBD B-VP O
10 1060 1061 8622978 a DT B-NP O
11 1062 1071 8622978 monomeric JJ I-NP O
12 1072 1080 8622978 molecule NN I-NP O
13 1081 1083 8622978 of IN B-PP O
14 1084 1092 8622978 apparent JJ B-NP O
15 1093 1102 8622978 molecular JJ I-NP O
16 1103 1107 8622978 mass NN I-NP O
17 1108 1110 8622978 of IN B-PP O
18 1111 1113 8622978 80 CD B-NP O
19 1114 1117 8622978 kDa NN I-NP O
20 1117 1118 8622978 , , O O
21 1119 1124 8622978 which WDT B-NP O
22 1125 1133 8622978 remained VBD B-VP O
23 1134 1143 8622978 unchanged JJ B-ADJP O
24 1144 1149 8622978 after IN B-PP O
25 1150 1159 8622978 reduction NN B-NP O
26 1159 1160 8622978 . . O O

1 1161 1163 8622978 We PRP B-NP O
2 1164 1172 8622978 conclude VBP B-VP O
3 1173 1177 8622978 that IN B-SBAR O
4 1178 1185 8622978 CyS2010 NN B-NP O
5 1186 1188 8622978 is VBZ B-VP O
6 1189 1198 8622978 essential JJ B-ADJP O
7 1199 1202 8622978 for IN B-PP O
8 1203 1209 8622978 normal JJ B-NP O
9 1210 1222 8622978 dimerization NN I-NP O
10 1223 1225 8622978 of IN B-PP O
11 1226 1229 8622978 vWF NN B-NP O
12 1230 1238 8622978 subunits NNS I-NP O
13 1239 1246 8622978 through IN B-PP O
14 1247 1256 8622978 disulfide NN B-NP O
15 1257 1264 8622978 bonding NN I-NP O
16 1265 1267 8622978 of IN B-PP O
17 1268 1276 8622978 carboxyl NN B-NP O
18 1276 1277 8622978 - HYPH B-NP O
19 1277 1285 8622978 terminal JJ I-NP O
20 1286 1293 8622978 domains NNS I-NP O
21 1294 1297 8622978 and CC O O
22 1298 1302 8622978 that IN B-SBAR O
23 1303 1304 8622978 a DT B-NP O
24 1305 1317 8622978 heterozygous JJ I-NP O
25 1318 1326 8622978 mutation NN I-NP O
26 1327 1329 8622978 in IN B-PP O
27 1330 1333 8622978 the DT B-NP O
28 1334 1347 8622978 corresponding JJ I-NP O
29 1348 1353 8622978 codon NN I-NP O
30 1354 1356 8622978 is VBZ B-VP O
31 1357 1368 8622978 responsible JJ B-ADJP O
32 1369 1372 8622978 for IN B-PP O
33 1373 1382 8622978 defective JJ B-NP O
34 1383 1391 8622978 multimer NN I-NP O
35 1392 1401 8622978 formation NN I-NP O
36 1402 1404 8622978 in IN B-PP O
37 1405 1409 8622978 type NN B-NP B-Disease
38 1410 1413 8622978 IID NN I-NP I-Disease
39 1414 1417 8622978 von NN I-NP I-Disease
40 1418 1428 8622978 Willebrand NN I-NP I-Disease
41 1429 1436 8622978 disease NN I-NP I-Disease
42 1436 1437 8622978 . . O O
43 1437 1438 8622978 . . O O

1 0 0 8944023 -DOCSTART- -X- -X- O

1 0 14 8944023 Identification NN B-NP O
2 15 17 8944023 of IN B-PP O
3 18 19 8944023 a DT B-NP O
4 20 24 8944023 RING NN I-NP O
5 25 32 8944023 protein NN I-NP O
6 33 37 8944023 that WDT B-NP O
7 38 41 8944023 can MD B-VP O
8 42 50 8944023 interact VB I-VP O
9 51 53 8944023 in FW B-ADVP O
10 54 58 8944023 vivo FW I-ADVP O
11 59 63 8944023 with IN B-PP O
12 64 67 8944023 the DT B-NP O
13 68 73 8944023 BRCA1 NN I-NP O
14 74 78 8944023 gene NN I-NP O
15 79 86 8944023 product NN I-NP O
16 86 87 8944023 . . O O
17 88 91 8944023 The DT B-NP O
18 92 102 8944023 hereditary JJ I-NP B-Disease
19 103 109 8944023 breast NN I-NP I-Disease
20 110 113 8944023 and CC O I-Disease
21 114 121 8944023 ovarian JJ B-NP I-Disease
22 122 128 8944023 cancer NN I-NP I-Disease
23 129 133 8944023 gene NN I-NP O
24 133 134 8944023 , , O O
25 135 140 8944023 BRCA1 NN B-NP O
26 140 141 8944023 , , O O
27 142 149 8944023 encodes VBZ B-VP O
28 150 151 8944023 a DT B-NP O
29 152 157 8944023 large JJ I-NP O
30 158 169 8944023 polypeptide NN I-NP O
31 170 174 8944023 that WDT B-NP O
32 175 183 8944023 contains VBZ B-VP O
33 184 187 8944023 the DT B-NP O
34 188 196 8944023 cysteine NN I-NP O
35 196 197 8944023 - HYPH B-NP O
36 197 201 8944023 rich JJ I-NP O
37 202 206 8944023 RING NN I-NP O
38 207 212 8944023 motif NN I-NP O
39 212 213 8944023 , , O O
40 214 215 8944023 a DT B-NP O
41 216 220 8944023 zinc NN I-NP O
42 220 221 8944023 - HYPH O O
43 221 228 8944023 binding VBG B-NP O
44 229 235 8944023 domain NN I-NP O
45 236 241 8944023 found VBN B-VP O
46 242 244 8944023 in IN B-PP O
47 245 246 8944023 a DT B-NP O
48 247 254 8944023 variety NN I-NP O
49 255 257 8944023 of IN B-PP O
50 258 268 8944023 regulatory JJ B-NP O
51 269 277 8944023 proteins NNS I-NP O
52 277 278 8944023 . . O O

1 279 283 8944023 Here RB B-ADVP O
2 284 286 8944023 we PRP B-NP O
3 287 295 8944023 describe VBP B-VP O
4 296 297 8944023 a DT B-NP O
5 298 303 8944023 novel JJ I-NP O
6 304 311 8944023 protein NN I-NP O
7 312 316 8944023 that WDT B-NP O
8 317 326 8944023 interacts VBZ B-VP O
9 327 329 8944023 in FW B-ADVP O
10 330 334 8944023 vivo FW I-ADVP O
11 335 339 8944023 with IN B-PP O
12 340 343 8944023 the DT B-NP O
13 344 345 8944023 N NN I-NP O
14 345 346 8944023 - HYPH B-NP O
15 346 354 8944023 terminal JJ I-NP O
16 355 361 8944023 region NN I-NP O
17 362 364 8944023 of IN B-PP O
18 365 370 8944023 BRCA1 NN B-NP O
19 370 371 8944023 . . O O

1 372 376 8944023 This DT B-NP O
2 377 382 8944023 BRCA1 NN I-NP O
3 382 383 8944023 - HYPH B-VP O
4 383 393 8944023 associated VBN B-NP O
5 394 398 8944023 RING NN I-NP O
6 399 405 8944023 domain NN I-NP O
7 406 407 8944023 ( ( O O
8 407 412 8944023 BARD1 NN B-NP O
9 412 413 8944023 ) ) O O
10 414 421 8944023 protein NN B-NP O
11 422 430 8944023 contains VBZ B-VP O
12 431 433 8944023 an DT B-NP O
13 434 435 8944023 N NN I-NP O
14 435 436 8944023 - HYPH B-NP O
15 436 444 8944023 terminal JJ I-NP O
16 445 449 8944023 RING NN I-NP O
17 450 455 8944023 motif NN I-NP O
18 455 456 8944023 , , O O
19 457 462 8944023 three CD B-NP O
20 463 469 8944023 tandem JJ I-NP O
21 470 477 8944023 ankyrin NN I-NP O
22 478 485 8944023 repeats NNS I-NP O
23 485 486 8944023 , , O O
24 487 490 8944023 and CC O O
25 491 492 8944023 a DT B-NP O
26 493 494 8944023 C NN I-NP O
27 494 495 8944023 - HYPH B-NP O
28 495 503 8944023 terminal JJ I-NP O
29 504 512 8944023 sequence NN I-NP O
30 513 517 8944023 with IN B-PP O
31 518 529 8944023 significant JJ B-NP O
32 530 538 8944023 homology NN I-NP O
33 539 541 8944023 to TO B-PP O
34 542 545 8944023 the DT B-NP O
35 546 562 8944023 phylogenetically RB I-NP O
36 563 572 8944023 conserved VBN I-NP O
37 573 577 8944023 BRCT NN I-NP O
38 578 585 8944023 domains NNS I-NP O
39 586 590 8944023 that WDT B-NP O
40 591 594 8944023 lie VBP B-VP O
41 595 599 8944023 near IN B-PP O
42 600 603 8944023 the DT B-NP O
43 604 605 8944023 C NN I-NP O
44 606 614 8944023 terminus NN I-NP O
45 615 617 8944023 of IN B-PP O
46 618 623 8944023 BRCA1 NN B-NP O
47 623 624 8944023 . . O O

1 625 628 8944023 The DT B-NP O
2 629 634 8944023 BARD1 NN I-NP O
3 634 635 8944023 / SYM B-VP O
4 635 640 8944023 BRCA1 NN B-NP O
5 641 652 8944023 interaction NN I-NP O
6 653 655 8944023 is VBZ B-VP O
7 656 665 8944023 disrupted VBN I-VP O
8 666 668 8944023 by IN B-PP O
9 669 674 8944023 BRCA1 NN B-NP O
10 675 683 8944023 missense JJ I-NP O
11 684 693 8944023 mutations NNS I-NP O
12 694 698 8944023 that WDT B-NP O
13 699 708 8944023 segregate VBP B-VP O
14 709 713 8944023 with IN B-PP O
15 714 720 8944023 breast NN B-NP B-Disease
16 721 727 8944023 cancer NN I-NP I-Disease
17 728 742 8944023 susceptibility NN I-NP O
18 742 743 8944023 , , O O
19 744 754 8944023 indicating VBG B-VP O
20 755 759 8944023 that IN B-SBAR O
21 760 765 8944023 BARD1 NN B-NP O
22 766 769 8944023 may MD B-VP O
23 770 772 8944023 be VB I-VP O
24 773 781 8944023 involved VBN I-VP O
25 782 784 8944023 in IN B-PP O
26 785 794 8944023 mediating VBG B-VP O
27 795 801 8944023 tumour NN B-NP B-Disease
28 802 813 8944023 suppression NN I-NP O
29 814 816 8944023 by IN B-PP O
30 817 822 8944023 BRCA1 NN B-NP O
31 822 823 8944023 . . O O
32 823 824 8944023 . . O O

1 0 0 8666397 -DOCSTART- -X- -X- O

1 0 3 8666397 The DT B-NP O
2 4 9 8666397 mouse NN I-NP O
3 10 17 8666397 homolog NN I-NP O
4 18 20 8666397 of IN B-PP O
5 21 24 8666397 the DT B-NP O
6 25 32 8666397 Wiskott NNP I-NP B-Disease
7 32 33 8666397 - HYPH I-NP I-Disease
8 33 40 8666397 Aldrich NNP I-NP I-Disease
9 41 49 8666397 syndrome NN I-NP I-Disease
10 50 57 8666397 protein NN I-NP O
11 58 59 8666397 ( ( O O
12 59 63 8666397 WASP NN B-NP O
13 63 64 8666397 ) ) O O
14 65 69 8666397 gene NN B-NP O
15 70 72 8666397 is VBZ B-VP O
16 73 79 8666397 highly RB I-VP O
17 80 89 8666397 conserved VBN I-VP O
18 90 93 8666397 and CC O O
19 94 98 8666397 maps NNS B-NP O
20 99 103 8666397 near IN B-PP O
21 104 107 8666397 the DT B-NP O
22 108 114 8666397 scurfy NN I-NP O
23 115 116 8666397 ( ( O O
24 116 118 8666397 sf NN B-NP O
25 118 119 8666397 ) ) O O
26 120 128 8666397 mutation NN B-NP O
27 129 131 8666397 on IN B-PP O
28 132 135 8666397 the DT B-NP O
29 136 137 8666397 X NN I-NP O
30 138 148 8666397 chromosome NN I-NP O
31 148 149 8666397 . . O O
32 150 153 8666397 The DT B-NP O
33 154 159 8666397 mouse NN I-NP O
34 160 164 8666397 WASP NN I-NP O
35 165 169 8666397 gene NN I-NP O
36 169 170 8666397 , , O O
37 171 174 8666397 the DT B-NP O
38 175 182 8666397 homolog NN I-NP O
39 183 185 8666397 of IN B-PP O
40 186 189 8666397 the DT B-NP O
41 190 194 8666397 gene NN I-NP O
42 195 202 8666397 mutated VBN B-VP O
43 203 205 8666397 in IN B-PP O
44 206 213 8666397 Wiskott NNP B-NP B-Disease
45 213 214 8666397 - HYPH I-NP I-Disease
46 214 221 8666397 Aldrich NNP I-NP I-Disease
47 222 230 8666397 syndrome NN I-NP I-Disease
48 230 231 8666397 , , O O
49 232 235 8666397 has VBZ B-VP O
50 236 240 8666397 been VBN I-VP O
51 241 249 8666397 isolated VBN I-VP O
52 250 253 8666397 and CC I-VP O
53 254 263 8666397 sequenced VBN I-VP O
54 263 264 8666397 . . O O

1 265 268 8666397 the DT B-NP O
2 269 278 8666397 predicted VBN I-NP O
3 279 284 8666397 amino NN I-NP O
4 285 289 8666397 acid NN I-NP O
5 290 298 8666397 sequence NN I-NP O
6 299 301 8666397 is VBZ B-VP O
7 302 305 8666397 86% CD B-NP O
8 306 315 8666397 identical JJ I-NP O
9 316 318 8666397 to TO B-PP O
10 319 322 8666397 the DT B-NP O
11 323 328 8666397 human JJ I-NP O
12 329 333 8666397 WASP NN I-NP O
13 334 342 8666397 sequence NN I-NP O
14 342 343 8666397 . . O O

1 344 345 8666397 A DT B-NP O
2 346 354 8666397 distinct JJ I-NP O
3 355 362 8666397 feature NN I-NP O
4 363 365 8666397 of IN B-PP O
5 366 369 8666397 the DT B-NP O
6 370 375 8666397 mouse NN I-NP O
7 376 380 8666397 gene NN I-NP O
8 381 383 8666397 is VBZ B-VP O
9 384 386 8666397 an DT B-NP O
10 387 395 8666397 expanded VBN I-NP O
11 396 407 8666397 polymorphic JJ I-NP O
12 408 411 8666397 GGA NN I-NP O
13 412 425 8666397 trinucleotide NN I-NP O
14 426 432 8666397 repeat NN I-NP O
15 433 437 8666397 that WDT B-NP O
16 438 443 8666397 codes VBZ B-VP O
17 444 447 8666397 for IN B-PP O
18 448 459 8666397 polyglycine NN B-NP O
19 460 463 8666397 and CC O O
20 464 470 8666397 varies VBZ B-VP O
21 471 475 8666397 from IN B-PP O
22 476 478 8666397 15 CD B-NP O
23 479 481 8666397 to TO I-NP O
24 482 484 8666397 17 CD I-NP O
25 485 493 8666397 triplets NNS I-NP O
26 494 496 8666397 in IN B-PP O
27 497 506 8666397 different JJ B-NP O
28 507 510 8666397 Mus NN I-NP O
29 511 519 8666397 musculus NN I-NP O
30 520 527 8666397 strains NNS I-NP O
31 527 528 8666397 . . O O

1 529 532 8666397 The DT B-NP O
2 533 540 8666397 genomic JJ I-NP O
3 541 550 8666397 structure NN I-NP O
4 551 553 8666397 of IN B-PP O
5 554 557 8666397 the DT B-NP O
6 558 563 8666397 mouse NN I-NP O
7 564 568 8666397 WASP NN I-NP O
8 569 573 8666397 gene NN I-NP O
9 574 576 8666397 is VBZ B-VP O
10 577 586 8666397 expressed VBN I-VP O
11 587 589 8666397 as IN B-PP O
12 590 592 8666397 an DT B-NP O
13 593 606 8666397 approximately RB I-NP O
14 607 608 8666397 2 CD I-NP O
15 608 609 8666397 . . I-NP O
16 610 611 8666397 4 CD I-NP O
17 611 612 8666397 - HYPH I-NP O
18 612 614 8666397 kb NN I-NP O
19 615 619 8666397 mRNA NN I-NP O
20 620 622 8666397 in IN B-PP O
21 623 629 8666397 thymus NN B-NP O
22 630 633 8666397 and CC I-NP O
23 634 640 8666397 spleen NN I-NP O
24 640 641 8666397 . . O O

1 642 653 8666397 Chromosomal JJ B-NP O
2 654 661 8666397 mapping NN I-NP O
3 662 664 8666397 in IN B-PP O
4 665 667 8666397 an DT B-NP O
5 668 681 8666397 interspecific JJ I-NP O
6 682 683 8666397 M NN I-NP O
7 683 684 8666397 . . I-NP O
8 685 693 8666397 Musculus NN I-NP O
9 693 694 8666397 / SYM B-NP O
10 694 695 8666397 M NN I-NP O
11 695 696 8666397 . SYM I-NP O
12 697 704 8666397 spretus NN I-NP O
13 705 714 8666397 backcross RB B-ADVP O
14 715 721 8666397 placed VBD B-VP O
15 722 725 8666397 the DT B-NP O
16 726 730 8666397 Wasp NNP I-NP O
17 731 736 8666397 locus NN I-NP O
18 737 741 8666397 near IN B-PP O
19 742 745 8666397 the DT B-NP O
20 746 756 8666397 centromere NN I-NP O
21 757 759 8666397 of IN B-PP O
22 760 763 8666397 the DT B-NP O
23 764 769 8666397 mouse NN I-NP O
24 770 771 8666397 X NN I-NP O
25 772 782 8666397 chromosome NN I-NP O
26 782 783 8666397 , , O O
27 784 795 8666397 inseparable JJ B-ADJP O
28 796 800 8666397 from IN B-PP O
29 801 806 8666397 Gata1 NN B-NP O
30 806 807 8666397 , , O O
31 808 813 8666397 Tcfe3 NN B-NP O
32 813 814 8666397 , , O O
33 815 818 8666397 and CC O O
34 819 825 8666397 scurfy NN B-NP O
35 826 827 8666397 ( ( O O
36 827 829 8666397 sf NN B-NP O
37 829 830 8666397 ) ) O O
38 830 831 8666397 . . O O

1 832 836 8666397 This DT B-NP O
2 837 849 8666397 localization NN I-NP O
3 850 855 8666397 makes VBZ B-VP O
4 856 860 8666397 Wasp NNP B-NP O
5 861 862 8666397 a DT B-NP O
6 863 872 8666397 candidate NN I-NP O
7 873 876 8666397 for IN B-PP O
8 877 888 8666397 involvement NN B-NP O
9 889 891 8666397 in IN B-PP O
10 892 898 8666397 scurfy NN B-NP O
11 898 899 8666397 , , O O
12 900 901 8666397 a DT B-NP O
13 902 903 8666397 T NN I-NP O
14 904 908 8666397 cell NN I-NP O
15 908 909 8666397 - HYPH O O
16 909 917 8666397 mediated VBN B-VP O
17 918 923 8666397 fatal JJ B-NP B-Disease
18 924 939 8666397 lymphoreticular JJ I-NP I-Disease
19 940 947 8666397 disease NN I-NP I-Disease
20 948 950 8666397 of IN B-PP O
21 951 955 8666397 mice NNS B-NP O
22 956 960 8666397 that WDT B-NP O
23 961 964 8666397 has VBZ B-VP O
24 965 975 8666397 previously RB I-VP O
25 976 980 8666397 been VBN I-VP O
26 981 989 8666397 proposed VBN I-VP O
27 990 992 8666397 as IN B-PP O
28 993 994 8666397 a DT B-NP O
29 995 1000 8666397 mouse NN I-NP O
30 1001 1008 8666397 homolog NN I-NP O
31 1009 1011 8666397 of IN B-PP O
32 1012 1019 8666397 Wiskott NNP B-NP B-Disease
33 1019 1020 8666397 - HYPH I-NP I-Disease
34 1020 1027 8666397 Aldrich NNP I-NP I-Disease
35 1028 1036 8666397 syndrome NN I-NP I-Disease
36 1036 1037 8666397 . . O O

1 1038 1046 8666397 Northern JJ B-NP O
2 1047 1055 8666397 analysis NN I-NP O
3 1056 1058 8666397 of IN B-PP O
4 1059 1061 8666397 sf NN B-NP O
5 1062 1068 8666397 tissue NN I-NP O
6 1069 1076 8666397 samples NNS I-NP O
7 1077 1086 8666397 indicated VBD B-VP O
8 1087 1090 8666397 the DT B-NP O
9 1091 1099 8666397 presence NN I-NP O
10 1100 1102 8666397 of IN B-PP O
11 1103 1107 8666397 WASP NN B-NP O
12 1108 1112 8666397 mRNA NN I-NP O
13 1113 1115 8666397 in IN B-PP O
14 1116 1121 8666397 liver NN B-NP O
15 1122 1125 8666397 and CC I-NP O
16 1126 1130 8666397 skin NN I-NP O
17 1130 1131 8666397 , , O O
18 1132 1142 8666397 presumably RB B-ADVP O
19 1143 1145 8666397 as IN B-PP O
20 1146 1147 8666397 a DT B-NP O
21 1148 1159 8666397 consequence NN I-NP O
22 1160 1162 8666397 of IN B-PP O
23 1163 1174 8666397 lymphocytic JJ B-NP O
24 1175 1187 8666397 infiltration NN I-NP O
25 1187 1188 8666397 , , O O
26 1189 1192 8666397 but CC O O
27 1193 1196 8666397 non JJ B-NP O
28 1197 1210 8666397 abnormalities NNS I-NP O
29 1211 1213 8666397 in IN B-PP O
30 1214 1217 8666397 the DT B-NP O
31 1218 1224 8666397 amount NN I-NP O
32 1225 1227 8666397 or CC I-NP O
33 1228 1232 8666397 size NN I-NP O
34 1233 1235 8666397 of IN B-PP O
35 1236 1240 8666397 mRNA NN B-NP O
36 1241 1248 8666397 present JJ B-ADJP O
37 1248 1249 8666397 . . O O

1 0 0 8944024 -DOCSTART- -X- -X- O

1 0 9 8944024 Detection NN B-NP O
2 10 12 8944024 of IN B-PP O
3 13 25 8944024 heterozygous JJ B-NP O
4 26 35 8944024 mutations NNS I-NP O
5 36 38 8944024 in IN B-PP O
6 39 44 8944024 BRCA1 NN B-NP O
7 45 50 8944024 using VBG B-VP O
8 51 55 8944024 high JJ B-NP O
9 56 63 8944024 density NN I-NP O
10 64 79 8944024 oligonucleotide NN I-NP O
11 80 86 8944024 arrays NNS I-NP O
12 87 90 8944024 and CC O O
13 91 94 8944024 two CD B-NP O
14 94 95 8944024 - HYPH I-NP O
15 95 101 8944024 colour NN I-NP O
16 102 114 8944024 fluorescence NN I-NP O
17 115 123 8944024 analysis NN I-NP O
18 123 124 8944024 . . O O
19 125 128 8944024 The DT B-NP O
20 129 136 8944024 ability NN I-NP O
21 137 139 8944024 to TO B-VP O
22 140 144 8944024 scan VB I-VP O
23 145 146 8944024 a DT B-NP O
24 147 152 8944024 large JJ I-NP O
25 153 157 8944024 gene NN I-NP O
26 158 165 8944024 rapidly RB B-ADVP O
27 166 169 8944024 and CC I-ADVP O
28 170 180 8944024 accurately RB I-ADVP O
29 181 184 8944024 for IN B-PP O
30 185 188 8944024 all DT B-NP O
31 189 197 8944024 possible JJ I-NP O
32 198 210 8944024 heterozygous JJ I-NP O
33 211 220 8944024 mutations NNS I-NP O
34 221 223 8944024 in IN B-PP O
35 224 229 8944024 large JJ B-NP O
36 230 237 8944024 numbers NNS I-NP O
37 238 240 8944024 of IN B-PP O
38 241 248 8944024 patient NN B-NP O
39 249 256 8944024 samples NNS I-NP O
40 257 261 8944024 will MD B-VP O
41 262 264 8944024 be VB I-VP O
42 265 273 8944024 critical JJ B-ADJP O
43 274 277 8944024 for IN B-PP O
44 278 281 8944024 the DT B-NP O
45 282 288 8944024 future NN I-NP O
46 289 291 8944024 of IN B-PP O
47 292 300 8944024 medicine NN B-NP O
48 300 301 8944024 . . O O

1 302 304 8944024 We PRP B-NP O
2 305 309 8944024 have VBP B-VP O
3 310 318 8944024 designed VBN I-VP O
4 319 323 8944024 high JJ B-NP O
5 323 324 8944024 - HYPH I-NP O
6 324 331 8944024 density NN I-NP O
7 332 338 8944024 arrays NNS I-NP O
8 339 349 8944024 consisting VBG B-VP O
9 350 352 8944024 of IN B-PP O
10 353 357 8944024 over IN B-PP O
11 358 360 8944024 96 CD B-NP O
12 360 361 8944024 , , O O
13 362 365 8944024 600 CD B-NP O
14 366 382 8944024 oligonucleotides NNS I-NP O
15 383 385 8944024 20 CD B-NP O
16 385 386 8944024 - HYPH I-NP O
17 386 397 8944024 nucleotides NNS I-NP O
18 398 399 8944024 ( ( O O
19 399 401 8944024 nt NN B-NP O
20 401 402 8944024 ) ) O O
21 403 405 8944024 in IN B-PP O
22 406 412 8944024 length NN B-NP O
23 413 415 8944024 to TO B-VP O
24 416 422 8944024 screen VB I-VP O
25 423 426 8944024 for IN B-PP O
26 427 428 8944024 a DT B-NP O
27 429 433 8944024 wide JJ I-NP O
28 434 439 8944024 range NN I-NP O
29 440 442 8944024 of IN B-PP O
30 443 455 8944024 heterozygous JJ B-NP O
31 456 465 8944024 mutations NNS I-NP O
32 466 468 8944024 in IN B-PP O
33 469 472 8944024 the DT B-NP O
34 473 474 8944024 3 CD I-NP O
35 474 475 8944024 . SYM I-NP O
36 476 478 8944024 45 CD I-NP O
37 478 479 8944024 - HYPH I-NP O
38 479 488 8944024 kilobases NNS I-NP O
39 489 490 8944024 ( ( O O
40 490 492 8944024 kb NN B-NP O
41 492 493 8944024 ) ) O O
42 494 498 8944024 exon NN B-NP O
43 499 501 8944024 11 CD I-NP O
44 502 504 8944024 of IN B-PP O
45 505 508 8944024 the DT B-NP O
46 509 519 8944024 hereditary JJ I-NP B-Disease
47 520 526 8944024 breast NN I-NP I-Disease
48 527 530 8944024 and CC O I-Disease
49 531 538 8944024 ovarian JJ B-NP I-Disease
50 539 545 8944024 cancer NN I-NP I-Disease
51 546 550 8944024 gene NN I-NP O
52 551 556 8944024 BRCA1 NN I-NP O
53 556 557 8944024 . . O O

1 558 567 8944024 Reference NN B-NP O
2 568 571 8944024 and CC I-NP O
3 572 576 8944024 test NN I-NP O
4 577 584 8944024 samples NNS I-NP O
5 585 589 8944024 were VBD B-VP O
6 590 592 8944024 co AFX O O
7 592 593 8944024 - HYPH O O
8 593 603 8944024 hybridized VBN B-VP O
9 604 606 8944024 to TO B-PP O
10 607 612 8944024 these DT B-NP O
11 613 619 8944024 arrays NNS I-NP O
12 620 623 8944024 and CC I-NP O
13 624 635 8944024 differences NNS I-NP O
14 636 638 8944024 in IN B-PP O
15 639 652 8944024 hybridization NN B-NP O
16 653 661 8944024 patterns NNS I-NP O
17 662 673 8944024 quantitated VBN B-VP O
18 674 676 8944024 by IN B-PP O
19 677 680 8944024 two CD B-NP O
20 680 681 8944024 - HYPH I-NP O
21 681 687 8944024 colour NN I-NP O
22 688 696 8944024 analysis NN I-NP O
23 696 697 8944024 . . O O

1 698 706 8944024 Fourteen CD B-NP O
2 707 709 8944024 of IN B-PP O
3 710 717 8944024 fifteen CD B-NP O
4 718 725 8944024 patient NN I-NP O
5 726 733 8944024 samples NNS I-NP O
6 734 738 8944024 with IN B-PP O
7 739 744 8944024 known JJ B-NP O
8 745 754 8944024 mutations NNS I-NP O
9 755 759 8944024 were VBD B-VP O
10 760 770 8944024 accurately RB I-VP O
11 771 780 8944024 diagnosed VBN I-VP O
12 780 781 8944024 , , O O
13 782 785 8944024 and CC O O
14 786 788 8944024 no DT B-NP O
15 789 794 8944024 false JJ I-NP O
16 795 803 8944024 positive JJ I-NP O
17 804 813 8944024 mutations NNS I-NP O
18 814 818 8944024 were VBD B-VP O
19 819 829 8944024 identified VBN I-VP O
20 830 832 8944024 in IN B-PP O
21 833 835 8944024 20 CD B-NP O
22 836 843 8944024 control NN I-NP O
23 844 851 8944024 samples NNS I-NP O
24 851 852 8944024 . . O O

1 853 858 8944024 Eight CD B-NP O
2 859 865 8944024 single JJ I-NP O
3 866 876 8944024 nucleotide NN I-NP O
4 877 890 8944024 polymorphisms NNS I-NP O
5 891 895 8944024 were VBD B-VP O
6 896 900 8944024 also RB B-ADVP O
7 901 908 8944024 readily RB B-ADJP O
8 909 917 8944024 detected VBN I-ADJP O
9 917 918 8944024 . . O O

1 919 922 8944024 DNA NN B-NP O
2 923 927 8944024 chip NN I-NP O
3 927 928 8944024 - HYPH B-NP O
4 928 933 8944024 based VBN I-NP O
5 934 940 8944024 assays NNS I-NP O
6 941 944 8944024 may MD B-VP O
7 945 952 8944024 provide VB I-VP O
8 953 954 8944024 a DT B-NP O
9 955 963 8944024 valuable JJ I-NP O
10 964 967 8944024 new JJ I-NP O
11 968 978 8944024 technology NN I-NP O
12 979 982 8944024 for IN B-PP O
13 983 987 8944024 high JJ B-NP O
14 987 988 8944024 - HYPH I-NP O
15 988 998 8944024 throughput NN I-NP O
16 999 1003 8944024 cost AFX O O
17 1003 1004 8944024 - HYPH B-NP O
18 1004 1013 8944024 efficient JJ I-NP O
19 1014 1023 8944024 detection NN I-NP O
20 1024 1026 8944024 of IN B-PP O
21 1027 1034 8944024 genetic JJ B-NP O
22 1035 1046 8944024 alterations NNS I-NP O
23 1046 1047 8944024 . . O O

1 0 0 9182899 -DOCSTART- -X- -X- O

1 0 12 9182899 Difficulties NNS B-NP O
2 13 15 9182899 in IN B-PP O
3 16 19 9182899 the DT B-NP O
4 20 33 9182899 ascertainment NN I-NP O
5 34 36 9182899 of IN B-PP O
6 37 39 9182899 C9 NN B-NP B-Disease
7 40 50 9182899 deficiency NN I-NP I-Disease
8 50 51 9182899 : : O O
9 52 59 9182899 lessons NNS B-NP O
10 60 62 9182899 to TO B-VP O
11 63 65 9182899 be VB I-VP O
12 66 71 9182899 drawn VBN I-VP O
13 72 76 9182899 from IN B-PP O
14 77 78 9182899 a DT B-NP O
15 79 87 9182899 compound NN I-NP O
16 88 100 9182899 heterozygote NN I-NP O
17 101 103 9182899 C9 NN I-NP B-Disease
18 103 104 9182899 - HYPH B-NP I-Disease
19 104 113 9182899 deficient JJ I-NP I-Disease
20 114 121 9182899 subject NN I-NP O
21 121 122 9182899 . . I-NP O
22 123 124 9182899 A NN I-NP O
23 125 130 9182899 group NN I-NP O
24 131 133 9182899 of IN B-PP O
25 134 142 9182899 patients NNS B-NP O
26 143 147 9182899 with IN B-PP O
27 148 152 9182899 long RB B-ADVP O
28 152 153 9182899 - HYPH O O
29 153 162 9182899 surviving VBG B-VP O
30 163 173 9182899 mismatched VBN B-NP O
31 174 180 9182899 kidney NN I-NP O
32 181 191 9182899 allografts NNS I-NP O
33 192 196 9182899 were VBD B-VP O
34 197 209 9182899 investigated VBN I-VP O
35 210 213 9182899 for IN B-PP O
36 214 224 9182899 complement NN B-NP O
37 225 233 9182899 function NN I-NP O
38 234 239 9182899 using VBG B-VP O
39 240 250 9182899 haemolytic JJ B-NP O
40 251 257 9182899 assays NNS I-NP O
41 258 260 9182899 in IN B-PP O
42 261 268 9182899 agarose NN B-NP O
43 269 273 9182899 gels NNS I-NP O
44 273 274 9182899 . . O O

1 275 278 9182899 One CD B-NP O
2 279 286 9182899 patient NN I-NP O
3 287 290 9182899 was VBD B-VP O
4 291 296 9182899 found VBN I-VP O
5 297 299 9182899 to TO I-VP O
6 300 304 9182899 have VB I-VP O
7 305 307 9182899 no DT B-NP O
8 308 319 9182899 alternative JJ I-NP O
9 320 327 9182899 pathway NN I-NP O
10 328 336 9182899 activity NN I-NP O
11 337 340 9182899 but CC O O
12 341 342 9182899 a DT B-NP O
13 343 346 9182899 low JJ I-NP O
14 347 353 9182899 normal JJ I-NP O
15 354 363 9182899 classical JJ I-NP O
16 364 371 9182899 pathway NN I-NP O
17 371 372 9182899 . . O O

1 373 385 9182899 Surprisingly RB B-ADVP O
2 385 386 9182899 , , O O
3 387 400 9182899 investigation NN B-NP O
4 401 409 9182899 revealed VBD B-VP O
5 410 414 9182899 that IN B-SBAR O
6 415 418 9182899 the DT B-NP O
7 419 427 9182899 patients NNS I-NP O
8 428 438 9182899 complement NN I-NP O
9 439 442 9182899 was VBD B-VP O
10 443 449 9182899 normal JJ B-ADJP O
11 450 453 9182899 for IN B-PP O
12 454 457 9182899 all DT B-NP O
13 458 468 9182899 components NNS I-NP O
14 469 475 9182899 except IN B-PP O
15 476 478 9182899 C9 NN B-NP O
16 478 479 9182899 , , O O
17 480 485 9182899 which WDT B-NP O
18 486 489 9182899 was VBD B-VP O
19 490 502 9182899 functionally RB B-ADJP O
20 503 509 9182899 absent JJ I-ADJP O
21 509 510 9182899 . . O O

1 511 514 9182899 The DT B-NP O
2 515 522 9182899 patient NN I-NP O
3 523 526 9182899 was VBD B-VP O
4 527 532 9182899 shown VBN I-VP O
5 533 535 9182899 to TO I-VP O
6 536 538 9182899 be VB I-VP O
7 539 551 9182899 heterozygous JJ B-ADJP O
8 552 555 9182899 for IN B-PP O
9 556 559 9182899 DNA NN B-NP O
10 560 567 9182899 markers NNS I-NP O
11 568 570 9182899 in IN B-PP O
12 571 574 9182899 the DT B-NP O
13 575 577 9182899 C6 NN I-NP O
14 577 578 9182899 , , I-NP O
15 579 581 9182899 C7 NN I-NP O
16 582 585 9182899 and CC I-NP O
17 586 588 9182899 C9 NN I-NP O
18 589 595 9182899 region NN I-NP O
19 596 598 9182899 of IN B-PP O
20 599 609 9182899 chromosome NN B-NP O
21 610 611 9182899 5 CD I-NP O
22 612 615 9182899 and CC O O
23 616 625 9182899 therefore RB B-VP O
24 626 633 9182899 appears VBZ I-VP O
25 634 636 9182899 to TO I-VP O
26 637 639 9182899 be VB I-VP O
27 640 641 9182899 a DT B-NP O
28 642 650 9182899 compound NN I-NP O
29 651 663 9182899 heterozygote NN I-NP O
30 664 667 9182899 for IN B-PP O
31 668 671 9182899 two CD B-NP O
32 672 687 9182899 uncharacterized JJ I-NP O
33 688 690 9182899 C9 NN I-NP B-Disease
34 691 701 9182899 deficiency NN I-NP I-Disease
35 702 707 9182899 genes NNS I-NP O
36 707 708 9182899 . . O O

1 709 720 9182899 Serological JJ B-NP O
2 721 729 9182899 analysis NN I-NP O
3 730 732 9182899 by IN B-PP O
4 733 738 9182899 ELISA NN B-NP O
5 739 747 9182899 revealed VBD B-VP O
6 748 752 9182899 that IN B-SBAR O
7 753 755 9182899 he PRP B-NP O
8 756 759 9182899 has VBZ B-VP O
9 760 765 9182899 trace NN B-NP O
10 766 780 9182899 concentrations NNS I-NP O
11 781 783 9182899 of IN B-PP O
12 784 785 9182899 a DT B-NP O
13 786 789 9182899 non AFX I-NP O
14 789 790 9182899 - HYPH I-NP O
15 790 800 9182899 functional JJ I-NP O
16 801 803 9182899 C9 NN I-NP O
17 804 812 9182899 molecule NN I-NP O
18 812 813 9182899 . . O O

1 814 821 9182899 Western NN B-NP O
2 822 826 9182899 blot NN I-NP O
3 827 835 9182899 analysis NN I-NP O
4 836 839 9182899 was VBD B-VP O
5 840 843 9182899 not RB O O
6 844 856 9182899 sufficiently RB B-ADJP O
7 857 866 9182899 sensitive JJ I-ADJP O
8 867 869 9182899 to TO B-VP O
9 870 876 9182899 permit VB I-VP O
10 877 886 9182899 detection NN B-NP O
11 887 889 9182899 of IN B-PP O
12 890 894 9182899 this DT B-NP O
13 895 903 9182899 molecule NN I-NP O
14 903 904 9182899 . . O O

1 905 907 9182899 We PRP B-NP O
2 908 919 9182899 hypothesize VBP B-VP O
3 920 924 9182899 that IN B-SBAR O
4 925 928 9182899 the DT B-NP O
5 929 936 9182899 patient NN I-NP O
6 937 939 9182899 is VBZ B-VP O
7 940 952 9182899 heterozygous JJ B-ADJP O
8 953 956 9182899 for IN B-PP O
9 957 958 9182899 a DT B-NP O
10 959 967 9182899 complete JJ I-NP B-Disease
11 968 978 9182899 deficiency NN I-NP I-Disease
12 979 981 9182899 of IN B-PP I-Disease
13 982 984 9182899 C9 NN B-NP I-Disease
14 985 988 9182899 and CC B-PP O
15 989 992 9182899 for IN B-PP O
16 993 994 9182899 a DT B-NP O
17 995 999 9182899 gene NN I-NP O
18 1000 1009 9182899 directing VBG B-VP O
19 1010 1023 9182899 hyposynthesis NN B-NP O
20 1024 1026 9182899 of IN B-PP O
21 1027 1028 9182899 a DT B-NP O
22 1029 1038 9182899 defective JJ I-NP O
23 1039 1041 9182899 C9 NN I-NP O
24 1041 1042 9182899 . . O O

1 1043 1045 9182899 We PRP B-NP O
2 1046 1050 9182899 also RB B-ADVP O
3 1051 1058 9182899 suggest VBP B-VP O
4 1059 1063 9182899 that IN B-SBAR O
5 1064 1066 9182899 C9 NN B-NP B-Disease
6 1067 1077 9182899 deficiency NN I-NP I-Disease
7 1078 1081 9182899 may MD B-VP O
8 1082 1084 9182899 be VB I-VP O
9 1085 1089 9182899 more RBR B-ADJP O
10 1090 1096 9182899 common JJ I-ADJP O
11 1097 1102 9182899 among IN B-PP O
12 1103 1113 9182899 Caucasians NNPS B-NP O
13 1114 1118 9182899 than IN B-SBAR O
14 1119 1122 9182899 has VBZ B-VP O
15 1123 1127 9182899 been VBN I-VP O
16 1128 1136 9182899 reported VBN I-VP O
17 1136 1137 9182899 . . O O
18 1137 1138 9182899 . . O O

1 0 0 9138149 -DOCSTART- -X- -X- O

1 0 3 9138149 The DT B-NP O
2 4 13 9138149 incidence NN I-NP O
3 14 16 9138149 of IN B-PP O
4 17 21 9138149 PAX6 NN B-NP O
5 22 30 9138149 mutation NN I-NP O
6 31 33 9138149 in IN B-PP O
7 34 42 9138149 patients NNS B-NP O
8 43 47 9138149 with IN B-PP O
9 48 54 9138149 simple JJ B-NP O
10 55 63 9138149 aniridia NN I-NP B-Disease
11 63 64 9138149 : : O O
12 65 67 9138149 an DT B-NP O
13 68 78 9138149 evaluation NN I-NP O
14 79 81 9138149 of IN B-PP O
15 82 90 9138149 mutation NN B-NP O
16 91 100 9138149 detection NN I-NP O
17 101 103 9138149 in IN B-PP O
18 104 106 9138149 12 CD B-NP O
19 107 112 9138149 cases NNS I-NP O
20 112 113 9138149 . . O O
21 114 120 9138149 Twelve CD B-NP O
22 121 129 9138149 aniridia NN I-NP B-Disease
23 130 138 9138149 patients NNS I-NP O
24 138 139 9138149 , , O O
25 140 144 9138149 five CD B-NP O
26 145 149 9138149 with IN B-PP O
27 150 151 9138149 a DT B-NP O
28 152 158 9138149 family NN I-NP O
29 159 166 9138149 history NN I-NP O
30 167 170 9138149 and CC O O
31 171 176 9138149 seven CD B-NP O
32 177 185 9138149 presumed VBN B-VP O
33 186 188 9138149 to TO I-VP O
34 189 191 9138149 be VB I-VP O
35 192 200 9138149 sporadic JJ B-ADJP O
36 200 201 9138149 , , O O
37 202 206 9138149 were VBD B-VP O
38 207 219 9138149 exhaustively RB I-VP O
39 220 228 9138149 screened VBN I-VP O
40 229 231 9138149 in IN B-SBAR O
41 232 237 9138149 order NN O O
42 238 240 9138149 to TO B-VP O
43 241 245 9138149 test VB I-VP O
44 246 250 9138149 what WP B-NP O
45 251 261 9138149 proportion NN I-NP O
46 262 264 9138149 of IN B-PP O
47 265 271 9138149 people NNS B-NP O
48 272 276 9138149 with IN B-PP O
49 277 285 9138149 aniridia NN B-NP B-Disease
50 285 286 9138149 , , O O
51 287 300 9138149 uncomplicated VBN B-VP O
52 301 303 9138149 by IN B-PP O
53 304 314 9138149 associated VBN B-NP O
54 315 324 9138149 anomalies NNS I-NP O
55 324 325 9138149 , , O O
56 326 331 9138149 carry VBP B-VP O
57 332 341 9138149 mutations NNS B-NP O
58 342 344 9138149 in IN B-PP O
59 345 348 9138149 the DT B-NP O
60 349 354 9138149 human JJ I-NP O
61 355 359 9138149 PAX6 NN I-NP O
62 360 364 9138149 gene NN I-NP O
63 364 365 9138149 . . O O

1 366 375 9138149 Mutations NNS B-NP O
2 376 380 9138149 were VBD B-VP O
3 381 389 9138149 detected VBN I-VP O
4 390 392 9138149 in IN B-PP O
5 393 396 9138149 90% CD B-NP O
6 397 399 9138149 of IN B-PP O
7 400 403 9138149 the DT B-NP O
8 404 409 9138149 cases NNS I-NP O
9 409 410 9138149 . . O O

1 411 416 9138149 Three CD B-NP O
2 417 425 9138149 mutation NN I-NP O
3 426 435 9138149 detection NN I-NP O
4 436 446 9138149 techniques NNS I-NP O
5 447 451 9138149 were VBD B-VP O
6 452 456 9138149 used VBN I-VP O
7 457 459 9138149 to TO B-VP O
8 460 469 9138149 determine VB I-VP O
9 470 472 9138149 if IN B-SBAR O
10 473 476 9138149 one CD B-NP O
11 477 483 9138149 method NN I-NP O
12 484 487 9138149 was VBD B-VP O
13 488 496 9138149 superior JJ B-ADJP O
14 497 500 9138149 for IN B-PP O
15 501 505 9138149 this DT B-NP O
16 506 510 9138149 gene NN I-NP O
17 510 511 9138149 . . O O

1 512 515 9138149 The DT B-NP O
2 516 523 9138149 protein NN I-NP O
3 524 534 9138149 truncation NN I-NP O
4 535 539 9138149 test NN I-NP O
5 540 541 9138149 ( ( O O
6 541 544 9138149 PTT NN B-NP O
7 544 545 9138149 ) ) O O
8 546 549 9138149 was VBD B-VP O
9 550 554 9138149 used VBN I-VP O
10 555 557 9138149 on IN B-PP O
11 558 560 9138149 RT NN B-NP O
12 560 561 9138149 - HYPH I-NP O
13 561 564 9138149 PCR NN I-NP O
14 565 573 9138149 products NNS I-NP O
15 573 574 9138149 , , O O
16 575 579 9138149 SSCP NN B-NP O
17 580 582 9138149 on IN B-PP O
18 583 590 9138149 genomic JJ B-NP O
19 591 594 9138149 PCR NN I-NP O
20 595 609 9138149 amplifications NNS I-NP O
21 609 610 9138149 , , O O
22 611 614 9138149 and CC O O
23 615 623 9138149 chemical JJ B-NP O
24 624 632 9138149 cleavage NN I-NP O
25 633 635 9138149 of IN B-PP O
26 636 644 9138149 mismatch NN B-NP O
27 645 647 9138149 on IN B-PP O
28 648 652 9138149 both CC O O
29 653 655 9138149 RT NN B-NP O
30 655 656 9138149 - HYPH B-NP O
31 656 659 9138149 PCR NN I-NP O
32 660 663 9138149 and CC O O
33 664 671 9138149 genomic JJ B-NP O
34 672 686 9138149 amplifications NNS I-NP O
35 686 687 9138149 . . O O

1 688 691 9138149 For IN B-PP O
2 692 694 9138149 RT NN B-NP O
3 694 695 9138149 - HYPH B-NP O
4 695 698 9138149 PCR NN I-NP O
5 699 707 9138149 products NNS I-NP O
6 707 708 9138149 , , O O
7 709 713 9138149 only RB B-NP O
8 714 717 9138149 the DT I-NP O
9 718 728 9138149 translated VBN I-NP O
10 729 736 9138149 portion NN I-NP O
11 737 739 9138149 of IN B-PP O
12 740 743 9138149 the DT B-NP O
13 744 748 9138149 gene NN I-NP O
14 749 752 9138149 was VBD B-VP O
15 753 761 9138149 screened VBN I-VP O
16 761 762 9138149 . . O O

1 763 765 9138149 On IN B-PP O
2 766 773 9138149 genomic JJ B-NP O
3 774 782 9138149 products NNS I-NP O
4 783 788 9138149 exons NNS I-NP O
5 789 790 9138149 1 CD B-NP O
6 791 793 9138149 to TO B-PP O
7 794 796 9138149 13 CD B-NP O
8 797 798 9138149 ( ( O O
9 798 807 9138149 including VBG B-PP O
10 808 811 9138149 740 CD B-NP O
11 812 814 9138149 bp NN I-NP O
12 815 817 9138149 of IN B-PP O
13 818 821 9138149 the DT B-NP O
14 822 823 9138149 3 CD I-NP O
15 824 836 9138149 untranslated JJ I-NP O
16 837 845 9138149 sequence NN I-NP O
17 846 849 9138149 and CC O O
18 850 853 9138149 all DT B-NP O
19 854 860 9138149 intron NN I-NP O
20 860 861 9138149 / SYM B-VP O
21 861 865 9138149 exon NN B-NP O
22 866 876 9138149 boundaries NNS I-NP O
23 876 877 9138149 ) ) O O
24 878 882 9138149 were VBD B-VP O
25 883 891 9138149 screened VBN I-VP O
26 891 892 9138149 , , O O
27 893 895 9138149 as IN B-SBAR O
28 896 899 9138149 was VBD B-VP O
29 900 901 9138149 a DT B-NP O
30 902 913 9138149 neuroretina NN I-NP O
31 914 922 9138149 specific JJ I-NP O
32 923 931 9138149 enhancer NN I-NP O
33 932 934 9138149 in IN B-PP O
34 935 941 9138149 intron NN B-NP O
35 942 943 9138149 4 CD I-NP O
36 943 944 9138149 . . O O

1 945 948 9138149 Ten CD B-NP O
2 949 951 9138149 of IN B-PP O
3 952 955 9138149 the DT B-NP O
4 956 964 9138149 possible JJ I-NP O
5 965 967 9138149 12 CD I-NP O
6 968 977 9138149 mutations NNS I-NP O
7 978 980 9138149 in IN B-PP O
8 981 984 9138149 the DT B-NP O
9 985 989 9138149 five CD I-NP O
10 990 998 9138149 familial JJ I-NP O
11 999 1004 9138149 cases NNS I-NP O
12 1005 1008 9138149 and CC O O
13 1009 1013 9138149 five CD B-NP O
14 1014 1016 9138149 of IN B-PP O
15 1017 1020 9138149 the DT B-NP O
16 1021 1029 9138149 sporadic JJ I-NP O
17 1030 1038 9138149 patients NNS I-NP O
18 1039 1043 9138149 were VBD B-VP O
19 1044 1049 9138149 found VBN I-VP O
20 1049 1050 9138149 , , O O
21 1051 1054 9138149 all DT B-NP O
22 1055 1057 9138149 of IN B-PP O
23 1058 1063 9138149 which WDT B-NP O
24 1064 1073 9138149 conformed VBD B-VP O
25 1074 1076 9138149 to TO B-PP O
26 1077 1078 9138149 a DT B-NP O
27 1079 1089 9138149 functional JJ I-NP O
28 1090 1097 9138149 outcome NN I-NP O
29 1098 1100 9138149 of IN B-PP O
30 1101 1119 9138149 haploinsufficiency NN B-NP O
31 1119 1120 9138149 . . O O

1 1121 1125 9138149 Five CD B-NP O
2 1126 1130 9138149 were VBD B-VP O
3 1131 1137 9138149 splice NN B-NP O
4 1138 1142 9138149 site NN I-NP O
5 1143 1152 9138149 mutations NNS I-NP O
6 1153 1154 9138149 ( ( O O
7 1154 1157 9138149 one CD B-NP O
8 1158 1160 9138149 in IN B-PP O
9 1161 1164 9138149 the DT B-NP O
10 1165 1170 9138149 donor NN I-NP O
11 1171 1175 9138149 site NN I-NP O
12 1176 1178 9138149 of IN B-PP O
13 1179 1185 9138149 intron NN B-NP O
14 1186 1187 9138149 4 CD I-NP O
15 1187 1188 9138149 , , I-NP O
16 1189 1192 9138149 two CD I-NP O
17 1193 1195 9138149 in IN B-PP O
18 1196 1199 9138149 the DT B-NP O
19 1200 1205 9138149 donor NN I-NP O
20 1206 1210 9138149 site NN I-NP O
21 1211 1213 9138149 of IN B-PP O
22 1214 1220 9138149 intron NN B-NP O
23 1221 1222 9138149 6 CD I-NP O
24 1222 1223 9138149 , , I-NP O
25 1224 1227 9138149 one CD I-NP O
26 1228 1230 9138149 in IN B-PP O
27 1231 1235 9138149 each DT B-NP O
28 1236 1238 9138149 of IN B-PP O
29 1239 1242 9138149 the DT B-NP O
30 1243 1251 9138149 acceptor NN I-NP O
31 1252 1257 9138149 sites NNS I-NP O
32 1258 1260 9138149 of IN B-PP O
33 1261 1268 9138149 introns NNS B-NP O
34 1269 1270 9138149 8 CD B-NP O
35 1271 1274 9138149 and CC I-NP O
36 1275 1276 9138149 9 CD I-NP O
37 1276 1277 9138149 ) ) O O
38 1278 1281 9138149 and CC O O
39 1282 1286 9138149 five CD B-NP O
40 1287 1291 9138149 were VBD B-VP O
41 1292 1300 9138149 nonsense JJ B-NP O
42 1301 1310 9138149 mutations NNS I-NP O
43 1311 1313 9138149 in IN B-PP O
44 1314 1319 9138149 exons NNS B-NP O
45 1320 1321 9138149 8 CD I-NP O
46 1321 1322 9138149 , , I-NP O
47 1323 1324 9138149 9 CD I-NP O
48 1324 1325 9138149 , , I-NP O
49 1326 1328 9138149 10 CD I-NP O
50 1328 1329 9138149 , , I-NP O
51 1330 1332 9138149 11 CD I-NP O
52 1332 1333 9138149 , , O O
53 1334 1337 9138149 and CC O O
54 1338 1340 9138149 12 CD B-NP O
55 1340 1341 9138149 . . O O

1 1342 1346 9138149 SSCP NN B-NP O
2 1347 1355 9138149 analysis NN I-NP O
3 1356 1358 9138149 of IN B-PP O
4 1359 1371 9138149 individually RB B-NP O
5 1372 1381 9138149 amplified VBN I-NP O
6 1382 1387 9138149 exons NNS I-NP O
7 1387 1388 9138149 , , O O
8 1389 1393 9138149 with IN B-PP O
9 1394 1399 9138149 which WDT B-NP O
10 1400 1404 9138149 nine CD B-NP O
11 1405 1407 9138149 of IN B-PP O
12 1408 1411 9138149 the DT B-NP O
13 1412 1414 9138149 10 CD I-NP O
14 1415 1424 9138149 mutations NNS I-NP O
15 1425 1429 9138149 were VBD B-VP O
16 1430 1434 9138149 seen VBN I-VP O
17 1434 1435 9138149 , , O O
18 1436 1439 9138149 was VBD B-VP O
19 1440 1443 9138149 the DT B-NP O
20 1444 1448 9138149 most RBS I-NP O
21 1449 1455 9138149 useful JJ I-NP O
22 1456 1465 9138149 detection NN I-NP O
23 1466 1472 9138149 method NN I-NP O
24 1473 1476 9138149 for IN B-PP O
25 1477 1481 9138149 PAX6 NN B-NP O
26 1481 1482 9138149 . . O O
27 1482 1483 9138149 . . O O

1 0 0 8673131 -DOCSTART- -X- -X- O

1 0 8 8673131 Abnormal JJ B-NP O
2 9 17 8673131 myotonic JJ I-NP B-Disease
3 18 27 8673131 dystrophy NN I-NP I-Disease
4 28 35 8673131 protein NN I-NP O
5 36 42 8673131 kinase NN I-NP O
6 43 49 8673131 levels NNS I-NP O
7 50 57 8673131 produce VBP B-VP O
8 58 62 8673131 only RB B-NP O
9 63 67 8673131 mild JJ I-NP O
10 68 76 8673131 myopathy NN I-NP B-Disease
11 77 79 8673131 in IN B-PP O
12 80 84 8673131 mice NNS B-NP O
13 84 85 8673131 . . O O
14 86 94 8673131 Myotonic JJ B-NP B-Disease
15 95 104 8673131 dystrophy NN I-NP I-Disease
16 105 106 8673131 ( ( O O
17 106 108 8673131 DM NN B-NP B-Disease
18 108 109 8673131 ) ) O O
19 110 112 8673131 is VBZ B-VP O
20 113 121 8673131 commonly RB I-VP O
21 122 132 8673131 associated VBN I-VP O
22 133 137 8673131 with IN B-PP O
23 138 141 8673131 CTG NN B-NP O
24 142 148 8673131 repeat NN I-NP O
25 149 159 8673131 expansions NNS I-NP O
26 160 166 8673131 within IN B-PP O
27 167 170 8673131 the DT B-NP O
28 171 175 8673131 gene NN I-NP O
29 176 179 8673131 for IN B-PP O
30 180 182 8673131 DM NN B-NP O
31 182 183 8673131 - HYPH O O
32 183 190 8673131 protein NN B-NP O
33 191 197 8673131 kinase NN I-NP O
34 198 199 8673131 ( ( O O
35 199 203 8673131 DMPK NN B-NP O
36 203 204 8673131 ) ) O O
37 204 205 8673131 . . O O

1 206 209 8673131 The DT B-NP O
2 210 216 8673131 effect NN I-NP O
3 217 219 8673131 of IN B-PP O
4 220 227 8673131 altered VBN B-NP O
5 228 238 8673131 expression NN I-NP O
6 239 245 8673131 levels NNS I-NP O
7 246 248 8673131 of IN B-PP O
8 249 253 8673131 DMPK NN B-NP O
9 253 254 8673131 , , O O
10 255 260 8673131 which WDT B-NP O
11 261 263 8673131 is VBZ B-VP O
12 264 276 8673131 ubiquitously RB I-VP O
13 277 286 8673131 expressed VBN I-VP O
14 287 289 8673131 in IN B-PP O
15 290 293 8673131 all DT B-NP O
16 294 300 8673131 muscle NN I-NP O
17 301 305 8673131 cell NN I-NP O
18 306 314 8673131 lineages NNS I-NP O
19 315 321 8673131 during IN B-PP O
20 322 333 8673131 development NN B-NP O
21 333 334 8673131 , , O O
22 335 338 8673131 was VBD B-VP O
23 339 347 8673131 examined VBN I-VP O
24 348 350 8673131 by IN B-PP O
25 351 361 8673131 disrupting VBG B-VP O
26 362 365 8673131 the DT B-NP O
27 366 376 8673131 endogenous JJ I-NP O
28 377 381 8673131 Dmpk NN I-NP O
29 382 386 8673131 gene NN I-NP O
30 387 390 8673131 and CC O O
31 391 405 8673131 overexpressing VBG B-VP O
32 406 407 8673131 a DT B-NP O
33 408 414 8673131 normal JJ I-NP O
34 415 420 8673131 human JJ I-NP O
35 421 425 8673131 DMPK NN I-NP O
36 426 435 8673131 transgene NN I-NP O
37 436 438 8673131 in IN B-PP O
38 439 443 8673131 mice NNS B-NP O
39 443 444 8673131 . . O O

1 445 456 8673131 Nullizygous JJ B-ADJP O
2 457 458 8673131 ( ( O O
3 458 459 8673131 - SYM O O
4 459 460 8673131 / SYM O O
5 460 461 8673131 - SYM O O
6 461 462 8673131 ) ) O O
7 463 467 8673131 mice NNS B-NP O
8 468 474 8673131 showed VBD B-VP O
9 475 479 8673131 only RB B-NP O
10 480 492 8673131 inconsistent JJ I-NP O
11 493 496 8673131 and CC I-NP O
12 497 502 8673131 minor JJ I-NP O
13 503 507 8673131 size NN I-NP O
14 508 515 8673131 changes NNS I-NP O
15 516 518 8673131 in IN B-PP O
16 519 523 8673131 head NN B-NP O
17 524 527 8673131 and CC I-NP O
18 528 532 8673131 neck NN I-NP O
19 533 539 8673131 muscle NN I-NP O
20 540 546 8673131 fibres NNS I-NP O
21 547 549 8673131 at IN B-PP O
22 550 555 8673131 older JJR B-NP O
23 556 559 8673131 age NN I-NP O
24 559 560 8673131 , , O O
25 561 568 8673131 animals NNS B-NP O
26 569 573 8673131 with IN B-PP O
27 574 577 8673131 the DT B-NP O
28 578 585 8673131 highest JJS I-NP O
29 586 590 8673131 DMPK NN I-NP O
30 591 600 8673131 transgene NN I-NP O
31 601 611 8673131 expression NN I-NP O
32 612 618 8673131 showed VBD B-VP O
33 619 631 8673131 hypertrophic JJ B-NP B-Disease
34 632 646 8673131 cardiomyopathy NN I-NP I-Disease
35 647 650 8673131 and CC O O
36 651 659 8673131 enhanced VBD B-VP O
37 660 668 8673131 neonatal JJ B-NP O
38 669 678 8673131 mortality NN I-NP O
39 678 679 8673131 . . O O

1 680 687 8673131 However RB B-ADVP O
2 687 688 8673131 , , O O
3 689 693 8673131 both DT B-NP O
4 694 700 8673131 models NNS I-NP O
5 701 705 8673131 lack VBP B-VP O
6 706 711 8673131 other JJ B-NP O
7 712 720 8673131 frequent JJ I-NP O
8 721 723 8673131 DM NN I-NP B-Disease
9 724 732 8673131 symptoms NNS I-NP O
10 733 742 8673131 including VBG B-PP O
11 743 746 8673131 the DT B-NP O
12 747 752 8673131 fibre NN I-NP O
13 752 753 8673131 - HYPH I-NP O
14 753 757 8673131 type NN I-NP O
15 758 767 8673131 dependent JJ I-NP O
16 768 775 8673131 atrophy NN I-NP B-Disease
17 775 776 8673131 , , O O
18 777 785 8673131 myotonia NN B-NP B-Disease
19 785 786 8673131 , , O O
20 787 795 8673131 cataract NN B-NP B-Disease
21 796 799 8673131 and CC O O
22 800 804 8673131 male JJ B-NP B-Disease
23 804 805 8673131 - HYPH I-NP I-Disease
24 805 816 8673131 infertility NN I-NP I-Disease
25 816 817 8673131 . . O O

1 818 823 8673131 These DT B-NP O
2 824 831 8673131 results NNS I-NP O
3 832 842 8673131 strengthen VBP B-VP O
4 843 846 8673131 the DT B-NP O
5 847 857 8673131 contention NN I-NP O
6 858 862 8673131 that IN B-SBAR O
7 863 869 8673131 simple JJ B-NP O
8 870 874 8673131 loss NN I-NP O
9 874 875 8673131 - HYPH B-NP O
10 876 878 8673131 or CC I-NP O
11 879 883 8673131 gain NN I-NP O
12 883 884 8673131 - HYPH B-NP O
13 884 886 8673131 of IN B-PP O
14 886 887 8673131 - HYPH B-NP O
15 887 897 8673131 expression NN I-NP O
16 898 900 8673131 of IN B-PP O
17 901 905 8673131 DMPK NN B-NP O
18 906 908 8673131 is VBZ B-VP O
19 909 912 8673131 not RB O O
20 913 916 8673131 the DT B-NP O
21 917 921 8673131 only JJ I-NP O
22 922 929 8673131 crucial JJ I-NP O
23 930 941 8673131 requirement NN I-NP O
24 942 945 8673131 for IN B-PP O
25 946 957 8673131 development NN B-NP O
26 958 960 8673131 of IN B-PP O
27 961 964 8673131 the DT B-NP O
28 965 972 8673131 disease NN I-NP O
29 972 973 8673131 . . O O
30 973 974 8673131 . . O O

1 0 0 8929264 -DOCSTART- -X- -X- O

1 0 3 8929264 The DT B-NP O
2 4 7 8929264 DCC NN I-NP O
3 8 15 8929264 protein NN I-NP O
4 16 19 8929264 and CC I-NP O
5 20 29 8929264 prognosis NN I-NP O
6 30 32 8929264 in IN B-PP O
7 33 43 8929264 colorectal JJ B-NP B-Disease
8 44 50 8929264 cancer NN I-NP I-Disease
9 50 51 8929264 . . O O
10 52 62 8929264 BACKGROUND NN B-NP O
11 64 71 8929264 Allelic JJ I-NP O
12 72 76 8929264 loss NN I-NP O
13 77 79 8929264 of IN B-PP O
14 80 90 8929264 chromosome NN B-NP O
15 91 94 8929264 18q NN I-NP O
16 95 103 8929264 predicts VBZ B-VP O
17 104 105 8929264 a DT B-NP O
18 106 110 8929264 poor JJ I-NP O
19 111 118 8929264 outcome NN I-NP O
20 119 121 8929264 in IN B-PP O
21 122 130 8929264 patients NNS B-NP O
22 131 135 8929264 with IN B-PP O
23 136 141 8929264 stage NN B-NP B-Disease
24 142 144 8929264 II CD I-NP I-Disease
25 145 155 8929264 colorectal JJ I-NP I-Disease
26 156 162 8929264 cancer NN I-NP I-Disease
27 162 163 8929264 . . O O

1 164 172 8929264 Although IN B-SBAR O
2 173 176 8929264 the DT B-NP O
3 177 185 8929264 specific JJ I-NP O
4 186 190 8929264 gene NN I-NP O
5 191 202 8929264 inactivated VBN B-VP O
6 203 205 8929264 by IN B-PP O
7 206 210 8929264 this DT B-NP O
8 211 218 8929264 allelic JJ I-NP O
9 219 223 8929264 loss NN I-NP O
10 224 227 8929264 has VBZ B-VP O
11 228 231 8929264 not RB I-VP O
12 232 236 8929264 been VBN I-VP O
13 237 247 8929264 elucidated VBN I-VP O
14 247 248 8929264 , , O O
15 249 252 8929264 the DT B-NP O
16 253 256 8929264 DCC NN I-NP O
17 257 258 8929264 ( ( O O
18 258 265 8929264 deleted VBN B-VP O
19 266 268 8929264 in IN B-PP O
20 269 279 8929264 colorectal JJ B-NP B-Disease
21 280 286 8929264 cancer NN I-NP I-Disease
22 286 287 8929264 ) ) O O
23 288 292 8929264 gene NN B-NP O
24 293 295 8929264 is VBZ B-VP O
25 296 297 8929264 a DT B-NP O
26 298 307 8929264 candidate NN I-NP O
27 307 308 8929264 . . O O

1 309 311 8929264 We PRP B-NP O
2 312 324 8929264 investigated VBD B-VP O
3 325 332 8929264 whether IN B-SBAR O
4 333 336 8929264 the DT B-NP O
5 337 347 8929264 expression NN I-NP O
6 348 350 8929264 of IN B-PP O
7 351 354 8929264 the DT B-NP O
8 355 358 8929264 DCC NN I-NP O
9 359 366 8929264 protein NN I-NP O
10 367 369 8929264 in IN B-PP O
11 370 375 8929264 tumor NN B-NP B-Disease
12 376 381 8929264 cells NNS I-NP O
13 382 384 8929264 is VBZ B-VP O
14 385 386 8929264 a DT B-NP O
15 387 397 8929264 prognostic JJ I-NP O
16 398 404 8929264 marker NN I-NP O
17 405 407 8929264 in IN B-PP O
18 408 418 8929264 colorectal JJ B-NP B-Disease
19 419 428 8929264 carcinoma NN I-NP I-Disease
20 428 429 8929264 . . O O

1 430 437 8929264 METHODS NNS B-NP O
2 439 442 8929264 The DT B-NP O
3 443 453 8929264 expression NN I-NP O
4 454 456 8929264 of IN B-PP O
5 457 460 8929264 DCC NN B-NP O
6 461 464 8929264 was VBD B-VP O
7 465 474 8929264 evaluated VBN I-VP O
8 475 496 8929264 immunohistochemically RB B-ADVP O
9 497 499 8929264 in IN B-PP O
10 500 503 8929264 132 CD B-NP O
11 504 512 8929264 paraffin NN I-NP O
12 512 513 8929264 - HYPH O O
13 513 521 8929264 embedded VBN B-VP O
14 522 529 8929264 samples NNS B-NP O
15 530 534 8929264 from IN B-PP O
16 535 543 8929264 patients NNS B-NP O
17 544 548 8929264 with IN B-PP O
18 549 559 8929264 curatively RB B-NP O
19 560 568 8929264 resected VBN I-NP O
20 569 574 8929264 stage NN I-NP B-Disease
21 575 577 8929264 II CD I-NP I-Disease
22 578 581 8929264 and CC I-NP I-Disease
23 582 585 8929264 III CD I-NP I-Disease
24 586 596 8929264 colorectal JJ I-NP I-Disease
25 597 607 8929264 carcinomas NNS I-NP I-Disease
26 607 608 8929264 . . O O

1 609 612 8929264 The DT B-NP O
2 613 616 8929264 Cox NNP I-NP O
3 617 629 8929264 proportional JJ I-NP O
4 629 630 8929264 - HYPH I-NP O
5 630 637 8929264 hazards NNS I-NP O
6 638 643 8929264 model NN I-NP O
7 644 647 8929264 was VBD B-VP O
8 648 652 8929264 used VBN I-VP O
9 653 655 8929264 to TO B-VP O
10 656 662 8929264 adjust VB I-VP O
11 663 666 8929264 for IN B-PP O
12 667 677 8929264 covariates NNS B-NP O
13 678 687 8929264 including VBG B-PP O
14 688 691 8929264 age NN B-NP O
15 691 692 8929264 , , O O
16 693 696 8929264 sex NN B-NP O
17 696 697 8929264 , , O O
18 698 703 8929264 tumor NN B-NP B-Disease
19 704 708 8929264 site NN I-NP O
20 708 709 8929264 , , O O
21 710 716 8929264 degree NN B-NP O
22 717 719 8929264 of IN B-PP O
23 720 725 8929264 tumor NN B-NP B-Disease
24 726 741 8929264 differentiation NN I-NP O
25 741 742 8929264 , , O O
26 743 746 8929264 and CC O O
27 747 750 8929264 use NN B-NP O
28 751 753 8929264 of IN B-PP O
29 754 762 8929264 adjuvant JJ B-NP O
30 763 770 8929264 therapy NN I-NP O
31 770 771 8929264 . . O O

1 772 779 8929264 RESULTS NNS B-NP O
2 781 784 8929264 The DT B-NP O
3 785 795 8929264 expression NN I-NP O
4 796 798 8929264 of IN B-PP O
5 799 802 8929264 DCC NN B-NP O
6 803 806 8929264 was VBD B-VP O
7 807 808 8929264 a DT B-NP O
8 809 815 8929264 strong JJ I-NP O
9 816 824 8929264 positive JJ I-NP O
10 825 835 8929264 predictive JJ I-NP O
11 836 842 8929264 factor NN I-NP O
12 843 846 8929264 for IN B-PP O
13 847 855 8929264 survival NN B-NP O
14 856 858 8929264 in IN B-PP O
15 859 863 8929264 both CC O O
16 864 869 8929264 stage NN B-NP B-Disease
17 870 872 8929264 II CD I-NP I-Disease
18 873 876 8929264 and CC O I-Disease
19 877 882 8929264 stage NN B-NP I-Disease
20 883 886 8929264 III CD I-NP I-Disease
21 887 897 8929264 colorectal JJ I-NP I-Disease
22 898 908 8929264 carcinomas NNS I-NP I-Disease
23 908 909 8929264 . . O O

1 910 912 8929264 In IN B-PP O
2 913 921 8929264 patients NNS B-NP O
3 922 926 8929264 with IN B-PP O
4 927 932 8929264 stage NN B-NP O
5 933 935 8929264 II CD I-NP O
6 936 943 8929264 disease NN I-NP O
7 944 949 8929264 whose WP$ B-NP O
8 950 956 8929264 tumors NNS I-NP B-Disease
9 957 966 8929264 expressed VBD B-VP O
10 967 970 8929264 DCC NN B-NP O
11 970 971 8929264 , , O O
12 972 975 8929264 the DT B-NP O
13 976 980 8929264 five CD I-NP O
14 980 981 8929264 - HYPH I-NP O
15 981 985 8929264 year NN I-NP O
16 986 994 8929264 survival NN I-NP O
17 995 999 8929264 rate NN I-NP O
18 1000 1003 8929264 was VBD B-VP O
19 1004 1006 8929264 94 CD B-NP O
20 1006 1007 8929264 . . O O

1 1008 1009 8929264 3 CD B-NP O
2 1010 1017 8929264 percent NN I-NP O
3 1017 1018 8929264 , , O O
4 1019 1026 8929264 whereas IN O O
5 1027 1029 8929264 in IN B-PP O
6 1030 1038 8929264 patients NNS B-NP O
7 1039 1043 8929264 with IN B-PP O
8 1044 1047 8929264 DCC NN B-NP B-Disease
9 1047 1048 8929264 - HYPH B-NP I-Disease
10 1048 1056 8929264 negative JJ I-NP I-Disease
11 1057 1063 8929264 tumors NNS I-NP I-Disease
12 1063 1064 8929264 , , O O
13 1065 1068 8929264 the DT B-NP O
14 1069 1077 8929264 survival NN I-NP O
15 1078 1082 8929264 rate NN I-NP O
16 1083 1086 8929264 was VBD B-VP O
17 1087 1089 8929264 61 CD B-NP O
18 1089 1090 8929264 . . O O

1 1091 1092 8929264 6 CD B-NP O
2 1093 1100 8929264 percent NN I-NP O
3 1101 1102 8929264 ( ( O O
4 1102 1103 8929264 P NN B-NP O
5 1104 1105 8929264 < SYM O O
6 1106 1107 8929264 0 CD B-NP O
7 1107 1108 8929264 . . O O

1 1109 1112 8929264 001 CD B-NP O
2 1112 1113 8929264 ) ) O O
3 1113 1114 8929264 . . O O

1 1115 1117 8929264 In IN B-PP O
2 1118 1126 8929264 patients NNS B-NP O
3 1127 1131 8929264 with IN B-PP O
4 1132 1137 8929264 stage NN B-NP B-Disease
5 1138 1141 8929264 III CD I-NP I-Disease
6 1142 1149 8929264 disease NN I-NP I-Disease
7 1149 1150 8929264 , , O O
8 1151 1154 8929264 the DT B-NP O
9 1155 1165 8929264 respective JJ I-NP O
10 1166 1174 8929264 survival NN I-NP O
11 1175 1180 8929264 rates NNS I-NP O
12 1181 1185 8929264 were VBD B-VP O
13 1186 1188 8929264 59 CD B-NP O
14 1188 1189 8929264 . . O O

1 1190 1191 8929264 3 CD B-NP O
2 1192 1199 8929264 percent NN I-NP O
3 1200 1203 8929264 and CC O O
4 1204 1206 8929264 33 CD B-NP O
5 1206 1207 8929264 . . O O

1 1208 1209 8929264 2 CD B-NP O
2 1210 1217 8929264 percent NN I-NP O
3 1218 1219 8929264 ( ( O O
4 1219 1220 8929264 P NN B-NP O
5 1221 1222 8929264 = SYM B-VP O
6 1223 1224 8929264 0 CD B-NP O
7 1224 1225 8929264 . . O O

1 1226 1228 8929264 03 CD B-NP O
2 1228 1229 8929264 ) ) O O
3 1229 1230 8929264 . . O O

1 1231 1242 8929264 CONCLUSIONS NNS B-NP O
2 1244 1247 8929264 DCC NN I-NP O
3 1248 1250 8929264 is VBZ B-VP O
4 1251 1252 8929264 a DT B-NP O
5 1253 1263 8929264 prognostic JJ I-NP O
6 1264 1270 8929264 marker NN I-NP O
7 1271 1273 8929264 in IN B-PP O
8 1274 1282 8929264 patients NNS B-NP O
9 1283 1287 8929264 with IN B-PP O
10 1288 1293 8929264 stage NN B-NP B-Disease
11 1294 1296 8929264 II CD I-NP I-Disease
12 1297 1299 8929264 or CC O I-Disease
13 1300 1305 8929264 stage NN B-NP I-Disease
14 1306 1309 8929264 III CD I-NP I-Disease
15 1310 1320 8929264 colorectal JJ I-NP I-Disease
16 1321 1327 8929264 cancer NN I-NP I-Disease
17 1327 1328 8929264 . . O O

1 1329 1331 8929264 In IN B-PP O
2 1332 1337 8929264 stage NN B-NP B-Disease
3 1338 1340 8929264 II CD I-NP I-Disease
4 1341 1351 8929264 colorectal JJ I-NP I-Disease
5 1352 1362 8929264 carcinomas NNS I-NP I-Disease
6 1362 1363 8929264 , , O O
7 1364 1367 8929264 the DT B-NP O
8 1368 1375 8929264 absence NN I-NP O
9 1376 1378 8929264 of IN B-PP O
10 1379 1382 8929264 DCC NN B-NP O
11 1383 1393 8929264 identifies VBZ B-VP O
12 1394 1395 8929264 a DT B-NP O
13 1396 1404 8929264 subgroup NN I-NP O
14 1405 1407 8929264 of IN B-PP O
15 1408 1416 8929264 patients NNS B-NP O
16 1417 1421 8929264 with IN B-PP O
17 1422 1429 8929264 lesions NNS B-NP O
18 1430 1434 8929264 that WDT B-NP O
19 1435 1441 8929264 behave VBP B-VP O
20 1442 1446 8929264 like IN B-PP O
21 1447 1452 8929264 stage NN B-NP B-Disease
22 1453 1456 8929264 III CD B-NP I-Disease
23 1457 1464 8929264 cancers NNS I-NP I-Disease
24 1464 1465 8929264 . . O O

1 1466 1471 8929264 These DT B-NP O
2 1472 1480 8929264 findings NNS I-NP O
3 1481 1484 8929264 may MD B-VP O
4 1485 1489 8929264 thus RB I-VP O
5 1490 1494 8929264 have VB I-VP O
6 1495 1506 8929264 therapeutic JJ B-NP O
7 1507 1519 8929264 implications NNS I-NP O
8 1520 1522 8929264 in IN B-PP O
9 1523 1527 8929264 this DT B-NP O
10 1528 1533 8929264 group NN I-NP O
11 1534 1536 8929264 of IN B-PP O
12 1537 1545 8929264 patients NNS B-NP O

1 0 0 9222760 -DOCSTART- -X- -X- O

1 0 9 9222760 Molecular JJ B-NP O
2 10 23 9222760 heterogeneity NN I-NP O
3 24 26 9222760 of IN B-PP O
4 27 36 9222760 classical JJ B-NP B-Disease
5 37 40 9222760 and CC I-NP I-Disease
6 41 47 9222760 Duarte JJ I-NP I-Disease
7 48 60 9222760 galactosemia NN I-NP I-Disease
8 60 61 9222760 : : O O
9 62 70 9222760 mutation NN B-NP O
10 71 79 9222760 analysis NN I-NP O
11 80 82 9222760 by IN B-PP O
12 83 93 9222760 denaturing VBG B-VP O
13 94 102 9222760 gradient NN B-NP O
14 103 106 9222760 gel NN I-NP O
15 107 122 9222760 electrophoresis NN I-NP O
16 122 123 9222760 . . O O
17 124 133 9222760 Classical JJ B-NP B-Disease
18 134 146 9222760 galactosemia NN I-NP I-Disease
19 147 149 9222760 is VBZ B-VP O
20 150 156 9222760 caused VBN I-VP O
21 157 159 9222760 by IN B-PP O
22 160 163 9222760 one CD B-NP O
23 164 170 9222760 common JJ I-NP O
24 171 179 9222760 missense JJ I-NP O
25 180 188 9222760 mutation NN I-NP O
26 189 190 9222760 ( ( O O
27 190 195 9222760 Q188R NN B-NP O
28 195 196 9222760 ) ) O O
29 197 200 9222760 and CC O O
30 201 203 9222760 by IN B-PP O
31 204 211 9222760 several JJ B-NP O
32 212 216 9222760 rare JJ I-NP O
33 217 226 9222760 mutations NNS I-NP O
34 227 229 9222760 in IN B-PP O
35 230 233 9222760 the DT B-NP O
36 234 243 9222760 galactose NN I-NP O
37 243 244 9222760 - HYPH B-NP O
38 244 245 9222760 1 CD I-NP O
39 245 246 9222760 - HYPH I-NP O
40 246 255 9222760 phosphate NN I-NP O
41 256 273 9222760 uridyltransferase NN I-NP O
42 274 275 9222760 ( ( O O
43 275 279 9222760 GALT NN B-NP O
44 279 280 9222760 ) ) O O
45 281 285 9222760 gene NN B-NP O
46 285 286 9222760 . . O O

1 287 290 9222760 The DT B-NP O
2 291 295 9222760 most RBS I-NP O
3 296 302 9222760 common JJ I-NP O
4 303 310 9222760 variant NN I-NP O
5 311 313 9222760 of IN B-PP O
6 314 318 9222760 GALT NN B-NP O
7 318 319 9222760 , , O O
8 320 323 9222760 the DT B-NP O
9 324 330 9222760 Duarte NNP I-NP O
10 331 338 9222760 variant NN I-NP O
11 338 339 9222760 , , O O
12 340 346 9222760 occurs VBZ B-VP O
13 347 349 9222760 as IN B-PP O
14 350 353 9222760 two CD B-NP O
15 354 359 9222760 types NNS I-NP O
16 359 360 9222760 , , O O
17 361 367 9222760 Duarte NNP B-NP O
18 367 368 9222760 - HYPH B-NP O
19 368 369 9222760 1 CD I-NP O
20 370 371 9222760 ( ( O O
21 371 372 9222760 D NN B-NP O
22 372 373 9222760 - HYPH B-NP O
23 373 374 9222760 1 CD I-NP O
24 374 375 9222760 ) ) O O
25 376 379 9222760 and CC O O
26 380 386 9222760 Duarte NN B-NP O
27 386 387 9222760 - HYPH O O
28 387 388 9222760 2 CD B-NP O
29 389 390 9222760 ( ( O O
30 390 391 9222760 D NN B-NP O
31 391 392 9222760 - HYPH O O
32 392 393 9222760 2 CD B-NP O
33 393 394 9222760 ) ) O O
34 394 395 9222760 , , O O
35 396 400 9222760 both DT B-NP O
36 401 403 9222760 of IN B-PP O
37 404 409 9222760 which WDT B-NP O
38 410 415 9222760 carry VBP B-VP O
39 416 419 9222760 the DT B-NP O
40 420 428 9222760 sequence NN I-NP O
41 429 435 9222760 change NN I-NP O
42 436 441 9222760 N314D NN I-NP O
43 441 442 9222760 . . O O

1 443 444 9222760 D NN B-NP O
2 444 445 9222760 - HYPH B-NP O
3 445 446 9222760 1 CD I-NP O
4 447 456 9222760 increases NNS I-NP O
5 456 457 9222760 , , O O
6 458 465 9222760 whereas IN O O
7 466 467 9222760 D NN B-NP O
8 467 468 9222760 - HYPH O O
9 468 469 9222760 2 CD B-NP O
10 470 479 9222760 decreases VBZ B-VP O
11 480 484 9222760 GALT NN B-NP O
12 485 493 9222760 activity NN I-NP O
13 493 494 9222760 . . O O

1 495 497 9222760 To TO B-VP O
2 498 503 9222760 study VB I-VP O
3 504 507 9222760 the DT B-NP O
4 508 517 9222760 molecular JJ I-NP O
5 518 526 9222760 genetics NNS I-NP O
6 527 529 9222760 of IN B-PP O
7 530 539 9222760 classical JJ B-NP B-Disease
8 540 543 9222760 and CC I-NP I-Disease
9 544 550 9222760 Duarte JJ I-NP I-Disease
10 551 563 9222760 galactosemia NN I-NP I-Disease
11 563 564 9222760 , , O O
12 565 567 9222760 we PRP B-NP O
13 568 576 9222760 analyzed VBD B-VP O
14 577 580 9222760 the DT B-NP O
15 581 585 9222760 GALT NN I-NP O
16 586 595 9222760 mutations NNS I-NP O
17 596 598 9222760 in IN B-PP O
18 599 601 9222760 30 CD B-NP O
19 602 610 9222760 families NNS I-NP O
20 611 615 9222760 with IN B-PP O
21 616 625 9222760 classical JJ B-NP B-Disease
22 626 638 9222760 galactosemia NN I-NP I-Disease
23 638 639 9222760 , , O O
24 640 642 9222760 in IN B-PP O
25 643 645 9222760 10 CD B-NP O
26 646 654 9222760 families NNS I-NP O
27 655 659 9222760 with IN B-PP O
28 660 663 9222760 the DT B-NP O
29 664 665 9222760 D NN I-NP O
30 665 666 9222760 - HYPH O O
31 666 667 9222760 2 CD B-NP O
32 668 675 9222760 variant NN I-NP O
33 676 679 9222760 and CC O O
34 680 682 9222760 in IN B-PP O
35 683 684 9222760 3 CD B-NP O
36 685 696 9222760 individuals NNS I-NP O
37 697 705 9222760 carrying VBG B-VP O
38 706 709 9222760 the DT B-NP O
39 710 711 9222760 D NN I-NP O
40 711 712 9222760 - HYPH B-NP O
41 712 713 9222760 1 CD I-NP O
42 714 720 9222760 allele NN I-NP O
43 721 723 9222760 by IN B-PP O
44 724 734 9222760 denaturing VBG B-VP O
45 735 743 9222760 gradient NN B-NP O
46 744 747 9222760 gel NN I-NP O
47 748 763 9222760 electrophoresis NN I-NP O
48 764 765 9222760 ( ( O O
49 765 769 9222760 DGGE NN B-NP O
50 769 770 9222760 ) ) O O
51 770 771 9222760 . . O O

1 772 776 9222760 DGGE NN B-NP O
2 777 785 9222760 detected VBD B-VP O
3 786 788 9222760 59 CD B-NP O
4 789 791 9222760 of IN B-PP O
5 792 795 9222760 the DT B-NP O
6 796 798 9222760 60 CD I-NP O
7 799 808 9222760 classical JJ I-NP O
8 809 821 9222760 galactosemia NN I-NP B-Disease
9 822 829 9222760 alleles NNS I-NP O
10 829 830 9222760 . . O O

1 831 836 9222760 Q188R NN B-NP O
2 837 846 9222760 accounted VBD B-VP O
3 847 850 9222760 for IN B-PP O
4 851 854 9222760 60% NN B-NP O
5 854 855 9222760 , , O O
6 856 861 9222760 K285N NN B-NP O
7 862 871 9222760 accounted VBD B-VP O
8 872 875 9222760 for IN B-PP O
9 876 879 9222760 28% CD B-NP O
10 880 882 9222760 of IN B-PP O
11 883 888 9222760 these DT B-NP O
12 889 896 9222760 alleles NNS I-NP O
13 896 897 9222760 . . O O

1 898 903 9222760 Eight CD B-NP O
2 904 909 9222760 novel JJ I-NP O
3 910 919 9222760 candidate NN I-NP O
4 920 932 9222760 galactosemia NN I-NP B-Disease
5 933 942 9222760 mutations NNS I-NP O
6 943 947 9222760 were VBD B-VP O
7 948 953 9222760 found VBN I-VP O
8 953 954 9222760 . . O O

1 955 957 9222760 On IN B-PP O
2 958 961 9222760 all DT B-NP O
3 962 963 9222760 D NN I-NP O
4 963 964 9222760 - HYPH B-NP O
5 964 965 9222760 2 CD I-NP O
6 966 973 9222760 alleles NNS I-NP O
7 974 979 9222760 N314D NN I-NP O
8 980 988 9222760 occurred VBD B-VP O
9 989 991 9222760 in IN B-PP O
10 992 995 9222760 cis NN B-NP O
11 996 1000 9222760 with IN B-PP O
12 1001 1004 9222760 two CD B-NP O
13 1005 1013 9222760 intronic JJ I-NP O
14 1014 1022 9222760 sequence NN I-NP O
15 1023 1030 9222760 changes NNS I-NP O
16 1030 1031 9222760 , , O O
17 1032 1034 9222760 on IN B-PP O
18 1035 1038 9222760 the DT B-NP O
19 1039 1040 9222760 D NN I-NP O
20 1040 1041 9222760 - HYPH B-NP O
21 1041 1042 9222760 1 CD I-NP O
22 1043 1050 9222760 alleles NNS I-NP O
23 1051 1053 9222760 in IN B-PP O
24 1054 1057 9222760 cis NN B-NP O
25 1058 1062 9222760 with IN B-PP O
26 1063 1064 9222760 a DT B-NP O
27 1065 1072 9222760 neutral JJ I-NP O
28 1073 1081 9222760 mutation NN I-NP O
29 1082 1084 9222760 in IN B-PP O
30 1085 1089 9222760 exon NN B-NP O
31 1090 1091 9222760 7 CD I-NP O
32 1091 1092 9222760 . . O O

1 1093 1095 9222760 We PRP B-NP O
2 1096 1104 9222760 conclude VBP B-VP O
3 1105 1109 9222760 that IN B-SBAR O
4 1110 1113 9222760 the DT B-NP O
5 1114 1123 9222760 mutations NNS I-NP O
6 1124 1131 9222760 causing VBG B-VP O
7 1132 1144 9222760 galactosemia NN B-NP B-Disease
8 1145 1148 9222760 are VBP B-VP O
9 1149 1155 9222760 highly RB B-ADJP O
10 1156 1169 9222760 heterogeneous JJ I-ADJP O
11 1170 1173 9222760 and CC O O
12 1174 1178 9222760 that IN B-SBAR O
13 1179 1184 9222760 K285N NN B-NP O
14 1185 1187 9222760 is VBZ B-VP O
15 1188 1189 9222760 a DT B-NP O
16 1190 1196 9222760 second JJ I-NP O
17 1197 1203 9222760 common JJ I-NP O
18 1204 1216 9222760 galactosemia NN I-NP B-Disease
19 1217 1225 9222760 mutation NN I-NP O
20 1226 1228 9222760 in IN B-PP O
21 1229 1232 9222760 our PRP$ B-NP O
22 1233 1243 9222760 population NN I-NP O
23 1243 1244 9222760 . . O O
24 1244 1245 9222760 . . O O

1 0 0 8673132 -DOCSTART- -X- -X- O

1 0 4 8673132 Mice NNS B-NP O
2 5 12 8673132 lacking VBG B-VP O
3 13 16 8673132 the DT B-NP O
4 17 25 8673132 myotonic JJ I-NP B-Disease
5 26 35 8673132 dystrophy NN I-NP I-Disease
6 36 43 8673132 protein NN I-NP O
7 44 50 8673132 kinase NN I-NP O
8 51 58 8673132 develop VBP B-VP O
9 59 60 8673132 a DT B-NP O
10 61 65 8673132 late JJ I-NP O
11 66 71 8673132 onset NN I-NP O
12 72 83 8673132 progressive JJ I-NP O
13 84 92 8673132 myopathy NN I-NP B-Disease
14 92 93 8673132 . . O O
15 94 102 8673132 Myotonic JJ B-NP B-Disease
16 103 112 8673132 dystrophy NN I-NP I-Disease
17 113 114 8673132 ( ( O O
18 114 116 8673132 DM NN B-NP B-Disease
19 116 117 8673132 ) ) O O
20 118 120 8673132 is VBZ B-VP O
21 121 123 8673132 an DT B-NP O
22 124 133 8673132 autosomal JJ I-NP B-Disease
23 134 142 8673132 dominant JJ I-NP I-Disease
24 143 151 8673132 disorder NN I-NP I-Disease
25 152 161 8673132 resulting VBG B-VP O
26 162 166 8673132 from IN B-PP O
27 167 170 8673132 the DT B-NP O
28 171 180 8673132 expansion NN I-NP O
29 181 183 8673132 of IN B-PP O
30 184 185 8673132 a DT B-NP O
31 186 189 8673132 CTG NN I-NP O
32 190 196 8673132 repeat NN I-NP O
33 197 199 8673132 in IN B-PP O
34 200 203 8673132 the DT B-NP O
35 204 205 8673132 3 CD I-NP O
36 206 218 8673132 untranslated JJ I-NP O
37 219 225 8673132 region NN I-NP O
38 226 228 8673132 of IN B-PP O
39 229 230 8673132 a DT B-NP O
40 231 239 8673132 putative JJ I-NP O
41 240 247 8673132 protein NN I-NP O
42 248 254 8673132 kinase NN I-NP O
43 255 256 8673132 ( ( O O
44 256 260 8673132 DMPK NN B-NP O
45 260 261 8673132 ) ) O O
46 261 262 8673132 . . O O

1 263 265 8673132 To TO B-VP O
2 266 275 8673132 elucidate VB I-VP O
3 276 279 8673132 the DT B-NP O
4 280 284 8673132 role NN I-NP O
5 285 287 8673132 of IN B-PP O
6 288 292 8673132 DMPK NN B-NP O
7 293 295 8673132 in IN B-PP O
8 296 298 8673132 DM NN B-NP B-Disease
9 299 311 8673132 pathogenesis NN I-NP O
10 312 314 8673132 we PRP B-NP O
11 315 319 8673132 have VBP B-VP O
12 320 329 8673132 developed VBN I-VP O
13 330 334 8673132 Dmpk NN B-NP B-Disease
14 335 344 8673132 deficient JJ I-NP I-Disease
15 345 346 8673132 ( ( O O
16 346 350 8673132 Dmpk NN B-NP O
17 350 351 8673132 - HYPH O O
18 351 352 8673132 / SYM O O
19 352 353 8673132 - SYM O O
20 353 354 8673132 ) ) O O
21 355 359 8673132 mice NNS B-NP O
22 359 360 8673132 . . O O

1 361 365 8673132 Dmpk NN B-NP O
2 365 366 8673132 - HYPH O O
3 366 367 8673132 / SYM O O
4 367 368 8673132 - HYPH O O
5 368 372 8673132 mice NNS B-NP O
6 373 380 8673132 develop VBP B-VP O
7 381 382 8673132 a DT B-NP O
8 383 387 8673132 late JJ I-NP O
9 387 388 8673132 - HYPH I-NP O
10 388 393 8673132 onset NN I-NP O
11 393 394 8673132 , , O O
12 395 406 8673132 progressive JJ B-NP B-Disease
13 407 415 8673132 skeletal JJ I-NP I-Disease
14 416 424 8673132 myopathy NN I-NP I-Disease
15 425 429 8673132 that WDT B-NP O
16 430 436 8673132 shares VBZ B-VP O
17 437 441 8673132 some DT B-NP O
18 442 454 8673132 pathological JJ I-NP O
19 455 463 8673132 features NNS I-NP O
20 464 468 8673132 with IN B-PP O
21 469 471 8673132 DM NN B-NP B-Disease
22 471 472 8673132 . . O O

1 473 480 8673132 Muscles NNS B-NP O
2 481 485 8673132 from IN B-PP O
3 486 492 8673132 mature JJ B-NP O
4 493 497 8673132 mice NNS I-NP O
5 498 502 8673132 show VBP B-VP O
6 503 512 8673132 variation NN B-NP O
7 513 515 8673132 in IN B-PP O
8 516 521 8673132 fibre NN B-NP O
9 522 526 8673132 size NN I-NP O
10 526 527 8673132 , , O O
11 528 537 8673132 increased VBD B-VP O
12 538 543 8673132 fibre NN B-NP B-Disease
13 544 556 8673132 degeneration NN I-NP I-Disease
14 557 560 8673132 and CC I-NP O
15 561 569 8673132 fibrosis NN I-NP B-Disease
16 569 570 8673132 . . O O

1 571 576 8673132 Adult JJ B-NP O
2 577 581 8673132 Dmpk NN I-NP O
3 581 582 8673132 - HYPH O O
4 582 583 8673132 / SYM O O
5 583 584 8673132 - HYPH O O
6 584 588 8673132 mice NNS B-NP O
7 589 593 8673132 show VBP B-VP O
8 594 609 8673132 ultrastructural JJ B-NP O
9 610 617 8673132 changes NNS I-NP O
10 618 620 8673132 in IN B-PP O
11 621 627 8673132 muscle NN B-NP O
12 628 631 8673132 and CC O O
13 632 633 8673132 a DT B-NP O
14 634 637 8673132 50% CD I-NP O
15 638 646 8673132 decrease NN I-NP O
16 647 649 8673132 in IN B-PP O
17 650 655 8673132 force NN B-NP O
18 656 666 8673132 generation NN I-NP O
19 667 675 8673132 compared VBN B-VP O
20 676 678 8673132 to TO B-PP O
21 679 684 8673132 young JJ B-NP O
22 685 689 8673132 mice NNS I-NP O
23 689 690 8673132 . . O O

1 691 694 8673132 Our PRP$ B-NP O
2 695 702 8673132 results NNS I-NP O
3 703 711 8673132 indicate VBP B-VP O
4 712 716 8673132 that IN B-SBAR O
5 717 721 8673132 DMPK NN B-NP O
6 722 725 8673132 may MD B-VP O
7 726 728 8673132 be VB I-VP O
8 729 738 8673132 necessary JJ B-ADJP O
9 739 742 8673132 for IN B-PP O
10 743 746 8673132 the DT B-NP O
11 747 758 8673132 maintenance NN I-NP O
12 759 761 8673132 of IN B-PP O
13 762 770 8673132 skeletal JJ B-NP O
14 771 777 8673132 muscle NN I-NP O
15 778 787 8673132 structure NN I-NP O
16 788 791 8673132 and CC I-NP O
17 792 800 8673132 function NN I-NP O
18 801 804 8673132 and CC O O
19 805 812 8673132 suggest VBP B-VP O
20 813 817 8673132 that IN B-SBAR O
21 818 819 8673132 a DT B-NP O
22 820 828 8673132 decrease NN I-NP O
23 829 831 8673132 in IN B-PP O
24 832 836 8673132 DMPK NN B-NP O
25 837 843 8673132 levels NNS I-NP O
26 844 847 8673132 may MD B-VP O
27 848 858 8673132 contribute VB I-VP O
28 859 861 8673132 to TO B-PP O
29 862 864 8673132 DM NN B-NP B-Disease
30 865 874 8673132 pathology NN I-NP O
31 874 875 8673132 . . O O
32 875 876 8673132 . . O O

1 0 0 8808605 -DOCSTART- -X- -X- O

1 0 7 8808605 Somatic JJ B-NP O
2 7 8 8808605 - HYPH I-NP O
3 8 12 8808605 cell NN I-NP O
4 13 22 8808605 selection NN I-NP O
5 23 25 8808605 is VBZ B-VP O
6 26 27 8808605 a DT B-NP O
7 28 33 8808605 major JJ I-NP O
8 34 45 8808605 determinant NN I-NP O
9 46 48 8808605 of IN B-PP O
10 49 52 8808605 the DT B-NP O
11 53 58 8808605 blood NN I-NP O
12 58 59 8808605 - HYPH B-NP O
13 59 63 8808605 cell NN I-NP O
14 64 73 8808605 phenotype NN I-NP O
15 74 76 8808605 in IN B-PP O
16 77 90 8808605 heterozygotes NNS B-NP O
17 91 94 8808605 for IN B-PP O
18 95 102 8808605 glucose NN B-NP O
19 102 103 8808605 - HYPH B-NP O
20 103 104 8808605 6 CD I-NP O
21 104 105 8808605 - HYPH I-NP O
22 105 114 8808605 phosphate NN I-NP O
23 115 128 8808605 dehydrogenase NN I-NP O
24 129 138 8808605 mutations NNS I-NP O
25 139 146 8808605 causing VBG B-VP O
26 147 153 8808605 severe JJ B-NP O
27 154 160 8808605 enzyme NN I-NP B-Disease
28 161 171 8808605 deficiency NN I-NP I-Disease
29 171 172 8808605 . . B-NP O
30 173 174 8808605 X NN I-NP O
31 174 175 8808605 - HYPH B-NP O
32 175 185 8808605 chromosome NN I-NP O
33 186 198 8808605 inactivation NN I-NP O
34 199 201 8808605 in IN B-PP O
35 202 209 8808605 mammals NNS B-NP O
36 210 212 8808605 is VBZ B-VP O
37 213 221 8808605 regarded VBN I-VP O
38 222 224 8808605 as IN B-PP O
39 225 227 8808605 an DT B-NP O
40 228 239 8808605 essentially RB I-NP O
41 240 246 8808605 random JJ I-NP O
42 247 254 8808605 process NN I-NP O
43 254 255 8808605 , , O O
44 256 259 8808605 but CC O O
45 260 263 8808605 the DT B-NP O
46 264 273 8808605 resulting VBG I-NP O
47 274 281 8808605 somatic JJ I-NP O
48 281 282 8808605 - HYPH I-NP O
49 282 286 8808605 cell NN I-NP O
50 287 296 8808605 mosaicism NN I-NP O
51 297 304 8808605 creates VBZ B-VP O
52 305 308 8808605 the DT B-NP O
53 309 320 8808605 opportunity NN I-NP O
54 321 324 8808605 for IN B-PP O
55 325 329 8808605 cell NN B-NP O
56 330 339 8808605 selection NN I-NP O
57 339 340 8808605 . . O O

1 341 343 8808605 In IN B-PP O
2 344 348 8808605 most JJS B-NP O
3 349 355 8808605 people NNS I-NP O
4 356 360 8808605 with IN B-PP O
5 361 364 8808605 red JJ B-NP O
6 364 365 8808605 - HYPH I-NP O
7 365 370 8808605 blood NN I-NP O
8 370 371 8808605 - HYPH O O
9 371 375 8808605 cell NN B-NP O
10 376 383 8808605 glucose NN I-NP B-Disease
11 383 384 8808605 - HYPH B-NP I-Disease
12 384 385 8808605 6 CD I-NP I-Disease
13 385 386 8808605 - HYPH I-NP I-Disease
14 386 395 8808605 phosphate NN I-NP I-Disease
15 396 409 8808605 dehydrogenase NN I-NP I-Disease
16 410 411 8808605 ( ( O I-Disease
17 411 415 8808605 G6PD NN B-NP I-Disease
18 415 416 8808605 ) ) O I-Disease
19 417 427 8808605 deficiency NN B-NP I-Disease
20 427 428 8808605 , , O O
21 429 432 8808605 the DT B-NP O
22 433 439 8808605 enzyme NN I-NP O
23 439 440 8808605 - HYPH B-NP O
24 440 449 8808605 deficient JJ I-NP O
25 450 459 8808605 phenotype NN I-NP O
26 460 462 8808605 is VBZ B-VP O
27 463 467 8808605 only RB I-VP O
28 468 478 8808605 moderately RB I-VP O
29 479 488 8808605 expressed VBN I-VP O
30 489 491 8808605 in IN B-PP O
31 492 501 8808605 nucleated JJ B-NP O
32 502 507 8808605 cells NNS I-NP O
33 507 508 8808605 . . O O

1 509 516 8808605 However RB B-ADVP O
2 516 517 8808605 , , O O
3 518 520 8808605 in IN B-PP O
4 521 522 8808605 a DT B-NP O
5 523 528 8808605 small JJ I-NP O
6 529 535 8808605 subset NN I-NP O
7 536 538 8808605 of IN B-PP O
8 539 549 8808605 hemizygous JJ B-NP O
9 550 555 8808605 males NNS I-NP O
10 556 559 8808605 who WP B-NP O
11 560 566 8808605 suffer VBP B-VP O
12 567 571 8808605 from IN B-PP O
13 572 579 8808605 chronic JJ B-NP B-Disease
14 580 594 8808605 nonspherocytic JJ I-NP I-Disease
15 595 604 8808605 hemolytic JJ I-NP I-Disease
16 605 611 8808605 anemia NN I-NP I-Disease
17 611 612 8808605 , , O O
18 613 616 8808605 the DT B-NP O
19 617 627 8808605 underlying VBG I-NP O
20 628 637 8808605 mutations NNS I-NP O
21 638 639 8808605 ( ( O O
22 639 649 8808605 designated VBN B-VP O
23 650 655 8808605 class NN B-NP O
24 656 657 8808605 I CD I-NP O
25 657 658 8808605 ) ) O O
26 659 664 8808605 cause VBP B-VP O
27 665 669 8808605 more JJR B-NP O
28 669 670 8808605 - HYPH I-NP O
29 670 676 8808605 severe JJ I-NP O
30 677 681 8808605 G6PD NN I-NP B-Disease
31 682 692 8808605 deficiency NN I-NP I-Disease
32 692 693 8808605 , , O O
33 694 697 8808605 and CC O O
34 698 702 8808605 this DT B-NP O
35 703 708 8808605 might MD B-VP O
36 709 716 8808605 provide VB I-VP O
37 717 719 8808605 an DT B-NP O
38 720 731 8808605 opportunity NN I-NP O
39 732 735 8808605 for IN B-PP O
40 736 745 8808605 selection NN B-NP O
41 746 748 8808605 in IN B-PP O
42 749 761 8808605 heterozygous JJ B-NP O
43 762 769 8808605 females NNS I-NP O
44 770 776 8808605 during IN B-PP O
45 777 788 8808605 development NN B-NP O
46 788 789 8808605 . . O O

1 790 792 8808605 In IN B-SBAR O
2 793 798 8808605 order NN O O
3 799 801 8808605 to TO B-VP O
4 802 806 8808605 test VB I-VP O
5 807 811 8808605 this DT B-NP O
6 812 823 8808605 possibility NN I-NP O
7 824 826 8808605 we PRP B-NP O
8 827 831 8808605 have VBP B-VP O
9 832 840 8808605 analyzed VBN I-VP O
10 841 845 8808605 four CD B-NP O
11 846 859 8808605 heterozygotes NNS I-NP O
12 860 863 8808605 for IN B-PP O
13 864 869 8808605 class NN B-NP O
14 870 871 8808605 I CD I-NP O
15 872 876 8808605 G6PD NN I-NP O
16 877 886 8808605 mutations NNS I-NP O
17 888 891 8808605 two CD B-NP O
18 892 896 8808605 with IN B-PP O
19 897 901 8808605 G6PD NN B-NP O
20 902 909 8808605 Portici NN I-NP O
21 910 911 8808605 ( ( O O
22 911 916 8808605 1178G NN B-NP O
23 916 917 8808605 - SYM O O
24 917 918 8808605 - HYPH B-NP O
25 919 920 8808605 > SYM I-NP O
26 921 922 8808605 A NN I-NP O
27 922 923 8808605 ) ) O O
28 924 927 8808605 and CC O O
29 928 931 8808605 two CD B-NP O
30 932 936 8808605 with IN B-PP O
31 937 941 8808605 G6PD NN B-NP O
32 942 946 8808605 Bari NN I-NP O
33 947 948 8808605 ( ( O O
34 948 953 8808605 1187C NN B-NP O
35 953 954 8808605 - SYM O O
36 954 955 8808605 - HYPH O O
37 956 957 8808605 > SYM O O
38 958 959 8808605 T NN B-NP O
39 959 960 8808605 ) ) O O
40 960 961 8808605 . . O O

1 962 964 8808605 We PRP B-NP O
2 965 970 8808605 found VBD B-VP O
3 971 975 8808605 that IN B-SBAR O
4 976 978 8808605 in IN B-PP O
5 979 991 8808605 fractionated VBN B-NP O
6 992 997 8808605 blood NN I-NP O
7 998 1002 8808605 cell NN I-NP O
8 1003 1008 8808605 types NNS I-NP O
9 1009 1010 8808605 ( ( O O
10 1010 1019 8808605 including VBG B-PP O
11 1020 1029 8808605 erythroid JJ B-NP O
12 1029 1030 8808605 , , I-NP O
13 1031 1038 8808605 myeloid JJ I-NP O
14 1038 1039 8808605 , , O O
15 1040 1043 8808605 and CC O O
16 1044 1052 8808605 lymphoid JJ B-NP O
17 1053 1057 8808605 cell NN I-NP O
18 1058 1066 8808605 lineages NNS I-NP O
19 1066 1067 8808605 ) ) O O
20 1068 1073 8808605 there EX B-NP O
21 1074 1077 8808605 was VBD B-VP O
22 1078 1079 8808605 a DT B-NP O
23 1080 1091 8808605 significant JJ I-NP O
24 1092 1098 8808605 excess NN I-NP O
25 1099 1101 8808605 of IN B-PP O
26 1102 1106 8808605 G6PD NN B-NP O
27 1106 1107 8808605 - HYPH B-NP O
28 1107 1113 8808605 normal JJ I-NP O
29 1114 1119 8808605 cells NNS I-NP O
30 1119 1120 8808605 . . O O

1 1121 1124 8808605 The DT B-NP O
2 1125 1136 8808605 significant JJ I-NP O
3 1137 1148 8808605 concordance NN I-NP O
4 1149 1153 8808605 that IN B-NP O
5 1154 1156 8808605 we PRP B-NP O
6 1157 1161 8808605 have VBP B-VP O
7 1162 1170 8808605 observed VBN I-VP O
8 1171 1173 8808605 in IN B-PP O
9 1174 1177 8808605 the DT B-NP O
10 1178 1184 8808605 degree NN I-NP O
11 1185 1187 8808605 of IN B-PP O
12 1188 1197 8808605 imbalance NN B-NP O
13 1198 1200 8808605 in IN B-PP O
14 1201 1204 8808605 the DT B-NP O
15 1205 1214 8808605 different JJ I-NP O
16 1215 1220 8808605 blood NN I-NP O
17 1220 1221 8808605 - HYPH B-NP O
18 1221 1225 8808605 cell NN I-NP O
19 1226 1234 8808605 lineages NNS I-NP O
20 1235 1244 8808605 indicates VBZ B-VP O
21 1245 1249 8808605 that IN B-SBAR O
22 1250 1251 8808605 a DT B-NP O
23 1252 1261 8808605 selective JJ I-NP O
24 1262 1271 8808605 mechanism NN I-NP O
25 1272 1274 8808605 is VBZ B-VP O
26 1275 1281 8808605 likely JJ B-ADJP O
27 1282 1284 8808605 to TO B-VP O
28 1285 1292 8808605 operate VB I-VP O
29 1293 1295 8808605 at IN B-PP O
30 1296 1299 8808605 the DT B-NP O
31 1300 1305 8808605 level NN I-NP O
32 1306 1308 8808605 of IN B-PP O
33 1309 1320 8808605 pluripotent JJ B-NP O
34 1321 1326 8808605 blood NN I-NP O
35 1327 1331 8808605 stem NN I-NP O
36 1332 1337 8808605 cells NNS I-NP O
37 1337 1338 8808605 . . O O

1 1339 1343 8808605 Thus RB B-ADVP O
2 1343 1344 8808605 , , O O
3 1345 1347 8808605 it PRP B-NP O
4 1348 1355 8808605 appears VBZ B-VP O
5 1356 1360 8808605 that IN B-SBAR O
6 1361 1367 8808605 severe JJ B-NP O
7 1368 1372 8808605 G6PD NN I-NP B-Disease
8 1373 1383 8808605 deficiency NN I-NP I-Disease
9 1384 1391 8808605 affects VBZ B-VP O
10 1392 1401 8808605 adversely RB B-ADVP O
11 1402 1405 8808605 the DT B-NP O
12 1406 1419 8808605 proliferation NN I-NP O
13 1420 1422 8808605 or CC O O
14 1423 1426 8808605 the DT B-NP O
15 1427 1435 8808605 survival NN I-NP O
16 1436 1438 8808605 of IN B-PP O
17 1439 1448 8808605 nucleated JJ B-NP O
18 1449 1454 8808605 blood NN I-NP O
19 1455 1460 8808605 cells NNS I-NP O
20 1461 1464 8808605 and CC O O
21 1465 1469 8808605 that IN B-SBAR O
22 1470 1474 8808605 this DT B-NP O
23 1475 1485 8808605 phenotypic JJ I-NP O
24 1486 1500 8808605 characteristic NN I-NP O
25 1501 1503 8808605 is VBZ B-VP O
26 1504 1512 8808605 critical JJ B-ADJP O
27 1513 1519 8808605 during IN B-PP O
28 1520 1533 8808605 hematopoiesis NN B-NP O
29 1533 1534 8808605 . . O O
30 1534 1535 8808605 . . O O

1 0 0 8938427 -DOCSTART- -X- -X- O

1 0 8 8938427 Complete JJ B-NP O
2 9 16 8938427 genomic JJ I-NP O
3 17 25 8938427 sequence NN I-NP O
4 26 29 8938427 and CC O O
5 30 38 8938427 analysis NN B-NP O
6 39 41 8938427 of IN B-PP O
7 42 45 8938427 117 CD B-NP O
8 46 48 8938427 kb NN I-NP O
9 49 51 8938427 of IN B-PP O
10 52 57 8938427 human JJ B-NP O
11 58 61 8938427 DNA NN I-NP O
12 62 72 8938427 containing VBG B-VP O
13 73 76 8938427 the DT B-NP O
14 77 81 8938427 gene NN I-NP O
15 82 87 8938427 BRCA1 NN I-NP O
16 87 88 8938427 . . O O
17 89 93 8938427 Over IN B-PP O
18 94 97 8938427 100 CD B-NP O
19 98 106 8938427 distinct JJ I-NP O
20 107 114 8938427 disease NN I-NP O
21 114 115 8938427 - HYPH B-NP O
22 115 125 8938427 associated VBN I-NP O
23 126 135 8938427 mutations NNS I-NP O
24 136 140 8938427 have VBP B-VP O
25 141 145 8938427 been VBN I-VP O
26 146 156 8938427 identified VBN I-VP O
27 157 159 8938427 in IN B-PP O
28 160 163 8938427 the DT B-NP O
29 164 170 8938427 breast NN I-NP B-Disease
30 170 171 8938427 - HYPH B-NP I-Disease
31 171 178 8938427 ovarian JJ I-NP I-Disease
32 179 185 8938427 cancer NN I-NP I-Disease
33 186 200 8938427 susceptibility NN I-NP O
34 201 205 8938427 gene NN I-NP O
35 206 211 8938427 BRCA1 NN I-NP O
36 211 212 8938427 . . O O

1 213 217 8938427 Loss NN B-NP O
2 218 220 8938427 of IN B-PP O
3 221 224 8938427 the DT B-NP O
4 225 229 8938427 wild JJ I-NP O
5 229 230 8938427 - HYPH I-NP O
6 230 234 8938427 type NN I-NP O
7 235 241 8938427 allele NN I-NP O
8 242 244 8938427 in IN B-PP O
9 245 246 8938427 > SYM B-NP O
10 247 250 8938427 90% CD I-NP O
11 251 253 8938427 of IN B-PP O
12 254 260 8938427 tumors NNS B-NP B-Disease
13 261 265 8938427 from IN B-PP O
14 266 274 8938427 patients NNS B-NP O
15 275 279 8938427 with IN B-PP O
16 280 289 8938427 inherited VBN B-NP O
17 290 295 8938427 BRCA1 NN I-NP O
18 296 305 8938427 mutations NNS I-NP O
19 306 315 8938427 indicates VBZ B-VP O
20 316 321 8938427 tumor NN B-NP B-Disease
21 322 333 8938427 suppressive JJ I-NP O
22 334 342 8938427 function NN I-NP O
23 342 343 8938427 . . O O

1 344 347 8938427 The DT B-NP O
2 348 351 8938427 low JJ I-NP O
3 352 361 8938427 incidence NN I-NP O
4 362 364 8938427 of IN B-PP O
5 365 372 8938427 somatic JJ B-NP O
6 373 382 8938427 mutations NNS I-NP O
7 383 391 8938427 suggests VBZ B-VP O
8 392 396 8938427 that IN B-SBAR O
9 397 402 8938427 BRCA1 NN B-NP O
10 403 415 8938427 inactivation NN I-NP O
11 416 418 8938427 in IN B-PP O
12 419 427 8938427 sporadic JJ B-NP O
13 428 434 8938427 tumors NNS I-NP B-Disease
14 435 441 8938427 occurs VBZ B-VP O
15 442 444 8938427 by IN B-PP O
16 445 456 8938427 alternative JJ B-NP O
17 457 467 8938427 mechanisms NNS I-NP O
18 467 468 8938427 , , O O
19 469 473 8938427 such JJ B-PP O
20 474 476 8938427 as IN I-PP O
21 477 489 8938427 interstitial JJ B-NP O
22 490 501 8938427 chromosomal JJ I-NP O
23 502 510 8938427 deletion NN I-NP O
24 511 513 8938427 or CC O O
25 514 521 8938427 reduced VBN B-NP O
26 522 535 8938427 transcription NN I-NP O
27 535 536 8938427 . . O O

1 537 539 8938427 To TO B-VP O
2 540 548 8938427 identify VB I-VP O
3 549 557 8938427 possible JJ B-NP O
4 558 566 8938427 features NNS I-NP O
5 567 569 8938427 of IN B-PP O
6 570 573 8938427 the DT B-NP O
7 574 579 8938427 BRCA1 NN I-NP O
8 580 587 8938427 genomic JJ I-NP O
9 588 594 8938427 region NN I-NP O
10 595 599 8938427 that WDT B-NP O
11 600 603 8938427 may MD B-VP O
12 604 614 8938427 contribute VB I-VP O
13 615 617 8938427 to TO B-PP O
14 618 629 8938427 chromosomal JJ B-NP O
15 630 641 8938427 instability NN I-NP O
16 642 644 8938427 as RB B-CONJP O
17 645 649 8938427 well RB I-CONJP O
18 650 652 8938427 as IN I-CONJP O
19 653 662 8938427 potential JJ B-NP O
20 663 678 8938427 transcriptional JJ I-NP O
21 679 689 8938427 regulatory JJ I-NP O
22 690 698 8938427 elements NNS I-NP O
23 698 699 8938427 , , O O
24 700 701 8938427 a DT B-NP O
25 702 705 8938427 117 CD I-NP O
26 705 706 8938427 , , I-NP O
27 707 710 8938427 143 CD I-NP O
28 710 711 8938427 - HYPH I-NP O
29 711 713 8938427 bp NN I-NP O
30 714 717 8938427 DNA NN I-NP O
31 718 726 8938427 sequence NN I-NP O
32 727 739 8938427 encompassing VBG B-VP O
33 740 745 8938427 BRCA1 NN B-NP O
34 746 749 8938427 was VBD B-VP O
35 750 758 8938427 obtained VBN I-VP O
36 759 761 8938427 by IN B-PP O
37 762 768 8938427 random JJ B-NP O
38 769 779 8938427 sequencing NN I-NP O
39 780 782 8938427 of IN B-PP O
40 783 787 8938427 four CD B-NP O
41 788 795 8938427 cosmids NNS I-NP O
42 796 806 8938427 identified VBN B-VP O
43 807 811 8938427 from IN B-PP O
44 812 813 8938427 a DT B-NP O
45 814 819 8938427 human JJ I-NP O
46 820 830 8938427 chromosome NN I-NP O
47 831 833 8938427 17 CD I-NP O
48 834 842 8938427 specific JJ I-NP O
49 843 850 8938427 library NN I-NP O
50 850 851 8938427 . . O O

1 852 855 8938427 The DT B-NP O
2 856 858 8938427 24 CD I-NP O
3 859 864 8938427 exons NNS I-NP O
4 865 867 8938427 of IN B-PP O
5 868 873 8938427 BRCA1 NN B-NP O
6 874 878 8938427 span VBP B-VP O
7 879 881 8938427 an DT B-NP O
8 882 884 8938427 81 CD I-NP O
9 884 885 8938427 - HYPH I-NP O
10 885 887 8938427 kb NN I-NP O
11 888 894 8938427 region NN I-NP O
12 895 899 8938427 that WDT B-NP O
13 900 903 8938427 has VBZ B-VP O
14 904 906 8938427 an DT B-NP O
15 907 916 8938427 unusually RB I-NP O
16 917 921 8938427 high JJ I-NP O
17 922 929 8938427 density NN I-NP O
18 930 932 8938427 of IN B-PP O
19 933 936 8938427 Alu NN B-NP O
20 937 947 8938427 repetitive JJ I-NP O
21 948 951 8938427 DNA NN I-NP O
22 952 953 8938427 ( ( O O
23 953 955 8938427 41 CD B-NP O
24 955 956 8938427 . . O O

1 957 959 8938427 5% LS B-LST O
2 959 960 8938427 ) ) O O
3 960 961 8938427 , , O O
4 962 965 8938427 but CC O O
5 966 976 8938427 relatively RB B-NP O
6 977 980 8938427 low JJ I-NP O
7 981 988 8938427 density NN I-NP O
8 989 990 8938427 ( ( O O
9 990 991 8938427 4 CD B-NP O
10 991 992 8938427 . . O O

1 993 995 8938427 8% LS B-LST O
2 995 996 8938427 ) ) O O
3 997 999 8938427 of IN B-PP O
4 1000 1005 8938427 other JJ B-NP O
5 1006 1016 8938427 repetitive JJ I-NP O
6 1017 1026 8938427 sequences NNS I-NP O
7 1026 1027 8938427 . . O O

1 1028 1033 8938427 BRCA1 NN B-NP O
2 1034 1040 8938427 intron NN I-NP O
3 1041 1048 8938427 lengths NNS I-NP O
4 1049 1054 8938427 range NN I-NP O
5 1055 1057 8938427 in IN B-PP O
6 1058 1062 8938427 size NN B-NP O
7 1063 1067 8938427 from IN B-PP O
8 1068 1071 8938427 403 CD B-NP O
9 1072 1074 8938427 bp NN I-NP O
10 1075 1077 8938427 to TO B-PP O
11 1078 1079 8938427 9 CD B-NP O
12 1079 1080 8938427 . . O O

1 1081 1082 8938427 2 CD B-NP O
2 1083 1085 8938427 kb NN I-NP O
3 1086 1089 8938427 and CC O O
4 1090 1097 8938427 contain VBP B-VP O
5 1098 1101 8938427 the DT B-NP O
6 1102 1112 8938427 intragenic JJ I-NP O
7 1113 1127 8938427 microsatellite NN I-NP O
8 1128 1135 8938427 markers NNS I-NP O
9 1136 1144 8938427 D17S1323 NN I-NP O
10 1144 1145 8938427 , , O O
11 1146 1154 8938427 D17S1322 NN B-NP O
12 1154 1155 8938427 , , O O
13 1156 1159 8938427 and CC O O
14 1160 1167 8938427 D17S855 NN B-NP O
15 1167 1168 8938427 , , O O
16 1169 1174 8938427 which WDT B-NP O
17 1175 1183 8938427 localize VBP B-VP O
18 1184 1186 8938427 to TO B-PP O
19 1187 1194 8938427 introns NNS B-NP O
20 1195 1197 8938427 12 CD I-NP O
21 1197 1198 8938427 , , I-NP O
22 1199 1201 8938427 19 CD I-NP O
23 1201 1202 8938427 , , O O
24 1203 1206 8938427 and CC O O
25 1207 1209 8938427 20 CD B-NP O
26 1209 1210 8938427 , , O O
27 1211 1223 8938427 respectively RB B-ADVP O
28 1223 1224 8938427 . . O O

1 1225 1227 8938427 In IN B-PP O
2 1228 1236 8938427 addition NN B-NP O
3 1237 1239 8938427 to TO B-PP O
4 1240 1245 8938427 BRCA1 NN B-NP O
5 1245 1246 8938427 , , O O
6 1247 1250 8938427 the DT B-NP O
7 1251 1257 8938427 contig NN I-NP O
8 1258 1266 8938427 contains VBZ B-VP O
9 1267 1270 8938427 two CD B-NP O
10 1271 1279 8938427 complete JJ I-NP O
11 1280 1285 8938427 genes NNS I-NP O
12 1287 1291 8938427 Rho7 NN I-NP O
13 1291 1292 8938427 , , O O
14 1293 1294 8938427 a DT B-NP O
15 1295 1301 8938427 member NN I-NP O
16 1302 1304 8938427 of IN B-PP O
17 1305 1308 8938427 the DT B-NP O
18 1309 1312 8938427 rho JJ I-NP O
19 1313 1319 8938427 family NN I-NP O
20 1320 1322 8938427 of IN B-PP O
21 1323 1326 8938427 GTP NN B-NP O
22 1327 1334 8938427 binding NN I-NP O
23 1335 1343 8938427 proteins NNS I-NP O
24 1343 1344 8938427 , , O O
25 1345 1348 8938427 and CC O O
26 1349 1353 8938427 VAT1 NN B-NP O
27 1353 1354 8938427 , , O O
28 1355 1357 8938427 an DT B-NP O
29 1358 1366 8938427 abundant JJ I-NP O
30 1367 1375 8938427 membrane NN I-NP O
31 1376 1383 8938427 protein NN I-NP O
32 1384 1386 8938427 of IN B-PP O
33 1387 1398 8938427 cholinergic JJ B-NP O
34 1399 1407 8938427 synaptic JJ I-NP O
35 1408 1416 8938427 vesicles NNS I-NP O
36 1416 1417 8938427 . . O O

1 1418 1425 8938427 Partial JJ B-NP O
2 1426 1435 8938427 sequences NNS I-NP O
3 1436 1438 8938427 of IN B-PP O
4 1439 1442 8938427 the DT B-NP O
5 1443 1446 8938427 1A1 NN I-NP O
6 1446 1447 8938427 - HYPH B-VP O
7 1447 1449 8938427 3B NN B-NP O
8 1450 1451 8938427 B NN I-NP O
9 1451 1452 8938427 - HYPH B-NP O
10 1452 1455 8938427 box NN I-NP O
11 1456 1463 8938427 protein NN I-NP O
12 1464 1474 8938427 pseudogene NN I-NP O
13 1475 1478 8938427 and CC O O
14 1479 1482 8938427 IFP NN B-NP O
15 1483 1485 8938427 35 CD I-NP O
16 1485 1486 8938427 , , O O
17 1487 1489 8938427 an DT B-NP O
18 1490 1500 8938427 interferon NN I-NP O
19 1501 1508 8938427 induced VBD B-VP O
20 1509 1516 8938427 leucine NN B-NP O
21 1517 1523 8938427 zipper NN I-NP O
22 1524 1531 8938427 protein NN I-NP O
23 1531 1532 8938427 , , O O
24 1533 1539 8938427 reside NN B-NP O
25 1540 1546 8938427 within IN B-PP O
26 1547 1550 8938427 the DT B-NP O
27 1551 1557 8938427 contig NN I-NP O
28 1557 1558 8938427 . . O O

1 1559 1561 8938427 An DT B-NP O
2 1562 1565 8938427 L21 NN I-NP O
3 1566 1575 8938427 ribosomal JJ I-NP O
4 1576 1583 8938427 protein NN I-NP O
5 1584 1594 8938427 pseudogene NN I-NP O
6 1595 1597 8938427 is VBZ B-VP O
7 1598 1606 8938427 embedded VBN I-VP O
8 1607 1609 8938427 in IN B-PP O
9 1610 1615 8938427 BRCA1 NN B-NP O
10 1616 1622 8938427 intron NN I-NP O
11 1623 1625 8938427 13 CD I-NP O
12 1625 1626 8938427 . . O O

1 1627 1630 8938427 The DT B-NP O
2 1631 1636 8938427 order NN I-NP O
3 1637 1639 8938427 of IN B-PP O
4 1640 1645 8938427 genes NNS B-NP O
5 1646 1648 8938427 on IN B-PP O
6 1649 1652 8938427 the DT B-NP O
7 1653 1663 8938427 chromosome NN I-NP O
8 1664 1666 8938427 is VBZ B-VP O
9 1668 1678 8938427 centromere JJ B-ADJP O
10 1678 1679 8938427 - HYPH O O
11 1679 1682 8938427 1FP NN B-NP O
12 1683 1685 8938427 35 CD I-NP O
13 1685 1686 8938427 - HYPH I-NP O
14 1686 1690 8938427 VAT1 NN I-NP O
15 1690 1691 8938427 - HYPH B-NP O
16 1691 1695 8938427 Rho7 NN I-NP O
17 1695 1696 8938427 - HYPH B-NP O
18 1696 1701 8938427 BRCA1 NN I-NP O
19 1701 1702 8938427 - HYPH B-NP O
20 1702 1705 8938427 1A1 NN I-NP O
21 1705 1706 8938427 - HYPH B-NP O
22 1706 1708 8938427 3B NN I-NP O
23 1708 1709 8938427 - HYPH O O
24 1709 1717 8938427 telomere NN B-NP O

1 0 0 8674108 -DOCSTART- -X- -X- O

1 0 3 8674108 The DT B-NP O
2 4 9 8674108 tumor NN I-NP B-Disease
3 10 20 8674108 suppressor NN I-NP O
4 21 25 8674108 gene NN I-NP O
5 26 31 8674108 Brca1 NN I-NP O
6 32 34 8674108 is VBZ B-VP O
7 35 43 8674108 required VBN I-VP O
8 44 47 8674108 for IN B-PP O
9 48 57 8674108 embryonic JJ B-NP O
10 58 66 8674108 cellular JJ I-NP O
11 67 80 8674108 proliferation NN I-NP O
12 81 83 8674108 in IN B-PP O
13 84 87 8674108 the DT B-NP O
14 88 93 8674108 mouse NN I-NP O
15 93 94 8674108 . . O O
16 95 104 8674108 Mutations NNS B-NP O
17 105 107 8674108 of IN B-PP O
18 108 111 8674108 the DT B-NP O
19 112 117 8674108 BRCA1 NN I-NP O
20 118 122 8674108 gone VBN B-VP O
21 123 125 8674108 in IN B-PP O
22 126 132 8674108 humans NNS B-NP O
23 133 136 8674108 are VBP B-VP O
24 137 147 8674108 associated VBN I-VP O
25 148 152 8674108 with IN B-PP O
26 153 167 8674108 predisposition NN B-NP O
27 168 170 8674108 to TO B-PP O
28 171 177 8674108 breast NN B-NP B-Disease
29 178 181 8674108 and CC O I-Disease
30 182 189 8674108 ovarian JJ B-NP I-Disease
31 190 197 8674108 cancers NNS I-NP I-Disease
32 197 198 8674108 . . O O

1 199 201 8674108 We PRP B-NP O
2 202 206 8674108 show VBP B-VP O
3 207 211 8674108 here RB B-ADVP O
4 212 216 8674108 that IN B-SBAR O
5 217 222 8674108 Brca1 NN B-NP O
6 223 224 8674108 + SYM O O
7 224 225 8674108 / SYM O O
8 225 226 8674108 - HYPH O O
9 227 231 8674108 mice NNS B-NP O
10 232 235 8674108 are VBP B-VP O
11 236 242 8674108 normal JJ B-NP O
12 243 246 8674108 and CC I-NP O
13 247 254 8674108 fertile JJ I-NP O
14 255 258 8674108 and CC I-NP O
15 259 263 8674108 lack JJ I-NP O
16 264 270 8674108 tumors NNS I-NP B-Disease
17 271 273 8674108 by IN B-PP O
18 274 277 8674108 age NN B-NP O
19 278 284 8674108 eleven CD B-NP O
20 285 291 8674108 months NNS I-NP O
21 291 292 8674108 . . O O

1 293 303 8674108 Homozygous JJ B-NP O
2 304 309 8674108 Brca1 NN I-NP O
3 310 311 8674108 ( ( O O
4 311 312 8674108 5 CD B-NP O
5 312 313 8674108 - HYPH I-NP O
6 313 314 8674108 6 CD I-NP O
7 314 315 8674108 ) ) O O
8 316 322 8674108 mutant JJ B-NP O
9 323 327 8674108 mice NNS I-NP O
10 328 331 8674108 die VBP B-VP O
11 332 338 8674108 before IN B-SBAR O
12 339 342 8674108 day NN B-NP O
13 343 344 8674108 7 CD I-NP O
14 344 345 8674108 . . O O

1 346 347 8674108 5 CD B-NP O
2 348 350 8674108 of IN B-PP O
3 351 364 8674108 embryogenesis NN B-NP O
4 364 365 8674108 . . O O

1 366 372 8674108 Mutant JJ B-NP O
2 373 380 8674108 embryos NNS I-NP O
3 381 384 8674108 are VBP B-VP O
4 385 391 8674108 poorly RB I-VP O
5 392 401 8674108 developed VBN I-VP O
6 401 402 8674108 , , O O
7 403 407 8674108 with IN B-PP O
8 408 410 8674108 no DT B-NP O
9 411 419 8674108 evidence NN I-NP O
10 420 422 8674108 of IN B-PP O
11 423 431 8674108 mesoderm NN B-NP O
12 432 441 8674108 formation NN I-NP O
13 441 442 8674108 . . O O

1 443 446 8674108 The DT B-NP O
2 447 461 8674108 extraembryonic JJ I-NP O
3 462 468 8674108 region NN I-NP O
4 469 471 8674108 is VBZ B-VP O
5 472 480 8674108 abnormal JJ B-ADJP O
6 480 481 8674108 , , O O
7 482 485 8674108 but CC O O
8 486 497 8674108 aggregation NN B-NP O
9 498 502 8674108 with IN B-PP O
10 503 507 8674108 wild JJ B-NP O
11 507 508 8674108 - HYPH I-NP O
12 508 512 8674108 type NN I-NP O
13 513 523 8674108 tetraploid JJ I-NP O
14 524 531 8674108 embryos NNS I-NP O
15 532 536 8674108 does VBZ B-VP O
16 537 540 8674108 not RB I-VP O
17 541 547 8674108 rescue VB I-VP O
18 548 551 8674108 the DT B-NP O
19 552 561 8674108 lethality NN I-NP O
20 561 562 8674108 . . O O

1 563 565 8674108 In FW B-ADVP O
2 566 570 8674108 vivo FW I-ADVP O
3 570 571 8674108 , , O O
4 572 578 8674108 mutant JJ B-NP O
5 579 586 8674108 embryos NNS I-NP O
6 587 589 8674108 do VBP B-VP O
7 590 593 8674108 not RB I-VP O
8 594 601 8674108 exhibit VB I-VP O
9 602 611 8674108 increased VBN B-NP O
10 612 621 8674108 apoptosis NN I-NP O
11 622 625 8674108 but CC O O
12 626 630 8674108 show VBP B-VP O
13 631 638 8674108 reduced VBN I-VP O
14 639 643 8674108 cell NN B-NP O
15 644 657 8674108 proliferation NN I-NP O
16 658 669 8674108 accompanied VBN B-VP O
17 670 672 8674108 by IN B-PP O
18 673 682 8674108 decreased VBN B-NP O
19 683 693 8674108 expression NN I-NP O
20 694 696 8674108 of IN B-PP O
21 697 703 8674108 cyclin NN B-NP O
22 704 705 8674108 E NN I-NP O
23 706 709 8674108 and CC I-NP O
24 710 713 8674108 mdm NN I-NP O
25 713 714 8674108 - HYPH O O
26 714 715 8674108 2 CD B-NP O
27 715 716 8674108 , , O O
28 717 718 8674108 a DT B-NP O
29 719 728 8674108 regulator NN I-NP O
30 729 731 8674108 of IN B-PP O
31 732 735 8674108 p53 NN B-NP O
32 736 744 8674108 activity NN I-NP O
33 744 745 8674108 . . O O

1 746 749 8674108 The DT B-NP O
2 750 760 8674108 expression NN I-NP O
3 761 763 8674108 of IN B-PP O
4 764 770 8674108 cyclin NN B-NP O
5 770 771 8674108 - HYPH B-NP O
6 771 780 8674108 dependent JJ I-NP O
7 781 787 8674108 kinase NN I-NP O
8 788 797 8674108 inhibitor NN I-NP O
9 798 801 8674108 p21 NN I-NP O
10 802 804 8674108 is VBZ B-VP O
11 805 817 8674108 dramatically RB I-VP O
12 818 827 8674108 increased VBN I-VP O
13 828 830 8674108 in IN B-PP O
14 831 834 8674108 the DT B-NP O
15 835 841 8674108 mutant JJ I-NP O
16 842 849 8674108 embryos NNS I-NP O
17 849 850 8674108 . . O O

1 851 862 8674108 Buttressing VBG B-VP O
2 863 868 8674108 these DT B-NP O
3 869 871 8674108 in FW I-NP O
4 872 876 8674108 vivo FW I-NP O
5 877 889 8674108 observations NNS I-NP O
6 890 892 8674108 is VBZ B-VP O
7 893 896 8674108 the DT B-NP O
8 897 901 8674108 fact NN I-NP O
9 902 906 8674108 that IN B-SBAR O
10 907 913 8674108 mutant JJ B-NP O
11 914 924 8674108 blastocyst JJ I-NP O
12 925 931 8674108 growth NN I-NP O
13 932 934 8674108 is VBZ B-VP O
14 935 942 8674108 grossly RB B-ADJP O
15 943 951 8674108 impaired JJ I-ADJP O
16 952 954 8674108 in FW B-ADJP O
17 955 960 8674108 vitro FW I-ADJP O
18 960 961 8674108 . . O O

1 962 966 8674108 Thus RB B-ADVP O
2 966 967 8674108 , , O O
3 968 971 8674108 the DT B-NP O
4 972 977 8674108 death NN I-NP O
5 978 980 8674108 of IN B-PP O
6 981 986 8674108 Brca1 NN B-NP O
7 987 988 8674108 ( ( O O
8 988 989 8674108 5 CD B-NP O
9 989 990 8674108 - HYPH I-NP O
10 990 991 8674108 6 CD I-NP O
11 991 992 8674108 ) ) O O
12 993 999 8674108 mutant JJ B-NP O
13 1000 1007 8674108 embryos NNS I-NP O
14 1008 1013 8674108 prior RB B-ADVP O
15 1014 1016 8674108 to TO B-PP O
16 1017 1029 8674108 gastrulation NN B-NP O
17 1030 1033 8674108 may MD B-VP O
18 1034 1036 8674108 be VB I-VP O
19 1037 1040 8674108 due JJ B-ADVP O
20 1041 1043 8674108 to TO B-PP O
21 1044 1045 8674108 a DT B-NP O
22 1046 1053 8674108 failure NN I-NP O
23 1054 1056 8674108 of IN B-PP O
24 1057 1060 8674108 the DT B-NP O
25 1061 1074 8674108 proliferative JJ I-NP O
26 1075 1080 8674108 burst NN I-NP O
27 1081 1089 8674108 required VBN B-VP O
28 1090 1093 8674108 for IN B-PP O
29 1094 1097 8674108 the DT B-NP O
30 1098 1109 8674108 development NN I-NP O
31 1110 1112 8674108 of IN B-PP O
32 1113 1116 8674108 the DT B-NP O
33 1117 1126 8674108 different JJ I-NP O
34 1127 1131 8674108 germ NN I-NP O
35 1132 1138 8674108 layers NNS I-NP O
36 1138 1139 8674108 . . O O

1 0 0 9241281 -DOCSTART- -X- -X- O

1 0 3 9241281 atm NN B-NP O
2 4 7 9241281 and CC I-NP O
3 8 11 9241281 p53 NN I-NP O
4 12 21 9241281 cooperate VBP B-VP O
5 22 24 9241281 in IN B-PP O
6 25 34 9241281 apoptosis NN B-NP O
7 35 38 9241281 and CC I-NP O
8 39 50 9241281 suppression NN I-NP O
9 51 53 9241281 of IN B-PP O
10 54 67 9241281 tumorigenesis NN B-NP O
11 67 68 9241281 , , B-PP O
12 69 72 9241281 but CC I-PP O
13 73 76 9241281 not RB B-PP O
14 77 79 9241281 in IN I-PP O
15 80 90 9241281 resistance NN B-NP O
16 91 93 9241281 to TO B-PP O
17 94 99 9241281 acute JJ B-NP B-Disease
18 100 109 9241281 radiation NN I-NP I-Disease
19 110 118 9241281 toxicity NN I-NP I-Disease
20 118 119 9241281 . . O O
21 120 129 9241281 Mutations NNS B-NP O
22 130 132 9241281 in IN B-PP O
23 133 136 9241281 atm NN B-NP O
24 137 140 9241281 and CC I-NP O
25 141 144 9241281 p53 NN I-NP O
26 145 150 9241281 cause VBP B-VP O
27 151 154 9241281 the DT B-NP O
28 155 160 9241281 human JJ I-NP O
29 161 167 9241281 cancer NN I-NP B-Disease
30 167 168 9241281 - HYPH B-NP I-Disease
31 168 178 9241281 associated VBN I-NP I-Disease
32 179 187 9241281 diseases NNS I-NP I-Disease
33 188 194 9241281 ataxia NN I-NP B-Disease
34 194 195 9241281 - HYPH B-NP I-Disease
35 195 209 9241281 telangiectasia NN I-NP I-Disease
36 210 213 9241281 and CC O O
37 214 216 9241281 Li NNP B-NP B-Disease
38 216 217 9241281 - HYPH I-NP I-Disease
39 217 225 9241281 Fraumeni NNP I-NP I-Disease
40 226 234 9241281 syndrome NN I-NP I-Disease
41 234 235 9241281 , , O O
42 236 248 9241281 respectively RB B-ADVP O
43 248 249 9241281 . . O O

1 250 253 9241281 The DT B-NP O
2 254 257 9241281 two CD I-NP O
3 258 263 9241281 genes NNS I-NP O
4 264 267 9241281 are VBP B-VP O
5 268 276 9241281 believed VBN I-VP O
6 277 279 9241281 to TO I-VP O
7 280 288 9241281 interact VB I-VP O
8 289 291 9241281 in IN B-PP O
9 292 293 9241281 a DT B-NP O
10 294 300 9241281 number NN I-NP O
11 301 303 9241281 of IN B-PP O
12 304 312 9241281 pathways NNS B-NP O
13 312 313 9241281 , , O O
14 314 323 9241281 including VBG B-PP O
15 324 334 9241281 regulation NN B-NP O
16 335 337 9241281 of IN B-PP O
17 338 341 9241281 DNA NN B-NP O
18 342 348 9241281 damage NN I-NP O
19 348 349 9241281 - HYPH B-VP O
20 349 356 9241281 induced VBN B-NP O
21 357 361 9241281 cell NN I-NP O
22 361 362 9241281 - HYPH B-NP O
23 362 367 9241281 cycle NN I-NP O
24 368 379 9241281 checkpoints NNS I-NP O
25 379 380 9241281 , , O O
26 381 390 9241281 apoptosis NN B-NP O
27 391 394 9241281 and CC I-NP O
28 395 404 9241281 radiation NN I-NP O
29 405 416 9241281 sensitivity NN I-NP O
30 416 417 9241281 , , O O
31 418 421 9241281 and CC O O
32 422 430 9241281 cellular JJ B-NP O
33 431 444 9241281 proliferation NN I-NP O
34 444 445 9241281 . . O O

1 446 449 9241281 Atm NN B-NP O
2 449 450 9241281 - HYPH I-NP O
3 450 454 9241281 null JJ I-NP O
4 455 459 9241281 mice NNS I-NP O
5 459 460 9241281 , , O O
6 461 463 9241281 as RB B-CONJP O
7 464 468 9241281 well RB I-CONJP O
8 469 471 9241281 as IN I-CONJP O
9 472 477 9241281 those DT B-NP O
10 478 482 9241281 null NN I-NP O
11 483 486 9241281 for IN B-PP O
12 487 490 9241281 p53 NN B-NP O
13 490 491 9241281 , , O O
14 492 499 9241281 develop VBP B-VP O
15 500 506 9241281 mainly RB B-ADVP O
16 507 508 9241281 T NN B-NP B-Disease
17 508 509 9241281 - HYPH B-NP I-Disease
18 509 513 9241281 cell NN I-NP I-Disease
19 514 523 9241281 lymphomas NNS I-NP I-Disease
20 523 524 9241281 , , O O
21 525 535 9241281 supporting VBG B-VP O
22 536 539 9241281 the DT B-NP O
23 540 544 9241281 view NN I-NP O
24 545 549 9241281 that IN B-SBAR O
25 550 555 9241281 these DT B-NP O
26 556 561 9241281 genes NNS I-NP O
27 562 566 9241281 have VBP B-VP O
28 567 574 9241281 similar JJ B-NP O
29 575 580 9241281 roles NNS I-NP O
30 581 583 9241281 in IN B-PP O
31 584 593 9241281 thymocyte NN B-NP O
32 594 605 9241281 development NN I-NP O
33 605 606 9241281 . . O O

1 607 609 9241281 To TO B-VP O
2 610 615 9241281 study VB I-VP O
3 616 619 9241281 the DT B-NP O
4 620 632 9241281 interactions NNS I-NP O
5 633 635 9241281 of IN B-PP O
6 636 641 9241281 these DT B-NP O
7 642 645 9241281 two CD I-NP O
8 646 651 9241281 genes NNS I-NP O
9 652 654 9241281 on IN B-PP O
10 655 657 9241281 an DT B-NP O
11 658 668 9241281 organismal JJ I-NP O
12 669 674 9241281 level NN I-NP O
13 674 675 9241281 , , O O
14 676 678 9241281 we PRP B-NP O
15 679 683 9241281 bred VBD B-VP O
16 684 688 9241281 mice NNS B-NP O
17 689 701 9241281 heterozygous JJ B-ADJP O
18 702 705 9241281 for IN B-PP O
19 706 710 9241281 null JJ B-NP O
20 711 718 9241281 alleles NNS I-NP O
21 719 721 9241281 of IN B-PP O
22 722 726 9241281 both CC O O
23 727 730 9241281 atm NN B-NP O
24 731 734 9241281 and CC O O
25 735 738 9241281 p53 NN B-NP O
26 739 741 9241281 to TO B-VP O
27 742 749 9241281 produce VB I-VP O
28 750 753 9241281 all DT B-NP O
29 754 763 9241281 genotypic JJ I-NP O
30 764 776 9241281 combinations NNS I-NP O
31 776 777 9241281 . . O O

1 778 782 9241281 Mice NNS B-NP O
2 783 789 9241281 doubly RB B-ADJP O
3 790 794 9241281 null JJ I-ADJP O
4 795 798 9241281 for IN B-PP O
5 799 802 9241281 atm NN B-NP O
6 803 806 9241281 and CC I-NP O
7 807 810 9241281 p53 NN I-NP O
8 811 820 9241281 exhibited VBD B-VP O
9 821 822 9241281 a DT B-NP O
10 823 831 9241281 dramatic JJ I-NP O
11 832 844 9241281 acceleration NN I-NP O
12 845 847 9241281 of IN B-PP O
13 848 854 9241281 tumour NN B-NP B-Disease
14 855 864 9241281 formation NN I-NP O
15 865 873 9241281 relative JJ B-ADVP O
16 874 876 9241281 to TO B-PP O
17 877 883 9241281 singly RB B-NP O
18 884 888 9241281 null JJ I-NP O
19 889 893 9241281 mice NNS I-NP O
20 893 894 9241281 , , O O
21 895 905 9241281 indicating VBG B-VP O
22 906 910 9241281 that IN B-SBAR O
23 911 915 9241281 both DT B-NP O
24 916 921 9241281 genes NNS I-NP O
25 922 933 9241281 collaborate VBP B-VP O
26 934 936 9241281 in IN B-PP O
27 937 938 9241281 a DT B-NP O
28 939 950 9241281 significant JJ I-NP O
29 951 957 9241281 manner NN I-NP O
30 958 960 9241281 to TO B-VP O
31 961 968 9241281 prevent VB I-VP O
32 969 982 9241281 tumorigenesis NN B-NP O
33 982 983 9241281 . . O O

1 984 988 9241281 With IN B-PP O
2 989 996 9241281 respect NN B-NP O
3 997 999 9241281 to TO B-PP O
4 1000 1005 9241281 their PRP$ B-NP O
5 1006 1011 9241281 roles NNS I-NP O
6 1012 1014 9241281 in IN B-PP O
7 1015 1024 9241281 apoptosis NN B-NP O
8 1024 1025 9241281 , , O O
9 1026 1030 9241281 loss NN B-NP O
10 1031 1033 9241281 of IN B-PP O
11 1034 1037 9241281 atm NN B-NP O
12 1038 1046 9241281 rendered JJ I-NP O
13 1047 1057 9241281 thymocytes NNS I-NP O
14 1058 1062 9241281 only RB B-ADJP O
15 1063 1069 9241281 partly RB I-ADJP O
16 1070 1079 9241281 resistant JJ I-ADJP O
17 1080 1082 9241281 to TO B-PP O
18 1083 1094 9241281 irradiation NN B-NP O
19 1094 1095 9241281 - HYPH B-NP O
20 1095 1102 9241281 induced VBN I-NP O
21 1103 1112 9241281 apoptosis NN I-NP O
22 1112 1113 9241281 , , O O
23 1114 1121 9241281 whereas IN O O
24 1122 1132 9241281 additional JJ B-NP O
25 1133 1137 9241281 loss NN I-NP O
26 1138 1140 9241281 of IN B-PP O
27 1141 1144 9241281 p53 NN B-NP O
28 1145 1155 9241281 engendered VBD B-VP O
29 1156 1164 9241281 complete JJ B-NP O
30 1165 1175 9241281 resistance NN I-NP O
31 1175 1176 9241281 . . O O

1 1177 1181 9241281 This DT B-NP O
2 1182 1189 9241281 implies VBZ B-VP O
3 1190 1194 9241281 that IN B-SBAR O
4 1195 1198 9241281 the DT B-NP O
5 1199 1210 9241281 irradiation NN I-NP O
6 1210 1211 9241281 - HYPH B-NP O
7 1211 1218 9241281 induced VBN I-NP O
8 1219 1222 9241281 atm NN I-NP O
9 1223 1226 9241281 and CC I-NP O
10 1227 1230 9241281 p53 NN I-NP O
11 1231 1240 9241281 apoptotic JJ I-NP O
12 1241 1249 9241281 pathways NNS I-NP O
13 1250 1253 9241281 are VBP B-VP O
14 1254 1257 9241281 not RB O O
15 1258 1268 9241281 completely RB B-ADJP O
16 1269 1278 9241281 congruent JJ I-ADJP O
17 1278 1279 9241281 . . O O

1 1280 1287 9241281 Finally RB B-ADVP O
2 1287 1288 9241281 - HYPH B-ADJP O
3 1288 1291 9241281 and CC O O
4 1292 1294 9241281 in IN B-PP O
5 1295 1303 9241281 contrast NN B-NP O
6 1304 1306 9241281 to TO B-PP O
7 1307 1312 9241281 prior JJ B-NP O
8 1313 1324 9241281 predictions NNS I-NP O
9 1324 1325 9241281 - HYPH B-NP O
10 1325 1328 9241281 atm NN I-NP O
11 1329 1332 9241281 and CC I-NP O
12 1333 1336 9241281 p53 NN I-NP O
13 1337 1339 9241281 do VBP B-VP O
14 1340 1343 9241281 not RB I-VP O
15 1344 1350 9241281 appear VB I-VP O
16 1351 1353 9241281 to TO I-VP O
17 1354 1362 9241281 interact VB I-VP O
18 1363 1365 9241281 in IN B-PP O
19 1366 1371 9241281 acute JJ B-NP B-Disease
20 1372 1381 9241281 radiation NN I-NP I-Disease
21 1382 1390 9241281 toxicity NN I-NP I-Disease
22 1390 1391 9241281 , , O O
23 1392 1402 9241281 suggesting VBG B-VP O
24 1403 1404 9241281 a DT B-NP O
25 1405 1413 9241281 separate JJ I-NP O
26 1414 1417 9241281 atm NN I-NP O
27 1418 1426 9241281 effector NN I-NP O
28 1427 1434 9241281 pathway NN I-NP O
29 1435 1438 9241281 for IN B-PP O
30 1439 1443 9241281 this DT B-NP O
31 1444 1447 9241281 DNA NN I-NP O
32 1448 1454 9241281 damage NN I-NP O
33 1455 1463 9241281 response NN I-NP O
34 1464 1467 9241281 and CC O O
35 1468 1474 9241281 having VBG B-VP O
36 1475 1487 9241281 implications NNS B-NP O
37 1488 1491 9241281 for IN B-PP O
38 1492 1495 9241281 the DT B-NP O
39 1496 1505 9241281 prognosis NN I-NP O
40 1506 1509 9241281 and CC I-NP O
41 1510 1519 9241281 treatment NN I-NP O
42 1520 1522 9241281 of IN B-PP O
43 1523 1528 9241281 human JJ B-NP O
44 1529 1536 9241281 tumours NNS I-NP B-Disease
45 1536 1537 9241281 . . O O
46 1537 1538 9241281 . . O O

1 0 0 8808606 -DOCSTART- -X- -X- O

1 0 8 8808606 Analysis NN B-NP O
2 9 11 8808606 of IN B-PP O
3 12 19 8808606 meiotic JJ B-NP O
4 20 31 8808606 segregation NN I-NP O
5 31 32 8808606 , , O O
6 33 38 8808606 using VBG B-VP O
7 39 45 8808606 single JJ B-NP O
8 45 46 8808606 - HYPH I-NP O
9 46 51 8808606 sperm NN I-NP O
10 52 58 8808606 typing NN I-NP O
11 58 59 8808606 : : O O
12 60 67 8808606 meiotic JJ B-NP O
13 68 73 8808606 drive NN I-NP O
14 74 76 8808606 at IN B-PP O
15 77 80 8808606 the DT B-NP O
16 81 89 8808606 myotonic JJ I-NP B-Disease
17 90 99 8808606 dystrophy NN I-NP I-Disease
18 100 105 8808606 locus NN I-NP O
19 105 106 8808606 . . O O
20 107 114 8808606 Meiotic JJ B-NP O
21 115 120 8808606 drive NN I-NP O
22 121 123 8808606 at IN B-PP O
23 124 127 8808606 the DT B-NP O
24 128 136 8808606 myotonic JJ I-NP B-Disease
25 137 146 8808606 dystrophy NN I-NP I-Disease
26 147 148 8808606 ( ( O O
27 148 150 8808606 DM NN B-NP B-Disease
28 150 151 8808606 ) ) O O
29 152 157 8808606 locus NN B-NP O
30 158 161 8808606 has VBZ B-VP O
31 162 170 8808606 recently RB I-VP O
32 171 175 8808606 been VBN I-VP O
33 176 185 8808606 suggested VBN I-VP O
34 186 188 8808606 as IN B-PP O
35 189 194 8808606 being VBG B-VP O
36 195 206 8808606 responsible JJ B-ADJP O
37 207 210 8808606 for IN B-PP O
38 211 222 8808606 maintaining VBG B-VP O
39 223 226 8808606 the DT B-NP O
40 227 236 8808606 frequency NN I-NP O
41 236 237 8808606 , , O O
42 238 240 8808606 in IN B-PP O
43 241 244 8808606 the DT B-NP O
44 245 250 8808606 human JJ I-NP O
45 251 261 8808606 population NN I-NP O
46 261 262 8808606 , , O O
47 263 265 8808606 of IN B-PP O
48 266 268 8808606 DM NN B-NP B-Disease
49 269 280 8808606 chromosomes NNS I-NP O
50 281 288 8808606 capable JJ B-ADJP O
51 289 291 8808606 of IN B-PP O
52 292 301 8808606 expansion NN B-NP O
53 302 304 8808606 to TO B-PP O
54 305 308 8808606 the DT B-NP O
55 309 316 8808606 disease NN I-NP O
56 317 322 8808606 state NN I-NP O
57 322 323 8808606 . . O O

1 324 326 8808606 In IN B-SBAR O
2 327 332 8808606 order NN O O
3 333 335 8808606 to TO B-VP O
4 336 340 8808606 test VB I-VP O
5 341 345 8808606 this DT B-NP O
6 346 356 8808606 hypothesis NN I-NP O
7 356 357 8808606 , , O O
8 358 360 8808606 we PRP B-NP O
9 361 365 8808606 have VBP B-VP O
10 366 373 8808606 studied VBN I-VP O
11 374 381 8808606 samples NNS B-NP O
12 382 384 8808606 of IN B-PP O
13 385 391 8808606 single JJ B-NP O
14 392 397 8808606 sperm NN I-NP O
15 398 402 8808606 from IN B-PP O
16 403 408 8808606 three CD B-NP O
17 409 420 8808606 individuals NNS I-NP O
18 421 433 8808606 heterozygous JJ B-ADJP O
19 434 436 8808606 at IN B-PP O
20 437 440 8808606 the DT B-NP O
21 441 443 8808606 DM NN I-NP B-Disease
22 444 449 8808606 locus NN I-NP O
23 449 450 8808606 , , O O
24 451 455 8808606 each DT B-NP O
25 456 460 8808606 with IN B-PP O
26 461 464 8808606 one CD B-NP O
27 465 471 8808606 allele NN I-NP O
28 472 478 8808606 larger JJR B-ADJP O
29 479 482 8808606 and CC O O
30 483 486 8808606 one CD B-NP O
31 487 493 8808606 allele NN I-NP O
32 494 501 8808606 smaller JJR B-NP O
33 502 506 8808606 than IN I-NP O
34 507 509 8808606 19 CD I-NP O
35 510 513 8808606 CTG NN I-NP O
36 514 521 8808606 repeats NNS I-NP O
37 521 522 8808606 . . O O

1 523 525 8808606 To TO B-VP O
2 526 531 8808606 guard VB I-VP O
3 532 539 8808606 against IN B-PP O
4 540 543 8808606 the DT B-NP O
5 544 552 8808606 possible JJ I-NP O
6 553 560 8808606 problem NN I-NP O
7 561 563 8808606 of IN B-PP O
8 564 576 8808606 differential JJ B-NP O
9 577 580 8808606 PCR NN I-NP O
10 581 594 8808606 amplification NN I-NP O
11 595 600 8808606 rates NNS I-NP O
12 601 606 8808606 based VBN B-PP O
13 607 609 8808606 on IN B-PP O
14 610 613 8808606 the DT B-NP O
15 614 621 8808606 lengths NNS I-NP O
16 622 624 8808606 of IN B-PP O
17 625 628 8808606 the DT B-NP O
18 629 636 8808606 alleles NNS I-NP O
19 636 637 8808606 , , O O
20 638 641 8808606 the DT B-NP O
21 642 647 8808606 sperm NN I-NP O
22 648 652 8808606 were VBD B-VP O
23 653 657 8808606 also RB I-VP O
24 658 663 8808606 typed VBN I-VP O
25 664 666 8808606 at IN B-PP O
26 667 674 8808606 another DT B-NP O
27 675 682 8808606 closely RB I-NP O
28 683 689 8808606 linked VBN I-NP O
29 690 696 8808606 marker NN I-NP O
30 697 702 8808606 whose WP$ B-NP O
31 703 709 8808606 allele NN I-NP O
32 710 714 8808606 size NN I-NP O
33 715 718 8808606 was VBD B-VP O
34 719 728 8808606 unrelated JJ B-ADJP O
35 729 731 8808606 to TO B-PP O
36 732 735 8808606 the DT B-NP O
37 736 742 8808606 allele NN I-NP O
38 743 747 8808606 size NN I-NP O
39 748 750 8808606 at IN B-PP O
40 751 754 8808606 the DT B-NP O
41 755 757 8808606 DM NN I-NP B-Disease
42 758 763 8808606 locus NN I-NP O
43 763 764 8808606 . . O O

1 765 770 8808606 Using VBG B-VP O
2 771 782 8808606 statistical JJ B-NP O
3 783 789 8808606 models NNS I-NP O
4 790 802 8808606 specifically RB B-VP O
5 803 811 8808606 designed VBN I-VP O
6 812 814 8808606 to TO B-VP O
7 815 820 8808606 study VB I-VP O
8 821 827 8808606 single JJ B-NP O
9 827 828 8808606 - HYPH I-NP O
10 828 833 8808606 sperm NN I-NP O
11 834 845 8808606 segregation NN I-NP O
12 846 850 8808606 data NNS I-NP O
13 850 851 8808606 , , O O
14 852 854 8808606 we PRP B-NP O
15 855 859 8808606 find VBP B-VP O
16 860 862 8808606 no DT B-NP O
17 863 871 8808606 evidence NN I-NP O
18 872 874 8808606 of IN B-PP O
19 875 882 8808606 meiotic JJ B-NP O
20 883 894 8808606 segregation NN I-NP O
21 895 905 8808606 distortion NN I-NP O
22 905 906 8808606 . . O O

1 907 910 8808606 The DT B-NP O
2 911 916 8808606 upper JJ I-NP O
3 917 922 8808606 limit NN I-NP O
4 923 925 8808606 of IN B-PP O
5 926 929 8808606 the DT B-NP O
6 930 933 8808606 two CD I-NP O
7 933 934 8808606 - HYPH I-NP O
8 934 939 8808606 sided JJ I-NP O
9 940 943 8808606 95% NN I-NP O
10 944 954 8808606 confidence NN I-NP O
11 955 963 8808606 interval NN I-NP O
12 964 967 8808606 for IN B-PP O
13 968 971 8808606 the DT B-NP O
14 972 980 8808606 estimate NN I-NP O
15 981 983 8808606 of IN B-PP O
16 984 987 8808606 the DT B-NP O
17 988 994 8808606 common JJ I-NP O
18 995 1006 8808606 segregation NN I-NP O
19 1007 1018 8808606 probability NN I-NP O
20 1019 1022 8808606 for IN B-PP O
21 1023 1026 8808606 the DT B-NP O
22 1027 1032 8808606 three CD I-NP O
23 1033 1039 8808606 donors NNS I-NP O
24 1040 1042 8808606 is VBZ B-VP O
25 1043 1045 8808606 at IN B-PP O
26 1046 1048 8808606 or CC I-PP O
27 1049 1054 8808606 below IN I-PP O
28 1054 1055 8808606 . . O O

1 1056 1059 8808606 515 CD B-NP O
2 1060 1063 8808606 for IN B-PP O
3 1064 1067 8808606 all DT B-NP O
4 1068 1074 8808606 models NNS I-NP O
5 1075 1085 8808606 considered VBN B-VP O
6 1085 1086 8808606 , , O O
7 1087 1090 8808606 and CC O O
8 1091 1093 8808606 no DT B-NP O
9 1094 1107 8808606 statistically RB I-NP O
10 1108 1119 8808606 significant JJ I-NP O
11 1120 1130 8808606 difference NN I-NP O
12 1131 1135 8808606 from IN B-PP O
13 1135 1136 8808606 . . O O

1 1137 1138 8808606 5 CD B-NP O
2 1139 1141 8808606 is VBZ B-VP O
3 1142 1150 8808606 detected VBN I-VP O
4 1151 1153 8808606 in IN B-PP O
5 1154 1157 8808606 any DT B-NP O
6 1158 1160 8808606 of IN B-PP O
7 1161 1164 8808606 the DT B-NP O
8 1165 1171 8808606 models NNS I-NP O
9 1171 1172 8808606 . . O O

1 1173 1177 8808606 This DT B-NP O
2 1178 1186 8808606 suggests VBZ B-VP O
3 1187 1191 8808606 that IN B-SBAR O
4 1192 1195 8808606 any DT B-NP O
5 1196 1203 8808606 greater JJR I-NP O
6 1204 1210 8808606 amount NN I-NP O
7 1211 1213 8808606 of IN B-PP O
8 1214 1225 8808606 segregation NN B-NP O
9 1226 1236 8808606 distortion NN I-NP O
10 1237 1239 8808606 at IN B-PP O
11 1240 1243 8808606 the DT B-NP O
12 1244 1252 8808606 myotonic JJ I-NP B-Disease
13 1253 1262 8808606 dystrophy NN I-NP I-Disease
14 1263 1268 8808606 locus NN I-NP O
15 1269 1273 8808606 must MD B-VP O
16 1274 1280 8808606 result VB I-VP O
17 1281 1285 8808606 from IN B-PP O
18 1286 1292 8808606 events NNS B-NP O
19 1293 1302 8808606 following VBG B-PP O
20 1303 1308 8808606 sperm NN B-NP O
21 1309 1320 8808606 ejaculation NN I-NP O
22 1320 1321 8808606 . . O O

1 0 0 9241282 -DOCSTART- -X- -X- O

1 0 13 9241282 Trinucleotide NN B-NP O
2 14 20 9241282 repeat NN I-NP O
3 21 30 9241282 expansion NN I-NP O
4 31 33 9241282 at IN B-PP O
5 34 37 9241282 the DT B-NP O
6 38 46 9241282 myotonic JJ I-NP B-Disease
7 47 56 9241282 dystrophy NN I-NP I-Disease
8 57 62 9241282 locus NN I-NP O
9 63 70 9241282 reduces VBZ B-VP O
10 71 81 9241282 expression NN B-NP O
11 82 84 9241282 of IN B-PP O
12 85 90 9241282 DMAHP NN B-NP O
13 90 91 9241282 . . O O
14 92 100 9241282 Myotonic JJ B-NP B-Disease
15 101 110 9241282 dystrophy NN I-NP I-Disease
16 110 111 9241282 , , O O
17 112 114 9241282 or CC O O
18 115 125 9241282 dystrophia NN B-NP B-Disease
19 126 135 9241282 myotonica NN I-NP I-Disease
20 136 137 9241282 ( ( O O
21 137 139 9241282 DM NN B-NP B-Disease
22 139 140 9241282 ) ) O O
23 140 141 9241282 , , O O
24 142 144 9241282 is VBZ B-VP O
25 145 147 9241282 an DT B-NP O
26 148 157 9241282 autosomal JJ I-NP B-Disease
27 158 166 9241282 dominant JJ I-NP I-Disease
28 167 178 9241282 multisystem NN I-NP I-Disease
29 179 187 9241282 disorder NN I-NP I-Disease
30 188 194 9241282 caused VBN B-VP O
31 195 197 9241282 by IN B-PP O
32 198 201 9241282 the DT B-NP O
33 202 211 9241282 expansion NN I-NP O
34 212 214 9241282 of IN B-PP O
35 215 216 9241282 a DT B-NP O
36 217 220 9241282 CTG NN I-NP O
37 221 234 9241282 trinucleotide NN I-NP O
38 235 241 9241282 repeat NN I-NP O
39 242 244 9241282 in IN B-PP O
40 245 248 9241282 the DT B-NP O
41 249 250 9241282 3 CD I-NP O
42 251 263 9241282 untranslated JJ I-NP O
43 264 270 9241282 region NN I-NP O
44 271 273 9241282 of IN B-PP O
45 274 277 9241282 the DT B-NP O
46 278 282 9241282 DMPK NN I-NP O
47 283 290 9241282 protein NN I-NP O
48 291 297 9241282 kinase NN I-NP O
49 298 302 9241282 gene NN I-NP O
50 303 305 9241282 on IN B-PP O
51 306 316 9241282 chromosome NN B-NP O
52 317 322 9241282 19q13 CD I-NP O
53 322 323 9241282 . . O O

1 324 325 9241282 3 CD B-NP O
2 326 327 9241282 ( ( O O
3 327 331 9241282 refs NNS B-NP O
4 332 333 9241282 1 CD I-NP O
5 333 334 9241282 - HYPH I-NP O
6 334 335 9241282 3 CD I-NP O
7 335 336 9241282 ) ) O O
8 336 337 9241282 . . O O

1 338 346 9241282 Although IN B-SBAR O
2 347 350 9241282 the DT B-NP O
3 351 353 9241282 DM NN I-NP B-Disease
4 354 362 9241282 mutation NN I-NP O
5 363 366 9241282 was VBD B-VP O
6 367 377 9241282 identified VBN I-VP O
7 378 382 9241282 more JJR B-NP O
8 383 387 9241282 than IN I-NP O
9 388 392 9241282 five CD I-NP O
10 393 398 9241282 years NNS I-NP O
11 399 402 9241282 ago RB B-ADVP O
12 402 403 9241282 , , O O
13 404 407 9241282 the DT B-NP O
14 408 418 9241282 pathogenic JJ I-NP O
15 419 429 9241282 mechanisms NNS I-NP O
16 430 440 9241282 underlying VBG B-VP O
17 441 445 9241282 this DT B-NP O
18 446 450 9241282 most RBS I-NP O
19 451 460 9241282 prevalent JJ I-NP O
20 461 465 9241282 form NN I-NP O
21 466 468 9241282 of IN B-PP O
22 469 479 9241282 hereditary JJ B-NP O
23 480 485 9241282 adult JJ I-NP O
24 486 499 9241282 neuromuscular JJ I-NP B-Disease
25 500 507 9241282 disease NN I-NP I-Disease
26 508 514 9241282 remain VBP B-VP O
27 515 522 9241282 elusive JJ B-ADJP O
28 522 523 9241282 . . O O

1 524 532 9241282 Previous JJ B-NP O
2 533 537 9241282 work NN I-NP O
3 538 542 9241282 from IN B-PP O
4 543 546 9241282 our PRP$ B-NP O
5 547 557 9241282 laboratory NN I-NP O
6 558 570 9241282 demonstrated VBD B-VP O
7 571 575 9241282 that IN B-SBAR O
8 576 577 9241282 a DT B-NP O
9 578 583 9241282 DNase NN I-NP O
10 584 585 9241282 l NN I-NP O
11 585 586 9241282 - HYPH B-NP O
12 586 600 9241282 hypersensitive JJ I-NP O
13 601 605 9241282 site NN I-NP O
14 606 613 9241282 located JJ I-NP O
15 614 622 9241282 adjacent JJ B-ADJP O
16 623 625 9241282 to TO B-PP O
17 626 629 9241282 the DT B-NP O
18 630 637 9241282 repeats NNS I-NP O
19 638 640 9241282 on IN B-PP O
20 641 644 9241282 the DT B-NP O
21 645 649 9241282 wild JJ I-NP O
22 649 650 9241282 - HYPH I-NP O
23 650 654 9241282 type NN I-NP O
24 655 661 9241282 allele NN I-NP O
25 662 664 9241282 is VBZ B-VP O
26 665 675 9241282 eliminated VBN I-VP O
27 676 678 9241282 by IN B-PP O
28 679 685 9241282 repeat NN B-NP O
29 686 695 9241282 expansion NN I-NP O
30 695 696 9241282 , , O O
31 697 707 9241282 indicating VBG B-VP O
32 708 712 9241282 that IN B-SBAR O
33 713 718 9241282 large JJ B-NP O
34 719 722 9241282 CTG NN I-NP O
35 722 723 9241282 - HYPH B-NP O
36 723 729 9241282 repeat NN I-NP O
37 730 736 9241282 arrays NNS I-NP O
38 737 740 9241282 may MD B-VP O
39 741 743 9241282 be VB I-VP O
40 744 754 9241282 associated VBN I-VP O
41 755 759 9241282 with IN B-PP O
42 760 761 9241282 a DT B-NP O
43 762 767 9241282 local JJ I-NP O
44 768 777 9241282 chromatin NN I-NP O
45 778 789 9241282 environment NN I-NP O
46 790 794 9241282 that WDT B-NP O
47 795 804 9241282 represses VBZ B-VP O
48 805 809 9241282 gene NN B-NP O
49 810 820 9241282 expression NN I-NP O
50 820 821 9241282 . . O O

1 822 826 9241282 Here RB B-ADVP O
2 827 829 9241282 we PRP B-NP O
3 830 836 9241282 report VBP B-VP O
4 837 841 9241282 that IN B-SBAR O
5 842 845 9241282 the DT B-NP O
6 846 860 9241282 hypersensitive JJ I-NP O
7 861 865 9241282 site NN I-NP O
8 866 874 9241282 contains VBZ B-VP O
9 875 877 9241282 an DT B-NP O
10 878 886 9241282 enhancer NN I-NP O
11 887 894 9241282 element NN I-NP O
12 895 899 9241282 that WDT B-NP O
13 900 909 9241282 regulates VBZ B-VP O
14 910 923 9241282 transcription NN B-NP O
15 924 926 9241282 of IN B-PP O
16 927 930 9241282 the DT B-NP O
17 931 939 9241282 adjacent JJ I-NP O
18 940 945 9241282 DMAHP NN I-NP O
19 946 954 9241282 homeobox NN I-NP O
20 955 959 9241282 gene NN I-NP O
21 959 960 9241282 . . O O

1 961 969 9241282 Analysis NN B-NP O
2 970 972 9241282 of IN B-PP O
3 973 978 9241282 DMAHP NN B-NP O
4 979 989 9241282 expression NN I-NP O
5 990 992 9241282 in IN B-PP O
6 993 996 9241282 the DT B-NP O
7 997 1002 9241282 cells NNS I-NP O
8 1003 1005 9241282 of IN B-PP O
9 1006 1008 9241282 DM NN B-NP B-Disease
10 1009 1017 9241282 patients NNS I-NP O
11 1018 1022 9241282 with IN B-PP O
12 1023 1027 9241282 loss NN B-NP O
13 1028 1030 9241282 of IN B-PP O
14 1031 1034 9241282 the DT B-NP O
15 1035 1049 9241282 hypersensitive JJ I-NP O
16 1050 1054 9241282 site NN I-NP O
17 1055 1063 9241282 revealed VBD B-VP O
18 1064 1065 9241282 a DT B-NP O
19 1066 1069 9241282 two CD I-NP O
20 1069 1070 9241282 - HYPH B-ADVP O
21 1071 1073 9241282 to TO B-PP O
22 1074 1082 9241282 fourfold JJ B-NP O
23 1083 1092 9241282 reduction NN I-NP O
24 1093 1095 9241282 in IN B-PP O
25 1096 1102 9241282 steady JJ B-NP O
26 1102 1103 9241282 - HYPH I-NP O
27 1103 1108 9241282 state NN I-NP O
28 1109 1114 9241282 DMAHP NN I-NP O
29 1115 1125 9241282 transcript NN I-NP O
30 1126 1132 9241282 levels NNS I-NP O
31 1133 1141 9241282 relative JJ B-ADJP O
32 1142 1144 9241282 to TO B-PP O
33 1145 1149 9241282 wild JJ B-NP O
34 1149 1150 9241282 - HYPH I-NP O
35 1150 1154 9241282 type NN I-NP O
36 1155 1163 9241282 controls NNS I-NP O
37 1163 1164 9241282 . . O O

1 1165 1171 9241282 Allele NN B-NP O
2 1171 1172 9241282 - HYPH I-NP O
3 1172 1180 9241282 specific JJ I-NP O
4 1181 1189 9241282 analysis NN I-NP O
5 1190 1192 9241282 of IN B-PP O
6 1193 1198 9241282 DMAHP NN B-NP O
7 1199 1209 9241282 expression NN I-NP O
8 1210 1216 9241282 showed VBD B-VP O
9 1217 1221 9241282 that IN B-SBAR O
10 1222 1228 9241282 steady JJ B-NP O
11 1228 1229 9241282 - HYPH I-NP O
12 1229 1234 9241282 state NN I-NP O
13 1235 1245 9241282 transcript NN I-NP O
14 1246 1252 9241282 levels NNS I-NP O
15 1253 1257 9241282 from IN B-PP O
16 1258 1261 9241282 the DT B-NP O
17 1262 1270 9241282 expanded VBN I-NP O
18 1271 1277 9241282 allele NN I-NP O
19 1278 1282 9241282 were VBD B-VP O
20 1283 1290 9241282 greatly RB I-VP O
21 1291 1298 9241282 reduced VBN I-VP O
22 1299 1301 9241282 in IN B-PP O
23 1302 1312 9241282 comparison NN B-NP O
24 1313 1315 9241282 to TO B-PP O
25 1316 1321 9241282 those DT B-NP O
26 1322 1326 9241282 from IN B-PP O
27 1327 1330 9241282 the DT B-NP O
28 1331 1335 9241282 wild JJ I-NP O
29 1335 1336 9241282 - HYPH I-NP O
30 1336 1340 9241282 type NN I-NP O
31 1341 1347 9241282 allele NN I-NP O
32 1347 1348 9241282 . . O O

1 1349 1357 9241282 Together RB B-ADVP O
2 1357 1358 9241282 , , O O
3 1359 1364 9241282 these DT B-NP O
4 1365 1372 9241282 results NNS I-NP O
5 1373 1384 9241282 demonstrate VBP B-VP O
6 1385 1389 9241282 that IN B-SBAR O
7 1390 1393 9241282 CTG NN B-NP O
8 1393 1394 9241282 - HYPH B-NP O
9 1394 1400 9241282 repeat NN I-NP O
10 1401 1411 9241282 expansions NNS I-NP O
11 1412 1415 9241282 can MD B-VP O
12 1416 1424 9241282 suppress VB I-VP O
13 1425 1430 9241282 local JJ B-NP O
14 1431 1435 9241282 gene NN I-NP O
15 1436 1446 9241282 expression NN I-NP O
16 1447 1450 9241282 and CC O O
17 1451 1460 9241282 implicate VBP B-VP O
18 1461 1466 9241282 DMAHP NN B-NP O
19 1467 1469 9241282 in IN B-PP O
20 1470 1472 9241282 DM NN B-NP B-Disease
21 1473 1485 9241282 pathogenesis NN I-NP O
22 1485 1486 9241282 . . O O

1 0 0 9272171 -DOCSTART- -X- -X- O

1 0 5 9272171 Adult JJ B-NP B-Disease
2 6 11 9272171 onset NN I-NP I-Disease
3 12 19 9272171 globoid JJ I-NP I-Disease
4 20 24 9272171 cell NN I-NP I-Disease
5 25 39 9272171 leukodystrophy NN I-NP I-Disease
6 40 41 9272171 ( ( O O
7 41 47 9272171 Krabbe NNP B-NP B-Disease
8 48 55 9272171 disease NN I-NP I-Disease
9 55 56 9272171 ) ) O O
10 56 57 9272171 : : O O
11 58 66 9272171 analysis NN B-NP O
12 67 69 9272171 of IN B-PP O
13 70 90 9272171 galactosylceramidase NN B-NP O
14 91 95 9272171 cDNA NN I-NP O
15 96 100 9272171 from IN B-PP O
16 101 105 9272171 four CD B-NP O
17 106 114 9272171 Japanese JJ I-NP O
18 115 123 9272171 patients NNS I-NP O
19 123 124 9272171 . . O O
20 125 127 9272171 We PRP B-NP O
21 128 136 9272171 examined VBD B-VP O
22 137 157 9272171 galactosylceramidase NN B-NP O
23 158 159 9272171 ( ( O O
24 159 163 9272171 GALC NN B-NP O
25 163 164 9272171 ) ) O O
26 165 169 9272171 cDNA NN B-NP O
27 170 172 9272171 in IN B-PP O
28 173 177 9272171 four CD B-NP O
29 178 186 9272171 Japanese JJ I-NP O
30 187 195 9272171 patients NNS I-NP O
31 196 200 9272171 with IN B-PP O
32 201 206 9272171 adult JJ B-NP B-Disease
33 207 212 9272171 onset NN I-NP I-Disease
34 213 220 9272171 globoid JJ I-NP I-Disease
35 221 225 9272171 cell NN I-NP I-Disease
36 226 240 9272171 leukodystrophy NN I-NP I-Disease
37 241 242 9272171 ( ( O O
38 242 248 9272171 Krabbe NNP B-NP B-Disease
39 249 256 9272171 disease NN I-NP I-Disease
40 256 257 9272171 ; : O O
41 258 260 9272171 AO NN B-NP B-Disease
42 260 261 9272171 - HYPH I-NP I-Disease
43 261 264 9272171 GLD NN I-NP I-Disease
44 264 265 9272171 ) ) O O
45 266 268 9272171 by IN B-PP O
46 269 279 9272171 polymerase NN B-NP O
47 280 285 9272171 chain NN I-NP O
48 286 294 9272171 reaction NN I-NP O
49 294 295 9272171 / SYM B-NP O
50 295 301 9272171 single JJ I-NP O
51 301 302 9272171 - HYPH I-NP O
52 302 308 9272171 strand NN I-NP O
53 309 321 9272171 conformation NN I-NP O
54 322 334 9272171 polymorphism NN I-NP O
55 335 336 9272171 ( ( O O
56 336 339 9272171 PCR NN B-NP O
57 339 340 9272171 - HYPH B-NP O
58 340 344 9272171 SSCP NN I-NP O
59 344 345 9272171 ) ) O O
60 346 354 9272171 analysis NN B-NP O
61 354 355 9272171 , , O O
62 356 366 9272171 subsequent JJ B-NP O
63 367 375 9272171 sequence NN I-NP O
64 376 389 9272171 determination NN I-NP O
65 389 390 9272171 , , O O
66 391 394 9272171 and CC O O
67 395 406 9272171 restriction NN B-NP O
68 407 413 9272171 enzyme NN I-NP O
69 414 423 9272171 digestion NN I-NP O
70 424 426 9272171 of IN B-PP O
71 427 430 9272171 PCR NN B-NP O
72 431 439 9272171 products NNS I-NP O
73 439 440 9272171 , , O O
74 441 448 9272171 initial JJ B-NP O
75 449 457 9272171 symptoms NNS I-NP O
76 458 462 9272171 were VBD B-VP O
77 463 466 9272171 the DT B-NP O
78 467 472 9272171 onset NN I-NP O
79 473 475 9272171 of IN B-PP O
80 476 482 9272171 slowly RB B-NP O
81 483 494 9272171 progressive JJ I-NP O
82 495 502 9272171 spastic JJ I-NP B-Disease
83 503 513 9272171 paraplegia NN I-NP I-Disease
84 514 518 9272171 from IN B-PP O
85 519 522 9272171 the DT B-NP O
86 523 529 9272171 middle NN I-NP O
87 530 532 9272171 of IN B-PP O
88 533 536 9272171 the DT B-NP O
89 537 543 9272171 second JJ I-NP O
90 544 550 9272171 decade NN I-NP O
91 550 551 9272171 , , O O
92 552 555 9272171 and CC O O
93 556 559 9272171 all DT B-NP O
94 560 568 9272171 patients NNS I-NP O
95 569 572 9272171 had VBD B-VP O
96 573 583 9272171 diminished VBN I-VP B-Disease
97 584 588 9272171 GALC NN B-NP I-Disease
98 589 597 9272171 activity NN I-NP I-Disease
99 598 600 9272171 in IN B-PP O
100 601 606 9272171 their PRP$ B-NP O
101 607 617 9272171 leukocytes NNS I-NP O
102 617 618 9272171 . . O O

1 619 621 9272171 We PRP B-NP O
2 622 632 9272171 identified VBD B-VP O
3 633 638 9272171 three CD B-NP O
4 639 647 9272171 missense JJ I-NP O
5 648 657 9272171 mutations NNS I-NP O
6 658 659 9272171 ( ( O O
7 659 663 9272171 I66M NN B-NP O
8 663 664 9272171 , , O O
9 665 670 9272171 G270D NN B-NP O
10 670 671 9272171 , , O O
11 672 677 9272171 L618S NN B-NP O
12 677 678 9272171 ) ) O O
13 679 682 9272171 and CC O O
14 683 686 9272171 one CD B-NP O
15 687 691 9272171 exon NN I-NP O
16 691 692 9272171 - HYPH O O
17 692 693 9272171 6 CD B-NP O
18 694 702 9272171 skipping NN I-NP O
19 703 704 9272171 ( ( O O
20 704 707 9272171 535 CD B-NP O
21 707 708 9272171 - HYPH I-NP O
22 708 714 9272171 573del NN I-NP O
23 714 715 9272171 ) ) O O
24 715 716 9272171 . . O O

1 717 720 9272171 Two CD B-NP O
2 721 723 9272171 of IN B-PP O
3 724 727 9272171 the DT B-NP O
4 728 736 9272171 patients NNS I-NP O
5 737 740 9272171 had VBD B-VP O
6 741 745 9272171 only RB B-NP O
7 746 749 9272171 the DT I-NP O
8 750 754 9272171 I66M NN I-NP O
9 755 761 9272171 mutant NN I-NP O
10 762 766 9272171 mRNA NN I-NP O
11 766 767 9272171 , , O O
12 768 771 9272171 and CC O O
13 772 775 9272171 one CD B-NP O
14 776 780 9272171 only RB I-NP O
15 781 784 9272171 the DT I-NP O
16 785 790 9272171 G27OD NN I-NP O
17 791 797 9272171 mutant NN I-NP O
18 798 802 9272171 mRNA NN I-NP O
19 802 803 9272171 . . O O

1 804 807 9272171 The DT B-NP O
2 808 814 9272171 fourth JJ I-NP O
3 815 822 9272171 patient NN I-NP O
4 823 830 9272171 carried VBD B-VP O
5 831 832 9272171 a DT B-NP O
6 833 841 9272171 compound NN I-NP O
7 842 854 9272171 heterozygous JJ I-NP O
8 855 863 9272171 mutation NN I-NP O
9 864 866 9272171 of IN B-PP O
10 867 870 9272171 535 CD B-NP O
11 870 871 9272171 - HYPH I-NP O
12 871 877 9272171 573del NN I-NP O
13 878 881 9272171 and CC I-NP O
14 882 887 9272171 L618S NN I-NP O
15 887 888 9272171 . . O O

1 889 891 9272171 To TO B-VP O
2 892 901 9272171 determine VB I-VP O
3 902 905 9272171 the DT B-NP O
4 906 915 9272171 enzymatic JJ I-NP O
5 916 926 9272171 activities NNS I-NP O
6 927 935 9272171 produced VBN B-VP O
7 936 938 9272171 by IN B-PP O
8 939 944 9272171 these DT B-NP O
9 945 954 9272171 mutations NNS I-NP O
10 954 955 9272171 , , O O
11 956 958 9272171 we PRP B-NP O
12 959 970 9272171 constructed VBD B-VP O
13 971 978 9272171 mutated VBN I-VP O
14 979 983 9272171 GALC NN B-NP O
15 984 989 9272171 cDNAs NNS I-NP O
16 990 993 9272171 and CC O O
17 994 1003 9272171 expressed VBD B-VP O
18 1004 1008 9272171 them PRP B-NP O
19 1009 1011 9272171 in IN B-PP O
20 1012 1015 9272171 COS NN B-NP O
21 1015 1016 9272171 - HYPH B-NP O
22 1016 1017 9272171 1 CD I-NP O
23 1018 1023 9272171 cells NNS I-NP O
24 1023 1024 9272171 . . O O

1 1025 1030 9272171 Three CD B-NP O
2 1031 1040 9272171 mutations NNS I-NP O
3 1040 1041 9272171 , , O O
4 1042 1045 9272171 viz NN B-NP O
5 1045 1046 9272171 . NN I-NP O
6 1046 1047 9272171 , , O O
7 1048 1053 9272171 G270D NN B-NP O
8 1053 1054 9272171 , , O O
9 1055 1060 9272171 L618S NN B-NP O
10 1060 1061 9272171 , , O O
11 1062 1065 9272171 and CC O O
12 1066 1070 9272171 exon NN B-NP O
13 1070 1071 9272171 - HYPH O O
14 1071 1072 9272171 6 CD B-NP O
15 1073 1081 9272171 skipping NN I-NP O
16 1082 1083 9272171 ( ( O O
17 1083 1086 9272171 535 CD B-NP O
18 1086 1087 9272171 - HYPH I-NP O
19 1087 1093 9272171 573del NN I-NP O
20 1093 1094 9272171 ) ) O O
21 1094 1095 9272171 , , O O
22 1096 1104 9272171 produced VBD B-VP O
23 1105 1115 9272171 diminished VBN I-VP B-Disease
24 1116 1120 9272171 GALC NN B-NP I-Disease
25 1121 1129 9272171 activity NN I-NP I-Disease
26 1130 1132 9272171 as IN B-SBAR O
27 1133 1141 9272171 expected VBN B-VP O
28 1141 1142 9272171 . . O O

1 1143 1146 9272171 The DT B-NP O
2 1147 1151 9272171 I66M NN I-NP O
3 1152 1160 9272171 mutation NN I-NP O
4 1161 1163 9272171 in IN B-PP O
5 1164 1167 9272171 the DT B-NP O
6 1168 1172 9272171 wild JJ I-NP O
7 1172 1173 9272171 - HYPH I-NP O
8 1173 1177 9272171 type NN I-NP O
9 1178 1182 9272171 GALC NN I-NP O
10 1183 1187 9272171 cDNA NN I-NP O
11 1188 1189 9272171 ( ( O O
12 1189 1193 9272171 I289 NN B-NP O
13 1193 1194 9272171 ) ) O O
14 1195 1198 9272171 had VBD B-VP O
15 1199 1205 9272171 normal JJ B-NP O
16 1206 1214 9272171 activity NN I-NP O
17 1214 1215 9272171 , , O O
18 1216 1219 9272171 but CC O O
19 1220 1224 9272171 when WRB B-ADVP O
20 1225 1229 9272171 this DT B-NP O
21 1230 1238 9272171 mutation NN I-NP O
22 1239 1242 9272171 and CC O O
23 1243 1246 9272171 the DT B-NP O
24 1247 1251 9272171 V289 NN I-NP O
25 1252 1264 9272171 polymorphism NN I-NP O
26 1265 1269 9272171 were VBD B-VP O
27 1270 1280 9272171 introduced VBN I-VP O
28 1281 1285 9272171 into IN B-PP O
29 1286 1289 9272171 the DT B-NP O
30 1290 1294 9272171 same JJ I-NP O
31 1295 1301 9272171 allele NN I-NP O
32 1301 1302 9272171 , , O O
33 1303 1305 9272171 it PRP B-NP O
34 1306 1309 9272171 had VBD B-VP O
35 1310 1319 9272171 decreased VBN I-VP O
36 1320 1328 9272171 activity NN B-NP O
37 1328 1329 9272171 . . O O

1 1330 1334 9272171 Thus RB B-ADVP O
2 1334 1335 9272171 , , O O
3 1336 1339 9272171 the DT B-NP O
4 1340 1351 9272171 combination NN I-NP O
5 1352 1354 9272171 of IN B-PP O
6 1355 1356 9272171 a DT B-NP O
7 1357 1363 9272171 unique JJ I-NP O
8 1364 1372 9272171 mutation NN I-NP O
9 1373 1376 9272171 and CC I-NP O
10 1377 1389 9272171 polymorphism NN I-NP O
11 1390 1396 9272171 causes VBZ B-VP O
12 1397 1411 9272171 conformational JJ B-NP O
13 1412 1418 9272171 change NN I-NP O
14 1419 1421 9272171 in IN B-PP O
15 1422 1425 9272171 the DT B-NP O
16 1426 1430 9272171 GALC NN I-NP O
17 1431 1437 9272171 enzyme NN I-NP O
18 1437 1438 9272171 , , O O
19 1439 1448 9272171 resulting VBG B-VP O
20 1449 1451 9272171 in IN B-PP O
21 1452 1455 9272171 low JJ B-NP O
22 1456 1465 9272171 enzymatic JJ I-NP O
23 1466 1474 9272171 activity NN I-NP O
24 1474 1475 9272171 . . O O

1 1476 1478 9272171 AO NN B-NP B-Disease
2 1478 1479 9272171 - HYPH I-NP I-Disease
3 1479 1482 9272171 GLD NN I-NP I-Disease
4 1483 1492 9272171 mutations NNS I-NP O
5 1492 1493 9272171 , , O O
6 1494 1503 9272171 including VBG B-PP O
7 1504 1509 9272171 those DT B-NP O
8 1510 1515 9272171 found VBN B-VP O
9 1516 1520 9272171 here RB B-ADVP O
10 1520 1521 9272171 , , O O
11 1522 1525 9272171 are VBP B-VP O
12 1526 1533 9272171 located JJ B-ADJP O
13 1534 1536 9272171 in IN B-PP O
14 1537 1540 9272171 the DT B-NP O
15 1541 1542 9272171 N NN I-NP O
16 1542 1543 9272171 - HYPH O O
17 1543 1551 9272171 terminus NN B-NP O
18 1552 1553 9272171 ( ( O O
19 1553 1557 9272171 I66M NN B-NP O
20 1557 1558 9272171 , , O O
21 1559 1564 9272171 G270D NN B-NP O
22 1564 1565 9272171 , , O O
23 1566 1569 9272171 535 CD B-NP O
24 1569 1570 9272171 - HYPH I-NP O
25 1570 1576 9272171 573del NN I-NP O
26 1576 1577 9272171 ) ) O O
27 1578 1580 9272171 or CC O O
28 1581 1582 9272171 C NN B-NP O
29 1582 1583 9272171 - HYPH O O
30 1583 1591 9272171 terminus NN B-NP O
31 1592 1593 9272171 ( ( O O
32 1593 1598 9272171 L618S NN B-NP O
33 1598 1599 9272171 ) ) O O
34 1600 1602 9272171 of IN B-PP O
35 1603 1606 9272171 the DT B-NP O
36 1607 1611 9272171 GALC NN I-NP O
37 1612 1618 9272171 enzyme NN I-NP O
38 1618 1619 9272171 , , O O
39 1620 1627 9272171 whereas IN O O
40 1628 1631 9272171 the DT B-NP O
41 1632 1640 9272171 reported VBN I-NP O
42 1641 1650 9272171 mutations NNS I-NP O
43 1651 1653 9272171 in IN B-PP O
44 1654 1657 9272171 the DT B-NP O
45 1658 1667 9272171 infantile JJ I-NP O
46 1668 1672 9272171 form NN I-NP O
47 1673 1674 9272171 ( ( O O
48 1674 1676 9272171 IF NN B-NP B-Disease
49 1676 1677 9272171 - HYPH B-NP I-Disease
50 1677 1680 9272171 GLD NN I-NP I-Disease
51 1680 1681 9272171 ) ) O O
52 1682 1685 9272171 are VBP B-VP O
53 1686 1688 9272171 in IN B-PP O
54 1689 1692 9272171 the DT B-NP O
55 1693 1700 9272171 central JJ I-NP O
56 1701 1707 9272171 domain NN I-NP O
57 1707 1708 9272171 . . O O

1 1709 1713 9272171 This DT B-NP O
2 1714 1724 9272171 difference NN I-NP O
3 1725 1727 9272171 in IN B-PP O
4 1728 1736 9272171 mutation NN B-NP O
5 1737 1742 9272171 sites NNS I-NP O
6 1743 1746 9272171 may MD B-VP O
7 1747 1753 9272171 affect VB I-VP O
8 1754 1757 9272171 the DT B-NP O
9 1758 1766 9272171 clinical JJ I-NP O
10 1767 1775 9272171 features NNS I-NP O
11 1776 1778 9272171 of IN B-PP O
12 1779 1782 9272171 GLD NN B-NP B-Disease
13 1782 1783 9272171 . . O O

1 0 0 8751855 -DOCSTART- -X- -X- O

1 0 7 8751855 Genetic JJ B-NP O
2 8 21 8751855 heterogeneity NN I-NP O
3 22 24 8751855 in IN B-PP O
4 25 35 8751855 hereditary JJ B-NP B-Disease
5 36 42 8751855 breast NN I-NP I-Disease
6 43 49 8751855 cancer NN I-NP I-Disease
7 49 50 8751855 : : O O
8 51 55 8751855 role NN B-NP O
9 56 58 8751855 of IN B-PP O
10 59 64 8751855 BRCA1 NN B-NP O
11 65 68 8751855 and CC I-NP O
12 69 74 8751855 BRCA2 NN I-NP O
13 74 75 8751855 . . O O
14 76 79 8751855 The DT B-NP O
15 80 86 8751855 common JJ I-NP O
16 87 97 8751855 hereditary JJ I-NP O
17 98 103 8751855 forms NNS I-NP O
18 104 106 8751855 of IN B-PP O
19 107 113 8751855 breast NN B-NP B-Disease
20 114 120 8751855 cancer NN I-NP I-Disease
21 121 125 8751855 have VBP B-VP O
22 126 130 8751855 been VBN I-VP O
23 131 138 8751855 largely RB I-VP O
24 139 149 8751855 attributed VBN I-VP O
25 150 152 8751855 to TO B-PP O
26 153 156 8751855 the DT B-NP O
27 157 168 8751855 inheritance NN I-NP O
28 169 171 8751855 of IN B-PP O
29 172 181 8751855 mutations NNS B-NP O
30 182 184 8751855 in IN B-PP O
31 185 188 8751855 the DT B-NP O
32 189 194 8751855 BRCA1 NN I-NP O
33 195 197 8751855 or CC I-NP O
34 198 203 8751855 BRCA2 NN I-NP O
35 204 209 8751855 genes NNS I-NP O
36 209 210 8751855 . . O O

1 211 218 8751855 However RB B-ADVP O
2 218 219 8751855 , , O O
3 220 222 8751855 it PRP B-NP O
4 223 225 8751855 is VBZ B-VP O
5 226 229 8751855 not RB O O
6 230 233 8751855 yet RB B-ADJP O
7 234 239 8751855 clear JJ I-ADJP O
8 240 244 8751855 what WDT B-NP O
9 245 255 8751855 proportion NN I-NP O
10 256 258 8751855 of IN B-PP O
11 259 269 8751855 hereditary JJ B-NP B-Disease
12 270 276 8751855 breast NN I-NP I-Disease
13 277 283 8751855 cancer NN I-NP I-Disease
14 284 286 8751855 is VBZ B-VP O
15 287 296 8751855 explained VBN I-VP O
16 297 299 8751855 by IN B-PP O
17 300 305 8751855 BRCA1 NN B-NP O
18 306 309 8751855 and CC I-NP O
19 310 315 8751855 BRCA2 NN I-NP O
20 316 318 8751855 or CC O O
21 319 321 8751855 by IN B-PP O
22 322 326 8751855 some DT B-NP O
23 327 332 8751855 other JJ I-NP O
24 333 345 8751855 unidentified JJ I-NP O
25 346 360 8751855 susceptibility NN I-NP O
26 361 365 8751855 gene NN I-NP O
27 366 367 8751855 ( ( I-NP O
28 367 368 8751855 s NNS I-NP O
29 368 369 8751855 ) ) O O
30 369 370 8751855 . . O O

1 371 373 8751855 We PRP B-NP O
2 374 382 8751855 describe VBP B-VP O
3 383 386 8751855 the DT B-NP O
4 387 397 8751855 proportion NN I-NP O
5 398 400 8751855 of IN B-PP O
6 401 411 8751855 hereditary JJ B-NP B-Disease
7 412 418 8751855 breast NN I-NP I-Disease
8 419 425 8751855 cancer NN I-NP I-Disease
9 426 435 8751855 explained VBN B-VP O
10 436 438 8751855 by IN B-PP O
11 439 444 8751855 BRCA1 NN B-NP O
12 445 447 8751855 or CC I-NP O
13 448 453 8751855 BRCA2 NN I-NP O
14 454 456 8751855 in IN B-PP O
15 457 458 8751855 a DT B-NP O
16 459 465 8751855 sample NN I-NP O
17 466 468 8751855 of IN B-PP O
18 469 474 8751855 North JJ B-NP O
19 475 483 8751855 American JJ I-NP O
20 484 494 8751855 hereditary JJ I-NP B-Disease
21 495 501 8751855 breast NN I-NP I-Disease
22 502 509 8751855 cancers NNS I-NP I-Disease
23 510 513 8751855 and CC O O
24 514 520 8751855 assess VB B-VP O
25 521 524 8751855 the DT B-NP O
26 525 533 8751855 evidence NN I-NP O
27 534 537 8751855 for IN B-PP O
28 538 548 8751855 additional JJ B-NP O
29 549 563 8751855 susceptibility NN I-NP O
30 564 569 8751855 genes NNS I-NP O
31 570 574 8751855 that WDT B-NP O
32 575 578 8751855 may MD B-VP O
33 579 585 8751855 confer VB I-VP O
34 586 596 8751855 hereditary JJ B-NP B-Disease
35 597 603 8751855 breast NN I-NP I-Disease
36 604 606 8751855 or CC O I-Disease
37 607 614 8751855 ovarian JJ B-NP I-Disease
38 615 621 8751855 cancer NN I-NP I-Disease
39 622 626 8751855 risk NN I-NP O
40 626 627 8751855 . . O O

1 628 634 8751855 Twenty CD B-NP O
2 634 635 8751855 - HYPH I-NP O
3 635 640 8751855 three CD I-NP O
4 641 649 8751855 families NNS I-NP O
5 650 654 8751855 were VBD B-VP O
6 655 665 8751855 identified VBN I-VP O
7 666 673 8751855 through IN B-PP O
8 674 677 8751855 two CD B-NP O
9 678 682 8751855 high JJ I-NP O
10 682 683 8751855 - HYPH I-NP O
11 683 687 8751855 risk NN I-NP O
12 688 694 8751855 breast NN I-NP B-Disease
13 695 701 8751855 cancer NN I-NP I-Disease
14 702 710 8751855 research NN I-NP O
15 711 719 8751855 programs NNS I-NP O
16 719 720 8751855 . . O O

1 721 728 8751855 Genetic JJ B-NP O
2 729 737 8751855 analysis NN I-NP O
3 738 741 8751855 was VBD B-VP O
4 742 752 8751855 undertaken VBN I-VP O
5 753 755 8751855 to TO I-VP O
6 756 765 8751855 establish VB I-VP O
7 766 773 8751855 linkage NN B-NP O
8 774 781 8751855 between IN B-PP O
9 782 785 8751855 the DT B-NP O
10 786 792 8751855 breast NN I-NP B-Disease
11 793 795 8751855 or CC O I-Disease
12 796 803 8751855 ovarian JJ B-NP I-Disease
13 804 810 8751855 cancer NN I-NP I-Disease
14 811 816 8751855 cases NNS I-NP O
15 817 820 8751855 and CC I-NP O
16 821 828 8751855 markers NNS I-NP O
17 829 831 8751855 on IN B-PP O
18 832 843 8751855 chromosomes NNS B-NP O
19 844 847 8751855 17q NN I-NP O
20 848 849 8751855 ( ( O O
21 849 854 8751855 BRCA1 NN B-NP O
22 854 855 8751855 ) ) O O
23 856 859 8751855 and CC O O
24 860 863 8751855 13q NN B-NP O
25 864 865 8751855 ( ( O O
26 865 870 8751855 BRCA2 NN B-NP O
27 870 871 8751855 ) ) O O
28 871 872 8751855 . . O O

1 873 881 8751855 Mutation NN B-NP O
2 882 890 8751855 analysis NN I-NP O
3 891 893 8751855 in IN B-PP O
4 894 897 8751855 the DT B-NP O
5 898 903 8751855 BRCA1 NN I-NP O
6 904 907 8751855 and CC I-NP O
7 908 913 8751855 BRCA2 NN I-NP O
8 914 919 8751855 genes NNS I-NP O
9 920 923 8751855 was VBD B-VP O
10 924 928 8751855 also RB I-VP O
11 929 939 8751855 undertaken VBN I-VP O
12 940 942 8751855 in IN B-PP O
13 943 946 8751855 all DT B-NP O
14 947 955 8751855 families NNS I-NP O
15 955 956 8751855 . . O O

1 957 960 8751855 The DT B-NP O
2 961 968 8751855 pattern NN I-NP O
3 969 971 8751855 of IN B-PP O
4 972 982 8751855 hereditary JJ B-NP B-Disease
5 983 989 8751855 cancer NN I-NP I-Disease
6 990 992 8751855 in IN B-PP O
7 993 995 8751855 14 CD B-NP O
8 996 997 8751855 ( ( O O
9 997 1000 8751855 61% CD B-NP O
10 1000 1001 8751855 ) ) O O
11 1002 1004 8751855 of IN B-PP O
12 1005 1008 8751855 the DT B-NP O
13 1009 1011 8751855 23 CD I-NP O
14 1012 1020 8751855 families NNS I-NP O
15 1021 1028 8751855 studied VBN B-VP O
16 1029 1032 8751855 was VBD B-VP O
17 1033 1043 8751855 attributed VBN I-VP O
18 1044 1046 8751855 to TO B-PP O
19 1047 1052 8751855 BRCA1 NN B-NP O
20 1053 1055 8751855 by IN B-PP O
21 1056 1057 8751855 a DT B-NP O
22 1058 1069 8751855 combination NN I-NP O
23 1070 1072 8751855 of IN B-PP O
24 1073 1080 8751855 linkage NN B-NP O
25 1081 1084 8751855 and CC I-NP O
26 1085 1093 8751855 mutation NN I-NP O
27 1094 1102 8751855 analyses NNS I-NP O
28 1102 1103 8751855 . . O O

1 1104 1106 8751855 No DT B-NP O
2 1107 1115 8751855 families NNS I-NP O
3 1116 1120 8751855 were VBD B-VP O
4 1121 1131 8751855 attributed VBN I-VP O
5 1132 1134 8751855 to TO B-PP O
6 1135 1140 8751855 BRCA2 NN B-NP O
7 1140 1141 8751855 . . O O

1 1142 1146 8751855 Five CD B-NP O
2 1147 1155 8751855 families NNS I-NP O
3 1156 1157 8751855 ( ( O O
4 1157 1160 8751855 22% NN B-NP O
5 1160 1161 8751855 ) ) O O
6 1162 1170 8751855 provided VBD B-VP O
7 1171 1179 8751855 evidence NN B-NP O
8 1180 1187 8751855 against IN B-PP O
9 1188 1195 8751855 linkage NN B-NP O
10 1196 1198 8751855 to TO B-PP O
11 1199 1203 8751855 both CC O O
12 1204 1209 8751855 BRCA1 NN B-NP O
13 1210 1213 8751855 and CC I-NP O
14 1214 1219 8751855 BRCA2 NN I-NP O
15 1219 1220 8751855 . . O O

1 1221 1223 8751855 No DT B-NP O
2 1224 1229 8751855 BRCA1 NN I-NP O
3 1230 1232 8751855 or CC I-NP O
4 1233 1238 8751855 BRCA2 NN I-NP O
5 1239 1248 8751855 mutations NNS I-NP O
6 1249 1253 8751855 were VBD B-VP O
7 1254 1262 8751855 detected VBN I-VP O
8 1263 1265 8751855 in IN B-PP O
9 1266 1271 8751855 these DT B-NP O
10 1272 1276 8751855 five CD I-NP O
11 1277 1285 8751855 families NNS I-NP O
12 1285 1286 8751855 . . O O

1 1287 1290 8751855 The DT B-NP O
2 1291 1296 8751855 BRCA1 NN I-NP O
3 1297 1299 8751855 or CC I-NP O
4 1300 1305 8751855 BRCA2 NN I-NP O
5 1306 1312 8751855 status NN I-NP O
6 1313 1315 8751855 of IN B-PP O
7 1316 1320 8751855 four CD B-NP O
8 1321 1329 8751855 families NNS I-NP O
9 1330 1331 8751855 ( ( O O
10 1331 1334 8751855 17% NN B-NP O
11 1334 1335 8751855 ) ) O O
12 1336 1341 8751855 could MD B-VP O
13 1342 1345 8751855 not RB I-VP O
14 1346 1348 8751855 be VB I-VP O
15 1349 1359 8751855 determined VBN I-VP O
16 1359 1360 8751855 . . O O

1 1361 1366 8751855 BRCA1 NN B-NP O
2 1367 1370 8751855 and CC I-NP O
3 1371 1376 8751855 BRCA2 NN I-NP O
4 1377 1385 8751855 probably RB B-ADVP O
5 1386 1393 8751855 explain VBP B-VP O
6 1394 1397 8751855 the DT B-NP O
7 1398 1406 8751855 majority NN I-NP O
8 1407 1409 8751855 of IN B-PP O
9 1410 1420 8751855 hereditary JJ B-NP B-Disease
10 1421 1427 8751855 breast NN I-NP I-Disease
11 1428 1434 8751855 cancer NN I-NP I-Disease
12 1435 1439 8751855 that WDT B-NP O
13 1440 1446 8751855 exists VBZ B-VP O
14 1447 1449 8751855 in IN B-PP O
15 1450 1453 8751855 the DT B-NP O
16 1454 1459 8751855 North JJ I-NP O
17 1460 1468 8751855 American JJ I-NP O
18 1469 1479 8751855 population NN I-NP O
19 1479 1480 8751855 . . O O

1 1481 1488 8751855 However RB B-ADVP O
2 1488 1489 8751855 , , O O
3 1490 1493 8751855 one CD B-NP O
4 1494 1496 8751855 or CC I-NP O
5 1497 1501 8751855 more JJR I-NP O
6 1502 1512 8751855 additional JJ I-NP O
7 1513 1518 8751855 genes NNS I-NP O
8 1519 1522 8751855 may MD B-VP O
9 1523 1526 8751855 yet RB I-VP O
10 1527 1529 8751855 be VB I-VP O
11 1530 1535 8751855 found VBN I-VP O
12 1536 1540 8751855 that IN B-SBAR O
13 1541 1548 8751855 explain VB B-VP O
14 1549 1553 8751855 some DT B-NP O
15 1554 1564 8751855 proportion NN I-NP O
16 1565 1567 8751855 of IN B-PP O
17 1568 1578 8751855 hereditary JJ B-NP B-Disease
18 1579 1585 8751855 breast NN I-NP I-Disease
19 1586 1592 8751855 cancer NN I-NP I-Disease
20 1592 1593 8751855 . . O O
21 1593 1594 8751855 . . O O

1 0 0 9072974 -DOCSTART- -X- -X- O

1 0 4 9072974 PTEN NN B-NP O
2 4 5 9072974 , , O O
3 6 7 9072974 a DT B-NP O
4 8 16 9072974 putative JJ I-NP O
5 17 24 9072974 protein NN I-NP O
6 25 33 9072974 tyrosine NN I-NP O
7 34 45 9072974 phosphatase NN I-NP O
8 46 50 9072974 gene NN I-NP O
9 51 58 9072974 mutated VBN B-VP O
10 59 61 9072974 in IN B-PP O
11 62 67 9072974 human JJ B-NP O
12 68 73 9072974 brain NN I-NP B-Disease
13 73 74 9072974 , , O I-Disease
14 75 81 9072974 breast NN B-NP I-Disease
15 81 82 9072974 , , O I-Disease
16 83 86 9072974 and CC O I-Disease
17 87 95 9072974 prostate NN B-NP I-Disease
18 96 102 9072974 cancer NN I-NP I-Disease
19 102 103 9072974 . . O O
20 104 111 9072974 Mapping NN B-NP O
21 112 114 9072974 of IN B-PP O
22 115 125 9072974 homozygous JJ B-NP O
23 126 135 9072974 deletions NNS I-NP O
24 136 138 9072974 on IN B-PP O
25 139 144 9072974 human JJ B-NP O
26 145 155 9072974 chromosome NN I-NP O
27 156 161 9072974 10q23 CD I-NP O
28 162 165 9072974 has VBZ B-VP O
29 166 169 9072974 led VBN I-VP O
30 170 172 9072974 to TO B-PP O
31 173 176 9072974 the DT B-NP O
32 177 186 9072974 isolation NN I-NP O
33 187 189 9072974 of IN B-PP O
34 190 191 9072974 a DT B-NP O
35 192 201 9072974 candidate NN I-NP O
36 202 207 9072974 tumor NN I-NP B-Disease
37 208 218 9072974 suppressor NN I-NP O
38 219 223 9072974 gene NN I-NP O
39 223 224 9072974 , , O O
40 225 229 9072974 PTEN NN B-NP O
41 229 230 9072974 , , O O
42 231 235 9072974 that WDT B-NP O
43 236 243 9072974 appears VBZ B-VP O
44 244 246 9072974 to TO I-VP O
45 247 249 9072974 be VB I-VP O
46 250 257 9072974 mutated VBN I-VP O
47 258 260 9072974 at IN B-PP O
48 261 273 9072974 considerable JJ B-NP O
49 274 283 9072974 frequency NN I-NP O
50 284 286 9072974 in IN B-PP O
51 287 292 9072974 human JJ B-NP O
52 293 300 9072974 cancers NNS I-NP B-Disease
53 300 301 9072974 . . O O

1 302 304 9072974 In IN B-PP O
2 305 316 9072974 preliminary JJ B-NP O
3 317 324 9072974 screens NNS I-NP O
4 324 325 9072974 , , O O
5 326 335 9072974 mutations NNS B-NP O
6 336 338 9072974 of IN B-PP O
7 339 343 9072974 PTEN NN B-NP O
8 344 348 9072974 were VBD B-VP O
9 349 357 9072974 detected VBN I-VP O
10 358 360 9072974 in IN B-PP O
11 361 364 9072974 31% CD B-NP O
12 365 366 9072974 ( ( O O
13 366 368 9072974 13 CD B-NP O
14 368 369 9072974 / SYM O O
15 369 371 9072974 42 CD B-NP O
16 371 372 9072974 ) ) O O
17 373 375 9072974 of IN B-PP O
18 376 388 9072974 glioblastoma NN B-NP B-Disease
19 389 393 9072974 cell NN I-NP O
20 394 399 9072974 lines NNS I-NP O
21 400 403 9072974 and CC O O
22 404 414 9072974 xenografts NNS B-NP O
23 414 415 9072974 , , O O
24 416 420 9072974 100% CD B-NP O
25 421 422 9072974 ( ( O O
26 422 423 9072974 4 CD B-NP O
27 423 424 9072974 / SYM O O
28 424 425 9072974 4 CD B-NP O
29 425 426 9072974 ) ) O O
30 427 429 9072974 of IN B-PP O
31 430 438 9072974 prostate NN B-NP B-Disease
32 439 445 9072974 cancer NN I-NP I-Disease
33 446 450 9072974 cell NN I-NP O
34 451 456 9072974 lines NNS I-NP O
35 456 457 9072974 , , O O
36 458 460 9072974 6% CD B-NP O
37 461 462 9072974 ( ( O O
38 462 463 9072974 4 CD B-NP O
39 463 464 9072974 / SYM O O
40 464 466 9072974 65 CD B-NP O
41 466 467 9072974 ) ) O O
42 468 470 9072974 of IN B-PP O
43 471 477 9072974 breast NN B-NP B-Disease
44 478 484 9072974 cancer NN I-NP I-Disease
45 485 489 9072974 cell NN I-NP O
46 490 495 9072974 lines NNS I-NP O
47 496 499 9072974 and CC O O
48 500 510 9072974 xenografts NNS B-NP O
49 510 511 9072974 , , O O
50 512 515 9072974 and CC O O
51 516 519 9072974 17% NN B-NP O
52 520 521 9072974 ( ( O O
53 521 522 9072974 3 CD B-NP O
54 522 523 9072974 / SYM O O
55 523 525 9072974 18 CD B-NP O
56 525 526 9072974 ) ) O O
57 527 529 9072974 of IN B-PP O
58 530 537 9072974 primary JJ B-NP B-Disease
59 538 551 9072974 glioblastomas NNS I-NP I-Disease
60 551 552 9072974 . . O O

1 553 556 9072974 The DT B-NP O
2 557 566 9072974 predicted VBN I-NP O
3 567 571 9072974 PTEN NN I-NP O
4 572 579 9072974 product NN I-NP O
5 580 583 9072974 has VBZ B-VP O
6 584 585 9072974 a DT B-NP O
7 586 593 9072974 protein NN I-NP O
8 594 602 9072974 tyrosine NN I-NP O
9 603 614 9072974 phosphatase NN I-NP O
10 615 621 9072974 domain NN I-NP O
11 622 625 9072974 and CC O O
12 626 635 9072974 extensive JJ B-NP O
13 636 644 9072974 homology NN I-NP O
14 645 647 9072974 to TO B-PP O
15 648 654 9072974 tensin NN B-NP O
16 654 655 9072974 , , O O
17 656 657 9072974 a DT B-NP O
18 658 665 9072974 protein NN I-NP O
19 666 670 9072974 that WDT B-NP O
20 671 680 9072974 interacts VBZ B-VP O
21 681 685 9072974 with IN B-PP O
22 686 691 9072974 actin NN B-NP O
23 692 701 9072974 filaments NNS I-NP O
24 702 704 9072974 at IN B-PP O
25 705 710 9072974 focal JJ B-NP O
26 711 720 9072974 adhesions NNS I-NP O
27 720 721 9072974 . . O O

1 722 727 9072974 These DT B-NP O
2 728 738 9072974 homologies NNS I-NP O
3 739 746 9072974 suggest VBP B-VP O
4 747 751 9072974 that IN B-SBAR O
5 752 756 9072974 PTEN NN B-NP O
6 757 760 9072974 may MD B-VP O
7 761 769 9072974 suppress VB I-VP O
8 770 775 9072974 tumor NN B-NP B-Disease
9 776 780 9072974 cell NN I-NP O
10 781 787 9072974 growth NN I-NP O
11 788 790 9072974 by IN B-PP O
12 791 803 9072974 antagonizing VBG B-VP O
13 804 811 9072974 protein NN B-NP O
14 812 820 9072974 tyrosine NN I-NP O
15 821 828 9072974 kinases NNS I-NP O
16 829 832 9072974 and CC O O
17 833 836 9072974 may MD B-VP O
18 837 845 9072974 regulate VB I-VP O
19 846 851 9072974 tumor NN B-NP B-Disease
20 852 856 9072974 cell NN I-NP O
21 857 865 9072974 invasion NN I-NP O
22 866 869 9072974 and CC O O
23 870 880 9072974 metastasis NN B-NP B-Disease
24 881 888 9072974 through IN B-PP O
25 889 901 9072974 interactions NNS B-NP O
26 902 904 9072974 at IN B-PP O
27 905 910 9072974 focal JJ B-NP O
28 911 920 9072974 adhesions NNS I-NP O
29 920 921 9072974 . . O O
30 921 922 9072974 . . O O

1 0 0 9012409 -DOCSTART- -X- -X- O

1 0 9 9012409 Molecular JJ B-NP O
2 10 15 9012409 basis NN I-NP O
3 16 19 9012409 for IN B-PP O
4 20 26 9012409 Duarte NNP B-NP B-Disease
5 27 30 9012409 and CC I-NP I-Disease
6 31 34 9012409 Los NNP I-NP I-Disease
7 35 42 9012409 Angeles NNP I-NP I-Disease
8 43 50 9012409 variant JJ I-NP I-Disease
9 51 63 9012409 galactosemia NN I-NP I-Disease
10 63 64 9012409 . . O O
11 65 70 9012409 Human JJ B-NP O
12 71 83 9012409 orythrocytes NNS I-NP O
13 84 88 9012409 that WDT B-NP O
14 89 92 9012409 are VBP B-VP O
15 93 103 9012409 homozygous JJ B-ADJP O
16 104 107 9012409 for IN B-PP O
17 108 111 9012409 the DT B-NP O
18 112 118 9012409 Duarte JJ I-NP B-Disease
19 119 125 9012409 enzyme NN I-NP I-Disease
20 126 133 9012409 variant NN I-NP I-Disease
21 134 136 9012409 of IN B-PP I-Disease
22 137 149 9012409 galactosemia NN B-NP I-Disease
23 150 151 9012409 ( ( O O
24 151 152 9012409 D NN B-NP O
25 152 153 9012409 / SYM B-NP O
26 153 154 9012409 D NN I-NP O
27 154 155 9012409 ) ) O O
28 156 160 9012409 have VBP B-VP O
29 161 162 9012409 a DT B-NP O
30 163 177 9012409 characteristic JJ I-NP O
31 178 185 9012409 isoform NN I-NP O
32 186 188 9012409 on IN B-PP O
33 189 200 9012409 isoelectric JJ B-NP O
34 201 209 9012409 focusing NN I-NP O
35 210 213 9012409 and CC O O
36 214 217 9012409 50% CD B-NP O
37 218 227 9012409 reduction NN I-NP O
38 228 230 9012409 in IN B-PP O
39 231 240 9012409 galactose NN B-NP O
40 240 241 9012409 - HYPH B-NP O
41 241 242 9012409 1 CD I-NP O
42 242 243 9012409 - HYPH I-NP O
43 243 252 9012409 phosphate NN I-NP O
44 253 270 9012409 uridyltransferase NN I-NP O
45 271 272 9012409 ( ( O O
46 272 276 9012409 GALT NN B-NP O
47 276 277 9012409 ) ) O O
48 278 284 9012409 enzyme NN B-NP O
49 285 293 9012409 activity NN I-NP O
50 293 294 9012409 . . O O

1 295 298 9012409 The DT B-NP O
2 299 305 9012409 Duarte NNP I-NP O
3 306 317 9012409 biochemical JJ I-NP O
4 318 327 9012409 phenotype NN I-NP O
5 328 331 9012409 has VBZ B-VP O
6 332 333 9012409 a DT B-NP O
7 334 343 9012409 molecular JJ I-NP O
8 344 352 9012409 genotype NN I-NP O
9 353 355 9012409 of IN B-PP O
10 356 361 9012409 N314D NN B-NP O
11 361 362 9012409 / SYM B-NP O
12 362 367 9012409 N314D NN I-NP O
13 367 368 9012409 . . O O

1 369 372 9012409 The DT B-NP O
2 373 387 9012409 characteristic JJ I-NP O
3 388 394 9012409 Duarte NNP I-NP O
4 395 402 9012409 isoform NN I-NP O
5 403 405 9012409 is VBZ B-VP O
6 406 410 9012409 also RB I-VP O
7 411 421 9012409 associated VBN I-VP O
8 422 426 9012409 with IN B-PP O
9 427 428 9012409 a DT B-NP O
10 429 436 9012409 variant JJ I-NP O
11 437 443 9012409 called VBN B-VP O
12 444 447 9012409 the DT B-NP O
13 448 449 9012409 " `` I-NP O
14 450 453 9012409 Los NNP I-NP O
15 454 461 9012409 Angeles NNP I-NP O
16 462 463 9012409 ( ( O O
17 463 465 9012409 LA NN B-NP O
18 465 466 9012409 ) ) O O
19 467 476 9012409 phenotype NN B-NP O
20 476 477 9012409 , , O O
21 478 479 9012409 " '' O O
22 480 485 9012409 which WDT B-NP O
23 486 489 9012409 has VBZ B-VP O
24 490 499 9012409 increased VBN I-VP O
25 500 504 9012409 GALT NN B-NP O
26 505 511 9012409 enzyme NN I-NP O
27 512 520 9012409 activity NN I-NP O
28 520 521 9012409 . . O O

1 522 524 9012409 We PRP B-NP O
2 525 534 9012409 evaluated VBD B-VP O
3 535 539 9012409 GALT NN B-NP O
4 540 546 9012409 enzyme NN I-NP O
5 547 555 9012409 activity NN I-NP O
6 556 559 9012409 and CC O O
7 560 568 9012409 screened VBD B-VP O
8 569 572 9012409 the DT B-NP O
9 573 577 9012409 GALT NN I-NP O
10 578 583 9012409 genes NNS I-NP O
11 584 586 9012409 of IN B-PP O
12 587 590 9012409 145 CD B-NP O
13 591 599 9012409 patients NNS I-NP O
14 600 604 9012409 with IN B-PP O
15 605 608 9012409 one CD B-NP O
16 609 611 9012409 or CC I-NP O
17 612 616 9012409 more JJR I-NP O
18 617 622 9012409 N314D NN I-NP O
19 622 623 9012409 - HYPH O O
20 623 633 9012409 containing VBG B-VP O
21 634 641 9012409 alleles NNS B-NP O
22 641 642 9012409 . . O O

1 643 645 9012409 We PRP B-NP O
2 646 651 9012409 found VBD B-VP O
3 652 657 9012409 seven CD B-NP O
4 658 662 9012409 with IN B-PP O
5 663 666 9012409 the DT B-NP O
6 667 669 9012409 LA NN I-NP O
7 670 681 9012409 biochemical JJ I-NP O
8 682 691 9012409 phenotype NN I-NP O
9 691 692 9012409 , , O O
10 693 696 9012409 and CC O O
11 697 700 9012409 all DT B-NP O
12 701 704 9012409 had VBD B-VP O
13 705 706 9012409 a DT B-NP O
14 707 712 9012409 1721C NN I-NP O
15 712 713 9012409 - SYM B-NP O
16 713 714 9012409 - SYM B-NP O
17 715 716 9012409 > SYM I-NP O
18 717 718 9012409 T NN I-NP O
19 719 729 9012409 transition NN I-NP O
20 730 732 9012409 in IN B-PP O
21 733 737 9012409 exon NN B-NP O
22 738 739 9012409 7 CD I-NP O
23 740 742 9012409 in IN B-PP O
24 743 746 9012409 cis NN B-NP O
25 747 751 9012409 with IN B-PP O
26 752 755 9012409 the DT B-NP O
27 756 761 9012409 N314D NN I-NP O
28 762 770 9012409 missense JJ I-NP O
29 771 779 9012409 mutation NN I-NP O
30 779 780 9012409 . . O O

1 781 784 9012409 The DT B-NP O
2 785 790 9012409 1721C NN I-NP O
3 790 791 9012409 - SYM B-VP O
4 791 792 9012409 - SYM B-NP O
5 793 794 9012409 > SYM I-NP O
6 795 796 9012409 T NN I-NP O
7 797 807 9012409 transition NN I-NP O
8 808 810 9012409 is VBZ B-VP O
9 811 812 9012409 a DT B-NP O
10 813 820 9012409 neutral JJ I-NP O
11 821 833 9012409 polymorphism NN I-NP O
12 834 837 9012409 for IN B-PP O
13 838 845 9012409 leucine NN B-NP O
14 846 848 9012409 at IN B-PP O
15 849 854 9012409 amino NN B-NP O
16 855 859 9012409 acid NN I-NP O
17 860 863 9012409 218 CD I-NP O
18 864 865 9012409 ( ( O O
19 865 870 9012409 L218L NN B-NP O
20 870 871 9012409 ) ) O O
21 871 872 9012409 . . O O

1 873 875 9012409 In IN B-PP O
2 876 884 9012409 pedigree NN B-NP O
3 885 893 9012409 analyses NNS I-NP O
4 893 894 9012409 , , O O
5 895 899 9012409 this DT B-NP O
6 900 905 9012409 1721C NN I-NP O
7 905 906 9012409 - SYM B-NP O
8 906 907 9012409 - SYM B-NP O
9 908 909 9012409 > SYM I-NP O
10 910 911 9012409 T NN I-NP O
11 912 922 9012409 transition NN I-NP O
12 923 933 9012409 segregated VBD B-VP O
13 934 938 9012409 with IN B-PP O
14 939 942 9012409 the DT B-NP O
15 943 945 9012409 LA NN I-NP O
16 946 955 9012409 phenotype NN I-NP O
17 956 958 9012409 of IN B-PP O
18 959 968 9012409 increased VBN B-NP O
19 969 973 9012409 GALT NN I-NP O
20 974 982 9012409 activity NN I-NP O
21 983 985 9012409 in IN B-PP O
22 986 991 9012409 three CD B-NP O
23 992 1001 9012409 different JJ I-NP O
24 1002 1013 9012409 biochemical JJ I-NP O
25 1014 1024 9012409 phenotypes NNS I-NP O
26 1025 1026 9012409 ( ( O O
27 1026 1028 9012409 LA NN B-NP O
28 1028 1029 9012409 / SYM O O
29 1029 1030 9012409 N NN B-NP O
30 1030 1031 9012409 , , O O
31 1032 1034 9012409 LA NN B-NP O
32 1034 1035 9012409 / SYM I-NP O
33 1035 1036 9012409 G NN I-NP O
34 1036 1037 9012409 , , O O
35 1038 1041 9012409 and CC O O
36 1042 1044 9012409 LA NN B-NP O
37 1044 1045 9012409 / SYM B-NP O
38 1045 1046 9012409 D NN I-NP O
39 1046 1047 9012409 ) ) O O
40 1047 1048 9012409 . . O O

1 1049 1051 9012409 To TO B-VP O
2 1052 1061 9012409 determine VB I-VP O
3 1062 1065 9012409 the DT B-NP O
4 1066 1075 9012409 mechanism NN I-NP O
5 1076 1079 9012409 for IN B-PP O
6 1080 1089 9012409 increased VBN B-NP O
7 1090 1098 9012409 activity NN I-NP O
8 1099 1101 9012409 of IN B-PP O
9 1102 1105 9012409 the DT B-NP O
10 1106 1108 9012409 LA NN I-NP O
11 1109 1116 9012409 variant NN I-NP O
12 1116 1117 9012409 , , O O
13 1118 1120 9012409 we PRP B-NP O
14 1121 1129 9012409 compared VBD B-VP O
15 1130 1134 9012409 GALT NN B-NP O
16 1135 1139 9012409 mRNA NN I-NP O
17 1139 1140 9012409 , , O O
18 1141 1148 9012409 protein NN B-NP O
19 1149 1158 9012409 abundance NN I-NP O
20 1158 1159 9012409 , , O O
21 1160 1163 9012409 and CC O O
22 1164 1170 9012409 enzyme NN B-NP O
23 1171 1178 9012409 thermal JJ I-NP O
24 1179 1188 9012409 stability NN I-NP O
25 1189 1191 9012409 in IN B-PP O
26 1192 1203 9012409 lymphoblast NN B-NP O
27 1204 1208 9012409 cell NN I-NP O
28 1209 1214 9012409 lines NNS I-NP O
29 1215 1217 9012409 of IN B-PP O
30 1218 1219 9012409 D NN B-NP O
31 1220 1223 9012409 and CC I-NP O
32 1224 1226 9012409 LA NN I-NP O
33 1227 1237 9012409 phenotypes NNS I-NP O
34 1238 1242 9012409 with IN B-PP O
35 1243 1253 9012409 comparable JJ B-NP O
36 1254 1263 9012409 genotypes NNS I-NP O
37 1263 1264 9012409 . . O O

1 1265 1269 9012409 GALT NN B-NP O
2 1270 1277 9012409 protein NN I-NP O
3 1278 1287 9012409 abundance NN I-NP O
4 1288 1291 9012409 was VBD B-VP O
5 1292 1301 9012409 increased VBN I-VP O
6 1302 1304 9012409 in IN B-PP O
7 1305 1307 9012409 LA NN B-NP O
8 1308 1316 9012409 compared VBN B-VP O
9 1317 1319 9012409 to TO B-PP O
10 1320 1321 9012409 D NN B-NP O
11 1322 1329 9012409 alleles NNS I-NP O
12 1329 1330 9012409 , , O O
13 1331 1334 9012409 but CC O O
14 1335 1339 9012409 mRNA NN B-NP O
15 1340 1343 9012409 was VBD B-VP O
16 1344 1351 9012409 similar JJ B-ADJP O
17 1352 1357 9012409 among IN B-PP O
18 1358 1361 9012409 all DT B-NP O
19 1362 1371 9012409 genotypes NNS I-NP O
20 1371 1372 9012409 . . O O

1 1373 1377 9012409 When WRB B-ADVP O
2 1378 1380 9012409 LA NN B-NP O
3 1380 1381 9012409 / SYM B-NP O
4 1381 1382 9012409 D NN I-NP O
5 1383 1386 9012409 and CC I-NP O
6 1387 1388 9012409 D NN I-NP O
7 1388 1389 9012409 / SYM B-NP O
8 1389 1390 9012409 D NN I-NP O
9 1391 1395 9012409 GALT NN I-NP O
10 1396 1407 9012409 biochemical JJ I-NP O
11 1408 1418 9012409 phenotypes NNS I-NP O
12 1419 1423 9012409 were VBD B-VP O
13 1424 1432 9012409 compared VBN I-VP O
14 1433 1435 9012409 to TO B-PP O
15 1436 1437 9012409 N NN B-NP O
16 1437 1438 9012409 / SYM B-NP O
17 1438 1439 9012409 N NN I-NP O
18 1440 1444 9012409 GALT NN I-NP O
19 1445 1455 9012409 phenotypes NNS I-NP O
20 1455 1456 9012409 , , O O
21 1457 1461 9012409 both DT B-NP O
22 1462 1465 9012409 had VBD B-VP O
23 1466 1469 9012409 50% CD B-NP O
24 1469 1470 9012409 , , O O
25 1471 1473 9012409 as IN B-SBAR O
26 1474 1482 9012409 compared VBN B-VP O
27 1483 1485 9012409 to TO B-PP O
28 1486 1489 9012409 21% CD B-NP O
29 1489 1490 9012409 , , O O
30 1491 1500 9012409 reduction NN B-NP O
31 1501 1503 9012409 in IN B-PP O
32 1504 1508 9012409 GALT NN B-NP O
33 1509 1517 9012409 activity NN I-NP O
34 1518 1520 9012409 in IN B-PP O
35 1521 1524 9012409 the DT B-NP O
36 1525 1529 9012409 wild JJ I-NP O
37 1530 1534 9012409 type NN I-NP O
38 1535 1536 9012409 ( ( O O
39 1536 1537 9012409 N NN B-NP O
40 1537 1538 9012409 / SYM B-NP O
41 1538 1539 9012409 N NN I-NP O
42 1539 1540 9012409 ) ) O O
43 1541 1546 9012409 after IN B-PP O
44 1547 1555 9012409 exposure NN B-NP O
45 1556 1558 9012409 at IN B-PP O
46 1559 1568 9012409 identical JJ B-NP O
47 1569 1576 9012409 initial JJ I-NP O
48 1577 1583 9012409 enzyme NN I-NP O
49 1584 1592 9012409 activity NN I-NP O
50 1593 1595 9012409 to TO B-PP O
51 1596 1598 9012409 50 CD B-NP O
52 1599 1606 9012409 degrees NNS I-NP O
53 1607 1608 9012409 C JJ B-ADJP O
54 1609 1612 9012409 for IN B-PP O
55 1613 1615 9012409 15 CD B-NP O
56 1616 1619 9012409 min NN I-NP O
57 1619 1620 9012409 . . O O

1 1621 1623 9012409 We PRP B-NP O
2 1624 1632 9012409 conclude VBP B-VP O
3 1633 1637 9012409 that IN B-SBAR O
4 1638 1641 9012409 the DT B-NP O
5 1642 1647 9012409 codon NN I-NP O
6 1648 1654 9012409 change NN I-NP O
7 1655 1660 9012409 N314D NN I-NP O
8 1661 1663 9012409 in IN B-PP O
9 1664 1667 9012409 cis NN B-NP O
10 1668 1672 9012409 with IN B-PP O
11 1673 1676 9012409 the DT B-NP O
12 1677 1681 9012409 base NN I-NP O
13 1681 1682 9012409 - HYPH I-NP O
14 1682 1686 9012409 pair NN I-NP O
15 1687 1697 9012409 transition NN I-NP O
16 1698 1703 9012409 1721C NN I-NP O
17 1703 1704 9012409 - SYM O O
18 1704 1705 9012409 - HYPH O O
19 1706 1707 9012409 > SYM O O
20 1708 1709 9012409 T NN B-NP O
21 1710 1718 9012409 produces VBZ B-VP O
22 1719 1722 9012409 the DT B-NP O
23 1723 1725 9012409 LA NN I-NP B-Disease
24 1726 1733 9012409 variant NN I-NP I-Disease
25 1734 1736 9012409 of IN B-PP I-Disease
26 1737 1749 9012409 galactosemia NN B-NP I-Disease
27 1750 1753 9012409 and CC O O
28 1754 1758 9012409 that IN B-SBAR O
29 1759 1763 9012409 this DT B-NP O
30 1764 1774 9012409 nucleotide NN I-NP O
31 1775 1781 9012409 change NN I-NP O
32 1782 1791 9012409 increases VBZ B-VP O
33 1792 1796 9012409 GALT NN B-NP O
34 1797 1805 9012409 activity NN I-NP O
35 1806 1808 9012409 by IN B-PP O
36 1809 1819 9012409 increasing VBG B-VP O
37 1820 1824 9012409 GALT NN B-NP O
38 1825 1832 9012409 protein NN I-NP O
39 1833 1842 9012409 abundance NN I-NP O
40 1843 1850 9012409 without IN B-PP O
41 1851 1861 9012409 increasing VBG B-VP O
42 1862 1875 9012409 transcription NN B-NP O
43 1876 1878 9012409 or CC O O
44 1879 1889 9012409 decreasing VBG B-VP O
45 1890 1897 9012409 thermal JJ B-NP O
46 1898 1906 9012409 lability NN I-NP O
47 1906 1907 9012409 . . O O

1 1908 1909 9012409 A DT B-NP O
2 1910 1919 9012409 favorable JJ I-NP O
3 1920 1925 9012409 codon NN I-NP O
4 1926 1930 9012409 bias NN I-NP O
5 1931 1934 9012409 for IN B-PP O
6 1935 1938 9012409 the DT B-NP O
7 1939 1946 9012409 mutated VBN I-NP O
8 1947 1952 9012409 codon NN I-NP O
9 1953 1957 9012409 with IN B-PP O
10 1958 1970 9012409 consequently RB B-NP O
11 1971 1980 9012409 increased VBN I-NP O
12 1981 1992 9012409 translation NN I-NP O
13 1993 1998 9012409 rates NNS I-NP O
14 1999 2001 9012409 is VBZ B-VP O
15 2002 2012 9012409 postulated VBN I-VP O
16 2013 2015 9012409 as IN B-PP O
17 2016 2019 9012409 the DT B-NP O
18 2020 2029 9012409 mechanism NN I-NP O
19 2029 2030 9012409 . . O O
20 2030 2031 9012409 . . O O

1 0 0 8929413 -DOCSTART- -X- -X- O

1 0 11 8929413 Association NN B-NP O
2 12 14 8929413 of IN B-PP O
3 15 22 8929413 anxiety NN B-NP B-Disease
4 22 23 8929413 - HYPH B-NP I-Disease
5 23 30 8929413 related VBN I-NP I-Disease
6 31 37 8929413 traits NNS I-NP I-Disease
7 38 42 8929413 with IN B-PP O
8 43 44 8929413 a DT B-NP O
9 45 57 8929413 polymorphism NN I-NP O
10 58 60 8929413 in IN B-PP O
11 61 64 8929413 the DT B-NP O
12 65 74 8929413 serotonin NN I-NP O
13 75 86 8929413 transporter NN I-NP O
14 87 91 8929413 gene NN I-NP O
15 92 102 8929413 regulatory JJ I-NP O
16 103 109 8929413 region NN I-NP O
17 109 110 8929413 . . I-NP O
18 111 122 8929413 Transporter NN I-NP O
19 122 123 8929413 - HYPH O O
20 123 134 8929413 facilitated VBN B-NP O
21 135 141 8929413 uptake NN I-NP O
22 142 144 8929413 of IN B-PP O
23 145 154 8929413 serotonin NN B-NP O
24 155 156 8929413 ( ( O O
25 156 157 8929413 5 CD B-NP O
26 157 158 8929413 - HYPH I-NP O
27 158 175 8929413 hydroxytryptamine NN I-NP O
28 176 178 8929413 or CC I-NP O
29 179 180 8929413 5 CD I-NP O
30 180 181 8929413 - HYPH I-NP O
31 181 183 8929413 HT NN I-NP O
32 183 184 8929413 ) ) O O
33 185 188 8929413 has VBZ B-VP O
34 189 193 8929413 been VBN I-VP O
35 194 204 8929413 implicated VBN I-VP O
36 205 207 8929413 in IN B-PP O
37 208 215 8929413 anxiety NN B-NP B-Disease
38 216 218 8929413 in IN B-PP O
39 219 225 8929413 humans NNS B-NP O
40 226 229 8929413 and CC I-NP O
41 230 236 8929413 animal NN I-NP O
42 237 243 8929413 models NNS I-NP O
43 244 247 8929413 and CC O O
44 248 250 8929413 is VBZ B-VP O
45 251 254 8929413 the DT B-NP O
46 255 259 8929413 site NN I-NP O
47 260 262 8929413 of IN B-PP O
48 263 269 8929413 action NN B-NP O
49 270 272 8929413 of IN B-PP O
50 273 279 8929413 widely RB B-NP O
51 280 284 8929413 used VBN I-NP O
52 285 291 8929413 uptake NN I-NP O
53 291 292 8929413 - HYPH O O
54 292 302 8929413 inhibiting VBG B-VP O
55 303 317 8929413 antidepressant NN B-NP O
56 318 321 8929413 and CC O O
57 322 333 8929413 antianxiety JJ B-NP O
58 334 339 8929413 drugs NNS I-NP O
59 339 340 8929413 . . O O

1 341 346 8929413 Human JJ B-NP O
2 347 348 8929413 5 CD I-NP O
3 348 349 8929413 - HYPH I-NP O
4 349 351 8929413 HT NN I-NP O
5 352 363 8929413 transporter NN I-NP O
6 364 365 8929413 ( ( O O
7 365 366 8929413 5 CD B-NP O
8 366 367 8929413 - HYPH I-NP O
9 367 370 8929413 HTT NN I-NP O
10 370 371 8929413 ) ) I-NP O
11 372 376 8929413 gene NN I-NP O
12 377 390 8929413 transcription NN I-NP O
13 391 393 8929413 is VBZ B-VP O
14 394 403 8929413 modulated VBN I-VP O
15 404 406 8929413 by IN B-PP O
16 407 408 8929413 a DT B-NP O
17 409 415 8929413 common JJ I-NP O
18 416 428 8929413 polymorphism NN I-NP O
19 429 431 8929413 in IN B-PP O
20 432 435 8929413 its PRP$ B-NP O
21 436 444 8929413 upstream JJ I-NP O
22 445 455 8929413 regulatory JJ I-NP O
23 456 462 8929413 region NN I-NP O
24 462 463 8929413 . . O O

1 464 467 8929413 The DT B-NP O
2 468 473 8929413 short JJ I-NP O
3 474 481 8929413 variant NN I-NP O
4 482 484 8929413 of IN B-PP O
5 485 488 8929413 the DT B-NP O
6 489 501 8929413 polymorphism NN I-NP O
7 502 509 8929413 reduces VBZ B-VP O
8 510 513 8929413 the DT B-NP O
9 514 529 8929413 transcriptional JJ I-NP O
10 530 540 8929413 efficiency NN I-NP O
11 541 543 8929413 of IN B-PP O
12 544 547 8929413 the DT B-NP O
13 548 549 8929413 5 CD I-NP O
14 549 550 8929413 - HYPH I-NP O
15 550 553 8929413 HTT NN I-NP O
16 554 558 8929413 gene NN I-NP O
17 559 567 8929413 promoter NN I-NP O
18 567 568 8929413 , , O O
19 569 578 8929413 resulting VBG B-VP O
20 579 581 8929413 in IN B-PP O
21 582 591 8929413 decreased VBN B-NP O
22 592 593 8929413 5 CD I-NP O
23 593 594 8929413 - HYPH I-NP O
24 594 597 8929413 HTT NN I-NP O
25 598 608 8929413 expression NN I-NP O
26 609 612 8929413 and CC O O
27 613 614 8929413 5 CD B-NP O
28 614 615 8929413 - HYPH I-NP O
29 615 617 8929413 HT NN I-NP O
30 618 624 8929413 uptake NN I-NP O
31 625 627 8929413 in IN B-PP O
32 628 640 8929413 lymphoblasts NNS B-NP O
33 640 641 8929413 . . O O

1 642 653 8929413 Association NN B-NP O
2 654 661 8929413 studies NNS I-NP O
3 662 664 8929413 in IN B-PP O
4 665 668 8929413 two CD B-NP O
5 669 680 8929413 independent JJ I-NP O
6 681 688 8929413 samples NNS I-NP O
7 689 697 8929413 totaling VBG B-VP O
8 698 701 8929413 505 CD B-NP O
9 702 713 8929413 individuals NNS I-NP O
10 714 722 8929413 revealed VBD B-VP O
11 723 727 8929413 that IN B-SBAR O
12 728 731 8929413 the DT B-NP O
13 732 733 8929413 5 CD I-NP O
14 733 734 8929413 - HYPH I-NP O
15 734 737 8929413 HTT NN I-NP O
16 738 750 8929413 polymorphism NN I-NP O
17 751 759 8929413 accounts VBZ B-VP O
18 760 763 8929413 for IN B-PP O
19 764 765 8929413 3 CD B-NP O
20 766 768 8929413 to TO I-NP O
21 769 770 8929413 4 CD I-NP O
22 771 778 8929413 percent NN I-NP O
23 779 781 8929413 of IN B-PP O
24 782 787 8929413 total JJ B-NP O
25 788 797 8929413 variation NN I-NP O
26 798 801 8929413 and CC O O
27 802 803 8929413 7 CD B-NP O
28 804 806 8929413 to TO I-NP O
29 807 808 8929413 9 CD I-NP O
30 809 816 8929413 percent NN I-NP O
31 817 819 8929413 of IN B-PP O
32 820 829 8929413 inherited VBN B-NP O
33 830 838 8929413 variance NN I-NP O
34 839 841 8929413 in IN B-PP O
35 842 849 8929413 anxiety NN B-NP B-Disease
36 849 850 8929413 - HYPH O I-Disease
37 850 857 8929413 related VBN B-NP I-Disease
38 858 869 8929413 personality NN I-NP I-Disease
39 870 876 8929413 traits NNS I-NP I-Disease
40 877 879 8929413 in IN B-PP O
41 880 891 8929413 individuals NNS B-NP O
42 892 894 8929413 as RB B-CONJP O
43 895 899 8929413 well RB I-CONJP O
44 900 902 8929413 as IN I-CONJP O
45 903 911 8929413 sibships NNS B-NP O
46 911 912 8929413 . . O O
47 912 913 8929413 . . O O

1 0 0 8682510 -DOCSTART- -X- -X- O

1 0 7 8682510 Wiskott NNP B-NP B-Disease
2 7 8 8682510 - HYPH I-NP I-Disease
3 8 15 8682510 Aldrich NNP I-NP I-Disease
4 16 24 8682510 syndrome NN I-NP I-Disease
5 24 25 8682510 : : O O
6 26 28 8682510 no DT B-NP O
7 29 35 8682510 strict JJ I-NP O
8 36 44 8682510 genotype NN I-NP O
9 44 45 8682510 - HYPH I-NP O
10 45 54 8682510 phenotype NN I-NP O
11 55 67 8682510 correlations NNS I-NP O
12 68 71 8682510 but CC O O
13 72 82 8682510 clustering VBG B-VP O
14 83 85 8682510 of IN B-PP O
15 86 94 8682510 missense JJ B-NP O
16 95 104 8682510 mutations NNS I-NP O
17 105 107 8682510 in IN B-PP O
18 108 111 8682510 the DT B-NP O
19 112 117 8682510 amino JJ I-NP O
20 117 118 8682510 - HYPH I-NP O
21 118 126 8682510 terminal JJ I-NP O
22 127 131 8682510 part NN I-NP O
23 132 134 8682510 of IN B-PP O
24 135 138 8682510 the DT B-NP O
25 139 143 8682510 WASP NN I-NP O
26 144 148 8682510 gene NN I-NP O
27 149 156 8682510 product NN I-NP O
28 156 157 8682510 . . O O
29 158 161 8682510 The DT B-NP O
30 162 169 8682510 Wiskott NNP I-NP B-Disease
31 169 170 8682510 - HYPH I-NP I-Disease
32 170 177 8682510 Aldrich NNP I-NP I-Disease
33 178 186 8682510 syndrome NN I-NP I-Disease
34 187 194 8682510 protein NN I-NP O
35 195 196 8682510 ( ( O O
36 196 200 8682510 WASP NN B-NP O
37 200 201 8682510 ) ) O O
38 202 206 8682510 gene NN B-NP O
39 207 210 8682510 was VBD B-VP O
40 211 216 8682510 found VBN I-VP O
41 217 219 8682510 to TO I-VP O
42 220 222 8682510 be VB I-VP O
43 223 230 8682510 mutated VBN I-VP O
44 231 233 8682510 in IN B-PP O
45 234 242 8682510 patients NNS B-NP O
46 243 253 8682510 presenting VBG B-VP O
47 254 258 8682510 with IN B-PP O
48 259 262 8682510 WAS NN B-NP B-Disease
49 263 266 8682510 and CC B-PP O
50 267 269 8682510 in IN B-PP O
51 270 278 8682510 patients NNS B-NP O
52 279 286 8682510 showing VBG B-VP O
53 287 288 8682510 X NN B-NP B-Disease
54 288 289 8682510 - HYPH O I-Disease
55 289 295 8682510 linked VBN B-NP I-Disease
56 296 312 8682510 thrombocytopenia NN I-NP I-Disease
57 312 313 8682510 . . O O

1 314 322 8682510 Mutation NN B-NP O
2 323 331 8682510 analysis NN I-NP O
3 332 334 8682510 in IN B-PP O
4 335 337 8682510 19 CD B-NP O
5 338 346 8682510 families NNS I-NP O
6 347 349 8682510 of IN B-PP O
7 350 356 8682510 German JJ B-NP O
8 356 357 8682510 , , I-NP O
9 358 363 8682510 Swiss JJ I-NP O
10 364 367 8682510 and CC I-NP O
11 368 375 8682510 Turkish JJ I-NP O
12 376 383 8682510 descent NN I-NP O
13 384 386 8682510 by IN B-PP O
14 387 393 8682510 single JJ B-NP O
15 393 394 8682510 - HYPH I-NP O
16 394 400 8682510 strand NN I-NP O
17 401 413 8682510 conformation NN I-NP O
18 414 426 8682510 polymorphism NN I-NP O
19 427 430 8682510 and CC I-NP O
20 431 441 8682510 sequencing NN I-NP O
21 442 450 8682510 resulted VBD B-VP O
22 451 453 8682510 in IN B-PP O
23 454 457 8682510 the DT B-NP O
24 458 467 8682510 detection NN I-NP O
25 468 470 8682510 of IN B-PP O
26 471 476 8682510 seven CD B-NP O
27 477 482 8682510 novel JJ I-NP O
28 483 486 8682510 and CC I-NP O
29 487 489 8682510 10 CD I-NP O
30 490 495 8682510 known VBN I-NP O
31 496 505 8682510 mutations NNS I-NP O
32 505 506 8682510 . . O O

1 507 508 8682510 A DT B-NP O
2 509 517 8682510 striking JJ I-NP O
3 518 528 8682510 clustering NN I-NP O
4 529 531 8682510 of IN B-PP O
5 532 540 8682510 missense JJ B-NP O
6 541 550 8682510 mutations NNS I-NP O
7 551 553 8682510 in IN B-PP O
8 554 557 8682510 the DT B-NP O
9 558 563 8682510 first JJ I-NP O
10 564 568 8682510 four CD I-NP O
11 569 574 8682510 exons NNS I-NP O
12 575 585 8682510 contrasted VBN B-VP O
13 586 590 8682510 with IN B-PP O
14 591 592 8682510 a DT B-NP O
15 593 599 8682510 random JJ I-NP O
16 600 612 8682510 distribution NN I-NP O
17 613 615 8682510 of IN B-PP O
18 616 624 8682510 nonsense JJ B-NP O
19 625 634 8682510 mutations NNS I-NP O
20 634 635 8682510 . . O O

1 636 640 8682510 More JJR B-NP O
2 641 645 8682510 than IN I-NP O
3 646 649 8682510 85% CD I-NP O
4 650 652 8682510 of IN B-PP O
5 653 656 8682510 all DT B-NP O
6 657 662 8682510 known VBN I-NP O
7 663 671 8682510 missense NN I-NP O
8 672 681 8682510 mutations NNS I-NP O
9 682 686 8682510 were VBD B-VP O
10 687 696 8682510 localized VBN I-VP O
11 697 699 8682510 in IN B-PP O
12 700 703 8682510 the DT B-NP O
13 704 709 8682510 amino JJ I-NP O
14 709 710 8682510 - HYPH I-NP O
15 710 718 8682510 terminal JJ I-NP O
16 719 726 8682510 stretch NN I-NP O
17 727 729 8682510 of IN B-PP O
18 730 733 8682510 the DT B-NP O
19 734 738 8682510 WASP NN I-NP O
20 739 743 8682510 gene NN I-NP O
21 744 751 8682510 product NN I-NP O
22 751 752 8682510 ; : O O
23 753 757 8682510 this DT B-NP O
24 758 764 8682510 region NN I-NP O
25 765 774 8682510 contained VBD B-VP O
26 775 776 8682510 a DT B-NP O
27 777 787 8682510 mutational JJ I-NP O
28 788 791 8682510 hot JJ I-NP O
29 792 796 8682510 spot NN I-NP O
30 797 799 8682510 at IN B-PP O
31 800 805 8682510 codon NN B-NP O
32 806 808 8682510 86 CD I-NP O
33 808 809 8682510 . . O O

1 810 812 8682510 No DT B-NP O
2 813 821 8682510 genotype NN I-NP O
3 821 822 8682510 - HYPH B-NP O
4 822 831 8682510 phenotype NN I-NP O
5 832 843 8682510 correlation NN I-NP O
6 844 851 8682510 emerged VBD B-VP O
7 852 857 8682510 after IN B-PP O
8 858 859 8682510 a DT B-NP O
9 860 870 8682510 comparison NN I-NP O
10 871 873 8682510 of IN B-PP O
11 874 877 8682510 the DT B-NP O
12 878 888 8682510 identified VBN I-NP O
13 889 898 8682510 mutations NNS I-NP O
14 899 903 8682510 with IN B-PP O
15 904 907 8682510 the DT B-NP O
16 908 917 8682510 resulting VBG I-NP O
17 918 926 8682510 clinical JJ I-NP O
18 927 934 8682510 picture NN I-NP O
19 935 938 8682510 for IN B-PP O
20 939 940 8682510 a DT B-NP O
21 941 950 8682510 classical JJ I-NP O
22 951 954 8682510 WAS NN I-NP B-Disease
23 955 964 8682510 phenotype NN I-NP O
24 964 965 8682510 . . O O

1 966 967 8682510 A DT B-NP O
2 968 980 8682510 substitution NN I-NP O
3 981 983 8682510 at IN B-PP O
4 984 989 8682510 codon NN B-NP O
5 990 992 8682510 86 CD I-NP O
6 993 1001 8682510 resulted VBD B-VP O
7 1002 1004 8682510 in IN B-PP O
8 1005 1007 8682510 an DT B-NP O
9 1008 1017 8682510 extremely RB I-NP O
10 1018 1026 8682510 variable JJ I-NP O
11 1027 1037 8682510 expression NN I-NP O
12 1038 1040 8682510 of IN B-PP O
13 1041 1044 8682510 the DT B-NP O
14 1045 1052 8682510 disease NN I-NP O
15 1053 1055 8682510 in IN B-PP O
16 1056 1057 8682510 a DT B-NP O
17 1058 1063 8682510 large JJ I-NP O
18 1064 1069 8682510 Swiss JJ I-NP O
19 1070 1076 8682510 family NN I-NP O
20 1076 1077 8682510 . . O O

1 1078 1080 8682510 An DT B-NP O
2 1081 1089 8682510 extended VBN I-NP O
3 1090 1098 8682510 homology NN I-NP O
4 1099 1105 8682510 search NN I-NP O
5 1106 1114 8682510 revealed VBD B-VP O
6 1115 1116 8682510 a DT B-NP O
7 1117 1124 8682510 distant JJ I-NP O
8 1125 1137 8682510 relationship NN I-NP O
9 1138 1140 8682510 of IN B-PP O
10 1141 1145 8682510 this DT B-NP O
11 1146 1153 8682510 stretch NN I-NP O
12 1154 1156 8682510 to TO B-PP O
13 1157 1160 8682510 the DT B-NP O
14 1161 1172 8682510 vasodilator NN I-NP O
15 1172 1173 8682510 - HYPH O O
16 1173 1183 8682510 stimulated VBN B-VP O
17 1184 1198 8682510 phosphoprotein NN B-NP O
18 1199 1200 8682510 ( ( O O
19 1200 1204 8682510 VASP NN B-NP O
20 1204 1205 8682510 ) ) O O
21 1205 1206 8682510 , , O O
22 1207 1212 8682510 which WDT B-NP O
23 1213 1215 8682510 is VBZ B-VP O
24 1216 1224 8682510 involved VBN I-VP O
25 1225 1227 8682510 in IN B-PP O
26 1228 1231 8682510 the DT B-NP O
27 1232 1243 8682510 maintenance NN I-NP O
28 1244 1246 8682510 of IN B-PP O
29 1247 1251 8682510 cyto AFX B-NP O
30 1251 1252 8682510 - HYPH I-NP O
31 1252 1264 8682510 architecture NN I-NP O
32 1265 1267 8682510 by IN B-PP O
33 1268 1279 8682510 interacting VBG B-VP O
34 1280 1284 8682510 with IN B-PP O
35 1285 1290 8682510 actin NN B-NP O
36 1290 1291 8682510 - HYPH B-NP O
37 1291 1295 8682510 like JJ I-NP O
38 1296 1305 8682510 filaments NNS I-NP O
39 1305 1306 8682510 . . O O
40 1306 1307 8682510 . . O O

1 0 0 9012404 -DOCSTART- -X- -X- O

1 0 8 9012404 Mutation NN B-NP O
2 9 17 9012404 analysis NN I-NP O
3 18 20 9012404 of IN B-PP O
4 21 26 9012404 BRCA1 NN B-NP O
5 27 30 9012404 and CC I-NP O
6 31 36 9012404 BRCA2 NN I-NP O
7 37 39 9012404 in IN B-PP O
8 40 41 9012404 a DT B-NP O
9 42 46 9012404 male JJ I-NP B-Disease
10 47 53 9012404 breast NN I-NP I-Disease
11 54 60 9012404 cancer NN I-NP I-Disease
12 61 71 9012404 population NN I-NP O
13 71 72 9012404 . . O O
14 73 74 9012404 A DT B-NP O
15 75 85 9012404 population NN I-NP O
16 85 86 9012404 - HYPH B-VP O
17 86 91 9012404 based VBN I-VP O
18 92 98 9012404 series NN B-NP O
19 99 101 9012404 of IN B-PP O
20 102 104 9012404 54 CD B-NP O
21 105 109 9012404 male JJ I-NP B-Disease
22 110 116 9012404 breast NN I-NP I-Disease
23 117 123 9012404 cancer NN I-NP I-Disease
24 124 129 9012404 cases NNS I-NP O
25 130 134 9012404 from IN B-PP O
26 135 143 9012404 Southern NNP B-NP O
27 144 154 9012404 California NNP I-NP O
28 155 159 9012404 were VBD B-VP O
29 160 168 9012404 analyzed VBN I-VP O
30 169 172 9012404 for IN B-PP O
31 173 177 9012404 germ NN B-NP O
32 177 178 9012404 - HYPH I-NP O
33 178 182 9012404 line NN I-NP O
34 183 192 9012404 mutations NNS I-NP O
35 193 195 9012404 in IN B-PP O
36 196 199 9012404 the DT B-NP O
37 200 209 9012404 inherited VBN I-NP B-Disease
38 210 216 9012404 breast NN I-NP I-Disease
39 216 217 9012404 / SYM B-NP I-Disease
40 217 224 9012404 ovarian JJ B-NP I-Disease
41 225 231 9012404 cancer NN I-NP I-Disease
42 232 237 9012404 genes NNS I-NP O
43 237 238 9012404 , , O O
44 239 244 9012404 BRCA1 NN B-NP O
45 245 248 9012404 and CC O O
46 249 254 9012404 BRCA2 NN B-NP O
47 254 255 9012404 . . O O

1 256 260 9012404 Nine CD B-NP O
2 261 262 9012404 ( ( O O
3 262 265 9012404 17% NN B-NP O
4 265 266 9012404 ) ) O O
5 267 269 9012404 of IN B-PP O
6 270 273 9012404 the DT B-NP O
7 274 282 9012404 patients NNS I-NP O
8 283 286 9012404 had VBD B-VP O
9 287 288 9012404 a DT B-NP O
10 289 295 9012404 family NN I-NP O
11 296 303 9012404 history NN I-NP O
12 304 306 9012404 of IN B-PP O
13 307 313 9012404 breast NN B-NP B-Disease
14 314 317 9012404 and CC O I-Disease
15 317 318 9012404 / SYM B-NP I-Disease
16 318 320 9012404 or CC O I-Disease
17 321 328 9012404 ovarian JJ B-NP I-Disease
18 329 335 9012404 cancer NN I-NP I-Disease
19 336 338 9012404 in IN B-PP O
20 339 341 9012404 at IN B-NP O
21 342 347 9012404 least JJS I-NP O
22 348 351 9012404 one CD I-NP O
23 352 357 9012404 first JJ I-NP O
24 357 358 9012404 - HYPH I-NP O
25 358 364 9012404 degree NN I-NP O
26 365 373 9012404 relative JJ B-ADJP O
27 373 374 9012404 . . O O

1 375 376 9012404 A DT B-NP O
2 377 384 9012404 further JJ I-NP O
3 385 390 9012404 seven CD I-NP O
4 391 392 9012404 ( ( O O
5 392 395 9012404 13% NN B-NP O
6 395 396 9012404 ) ) O O
7 397 399 9012404 of IN B-PP O
8 400 403 9012404 the DT B-NP O
9 404 412 9012404 patients NNS I-NP O
10 413 421 9012404 reported VBD B-VP O
11 422 428 9012404 breast NN B-NP B-Disease
12 428 429 9012404 / SYM B-NP I-Disease
13 429 436 9012404 ovarian JJ I-NP I-Disease
14 437 443 9012404 cancer NN I-NP I-Disease
15 444 446 9012404 in IN B-PP O
16 447 449 9012404 at IN B-NP O
17 450 455 9012404 least JJS I-NP O
18 456 459 9012404 one CD I-NP O
19 460 466 9012404 second JJ I-NP O
20 466 467 9012404 - HYPH I-NP O
21 467 473 9012404 degree NN I-NP O
22 474 482 9012404 relative JJ B-ADJP O
23 483 486 9012404 and CC O O
24 487 489 9012404 in IN B-PP O
25 490 492 9012404 no DT B-NP O
26 493 498 9012404 first JJ I-NP O
27 498 499 9012404 - HYPH I-NP O
28 499 505 9012404 degree NN I-NP O
29 506 515 9012404 relatives NNS I-NP O
30 515 516 9012404 . . O O

1 517 519 9012404 No DT B-NP O
2 520 524 9012404 germ NN I-NP O
3 524 525 9012404 - HYPH B-NP O
4 525 529 9012404 line NN I-NP O
5 530 535 9012404 BRCA1 NN I-NP O
6 536 545 9012404 mutations NNS I-NP O
7 546 550 9012404 were VBD B-VP O
8 551 556 9012404 found VBN I-VP O
9 556 557 9012404 . . O O

1 558 561 9012404 Two CD B-NP O
2 562 566 9012404 male JJ I-NP B-Disease
3 567 573 9012404 breast NN I-NP I-Disease
4 574 580 9012404 cancer NN I-NP I-Disease
5 581 589 9012404 patients NNS I-NP O
6 590 591 9012404 ( ( O O
7 591 593 9012404 4% CD B-NP O
8 594 596 9012404 of IN B-PP O
9 597 600 9012404 the DT B-NP O
10 601 606 9012404 total NN I-NP O
11 606 607 9012404 ) ) O O
12 608 612 9012404 were VBD B-VP O
13 613 618 9012404 found VBN I-VP O
14 619 621 9012404 to TO I-VP O
15 622 627 9012404 carry VB I-VP O
16 628 633 9012404 novel JJ B-NP O
17 634 644 9012404 truncating VBG I-NP O
18 645 654 9012404 mutations NNS I-NP O
19 655 657 9012404 in IN B-PP O
20 658 661 9012404 the DT B-NP O
21 662 667 9012404 BRCA2 NN I-NP O
22 668 672 9012404 gene NN I-NP O
23 672 673 9012404 . . O O

1 674 678 9012404 Only RB B-NP O
2 679 682 9012404 one CD I-NP O
3 683 685 9012404 of IN B-PP O
4 686 689 9012404 the DT B-NP O
5 690 693 9012404 two CD I-NP O
6 694 698 9012404 male JJ I-NP B-Disease
7 699 705 9012404 breast NN I-NP I-Disease
8 706 712 9012404 cancer NN I-NP I-Disease
9 713 721 9012404 patients NNS I-NP O
10 722 730 9012404 carrying VBG B-VP O
11 731 732 9012404 a DT B-NP O
12 733 738 9012404 BRCA2 NN I-NP O
13 739 747 9012404 mutation NN I-NP O
14 748 751 9012404 had VBD B-VP O
15 752 753 9012404 a DT B-NP O
16 754 760 9012404 family NN I-NP O
17 761 768 9012404 history NN I-NP O
18 769 771 9012404 of IN B-PP O
19 772 778 9012404 cancer NN B-NP B-Disease
20 778 779 9012404 , , O O
21 780 784 9012404 with IN B-PP O
22 785 788 9012404 one CD B-NP O
23 789 793 9012404 case NN I-NP O
24 794 796 9012404 of IN B-PP O
25 797 804 9012404 ovarian JJ B-NP B-Disease
26 805 811 9012404 cancer NN I-NP I-Disease
27 812 814 9012404 in IN B-PP O
28 815 816 9012404 a DT B-NP O
29 817 822 9012404 first JJ I-NP O
30 822 823 9012404 - HYPH I-NP O
31 823 829 9012404 degree NN I-NP O
32 830 838 9012404 relative JJ B-ADJP O
33 838 839 9012404 . . O O

1 840 843 9012404 The DT B-NP O
2 844 853 9012404 remaining VBG I-NP O
3 854 859 9012404 eight CD I-NP O
4 860 865 9012404 cases NNS I-NP O
5 866 867 9012404 ( ( O O
6 867 870 9012404 89% NN B-NP O
7 870 871 9012404 ) ) O O
8 872 874 9012404 of IN B-PP O
9 875 879 9012404 male JJ B-NP B-Disease
10 880 886 9012404 breast NN I-NP I-Disease
11 887 893 9012404 cancer NN I-NP I-Disease
12 894 898 9012404 with IN B-PP O
13 899 900 9012404 a DT B-NP O
14 901 907 9012404 family NN I-NP O
15 908 915 9012404 history NN I-NP O
16 916 918 9012404 of IN B-PP O
17 919 925 9012404 breast NN B-NP B-Disease
18 925 926 9012404 / SYM B-NP I-Disease
19 926 933 9012404 ovarian JJ I-NP I-Disease
20 934 940 9012404 cancer NN I-NP I-Disease
21 941 943 9012404 in IN B-PP O
22 944 949 9012404 first JJ B-NP O
23 949 950 9012404 - HYPH I-NP O
24 950 956 9012404 degree NN I-NP O
25 957 966 9012404 relatives NNS I-NP O
26 967 973 9012404 remain VBP B-VP O
27 974 985 9012404 unaccounted JJ B-ADJP O
28 986 989 9012404 for IN B-PP O
29 990 992 9012404 by IN B-PP O
30 993 1002 9012404 mutations NNS B-NP O
31 1003 1005 9012404 in IN B-PP O
32 1006 1012 9012404 either CC O O
33 1013 1016 9012404 the DT B-NP O
34 1017 1022 9012404 BRCA1 NN I-NP O
35 1023 1027 9012404 gene NN I-NP O
36 1028 1030 9012404 or CC O O
37 1031 1034 9012404 the DT B-NP O
38 1035 1040 9012404 BRCA2 NN I-NP O
39 1041 1045 9012404 gene NN I-NP O
40 1045 1046 9012404 . . O O
41 1046 1047 9012404 . . O O

1 0 0 8825599 -DOCSTART- -X- -X- O

1 0 6 8825599 Muscle NN B-NP O
2 7 17 8825599 expression NN I-NP O
3 18 20 8825599 of IN B-PP O
4 21 28 8825599 glucose NN B-NP B-Disease
5 28 29 8825599 - HYPH B-NP I-Disease
6 29 30 8825599 6 CD I-NP I-Disease
7 30 31 8825599 - HYPH I-NP I-Disease
8 31 40 8825599 phosphate NN I-NP I-Disease
9 41 54 8825599 dehydrogenase NN I-NP I-Disease
10 55 65 8825599 deficiency NN I-NP I-Disease
11 66 68 8825599 in IN B-PP O
12 69 78 8825599 different JJ B-NP O
13 79 87 8825599 variants NNS I-NP O
14 87 88 8825599 . . O O
15 89 95 8825599 Muscle NN B-NP O
16 96 106 8825599 expression NN I-NP O
17 107 109 8825599 of IN B-PP O
18 110 114 8825599 G6PD NN B-NP B-Disease
19 115 125 8825599 deficiency NN I-NP I-Disease
20 126 129 8825599 has VBZ B-VP O
21 130 134 8825599 been VBN I-VP O
22 135 147 8825599 investigated VBN I-VP O
23 148 150 8825599 in IN B-PP O
24 151 164 8825599 Mediterranean NNP B-NP O
25 164 165 8825599 , , O O
26 166 173 8825599 Seattle NNP B-NP O
27 173 174 8825599 - HYPH B-NP O
28 174 178 8825599 like JJ I-NP O
29 179 182 8825599 and CC I-NP O
30 183 184 8825599 A NN I-NP O
31 184 185 8825599 - HYPH I-NP O
32 185 193 8825599 variants NNS I-NP O
33 193 194 8825599 . . O O

1 195 199 8825599 G6PD NN B-NP O
2 200 208 8825599 activity NN I-NP O
3 209 212 8825599 was VBD B-VP O
4 213 221 8825599 detected VBN I-VP O
5 222 224 8825599 in IN B-PP O
6 225 232 8825599 samples NNS B-NP O
7 233 241 8825599 obtained VBN B-VP O
8 242 246 8825599 from IN B-PP O
9 247 255 8825599 biopsies NNS B-NP O
10 256 258 8825599 on IN B-PP O
11 259 262 8825599 the DT B-NP O
12 263 273 8825599 quadriceps NNS I-NP O
13 274 280 8825599 muscle NN I-NP O
14 281 283 8825599 of IN B-PP O
15 284 289 8825599 seven CD B-NP O
16 290 295 8825599 males NNS I-NP O
17 296 299 8825599 and CC O O
18 300 303 8825599 one CD B-NP O
19 304 310 8825599 female JJ I-NP O
20 310 311 8825599 . . O O

1 312 315 8825599 The DT B-NP O
2 316 320 8825599 type NN I-NP O
3 321 323 8825599 of IN B-PP O
4 324 331 8825599 genetic JJ B-NP O
5 332 339 8825599 variant NN I-NP O
6 340 343 8825599 was VBD B-VP O
7 344 354 8825599 determined VBN I-VP O
8 355 357 8825599 by IN B-PP O
9 358 367 8825599 molecular JJ B-NP O
10 368 376 8825599 analysis NN I-NP O
11 377 379 8825599 of IN B-PP O
12 380 383 8825599 DNA NN B-NP O
13 383 384 8825599 , , O O
14 385 394 8825599 extracted VBN B-VP O
15 395 399 8825599 from IN B-PP O
16 400 405 8825599 blood NN B-NP O
17 406 413 8825599 samples NNS I-NP O
18 413 414 8825599 . . O O

1 415 418 8825599 All DT B-NP O
2 419 427 8825599 variants NNS I-NP O
3 428 434 8825599 showed VBD B-VP O
4 435 438 8825599 the DT B-NP O
5 439 445 8825599 enzyme NN I-NP O
6 446 452 8825599 defect NN I-NP O
7 453 455 8825599 in IN B-PP O
8 456 462 8825599 muscle NN B-NP O
9 462 463 8825599 . . O O

1 464 465 8825599 A DT B-NP O
2 466 479 8825599 statistically RB I-NP O
3 480 491 8825599 significant JJ I-NP O
4 492 504 8825599 relationship NN I-NP O
5 505 508 8825599 was VBD B-VP O
6 509 514 8825599 found VBN I-VP O
7 515 517 8825599 in IN B-PP O
8 518 521 8825599 the DT B-NP O
9 522 530 8825599 activity NN I-NP O
10 531 533 8825599 of IN B-PP O
11 534 538 8825599 G6PD NN B-NP O
12 539 546 8825599 between IN B-PP O
13 547 559 8825599 erythrocytes NNS B-NP O
14 560 563 8825599 and CC O O
15 564 570 8825599 muscle NN B-NP O
16 571 573 8825599 of IN B-PP O
17 574 577 8825599 the DT B-NP O
18 578 582 8825599 male JJ I-NP O
19 583 591 8825599 subjects NNS I-NP O
20 592 593 8825599 ( ( O O
21 593 594 8825599 r NN B-NP O
22 595 596 8825599 = SYM B-VP O
23 597 598 8825599 0 CD B-NP O
24 598 599 8825599 . . O O

1 600 603 8825599 968 CD B-NP O
2 603 604 8825599 ; : O O
3 605 606 8825599 p NN B-NP O
4 607 608 8825599 = SYM B-VP O
5 609 610 8825599 0 CD B-NP O
6 610 611 8825599 . . O O

1 612 617 8825599 00008 CD B-NP O
2 617 618 8825599 ) ) O O
3 618 619 8825599 . . O O

1 620 623 8825599 The DT B-NP O
2 624 632 8825599 equation NN I-NP O
3 633 636 8825599 for IN B-PP O
4 637 640 8825599 the DT B-NP O
5 641 645 8825599 best JJS I-NP O
6 646 649 8825599 fit NN I-NP O
7 650 654 8825599 line NN I-NP O
8 655 658 8825599 was VBD B-VP O
9 660 661 8825599 Y NN B-NP O
10 662 663 8825599 = SYM B-VP O
11 664 665 8825599 0 CD B-NP O
12 665 666 8825599 . . O O

1 667 671 8825599 390X NN B-NP O
2 672 673 8825599 + SYM B-VP O
3 674 675 8825599 0 CD B-NP O
4 675 676 8825599 . . O O

1 677 680 8825599 198 CD B-NP O
2 681 684 8825599 198 CD I-NP O
3 684 685 8825599 . . O O

1 686 689 8825599 The DT B-NP O
2 690 697 8825599 results NNS I-NP O
3 698 705 8825599 suggest VBP B-VP O
4 706 710 8825599 that IN B-SBAR O
5 710 711 8825599 , , O O
6 712 715 8825599 for IN B-PP O
7 716 717 8825599 a DT B-NP O
8 718 723 8825599 given VBN I-NP O
9 724 731 8825599 variant NN I-NP O
10 731 732 8825599 , , O O
11 733 736 8825599 the DT B-NP O
12 737 743 8825599 extent NN I-NP O
13 744 746 8825599 of IN B-PP O
14 747 750 8825599 the DT B-NP O
15 751 757 8825599 enzyme NN I-NP O
16 758 764 8825599 defect NN I-NP O
17 765 767 8825599 in IN B-PP O
18 768 774 8825599 muscle NN B-NP O
19 775 778 8825599 may MD B-VP O
20 779 781 8825599 be VB I-VP O
21 782 792 8825599 determined VBN I-VP O
22 792 793 8825599 , , O O
23 794 799 8825599 using VBG B-VP O
24 800 804 8825599 this DT B-NP O
25 805 813 8825599 equation NN I-NP O
26 813 814 8825599 , , O O
27 815 819 8825599 from IN B-PP O
28 820 823 8825599 the DT B-NP O
29 824 828 8825599 G6PD NN I-NP O
30 829 837 8825599 activity NN I-NP O
31 838 840 8825599 of IN B-PP O
32 841 853 8825599 erythrocytes NNS B-NP O

1 0 0 8789439 -DOCSTART- -X- -X- O

1 0 2 8789439 An DT B-NP O
2 3 9 8789439 animal NN I-NP O
3 10 15 8789439 model NN I-NP O
4 16 19 8789439 for IN B-PP O
5 20 26 8789439 Norrie NNP B-NP B-Disease
6 27 34 8789439 disease NN I-NP I-Disease
7 35 36 8789439 ( ( O O
8 36 38 8789439 ND NN B-NP B-Disease
9 38 39 8789439 ) ) O O
10 39 40 8789439 : : O O
11 41 45 8789439 gene NN B-NP O
12 46 55 8789439 targeting NN I-NP O
13 56 58 8789439 of IN B-PP O
14 59 62 8789439 the DT B-NP O
15 63 68 8789439 mouse NN I-NP O
16 69 71 8789439 ND NN I-NP B-Disease
17 72 76 8789439 gene NN I-NP O
18 76 77 8789439 . . O O
19 78 80 8789439 In IN B-SBAR O
20 81 86 8789439 order NN O O
21 87 89 8789439 to TO B-VP O
22 90 99 8789439 elucidate VB I-VP O
23 100 103 8789439 the DT B-NP O
24 104 112 8789439 cellular JJ I-NP O
25 113 116 8789439 and CC I-NP O
26 117 126 8789439 molecular JJ I-NP O
27 127 136 8789439 processes NNS I-NP O
28 137 142 8789439 which WDT B-NP O
29 143 146 8789439 are VBP B-VP O
30 147 155 8789439 involved VBN I-VP O
31 156 158 8789439 in IN B-PP O
32 159 165 8789439 Norrie NNP B-NP B-Disease
33 166 173 8789439 disease NN I-NP I-Disease
34 174 175 8789439 ( ( O O
35 175 177 8789439 ND NN B-NP B-Disease
36 177 178 8789439 ) ) O O
37 178 179 8789439 , , O O
38 180 182 8789439 we PRP B-NP O
39 183 187 8789439 have VBP B-VP O
40 188 192 8789439 used VBN I-VP O
41 193 197 8789439 gene NN B-NP O
42 198 207 8789439 targeting VBG B-VP O
43 208 218 8789439 technology NN B-NP O
44 219 221 8789439 to TO B-VP O
45 222 230 8789439 generate VB I-VP O
46 231 233 8789439 ND NN B-NP B-Disease
47 234 240 8789439 mutant JJ I-NP O
48 241 245 8789439 mice NNS I-NP O
49 245 246 8789439 . . O O

1 247 250 8789439 The DT B-NP O
2 251 257 8789439 murine JJ I-NP O
3 258 267 8789439 homologue NN I-NP O
4 268 270 8789439 of IN B-PP O
5 271 274 8789439 the DT B-NP O
6 275 277 8789439 ND NN I-NP B-Disease
7 278 282 8789439 gene NN I-NP O
8 283 286 8789439 was VBD B-VP O
9 287 293 8789439 cloned VBN I-VP O
10 294 297 8789439 and CC O O
11 298 303 8789439 shown VBN B-VP O
12 304 306 8789439 to TO I-VP O
13 307 313 8789439 encode VB I-VP O
14 314 315 8789439 a DT B-NP O
15 316 327 8789439 polypeptide NN I-NP O
16 328 332 8789439 that WDT B-NP O
17 333 339 8789439 shares VBZ B-VP O
18 340 343 8789439 94% CD B-NP O
19 344 346 8789439 of IN B-PP O
20 347 350 8789439 the DT B-NP O
21 351 356 8789439 amino JJ I-NP O
22 357 361 8789439 acid NN I-NP O
23 362 370 8789439 sequence NN I-NP O
24 371 375 8789439 with IN B-PP O
25 376 379 8789439 its PRP$ B-NP O
26 380 385 8789439 human JJ I-NP O
27 386 397 8789439 counterpart NN I-NP O
28 397 398 8789439 . . O O

1 399 402 8789439 RNA NN B-NP O
2 403 405 8789439 in FW B-NP O
3 406 410 8789439 situ FW I-NP O
4 411 424 8789439 hybridization NN I-NP O
5 425 433 8789439 revealed VBD B-VP O
6 434 444 8789439 expression NN B-NP O
7 445 447 8789439 in IN B-PP O
8 448 454 8789439 retina NN B-NP O
9 454 455 8789439 , , O O
10 456 461 8789439 brain NN B-NP O
11 462 465 8789439 and CC O O
12 466 469 8789439 the DT B-NP O
13 470 479 8789439 olfactory JJ I-NP O
14 480 484 8789439 bulb NN I-NP O
15 485 488 8789439 and CC I-NP O
16 489 499 8789439 epithelium NN I-NP O
17 500 502 8789439 of IN B-PP O
18 503 504 8789439 2 CD B-NP O
19 505 509 8789439 week NN I-NP O
20 510 513 8789439 old JJ I-NP O
21 514 518 8789439 mice NNS I-NP O
22 518 519 8789439 . . O O

1 520 530 8789439 Hemizygous JJ B-NP O
2 531 535 8789439 mice NNS I-NP O
3 536 544 8789439 carrying VBG B-VP O
4 545 546 8789439 a DT B-NP O
5 547 558 8789439 replacement NN I-NP O
6 559 567 8789439 mutation NN I-NP O
7 568 570 8789439 in IN B-PP O
8 571 575 8789439 exon NN B-NP O
9 576 577 8789439 2 CD I-NP O
10 578 580 8789439 of IN B-PP O
11 581 584 8789439 the DT B-NP O
12 585 587 8789439 ND NN I-NP B-Disease
13 588 592 8789439 gene NN I-NP O
14 593 602 8789439 developed VBD B-VP O
15 603 614 8789439 retrolental JJ B-NP O
16 615 625 8789439 structures NNS I-NP O
17 626 628 8789439 in IN B-PP O
18 629 632 8789439 the DT B-NP O
19 633 641 8789439 vitreous JJ I-NP O
20 642 646 8789439 body NN I-NP O
21 647 650 8789439 and CC O O
22 651 657 8789439 showed VBD B-VP O
23 658 660 8789439 an DT B-NP O
24 661 668 8789439 overall JJ I-NP O
25 669 684 8789439 disorganization NN I-NP O
26 685 687 8789439 of IN B-PP O
27 688 691 8789439 the DT B-NP O
28 692 699 8789439 retinal JJ I-NP O
29 700 708 8789439 ganglion NN I-NP O
30 709 713 8789439 cell NN I-NP O
31 714 719 8789439 layer NN I-NP O
32 719 720 8789439 . . O O

1 721 724 8789439 The DT B-NP O
2 725 730 8789439 outer JJ I-NP O
3 731 740 8789439 plexiform NN I-NP O
4 741 746 8789439 layer NN I-NP O
5 747 757 8789439 disappears VBZ B-VP O
6 758 770 8789439 occasionally RB B-ADVP O
7 770 771 8789439 , , O O
8 772 781 8789439 resulting VBG B-VP O
9 782 784 8789439 in IN B-PP O
10 785 786 8789439 a DT B-NP O
11 787 797 8789439 juxtaposed VBN I-NP O
12 798 803 8789439 inner JJ I-NP O
13 804 807 8789439 and CC I-NP O
14 808 813 8789439 outer JJ I-NP O
15 814 821 8789439 nuclear JJ I-NP O
16 822 827 8789439 layer NN I-NP O
17 827 828 8789439 . . O O

1 829 831 8789439 At IN B-PP O
2 832 835 8789439 the DT B-NP O
3 836 840 8789439 same JJ I-NP O
4 841 848 8789439 regions NNS I-NP O
5 848 849 8789439 , , O O
6 850 853 8789439 the DT B-NP O
7 854 859 8789439 outer JJ I-NP O
8 860 868 8789439 segments NNS I-NP O
9 869 871 8789439 of IN B-PP O
10 872 875 8789439 the DT B-NP O
11 876 889 8789439 photoreceptor NN I-NP O
12 890 894 8789439 cell NN I-NP O
13 895 900 8789439 layer NN I-NP O
14 901 904 8789439 are VBP B-VP O
15 905 907 8789439 no RB I-VP O
16 908 914 8789439 longer RB I-VP O
17 915 922 8789439 present JJ I-VP O
18 922 923 8789439 . . O O

1 924 929 8789439 These DT B-NP O
2 930 936 8789439 ocular JJ I-NP O
3 937 945 8789439 findings NNS I-NP O
4 946 949 8789439 are VBP B-VP O
5 950 960 8789439 consistent JJ B-ADJP O
6 961 965 8789439 with IN B-PP O
7 966 978 8789439 observations NNS B-NP O
8 979 981 8789439 in IN B-PP O
9 982 984 8789439 ND NN B-NP B-Disease
10 985 993 8789439 patients NNS I-NP O
11 994 997 8789439 and CC O O
12 998 1001 8789439 the DT B-NP O
13 1002 1011 8789439 generated VBN I-NP O
14 1012 1017 8789439 mouse NN I-NP O
15 1018 1022 8789439 line NN I-NP O
16 1023 1031 8789439 provides VBZ B-VP O
17 1032 1033 8789439 a DT B-NP O
18 1034 1042 8789439 faithful JJ I-NP O
19 1043 1048 8789439 model NN I-NP O
20 1049 1052 8789439 for IN B-PP O
21 1053 1058 8789439 study NN B-NP O
22 1059 1061 8789439 of IN B-PP O
23 1062 1067 8789439 early JJ B-NP O
24 1068 1078 8789439 pathogenic JJ I-NP O
25 1079 1085 8789439 events NNS I-NP O
26 1086 1088 8789439 in IN B-PP O
27 1089 1093 8789439 this DT B-NP O
28 1094 1100 8789439 severe JJ I-NP O
29 1101 1102 8789439 X NN I-NP B-Disease
30 1102 1103 8789439 - HYPH O I-Disease
31 1103 1109 8789439 linked VBN B-VP I-Disease
32 1110 1119 8789439 recessive JJ B-NP I-Disease
33 1120 1132 8789439 neurological JJ I-NP I-Disease
34 1133 1141 8789439 disorder NN I-NP I-Disease
35 1141 1142 8789439 . . O O
36 1142 1143 8789439 . . O O

1 0 0 8790412 -DOCSTART- -X- -X- O

1 0 3 8790412 The DT B-NP O
2 4 10 8790412 hybrid NN I-NP O
3 11 15 8790412 PAX3 NN I-NP O
4 15 16 8790412 - HYPH B-NP O
5 16 20 8790412 FKHR NN I-NP O
6 21 27 8790412 fusion NN I-NP O
7 28 35 8790412 protein NN I-NP O
8 36 38 8790412 of IN B-PP O
9 39 47 8790412 alveolar JJ B-NP B-Disease
10 48 64 8790412 rhabdomyosarcoma NN I-NP I-Disease
11 65 75 8790412 transforms VBZ B-VP O
12 76 87 8790412 fibroblasts NNS B-NP O
13 88 90 8790412 in IN B-PP O
14 91 98 8790412 culture NN B-NP O
15 98 99 8790412 . . O O
16 100 109 8790412 Pediatric JJ B-NP B-Disease
17 110 118 8790412 alveolar JJ I-NP I-Disease
18 119 135 8790412 rhabdomyosarcoma NN I-NP I-Disease
19 136 138 8790412 is VBZ B-VP O
20 139 152 8790412 characterized VBN I-VP O
21 153 155 8790412 by IN B-PP O
22 156 157 8790412 a DT B-NP O
23 158 169 8790412 chromosomal JJ I-NP O
24 170 183 8790412 translocation NN I-NP O
25 184 188 8790412 that WDT B-NP O
26 189 194 8790412 fuses VBZ B-VP O
27 195 200 8790412 parts NNS B-NP O
28 201 203 8790412 of IN B-PP O
29 204 207 8790412 the DT B-NP O
30 208 212 8790412 PAX3 NN I-NP O
31 213 216 8790412 and CC I-NP O
32 217 221 8790412 FKHR NN I-NP O
33 222 227 8790412 genes NNS I-NP O
34 227 228 8790412 . . O O

1 229 233 8790412 PAX3 NN B-NP O
2 234 239 8790412 codes VBZ B-VP O
3 240 243 8790412 for IN B-PP O
4 244 245 8790412 a DT B-NP O
5 246 261 8790412 transcriptional JJ I-NP O
6 262 271 8790412 regulator NN I-NP O
7 272 276 8790412 that WDT B-NP O
8 277 285 8790412 controls VBZ B-VP O
9 286 299 8790412 developmental JJ B-NP O
10 300 308 8790412 programs NNS I-NP O
11 308 309 8790412 , , O O
12 310 313 8790412 and CC O O
13 314 318 8790412 FKHR NN B-NP O
14 319 324 8790412 codes NNS I-NP O
15 325 328 8790412 for IN B-PP O
16 329 330 8790412 a DT B-NP O
17 331 339 8790412 forkhead NN I-NP O
18 339 340 8790412 - HYPH O O
19 340 346 8790412 winged VBN B-NP O
20 347 352 8790412 helix NN I-NP O
21 353 360 8790412 protein NN I-NP O
22 360 361 8790412 , , O O
23 362 366 8790412 also RB B-ADVP O
24 367 368 8790412 a DT B-NP O
25 369 375 8790412 likely JJ I-NP O
26 376 389 8790412 transcription NN I-NP O
27 390 396 8790412 factor NN I-NP O
28 396 397 8790412 . . O O

1 398 401 8790412 The DT B-NP O
2 402 406 8790412 PAX3 NN I-NP O
3 406 407 8790412 - HYPH I-NP O
4 407 411 8790412 FKHR NN I-NP O
5 412 418 8790412 fusion NN I-NP O
6 419 426 8790412 product NN I-NP O
7 427 434 8790412 retains VBZ B-VP O
8 435 438 8790412 the DT B-NP O
9 439 442 8790412 DNA NN I-NP O
10 443 450 8790412 binding NN I-NP O
11 451 458 8790412 domains NNS I-NP O
12 459 461 8790412 of IN B-PP O
13 462 465 8790412 the DT B-NP O
14 466 470 8790412 PAX3 NN I-NP O
15 471 478 8790412 protein NN I-NP O
16 479 482 8790412 and CC O O
17 483 486 8790412 the DT B-NP O
18 487 495 8790412 putative JJ I-NP O
19 496 505 8790412 activator NN I-NP O
20 506 512 8790412 domain NN I-NP O
21 513 515 8790412 of IN B-PP O
22 516 519 8790412 the DT B-NP O
23 520 524 8790412 FKHR NN I-NP O
24 525 532 8790412 protein NN I-NP O
25 532 533 8790412 . . O O

1 534 537 8790412 The DT B-NP O
2 538 542 8790412 PAX3 NN I-NP O
3 542 543 8790412 - HYPH I-NP O
4 543 547 8790412 FKHR NN I-NP O
5 548 555 8790412 protein NN I-NP O
6 556 559 8790412 has VBZ B-VP O
7 560 564 8790412 been VBN I-VP O
8 565 570 8790412 shown VBN I-VP O
9 571 573 8790412 to TO I-VP O
10 574 582 8790412 function VB I-VP O
11 583 585 8790412 as IN B-PP O
12 586 587 8790412 a DT B-NP O
13 588 603 8790412 transcriptional JJ I-NP O
14 604 613 8790412 activator NN I-NP O
15 613 614 8790412 . . O O

1 615 620 8790412 Using VBG B-VP O
2 621 624 8790412 the DT B-NP O
3 625 629 8790412 RCAS NN I-NP O
4 630 640 8790412 retroviral JJ I-NP O
5 641 647 8790412 vector NN I-NP O
6 647 648 8790412 , , O O
7 649 651 8790412 we PRP B-NP O
8 652 656 8790412 have VBP B-VP O
9 657 667 8790412 introduced VBN I-VP O
10 668 671 8790412 the DT B-NP O
11 672 676 8790412 PAX3 NN I-NP O
12 676 677 8790412 - HYPH B-NP O
13 677 681 8790412 FKHR NN I-NP O
14 682 686 8790412 gene NN I-NP O
15 687 691 8790412 into IN B-PP O
16 692 699 8790412 chicken NN B-NP O
17 700 706 8790412 embryo NN I-NP O
18 707 718 8790412 fibroblasts NNS I-NP O
19 718 719 8790412 . . O O

1 720 730 8790412 Expression NN B-NP O
2 731 733 8790412 of IN B-PP O
3 734 737 8790412 the DT B-NP O
4 738 742 8790412 PAX3 NN I-NP O
5 742 743 8790412 - HYPH B-NP O
6 743 747 8790412 FKHR NN I-NP O
7 748 755 8790412 protein NN I-NP O
8 756 758 8790412 in IN B-PP O
9 759 764 8790412 these DT B-NP O
10 765 770 8790412 cells NNS I-NP O
11 771 776 8790412 leads VBZ B-VP O
12 777 779 8790412 to TO I-VP O
13 780 794 8790412 transformation VB I-VP O
14 796 799 8790412 the DT B-NP O
15 800 805 8790412 cells NNS I-NP O
16 806 812 8790412 become VBP B-VP O
17 813 821 8790412 enlarged VBN I-VP O
18 821 822 8790412 , , O O
19 823 827 8790412 grow VB B-VP O
20 828 835 8790412 tightly RB I-VP O
21 836 842 8790412 packed VBN I-VP O
22 843 846 8790412 and CC O O
23 847 849 8790412 in IN B-PP O
24 850 858 8790412 multiple JJ B-NP O
25 859 865 8790412 layers NNS I-NP O
26 865 866 8790412 , , O O
27 867 870 8790412 and CC O O
28 871 878 8790412 acquire VB B-VP O
29 879 882 8790412 the DT B-NP O
30 883 890 8790412 ability NN I-NP O
31 891 894 8790412 for IN B-PP O
32 895 904 8790412 anchorage NN B-NP O
33 904 905 8790412 - HYPH B-NP O
34 905 916 8790412 independent JJ I-NP O
35 917 923 8790412 growth NN I-NP O
36 923 924 8790412 . . O O

1 925 929 8790412 This DT B-NP O
2 930 938 8790412 cellular JJ I-NP O
3 939 953 8790412 transformation NN I-NP O
4 954 956 8790412 in FW B-ADVP O
5 957 962 8790412 vitro FW I-ADVP O
6 963 967 8790412 will MD B-VP O
7 968 978 8790412 facilitate VB I-VP O
8 979 986 8790412 studies NNS B-NP O
9 987 989 8790412 on IN B-PP O
10 990 993 8790412 the DT B-NP O
11 994 1003 8790412 mechanism NN I-NP O
12 1004 1006 8790412 of IN B-PP O
13 1007 1011 8790412 PAX3 NN B-NP O
14 1011 1012 8790412 - HYPH B-NP O
15 1012 1016 8790412 FKHR NN I-NP O
16 1016 1017 8790412 - HYPH B-NP O
17 1017 1024 8790412 induced VBN I-NP O
18 1025 1036 8790412 oncogenesis NN I-NP O
19 1036 1037 8790412 . . O O
20 1037 1038 8790412 . . O O

1 0 0 8733131 -DOCSTART- -X- -X- O

1 0 10 8733131 Expression NN B-NP O
2 11 13 8733131 of IN B-PP O
3 14 17 8733131 the DT B-NP O
4 18 21 8733131 von NNP I-NP B-Disease
5 22 28 8733131 Hippel NNP I-NP I-Disease
6 28 29 8733131 - HYPH I-NP I-Disease
7 29 35 8733131 Lindau NNP I-NP I-Disease
8 36 43 8733131 disease NN I-NP I-Disease
9 44 50 8733131 tumour NN I-NP I-Disease
10 51 61 8733131 suppressor NN I-NP O
11 62 66 8733131 gene NN I-NP O
12 67 73 8733131 during IN B-PP O
13 74 79 8733131 human JJ B-NP O
14 80 93 8733131 embryogenesis NN I-NP O
15 93 94 8733131 . . O O
16 95 98 8733131 The DT B-NP O
17 99 102 8733131 von NNP I-NP B-Disease
18 103 109 8733131 Hippel NNP I-NP I-Disease
19 109 110 8733131 - HYPH I-NP I-Disease
20 110 116 8733131 Lindau NNP I-NP I-Disease
21 117 118 8733131 ( ( O I-Disease
22 118 121 8733131 VHL NNP O I-Disease
23 121 122 8733131 ) ) O I-Disease
24 123 130 8733131 disease NN B-NP I-Disease
25 131 138 8733131 product NN I-NP O
26 139 141 8733131 is VBZ B-VP O
27 142 149 8733131 thought VBN I-VP O
28 150 152 8733131 to TO B-PP O
29 153 157 8733131 down RB B-VP O
30 157 158 8733131 - HYPH I-VP O
31 158 166 8733131 regulate VB I-VP O
32 167 180 8733131 transcription NN B-NP O
33 181 183 8733131 by IN B-PP O
34 184 196 8733131 antagonizing VBG B-VP O
35 197 204 8733131 elongin NN B-NP O
36 204 205 8733131 - HYPH O O
37 205 213 8733131 enhanced VBN B-VP O
38 214 229 8733131 transcriptional JJ B-NP O
39 230 240 8733131 elongation NN I-NP O
40 240 241 8733131 . . O O

1 242 250 8733131 Germline NN B-NP O
2 251 254 8733131 VHL NN I-NP B-Disease
3 255 259 8733131 gene NN I-NP O
4 260 269 8733131 mutations NNS I-NP O
5 270 280 8733131 predispose VBP B-VP O
6 281 283 8733131 to TO B-PP O
7 284 287 8733131 the DT B-NP O
8 288 299 8733131 development NN I-NP O
9 300 302 8733131 of IN B-PP O
10 303 310 8733131 retinal JJ B-NP B-Disease
11 310 311 8733131 , , I-NP I-Disease
12 312 322 8733131 cerebellar JJ I-NP I-Disease
13 323 326 8733131 and CC I-NP I-Disease
14 327 333 8733131 spinal JJ I-NP I-Disease
15 334 352 8733131 haemangioblastomas NNS I-NP I-Disease
16 352 353 8733131 , , O O
17 354 359 8733131 renal JJ B-NP B-Disease
18 360 364 8733131 cell NN I-NP I-Disease
19 365 374 8733131 carcinoma NN I-NP I-Disease
20 375 378 8733131 and CC I-NP O
21 379 396 8733131 phaeochromocytoma NN I-NP B-Disease
22 396 397 8733131 . . O O

1 398 400 8733131 In IN B-PP O
2 401 409 8733131 addition NN B-NP O
3 409 410 8733131 , , O O
4 411 418 8733131 somatic JJ B-NP O
5 419 431 8733131 Inactivation NN I-NP O
6 432 434 8733131 of IN B-PP O
7 435 438 8733131 the DT B-NP O
8 439 442 8733131 VHL NN I-NP B-Disease
9 443 447 8733131 gene NN I-NP O
10 448 450 8733131 is VBZ B-VP O
11 451 459 8733131 frequent JJ B-ADJP O
12 460 462 8733131 in IN B-PP O
13 463 471 8733131 sporadic JJ B-NP B-Disease
14 472 477 8733131 renal JJ I-NP I-Disease
15 478 482 8733131 cell NN I-NP I-Disease
16 483 492 8733131 carcinoma NN I-NP I-Disease
17 493 496 8733131 and CC I-NP O
18 497 514 8733131 haemangioblastoma NN I-NP B-Disease
19 514 515 8733131 . . O O

1 516 526 8733131 Regulation NN B-NP O
2 527 529 8733131 of IN B-PP O
3 530 540 8733131 transcript NN B-NP O
4 541 551 8733131 elongation NN I-NP O
5 552 554 8733131 is VBZ B-VP O
6 555 557 8733131 an DT B-NP O
7 558 567 8733131 important JJ I-NP O
8 568 575 8733131 control NN I-NP O
9 576 585 8733131 mechanism NN I-NP O
10 586 589 8733131 for IN B-PP O
11 590 594 8733131 gene NN B-NP O
12 595 605 8733131 expression NN I-NP O
13 606 609 8733131 and CC O O
14 610 613 8733131 the DT B-NP O
15 614 617 8733131 VHL NN I-NP B-Disease
16 618 622 8733131 gene NN I-NP O
17 623 628 8733131 might MD B-VP O
18 629 635 8733131 modify VB I-VP O
19 636 639 8733131 the DT B-NP O
20 640 650 8733131 expression NN I-NP O
21 651 653 8733131 of IN B-PP O
22 654 659 8733131 proto AFX B-NP O
23 659 660 8733131 - HYPH I-NP O
24 660 669 8733131 oncogenes NNS B-NP O
25 670 673 8733131 and CC O O
26 674 680 8733131 growth NN B-NP O
27 681 691 8733131 suppressor NN I-NP O
28 692 697 8733131 genes NNS I-NP O
29 698 704 8733131 during IN B-PP O
30 705 718 8733131 embryogenesis NN B-NP O
31 718 719 8733131 . . O O

1 720 722 8733131 We PRP B-NP O
2 723 732 8733131 therefore RB B-ADVP O
3 733 745 8733131 investigated VBD B-VP O
4 746 749 8733131 the DT B-NP O
5 750 760 8733131 expression NN I-NP O
6 761 763 8733131 of IN B-PP O
7 764 767 8733131 VHL NN B-NP B-Disease
8 768 772 8733131 mRNA NN I-NP O
9 773 779 8733131 during IN B-PP O
10 780 785 8733131 human JJ B-NP O
11 786 799 8733131 embryogenesis NN I-NP O
12 800 802 8733131 by IN B-PP O
13 803 805 8733131 in FW B-NP O
14 806 810 8733131 situ FW I-NP O
15 811 824 8733131 hybridization NN I-NP O
16 825 832 8733131 studies NNS I-NP O
17 833 835 8733131 at IN B-PP O
18 836 837 8733131 4 CD B-NP O
19 837 838 8733131 , , I-NP O
20 839 840 8733131 6 CD I-NP O
21 841 844 8733131 and CC I-NP O
22 845 847 8733131 10 CD I-NP O
23 848 853 8733131 weeks NNS I-NP O
24 854 858 8733131 post JJ I-NP O
25 859 869 8733131 conception NN I-NP O
26 869 870 8733131 . . O O

1 871 879 8733131 Although IN B-SBAR O
2 880 883 8733131 VHL NN B-NP B-Disease
3 884 888 8733131 mRNA NN I-NP O
4 889 892 8733131 was VBD B-VP O
5 893 902 8733131 expressed VBN I-VP O
6 903 905 8733131 in IN B-PP O
7 906 909 8733131 all DT B-NP O
8 910 915 8733131 three CD I-NP O
9 916 920 8733131 germ NN I-NP O
10 921 927 8733131 layers NNS I-NP O
11 927 928 8733131 , , O O
12 929 935 8733131 strong JJ B-NP O
13 936 946 8733131 expression NN I-NP O
14 947 950 8733131 was VBD B-VP O
15 951 956 8733131 noted VBN I-VP O
16 957 959 8733131 in IN B-PP O
17 960 963 8733131 the DT B-NP O
18 964 971 8733131 central JJ I-NP O
19 972 979 8733131 nervous JJ I-NP O
20 980 986 8733131 system NN I-NP O
21 986 987 8733131 , , O O
22 988 995 8733131 kidneys NNS B-NP O
23 995 996 8733131 , , O O
24 997 1003 8733131 testis NN B-NP O
25 1004 1007 8733131 and CC I-NP O
26 1008 1012 8733131 lung NN I-NP O
27 1012 1013 8733131 . . O O

1 1014 1020 8733131 Within IN B-PP O
2 1021 1024 8733131 the DT B-NP O
3 1025 1031 8733131 kidney NN I-NP O
4 1031 1032 8733131 , , O O
5 1033 1036 8733131 VHL NN B-NP B-Disease
6 1037 1041 8733131 mRNA NN I-NP O
7 1042 1045 8733131 was VBD B-VP O
8 1046 1060 8733131 differentially RB I-VP O
9 1061 1070 8733131 expressed VBN I-VP O
10 1071 1077 8733131 within IN B-PP O
11 1078 1083 8733131 renal JJ B-NP O
12 1084 1091 8733131 tubules NNS I-NP O
13 1092 1102 8733131 suggesting VBG B-VP O
14 1103 1107 8733131 that IN B-SBAR O
15 1108 1111 8733131 the DT B-NP O
16 1112 1115 8733131 VHL NN I-NP B-Disease
17 1116 1120 8733131 gene NN I-NP O
18 1121 1128 8733131 product NN I-NP O
19 1129 1132 8733131 may MD B-VP O
20 1133 1137 8733131 have VB I-VP O
21 1138 1139 8733131 a DT B-NP O
22 1140 1148 8733131 specific JJ I-NP O
23 1149 1153 8733131 role NN I-NP O
24 1154 1156 8733131 in IN B-PP O
25 1157 1163 8733131 kidney NN B-NP O
26 1164 1175 8733131 development NN I-NP O
27 1175 1176 8733131 . . O O

1 1177 1180 8733131 Two CD B-NP O
2 1181 1194 8733131 alternatively RB I-NP O
3 1195 1202 8733131 spliced VBN I-NP O
4 1203 1206 8733131 VHL NN I-NP B-Disease
5 1207 1212 8733131 mRNAs NNS I-NP O
6 1213 1226 8733131 characterized VBN B-VP O
7 1227 1229 8733131 by IN B-PP O
8 1230 1239 8733131 inclusion NN B-NP O
9 1240 1241 8733131 ( ( O O
10 1241 1248 8733131 isoform NN B-NP O
11 1249 1250 8733131 I CD I-NP O
12 1250 1251 8733131 ) ) O O
13 1252 1254 8733131 or CC O O
14 1255 1264 8733131 exclusion NN B-NP O
15 1265 1266 8733131 ( ( O O
16 1266 1273 8733131 isoform NN B-NP O
17 1274 1276 8733131 II CD I-NP O
18 1276 1277 8733131 ) ) O O
19 1278 1280 8733131 of IN B-PP O
20 1281 1285 8733131 exon NN B-NP O
21 1286 1287 8733131 2 CD I-NP O
22 1288 1291 8733131 are VBP B-VP O
23 1292 1303 8733131 transcribed VBN I-VP O
24 1304 1306 8733131 in IN B-PP O
25 1307 1312 8733131 adult JJ B-NP O
26 1313 1320 8733131 tissues NNS I-NP O
27 1320 1321 8733131 . . O O

1 1322 1324 8733131 To TO B-VP O
2 1325 1336 8733131 investigate VB I-VP O
3 1337 1339 8733131 if IN B-SBAR O
4 1340 1343 8733131 the DT B-NP O
5 1344 1347 8733131 two CD I-NP O
6 1348 1356 8733131 isoforms NNS I-NP O
7 1357 1360 8733131 are VBP B-VP O
8 1361 1375 8733131 differentially RB I-VP O
9 1376 1385 8733131 expressed VBN I-VP O
10 1386 1392 8733131 during IN B-PP O
11 1393 1406 8733131 embryogenesis NN B-NP O
12 1406 1407 8733131 , , O O
13 1408 1411 8733131 VHL NN B-NP B-Disease
14 1412 1416 8733131 mRNA NN I-NP O
15 1417 1420 8733131 was VBD B-VP O
16 1421 1428 8733131 reverse NN B-NP O
17 1429 1440 8733131 transcribed VBN B-VP O
18 1441 1445 8733131 from IN B-PP O
19 1446 1448 8733131 13 CD B-NP O
20 1449 1454 8733131 fetal JJ I-NP O
21 1455 1462 8733131 tissues NNS I-NP O
22 1463 1464 8733131 ( ( O O
23 1464 1465 8733131 8 CD B-NP O
24 1465 1466 8733131 - HYPH I-NP O
25 1466 1468 8733131 10 CD I-NP O
26 1469 1474 8733131 weeks NNS I-NP O
27 1475 1484 8733131 gestation NN I-NP O
28 1484 1485 8733131 ) ) O O
29 1485 1486 8733131 . . O O

1 1487 1490 8733131 The DT B-NP O
2 1491 1503 8733131 quantitative JJ I-NP O
3 1504 1516 8733131 distribution NN I-NP O
4 1517 1519 8733131 of IN B-PP O
5 1520 1523 8733131 VHL NN B-NP B-Disease
6 1524 1528 8733131 mRNA NN I-NP O
7 1529 1535 8733131 within IN B-PP O
8 1536 1541 8733131 fetal JJ B-NP O
9 1542 1549 8733131 tissues NNS I-NP O
10 1550 1559 8733131 reflected VBD B-VP O
11 1560 1564 8733131 that IN B-SBAR O
12 1565 1569 8733131 seen VBN B-VP O
13 1570 1572 8733131 by IN B-PP O
14 1573 1575 8733131 in FW B-NP O
15 1576 1580 8733131 situ FW I-NP O
16 1581 1594 8733131 hybridization NN I-NP O
17 1595 1598 8733131 and CC O O
18 1599 1602 8733131 the DT B-NP O
19 1603 1608 8733131 ratio NN I-NP O
20 1609 1611 8733131 of IN B-PP O
21 1612 1615 8733131 the DT B-NP O
22 1616 1619 8733131 two CD I-NP O
23 1620 1623 8733131 VHL NN I-NP B-Disease
24 1624 1632 8733131 isoforms NNS I-NP O
25 1633 1636 8733131 was VBD B-VP O
26 1637 1644 8733131 similar JJ B-ADJP O
27 1645 1652 8733131 between IN B-PP O
28 1653 1660 8733131 tissues NNS B-NP O
29 1660 1661 8733131 . . O O

1 1662 1670 8733131 Although IN B-SBAR O
2 1671 1674 8733131 the DT B-NP O
3 1675 1680 8733131 genes NNS I-NP O
4 1681 1690 8733131 regulated VBN B-VP O
5 1691 1693 8733131 by IN B-PP O
6 1694 1697 8733131 the DT B-NP O
7 1698 1701 8733131 VHL NN I-NP B-Disease
8 1702 1706 8733131 gene NN I-NP O
9 1707 1714 8733131 product NN I-NP O
10 1715 1719 8733131 have VBP B-VP O
11 1720 1723 8733131 not RB I-VP O
12 1724 1727 8733131 yet RB I-VP O
13 1728 1732 8733131 been VBN I-VP O
14 1733 1743 8733131 identified VBN I-VP O
15 1743 1744 8733131 , , O O
16 1745 1748 8733131 our PRP$ B-NP O
17 1749 1757 8733131 findings NNS I-NP O
18 1758 1761 8733131 are VBP B-VP O
19 1762 1772 8733131 compatible JJ B-ADJP O
20 1773 1777 8733131 with IN B-PP O
21 1778 1781 8733131 the DT B-NP O
22 1782 1792 8733131 hypothesis NN I-NP O
23 1793 1797 8733131 that IN B-SBAR O
24 1798 1801 8733131 VHL NN B-NP B-Disease
25 1801 1802 8733131 - HYPH O O
26 1802 1810 8733131 mediated VBN B-VP O
27 1811 1818 8733131 control NN B-NP O
28 1819 1821 8733131 of IN B-PP O
29 1822 1837 8733131 transcriptional JJ B-NP O
30 1838 1848 8733131 elongation NN I-NP O
31 1849 1852 8733131 may MD B-VP O
32 1853 1857 8733131 have VB I-VP O
33 1858 1859 8733131 a DT B-NP O
34 1860 1864 8733131 role NN I-NP O
35 1865 1867 8733131 in IN B-PP O
36 1868 1874 8733131 normal JJ B-NP O
37 1875 1880 8733131 human JJ I-NP O
38 1881 1892 8733131 development NN I-NP O
39 1892 1893 8733131 . . O O
40 1893 1894 8733131 . . O O

1 0 0 9223307 -DOCSTART- -X- -X- O

1 0 9 9223307 Isolation NN B-NP O
2 10 12 9223307 of IN B-PP O
3 13 17 9223307 full JJ B-NP O
4 17 18 9223307 - HYPH I-NP O
5 18 24 9223307 length NN I-NP O
6 25 28 9223307 ATM NN I-NP O
7 29 33 9223307 cDNA NN I-NP O
8 34 37 9223307 and CC I-NP O
9 38 48 9223307 correction NN I-NP O
10 49 51 9223307 of IN B-PP O
11 52 55 9223307 the DT B-NP O
12 56 62 9223307 ataxia NN I-NP B-Disease
13 62 63 9223307 - HYPH B-NP I-Disease
14 63 77 9223307 telangiectasia NN I-NP I-Disease
15 78 86 9223307 cellular JJ I-NP O
16 87 96 9223307 phenotype NN I-NP O
17 96 97 9223307 . . I-NP O
18 98 99 9223307 A NN I-NP O
19 100 104 9223307 gene NN I-NP O
20 105 112 9223307 mutated VBN B-VP O
21 113 115 9223307 in IN B-PP O
22 116 119 9223307 the DT B-NP O
23 120 125 9223307 human JJ I-NP O
24 126 133 9223307 genetic JJ I-NP B-Disease
25 134 142 9223307 disorder NN I-NP I-Disease
26 143 149 9223307 ataxia NN I-NP B-Disease
27 149 150 9223307 - HYPH B-NP I-Disease
28 150 164 9223307 telangiectasia NN I-NP I-Disease
29 165 166 9223307 ( ( O O
30 166 167 9223307 A NN B-NP B-Disease
31 167 168 9223307 - HYPH I-NP I-Disease
32 168 169 9223307 T NN I-NP I-Disease
33 169 170 9223307 ) ) O O
34 170 171 9223307 , , O O
35 172 175 9223307 ATM NN B-NP O
36 175 176 9223307 , , O O
37 177 180 9223307 was VBD B-VP O
38 181 189 9223307 recently RB I-VP O
39 190 200 9223307 identified VBN I-VP O
40 201 203 9223307 by IN B-PP O
41 204 214 9223307 positional JJ B-NP O
42 215 222 9223307 cloning NN I-NP O
43 222 223 9223307 . . O O

1 224 227 9223307 ATM NN B-NP O
2 228 230 9223307 is VBZ B-VP O
3 231 232 9223307 a DT B-NP O
4 233 239 9223307 member NN I-NP O
5 240 242 9223307 of IN B-PP O
6 243 246 9223307 the DT B-NP O
7 247 267 9223307 phosphatidylinositol NN I-NP O
8 267 268 9223307 - HYPH B-NP O
9 268 269 9223307 3 CD I-NP O
10 269 270 9223307 - HYPH I-NP O
11 270 276 9223307 kinase NN I-NP O
12 277 288 9223307 superfamily NN I-NP O
13 288 289 9223307 , , O O
14 290 294 9223307 some DT B-NP O
15 295 297 9223307 of IN B-PP O
16 298 303 9223307 which WDT B-NP O
17 304 307 9223307 are VBP B-VP O
18 308 315 9223307 protein NN B-NP O
19 316 323 9223307 kinases NNS I-NP O
20 324 327 9223307 and CC O O
21 328 334 9223307 appear VBP B-VP O
22 335 337 9223307 to TO I-VP O
23 338 342 9223307 have VB I-VP O
24 343 352 9223307 important JJ B-NP O
25 353 358 9223307 roles NNS I-NP O
26 359 361 9223307 in IN B-PP O
27 362 366 9223307 cell NN B-NP O
28 367 372 9223307 cycle NN I-NP O
29 373 380 9223307 control NN I-NP O
30 381 384 9223307 and CC O O
31 385 394 9223307 radiation NN B-NP O
32 395 401 9223307 signal NN I-NP O
33 402 414 9223307 transduction NN I-NP O
34 414 415 9223307 . . O O

1 416 418 9223307 We PRP B-NP O
2 419 427 9223307 describe VBP B-VP O
3 428 434 9223307 herein RB B-ADVP O
4 434 435 9223307 , , O O
5 436 438 9223307 to TO B-PP O
6 439 442 9223307 our PRP$ B-NP O
7 443 452 9223307 knowledge NN I-NP O
8 452 453 9223307 , , O O
9 454 457 9223307 for IN B-PP O
10 458 461 9223307 the DT B-NP O
11 462 467 9223307 first JJ I-NP O
12 468 472 9223307 time NN I-NP O
13 472 473 9223307 , , O O
14 474 477 9223307 the DT B-NP O
15 478 485 9223307 cloning NN I-NP O
16 486 488 9223307 of IN B-PP O
17 489 490 9223307 a DT B-NP O
18 491 495 9223307 full JJ I-NP O
19 495 496 9223307 - HYPH I-NP O
20 496 502 9223307 length NN I-NP O
21 503 507 9223307 cDNA NN I-NP O
22 508 511 9223307 for IN B-PP O
23 512 515 9223307 ATM NN B-NP O
24 516 519 9223307 and CC I-NP O
25 520 530 9223307 correction NN I-NP O
26 531 533 9223307 of IN B-PP O
27 534 542 9223307 multiple JJ B-NP O
28 543 550 9223307 aspects NNS I-NP O
29 551 553 9223307 of IN B-PP O
30 554 557 9223307 the DT B-NP O
31 558 563 9223307 radio AFX I-NP O
32 563 564 9223307 - HYPH I-NP O
33 564 573 9223307 sensitive JJ I-NP O
34 574 583 9223307 phenotype NN I-NP O
35 584 586 9223307 of IN B-PP O
36 587 588 9223307 A NN B-NP B-Disease
37 588 589 9223307 - HYPH I-NP I-Disease
38 589 590 9223307 T NN I-NP I-Disease
39 591 596 9223307 cells NNS I-NP O
40 597 599 9223307 by IN B-PP O
41 600 612 9223307 transfection NN B-NP O
42 613 617 9223307 with IN B-PP O
43 618 622 9223307 this DT B-NP O
44 623 627 9223307 cDNA NN I-NP O
45 627 628 9223307 . . O O

1 629 643 9223307 Overexpression NN B-NP O
2 644 646 9223307 of IN B-PP O
3 647 650 9223307 ATM NN B-NP O
4 651 655 9223307 cDNA NN I-NP O
5 656 658 9223307 in IN B-PP O
6 659 660 9223307 A NN B-NP B-Disease
7 660 661 9223307 - HYPH I-NP I-Disease
8 661 662 9223307 T NN I-NP I-Disease
9 663 668 9223307 cells NNS I-NP O
10 669 677 9223307 enhanced VBD B-VP O
11 678 681 9223307 the DT B-NP O
12 682 690 9223307 survival NN I-NP O
13 691 693 9223307 of IN B-PP O
14 694 699 9223307 these DT B-NP O
15 700 705 9223307 cells NNS I-NP O
16 706 708 9223307 in IN B-PP O
17 709 717 9223307 response NN I-PP O
18 718 720 9223307 to TO I-PP O
19 721 730 9223307 radiation NN B-NP O
20 731 739 9223307 exposure NN I-NP O
21 739 740 9223307 , , O O
22 741 750 9223307 decreased VBD B-VP O
23 751 760 9223307 radiation NN B-NP O
24 760 761 9223307 - HYPH B-NP O
25 761 768 9223307 induced VBN I-NP O
26 769 779 9223307 chromosome NN I-NP O
27 780 791 9223307 aberrations NNS I-NP O
28 791 792 9223307 , , O O
29 793 800 9223307 reduced VBD B-VP O
30 801 806 9223307 radio AFX B-NP O
31 806 807 9223307 - HYPH B-NP O
32 807 816 9223307 resistant JJ I-NP O
33 817 820 9223307 DNA NN I-NP O
34 821 830 9223307 synthesis NN I-NP O
35 830 831 9223307 , , O O
36 832 835 9223307 and CC O O
37 836 845 9223307 partially RB B-VP O
38 846 855 9223307 corrected VBN I-VP O
39 856 865 9223307 defective JJ B-NP O
40 866 870 9223307 cell NN I-NP O
41 871 876 9223307 cycle NN I-NP O
42 877 888 9223307 checkpoints NNS I-NP O
43 889 892 9223307 and CC O O
44 893 902 9223307 induction NN B-NP O
45 903 905 9223307 of IN B-PP O
46 906 912 9223307 stress NN B-NP O
47 912 913 9223307 - HYPH B-NP O
48 913 922 9223307 activated VBN I-NP O
49 923 930 9223307 protein NN I-NP O
50 931 937 9223307 kinase NN I-NP O
51 937 938 9223307 . . O O

1 939 943 9223307 This DT B-NP O
2 944 954 9223307 correction NN I-NP O
3 955 957 9223307 of IN B-PP O
4 958 961 9223307 the DT B-NP O
5 962 969 9223307 defects NNS I-NP O
6 970 972 9223307 in IN B-PP O
7 973 974 9223307 A NN B-NP B-Disease
8 974 975 9223307 - HYPH I-NP I-Disease
9 975 976 9223307 T NN I-NP I-Disease
10 977 982 9223307 cells NNS I-NP O
11 983 991 9223307 provides VBZ B-VP O
12 992 999 9223307 further JJR B-NP O
13 1000 1008 9223307 evidence NN I-NP O
14 1009 1011 9223307 of IN B-PP O
15 1012 1015 9223307 the DT B-NP O
16 1016 1028 9223307 multiplicity NN I-NP O
17 1029 1031 9223307 of IN B-PP O
18 1032 1040 9223307 effector NN B-NP O
19 1041 1050 9223307 functions NNS I-NP O
20 1051 1053 9223307 of IN B-PP O
21 1054 1057 9223307 the DT B-NP O
22 1058 1061 9223307 ATM NN I-NP O
23 1062 1069 9223307 protein NN I-NP O
24 1070 1073 9223307 and CC O O
25 1074 1082 9223307 suggests VBZ B-VP O
26 1083 1091 9223307 possible JJ B-NP O
27 1092 1102 9223307 approaches NNS I-NP O
28 1103 1105 9223307 to TO B-PP O
29 1106 1110 9223307 gene NN B-NP O
30 1111 1118 9223307 therapy NN I-NP O
31 1118 1119 9223307 . . O O
32 1119 1120 9223307 . . O O

1 0 0 8954016 -DOCSTART- -X- -X- O

1 0 9 8954016 Autosomal JJ B-NP O
2 10 18 8954016 dominant JJ I-NP O
3 19 26 8954016 primary JJ I-NP O
4 27 46 8954016 hyperparathyroidism NN I-NP B-Disease
5 47 50 8954016 and CC I-NP I-Disease
6 51 54 8954016 jaw NN I-NP I-Disease
7 55 60 8954016 tumor NN I-NP I-Disease
8 61 69 8954016 syndrome NN I-NP I-Disease
9 70 80 8954016 associated VBN B-VP O
10 81 85 8954016 with IN B-PP O
11 86 91 8954016 renal JJ B-NP B-Disease
12 92 102 8954016 hamartomas NNS I-NP I-Disease
13 103 106 8954016 and CC O O
14 107 113 8954016 cystic JJ B-NP B-Disease
15 114 120 8954016 kidney NN I-NP I-Disease
16 121 128 8954016 disease NN I-NP I-Disease
17 128 129 8954016 : : O O
18 130 137 8954016 linkage NN B-NP O
19 138 140 8954016 to TO B-PP O
20 141 145 8954016 1q21 NN B-NP O
21 145 146 8954016 - HYPH B-NP O
22 146 149 8954016 q32 NN I-NP O
23 150 153 8954016 and CC I-NP O
24 154 158 8954016 loss NN I-NP O
25 159 161 8954016 of IN B-PP O
26 162 165 8954016 the DT B-NP O
27 166 170 8954016 wild JJ I-NP O
28 171 175 8954016 type NN I-NP O
29 176 182 8954016 allele NN I-NP O
30 183 185 8954016 in IN B-PP O
31 186 191 8954016 renal JJ B-NP B-Disease
32 192 202 8954016 hamartomas NNS I-NP I-Disease
33 202 203 8954016 . . O O
34 204 214 8954016 Hereditary JJ B-NP B-Disease
35 215 234 8954016 hyperparathyroidism NN I-NP I-Disease
36 234 235 8954016 - HYPH B-NP I-Disease
37 235 238 8954016 jaw NN I-NP I-Disease
38 239 244 8954016 tumor NN I-NP I-Disease
39 245 253 8954016 syndrome NN I-NP I-Disease
40 254 255 8954016 ( ( O O
41 255 258 8954016 HPT NN B-NP B-Disease
42 258 259 8954016 - HYPH B-NP I-Disease
43 259 261 8954016 JT NN I-NP I-Disease
44 261 262 8954016 ) ) O O
45 263 265 8954016 is VBZ B-VP O
46 266 268 8954016 an DT B-NP O
47 269 278 8954016 autosomal JJ I-NP B-Disease
48 279 287 8954016 dominant JJ I-NP I-Disease
49 288 295 8954016 disease NN I-NP I-Disease
50 296 297 8954016 ( ( O O
51 297 301 8954016 OMIM NN B-NP O
52 302 308 8954016 145001 CD I-NP O
53 308 309 8954016 ) ) O O
54 310 314 8954016 that WDT B-NP O
55 315 318 8954016 has VBZ B-VP O
56 319 327 8954016 recently RB I-VP O
57 328 332 8954016 been VBN I-VP O
58 333 339 8954016 mapped VBN I-VP O
59 340 342 8954016 to TO B-PP O
60 343 354 8954016 chromosomal JJ B-NP O
61 355 361 8954016 region NN I-NP O
62 362 366 8954016 1q21 NN I-NP O
63 366 367 8954016 - HYPH O O
64 367 370 8954016 q32 NN B-NP O
65 371 372 8954016 ( ( O O
66 372 377 8954016 HRPT2 NN B-NP O
67 377 378 8954016 ) ) O O
68 378 379 8954016 . . O O

1 380 384 8954016 Here RB B-ADVP O
2 385 387 8954016 we PRP B-NP O
3 388 394 8954016 report VBP B-VP O
4 395 398 8954016 two CD B-NP O
5 399 407 8954016 families NNS I-NP O
6 408 412 8954016 with IN B-PP O
7 413 416 8954016 HPT NN B-NP B-Disease
8 416 417 8954016 - HYPH I-NP I-Disease
9 417 419 8954016 JT NN I-NP I-Disease
10 420 428 8954016 syndrome NN I-NP I-Disease
11 429 431 8954016 in IN B-PP O
12 432 437 8954016 which WDT B-NP O
13 438 443 8954016 adult JJ B-NP B-Disease
14 444 449 8954016 renal JJ I-NP I-Disease
15 450 460 8954016 hamartomas NNS I-NP I-Disease
16 461 463 8954016 or CC O O
17 464 470 8954016 cystic JJ B-NP B-Disease
18 471 477 8954016 kidney NN I-NP I-Disease
19 478 485 8954016 disease NN I-NP I-Disease
20 486 490 8954016 were VBD B-VP O
21 491 500 8954016 prominent JJ B-NP O
22 501 511 8954016 associated VBN I-NP O
23 512 520 8954016 features NNS I-NP O
24 520 521 8954016 , , O O
25 522 530 8954016 possibly RB B-ADVP O
26 531 543 8954016 representing VBG B-VP O
27 544 545 8954016 a DT B-NP O
28 546 549 8954016 new JJ I-NP O
29 550 560 8954016 phenotypic JJ I-NP O
30 561 568 8954016 variant NN I-NP O
31 569 571 8954016 of IN B-PP O
32 572 575 8954016 the DT B-NP O
33 576 579 8954016 HPT NN I-NP B-Disease
34 579 580 8954016 - HYPH B-NP I-Disease
35 580 582 8954016 JT NN I-NP I-Disease
36 583 591 8954016 syndrome NN I-NP I-Disease
37 591 592 8954016 . . O O

1 593 595 8954016 In IN B-PP O
2 596 599 8954016 the DT B-NP O
3 600 605 8954016 first JJ I-NP O
4 606 612 8954016 family NN I-NP O
5 612 613 8954016 , , O O
6 614 619 8954016 renal JJ B-NP B-Disease
7 620 627 8954016 lesions NNS I-NP I-Disease
8 628 632 8954016 were VBD B-VP O
9 633 640 8954016 present JJ B-ADJP O
10 641 643 8954016 in IN B-PP O
11 644 648 8954016 five CD B-NP O
12 649 652 8954016 out IN I-NP O
13 653 655 8954016 of IN I-NP O
14 656 659 8954016 six CD I-NP O
15 660 668 8954016 affected VBN I-NP O
16 669 680 8954016 individuals NNS I-NP O
17 680 681 8954016 , , O O
18 682 689 8954016 whereas IN O O
19 690 693 8954016 HPT NN B-NP B-Disease
20 694 697 8954016 and CC I-NP O
21 698 700 8954016 JT NN I-NP B-Disease
22 701 705 8954016 were VBD B-VP O
23 706 710 8954016 seen VBN I-VP O
24 711 713 8954016 in IN B-PP O
25 714 718 8954016 four CD B-NP O
26 719 722 8954016 and CC I-NP O
27 723 726 8954016 two CD I-NP O
28 727 732 8954016 cases NNS I-NP O
29 732 733 8954016 , , O O
30 734 746 8954016 respectively RB B-ADVP O
31 746 747 8954016 . . O O

1 748 750 8954016 In IN B-PP O
2 751 754 8954016 the DT B-NP O
3 755 761 8954016 second JJ I-NP O
4 762 768 8954016 family NN I-NP O
5 768 769 8954016 , , O O
6 770 772 8954016 JT NN B-NP B-Disease
7 773 776 8954016 was VBD B-VP O
8 777 782 8954016 found VBN I-VP O
9 783 785 8954016 in IN B-PP O
10 786 791 8954016 three CD B-NP O
11 792 794 8954016 of IN B-PP O
12 795 798 8954016 the DT B-NP O
13 799 803 8954016 five CD I-NP O
14 804 812 8954016 affected VBN I-NP O
15 813 824 8954016 individuals NNS I-NP O
16 825 828 8954016 and CC O O
17 829 832 8954016 two CD B-NP O
18 833 841 8954016 affected VBN I-NP O
19 842 849 8954016 members NNS I-NP O
20 850 854 8954016 also RB B-ADVP O
21 855 864 8954016 exhibited VBD B-VP O
22 865 875 8954016 polycystic JJ B-NP B-Disease
23 876 882 8954016 kidney NN I-NP I-Disease
24 883 890 8954016 disease NN I-NP I-Disease
25 890 891 8954016 . . O O

1 892 895 8954016 The DT B-NP O
2 896 907 8954016 possibility NN I-NP O
3 908 910 8954016 of IN B-PP O
4 911 914 8954016 the DT B-NP O
5 915 921 8954016 latter JJ I-NP O
6 922 935 8954016 cosegregating NN I-NP O
7 936 938 8954016 as IN B-PP O
8 939 940 8954016 a DT B-NP O
9 941 949 8954016 separate JJ I-NP O
10 950 959 8954016 autosomal JJ I-NP O
11 960 968 8954016 dominant JJ I-NP O
12 969 973 8954016 gene NN I-NP O
13 974 977 8954016 can MD B-VP O
14 978 981 8954016 not RB I-VP O
15 982 984 8954016 be VB I-VP O
16 985 990 8954016 ruled VBN I-VP O
17 991 994 8954016 out RP B-PRT O
18 994 995 8954016 . . O O

1 996 997 8954016 A DT B-NP O
2 998 1001 8954016 sex NN I-NP O
3 1001 1002 8954016 - HYPH B-NP O
4 1002 1011 8954016 dependent JJ I-NP O
5 1012 1022 8954016 penetrance NN I-NP O
6 1023 1025 8954016 of IN B-PP O
7 1026 1033 8954016 primary JJ B-NP B-Disease
8 1034 1037 8954016 HPT NN I-NP I-Disease
9 1037 1038 8954016 , , O O
10 1039 1048 8954016 resulting VBG B-VP O
11 1049 1051 8954016 in IN B-PP O
12 1052 1065 8954016 predominantly RB B-NP O
13 1066 1070 8954016 male JJ I-NP O
14 1070 1071 8954016 - HYPH I-NP O
15 1071 1079 8954016 affected VBN I-NP O
16 1080 1085 8954016 cases NNS I-NP O
17 1086 1089 8954016 was VBD B-VP O
18 1090 1097 8954016 evident JJ B-ADJP O
19 1098 1100 8954016 in IN B-PP O
20 1101 1104 8954016 the DT B-NP O
21 1105 1108 8954016 two CD I-NP O
22 1109 1117 8954016 families NNS I-NP O
23 1117 1118 8954016 . . O O

1 1119 1125 8954016 Twenty CD B-NP O
2 1126 1140 8954016 microsatellite NN I-NP O
3 1141 1148 8954016 markers NNS I-NP O
4 1149 1151 8954016 in IN B-PP O
5 1152 1155 8954016 the DT B-NP O
6 1156 1161 8954016 HRPT2 NN I-NP O
7 1162 1168 8954016 region NN I-NP O
8 1169 1173 8954016 were VBD B-VP O
9 1174 1179 8954016 typed VBN I-VP O
10 1179 1180 8954016 , , O O
11 1181 1183 8954016 in IN B-PP O
12 1184 1192 8954016 addition NN B-NP O
13 1193 1195 8954016 to TO B-PP O
14 1196 1203 8954016 markers NNS B-NP O
15 1204 1206 8954016 in IN B-PP O
16 1207 1210 8954016 the DT B-NP O
17 1211 1219 8954016 multiple JJ I-NP B-Disease
18 1220 1229 8954016 endocrine JJ I-NP I-Disease
19 1230 1239 8954016 neoplasia NN I-NP I-Disease
20 1240 1241 8954016 ( ( O I-Disease
21 1241 1244 8954016 MEN NN B-NP I-Disease
22 1244 1245 8954016 ) ) O I-Disease
23 1246 1251 8954016 types NNS B-NP I-Disease
24 1252 1253 8954016 1 CD I-NP I-Disease
25 1254 1257 8954016 and CC I-NP I-Disease
26 1258 1259 8954016 2 CD I-NP I-Disease
27 1260 1267 8954016 regions NNS I-NP O
28 1268 1270 8954016 at IN B-PP O
29 1271 1276 8954016 11q13 CD B-NP O
30 1277 1280 8954016 and CC I-NP O
31 1281 1286 8954016 10q11 CD I-NP O
32 1286 1287 8954016 . . O O

1 1288 1291 8954016 The DT B-NP O
2 1292 1299 8954016 disease NN I-NP O
3 1300 1302 8954016 in IN B-PP O
4 1303 1308 8954016 these DT B-NP O
5 1309 1312 8954016 two CD I-NP O
6 1313 1321 8954016 kindreds NNS I-NP O
7 1322 1325 8954016 was VBD B-VP O
8 1326 1332 8954016 linked VBN I-VP O
9 1333 1335 8954016 to TO B-PP O
10 1336 1340 8954016 five CD B-NP O
11 1341 1348 8954016 markers NNS I-NP O
12 1349 1351 8954016 in IN B-PP O
13 1352 1355 8954016 the DT B-NP O
14 1356 1360 8954016 1q21 NN I-NP O
15 1360 1361 8954016 - HYPH O O
16 1361 1364 8954016 q32 NN B-NP O
17 1365 1371 8954016 region NN I-NP O
18 1372 1373 8954016 ( ( O O
19 1373 1382 8954016 logarithm NN B-NP O
20 1382 1383 8954016 - HYPH O O
21 1383 1385 8954016 of IN B-PP O
22 1385 1386 8954016 - HYPH B-NP O
23 1386 1390 8954016 odds VBZ B-VP O
24 1391 1397 8954016 scores NNS B-NP O
25 1399 1400 8954016 3 CD B-NP O
26 1400 1401 8954016 . . I-NP O
27 1402 1403 8954016 2 CD I-NP O
28 1403 1404 8954016 - : O O
29 1404 1405 8954016 4 CD B-NP O
30 1406 1407 8954016 2 CD I-NP O
31 1407 1408 8954016 - : O O
32 1408 1409 8954016 4 CD B-NP O
33 1409 1410 8954016 . . O O

1 1411 1412 8954016 2 LS B-LST O
2 1412 1413 8954016 ) ) O O
3 1413 1414 8954016 , , O O
4 1415 1422 8954016 whereas IN O O
5 1423 1430 8954016 linkage NN B-NP O
6 1431 1433 8954016 to TO B-PP O
7 1434 1437 8954016 the DT B-NP O
8 1438 1442 8954016 MEN1 NN I-NP B-Disease
9 1443 1446 8954016 and CC I-NP O
10 1447 1451 8954016 MEN2 NN I-NP B-Disease
11 1452 1459 8954016 regions NNS I-NP O
12 1460 1463 8954016 was VBD B-VP O
13 1464 1472 8954016 excluded VBN I-VP O
14 1472 1473 8954016 . . O O

1 1474 1481 8954016 Meiotic JJ B-NP O
2 1482 1496 8954016 recombinations NNS I-NP O
3 1497 1505 8954016 detected VBN B-VP O
4 1506 1508 8954016 in IN B-PP O
5 1509 1517 8954016 affected VBN B-NP O
6 1518 1529 8954016 individuals NNS I-NP O
7 1530 1536 8954016 placed VBD B-VP O
8 1537 1540 8954016 the DT B-NP O
9 1541 1546 8954016 locus NN I-NP O
10 1547 1556 8954016 telomeric NN I-NP O
11 1557 1559 8954016 of IN B-PP O
12 1560 1566 8954016 D1S215 NN B-NP O
13 1566 1567 8954016 , , O O
14 1568 1572 8954016 thus RB B-ADVP O
15 1573 1582 8954016 narrowing VBG B-VP O
16 1583 1586 8954016 the DT B-NP O
17 1587 1592 8954016 HRPT2 NN I-NP O
18 1593 1599 8954016 region NN I-NP O
19 1600 1604 8954016 from IN B-PP O
20 1605 1606 8954016 > SYM B-NP O
21 1607 1609 8954016 60 CD I-NP O
22 1610 1612 8954016 to TO B-PP O
23 1613 1626 8954016 approximately RB B-NP O
24 1627 1629 8954016 34 CD I-NP O
25 1630 1642 8954016 centimorgans NNS I-NP O
26 1642 1643 8954016 . . O O

1 1644 1648 8954016 Loss NN B-NP O
2 1649 1651 8954016 of IN B-PP O
3 1652 1666 8954016 heterozygosity NN B-NP O
4 1667 1670 8954016 was VBD B-VP O
5 1671 1678 8954016 studied VBN I-VP O
6 1679 1681 8954016 in IN B-PP O
7 1682 1687 8954016 seven CD B-NP O
8 1688 1693 8954016 renal JJ I-NP B-Disease
9 1694 1704 8954016 hamartomas NNS I-NP I-Disease
10 1705 1709 8954016 from IN B-PP O
11 1710 1713 8954016 two CD B-NP O
12 1714 1722 8954016 affected VBN I-NP O
13 1723 1734 8954016 individuals NNS I-NP O
14 1735 1737 8954016 in IN B-PP O
15 1738 1741 8954016 the DT B-NP O
16 1742 1747 8954016 first JJ I-NP O
17 1748 1754 8954016 family NN I-NP O
18 1754 1755 8954016 , , O O
19 1756 1758 8954016 as RB B-CONJP O
20 1759 1763 8954016 well RB I-CONJP O
21 1764 1766 8954016 as IN I-CONJP O
22 1767 1769 8954016 in IN B-PP O
23 1770 1771 8954016 a DT B-NP O
24 1772 1775 8954016 jaw JJ I-NP B-Disease
25 1776 1781 8954016 tumor NN I-NP I-Disease
26 1782 1785 8954016 and CC O O
27 1786 1787 8954016 a DT B-NP O
28 1788 1799 8954016 parathyroid JJ I-NP B-Disease
29 1800 1805 8954016 tumor NN I-NP I-Disease
30 1806 1810 8954016 from IN B-PP O
31 1811 1814 8954016 the DT B-NP O
32 1815 1821 8954016 second JJ I-NP O
33 1822 1828 8954016 family NN I-NP O
34 1828 1829 8954016 . . O O

1 1830 1833 8954016 All DT B-NP O
2 1834 1839 8954016 renal JJ I-NP B-Disease
3 1840 1850 8954016 hamartomas NNS I-NP I-Disease
4 1851 1857 8954016 showed VBD B-VP O
5 1858 1862 8954016 loss NN B-NP O
6 1863 1865 8954016 of IN B-PP O
7 1866 1880 8954016 heterozygosity NN B-NP O
8 1881 1883 8954016 at IN B-PP O
9 1884 1887 8954016 the DT B-NP O
10 1888 1892 8954016 1q21 NN I-NP O
11 1892 1893 8954016 - HYPH B-NP O
12 1893 1896 8954016 q32 NN I-NP O
13 1897 1903 8954016 region NN I-NP O
14 1903 1904 8954016 . . O O

1 1905 1908 8954016 The DT B-NP O
2 1909 1915 8954016 losses NNS I-NP O
3 1916 1926 8954016 invariably RB B-ADVP O
4 1927 1935 8954016 involved VBD B-VP O
5 1936 1939 8954016 the DT B-NP O
6 1940 1944 8954016 wild JJ I-NP O
7 1945 1949 8954016 type NN I-NP O
8 1950 1956 8954016 allele NN I-NP O
9 1957 1964 8954016 derived VBN B-VP O
10 1965 1969 8954016 from IN B-PP O
11 1970 1973 8954016 the DT B-NP O
12 1974 1984 8954016 unaffected JJ I-NP O
13 1985 1991 8954016 parent NN I-NP O
14 1991 1992 8954016 , , O O
15 1993 2003 8954016 suggesting VBG B-VP O
16 2004 2007 8954016 the DT B-NP O
17 2008 2020 8954016 inactivation NN I-NP O
18 2021 2023 8954016 of IN B-PP O
19 2024 2025 8954016 a DT B-NP O
20 2026 2031 8954016 tumor NN I-NP B-Disease
21 2032 2042 8954016 suppressor NN I-NP O
22 2043 2047 8954016 gene NN I-NP O
23 2048 2050 8954016 in IN B-PP O
24 2051 2055 8954016 this DT B-NP O
25 2056 2062 8954016 region NN I-NP O

1 0 0 9063749 -DOCSTART- -X- -X- O

1 0 6 9063749 Common JJ B-NP O
2 7 12 9063749 BRCA1 NN I-NP O
3 13 21 9063749 variants NNS I-NP O
4 22 25 9063749 and CC O O
5 26 40 9063749 susceptibility NN B-NP O
6 41 43 9063749 to TO B-PP O
7 44 50 9063749 breast NN B-NP B-Disease
8 51 54 9063749 and CC O I-Disease
9 55 62 9063749 ovarian JJ B-NP I-Disease
10 63 69 9063749 cancer NN I-NP I-Disease
11 70 72 9063749 in IN B-PP O
12 73 76 9063749 the DT B-NP O
13 77 84 9063749 general JJ I-NP O
14 85 95 9063749 population NN I-NP O
15 95 96 9063749 . . I-NP O
16 97 101 9063749 Most RBS I-NP O
17 102 110 9063749 multiple JJ I-NP O
18 111 115 9063749 case NN I-NP O
19 116 124 9063749 families NNS I-NP O
20 125 127 9063749 of IN B-PP O
21 128 133 9063749 young JJ B-NP O
22 134 139 9063749 onset NN I-NP O
23 140 146 9063749 breast NN I-NP B-Disease
24 147 153 9063749 cancer NN I-NP I-Disease
25 154 157 9063749 and CC O O
26 158 165 9063749 ovarian JJ B-NP B-Disease
27 166 172 9063749 cancer NN I-NP I-Disease
28 173 176 9063749 are VBP B-VP O
29 177 184 9063749 thought VBN I-VP O
30 185 187 9063749 to TO I-VP O
31 188 190 9063749 be VB I-VP O
32 191 194 9063749 due IN B-PP O
33 195 197 9063749 to TO B-PP O
34 198 204 9063749 highly RB B-NP O
35 205 214 9063749 penetrant JJ I-NP O
36 215 224 9063749 mutations NNS I-NP O
37 225 227 9063749 in IN B-PP O
38 228 231 9063749 the DT B-NP O
39 232 244 9063749 predisposing VBG I-NP O
40 245 250 9063749 genes NNS I-NP O
41 251 256 9063749 BRCA1 NN I-NP O
42 257 260 9063749 and CC I-NP O
43 261 266 9063749 BRCA2 NN I-NP O
44 266 267 9063749 . . O O

1 268 275 9063749 However RB B-ADVP O
2 275 276 9063749 , , O O
3 277 282 9063749 these DT B-NP O
4 283 292 9063749 mutations NNS I-NP O
5 293 296 9063749 are VBP B-VP O
6 297 305 9063749 uncommon JJ B-ADJP O
7 306 308 9063749 in IN B-PP O
8 309 312 9063749 the DT B-NP O
9 313 323 9063749 population NN I-NP O
10 324 327 9063749 and CC O O
11 328 332 9063749 they PRP B-NP O
12 333 341 9063749 probably RB B-ADVP O
13 342 349 9063749 account VBP B-VP O
14 350 353 9063749 for IN B-PP O
15 354 358 9063749 only RB B-NP O
16 359 360 9063749 a DT I-NP O
17 361 364 9063749 few JJ I-NP O
18 365 372 9063749 percent NN I-NP O
19 373 375 9063749 of IN B-PP O
20 376 379 9063749 all DT B-NP O
21 380 386 9063749 breast NN I-NP B-Disease
22 387 393 9063749 cancer NN I-NP I-Disease
23 394 403 9063749 incidence NN I-NP O
24 403 404 9063749 . . O O

1 405 406 9063749 A DT B-NP O
2 407 411 9063749 much RB I-NP O
3 412 418 9063749 larger JJR I-NP O
4 419 427 9063749 fraction NN I-NP O
5 428 430 9063749 of IN B-PP O
6 431 437 9063749 breast NN B-NP B-Disease
7 438 444 9063749 cancer NN I-NP I-Disease
8 445 450 9063749 might MD B-VP O
9 450 451 9063749 , , O O
10 452 454 9063749 in IN B-PP O
11 455 464 9063749 principle NN B-NP O
12 464 465 9063749 , , O O
13 466 468 9063749 be VB B-VP O
14 469 472 9063749 due JJ B-PP O
15 473 475 9063749 to TO B-PP O
16 476 482 9063749 common JJ B-NP O
17 483 491 9063749 variants NNS I-NP O
18 492 497 9063749 which WDT B-NP O
19 498 504 9063749 confer VBP B-VP O
20 505 509 9063749 more RBR B-NP O
21 510 516 9063749 modest JJ I-NP O
22 517 527 9063749 individual JJ I-NP O
23 528 533 9063749 risks NNS I-NP O
24 533 534 9063749 . . O O

1 535 540 9063749 There EX B-NP O
2 541 544 9063749 are VBP B-VP O
3 545 552 9063749 several JJ B-NP O
4 553 559 9063749 common JJ I-NP O
5 560 573 9063749 polymorphisms NNS I-NP O
6 574 576 9063749 in IN B-PP O
7 577 580 9063749 the DT B-NP O
8 581 586 9063749 BRCA1 NN I-NP O
9 587 591 9063749 gene NN I-NP O
10 592 597 9063749 which WDT B-NP O
11 598 606 9063749 generate VBP B-VP O
12 607 612 9063749 amino JJ B-NP O
13 613 617 9063749 acid NN I-NP O
14 618 631 9063749 substitutions NNS I-NP O
15 631 632 9063749 . . O O

1 633 635 9063749 We PRP B-NP O
2 636 640 9063749 have VBP B-VP O
3 641 649 9063749 examined VBN I-VP O
4 650 653 9063749 the DT B-NP O
5 654 663 9063749 frequency NN I-NP O
6 664 666 9063749 of IN B-PP O
7 667 671 9063749 four CD B-NP O
8 672 674 9063749 of IN B-PP O
9 675 680 9063749 these DT B-NP O
10 681 694 9063749 polymorphisms NNS I-NP O
11 696 705 9063749 Gln356Arg NN I-NP O
12 705 706 9063749 , , O O
13 707 716 9063749 Pro871Leu NN B-NP O
14 716 717 9063749 , , O O
15 718 728 9063749 Glu1038Gly NN B-NP O
16 729 732 9063749 and CC I-NP O
17 733 743 9063749 Ser1613Gly NN I-NP O
18 744 746 9063749 in IN B-PP O
19 747 752 9063749 large JJ B-NP O
20 753 759 9063749 series NN I-NP O
21 760 762 9063749 of IN B-PP O
22 763 769 9063749 breast NN B-NP B-Disease
23 770 773 9063749 and CC O I-Disease
24 774 781 9063749 ovarian JJ B-NP I-Disease
25 782 788 9063749 cancer NN I-NP I-Disease
26 789 794 9063749 cases NNS I-NP O
27 795 798 9063749 and CC O O
28 799 806 9063749 matched JJ B-NP O
29 807 815 9063749 controls NNS I-NP O
30 815 816 9063749 . . O O

1 817 820 9063749 Due JJ B-PP O
2 821 823 9063749 to TO B-PP O
3 824 830 9063749 strong JJ B-NP O
4 831 838 9063749 linkage NN I-NP O
5 839 853 9063749 disequilibrium NN I-NP O
6 853 854 9063749 , , O O
7 855 860 9063749 these DT B-NP O
8 861 865 9063749 four CD I-NP O
9 866 871 9063749 sites NNS I-NP O
10 872 880 9063749 generate VBP B-VP O
11 881 885 9063749 only RB B-NP O
12 886 891 9063749 three CD I-NP O
13 892 902 9063749 haplotypes NNS I-NP O
14 903 907 9063749 with IN B-PP O
15 908 909 9063749 a DT B-NP O
16 910 919 9063749 frequency NN I-NP O
17 920 921 9063749 > JJR B-NP O
18 922 923 9063749 1 CD I-NP O
19 923 924 9063749 . . O O

1 925 927 9063749 3% LS B-LST O
2 927 928 9063749 . . O O

1 929 932 9063749 The DT B-NP O
2 933 937 9063749 most RBS I-NP O
3 938 944 9063749 common JJ I-NP O
4 945 955 9063749 haplotypes NNS I-NP O
5 955 956 9063749 , , O O
6 957 964 9063749 defined VBN B-VP O
7 965 967 9063749 by IN B-PP O
8 968 971 9063749 the DT B-NP O
9 972 979 9063749 alleles NNS I-NP O
10 980 1006 9063749 Gln356Pro871Glu1038Ser1613 NN I-NP O
11 1007 1010 9063749 and CC I-NP O
12 1011 1037 9063749 Gln356Leu871Gly1038Gly1613 NN I-NP O
13 1037 1038 9063749 , , O O
14 1039 1043 9063749 have VBP B-VP O
15 1044 1055 9063749 frequencies NNS B-NP O
16 1056 1058 9063749 of IN B-PP O
17 1059 1060 9063749 0 CD B-NP O
18 1060 1061 9063749 . . O O

1 1062 1064 9063749 57 CD B-NP O
2 1065 1068 9063749 and CC I-NP O
3 1069 1070 9063749 0 CD I-NP O
4 1070 1071 9063749 . . O O

1 1072 1074 9063749 32 CD B-NP O
2 1075 1087 9063749 respectively RB I-NP O
3 1087 1088 9063749 , , O O
4 1089 1092 9063749 and CC O O
5 1093 1098 9063749 these DT B-NP O
6 1099 1110 9063749 frequencies NNS I-NP O
7 1111 1113 9063749 do VBP B-VP O
8 1114 1117 9063749 not RB I-VP O
9 1118 1124 9063749 differ VB I-VP O
10 1125 1138 9063749 significantly RB B-ADVP O
11 1139 1146 9063749 between IN B-PP O
12 1147 1154 9063749 patient NN B-NP O
13 1155 1158 9063749 and CC I-NP O
14 1159 1166 9063749 control NN I-NP O
15 1167 1173 9063749 groups NNS I-NP O
16 1173 1174 9063749 . . O O

1 1175 1179 9063749 Thus RB B-ADVP O
2 1180 1183 9063749 the DT B-NP O
3 1184 1188 9063749 most RBS I-NP O
4 1189 1195 9063749 common JJ I-NP O
5 1196 1209 9063749 polymorphisms NNS I-NP O
6 1210 1212 9063749 of IN B-PP O
7 1213 1216 9063749 the DT B-NP O
8 1217 1222 9063749 BRCA1 NN I-NP O
9 1223 1227 9063749 gene NN I-NP O
10 1228 1230 9063749 do VBP B-VP O
11 1231 1234 9063749 not RB I-VP O
12 1235 1239 9063749 make VB I-VP O
13 1240 1241 9063749 a DT B-NP O
14 1242 1253 9063749 significant JJ I-NP O
15 1254 1266 9063749 contribution NN I-NP O
16 1267 1269 9063749 to TO B-PP O
17 1270 1276 9063749 breast NN B-NP B-Disease
18 1277 1279 9063749 or CC O I-Disease
19 1280 1287 9063749 ovarian JJ B-NP I-Disease
20 1288 1294 9063749 cancer NN I-NP I-Disease
21 1295 1299 9063749 risk NN I-NP O
22 1299 1300 9063749 . . O O

1 1301 1308 9063749 However RB B-ADVP O
2 1308 1309 9063749 , , O O
3 1310 1313 9063749 our PRP$ B-NP O
4 1314 1318 9063749 data NNS I-NP O
5 1319 1326 9063749 suggest VBP B-VP O
6 1327 1331 9063749 that IN B-SBAR O
7 1332 1335 9063749 the DT B-NP O
8 1336 1342 9063749 Arg356 NN I-NP O
9 1343 1349 9063749 allele NN I-NP O
10 1350 1353 9063749 may MD B-VP O
11 1354 1358 9063749 have VB I-VP O
12 1359 1360 9063749 a DT B-NP O
13 1361 1370 9063749 different JJ I-NP O
14 1371 1379 9063749 genotype NN I-NP O
15 1380 1392 9063749 distribution NN I-NP O
16 1393 1395 9063749 in IN B-PP O
17 1396 1402 9063749 breast NN B-NP B-Disease
18 1403 1409 9063749 cancer NN I-NP I-Disease
19 1410 1418 9063749 patients NNS I-NP O
20 1419 1423 9063749 from IN B-PP O
21 1424 1428 9063749 that DT B-NP O
22 1429 1431 9063749 in IN B-PP O
23 1432 1440 9063749 controls NNS B-NP O
24 1441 1442 9063749 ( ( O O
25 1442 1448 9063749 Arg356 NN B-NP O
26 1449 1460 9063749 homozygotes NNS I-NP O
27 1461 1464 9063749 are VBP B-VP O
28 1465 1469 9063749 more RBR B-ADJP O
29 1470 1478 9063749 frequent JJ I-ADJP O
30 1479 1481 9063749 in IN B-PP O
31 1482 1485 9063749 the DT B-NP O
32 1486 1493 9063749 control NN I-NP O
33 1494 1500 9063749 groups NNS I-NP O
34 1500 1501 9063749 , , O O
35 1502 1503 9063749 P NN B-NP O
36 1504 1505 9063749 = SYM B-VP O
37 1506 1507 9063749 0 CD B-NP O
38 1507 1508 9063749 . . O O

1 1509 1511 9063749 01 CD B-NP O
2 1511 1512 9063749 ) ) O O
3 1512 1513 9063749 , , O O
4 1514 1524 9063749 indicating VBG B-VP O
5 1525 1529 9063749 that IN B-SBAR O
6 1530 1532 9063749 it PRP B-NP O
7 1533 1536 9063749 may MD B-VP O
8 1537 1539 9063749 be VB I-VP O
9 1540 1550 9063749 protective JJ B-ADJP O
10 1551 1558 9063749 against IN B-PP O
11 1559 1565 9063749 breast NN B-NP B-Disease
12 1566 1572 9063749 cancer NN I-NP I-Disease
13 1572 1573 9063749 . . O O

1 1574 1576 9063749 If IN B-SBAR O
2 1577 1581 9063749 this DT B-NP O
3 1582 1589 9063749 finding NN I-NP O
4 1590 1593 9063749 can MD B-VP O
5 1594 1596 9063749 be VB I-VP O
6 1597 1606 9063749 confirmed VBN I-VP O
7 1606 1607 9063749 , , O O
8 1608 1610 9063749 it PRP B-NP O
9 1611 1614 9063749 may MD B-VP O
10 1615 1622 9063749 provide VB I-VP O
11 1623 1625 9063749 an DT B-NP O
12 1626 1633 9063749 insight NN I-NP O
13 1634 1638 9063749 into IN B-PP O
14 1639 1642 9063749 the DT B-NP O
15 1643 1653 9063749 structural JJ I-NP O
16 1654 1662 9063749 features NNS I-NP O
17 1663 1665 9063749 of IN B-PP O
18 1666 1669 9063749 the DT B-NP O
19 1670 1675 9063749 BRCA1 NN I-NP O
20 1676 1683 9063749 protein NN I-NP O
21 1684 1688 9063749 that WDT B-NP O
22 1689 1692 9063749 are VBP B-VP O
23 1693 1702 9063749 important JJ B-ADJP O
24 1703 1706 9063749 for IN B-PP O
25 1707 1710 9063749 its PRP$ B-NP O
26 1711 1719 9063749 function NN I-NP O
27 1719 1720 9063749 . . O O

1 0 0 9223312 -DOCSTART- -X- -X- O

1 0 6 9223312 Fusion NN B-NP O
2 7 12 9223312 genes NNS I-NP O
3 13 22 9223312 resulting VBG B-VP O
4 23 27 9223312 from IN B-PP O
5 28 39 9223312 alternative JJ B-NP O
6 40 51 9223312 chromosomal JJ I-NP O
7 52 66 9223312 translocations NNS I-NP O
8 67 70 9223312 are VBP B-VP O
9 71 84 9223312 overexpressed VBN I-VP O
10 85 87 9223312 by IN B-PP O
11 88 92 9223312 gene NN B-NP O
12 92 93 9223312 - HYPH B-NP O
13 93 101 9223312 specific JJ I-NP O
14 102 112 9223312 mechanisms NNS I-NP O
15 113 115 9223312 in IN B-PP O
16 116 124 9223312 alveolar JJ B-NP B-Disease
17 125 141 9223312 rhabdomyosarcoma NN I-NP I-Disease
18 141 142 9223312 . . O O
19 143 154 9223312 Chromosomal JJ B-NP O
20 155 169 9223312 translocations NNS I-NP O
21 170 180 9223312 identified VBN B-VP O
22 181 183 9223312 in IN B-PP O
23 184 197 9223312 hematopoietic JJ B-NP B-Disease
24 198 201 9223312 and CC I-NP I-Disease
25 202 207 9223312 solid JJ I-NP I-Disease
26 208 214 9223312 tumors NNS I-NP I-Disease
27 215 221 9223312 result VBP B-VP O
28 222 224 9223312 in IN B-PP O
29 225 236 9223312 deregulated VBN B-NP O
30 237 247 9223312 expression NN I-NP O
31 248 250 9223312 of IN B-PP O
32 251 265 9223312 protooncogenes NNS B-NP O
33 266 268 9223312 or CC O O
34 269 277 9223312 creation NN B-NP O
35 278 280 9223312 of IN B-PP O
36 281 289 9223312 chimeric JJ B-NP O
37 290 298 9223312 proteins NNS I-NP O
38 299 303 9223312 with IN B-PP O
39 304 315 9223312 tumorigenic JJ B-NP O
40 316 325 9223312 potential NN I-NP O
41 325 326 9223312 . . O O

1 327 329 9223312 In IN B-PP O
2 330 333 9223312 the DT B-NP O
3 334 343 9223312 pediatric JJ I-NP O
4 344 349 9223312 solid JJ I-NP B-Disease
5 350 355 9223312 tumor NN I-NP I-Disease
6 356 364 9223312 alveolar JJ I-NP B-Disease
7 365 381 9223312 rhabdomyosarcoma NN I-NP I-Disease
8 381 382 9223312 , , O O
9 383 384 9223312 a DT B-NP O
10 385 395 9223312 consistent JJ I-NP O
11 396 397 9223312 t NN I-NP O
12 398 399 9223312 ( ( O O
13 399 400 9223312 2 CD B-NP O
14 400 401 9223312 ; : O O
15 402 404 9223312 13 CD B-NP O
16 404 405 9223312 ) ) O O
17 406 407 9223312 ( ( O O
18 407 410 9223312 q35 NN B-NP O
19 410 411 9223312 ; : O O
20 412 415 9223312 q14 NN B-NP O
21 415 416 9223312 ) ) O O
22 417 419 9223312 or CC O O
23 420 427 9223312 variant JJ B-NP O
24 428 429 9223312 t NN I-NP O
25 430 431 9223312 ( ( O O
26 431 432 9223312 1 CD B-NP O
27 432 433 9223312 ; : O O
28 434 436 9223312 13 CD B-NP O
29 436 437 9223312 ) ) O O
30 438 439 9223312 ( ( O O
31 439 442 9223312 p36 NN B-NP O
32 442 443 9223312 ; : O O
33 444 447 9223312 q14 NN B-NP O
34 447 448 9223312 ) ) O O
35 449 462 9223312 translocation NN B-NP O
36 463 472 9223312 generates VBZ B-VP O
37 473 477 9223312 PAX3 NN B-NP O
38 477 478 9223312 - HYPH I-NP O
39 478 482 9223312 FKHR NN I-NP O
40 483 485 9223312 or CC I-NP O
41 486 490 9223312 PAX7 NN I-NP O
42 490 491 9223312 - HYPH B-NP O
43 491 495 9223312 FKHR NN I-NP O
44 496 502 9223312 fusion NN I-NP O
45 503 511 9223312 proteins NNS I-NP O
46 511 512 9223312 , , O O
47 513 525 9223312 respectively RB B-ADVP O
48 525 526 9223312 . . O O

1 527 529 9223312 In IN B-PP O
2 530 534 9223312 this DT B-NP O
3 535 541 9223312 report NN I-NP O
4 541 542 9223312 , , O O
5 543 545 9223312 we PRP B-NP O
6 546 557 9223312 demonstrate VBP B-VP O
7 558 562 9223312 that IN B-SBAR O
8 563 565 9223312 in IN B-PP O
9 566 574 9223312 addition NN B-NP O
10 575 577 9223312 to TO B-PP O
11 578 588 9223312 functional JJ B-NP O
12 589 600 9223312 alterations NNS I-NP O
13 601 606 9223312 these DT B-NP O
14 607 621 9223312 translocations NNS I-NP O
15 622 625 9223312 are VBP B-VP O
16 626 636 9223312 associated VBN I-VP O
17 637 641 9223312 with IN B-PP O
18 642 648 9223312 fusion NN B-NP O
19 649 656 9223312 product NN I-NP O
20 657 671 9223312 overexpression NN I-NP O
21 671 672 9223312 . . O O

1 673 684 9223312 Furthermore RB B-ADVP O
2 684 685 9223312 , , O O
3 686 690 9223312 PAX3 NN B-NP O
4 690 691 9223312 - HYPH I-NP O
5 691 695 9223312 FKHR NN I-NP O
6 696 699 9223312 and CC I-NP O
7 700 704 9223312 PAX7 NN I-NP O
8 704 705 9223312 - HYPH B-NP O
9 705 709 9223312 FKHR NN I-NP O
10 710 724 9223312 overexpression NN I-NP O
11 725 731 9223312 occurs VBZ B-VP O
12 732 734 9223312 by IN B-PP O
13 735 743 9223312 distinct JJ B-NP O
14 744 754 9223312 mechanisms NNS I-NP O
15 754 755 9223312 . . O O

1 756 769 9223312 Transcription NN B-NP O
2 770 772 9223312 of IN B-PP O
3 773 777 9223312 PAX3 NN B-NP O
4 777 778 9223312 - HYPH B-NP O
5 778 782 9223312 FKHR NN I-NP O
6 783 785 9223312 is VBZ B-VP O
7 786 795 9223312 increased VBN I-VP O
8 796 804 9223312 relative JJ B-ADVP O
9 805 807 9223312 to TO B-PP O
10 808 812 9223312 wild JJ B-NP O
11 812 813 9223312 - HYPH I-NP O
12 813 817 9223312 type NN I-NP O
13 818 822 9223312 PAX3 NN I-NP O
14 823 825 9223312 by IN B-PP O
15 826 827 9223312 a DT B-NP O
16 828 832 9223312 copy NN I-NP O
17 833 839 9223312 number NN I-NP O
18 839 840 9223312 - HYPH B-NP O
19 840 851 9223312 independent JJ I-NP O
20 852 859 9223312 process NN I-NP O
21 859 860 9223312 . . O O

1 861 863 9223312 In IN B-PP O
2 864 872 9223312 contrast NN B-NP O
3 872 873 9223312 , , O O
4 874 878 9223312 PAX7 NN B-NP O
5 878 879 9223312 - HYPH I-NP O
6 879 883 9223312 FKHR NN I-NP O
7 884 898 9223312 overexpression NN I-NP O
8 899 906 9223312 results VBZ B-VP O
9 907 911 9223312 from IN B-PP O
10 912 918 9223312 fusion NN B-NP O
11 919 923 9223312 gene NN I-NP O
12 924 937 9223312 amplification NN I-NP O
13 937 938 9223312 . . O O

1 939 943 9223312 Thus RB B-ADVP O
2 943 944 9223312 , , O O
3 945 949 9223312 gene NN B-NP O
4 949 950 9223312 - HYPH B-NP O
5 950 958 9223312 specific JJ I-NP O
6 959 969 9223312 mechanisms NNS I-NP O
7 970 974 9223312 were VBD B-VP O
8 975 983 9223312 selected VBN I-VP O
9 984 986 9223312 to TO I-VP O
10 987 998 9223312 overexpress VB I-VP O
11 999 1003 9223312 PAX3 NN B-NP O
12 1003 1004 9223312 - HYPH B-NP O
13 1004 1008 9223312 FKHR NN I-NP O
14 1009 1012 9223312 and CC I-NP O
15 1013 1017 9223312 PAX7 NN I-NP O
16 1017 1018 9223312 - HYPH B-NP O
17 1018 1022 9223312 FKHR NN I-NP O
18 1023 1025 9223312 in IN B-PP O
19 1026 1034 9223312 alveolar JJ B-NP B-Disease
20 1035 1051 9223312 rhabdomyosarcoma NN I-NP I-Disease
21 1051 1052 9223312 , , O O
22 1053 1063 9223312 presumably RB B-ADJP O
23 1064 1067 9223312 due JJ I-ADJP O
24 1068 1070 9223312 to TO B-PP O
25 1071 1082 9223312 differences NNS B-NP O
26 1083 1085 9223312 in IN B-PP O
27 1086 1096 9223312 regulation NN B-NP O
28 1097 1104 9223312 between IN B-PP O
29 1105 1108 9223312 the DT B-NP O
30 1109 1113 9223312 wild JJ I-NP O
31 1113 1114 9223312 - HYPH I-NP O
32 1114 1118 9223312 type NN I-NP O
33 1119 1123 9223312 loci NNS I-NP O
34 1123 1124 9223312 . . O O

1 1125 1127 9223312 We PRP B-NP O
2 1128 1137 9223312 postulate VBP B-VP O
3 1138 1142 9223312 that IN B-SBAR O
4 1143 1148 9223312 these DT B-NP O
5 1149 1163 9223312 overexpression NN I-NP O
6 1164 1174 9223312 mechanisms NNS I-NP O
7 1175 1181 9223312 ensure VBP B-VP O
8 1182 1183 9223312 a DT B-NP O
9 1184 1192 9223312 critical JJ I-NP O
10 1193 1198 9223312 level NN I-NP O
11 1199 1201 9223312 of IN B-PP O
12 1202 1206 9223312 gene NN B-NP O
13 1207 1214 9223312 product NN I-NP O
14 1215 1218 9223312 for IN B-PP O
15 1219 1222 9223312 the DT B-NP O
16 1223 1232 9223312 oncogenic JJ I-NP O
17 1233 1240 9223312 effects NNS I-NP O
18 1241 1243 9223312 of IN B-PP O
19 1244 1249 9223312 these DT B-NP O
20 1250 1257 9223312 fusions NNS I-NP O
21 1257 1258 9223312 . . O O
22 1258 1259 9223312 . . O O

1 0 0 8956035 -DOCSTART- -X- -X- O

1 0 11 8956035 Independent JJ B-NP O
2 12 18 8956035 origin NN I-NP O
3 19 21 8956035 of IN B-PP O
4 22 28 8956035 single JJ B-NP O
5 29 32 8956035 and CC I-NP O
6 33 39 8956035 double JJ I-NP O
7 40 49 8956035 mutations NNS I-NP O
8 50 52 8956035 in IN B-PP O
9 53 56 8956035 the DT B-NP O
10 57 62 8956035 human JJ I-NP O
11 63 70 8956035 glucose NN I-NP O
12 71 72 8956035 6 CD I-NP O
13 72 73 8956035 - HYPH I-NP O
14 73 82 8956035 phosphate NN I-NP O
15 83 96 8956035 dehydrogenase NN I-NP O
16 97 101 8956035 gene NN I-NP O
17 101 102 8956035 . . O O
18 103 106 8956035 The DT B-NP O
19 107 111 8956035 vast JJ I-NP O
20 112 120 8956035 majority NN I-NP O
21 121 123 8956035 of IN B-PP O
22 124 128 8956035 both CC B-NP O
23 129 140 8956035 polymorphic JJ I-NP O
24 141 144 8956035 and CC I-NP O
25 145 153 8956035 sporadic JJ I-NP O
26 154 158 8956035 G6PD NN I-NP O
27 159 167 8956035 variants NNS I-NP O
28 168 171 8956035 are VBP B-VP O
29 172 175 8956035 due JJ B-ADJP O
30 176 178 8956035 to TO B-PP O
31 179 185 8956035 single JJ B-NP O
32 186 194 8956035 missense JJ I-NP O
33 195 204 8956035 mutations NNS I-NP O
34 204 205 8956035 . . O O

1 206 208 8956035 In IN B-PP O
2 209 212 8956035 the DT B-NP O
3 213 217 8956035 four CD I-NP O
4 218 229 8956035 polymorphic JJ I-NP O
5 230 238 8956035 variants NNS I-NP O
6 239 243 8956035 that WDT B-NP O
7 244 248 8956035 have VBP B-VP O
8 249 252 8956035 two CD B-NP O
9 253 258 8956035 point NN I-NP O
10 259 268 8956035 mutations NNS I-NP O
11 268 269 8956035 , , O O
12 270 273 8956035 one CD B-NP O
13 274 276 8956035 of IN B-PP O
14 277 280 8956035 the DT B-NP O
15 281 290 8956035 mutations NNS I-NP O
16 291 293 8956035 is VBZ B-VP O
17 294 300 8956035 always RB B-ADVP O
18 301 304 8956035 376 CD B-NP O
19 305 306 8956035 A NN I-NP O
20 306 307 8956035 - SYM O O
21 307 308 8956035 - HYPH O O
22 309 310 8956035 > SYM O O
23 311 312 8956035 G NN B-NP O
24 313 314 8956035 ( ( O O
25 314 317 8956035 126 CD B-NP O
26 318 321 8956035 Asn NN I-NP O
27 321 322 8956035 - SYM B-NP O
28 322 323 8956035 - HYPH B-NP O
29 324 325 8956035 > SYM I-NP O
30 326 329 8956035 Asp NN I-NP O
31 329 330 8956035 ) ) O O
32 330 331 8956035 , , O O
33 332 337 8956035 which WDT B-NP O
34 338 340 8956035 on IN B-PP O
35 341 344 8956035 its PRP$ B-NP O
36 345 348 8956035 own JJ I-NP O
37 349 354 8956035 gives NNS I-NP O
38 355 359 8956035 rise NN I-NP O
39 360 362 8956035 to TO B-PP O
40 363 366 8956035 the DT B-NP O
41 367 379 8956035 nondeficient JJ I-NP O
42 380 391 8956035 polymorphic JJ I-NP O
43 392 399 8956035 variant NN I-NP O
44 399 400 8956035 , , O O
45 401 405 8956035 G6PD NN B-NP O
46 406 407 8956035 A NN I-NP O
47 407 408 8956035 . . O O

1 409 411 8956035 In IN B-PP O
2 412 413 8956035 a DT B-NP O
3 414 419 8956035 study NN I-NP O
4 420 422 8956035 of IN B-PP O
5 423 427 8956035 G6PD NN B-NP B-Disease
6 428 437 8956035 deficient JJ I-NP I-Disease
7 438 446 8956035 patients NNS I-NP O
8 447 450 8956035 who WP B-NP O
9 451 460 8956035 presented VBD B-VP O
10 461 465 8956035 with IN B-PP O
11 466 474 8956035 clinical JJ B-NP O
12 475 481 8956035 favism NN I-NP B-Disease
13 482 484 8956035 in IN B-PP O
14 485 490 8956035 Spain NNP B-NP O
15 490 491 8956035 , , O O
16 492 494 8956035 we PRP B-NP O
17 495 499 8956035 have VBP B-VP O
18 500 505 8956035 found VBN I-VP O
19 506 507 8956035 a DT B-NP O
20 508 511 8956035 new JJ I-NP O
21 512 523 8956035 polymorphic JJ I-NP O
22 524 531 8956035 variant NN I-NP O
23 532 536 8956035 that IN B-NP O
24 537 539 8956035 we PRP B-NP O
25 540 544 8956035 have VBP B-VP O
26 545 551 8956035 called VBN I-VP O
27 552 556 8956035 G6PD NNP B-NP O
28 557 563 8956035 Malaga NNP I-NP O
29 563 564 8956035 , , O O
30 565 570 8956035 whose WP$ B-NP O
31 571 575 8956035 only RB I-NP O
32 576 587 8956035 abnormality NN I-NP O
33 588 590 8956035 is VBZ B-VP O
34 591 592 8956035 a DT B-NP O
35 593 596 8956035 542 CD I-NP O
36 597 598 8956035 A NN I-NP O
37 598 599 8956035 - SYM O O
38 599 600 8956035 - HYPH O O
39 601 602 8956035 > SYM O O
40 603 604 8956035 T NN B-NP O
41 605 606 8956035 ( ( O O
42 606 609 8956035 181 CD B-NP O
43 610 613 8956035 Asp NN I-NP O
44 613 614 8956035 - SYM B-NP O
45 614 615 8956035 - HYPH B-NP O
46 616 617 8956035 > SYM I-NP O
47 618 621 8956035 Val NN I-NP O
48 621 622 8956035 ) ) O O
49 623 631 8956035 mutation NN B-NP O
50 631 632 8956035 . . O O

1 633 637 8956035 This DT B-NP O
2 638 640 8956035 is VBZ B-VP O
3 641 644 8956035 the DT B-NP O
4 645 649 8956035 same JJ I-NP O
5 650 658 8956035 mutation NN I-NP O
6 659 661 8956035 as IN B-SBAR O
7 662 672 8956035 previously RB B-ADVP O
8 673 678 8956035 found VBN B-VP O
9 679 681 8956035 in IN B-PP O
10 682 693 8956035 association NN B-NP O
11 694 698 8956035 with IN B-PP O
12 699 702 8956035 the DT B-NP O
13 703 711 8956035 mutation NN I-NP O
14 712 714 8956035 of IN B-PP O
15 715 719 8956035 G6PD NN B-NP O
16 720 721 8956035 A NN I-NP O
17 722 724 8956035 in IN B-PP O
18 725 728 8956035 the DT B-NP O
19 729 735 8956035 double JJ I-NP O
20 736 742 8956035 mutant NN I-NP O
21 742 743 8956035 , , O O
22 744 748 8956035 G6PD NN B-NP O
23 749 759 8956035 Santamaria NNP I-NP O
24 759 760 8956035 . . O O

1 761 765 8956035 G6PD NN B-NP O
2 766 772 8956035 Malaga NNP I-NP O
3 773 775 8956035 is VBZ B-VP O
4 776 786 8956035 associated VBN I-VP O
5 787 791 8956035 with IN B-PP O
6 792 798 8956035 enzyme NN B-NP B-Disease
7 799 809 8956035 deficiency NN I-NP I-Disease
8 810 811 8956035 ( ( O O
9 811 816 8956035 class NN B-NP O
10 817 820 8956035 III CD I-NP O
11 820 821 8956035 ) ) O O
12 821 822 8956035 , , O O
13 823 826 8956035 and CC O O
14 827 830 8956035 the DT B-NP O
15 831 838 8956035 enzymic JJ I-NP O
16 839 849 8956035 properties NNS I-NP O
17 850 852 8956035 of IN B-PP O
18 853 857 8956035 G6PD NN B-NP O
19 858 864 8956035 Malaga NN I-NP O
20 865 868 8956035 and CC O O
21 869 873 8956035 G6PD NN B-NP O
22 874 884 8956035 Santamaria NNP I-NP O
23 885 888 8956035 are VBP B-VP O
24 889 894 8956035 quite RB B-ADJP O
25 895 902 8956035 similar JJ I-ADJP O
26 902 903 8956035 , , O O
27 904 914 8956035 indicating VBG B-VP O
28 915 919 8956035 that IN B-SBAR O
29 920 922 8956035 in IN B-PP O
30 923 927 8956035 this DT B-NP O
31 928 932 8956035 case NN I-NP O
32 933 936 8956035 the DT B-NP O
33 937 944 8956035 effects NNS I-NP O
34 945 947 8956035 of IN B-PP O
35 948 951 8956035 the DT B-NP O
36 952 955 8956035 two CD I-NP O
37 956 965 8956035 mutations NNS I-NP O
38 966 969 8956035 are VBP B-VP O
39 970 978 8956035 additive JJ B-ADJP O
40 979 985 8956035 rather RB B-PP O
41 986 990 8956035 than IN I-PP O
42 991 1002 8956035 synergistic JJ B-ADJP O
43 1002 1003 8956035 . . O O

1 1004 1008 8956035 G6PD NN B-NP O
2 1009 1019 8956035 Santamaria NNP I-NP O
3 1020 1025 8956035 might MD B-VP O
4 1026 1030 8956035 have VB I-VP O
5 1031 1035 8956035 been VBN I-VP O
6 1036 1044 8956035 produced VBN I-VP O
7 1045 1047 8956035 by IN B-PP O
8 1048 1061 8956035 recombination NN B-NP O
9 1062 1069 8956035 between IN B-PP O
10 1070 1074 8956035 G6PD NN B-NP O
11 1075 1076 8956035 A NN I-NP O
12 1077 1080 8956035 and CC O O
13 1081 1085 8956035 G6PD NN B-NP O
14 1086 1092 8956035 Malaga NNP I-NP O
15 1092 1093 8956035 ; : O O
16 1094 1101 8956035 however RB B-NP O
17 1102 1111 8956035 haplotype NN I-NP O
18 1112 1120 8956035 analysis NN I-NP O
19 1120 1121 8956035 , , O O
20 1122 1131 8956035 including VBG B-PP O
21 1132 1135 8956035 the DT B-NP O
22 1136 1139 8956035 use NN I-NP O
23 1140 1142 8956035 of IN B-PP O
24 1143 1144 8956035 a DT B-NP O
25 1145 1148 8956035 new JJ I-NP O
26 1149 1155 8956035 silent JJ I-NP O
27 1156 1168 8956035 polymorphism NN I-NP O
28 1168 1169 8956035 , , O O
29 1170 1178 8956035 suggests VBZ B-VP O
30 1179 1183 8956035 that IN B-SBAR O
31 1184 1187 8956035 the DT B-NP O
32 1188 1192 8956035 same JJ I-NP O
33 1193 1196 8956035 542 CD I-NP O
34 1197 1198 8956035 A NN I-NP O
35 1198 1199 8956035 - SYM B-NP O
36 1199 1200 8956035 - HYPH I-NP O
37 1201 1202 8956035 > SYM I-NP O
38 1203 1204 8956035 T NN I-NP O
39 1205 1213 8956035 mutation NN I-NP O
40 1214 1217 8956035 has VBZ B-VP O
41 1218 1223 8956035 taken VBN I-VP O
42 1224 1229 8956035 place NN B-NP O
43 1230 1243 8956035 independently RB B-ADVP O
44 1244 1246 8956035 in IN B-PP O
45 1247 1248 8956035 a DT B-NP O
46 1249 1253 8956035 G6PD NN I-NP O
47 1254 1255 8956035 B NN I-NP O
48 1256 1260 8956035 gene NN I-NP O
49 1261 1263 8956035 to TO B-VP O
50 1264 1268 8956035 give VB I-VP O
51 1269 1273 8956035 G6PD NN B-NP O
52 1274 1280 8956035 Malaga NNP I-NP O
53 1281 1284 8956035 and CC B-PP O
54 1285 1287 8956035 in IN B-PP O
55 1288 1289 8956035 a DT B-NP O
56 1290 1294 8956035 G6PD NN I-NP O
57 1295 1296 8956035 A NN I-NP O
58 1297 1301 8956035 gene NN I-NP O
59 1302 1304 8956035 to TO B-VP O
60 1305 1309 8956035 give VB I-VP O
61 1310 1314 8956035 G6PD NN B-NP O
62 1315 1325 8956035 Santamaria NNP B-NP O
63 1325 1326 8956035 . . O O

1 1327 1332 8956035 These DT B-NP O
2 1333 1341 8956035 findings NNS I-NP O
3 1342 1346 8956035 help VBP B-VP O
4 1347 1349 8956035 to TO I-VP O
5 1350 1357 8956035 outline VB I-VP O
6 1358 1361 8956035 the DT B-NP O
7 1362 1374 8956035 relationship NN I-NP O
8 1375 1378 8956035 and CC I-NP O
9 1379 1388 8956035 evolution NN I-NP O
10 1389 1391 8956035 of IN B-PP O
11 1392 1401 8956035 mutations NNS B-NP O
12 1402 1404 8956035 in IN B-PP O
13 1405 1408 8956035 the DT B-NP O
14 1409 1414 8956035 human JJ I-NP O
15 1415 1419 8956035 G6PD NN I-NP O
16 1420 1425 8956035 locus NN I-NP O
17 1425 1426 8956035 . . O O
18 1426 1427 8956035 . . O O

1 0 0 8871666 -DOCSTART- -X- -X- O

1 0 9 8871666 Molecular JJ B-NP O
2 10 15 8871666 bases NNS I-NP O
3 16 18 8871666 of IN B-PP O
4 19 27 8871666 combined JJ B-NP B-Disease
5 28 36 8871666 subtotal JJ I-NP I-Disease
6 37 49 8871666 deficiencies NNS I-NP I-Disease
7 50 52 8871666 of IN B-PP I-Disease
8 53 55 8871666 C6 NN B-NP I-Disease
9 56 59 8871666 and CC I-NP I-Disease
10 60 62 8871666 C7 NN I-NP I-Disease
11 62 63 8871666 : : O O
12 64 69 8871666 their PRP$ B-NP O
13 70 77 8871666 effects NNS I-NP O
14 78 80 8871666 in IN B-PP O
15 81 92 8871666 combination NN B-NP O
16 93 97 8871666 with IN B-PP O
17 98 103 8871666 other JJ B-NP O
18 104 106 8871666 C6 NN I-NP B-Disease
19 107 110 8871666 and CC I-NP I-Disease
20 111 113 8871666 C7 NN I-NP I-Disease
21 114 126 8871666 deficiencies NNS I-NP I-Disease
22 126 127 8871666 . . O O
23 128 136 8871666 Combined VBN B-VP B-Disease
24 137 145 8871666 subtotal JJ B-NP I-Disease
25 146 156 8871666 deficiency NN I-NP I-Disease
26 157 159 8871666 of IN B-PP I-Disease
27 160 162 8871666 C6 NN B-NP I-Disease
28 163 166 8871666 and CC I-NP I-Disease
29 167 169 8871666 C7 NN I-NP I-Disease
30 169 170 8871666 , , O O
31 171 173 8871666 in IN B-PP O
32 174 179 8871666 which WDT B-NP O
33 180 184 8871666 both DT B-NP O
34 185 193 8871666 proteins NNS I-NP O
35 194 197 8871666 are VBP B-VP O
36 198 207 8871666 expressed VBN I-VP O
37 208 210 8871666 at IN B-PP O
38 211 215 8871666 very RB B-NP O
39 216 219 8871666 low JJ I-NP O
40 220 226 8871666 levels NNS I-NP O
41 226 227 8871666 , , O O
42 228 231 8871666 has VBZ B-VP O
43 232 236 8871666 been VBN I-VP O
44 237 245 8871666 observed VBN I-VP O
45 246 248 8871666 in IN B-PP O
46 249 259 8871666 homozygous JJ B-NP O
47 260 264 8871666 form NN I-NP O
48 265 267 8871666 in IN B-PP O
49 268 271 8871666 two CD B-NP O
50 272 280 8871666 families NNS I-NP O
51 280 281 8871666 . . O O

1 282 283 8871666 A DT B-NP O
2 284 290 8871666 defect NN I-NP O
3 291 293 8871666 at IN B-PP O
4 294 297 8871666 the DT B-NP O
5 298 299 8871666 5 CD I-NP O
6 300 306 8871666 splice NN I-NP O
7 307 312 8871666 donor NN I-NP O
8 313 317 8871666 site NN I-NP O
9 318 320 8871666 of IN B-PP O
10 321 327 8871666 intron NN B-NP O
11 328 330 8871666 15 CD I-NP O
12 331 333 8871666 of IN B-PP O
13 334 337 8871666 the DT B-NP O
14 338 340 8871666 C6 NN I-NP O
15 341 345 8871666 gene NN I-NP O
16 346 354 8871666 explains VBZ B-VP O
17 355 358 8871666 the DT B-NP O
18 359 362 8871666 low JJ I-NP O
19 363 372 8871666 molecular JJ I-NP O
20 373 379 8871666 weight NN I-NP O
21 380 382 8871666 of IN B-PP O
22 383 386 8871666 the DT B-NP O
23 387 389 8871666 C6 NN I-NP O
24 390 397 8871666 protein NN I-NP O
25 398 401 8871666 and CC O O
26 402 404 8871666 is VBZ B-VP O
27 405 413 8871666 probably RB B-ADVP O
28 414 425 8871666 responsible JJ B-ADJP O
29 426 429 8871666 for IN B-PP O
30 430 433 8871666 its PRP$ B-NP O
31 434 437 8871666 low JJ I-NP O
32 438 447 8871666 expressed VBN I-NP O
33 448 461 8871666 concentration NN I-NP O
34 461 462 8871666 . . O O

1 463 466 8871666 The DT B-NP O
2 467 469 8871666 C7 NN I-NP O
3 470 476 8871666 defect NN I-NP O
4 477 479 8871666 is VBZ B-VP O
5 480 484 8871666 more RBR B-ADJP O
6 485 494 8871666 enigmatic JJ I-ADJP O
7 496 499 8871666 the DT B-NP O
8 500 507 8871666 protein NN I-NP O
9 508 510 8871666 is VBZ B-VP O
10 511 513 8871666 of IN B-PP O
11 514 520 8871666 normal JJ B-NP O
12 521 530 8871666 molecular JJ I-NP O
13 531 537 8871666 weight NN I-NP O
14 537 538 8871666 , , O O
15 539 542 8871666 low JJ B-NP O
16 543 554 8871666 circulating VBG I-NP O
17 555 568 8871666 concentration NN I-NP O
18 568 569 8871666 , , O O
19 570 573 8871666 and CC O O
20 574 581 8871666 altered VBN B-VP O
21 582 593 8871666 isoelectric JJ B-NP O
22 594 599 8871666 point NN I-NP O
23 599 600 8871666 . . O O

1 601 603 8871666 An DT B-NP O
2 604 607 8871666 Arg NN I-NP O
3 608 609 8871666 > SYM B-NP O
4 610 613 8871666 Ser NN I-NP O
5 614 619 8871666 codon NN I-NP O
6 620 632 8871666 substitution NN I-NP O
7 633 635 8871666 in IN B-PP O
8 636 640 8871666 exon NN B-NP O
9 641 643 8871666 11 CD I-NP O
10 644 646 8871666 is VBZ B-VP O
11 647 650 8871666 the DT B-NP O
12 651 655 8871666 only RB I-NP O
13 656 665 8871666 molecular JJ I-NP O
14 666 676 8871666 alteration NN I-NP O
15 677 683 8871666 within IN B-PP O
16 684 687 8871666 the DT B-NP O
17 688 694 8871666 mature JJ I-NP O
18 695 697 8871666 C7 NN I-NP O
19 698 705 8871666 protein NN I-NP O
20 705 706 8871666 . . O O

1 707 712 8871666 These DT B-NP O
2 713 720 8871666 defects NNS I-NP O
3 721 724 8871666 are VBP B-VP O
4 725 735 8871666 associated VBN I-VP O
5 736 740 8871666 with IN B-PP O
6 741 742 8871666 a DT B-NP O
7 743 757 8871666 characteristic JJ I-NP O
8 758 761 8871666 set NN I-NP O
9 762 764 8871666 of IN B-PP O
10 765 776 8871666 polymorphic JJ B-NP O
11 777 780 8871666 DNA NN I-NP O
12 781 788 8871666 markers NNS I-NP O
13 789 791 8871666 in IN B-PP O
14 792 795 8871666 the DT B-NP O
15 796 798 8871666 C6 NN I-NP O
16 798 799 8871666 / SYM B-NP O
17 799 801 8871666 C7 NN I-NP O
18 802 808 8871666 region NN I-NP O
19 808 809 8871666 , , O O
20 810 817 8871666 forming VBG B-VP O
21 818 819 8871666 a DT B-NP O
22 820 828 8871666 distinct JJ I-NP O
23 829 838 8871666 haplotype NN I-NP O
24 838 839 8871666 . . O O

1 840 843 8871666 The DT B-NP O
2 844 853 8871666 haplotype NN I-NP O
3 854 857 8871666 has VBZ B-VP O
4 858 862 8871666 been VBN I-VP O
5 863 868 8871666 found VBN I-VP O
6 869 871 8871666 in IN B-PP O
7 872 883 8871666 combination NN B-NP O
8 884 888 8871666 with IN B-PP O
9 889 890 8871666 a DT B-NP O
10 891 897 8871666 number NN I-NP O
11 898 900 8871666 of IN B-PP O
12 901 906 8871666 other JJ B-NP O
13 907 917 8871666 haplotypes NNS I-NP O
14 918 928 8871666 containing VBG B-VP O
15 929 938 8871666 defective JJ B-NP O
16 939 944 8871666 genes NNS I-NP O
17 945 949 8871666 that WDT B-NP O
18 950 954 8871666 lead VBP B-VP O
19 955 961 8871666 either CC B-PP O
20 962 964 8871666 to TO B-PP O
21 965 967 8871666 C6 NN B-NP B-Disease
22 968 970 8871666 or CC I-NP I-Disease
23 971 973 8871666 C7 NN I-NP I-Disease
24 974 984 8871666 deficiency NN I-NP I-Disease
25 984 985 8871666 , , O O
26 986 989 8871666 but CC O O
27 990 994 8871666 with IN B-PP O
28 995 1004 8871666 different JJ B-NP O
29 1005 1017 8871666 consequences NNS I-NP O
30 1017 1018 8871666 . . O O

1 1019 1024 8871666 Where WRB B-ADVP O
2 1025 1027 8871666 it PRP B-NP O
3 1028 1030 8871666 is VBZ B-VP O
4 1031 1039 8871666 combined VBN I-VP O
5 1040 1044 8871666 with IN B-PP O
6 1045 1046 8871666 a DT B-NP O
7 1047 1049 8871666 C6 NN I-NP B-Disease
8 1049 1050 8871666 - HYPH B-NP I-Disease
9 1050 1059 8871666 deficient JJ I-NP I-Disease
10 1060 1064 8871666 gene NN I-NP O
11 1064 1065 8871666 , , O O
12 1066 1069 8871666 the DT B-NP O
13 1070 1075 8871666 serum NN I-NP O
14 1076 1078 8871666 C7 NN I-NP O
15 1079 1085 8871666 levels NNS I-NP O
16 1086 1089 8871666 can MD B-VP O
17 1090 1092 8871666 be VB I-VP O
18 1093 1105 8871666 surprisingly RB B-ADJP O
19 1106 1110 8871666 high JJ I-ADJP O
20 1110 1111 8871666 , , O O
21 1112 1120 8871666 possibly RB B-ADVP O
22 1121 1128 8871666 because IN B-SBAR O
23 1129 1134 8871666 there EX B-NP O
24 1135 1137 8871666 is VBZ B-VP O
25 1138 1140 8871666 no DT B-NP O
26 1141 1143 8871666 C6 NN I-NP O
27 1144 1154 8871666 generating VBG B-VP O
28 1155 1158 8871666 C56 NN B-NP O
29 1159 1161 8871666 to TO B-VP O
30 1162 1169 8871666 consume VB I-VP O
31 1170 1173 8871666 the DT B-NP O
32 1174 1176 8871666 C7 NN I-NP O
33 1176 1177 8871666 . . O O

1 1178 1180 8871666 In IN B-PP O
2 1181 1189 8871666 contrast NN B-NP O
3 1189 1190 8871666 , , O O
4 1191 1196 8871666 where WRB B-ADVP O
5 1197 1200 8871666 the DT B-NP O
6 1201 1203 8871666 C7 NN I-NP O
7 1204 1209 8871666 genes NNS I-NP O
8 1210 1213 8871666 are VBP B-VP O
9 1214 1218 8871666 both CC O O
10 1219 1228 8871666 defective JJ O O
11 1229 1230 8871666 ( ( O O
12 1230 1233 8871666 but CC O O
13 1234 1239 8871666 still RB B-ADJP O
14 1240 1249 8871666 partially RB I-ADJP O
15 1250 1260 8871666 functional JJ I-ADJP O
16 1260 1261 8871666 ) ) O O
17 1261 1262 8871666 , , O O
18 1263 1268 8871666 there EX B-NP O
19 1269 1272 8871666 may MD B-VP O
20 1273 1275 8871666 be VB I-VP O
21 1276 1277 8871666 a DT B-NP O
22 1278 1286 8871666 profound JJ I-NP O
23 1287 1294 8871666 deficit NN I-NP O
24 1295 1297 8871666 of IN B-PP O
25 1298 1309 8871666 circulating VBG B-VP O
26 1310 1312 8871666 C7 NN B-NP O
27 1313 1320 8871666 because IN B-SBAR O
28 1321 1326 8871666 there EX B-NP O
29 1327 1329 8871666 is VBZ B-VP O
30 1330 1335 8871666 ample JJ B-NP O
31 1336 1338 8871666 C6 NN I-NP O
32 1339 1341 8871666 to TO B-VP O
33 1342 1349 8871666 produce VB I-VP O
34 1350 1353 8871666 C56 NN B-NP O
35 1354 1357 8871666 and CC O O
36 1358 1365 8871666 consume VB B-VP O
37 1366 1369 8871666 the DT B-NP O
38 1370 1377 8871666 already RB I-NP O
39 1378 1383 8871666 small JJ I-NP O
40 1384 1390 8871666 amount NN I-NP O
41 1391 1393 8871666 of IN B-PP O
42 1394 1396 8871666 C7 NN B-NP O
43 1396 1397 8871666 . . O O

1 1398 1402 8871666 Each DT B-NP O
2 1403 1412 8871666 molecular JJ I-NP O
3 1413 1419 8871666 defect NN I-NP O
4 1420 1423 8871666 has VBZ B-VP O
5 1424 1428 8871666 also RB I-VP O
6 1429 1433 8871666 been VBN I-VP O
7 1434 1439 8871666 found VBN I-VP O
8 1440 1442 8871666 in IN B-PP O
9 1443 1452 8871666 isolation NN B-NP O
10 1453 1456 8871666 and CC O O
11 1457 1460 8871666 has VBZ B-VP O
12 1461 1464 8871666 the DT B-NP O
13 1465 1473 8871666 expected VBN I-NP O
14 1474 1480 8871666 effect NN I-NP O
15 1480 1481 8871666 . . O O
16 1481 1482 8871666 . . O O

1 0 0 8824873 -DOCSTART- -X- -X- O

1 0 7 8824873 Absence NN B-NP O
2 8 10 8824873 of IN B-PP O
3 11 18 8824873 disease NN B-NP O
4 19 28 8824873 phenotype NN I-NP O
5 29 32 8824873 and CC O O
6 33 50 8824873 intergenerational JJ B-NP O
7 51 60 8824873 stability NN I-NP O
8 61 63 8824873 of IN B-PP O
9 64 67 8824873 the DT B-NP O
10 68 71 8824873 CAG NN I-NP O
11 72 78 8824873 repeat NN I-NP O
12 79 81 8824873 in IN B-PP O
13 82 92 8824873 transgenic JJ B-NP O
14 93 97 8824873 mice NNS I-NP O
15 98 108 8824873 expressing VBG B-VP O
16 109 112 8824873 the DT B-NP O
17 113 118 8824873 human JJ I-NP O
18 119 129 8824873 Huntington NNP I-NP B-Disease
19 130 137 8824873 disease NN I-NP I-Disease
20 138 148 8824873 transcript NN I-NP O
21 148 149 8824873 . . O O
22 150 153 8824873 The DT B-NP O
23 154 162 8824873 mutation NN I-NP O
24 163 173 8824873 underlying VBG B-VP O
25 174 184 8824873 Huntington NNP B-NP B-Disease
26 185 192 8824873 disease NN I-NP I-Disease
27 193 194 8824873 ( ( O O
28 194 196 8824873 HD NN B-NP B-Disease
29 196 197 8824873 ) ) O O
30 198 200 8824873 is VBZ B-VP O
31 201 204 8824873 CAG NN B-NP O
32 205 214 8824873 expansion NN I-NP O
33 215 217 8824873 in IN B-PP O
34 218 221 8824873 the DT B-NP O
35 222 227 8824873 first JJ I-NP O
36 228 232 8824873 exon NN I-NP O
37 233 235 8824873 of IN B-PP O
38 236 239 8824873 the DT B-NP O
39 240 242 8824873 HD NN I-NP B-Disease
40 243 247 8824873 gene NN I-NP O
41 247 248 8824873 . . O O

1 249 251 8824873 In IN B-SBAR O
2 252 257 8824873 order NN O O
3 258 260 8824873 to TO B-VP O
4 261 272 8824873 investigate VB I-VP O
5 273 276 8824873 the DT B-NP O
6 277 281 8824873 role NN I-NP O
7 282 284 8824873 of IN B-PP O
8 285 288 8824873 CAG NN B-NP O
9 289 298 8824873 expansion NN I-NP O
10 299 301 8824873 in IN B-PP O
11 302 305 8824873 the DT B-NP O
12 306 318 8824873 pathogenesis NN I-NP O
13 319 321 8824873 of IN B-PP O
14 322 324 8824873 HD NN B-NP B-Disease
15 324 325 8824873 , , O O
16 326 328 8824873 we PRP B-NP O
17 329 333 8824873 have VBP B-VP O
18 334 342 8824873 produced VBN I-VP O
19 343 353 8824873 transgenic JJ B-NP O
20 354 358 8824873 mice NNS I-NP O
21 359 369 8824873 containing VBG B-VP O
22 370 373 8824873 the DT B-NP O
23 374 378 8824873 full JJ I-NP O
24 379 385 8824873 length NN I-NP O
25 386 391 8824873 human JJ I-NP O
26 392 394 8824873 HD NN I-NP B-Disease
27 395 399 8824873 cDNA NN I-NP O
28 400 404 8824873 with IN B-PP O
29 405 407 8824873 44 CD B-NP O
30 408 411 8824873 CAG NN I-NP O
31 412 419 8824873 repeats NNS I-NP O
32 419 420 8824873 . . O O

1 421 423 8824873 By IN B-PP O
2 424 425 8824873 1 CD B-NP O
3 426 430 8824873 year NN I-NP O
4 430 431 8824873 , , O O
5 432 437 8824873 these DT B-NP O
6 438 442 8824873 mice NNS I-NP O
7 443 447 8824873 have VBP B-VP O
8 448 450 8824873 no DT B-NP O
9 451 461 8824873 behavioral JJ I-NP B-Disease
10 462 475 8824873 abnormalities NNS I-NP I-Disease
11 476 479 8824873 and CC O O
12 480 492 8824873 morphometric JJ B-NP O
13 493 501 8824873 analysis NN I-NP O
14 502 504 8824873 at IN B-PP O
15 505 506 8824873 6 CD B-NP O
16 507 508 8824873 ( ( O O
17 508 511 8824873 one CD B-NP O
18 512 518 8824873 animal NN I-NP O
19 518 519 8824873 ) ) O O
20 520 523 8824873 and CC O O
21 524 525 8824873 9 CD B-NP O
22 526 527 8824873 ( ( O O
23 527 530 8824873 two CD B-NP O
24 531 538 8824873 animals NNS I-NP O
25 538 539 8824873 ) ) O O
26 540 546 8824873 months NNS B-NP O
27 547 550 8824873 age NN I-NP O
28 551 559 8824873 revealed VBD B-VP O
29 560 562 8824873 no DT B-NP O
30 563 570 8824873 changes NNS I-NP O
31 570 571 8824873 . . O O

1 572 579 8824873 Despite IN B-PP O
2 580 584 8824873 high JJ B-NP O
3 585 591 8824873 levels NNS I-NP O
4 592 594 8824873 of IN B-PP O
5 595 599 8824873 mRNA NN B-NP O
6 600 610 8824873 expression NN I-NP O
7 610 611 8824873 , , O O
8 612 617 8824873 there EX B-NP O
9 618 621 8824873 was VBD B-VP O
10 622 624 8824873 no DT B-NP O
11 625 633 8824873 evidence NN I-NP O
12 634 636 8824873 of IN B-PP O
13 637 640 8824873 the DT B-NP O
14 641 643 8824873 HD NN I-NP B-Disease
15 644 648 8824873 gene NN I-NP O
16 649 656 8824873 product NN I-NP O
17 657 659 8824873 in IN B-PP O
18 660 663 8824873 any DT B-NP O
19 664 666 8824873 of IN B-PP O
20 667 672 8824873 these DT B-NP O
21 673 683 8824873 transgenic JJ I-NP O
22 684 688 8824873 mice NNS I-NP O
23 688 689 8824873 . . O O

1 690 692 8824873 In FW B-NP O
2 693 698 8824873 vitro FW I-NP O
3 699 711 8824873 transfection NN I-NP O
4 712 719 8824873 studies NNS I-NP O
5 720 729 8824873 indicated VBD B-VP O
6 730 734 8824873 that IN B-SBAR O
7 735 738 8824873 the DT B-NP O
8 739 748 8824873 inclusion NN I-NP O
9 749 751 8824873 of IN B-PP O
10 752 755 8824873 120 CD B-NP O
11 756 758 8824873 bp NN I-NP O
12 759 761 8824873 of IN B-PP O
13 762 765 8824873 the DT B-NP O
14 766 767 8824873 5 CD I-NP O
15 768 771 8824873 UTR NN I-NP O
16 772 774 8824873 in IN B-PP O
17 775 778 8824873 the DT B-NP O
18 779 783 8824873 cDNA NN I-NP O
19 784 793 8824873 construct NN I-NP O
20 794 797 8824873 and CC O O
21 798 801 8824873 the DT B-NP O
22 802 810 8824873 presence NN I-NP O
23 811 813 8824873 of IN B-PP O
24 814 815 8824873 a DT B-NP O
25 816 826 8824873 frameshift NN I-NP O
26 827 835 8824873 mutation NN I-NP O
27 836 838 8824873 at IN B-PP O
28 839 849 8824873 nucleotide NN B-NP O
29 850 854 8824873 2349 CD I-NP O
30 855 864 8824873 prevented VBD B-VP O
31 865 875 8824873 expression NN B-NP O
32 876 878 8824873 of IN B-PP O
33 879 882 8824873 the DT B-NP O
34 883 885 8824873 HD NN I-NP B-Disease
35 886 890 8824873 cDNA NN I-NP O
36 890 891 8824873 . . O O

1 892 897 8824873 These DT B-NP O
2 898 906 8824873 findings NNS I-NP O
3 907 914 8824873 suggest VBP B-VP O
4 915 919 8824873 that IN B-SBAR O
5 920 923 8824873 the DT B-NP O
6 924 936 8824873 pathogenesis NN I-NP O
7 937 939 8824873 of IN B-PP O
8 940 942 8824873 HD NN B-NP B-Disease
9 943 945 8824873 is VBZ B-VP O
10 946 949 8824873 not RB I-VP O
11 950 958 8824873 mediated VBN I-VP O
12 959 966 8824873 through IN B-PP O
13 967 970 8824873 DNA NN B-NP O
14 970 971 8824873 - HYPH B-NP O
15 971 978 8824873 protein NN I-NP O
16 979 990 8824873 interaction NN I-NP O
17 991 994 8824873 and CC O O
18 995 999 8824873 that IN B-SBAR O
19 1000 1008 8824873 presence NN B-NP O
20 1009 1011 8824873 of IN B-PP O
21 1012 1015 8824873 the DT B-NP O
22 1016 1019 8824873 RNA NN I-NP O
23 1020 1030 8824873 transcript NN I-NP O
24 1031 1035 8824873 with IN B-PP O
25 1036 1038 8824873 an DT B-NP O
26 1039 1047 8824873 expanded VBN I-NP O
27 1048 1051 8824873 CAG NN I-NP O
28 1052 1058 8824873 repeat NN I-NP O
29 1059 1061 8824873 is VBZ B-VP O
30 1062 1074 8824873 insufficient JJ B-ADJP O
31 1075 1077 8824873 to TO B-VP O
32 1078 1083 8824873 cause VB I-VP O
33 1084 1087 8824873 the DT B-NP O
34 1088 1095 8824873 disease NN I-NP O
35 1095 1096 8824873 . . O O

1 1097 1103 8824873 Rather RB B-ADVP O
2 1103 1104 8824873 , , O O
3 1105 1116 8824873 translation NN B-NP O
4 1117 1119 8824873 of IN B-PP O
5 1120 1123 8824873 the DT B-NP O
6 1124 1127 8824873 CAG NN I-NP O
7 1128 1130 8824873 is VBZ B-VP O
8 1131 1138 8824873 crucial JJ B-ADJP O
9 1139 1142 8824873 for IN B-PP O
10 1143 1146 8824873 the DT B-NP O
11 1147 1159 8824873 pathogenesis NN I-NP O
12 1160 1162 8824873 of IN B-PP O
13 1163 1165 8824873 HD NN B-NP B-Disease
14 1165 1166 8824873 . . O O

1 1167 1169 8824873 In IN B-PP O
2 1170 1178 8824873 contrast NN B-NP O
3 1179 1181 8824873 to TO B-PP O
4 1182 1186 8824873 that DT B-NP O
5 1187 1191 8824873 seen VBN B-VP O
6 1192 1194 8824873 in IN B-PP O
7 1195 1201 8824873 humans NNS B-NP O
8 1201 1202 8824873 , , O O
9 1203 1206 8824873 the DT B-NP O
10 1207 1210 8824873 CAG NN I-NP O
11 1211 1217 8824873 repeat NN I-NP O
12 1218 1220 8824873 in IN B-PP O
13 1221 1226 8824873 these DT B-NP O
14 1227 1231 8824873 mice NNS I-NP O
15 1232 1235 8824873 was VBD B-VP O
16 1236 1246 8824873 remarkably RB B-ADJP O
17 1247 1253 8824873 stable JJ I-ADJP O
18 1254 1256 8824873 in IN B-PP O
19 1257 1259 8824873 97 CD B-NP O
20 1260 1267 8824873 meioses NNS I-NP O
21 1267 1268 8824873 . . O O

1 1269 1273 8824873 This DT B-NP O
2 1274 1282 8824873 suggests VBZ B-VP O
3 1283 1287 8824873 that IN B-SBAR O
4 1288 1295 8824873 genomic JJ B-NP O
5 1296 1305 8824873 sequences NNS I-NP O
6 1306 1309 8824873 may MD B-VP O
7 1310 1314 8824873 play VB I-VP O
8 1315 1316 8824873 a DT B-NP O
9 1317 1325 8824873 critical JJ I-NP O
10 1326 1330 8824873 role NN I-NP O
11 1331 1333 8824873 in IN B-PP O
12 1334 1345 8824873 influencing VBG B-VP O
13 1346 1352 8824873 repeat NN B-NP O
14 1353 1364 8824873 instability NN I-NP O
15 1364 1365 8824873 . . O O
16 1365 1366 8824873 . . O O

1 0 0 8659522 -DOCSTART- -X- -X- O

1 0 10 8659522 Phenotypic JJ B-NP O
2 11 27 8659522 characterization NN I-NP O
3 28 30 8659522 of IN B-PP O
4 31 42 8659522 individuals NNS B-NP O
5 43 47 8659522 with IN B-PP O
6 48 50 8659522 30 CD B-NP O
7 50 51 8659522 - HYPH I-NP O
8 51 53 8659522 40 CD I-NP O
9 54 57 8659522 CAG NN I-NP O
10 58 65 8659522 repeats NNS I-NP O
11 66 68 8659522 in IN B-PP O
12 69 72 8659522 the DT B-NP O
13 73 83 8659522 Huntington NNP I-NP B-Disease
14 84 91 8659522 disease NN I-NP I-Disease
15 92 93 8659522 ( ( O O
16 93 95 8659522 HD NN B-NP B-Disease
17 95 96 8659522 ) ) O O
18 97 101 8659522 gene NN B-NP O
19 102 109 8659522 reveals VBZ B-VP O
20 110 112 8659522 HD NN B-NP B-Disease
21 113 118 8659522 cases NNS I-NP O
22 119 123 8659522 with IN B-PP O
23 124 126 8659522 36 CD B-NP O
24 127 134 8659522 repeats NNS I-NP O
25 135 138 8659522 and CC O O
26 139 149 8659522 apparently RB B-ADVP O
27 150 156 8659522 normal JJ B-NP O
28 157 164 8659522 elderly JJ I-NP O
29 165 176 8659522 individuals NNS I-NP O
30 177 181 8659522 with IN B-PP O
31 182 184 8659522 36 CD B-NP O
32 184 185 8659522 - HYPH I-NP O
33 185 187 8659522 39 CD I-NP O
34 188 195 8659522 repeats NNS I-NP O
35 195 196 8659522 . . O O
36 197 205 8659522 Abnormal JJ B-NP O
37 206 209 8659522 CAG NN I-NP O
38 210 220 8659522 expansions NNS I-NP O
39 221 223 8659522 in IN B-PP O
40 224 227 8659522 the DT B-NP O
41 228 230 8659522 IT NN I-NP O
42 230 231 8659522 - HYPH B-NP O
43 231 233 8659522 15 CD I-NP O
44 234 238 8659522 gene NN I-NP O
45 239 242 8659522 are VBP B-VP O
46 243 253 8659522 associated VBN I-VP O
47 254 258 8659522 with IN B-PP O
48 259 269 8659522 Huntington NNP B-NP B-Disease
49 270 277 8659522 disease NN I-NP I-Disease
50 278 279 8659522 ( ( O O
51 279 281 8659522 HD NN B-NP B-Disease
52 281 282 8659522 ) ) O O
53 282 283 8659522 . . O O

1 284 286 8659522 In IN B-PP O
2 287 290 8659522 the DT B-NP O
3 291 301 8659522 diagnostic JJ I-NP O
4 302 309 8659522 setting NN I-NP O
5 310 312 8659522 it PRP B-NP O
6 313 315 8659522 is VBZ B-VP O
7 316 325 8659522 necessary JJ B-ADJP O
8 326 328 8659522 to TO B-VP O
9 329 335 8659522 define VB I-VP O
10 336 339 8659522 the DT B-NP O
11 340 346 8659522 limits NNS I-NP O
12 347 349 8659522 of IN B-PP O
13 350 353 8659522 the DT B-NP O
14 354 357 8659522 CAG NN I-NP O
15 358 362 8659522 size NN I-NP O
16 363 369 8659522 ranges NNS I-NP O
17 370 372 8659522 on IN B-PP O
18 373 379 8659522 normal JJ B-NP O
19 380 383 8659522 and CC I-NP O
20 384 386 8659522 HD NN I-NP B-Disease
21 386 387 8659522 - HYPH B-NP O
22 387 397 8659522 associated VBN I-NP O
23 398 409 8659522 chromosomes NNS I-NP O
24 409 410 8659522 . . O O

1 411 415 8659522 Most JJS B-NP O
2 416 421 8659522 large JJ I-NP O
3 422 430 8659522 analyses NNS I-NP O
4 431 435 8659522 that WDT B-NP O
5 436 443 8659522 defined VBD B-VP O
6 444 447 8659522 the DT B-NP O
7 448 454 8659522 limits NNS I-NP O
8 455 457 8659522 of IN B-PP O
9 458 461 8659522 the DT B-NP O
10 462 468 8659522 normal JJ I-NP O
11 469 472 8659522 and CC I-NP O
12 473 485 8659522 pathological JJ I-NP O
13 486 490 8659522 size NN I-NP O
14 491 497 8659522 ranges VBZ B-VP O
15 498 506 8659522 employed VBN I-VP O
16 507 510 8659522 PCR NN B-NP O
17 511 517 8659522 assays NNS I-NP O
18 517 518 8659522 , , O O
19 519 524 8659522 which WDT B-NP O
20 525 533 8659522 included VBD B-VP O
21 534 537 8659522 the DT B-NP O
22 538 541 8659522 CAG NN I-NP O
23 542 549 8659522 repeats NNS I-NP O
24 550 553 8659522 and CC O O
25 554 555 8659522 a DT B-NP O
26 556 559 8659522 CCG NN I-NP O
27 560 566 8659522 repeat NN I-NP O
28 567 572 8659522 tract NN I-NP O
29 573 577 8659522 that WDT B-NP O
30 578 581 8659522 was VBD B-VP O
31 582 589 8659522 thought VBN I-VP O
32 590 592 8659522 to TO I-VP O
33 593 595 8659522 be VB I-VP O
34 596 605 8659522 invariant JJ B-ADJP O
35 605 606 8659522 . . O O

1 607 611 8659522 Many JJ B-NP O
2 612 614 8659522 of IN B-PP O
3 615 620 8659522 these DT B-NP O
4 621 632 8659522 experiments NNS I-NP O
5 633 638 8659522 found VBD B-VP O
6 639 641 8659522 an DT B-NP O
7 642 649 8659522 overlap NN I-NP O
8 650 657 8659522 between IN B-PP O
9 658 661 8659522 the DT B-NP O
10 662 668 8659522 normal JJ I-NP O
11 669 672 8659522 and CC I-NP O
12 673 680 8659522 disease NN I-NP O
13 681 685 8659522 size NN I-NP O
14 686 692 8659522 ranges NNS I-NP O
15 692 693 8659522 . . O O

1 694 704 8659522 Subsequent JJ B-NP O
2 705 713 8659522 findings NNS I-NP O
3 714 718 8659522 that IN B-SBAR O
4 719 722 8659522 the DT B-NP O
5 723 726 8659522 CCG NN I-NP O
6 727 734 8659522 repeats NNS I-NP O
7 735 739 8659522 vary VBP B-VP O
8 740 742 8659522 by IN B-PP O
9 743 744 8659522 8 CD B-NP O
10 745 758 8659522 trinucleotide NN I-NP O
11 759 766 8659522 lengths NNS I-NP O
12 767 776 8659522 suggested VBD B-VP O
13 777 781 8659522 that IN B-SBAR O
14 782 785 8659522 the DT B-NP O
15 786 792 8659522 limits NNS I-NP O
16 793 795 8659522 of IN B-PP O
17 796 799 8659522 the DT B-NP O
18 800 806 8659522 normal JJ I-NP O
19 807 810 8659522 and CC I-NP O
20 811 818 8659522 disease NN I-NP O
21 819 823 8659522 size NN I-NP O
22 824 830 8659522 ranges NNS I-NP O
23 831 837 8659522 should MD B-VP O
24 838 840 8659522 be VB I-VP O
25 841 852 8659522 reevaluated VBN I-VP O
26 853 857 8659522 with IN B-PP O
27 858 864 8659522 assays NNS B-NP O
28 865 869 8659522 that WDT B-NP O
29 870 877 8659522 exclude VBP B-VP O
30 878 881 8659522 the DT B-NP O
31 882 885 8659522 CCG NN I-NP O
32 886 898 8659522 polymorphism NN I-NP O
33 898 899 8659522 . . O O

1 900 905 8659522 Since IN B-SBAR O
2 906 914 8659522 patients NNS B-NP O
3 915 919 8659522 with IN B-PP O
4 920 927 8659522 between IN B-NP O
5 928 930 8659522 30 CD I-NP O
6 931 934 8659522 and CC I-NP O
7 935 937 8659522 40 CD I-NP O
8 938 945 8659522 repeats NNS I-NP O
9 946 949 8659522 are VBP B-VP O
10 950 954 8659522 rare JJ B-ADJP O
11 954 955 8659522 , , O O
12 956 957 8659522 a DT B-NP O
13 958 968 8659522 consortium NN I-NP O
14 969 972 8659522 was VBD B-VP O
15 973 982 8659522 assembled VBN I-VP O
16 983 985 8659522 to TO I-VP O
17 986 993 8659522 collect VB I-VP O
18 994 998 8659522 such JJ B-NP O
19 999 1010 8659522 individuals NNS I-NP O
20 1010 1011 8659522 . . O O

1 1012 1015 8659522 All DT B-NP O
2 1016 1019 8659522 178 CD I-NP O
3 1020 1027 8659522 samples NNS I-NP O
4 1028 1032 8659522 were VBD B-VP O
5 1033 1043 8659522 reanalyzed VBN I-VP O
6 1044 1046 8659522 in IN B-PP O
7 1047 1056 8659522 Cambridge NNP B-NP O
8 1057 1059 8659522 by IN B-PP O
9 1060 1065 8659522 using VBG B-VP O
10 1066 1072 8659522 assays NNS B-NP O
11 1073 1081 8659522 specific JJ B-ADJP O
12 1082 1085 8659522 for IN B-PP O
13 1086 1089 8659522 the DT B-NP O
14 1090 1093 8659522 CAG NN I-NP O
15 1094 1101 8659522 repeats NNS I-NP O
16 1101 1102 8659522 . . O O

1 1103 1105 8659522 We PRP B-NP O
2 1106 1110 8659522 have VBP B-VP O
3 1111 1120 8659522 optimized VBN I-VP O
4 1121 1128 8659522 methods NNS B-NP O
5 1129 1132 8659522 for IN B-PP O
6 1133 1141 8659522 reliable JJ B-NP O
7 1142 1148 8659522 sizing NN I-NP O
8 1149 1151 8659522 of IN B-PP O
9 1152 1155 8659522 CAG NN B-NP O
10 1156 1163 8659522 repeats NNS I-NP O
11 1164 1167 8659522 and CC O O
12 1168 1172 8659522 show NN B-NP O
13 1173 1178 8659522 cases NNS I-NP O
14 1179 1183 8659522 that WDT B-NP O
15 1184 1195 8659522 demonstrate VBP B-VP O
16 1196 1199 8659522 the DT B-NP O
17 1200 1207 8659522 dangers NNS I-NP O
18 1208 1210 8659522 of IN B-PP O
19 1211 1216 8659522 using VBG B-VP O
20 1217 1220 8659522 PCR NN B-NP O
21 1221 1227 8659522 assays NNS I-NP O
22 1228 1232 8659522 that WDT B-NP O
23 1233 1240 8659522 include VBP B-VP O
24 1241 1245 8659522 both CC O O
25 1246 1249 8659522 the DT B-NP O
26 1250 1253 8659522 CAG NN I-NP O
27 1254 1257 8659522 and CC I-NP O
28 1258 1261 8659522 CCG NN I-NP O
29 1262 1275 8659522 polymorphisms NNS I-NP O
30 1275 1276 8659522 . . O O

1 1277 1282 8659522 Seven CD B-NP O
2 1283 1285 8659522 HD NN I-NP B-Disease
3 1286 1294 8659522 patients NNS I-NP O
4 1295 1298 8659522 had VBD B-VP O
5 1299 1301 8659522 36 CD B-NP O
6 1302 1309 8659522 repeats NNS I-NP O
7 1309 1310 8659522 , , O O
8 1311 1316 8659522 which WDT B-NP O
9 1317 1325 8659522 confirms VBZ B-VP O
10 1326 1330 8659522 that IN B-SBAR O
11 1331 1335 8659522 this DT B-NP O
12 1336 1342 8659522 allele NN I-NP O
13 1343 1345 8659522 is VBZ B-VP O
14 1346 1356 8659522 associated VBN I-VP O
15 1357 1361 8659522 with IN B-PP O
16 1362 1369 8659522 disease NN B-NP O
17 1369 1370 8659522 . . O O

1 1371 1382 8659522 Individuals NNS B-NP O
2 1383 1390 8659522 without IN B-PP O
3 1391 1399 8659522 apparent JJ B-NP O
4 1400 1408 8659522 symptoms NNS I-NP O
5 1409 1411 8659522 or CC I-NP O
6 1412 1417 8659522 signs NNS I-NP O
7 1418 1420 8659522 of IN B-PP O
8 1421 1423 8659522 HD NN B-NP B-Disease
9 1424 1428 8659522 were VBD B-VP O
10 1429 1434 8659522 found VBN I-VP O
11 1435 1437 8659522 at IN B-PP O
12 1438 1440 8659522 36 CD B-NP O
13 1441 1448 8659522 repeats NNS I-NP O
14 1449 1450 8659522 ( ( O O
15 1450 1454 8659522 aged VBN B-NP O
16 1455 1457 8659522 74 CD I-NP O
17 1457 1458 8659522 , , I-NP O
18 1459 1461 8659522 78 CD I-NP O
19 1461 1462 8659522 , , I-NP O
20 1463 1465 8659522 79 CD I-NP O
21 1465 1466 8659522 , , O O
22 1467 1470 8659522 and CC O O
23 1471 1473 8659522 87 CD B-NP O
24 1474 1479 8659522 years NNS I-NP O
25 1479 1480 8659522 ) ) O O
26 1480 1481 8659522 , , O O
27 1482 1484 8659522 37 CD B-NP O
28 1485 1492 8659522 repeats NNS I-NP O
29 1493 1494 8659522 ( ( O O
30 1494 1498 8659522 aged VBN B-VP O
31 1499 1501 8659522 69 CD B-NP O
32 1502 1507 8659522 years NNS I-NP O
33 1507 1508 8659522 ) ) O O
34 1508 1509 8659522 , , O O
35 1510 1512 8659522 38 CD B-NP O
36 1513 1520 8659522 repeats NNS I-NP O
37 1521 1522 8659522 ( ( O O
38 1522 1526 8659522 aged VBN B-VP O
39 1527 1529 8659522 69 CD B-NP O
40 1530 1533 8659522 and CC I-NP O
41 1534 1536 8659522 90 CD I-NP O
42 1537 1542 8659522 years NNS I-NP O
43 1542 1543 8659522 ) ) O O
44 1543 1544 8659522 , , O O
45 1545 1548 8659522 and CC O O
46 1549 1551 8659522 39 CD B-NP O
47 1552 1559 8659522 repeats NNS I-NP O
48 1560 1561 8659522 ( ( O O
49 1561 1565 8659522 aged VBN B-NP O
50 1566 1568 8659522 67 CD I-NP O
51 1568 1569 8659522 , , I-NP O
52 1570 1572 8659522 90 CD I-NP O
53 1572 1573 8659522 , , O O
54 1574 1577 8659522 and CC O O
55 1578 1580 8659522 95 CD B-NP O
56 1581 1586 8659522 years NNS I-NP O
57 1586 1587 8659522 ) ) O O
58 1587 1588 8659522 . . O O

1 1589 1592 8659522 The DT B-NP O
2 1593 1601 8659522 detailed JJ I-NP O
3 1602 1606 8659522 case NN I-NP O
4 1607 1616 8659522 histories NNS I-NP O
5 1617 1619 8659522 of IN B-PP O
6 1620 1622 8659522 an DT B-NP O
7 1623 1634 8659522 exceptional JJ I-NP O
8 1635 1639 8659522 case NN I-NP O
9 1640 1644 8659522 from IN B-PP O
10 1645 1649 8659522 this DT B-NP O
11 1650 1656 8659522 series NN I-NP O
12 1657 1661 8659522 will MD B-VP O
13 1662 1664 8659522 be VB I-VP O
14 1665 1674 8659522 presented VBN I-VP O
15 1676 1677 8659522 a DT B-NP O
16 1678 1680 8659522 95 CD I-NP O
17 1680 1681 8659522 - HYPH I-NP O
18 1681 1685 8659522 year NN I-NP O
19 1685 1686 8659522 - HYPH O O
20 1686 1689 8659522 old JJ B-NP O
21 1690 1693 8659522 man NN I-NP O
22 1694 1698 8659522 with IN B-PP O
23 1699 1701 8659522 39 CD B-NP O
24 1702 1709 8659522 repeats NNS I-NP O
25 1710 1713 8659522 who WP B-NP O
26 1714 1717 8659522 did VBD B-VP O
27 1718 1721 8659522 not RB I-VP O
28 1722 1726 8659522 have VB I-VP O
29 1727 1736 8659522 classical JJ B-NP O
30 1737 1745 8659522 features NNS I-NP O
31 1746 1748 8659522 of IN B-PP O
32 1749 1751 8659522 HD NN B-NP B-Disease
33 1751 1752 8659522 . . O O

1 1753 1756 8659522 The DT B-NP O
2 1757 1767 8659522 apparently RB I-NP O
3 1768 1775 8659522 healthy JJ I-NP O
4 1776 1784 8659522 survival NN I-NP O
5 1785 1789 8659522 into IN B-PP O
6 1790 1793 8659522 old JJ B-NP O
7 1794 1797 8659522 age NN I-NP O
8 1798 1800 8659522 of IN B-PP O
9 1801 1805 8659522 some DT B-NP O
10 1806 1817 8659522 individuals NNS I-NP O
11 1818 1822 8659522 with IN B-PP O
12 1823 1825 8659522 36 CD B-NP O
13 1825 1826 8659522 - HYPH I-NP O
14 1826 1828 8659522 39 CD I-NP O
15 1829 1836 8659522 repeats NNS I-NP O
16 1837 1845 8659522 suggests VBZ B-VP O
17 1846 1850 8659522 that IN B-SBAR O
18 1851 1854 8659522 the DT B-NP O
19 1855 1857 8659522 HD NN I-NP B-Disease
20 1858 1866 8659522 mutation NN I-NP O
21 1867 1870 8659522 may MD B-VP O
22 1871 1874 8659522 not RB I-VP O
23 1875 1881 8659522 always RB I-VP O
24 1882 1884 8659522 be VB I-VP O
25 1885 1890 8659522 fully RB B-ADJP O
26 1891 1900 8659522 penetrant JJ I-ADJP O
27 1900 1901 8659522 . . O O
28 1901 1902 8659522 . . O O

1 0 0 9195227 -DOCSTART- -X- -X- O

1 0 9 9195227 Screening NN B-NP O
2 10 13 9195227 for IN B-PP O
3 14 17 9195227 ESR NN B-NP O
4 18 27 9195227 mutations NNS I-NP O
5 28 30 9195227 in IN B-PP O
6 31 37 9195227 breast NN B-NP B-Disease
7 38 41 9195227 and CC O I-Disease
8 42 49 9195227 ovarian JJ B-NP I-Disease
9 50 56 9195227 cancer NN I-NP I-Disease
10 57 65 9195227 patients NNS I-NP O
11 65 66 9195227 . . O O
12 67 69 9195227 In IN B-PP O
13 70 73 9195227 the DT B-NP O
14 74 81 9195227 present JJ I-NP O
15 82 87 9195227 study NN I-NP O
16 87 88 9195227 , , O O
17 89 98 9195227 leukocyte NN B-NP O
18 99 102 9195227 DNA NN I-NP O
19 103 107 9195227 from IN B-PP O
20 108 111 9195227 143 CD B-NP O
21 112 120 9195227 patients NNS I-NP O
22 121 125 9195227 with IN B-PP O
23 126 134 9195227 familial JJ B-NP O
24 135 145 9195227 clustering NN I-NP O
25 146 148 9195227 of IN B-PP O
26 149 155 9195227 breast NN B-NP B-Disease
27 156 159 9195227 and CC O I-Disease
28 159 160 9195227 / SYM B-NP I-Disease
29 160 162 9195227 or CC O I-Disease
30 163 170 9195227 ovarian JJ B-NP I-Disease
31 171 177 9195227 cancer NN I-NP I-Disease
32 178 181 9195227 and CC O O
33 182 188 9195227 tumour NN B-NP B-Disease
34 189 192 9195227 DNA NN I-NP O
35 193 197 9195227 from IN B-PP O
36 198 200 9195227 96 CD B-NP O
37 201 207 9195227 breast NN I-NP B-Disease
38 208 218 9195227 carcinomas NNS I-NP I-Disease
39 219 223 9195227 were VBD B-VP O
40 224 232 9195227 screened VBN I-VP O
41 233 236 9195227 for IN B-PP O
42 237 241 9195227 base NN B-NP O
43 242 251 9195227 mutations NNS I-NP O
44 252 254 9195227 in IN B-PP O
45 255 258 9195227 the DT B-NP O
46 259 267 9195227 estrogen NN I-NP O
47 268 276 9195227 receptor NN I-NP O
48 277 281 9195227 gene NN I-NP O
49 282 283 9195227 ( ( O O
50 283 286 9195227 ESR NN B-NP O
51 286 287 9195227 ) ) O O
52 287 288 9195227 . . O O

1 289 294 9195227 Three CD B-NP O
2 295 303 9195227 patients NNS I-NP O
3 304 308 9195227 with IN B-PP O
4 309 310 9195227 a DT B-NP O
5 311 317 9195227 family NN I-NP O
6 318 325 9195227 history NN I-NP O
7 326 328 9195227 of IN B-PP O
8 329 335 9195227 cancer NN B-NP B-Disease
9 336 340 9195227 were VBD B-VP O
10 341 349 9195227 carrying VBG I-VP O
11 350 351 9195227 a DT B-NP O
12 352 361 9195227 Gly160Cys NN I-NP O
13 362 370 9195227 germline NN I-NP O
14 371 383 9195227 substitution NN I-NP O
15 383 384 9195227 . . O O

1 385 389 9195227 This DT B-NP O
2 390 400 9195227 alteration NN I-NP O
3 401 404 9195227 was VBD B-VP O
4 405 409 9195227 also RB I-VP O
5 410 418 9195227 detected VBN I-VP O
6 419 421 9195227 in IN B-PP O
7 422 427 9195227 eight CD B-NP O
8 428 429 9195227 ( ( O O
9 429 433 9195227 four CD B-NP O
10 434 441 9195227 females NNS I-NP O
11 442 445 9195227 and CC O O
12 446 450 9195227 four CD B-NP O
13 451 456 9195227 males NNS I-NP O
14 456 457 9195227 ) ) O O
15 458 460 9195227 of IN B-PP O
16 461 464 9195227 729 CD B-NP O
17 465 473 9195227 controls NNS I-NP O
18 474 475 9195227 ( ( O O
19 475 478 9195227 366 CD B-NP O
20 479 485 9195227 female JJ I-NP O
21 485 486 9195227 , , O O
22 487 490 9195227 363 CD B-NP O
23 491 496 9195227 males NNS I-NP O
24 496 497 9195227 ) ) O O
25 497 498 9195227 , , O O
26 499 509 9195227 indicating VBG B-VP O
27 510 514 9195227 that IN B-SBAR O
28 515 518 9195227 the DT B-NP O
29 519 531 9195227 substitution NN I-NP O
30 532 540 9195227 probably RB B-ADVP O
31 541 551 9195227 represents VBZ B-VP O
32 552 553 9195227 a DT B-NP O
33 554 566 9195227 polymorphism NN I-NP O
34 566 567 9195227 . . O O

1 568 575 9195227 However RB B-ADVP O
2 575 576 9195227 , , O O
3 577 579 9195227 in IN B-PP O
4 580 583 9195227 the DT B-NP O
5 584 587 9195227 229 CD I-NP O
6 588 594 9195227 female JJ I-NP O
7 595 603 9195227 controls NNS I-NP O
8 604 606 9195227 in IN B-PP O
9 607 611 9195227 whom WP B-NP O
10 612 618 9195227 family NN B-NP O
11 619 626 9195227 history NN I-NP O
12 627 629 9195227 of IN B-PP O
13 630 636 9195227 cancer NN B-NP B-Disease
14 637 640 9195227 was VBD B-VP O
15 641 646 9195227 known VBN I-VP O
16 646 647 9195227 , , O O
17 648 651 9195227 one CD B-NP O
18 652 654 9195227 of IN B-PP O
19 655 658 9195227 two CD B-NP O
20 659 662 9195227 who WP B-NP O
21 663 666 9195227 had VBD B-VP O
22 667 668 9195227 a DT B-NP O
23 669 675 9195227 sister NN I-NP O
24 676 680 9195227 with IN B-PP O
25 681 687 9195227 breast NN B-NP B-Disease
26 688 694 9195227 cancer NN I-NP I-Disease
27 695 698 9195227 was VBD B-VP O
28 699 707 9195227 carrying VBG I-VP O
29 708 711 9195227 the DT B-NP O
30 712 719 9195227 variant JJ I-NP O
31 720 726 9195227 allele NN I-NP O
32 726 727 9195227 . . O O

1 728 733 9195227 Hence RB B-ADVP O
2 733 734 9195227 , , O O
3 735 736 9195227 a DT B-NP O
4 737 745 9195227 possible JJ I-NP O
5 746 754 9195227 clinical JJ I-NP O
6 755 767 9195227 significance NN I-NP O
7 768 770 9195227 of IN B-PP O
8 771 774 9195227 the DT B-NP O
9 775 782 9195227 glycine NN I-NP O
10 783 787 9195227 into IN B-PP O
11 788 796 9195227 cysteine NN B-NP O
12 797 803 9195227 cannot MD B-VP O
13 804 806 9195227 be VB I-VP O
14 807 817 9195227 completely RB I-VP O
15 818 823 9195227 ruled VBN I-VP O
16 824 827 9195227 out RP B-PRT O
17 828 831 9195227 and CC O O
18 832 838 9195227 should MD B-VP O
19 839 841 9195227 be VB I-VP O
20 842 849 9195227 further RBR B-ADJP O
21 850 862 9195227 investigated VBN I-ADJP O
22 862 863 9195227 . . O O

1 864 871 9195227 Somatic JJ B-NP O
2 872 881 9195227 mutations NNS I-NP O
3 882 886 9195227 were VBD B-VP O
4 887 890 9195227 not RB I-VP O
5 891 899 9195227 detected VBN I-VP O
6 900 902 9195227 in IN B-PP O
7 903 906 9195227 any DT B-NP O
8 907 909 9195227 of IN B-PP O
9 910 913 9195227 the DT B-NP O
10 914 921 9195227 tumours NNS I-NP B-Disease
11 922 929 9195227 studied VBN B-VP O
12 929 930 9195227 , , O O
13 931 934 9195227 and CC O O
14 935 938 9195227 the DT B-NP O
15 939 946 9195227 present JJ I-NP O
16 947 951 9195227 data NNS I-NP O
17 952 954 9195227 do VBP B-VP O
18 955 958 9195227 not RB I-VP O
19 959 966 9195227 provide VB I-VP O
20 967 974 9195227 support NN B-NP O
21 975 978 9195227 for IN B-PP O
22 979 986 9195227 somatic JJ B-NP O
23 987 990 9195227 ESR NN I-NP O
24 991 995 9195227 base NN I-NP O
25 996 1005 9195227 mutations NNS I-NP O
26 1006 1008 9195227 as IN B-PP O
27 1009 1011 9195227 an DT B-NP O
28 1012 1021 9195227 important JJ I-NP O
29 1022 1031 9195227 mechanism NN I-NP O
30 1032 1035 9195227 for IN B-PP O
31 1036 1044 9195227 hormonal JJ B-NP O
32 1045 1052 9195227 therapy NN I-NP O
33 1053 1063 9195227 resistance NN I-NP O
34 1064 1066 9195227 in IN B-PP O
35 1067 1075 9195227 estrogen NN B-NP B-Disease
36 1076 1084 9195227 receptor NN I-NP I-Disease
37 1084 1085 9195227 - HYPH B-NP I-Disease
38 1085 1093 9195227 positive JJ I-NP I-Disease
39 1094 1100 9195227 breast NN I-NP I-Disease
40 1101 1111 9195227 carcinomas NNS I-NP I-Disease
41 1111 1112 9195227 . . O O
42 1112 1113 9195227 . . O O

1 0 0 8917548 -DOCSTART- -X- -X- O

1 0 11 8917548 Pleiotropic JJ B-NP O
2 12 19 8917548 defects NNS I-NP O
3 20 22 8917548 in IN B-PP O
4 23 29 8917548 ataxia NN B-NP B-Disease
5 29 30 8917548 - HYPH O I-Disease
6 30 44 8917548 telangiectasia NN B-NP I-Disease
7 45 52 8917548 protein NN I-NP O
8 52 53 8917548 - HYPH B-NP O
9 53 62 8917548 deficient JJ I-NP O
10 63 67 8917548 mice NNS I-NP O
11 67 68 8917548 . . O O
12 69 71 8917548 We PRP B-NP O
13 72 76 8917548 have VBP B-VP O
14 77 86 8917548 generated VBN I-VP O
15 87 88 8917548 a DT B-NP O
16 89 94 8917548 mouse NN I-NP O
17 95 100 8917548 model NN I-NP O
18 101 104 8917548 for IN B-PP O
19 105 111 8917548 ataxia NN B-NP B-Disease
20 111 112 8917548 - HYPH B-NP I-Disease
21 112 126 8917548 telangiectasia NN I-NP I-Disease
22 127 129 8917548 by IN B-PP O
23 130 135 8917548 using VBG B-VP O
24 136 140 8917548 gene NN B-NP O
25 141 150 8917548 targeting NN I-NP O
26 151 153 8917548 to TO B-VP O
27 154 162 8917548 generate VB I-VP O
28 163 167 8917548 mice NNS B-NP O
29 168 172 8917548 that WDT B-NP O
30 173 175 8917548 do VBP B-VP O
31 176 179 8917548 not RB I-VP O
32 180 187 8917548 express VB I-VP O
33 188 191 8917548 the DT B-NP O
34 192 195 8917548 Atm NNP I-NP O
35 196 203 8917548 protein NN I-NP O
36 203 204 8917548 . . O O

1 205 208 8917548 Atm NN B-NP O
2 208 209 8917548 - HYPH I-NP O
3 209 218 8917548 deficient JJ I-NP O
4 219 223 8917548 mice NNS I-NP O
5 224 227 8917548 are VBP B-VP O
6 228 236 8917548 retarded VBN I-VP O
7 237 239 8917548 in IN B-PP O
8 240 246 8917548 growth NN B-NP O
9 246 247 8917548 , , O O
10 248 250 8917548 do VBP B-VP O
11 251 254 8917548 not RB I-VP O
12 255 262 8917548 produce VB I-VP O
13 263 269 8917548 mature JJ B-NP O
14 270 275 8917548 sperm NN I-NP O
15 275 276 8917548 , , O O
16 277 280 8917548 and CC O O
17 281 288 8917548 exhibit VBP B-VP O
18 289 295 8917548 severe JJ B-NP O
19 296 303 8917548 defects NNS I-NP O
20 304 306 8917548 in IN B-PP O
21 307 308 8917548 T NN B-NP O
22 309 313 8917548 cell NN I-NP O
23 314 324 8917548 maturation NN I-NP O
24 325 330 8917548 while IN B-SBAR O
25 331 336 8917548 going VBG B-VP O
26 337 339 8917548 on RP B-PRT O
27 340 342 8917548 to TO B-VP O
28 343 350 8917548 develop VB I-VP O
29 351 359 8917548 thymomas NNS B-NP B-Disease
30 359 360 8917548 . . O O

1 361 364 8917548 Atm NN B-NP O
2 364 365 8917548 - HYPH I-NP O
3 365 374 8917548 deficient JJ I-NP O
4 375 386 8917548 fibroblasts NNS I-NP O
5 387 391 8917548 grow VBP B-VP O
6 392 398 8917548 poorly RB B-ADVP O
7 399 401 8917548 in IN B-PP O
8 402 409 8917548 culture NN B-NP O
9 410 413 8917548 and CC O O
10 414 421 8917548 display VBP B-VP O
11 422 423 8917548 a DT B-NP O
12 424 428 8917548 high JJ I-NP O
13 429 434 8917548 level NN I-NP O
14 435 437 8917548 of IN B-PP O
15 438 444 8917548 double JJ B-NP O
16 444 445 8917548 - HYPH I-NP O
17 445 453 8917548 stranded JJ I-NP O
18 454 464 8917548 chromosome NN I-NP O
19 465 471 8917548 breaks NNS I-NP O
20 471 472 8917548 . . O O

1 473 476 8917548 Atm NN B-NP O
2 476 477 8917548 - HYPH I-NP O
3 477 486 8917548 deficient JJ I-NP O
4 487 497 8917548 thymocytes NNS I-NP O
5 498 505 8917548 undergo VBP B-VP O
6 506 517 8917548 spontaneous JJ B-NP O
7 518 527 8917548 apoptosis NN I-NP O
8 528 530 8917548 in FW B-ADVP O
9 531 536 8917548 vitro FW I-ADVP O
10 537 550 8917548 significantly RB B-NP O
11 551 555 8917548 more JJR I-NP O
12 556 560 8917548 than IN B-PP O
13 561 569 8917548 controls NNS B-NP O
14 569 570 8917548 . . O O

1 571 574 8917548 Atm NN B-NP O
2 574 575 8917548 - HYPH I-NP O
3 575 584 8917548 deficient JJ I-NP O
4 585 589 8917548 mice NNS I-NP O
5 590 594 8917548 then RB B-ADVP O
6 595 602 8917548 exhibit VBP B-VP O
7 603 607 8917548 many JJ B-NP O
8 608 610 8917548 of IN B-PP O
9 611 614 8917548 the DT B-NP O
10 615 619 8917548 same JJ I-NP O
11 620 628 8917548 symptoms NNS I-NP O
12 629 634 8917548 found VBN B-VP O
13 635 637 8917548 in IN B-PP O
14 638 644 8917548 ataxia NN B-NP B-Disease
15 644 645 8917548 - HYPH B-NP I-Disease
16 645 659 8917548 telangiectasia NN I-NP I-Disease
17 660 668 8917548 patients NNS I-NP O
18 669 672 8917548 and CC B-PP O
19 673 675 8917548 in IN B-PP O
20 676 681 8917548 cells NNS B-NP O
21 682 689 8917548 derived VBN B-VP O
22 690 694 8917548 from IN B-PP O
23 695 699 8917548 them PRP B-NP O
24 699 700 8917548 . . O O

1 701 712 8917548 Furthermore RB B-ADVP O
2 712 713 8917548 , , O O
3 714 716 8917548 we PRP B-NP O
4 717 728 8917548 demonstrate VBP B-VP O
5 729 733 8917548 that IN B-SBAR O
6 734 737 8917548 the DT B-NP O
7 738 741 8917548 Atm NN I-NP O
8 742 749 8917548 protein NN I-NP O
9 750 756 8917548 exists VBZ B-VP O
10 757 759 8917548 as IN B-SBAR O
11 760 763 8917548 two CD B-NP O
12 764 772 8917548 discrete JJ I-NP O
13 773 782 8917548 molecular JJ I-NP O
14 783 790 8917548 species NNS I-NP O
15 790 791 8917548 , , O O
16 792 795 8917548 and CC O O
17 796 800 8917548 that IN B-SBAR O
18 801 805 8917548 loss NN B-NP O
19 806 808 8917548 of IN B-PP O
20 809 812 8917548 one CD B-NP O
21 813 815 8917548 or CC I-NP O
22 816 818 8917548 of IN B-PP O
23 819 823 8917548 both DT B-NP O
24 824 826 8917548 of IN B-PP O
25 827 832 8917548 these DT B-NP O
26 833 836 8917548 can MD B-VP O
27 837 841 8917548 lead VB I-VP O
28 842 844 8917548 to TO B-PP O
29 845 848 8917548 the DT B-NP O
30 849 860 8917548 development NN I-NP O
31 861 863 8917548 of IN B-PP O
32 864 867 8917548 the DT B-NP O
33 868 875 8917548 disease NN I-NP O
34 875 876 8917548 . . O O
35 876 877 8917548 . . O O

1 0 0 8776595 -DOCSTART- -X- -X- O

1 0 3 8776595 The DT B-NP O
2 4 9 8776595 Emery NNP I-NP B-Disease
3 9 10 8776595 - HYPH I-NP I-Disease
4 10 18 8776595 Dreifuss NNP I-NP I-Disease
5 19 27 8776595 muscular JJ I-NP I-Disease
6 28 37 8776595 dystrophy NN I-NP I-Disease
7 38 45 8776595 protein NN I-NP O
8 45 46 8776595 , , O O
9 47 53 8776595 emerin NN B-NP O
10 53 54 8776595 , , O O
11 55 57 8776595 is VBZ B-VP O
12 58 59 8776595 a DT B-NP O
13 60 67 8776595 nuclear JJ I-NP O
14 68 76 8776595 membrane NN I-NP O
15 77 84 8776595 protein NN I-NP O
16 84 85 8776595 . . O O
17 86 87 8776595 A DT B-NP O
18 88 93 8776595 large JJ I-NP O
19 94 102 8776595 fragment NN I-NP O
20 103 105 8776595 of IN B-PP O
21 106 112 8776595 emerin NN B-NP O
22 113 117 8776595 cDNA NN I-NP O
23 118 121 8776595 was VBD B-VP O
24 122 130 8776595 prepared VBN I-VP O
25 131 133 8776595 by IN B-PP O
26 134 137 8776595 PCR NN B-NP O
27 138 141 8776595 and CC O O
28 142 151 8776595 expressed VBN B-VP O
29 152 154 8776595 as IN B-PP O
30 155 156 8776595 a DT B-NP O
31 157 168 8776595 recombinant JJ I-NP O
32 169 176 8776595 protein NN I-NP O
33 177 179 8776595 in IN B-PP O
34 180 191 8776595 Escherichia NNP B-NP O
35 192 196 8776595 coli NNP I-NP O
36 196 197 8776595 . . O O

1 198 203 8776595 Using VBG B-VP O
2 204 208 8776595 this DT B-NP O
3 209 211 8776595 as IN B-PP O
4 212 221 8776595 immunogen NN B-NP O
5 221 222 8776595 , , O O
6 223 225 8776595 we PRP B-NP O
7 226 234 8776595 prepared VBD B-VP O
8 235 236 8776595 a DT B-NP O
9 237 242 8776595 panel NN I-NP O
10 243 245 8776595 of IN B-PP O
11 246 248 8776595 12 CD B-NP O
12 249 259 8776595 monoclonal JJ I-NP O
13 260 270 8776595 antibodies NNS I-NP O
14 271 276 8776595 which WDT B-NP O
15 277 286 8776595 recognise VBP B-VP O
16 287 289 8776595 at IN B-NP O
17 290 295 8776595 least JJS I-NP O
18 296 300 8776595 four CD I-NP O
19 301 310 8776595 different JJ I-NP O
20 311 319 8776595 epitopes NNS I-NP O
21 320 322 8776595 on IN B-PP O
22 323 329 8776595 emerin NN B-NP O
23 330 332 8776595 in IN B-SBAR O
24 333 338 8776595 order NN O O
25 339 341 8776595 to TO B-VP O
26 342 348 8776595 ensure VB I-VP O
27 349 353 8776595 that DT B-NP O
28 354 360 8776595 emerin NN I-NP O
29 361 364 8776595 can MD B-VP O
30 365 367 8776595 be VB I-VP O
31 368 381 8776595 distinguished VBN I-VP O
32 382 386 8776595 from IN B-PP O
33 387 390 8776595 non AFX B-NP O
34 390 391 8776595 - HYPH I-NP O
35 391 399 8776595 specific JJ I-NP O
36 400 405 8776595 cross AFX I-NP O
37 405 406 8776595 - HYPH I-NP O
38 406 414 8776595 reacting VBG B-VP O
39 415 423 8776595 proteins NNS B-NP O
40 423 424 8776595 . . O O

1 425 428 8776595 All PDT B-NP O
2 429 432 8776595 the DT I-NP O
3 433 437 8776595 mAbs NNS I-NP O
4 438 448 8776595 recognised VBD B-VP O
5 449 450 8776595 a DT B-NP O
6 451 453 8776595 34 CD I-NP O
7 454 457 8776595 kDa NN I-NP O
8 458 465 8776595 protein NN I-NP O
9 466 468 8776595 in IN B-PP O
10 469 472 8776595 all DT B-NP O
11 473 480 8776595 tissues NNS I-NP O
12 481 487 8776595 tested VBN B-VP O
13 487 488 8776595 , , O O
14 489 495 8776595 though IN B-SBAR O
15 496 501 8776595 minor JJ B-NP O
16 502 508 8776595 emerin NN I-NP O
17 508 509 8776595 - HYPH B-NP O
18 509 516 8776595 related VBN I-NP O
19 517 522 8776595 bands NNS I-NP O
20 523 527 8776595 were VBD B-VP O
21 528 532 8776595 also RB I-VP O
22 533 541 8776595 detected VBN I-VP O
23 542 544 8776595 in IN B-PP O
24 545 549 8776595 some DT B-NP O
25 550 557 8776595 tissues NNS I-NP O
26 557 558 8776595 . . O O

1 559 577 8776595 Immunofluorescence NN B-NP O
2 578 588 8776595 microscopy NN I-NP O
3 589 595 8776595 showed VBD B-VP O
4 596 600 8776595 that IN B-SBAR O
5 601 607 8776595 emerin NN B-NP O
6 608 610 8776595 is VBZ B-VP O
7 611 618 8776595 located JJ B-ADJP O
8 619 621 8776595 at IN B-PP O
9 622 625 8776595 the DT B-NP O
10 626 633 8776595 nuclear JJ I-NP O
11 634 637 8776595 rim NN I-NP O
12 638 640 8776595 in IN B-PP O
13 641 644 8776595 all DT B-NP O
14 645 652 8776595 tissues NNS I-NP O
15 653 661 8776595 examined VBN B-VP O
16 661 662 8776595 . . O O

1 663 664 8776595 A DT B-NP O
2 665 671 8776595 muscle NN I-NP O
3 672 678 8776595 biopsy NN I-NP O
4 679 683 8776595 from IN B-PP O
5 684 686 8776595 an DT B-NP O
6 687 692 8776595 Emery NNP I-NP B-Disease
7 692 693 8776595 - HYPH I-NP I-Disease
8 693 701 8776595 Dreifuss NNP I-NP I-Disease
9 702 710 8776595 muscular JJ I-NP I-Disease
10 711 720 8776595 dystrophy NN I-NP I-Disease
11 721 722 8776595 ( ( O O
12 722 726 8776595 EMDM NN B-NP B-Disease
13 726 727 8776595 ) ) O O
14 728 735 8776595 patient NN B-NP O
15 736 742 8776595 showed VBD B-VP O
16 743 751 8776595 complete JJ B-NP O
17 752 759 8776595 absence NN I-NP O
18 760 762 8776595 of IN B-PP O
19 763 769 8776595 emerin NN B-NP O
20 770 772 8776595 by IN B-PP O
21 773 777 8776595 both CC O O
22 778 785 8776595 Western JJ B-NP O
23 786 794 8776595 blotting NN I-NP O
24 795 798 8776595 and CC O O
25 799 819 8776595 immunohistochemistry NN B-NP O
26 819 820 8776595 , , O O
27 821 831 8776595 suggesting VBG B-VP O
28 832 833 8776595 a DT B-NP O
29 834 840 8776595 simple JJ I-NP O
30 841 851 8776595 diagnostic JJ I-NP O
31 852 860 8776595 antibody NN I-NP O
32 861 865 8776595 test NN I-NP O
33 866 869 8776595 for IN B-PP O
34 870 874 8776595 EDMD NN B-NP B-Disease
35 875 883 8776595 families NNS I-NP O
36 883 884 8776595 . . O O

1 885 896 8776595 Biochemical JJ B-NP O
2 897 910 8776595 fractionation NN I-NP O
3 911 913 8776595 of IN B-PP O
4 914 919 8776595 brain NN B-NP O
5 920 923 8776595 and CC I-NP O
6 924 929 8776595 liver NN I-NP O
7 930 937 8776595 tissues NNS I-NP O
8 938 944 8776595 showed VBD B-VP O
9 945 949 8776595 that IN B-SBAR O
10 950 956 8776595 emerin NN B-NP O
11 957 960 8776595 was VBD B-VP O
12 961 968 8776595 present JJ B-ADJP O
13 969 971 8776595 in IN B-PP O
14 972 978 8776595 nuclei NNS B-NP O
15 979 987 8776595 purified VBN B-VP O
16 988 990 8776595 by IN B-PP O
17 991 1005 8776595 centrifugation NN B-NP O
18 1006 1013 8776595 through IN B-PP O
19 1014 1017 8776595 65% CD B-NP O
20 1018 1025 8776595 sucrose NN I-NP O
21 1026 1029 8776595 and CC O O
22 1030 1033 8776595 was VBD B-VP O
23 1034 1040 8776595 absent JJ B-ADJP O
24 1041 1045 8776595 from IN B-PP O
25 1046 1053 8776595 soluble JJ B-NP O
26 1054 1063 8776595 fractions NNS I-NP O
27 1064 1065 8776595 ( ( O O
28 1065 1069 8776595 post AFX B-NP O
29 1069 1070 8776595 - HYPH I-NP O
30 1070 1073 8776595 100 CD B-NP O
31 1073 1074 8776595 , , O O
32 1075 1078 8776595 000 CD B-NP O
33 1079 1080 8776595 g NN I-NP O
34 1080 1081 8776595 ) ) O O
35 1081 1082 8776595 . . O O

1 1083 1087 8776595 From IN B-PP O
2 1088 1093 8776595 these DT B-NP O
3 1094 1101 8776595 results NNS I-NP O
4 1101 1102 8776595 , , O O
5 1103 1111 8776595 together RB B-ADVP O
6 1112 1116 8776595 with IN B-PP O
7 1117 1125 8776595 sequence NN B-NP O
8 1126 1129 8776595 and CC O O
9 1130 1140 8776595 structural JJ B-NP O
10 1141 1151 8776595 homologies NNS I-NP O
11 1152 1159 8776595 between IN B-PP O
12 1160 1166 8776595 emerin NN B-NP O
13 1166 1167 8776595 , , O O
14 1168 1181 8776595 thymopoietins NNS B-NP O
15 1182 1185 8776595 and CC O O
16 1186 1189 8776595 the DT B-NP O
17 1190 1197 8776595 nuclear JJ I-NP O
18 1198 1204 8776595 lamina NN I-NP O
19 1204 1205 8776595 - HYPH O O
20 1205 1215 8776595 associated VBN B-NP O
21 1216 1223 8776595 protein NN I-NP O
22 1223 1224 8776595 , , O O
23 1225 1229 8776595 LAP2 NN B-NP O
24 1229 1230 8776595 , , O O
25 1231 1233 8776595 we PRP B-NP O
26 1234 1241 8776595 suggest VBP B-VP O
27 1242 1246 8776595 that IN B-SBAR O
28 1247 1253 8776595 emerin NN B-NP O
29 1254 1258 8776595 will MD B-VP O
30 1259 1264 8776595 prove VB I-VP O
31 1265 1267 8776595 to TO I-VP O
32 1268 1270 8776595 be VB I-VP O
33 1271 1274 8776595 one CD B-NP O
34 1275 1281 8776595 member NN I-NP O
35 1282 1284 8776595 of IN B-PP O
36 1285 1286 8776595 a DT B-NP O
37 1287 1293 8776595 family NN I-NP O
38 1294 1296 8776595 of IN B-PP O
39 1297 1302 8776595 inner JJ B-NP O
40 1303 1310 8776595 nuclear JJ I-NP O
41 1311 1319 8776595 membrane NN I-NP O
42 1320 1328 8776595 proteins NNS I-NP O
43 1328 1329 8776595 . . O O
44 1329 1330 8776595 . . O O

1 0 0 8689689 -DOCSTART- -X- -X- O

1 0 9 8689689 Influence NN B-NP O
2 10 12 8689689 of IN B-PP O
3 13 17 8689689 PAX6 NN B-NP O
4 18 22 8689689 gene NN I-NP O
5 23 29 8689689 dosage NN I-NP O
6 30 32 8689689 on IN B-PP O
7 33 44 8689689 development NN B-NP O
8 44 45 8689689 : : O O
9 46 60 8689689 overexpression NN B-NP O
10 61 67 8689689 causes VBZ B-VP O
11 68 74 8689689 severe JJ B-NP O
12 75 78 8689689 eye NN I-NP B-Disease
13 79 92 8689689 abnormalities NNS I-NP I-Disease
14 92 93 8689689 . . O O
15 94 102 8689689 Aniridia NNP B-NP B-Disease
16 103 105 8689689 in IN B-PP O
17 106 109 8689689 man NN B-NP O
18 110 113 8689689 and CC O O
19 114 119 8689689 Small JJ B-NP O
20 120 123 8689689 eye NN I-NP O
21 124 126 8689689 in IN B-PP O
22 127 131 8689689 mice NNS B-NP O
23 132 135 8689689 are VBP B-VP O
24 136 148 8689689 semidominant JJ B-NP B-Disease
25 149 162 8689689 developmental JJ I-NP I-Disease
26 163 172 8689689 disorders NNS I-NP I-Disease
27 173 179 8689689 caused VBN B-VP O
28 180 182 8689689 by IN B-PP O
29 183 192 8689689 mutations NNS B-NP O
30 193 199 8689689 within IN B-PP O
31 200 203 8689689 the DT B-NP O
32 204 210 8689689 paired JJ I-NP O
33 211 214 8689689 box NN I-NP O
34 215 219 8689689 gene NN I-NP O
35 220 224 8689689 PAX6 NN I-NP O
36 224 225 8689689 . . O O

1 226 233 8689689 Whereas IN B-SBAR O
2 234 247 8689689 heterozygotes NNS B-NP O
3 248 254 8689689 suffer VBP B-VP O
4 255 259 8689689 from IN B-PP O
5 260 264 8689689 iris NN B-NP B-Disease
6 265 275 8689689 hypoplasia NN I-NP I-Disease
7 275 276 8689689 , , O O
8 277 287 8689689 homozygous JJ B-NP O
9 288 292 8689689 mice NNS I-NP O
10 293 297 8689689 lack VBP B-VP O
11 298 302 8689689 eyes NNS B-NP O
12 303 306 8689689 and CC O O
13 307 312 8689689 nasal JJ B-NP O
14 313 321 8689689 cavities NNS I-NP O
15 322 325 8689689 and CC O O
16 326 333 8689689 exhibit VBP B-VP O
17 334 339 8689689 brain NN B-NP B-Disease
18 340 353 8689689 abnormalities NNS I-NP I-Disease
19 353 354 8689689 . . O O

1 355 357 8689689 To TO B-VP O
2 358 369 8689689 investigate VB I-VP O
3 370 373 8689689 the DT B-NP O
4 374 378 8689689 role NN I-NP O
5 379 381 8689689 of IN B-PP O
6 382 386 8689689 gene NN B-NP O
7 387 393 8689689 dosage NN I-NP O
8 394 396 8689689 in IN B-PP O
9 397 401 8689689 more JJR B-NP O
10 402 408 8689689 detail NN I-NP O
11 408 409 8689689 , , O O
12 410 412 8689689 we PRP B-NP O
13 413 417 8689689 have VBP B-VP O
14 418 427 8689689 generated VBN I-VP O
15 428 433 8689689 yeast NN B-NP O
16 434 444 8689689 artificial JJ I-NP O
17 445 455 8689689 chromosome NN I-NP O
18 456 466 8689689 transgenic JJ I-NP O
19 467 471 8689689 mice NNS I-NP O
20 472 480 8689689 carrying VBG B-VP O
21 481 484 8689689 the DT B-NP O
22 485 490 8689689 human JJ I-NP O
23 491 495 8689689 PAX6 NN I-NP O
24 496 501 8689689 locus NN I-NP O
25 501 502 8689689 . . O O

1 503 507 8689689 When WRB B-ADVP O
2 508 515 8689689 crossed VBN B-VP O
3 516 520 8689689 onto IN B-PP O
4 521 524 8689689 the DT B-NP O
5 525 530 8689689 Small JJ I-NP O
6 531 534 8689689 eye NN I-NP O
7 535 545 8689689 background NN I-NP O
8 545 546 8689689 , , O O
9 547 550 8689689 the DT B-NP O
10 551 560 8689689 transgene NN I-NP O
11 561 568 8689689 rescues VBZ B-VP O
12 569 572 8689689 the DT B-NP O
13 573 579 8689689 mutant JJ I-NP O
14 580 589 8689689 phenotype NN I-NP O
15 589 590 8689689 . . O O

1 591 601 8689689 Strikingly RB B-ADVP O
2 601 602 8689689 , , O O
3 603 607 8689689 mice NNS B-NP O
4 608 616 8689689 carrying VBG B-VP O
5 617 625 8689689 multiple JJ B-NP O
6 626 632 8689689 copies NNS I-NP O
7 633 635 8689689 on IN B-PP O
8 636 637 8689689 a DT B-NP O
9 638 642 8689689 wild JJ I-NP O
10 642 643 8689689 - HYPH I-NP O
11 643 647 8689689 type NN I-NP O
12 648 658 8689689 background NN I-NP O
13 659 663 8689689 show VBP B-VP O
14 664 672 8689689 specific JJ B-NP O
15 673 686 8689689 developmental JJ I-NP B-Disease
16 687 700 8689689 abnormalities NNS I-NP I-Disease
17 701 703 8689689 of IN B-PP I-Disease
18 704 707 8689689 the DT B-NP I-Disease
19 708 711 8689689 eye NN I-NP I-Disease
20 711 712 8689689 , , O O
21 713 716 8689689 but CC O O
22 717 720 8689689 not RB O O
23 721 723 8689689 of IN B-PP O
24 724 729 8689689 other JJ B-NP O
25 730 737 8689689 tissues NNS I-NP O
26 738 748 8689689 expressing VBG B-VP O
27 749 752 8689689 the DT B-NP O
28 753 757 8689689 gene NN I-NP O
29 757 758 8689689 . . O O

1 759 763 8689689 Thus RB B-ADVP O
2 763 764 8689689 , , O O
3 765 767 8689689 at IN B-NP O
4 768 773 8689689 least JJS I-NP O
5 774 778 8689689 five CD I-NP O
6 779 788 8689689 different JJ I-NP O
7 789 792 8689689 eye NN I-NP O
8 793 803 8689689 phenotypes NNS I-NP O
9 804 807 8689689 are VBP B-VP O
10 808 818 8689689 associated VBN I-VP O
11 819 823 8689689 with IN B-PP O
12 824 831 8689689 changes NNS B-NP O
13 832 834 8689689 in IN B-PP O
14 835 839 8689689 PAX6 NN B-NP O
15 840 850 8689689 expression NN I-NP O
16 850 851 8689689 . . O O

1 852 854 8689689 We PRP B-NP O
2 855 862 8689689 provide VBP B-VP O
3 863 871 8689689 evidence NN B-NP O
4 872 876 8689689 that IN B-SBAR O
5 877 880 8689689 not RB B-CONJP O
6 881 885 8689689 only RB I-CONJP O
7 886 893 8689689 reduced VBN B-VP O
8 893 894 8689689 , , O O
9 895 898 8689689 but CC B-CONJP O
10 899 903 8689689 also RB I-CONJP O
11 904 913 8689689 increased VBN B-NP O
12 914 920 8689689 levels NNS I-NP O
13 921 923 8689689 of IN B-PP O
14 924 939 8689689 transcriptional JJ B-NP O
15 940 950 8689689 regulators NNS I-NP O
16 951 954 8689689 can MD B-VP O
17 955 960 8689689 cause VB I-VP O
18 961 974 8689689 developmental JJ B-NP B-Disease
19 975 982 8689689 defects NNS I-NP I-Disease
20 982 983 8689689 . . O O
21 983 984 8689689 . . O O

1 0 0 9090524 -DOCSTART- -X- -X- O

1 0 1 9090524 A DT B-NP O
2 2 10 9090524 clinical JJ I-NP O
3 11 19 9090524 overview NN I-NP O
4 20 22 9090524 of IN B-PP O
5 23 26 9090524 WT1 NN B-NP O
6 27 31 9090524 gene NN I-NP O
7 32 41 9090524 mutations NNS I-NP O
8 41 42 9090524 . . O O
9 43 52 9090524 Mutations NNS B-NP O
10 53 55 9090524 in IN B-PP O
11 56 59 9090524 the DT B-NP O
12 60 63 9090524 WT1 NN I-NP O
13 64 68 9090524 gene NN I-NP O
14 69 73 9090524 were VBD B-VP O
15 74 85 9090524 anticipated VBN I-VP O
16 86 88 9090524 to TO B-VP O
17 89 96 9090524 explain VB I-VP O
18 97 100 9090524 the DT B-NP O
19 101 108 9090524 genetic JJ I-NP O
20 109 114 9090524 basis NN I-NP O
21 115 117 9090524 of IN B-PP O
22 118 121 9090524 the DT B-NP O
23 122 131 9090524 childhood NN I-NP O
24 132 138 9090524 kidney NN I-NP B-Disease
25 139 145 9090524 cancer NN I-NP I-Disease
26 145 146 9090524 , , O O
27 147 152 9090524 Wilms NNP B-NP B-Disease
28 153 159 9090524 tumour NN I-NP I-Disease
29 160 161 9090524 ( ( O O
30 161 163 9090524 WT NN B-NP B-Disease
31 163 164 9090524 ) ) O O
32 164 165 9090524 . . O O

1 166 169 9090524 Six CD B-NP O
2 170 175 9090524 years NNS I-NP O
3 176 178 9090524 on IN B-ADVP O
4 178 179 9090524 , , O O
5 180 182 9090524 we PRP B-NP O
6 183 189 9090524 review VBP B-VP O
7 190 193 9090524 100 CD B-NP O
8 194 201 9090524 reports NNS I-NP O
9 202 204 9090524 of IN B-PP O
10 205 215 9090524 intragenic JJ B-NP O
11 216 219 9090524 WT1 NN I-NP O
12 220 229 9090524 mutations NNS I-NP O
13 230 233 9090524 and CC O O
14 234 241 9090524 examine VB B-VP O
15 242 245 9090524 the DT B-NP O
16 246 258 9090524 accompanying VBG I-NP O
17 259 267 9090524 clinical JJ I-NP O
18 268 278 9090524 phenotypes NNS I-NP O
19 278 279 9090524 . . O O

1 280 285 9090524 While IN B-SBAR O
2 286 290 9090524 only RB B-NP O
3 291 293 9090524 5% CD I-NP O
4 294 296 9090524 of IN B-PP O
5 297 305 9090524 sporadic JJ B-NP B-Disease
6 306 311 9090524 Wilms NNP I-NP I-Disease
7 312 319 9090524 tumours NNS I-NP I-Disease
8 320 324 9090524 have VBP B-VP O
9 325 335 9090524 intragenic JJ B-NP O
10 336 339 9090524 WT1 NN I-NP O
11 340 349 9090524 mutations NNS I-NP O
12 349 350 9090524 , , O O
13 351 352 9090524 > SYM B-NP O
14 353 356 9090524 90% CD B-NP O
15 357 359 9090524 of IN B-PP O
16 360 368 9090524 patients NNS B-NP O
17 369 373 9090524 with IN B-PP O
18 374 377 9090524 the DT B-NP O
19 378 383 9090524 Denys NNPS I-NP B-Disease
20 383 384 9090524 - HYPH I-NP I-Disease
21 384 389 9090524 Drash NN I-NP I-Disease
22 390 398 9090524 syndrome NN I-NP I-Disease
23 399 400 9090524 ( ( O O
24 400 405 9090524 renal JJ B-NP B-Disease
25 406 417 9090524 nephropathy NN I-NP I-Disease
26 417 418 9090524 , , O O
27 419 426 9090524 gonadal JJ B-ADJP B-Disease
28 427 434 9090524 anomaly RB B-ADVP I-Disease
29 434 435 9090524 , , O O
30 436 450 9090524 predisposition NN B-NP B-Disease
31 451 453 9090524 to TO B-PP I-Disease
32 454 456 9090524 WT NN B-NP I-Disease
33 456 457 9090524 ) ) O O
34 458 463 9090524 carry VBP B-VP O
35 464 478 9090524 constitutional JJ B-NP O
36 479 489 9090524 intragenic JJ I-NP O
37 490 493 9090524 WT1 NN I-NP O
38 494 503 9090524 mutations NNS I-NP O
39 503 504 9090524 . . O O

1 505 508 9090524 WT1 NN B-NP O
2 509 518 9090524 mutations NNS I-NP O
3 519 523 9090524 have VBP B-VP O
4 524 528 9090524 also RB I-VP O
5 529 533 9090524 been VBN I-VP O
6 534 542 9090524 reported VBN I-VP O
7 543 545 9090524 in IN B-PP O
8 546 554 9090524 juvenile JJ B-NP B-Disease
9 555 564 9090524 granulosa NN I-NP I-Disease
10 565 569 9090524 cell NN I-NP I-Disease
11 570 576 9090524 tumour NN I-NP I-Disease
12 576 577 9090524 , , O O
13 578 581 9090524 non AFX B-NP B-Disease
14 581 582 9090524 - HYPH I-NP I-Disease
15 582 590 9090524 asbestos NN I-NP I-Disease
16 591 598 9090524 related VBN I-NP I-Disease
17 599 611 9090524 mesothelioma NN I-NP I-Disease
18 611 612 9090524 , , O O
19 613 625 9090524 desmoplastic JJ B-NP B-Disease
20 626 631 9090524 small JJ I-NP I-Disease
21 632 637 9090524 round JJ I-NP I-Disease
22 638 642 9090524 cell NN I-NP I-Disease
23 643 649 9090524 tumour NN I-NP I-Disease
24 650 653 9090524 and CC O O
25 653 654 9090524 , , O O
26 655 659 9090524 most RBS B-ADVP O
27 660 668 9090524 recently RB I-ADVP O
28 668 669 9090524 , , O O
29 670 675 9090524 acute JJ B-NP B-Disease
30 676 683 9090524 myeloid JJ I-NP I-Disease
31 684 692 9090524 leukemia NN I-NP I-Disease
32 692 693 9090524 . . O O
33 693 694 9090524 . . O O

1 0 0 8825052 -DOCSTART- -X- -X- O

1 0 4 8825052 FISH NN B-NP O
2 5 12 8825052 studies NNS I-NP O
3 13 15 8825052 in IN B-PP O
4 16 17 8825052 a DT B-NP O
5 18 25 8825052 patient NN I-NP O
6 26 30 8825052 with IN B-PP O
7 31 39 8825052 sporadic JJ B-NP B-Disease
8 40 48 8825052 aniridia NN I-NP I-Disease
9 49 52 8825052 and CC O O
10 53 60 8825052 t(7;11) NN B-NP O
11 61 62 8825052 ( ( O O
12 62 71 8825052 q31.2;p13 NN B-NP O
13 71 72 8825052 ) ) O O
14 72 73 8825052 . . O O
15 74 75 8825052 A DT B-NP O
16 76 77 8825052 2 CD I-NP O
17 78 82 8825052 year NN I-NP O
18 83 86 8825052 old JJ I-NP O
19 87 93 8825052 female NN I-NP O
20 94 104 8825052 presenting VBG B-VP O
21 105 109 8825052 with IN B-PP O
22 110 119 8825052 bilateral JJ B-NP B-Disease
23 120 128 8825052 sporadic JJ I-NP I-Disease
24 129 137 8825052 aniridia NN I-NP I-Disease
25 138 141 8825052 was VBD B-VP O
26 142 147 8825052 found VBN I-VP O
27 148 150 8825052 to TO I-VP O
28 151 155 8825052 have VB I-VP O
29 156 158 8825052 an DT B-NP O
30 159 169 8825052 apparently RB I-NP O
31 170 178 8825052 balanced JJ I-NP O
32 179 189 8825052 reciprocal JJ I-NP O
33 190 203 8825052 translocation NN I-NP O
34 204 208 8825052 with IN B-PP O
35 209 210 8825052 a DT B-NP O
36 211 221 8825052 chromosome NN I-NP O
37 222 224 8825052 11 CD I-NP O
38 225 235 8825052 breakpoint NN I-NP O
39 236 242 8825052 within IN B-PP O
40 243 247 8825052 band NN B-NP O
41 248 251 8825052 p13 NN I-NP O
42 251 252 8825052 . . O O

1 253 265 8825052 Fluorescence NN B-NP O
2 266 268 8825052 in FW B-NP O
3 269 273 8825052 situ FW I-NP O
4 274 287 8825052 hybridisation NN I-NP O
5 288 289 8825052 ( ( O O
6 289 293 8825052 FISH NN B-NP O
7 293 294 8825052 ) ) O O
8 295 302 8825052 studies NNS B-NP O
9 303 307 8825052 with IN B-PP O
10 308 314 8825052 distal JJ B-NP O
11 315 320 8825052 11p13 NN I-NP O
12 321 329 8825052 specific JJ I-NP O
13 330 337 8825052 cosmids NNS I-NP O
14 338 344 8825052 showed VBD B-VP O
15 345 349 8825052 that IN B-SBAR O
16 350 353 8825052 the DT B-NP O
17 354 364 8825052 chromosome NN I-NP O
18 365 367 8825052 11 CD I-NP O
19 368 378 8825052 breakpoint NN I-NP O
20 379 382 8825052 lay NN I-NP O
21 383 390 8825052 between IN B-PP O
22 391 394 8825052 the DT B-NP O
23 395 403 8825052 aniridia NN I-NP B-Disease
24 404 405 8825052 ( ( O O
25 405 409 8825052 PAX6 NN B-NP O
26 409 410 8825052 ) ) O O
27 411 416 8825052 locus NN B-NP O
28 417 420 8825052 and CC O O
29 421 422 8825052 a DT B-NP O
30 423 429 8825052 region NN I-NP O
31 430 443 8825052 approximately RB B-NP O
32 444 447 8825052 100 CD I-NP O
33 448 450 8825052 kb NN I-NP O
34 451 457 8825052 distal JJ B-ADJP O
35 458 460 8825052 to TO B-PP O
36 461 465 8825052 PAX6 NN B-NP O
37 466 473 8825052 defined VBN B-VP O
38 474 476 8825052 by IN B-PP O
39 477 480 8825052 the DT B-NP O
40 481 487 8825052 cosmid NN I-NP O
41 488 494 8825052 FO2121 NN I-NP O
42 494 495 8825052 . . O O

1 496 504 8825052 Although IN B-SBAR O
2 505 509 8825052 this DT B-NP O
3 510 517 8825052 patient NN I-NP O
4 518 521 8825052 did VBD B-VP O
5 522 525 8825052 not RB I-VP O
6 526 530 8825052 have VB I-VP O
7 531 532 8825052 a DT B-NP O
8 533 543 8825052 detectable JJ I-NP O
9 544 552 8825052 deletion NN I-NP O
10 553 559 8825052 within IN B-PP O
11 560 564 8825052 PAX6 NN B-NP O
12 564 565 8825052 , , O O
13 566 569 8825052 her PRP$ B-NP O
14 570 578 8825052 aniridia NN I-NP B-Disease
15 579 582 8825052 may MD B-VP O
16 583 587 8825052 have VB I-VP O
17 588 596 8825052 resulted VBN I-VP O
18 597 601 8825052 from IN B-PP O
19 602 603 8825052 a DT B-NP O
20 604 614 8825052 disruption NN I-NP O
21 615 617 8825052 of IN B-PP O
22 618 621 8825052 the DT B-NP O
23 622 628 8825052 distal JJ I-NP O
24 629 638 8825052 chromatin NN I-NP O
25 639 645 8825052 domain NN I-NP O
26 646 656 8825052 containing VBG B-VP O
27 657 663 8825052 either CC O O
28 664 673 8825052 enhancers NNS B-NP O
29 674 676 8825052 or CC O O
30 677 687 8825052 regulators NNS B-NP O
31 688 691 8825052 for IN B-PP O
32 692 696 8825052 PAX6 NN B-NP O
33 696 697 8825052 . . O O

1 698 702 8825052 This DT B-NP O
2 703 707 8825052 case NN I-NP O
3 708 711 8825052 may MD B-VP O
4 712 721 8825052 therefore RB I-VP O
5 722 724 8825052 be VB I-VP O
6 725 732 8825052 another DT B-NP O
7 733 740 8825052 example NN I-NP O
8 741 743 8825052 of IN B-PP O
9 744 752 8825052 aniridia NN B-NP B-Disease
10 753 759 8825052 caused VBN B-VP O
11 760 762 8825052 by IN B-PP O
12 763 764 8825052 a DT B-NP O
13 765 773 8825052 position NN I-NP O
14 774 780 8825052 effect NN I-NP O
15 781 783 8825052 as IN B-PP O
16 784 792 8825052 recently RB B-ADVP O
17 793 802 8825052 described VBN B-VP O
18 803 805 8825052 in IN B-PP O
19 806 809 8825052 two CD B-NP O
20 810 818 8825052 familial JJ I-NP B-Disease
21 819 827 8825052 aniridia NN I-NP I-Disease
22 828 836 8825052 patients NNS I-NP O
23 837 839 8825052 in IN B-PP O
24 840 845 8825052 which WDT B-NP O
25 846 849 8825052 the DT B-NP O
26 850 859 8825052 phenotype NN I-NP O
27 860 872 8825052 cosegregated VBN B-VP O
28 873 877 8825052 with IN B-PP O
29 878 888 8825052 chromosome NN B-NP B-Disease
30 889 902 8825052 abnormalities NNS I-NP I-Disease
31 903 907 8825052 with IN B-PP O
32 908 913 8825052 11p13 NN B-NP O
33 914 925 8825052 breakpoints NNS I-NP O
34 925 926 8825052 . . O O
35 926 927 8825052 . . O O

1 0 0 9144525 -DOCSTART- -X- -X- O

1 0 3 9144525 The DT B-NP O
2 4 9 9144525 human JJ I-NP O
3 10 20 9144525 complement NN I-NP O
4 21 23 9144525 C9 NN I-NP O
5 24 28 9144525 gene NN I-NP O
6 28 29 9144525 : : O O
7 30 44 9144525 identification NN B-NP O
8 45 47 9144525 of IN B-PP O
9 48 51 9144525 two CD B-NP O
10 52 61 9144525 mutations NNS I-NP O
11 62 69 9144525 causing VBG B-VP O
12 70 80 9144525 deficiency NN B-NP O
13 81 84 9144525 and CC I-NP O
14 85 93 9144525 revision NN I-NP O
15 94 96 9144525 of IN B-PP O
16 97 100 9144525 the DT B-NP O
17 101 105 9144525 gene NN I-NP O
18 106 115 9144525 structure NN I-NP O
19 115 116 9144525 . . O O
20 117 120 9144525 The DT B-NP O
21 121 126 9144525 ninth JJ I-NP O
22 127 136 9144525 component NN I-NP O
23 137 139 9144525 of IN B-PP O
24 140 145 9144525 human JJ B-NP O
25 146 156 9144525 complement NN I-NP O
26 157 158 9144525 ( ( O O
27 158 160 9144525 C9 NN B-NP O
28 160 161 9144525 ) ) O O
29 162 164 9144525 is VBZ B-VP O
30 165 168 9144525 the DT B-NP O
31 169 173 9144525 last JJ I-NP O
32 174 176 9144525 of IN B-PP O
33 177 180 9144525 the DT B-NP O
34 181 189 9144525 terminal JJ I-NP O
35 190 200 9144525 complement NN I-NP O
36 201 211 9144525 components NNS I-NP O
37 212 220 9144525 creating VBG B-VP O
38 221 224 9144525 the DT B-NP O
39 225 233 9144525 membrane NN I-NP O
40 234 240 9144525 attack NN I-NP O
41 241 248 9144525 complex NN I-NP O
42 248 249 9144525 . . O O

1 250 252 9144525 C9 NN B-NP O
2 253 255 9144525 is VBZ B-VP O
3 256 257 9144525 a DT B-NP O
4 258 264 9144525 single JJ I-NP O
5 264 265 9144525 - HYPH I-NP O
6 265 270 9144525 chain NN I-NP O
7 271 276 9144525 serum NN I-NP O
8 277 284 9144525 protein NN I-NP O
9 285 289 9144525 that WDT B-NP O
10 290 292 9144525 is VBZ B-VP O
11 293 300 9144525 encoded VBN I-VP O
12 301 303 9144525 by IN B-PP O
13 304 305 9144525 a DT B-NP O
14 306 310 9144525 gene NN I-NP O
15 311 318 9144525 located VBN B-VP O
16 319 321 9144525 on IN B-PP O
17 322 332 9144525 chromosome NN B-NP O
18 333 335 9144525 5p NN I-NP O
19 335 336 9144525 . . O O

1 337 347 9144525 Deficiency NN B-NP B-Disease
2 348 350 9144525 of IN B-PP I-Disease
3 351 359 9144525 terminal JJ B-NP I-Disease
4 360 370 9144525 complement NN I-NP I-Disease
5 371 381 9144525 components NNS I-NP I-Disease
6 382 384 9144525 is VBZ B-VP O
7 385 394 9144525 generally RB I-VP O
8 395 405 9144525 associated VBN I-VP O
9 406 410 9144525 with IN B-PP O
10 411 420 9144525 recurrent JJ B-NP O
11 421 430 9144525 neisseria NN I-NP B-Disease
12 431 441 9144525 infections NNS I-NP I-Disease
13 441 442 9144525 . . O O

1 443 445 9144525 We PRP B-NP O
2 446 453 9144525 studied VBD B-VP O
3 454 455 9144525 a DT B-NP O
4 456 466 9144525 previously RB I-NP O
5 467 476 9144525 described VBN I-NP O
6 477 482 9144525 Swiss JJ I-NP O
7 483 489 9144525 family NN I-NP O
8 490 494 9144525 with IN B-PP O
9 495 504 9144525 inherited VBN B-NP B-Disease
10 505 507 9144525 C9 NN I-NP I-Disease
11 508 518 9144525 deficiency NN I-NP I-Disease
12 518 519 9144525 . . O O

1 520 522 9144525 To TO B-VP O
2 523 531 9144525 identify VB I-VP O
3 532 535 9144525 the DT B-NP O
4 536 543 9144525 genetic JJ I-NP O
5 544 549 9144525 basis NN I-NP O
6 550 552 9144525 of IN B-PP O
7 553 555 9144525 C9 NN B-NP B-Disease
8 556 566 9144525 deficiency NN I-NP I-Disease
9 566 567 9144525 , , O O
10 568 570 9144525 we PRP B-NP O
11 571 580 9144525 developed VBD B-VP O
12 581 583 9144525 an DT B-NP O
13 584 592 9144525 approach NN I-NP O
14 593 598 9144525 using VBG B-VP O
15 599 603 9144525 exon NN B-NP O
16 603 604 9144525 - HYPH B-NP O
17 604 612 9144525 specific JJ I-NP O
18 613 616 9144525 PCR NN I-NP O
19 617 620 9144525 and CC O O
20 621 627 9144525 direct JJ B-NP O
21 628 631 9144525 DNA NN I-NP O
22 632 642 9144525 sequencing NN I-NP O
23 642 643 9144525 . . O O

1 644 646 9144525 As IN B-PP O
2 647 648 9144525 a DT B-NP O
3 649 654 9144525 cause NN I-NP O
4 655 657 9144525 of IN B-PP O
5 658 660 9144525 C9 NN B-NP B-Disease
6 661 671 9144525 deficiency NN I-NP I-Disease
7 672 673 9144525 , , O O
8 674 676 9144525 we PRP B-NP O
9 677 682 9144525 found VBD B-VP O
10 683 686 9144525 two CD B-NP O
11 687 696 9144525 different JJ I-NP O
12 697 702 9144525 point NN I-NP O
13 703 712 9144525 mutations NNS I-NP O
14 712 713 9144525 , , O O
15 714 718 9144525 both DT B-NP O
16 719 729 9144525 generating VBG I-NP O
17 730 733 9144525 TGA NN I-NP O
18 734 738 9144525 stop NN I-NP O
19 739 745 9144525 codons NNS I-NP O
20 746 748 9144525 in IN B-PP O
21 749 752 9144525 the DT B-NP O
22 753 759 9144525 coding VBG I-NP O
23 760 768 9144525 sequence NN I-NP O
24 768 769 9144525 . . O O

1 770 773 9144525 One CD B-NP O
2 774 782 9144525 mutation NN I-NP O
3 782 783 9144525 , , O O
4 784 785 9144525 a DT B-NP O
5 786 787 9144525 C NN I-NP O
6 788 790 9144525 to TO B-PP O
7 791 792 9144525 A NN B-NP O
8 793 801 9144525 exchange NN I-NP O
9 801 802 9144525 , , O O
10 803 806 9144525 was VBD B-VP O
11 807 815 9144525 detected VBN I-VP O
12 816 818 9144525 in IN B-PP O
13 819 823 9144525 exon NN B-NP O
14 824 825 9144525 2 CD I-NP O
15 826 828 9144525 at IN B-PP O
16 829 833 9144525 cDNA NN B-NP O
17 834 842 9144525 position NN I-NP O
18 843 846 9144525 166 CD I-NP O
19 846 847 9144525 , , O O
20 848 851 9144525 the DT B-NP O
21 852 857 9144525 other JJ I-NP O
22 857 858 9144525 , , O O
23 859 860 9144525 a DT B-NP O
24 861 862 9144525 C NN I-NP O
25 863 865 9144525 to TO B-PP O
26 866 867 9144525 T NN B-NP O
27 868 876 9144525 exchange NN I-NP O
28 876 877 9144525 , , O O
29 878 881 9144525 was VBD B-VP O
30 882 889 9144525 located VBN I-VP O
31 890 892 9144525 in IN B-PP O
32 893 897 9144525 exon NN B-NP O
33 898 899 9144525 4 CD I-NP O
34 900 901 9144525 ( ( O O
35 901 905 9144525 cDNA NN B-NP O
36 906 914 9144525 position NN I-NP O
37 915 918 9144525 464 CD I-NP O
38 918 919 9144525 ) ) O O
39 919 920 9144525 . . O O

1 921 923 9144525 In IN B-PP O
2 924 930 9144525 family NN B-NP O
3 931 938 9144525 studies NNS I-NP O
4 939 941 9144525 of IN B-PP O
5 942 947 9144525 three CD B-NP O
6 948 953 9144525 first JJ I-NP O
7 953 954 9144525 - HYPH I-NP O
8 954 960 9144525 degree NN I-NP O
9 961 970 9144525 relatives NNS I-NP O
10 971 975 9144525 with IN B-PP O
11 976 988 9144525 heterozygous JJ B-NP O
12 989 991 9144525 C9 NN I-NP B-Disease
13 992 1002 9144525 deficiency NN I-NP I-Disease
14 1002 1003 9144525 , , O O
15 1004 1006 9144525 we PRP B-NP O
16 1007 1019 9144525 demonstrated VBD B-VP O
17 1020 1024 9144525 that IN B-SBAR O
18 1025 1028 9144525 the DT B-NP O
19 1029 1032 9144525 two CD I-NP O
20 1033 1042 9144525 mutations NNS I-NP O
21 1043 1046 9144525 are VBP B-VP O
22 1047 1058 9144525 segregating VBG I-VP O
23 1059 1072 9144525 independently RB B-ADVP O
24 1072 1073 9144525 . . O O

1 1074 1083 9144525 Therefore RB B-ADVP O
2 1083 1084 9144525 , , O O
3 1085 1090 9144525 these DT B-NP O
4 1091 1100 9144525 mutations NNS I-NP O
5 1101 1104 9144525 are VBP B-VP O
6 1105 1115 9144525 sufficient JJ B-ADJP O
7 1116 1118 9144525 to TO B-VP O
8 1119 1126 9144525 explain VB I-VP O
9 1127 1130 9144525 the DT B-NP O
10 1131 1139 9144525 complete JJ I-NP O
11 1140 1150 9144525 deficiency NN I-NP O
12 1151 1153 9144525 of IN B-PP O
13 1154 1158 9144525 both PDT O O
14 1159 1162 9144525 the DT B-NP O
15 1163 1171 9144525 probands NNS I-NP O
16 1172 1179 9144525 studied VBN B-VP O
17 1179 1180 9144525 . . O O

1 1181 1184 9144525 DNA NN B-NP O
2 1185 1195 9144525 sequencing NN I-NP O
3 1196 1198 9144525 of IN B-PP O
4 1199 1202 9144525 the DT B-NP O
5 1203 1207 9144525 exon NN I-NP O
6 1207 1208 9144525 - HYPH B-NP O
7 1208 1214 9144525 intron NN I-NP O
8 1215 1224 9144525 junctions NNS I-NP O
9 1225 1233 9144525 revealed VBD B-VP O
10 1234 1235 9144525 a DT B-NP O
11 1236 1242 9144525 number NN I-NP O
12 1243 1245 9144525 of IN B-PP O
13 1246 1255 9144525 revisions NNS B-NP O
14 1256 1265 9144525 regarding VBG B-VP O
15 1266 1269 9144525 the DT B-NP O
16 1270 1280 9144525 boundaries NNS I-NP O
17 1281 1288 9144525 between IN B-PP O
18 1289 1294 9144525 exons NNS B-NP O
19 1295 1296 9144525 4 CD I-NP O
20 1296 1297 9144525 , , I-NP O
21 1298 1299 9144525 5 CD I-NP O
22 1299 1300 9144525 , , O O
23 1301 1304 9144525 and CC O O
24 1305 1306 9144525 6 CD B-NP O
25 1307 1309 9144525 as RB B-CONJP O
26 1310 1314 9144525 well RB I-CONJP O
27 1315 1317 9144525 as IN I-CONJP O
28 1318 1325 9144525 between IN B-PP O
29 1326 1331 9144525 exons NNS B-NP O
30 1332 1334 9144525 10 CD B-NP O
31 1335 1338 9144525 and CC I-NP O
32 1339 1341 9144525 11 CD I-NP O
33 1341 1342 9144525 . . O O

1 1343 1345 9144525 No DT B-NP O
2 1346 1356 9144525 additional JJ I-NP O
3 1357 1364 9144525 introns NNS I-NP O
4 1365 1369 9144525 were VBD B-VP O
5 1370 1378 9144525 detected VBN I-VP O
6 1379 1381 9144525 in IN B-PP O
7 1382 1387 9144525 exons NNS B-NP O
8 1388 1389 9144525 6 CD B-NP O
9 1390 1393 9144525 and CC I-NP O
10 1394 1396 9144525 10 CD I-NP O
11 1396 1397 9144525 . . O O

1 1398 1409 9144525 Furthermore RB B-ADVP O
2 1409 1410 9144525 , , O O
3 1411 1414 9144525 DNA NN B-NP O
4 1415 1421 9144525 marker NN I-NP O
5 1422 1429 9144525 studies NNS I-NP O
6 1430 1434 9144525 were VBD B-VP O
7 1435 1444 9144525 conducted VBN I-VP O
8 1445 1450 9144525 using VBG B-VP O
9 1451 1456 9144525 known JJ B-NP O
10 1457 1470 9144525 polymorphisms NNS I-NP O
11 1471 1473 9144525 of IN B-PP O
12 1474 1477 9144525 the DT B-NP O
13 1478 1480 9144525 C6 NN I-NP O
14 1480 1481 9144525 , , O O
15 1482 1484 9144525 C7 NN B-NP O
16 1484 1485 9144525 , , O O
17 1486 1489 9144525 and CC O O
18 1490 1492 9144525 C9 NN B-NP O
19 1493 1498 9144525 genes NNS I-NP O
20 1498 1499 9144525 , , O O
21 1500 1510 9144525 confirming VBG B-VP O
22 1511 1514 9144525 the DT B-NP O
23 1515 1522 9144525 linkage NN I-NP O
24 1523 1525 9144525 of IN B-PP O
25 1526 1529 9144525 the DT B-NP O
26 1530 1538 9144525 observed VBN I-NP O
27 1539 1541 9144525 C9 NN I-NP O
28 1542 1551 9144525 mutations NNS I-NP O
29 1552 1556 9144525 with IN B-PP O
30 1557 1564 9144525 defined VBN B-NP O
31 1565 1575 9144525 haplotypes NNS I-NP O
32 1575 1576 9144525 . . O O
33 1576 1577 9144525 . . O O

1 0 0 8828602 -DOCSTART- -X- -X- O

1 0 4 8828602 Gene NN B-NP O
2 5 12 8828602 therapy NN I-NP O
3 13 16 8828602 for IN B-PP O
4 17 32 8828602 phenylketonuria NN B-NP B-Disease
5 32 33 8828602 . . O O
6 34 43 8828602 Classical JJ B-NP O
7 44 59 8828602 phenylketonuria NN I-NP B-Disease
8 60 61 8828602 ( ( O O
9 61 64 8828602 PKU NN B-NP B-Disease
10 64 65 8828602 ) ) O O
11 66 68 8828602 is VBZ B-VP O
12 69 71 8828602 an DT B-NP O
13 72 81 8828602 autosomal JJ I-NP B-Disease
14 82 91 8828602 recessive JJ I-NP I-Disease
15 92 100 8828602 disorder NN I-NP I-Disease
16 101 107 8828602 caused VBN B-VP O
17 108 110 8828602 by IN B-PP O
18 111 112 8828602 a DT B-NP O
19 113 123 8828602 deficiency NN I-NP B-Disease
20 124 126 8828602 of IN B-PP I-Disease
21 127 134 8828602 hepatic JJ B-NP I-Disease
22 135 148 8828602 phenylalanine NN I-NP I-Disease
23 149 160 8828602 hydroxylase NN I-NP I-Disease
24 161 162 8828602 ( ( O O
25 162 165 8828602 PAH NN B-NP O
26 165 166 8828602 ) ) O O
27 166 167 8828602 . . O O

1 168 179 8828602 Limitations NNS B-NP O
2 180 182 8828602 of IN B-PP O
3 183 186 8828602 the DT B-NP O
4 187 194 8828602 current JJ I-NP O
5 195 202 8828602 dietary JJ I-NP O
6 203 212 8828602 treatment NN I-NP O
7 213 216 8828602 for IN B-PP O
8 217 220 8828602 PKU NN B-NP B-Disease
9 221 225 8828602 have VBP B-VP O
10 226 229 8828602 led VBN I-VP O
11 230 232 8828602 to TO B-PP O
12 233 236 8828602 the DT B-NP O
13 237 248 8828602 development NN I-NP O
14 249 251 8828602 of IN B-PP O
15 252 261 8828602 potential JJ B-NP O
16 262 272 8828602 treatments NNS I-NP O
17 273 278 8828602 based VBN B-VP O
18 279 281 8828602 on IN B-PP O
19 282 289 8828602 somatic JJ B-NP O
20 290 294 8828602 gene NN I-NP O
21 295 303 8828602 transfer NN I-NP O
22 303 304 8828602 . . O O

1 305 310 8828602 Three CD B-NP O
2 311 320 8828602 different JJ I-NP O
3 321 327 8828602 vector NN I-NP O
4 328 335 8828602 systems NNS I-NP O
5 336 340 8828602 have VBP B-VP O
6 341 345 8828602 been VBN I-VP O
7 346 354 8828602 examined VBN I-VP O
8 354 355 8828602 . . O O

1 356 363 8828602 Vectors NNS B-NP O
2 364 371 8828602 derived VBN B-VP O
3 372 376 8828602 from IN B-PP O
4 377 378 8828602 a DT B-NP O
5 379 390 8828602 recombinant JJ I-NP O
6 391 401 8828602 retrovirus NN I-NP O
7 402 404 8828602 or CC O O
8 405 406 8828602 a DT B-NP O
9 407 410 8828602 DNA NN I-NP O
10 410 411 8828602 / SYM B-NP O
11 411 418 8828602 protein NN I-NP O
12 419 426 8828602 complex NN I-NP O
13 427 430 8828602 can MD B-VP O
14 431 442 8828602 efficiently RB I-VP O
15 443 452 8828602 transduce VB I-VP O
16 453 456 8828602 the DT B-NP O
17 457 460 8828602 PAH NN I-NP O
18 461 465 8828602 cDNA NN I-NP O
19 466 470 8828602 into IN B-PP O
20 471 474 8828602 PAH NN B-NP B-Disease
21 474 475 8828602 - HYPH B-NP I-Disease
22 475 484 8828602 deficient JJ I-NP I-Disease
23 485 496 8828602 hepatocytes NNS I-NP O
24 497 499 8828602 in FW B-ADVP O
25 500 505 8828602 vitro FW I-ADVP O
26 505 506 8828602 , , O O
27 507 510 8828602 but CC O O
28 511 514 8828602 the DT B-NP O
29 515 526 8828602 application NN I-NP O
30 527 529 8828602 of IN B-PP O
31 530 535 8828602 these DT B-NP O
32 536 542 8828602 vector NN I-NP O
33 543 550 8828602 systems NNS I-NP O
34 551 553 8828602 is VBZ B-VP O
35 554 563 8828602 presently RB I-VP O
36 564 571 8828602 limited VBN I-VP O
37 572 574 8828602 by IN B-PP O
38 575 580 8828602 their PRP$ B-NP O
39 581 584 8828602 low JJ I-NP O
40 585 597 8828602 transduction NN I-NP O
41 598 608 8828602 efficiency NN I-NP O
42 609 611 8828602 in FW B-ADVP O
43 612 616 8828602 vivo FW I-ADVP O
44 616 617 8828602 . . O O

1 618 620 8828602 In IN B-PP O
2 621 629 8828602 contrast NN B-NP O
3 629 630 8828602 , , O O
4 631 632 8828602 a DT B-NP O
5 633 639 8828602 vector NN I-NP O
6 640 647 8828602 derived VBN B-VP O
7 648 652 8828602 from IN B-PP O
8 653 654 8828602 a DT B-NP O
9 655 666 8828602 recombinant JJ I-NP O
10 667 677 8828602 adenovirus NN I-NP O
11 678 681 8828602 can MD B-VP O
12 682 689 8828602 restore VB I-VP O
13 690 693 8828602 10% CD B-NP O
14 694 695 8828602 - HYPH I-NP O
15 695 698 8828602 80% CD I-NP O
16 699 701 8828602 of IN B-PP O
17 702 708 8828602 normal JJ B-NP O
18 709 716 8828602 hepatic JJ I-NP O
19 717 720 8828602 PAH NN I-NP O
20 721 729 8828602 activity NN I-NP O
21 730 734 8828602 into IN B-PP O
22 735 738 8828602 PAH NN B-NP B-Disease
23 738 739 8828602 - HYPH B-NP I-Disease
24 739 748 8828602 deficient JJ I-NP I-Disease
25 749 753 8828602 mice NNS I-NP O
26 753 754 8828602 , , O O
27 755 760 8828602 which WDT B-NP O
28 761 771 8828602 completely RB B-VP O
29 772 782 8828602 normalizes VBZ I-VP O
30 783 788 8828602 serum NN B-NP O
31 789 802 8828602 phenylalanine NN I-NP O
32 803 809 8828602 levels NNS I-NP O
33 809 810 8828602 . . O O

1 811 815 8828602 This DT B-NP O
2 816 825 8828602 treatment NN I-NP O
3 826 828 8828602 is VBZ B-VP O
4 829 838 8828602 transient JJ B-ADJP O
5 839 842 8828602 and CC O O
6 843 849 8828602 cannot MD B-VP O
7 850 852 8828602 be VB I-VP O
8 853 864 8828602 effectively RB B-ADVP O
9 865 867 8828602 re AFX O O
10 867 868 8828602 - HYPH O O
11 868 880 8828602 administered VBN B-VP O
12 881 884 8828602 due JJ B-ADJP O
13 885 887 8828602 to TO B-PP O
14 888 891 8828602 the DT B-NP O
15 892 900 8828602 presence NN I-NP O
16 901 903 8828602 of IN B-PP O
17 904 916 8828602 neutralizing VBG B-VP O
18 917 927 8828602 antibodies NNS B-NP O
19 928 936 8828602 directed VBN B-VP O
20 937 944 8828602 against IN B-PP O
21 945 948 8828602 the DT B-NP O
22 949 960 8828602 recombinant JJ I-NP O
23 961 971 8828602 adenoviral JJ I-NP O
24 972 978 8828602 vector NN I-NP O
25 978 979 8828602 . . O O

1 980 987 8828602 However RB B-ADVP O
2 987 988 8828602 , , O O
3 989 994 8828602 these DT B-NP O
4 995 1003 8828602 findings NNS I-NP O
5 1004 1011 8828602 suggest VBP B-VP O
6 1012 1016 8828602 that IN B-SBAR O
7 1017 1020 8828602 PKU NN B-NP B-Disease
8 1021 1024 8828602 can MD B-VP O
9 1025 1027 8828602 be VB I-VP O
10 1028 1038 8828602 completely RB I-VP O
11 1039 1048 8828602 corrected VBN I-VP O
12 1049 1051 8828602 by IN B-PP O
13 1052 1059 8828602 somatic JJ B-NP O
14 1060 1064 8828602 gene NN I-NP O
15 1065 1072 8828602 therapy NN I-NP O
16 1072 1073 8828602 , , O O
17 1074 1077 8828602 and CC O O
18 1078 1085 8828602 provide VBP B-VP O
19 1086 1090 8828602 some DT B-NP O
20 1091 1100 8828602 direction NN I-NP O
21 1101 1104 8828602 for IN B-PP O
22 1105 1108 8828602 the DT B-NP O
23 1109 1115 8828602 future JJ I-NP O
24 1116 1127 8828602 development NN I-NP O
25 1128 1130 8828602 of IN B-PP O
26 1131 1141 8828602 adenoviral JJ B-NP O
27 1142 1149 8828602 vectors NNS I-NP O
28 1149 1150 8828602 . . O O
29 1150 1151 8828602 . . O O

1 0 0 8968760 -DOCSTART- -X- -X- O

1 0 6 8968760 Ataxia NN B-NP B-Disease
2 6 7 8968760 - HYPH I-NP I-Disease
3 7 21 8968760 telangiectasia NN I-NP I-Disease
4 21 22 8968760 : : O O
5 23 30 8968760 founder NN B-NP O
6 31 37 8968760 effect NN I-NP O
7 38 43 8968760 among IN B-PP O
8 44 49 8968760 north JJ B-NP O
9 50 57 8968760 African JJ I-NP O
10 58 62 8968760 Jews NNS I-NP O
11 62 63 8968760 . . O O
12 64 67 8968760 The DT B-NP O
13 68 71 8968760 ATM NN I-NP O
14 72 76 8968760 gene NN I-NP O
15 77 79 8968760 is VBZ B-VP O
16 80 91 8968760 responsible JJ B-ADJP O
17 92 95 8968760 for IN B-PP O
18 96 99 8968760 the DT B-NP O
19 100 109 8968760 autosomal JJ I-NP B-Disease
20 110 119 8968760 recessive JJ I-NP I-Disease
21 120 128 8968760 disorder NN I-NP I-Disease
22 129 135 8968760 ataxia NN I-NP B-Disease
23 135 136 8968760 - HYPH B-NP I-Disease
24 136 150 8968760 telangiectasia NN I-NP I-Disease
25 151 152 8968760 ( ( O O
26 152 153 8968760 A NN B-NP B-Disease
27 153 154 8968760 - HYPH O I-Disease
28 154 155 8968760 T NN B-NP I-Disease
29 155 156 8968760 ) ) O O
30 156 157 8968760 , , O O
31 158 171 8968760 characterized VBN B-VP O
32 172 174 8968760 by IN B-PP O
33 175 185 8968760 cerebellar JJ B-NP B-Disease
34 186 198 8968760 degeneration NN I-NP I-Disease
35 198 199 8968760 , , O O
36 200 216 8968760 immunodeficiency NN B-NP B-Disease
37 217 220 8968760 and CC O O
38 221 227 8968760 cancer NN B-NP B-Disease
39 228 242 8968760 predisposition NN I-NP I-Disease
40 242 243 8968760 . . O O

1 244 245 8968760 A DT B-NP B-Disease
2 245 246 8968760 - HYPH I-NP I-Disease
3 246 247 8968760 T NN I-NP I-Disease
4 248 256 8968760 carriers NNS I-NP O
5 257 261 8968760 were VBD B-VP O
6 262 270 8968760 reported VBN I-VP O
7 271 273 8968760 to TO I-VP O
8 274 276 8968760 be VB I-VP O
9 277 287 8968760 moderately RB B-NP O
10 288 294 8968760 cancer NN I-NP B-Disease
11 294 295 8968760 - HYPH O I-Disease
12 295 300 8968760 prone NN B-NP I-Disease
13 300 301 8968760 . . O O

1 302 303 8968760 A DT B-NP O
2 304 308 8968760 wide JJ I-NP O
3 309 316 8968760 variety NN I-NP O
4 317 319 8968760 of IN B-PP O
5 320 321 8968760 A NN B-NP B-Disease
6 321 322 8968760 - HYPH I-NP I-Disease
7 322 323 8968760 T NN I-NP I-Disease
8 324 333 8968760 mutations NNS I-NP O
9 333 334 8968760 , , O O
10 335 339 8968760 most JJS B-NP O
11 340 342 8968760 of IN B-PP O
12 343 348 8968760 which WDT B-NP O
13 349 352 8968760 are VBP B-VP O
14 353 359 8968760 unique JJ B-ADJP O
15 360 362 8968760 to TO B-PP O
16 363 369 8968760 single JJ B-NP O
17 370 378 8968760 families NNS I-NP O
18 378 379 8968760 , , O O
19 380 384 8968760 were VBD B-VP O
20 385 395 8968760 identified VBN I-VP O
21 396 398 8968760 in IN B-PP O
22 399 406 8968760 various JJ B-NP O
23 407 413 8968760 ethnic JJ I-NP O
24 414 420 8968760 groups NNS I-NP O
25 420 421 8968760 , , O O
26 422 432 8968760 precluding VBG B-VP O
27 433 440 8968760 carrier NN B-NP O
28 441 450 8968760 screening NN I-NP O
29 451 455 8968760 with IN B-PP O
30 456 464 8968760 mutation NN B-NP O
31 464 465 8968760 - HYPH B-NP O
32 465 473 8968760 specific JJ I-NP O
33 474 480 8968760 assays NNS I-NP O
34 480 481 8968760 . . O O

1 482 489 8968760 However RB B-ADVP O
2 489 490 8968760 , , O O
3 491 492 8968760 a DT B-NP O
4 493 499 8968760 single JJ I-NP O
5 500 508 8968760 mutation NN I-NP O
6 509 512 8968760 was VBD B-VP O
7 513 521 8968760 observed VBN I-VP O
8 522 524 8968760 in IN B-PP O
9 525 527 8968760 32 CD B-NP O
10 527 528 8968760 / SYM O O
11 528 530 8968760 33 CD B-NP O
12 531 540 8968760 defective JJ I-NP O
13 541 544 8968760 ATM NN I-NP O
14 545 552 8968760 alleles NNS I-NP O
15 553 555 8968760 in IN B-PP O
16 556 562 8968760 Jewish JJ B-NP O
17 563 564 8968760 A NN I-NP B-Disease
18 564 565 8968760 - HYPH I-NP I-Disease
19 565 566 8968760 T NN I-NP I-Disease
20 567 575 8968760 families NNS I-NP O
21 576 578 8968760 of IN B-PP O
22 579 584 8968760 North JJ B-NP O
23 585 592 8968760 African JJ I-NP O
24 593 599 8968760 origin NN I-NP O
25 599 600 8968760 , , O O
26 601 607 8968760 coming VBG B-VP O
27 608 612 8968760 from IN B-PP O
28 613 620 8968760 various JJ B-NP O
29 621 628 8968760 regions NNS I-NP O
30 629 631 8968760 of IN B-PP O
31 632 639 8968760 Morocco NNP B-NP O
32 640 643 8968760 and CC I-NP O
33 644 651 8968760 Tunisia NNP I-NP O
34 651 652 8968760 . . O O

1 653 657 8968760 This DT B-NP O
2 658 666 8968760 mutation NN I-NP O
3 666 667 8968760 , , O O
4 668 672 8968760 103C NN B-NP O
5 672 673 8968760 - HYPH O O
6 673 674 8968760 - HYPH O O
7 675 676 8968760 > SYM O O
8 677 678 8968760 T NNP B-NP O
9 678 679 8968760 , , O O
10 680 687 8968760 results VBZ B-VP O
11 688 690 8968760 in IN B-PP O
12 691 692 8968760 a DT B-NP O
13 693 697 8968760 stop NN I-NP O
14 698 703 8968760 codon NN I-NP O
15 704 706 8968760 at IN B-PP O
16 707 715 8968760 position NN B-NP O
17 716 718 8968760 35 CD I-NP O
18 719 721 8968760 of IN B-PP O
19 722 725 8968760 the DT B-NP O
20 726 729 8968760 ATM NN I-NP O
21 730 737 8968760 protein NN I-NP O
22 737 738 8968760 . . O O

1 739 741 8968760 In IN B-PP O
2 742 749 8968760 keeping VBG B-NP O
3 750 754 8968760 with IN B-PP O
4 755 758 8968760 the DT B-NP O
5 759 765 8968760 nature NN I-NP O
6 766 768 8968760 of IN B-PP O
7 769 773 8968760 this DT B-NP O
8 774 782 8968760 mutation NN I-NP O
9 782 783 8968760 , , O O
10 784 791 8968760 various JJ B-NP O
11 792 802 8968760 antibodies NNS I-NP O
12 803 811 8968760 directed VBN B-VP O
13 812 819 8968760 against IN B-PP O
14 820 823 8968760 the DT B-NP O
15 824 827 8968760 ATM NN I-NP O
16 828 835 8968760 protein NN I-NP O
17 836 842 8968760 failed VBD B-VP O
18 843 845 8968760 to TO I-VP O
19 846 852 8968760 defect VB I-VP O
20 853 857 8968760 this DT B-NP O
21 858 865 8968760 protein NN I-NP O
22 866 868 8968760 in IN B-PP O
23 869 876 8968760 patient NN B-NP O
24 877 882 8968760 cells NNS I-NP O
25 882 883 8968760 . . O O

1 884 885 8968760 A DT B-NP O
2 886 891 8968760 rapid JJ I-NP O
3 892 899 8968760 carrier NN I-NP O
4 900 909 8968760 detection NN I-NP O
5 910 915 8968760 assay NN I-NP O
6 916 924 8968760 detected VBD B-VP O
7 925 929 8968760 this DT B-NP O
8 930 938 8968760 mutation NN I-NP O
9 939 941 8968760 in IN B-PP O
10 942 947 8968760 three CD B-NP O
11 948 951 8968760 out IN I-NP O
12 952 954 8968760 of IN I-NP O
13 955 958 8968760 488 CD I-NP O
14 959 962 8968760 ATM NN I-NP O
15 963 970 8968760 alleles NNS I-NP O
16 971 973 8968760 of IN B-PP O
17 974 980 8968760 Jewish JJ B-NP O
18 981 989 8968760 Moroccan NN I-NP O
19 990 992 8968760 or CC O O
20 993 1001 8968760 Tunisian JJ B-NP O
21 1002 1008 8968760 origin NN I-NP O
22 1008 1009 8968760 . . O O

1 1010 1014 8968760 This DT B-NP O
2 1015 1022 8968760 founder NN I-NP O
3 1023 1029 8968760 effect NN I-NP O
4 1030 1038 8968760 provides VBZ B-VP O
5 1039 1040 8968760 a DT B-NP O
6 1041 1047 8968760 unique JJ I-NP O
7 1048 1059 8968760 opportunity NN I-NP O
8 1060 1063 8968760 for IN B-PP O
9 1064 1074 8968760 population NN B-NP O
10 1074 1075 8968760 - HYPH O O
11 1075 1080 8968760 based VBN B-NP O
12 1081 1090 8968760 screening NN I-NP O
13 1091 1094 8968760 for IN B-PP O
14 1095 1096 8968760 A NN B-NP B-Disease
15 1096 1097 8968760 - HYPH I-NP I-Disease
16 1097 1098 8968760 T NN I-NP I-Disease
17 1099 1107 8968760 carriers NNS I-NP O
18 1108 1110 8968760 in IN B-PP O
19 1111 1112 8968760 a DT B-NP O
20 1113 1118 8968760 large JJ I-NP O
21 1119 1125 8968760 Jewish JJ I-NP O
22 1126 1135 8968760 community NN I-NP O
23 1135 1136 8968760 . . O O
24 1136 1137 8968760 . . O O

1 0 0 8723064 -DOCSTART- -X- -X- O

1 0 8 8723064 Deletion NN B-NP O
2 9 11 8723064 of IN B-PP O
3 12 17 8723064 small JJ B-NP O
4 18 25 8723064 nuclear JJ I-NP O
5 26 43 8723064 ribonucleoprotein NN I-NP O
6 44 55 8723064 polypeptide NN I-NP O
7 56 57 8723064 N NN I-NP O
8 58 59 8723064 ( ( O O
9 59 64 8723064 SNRPN NN B-NP O
10 64 65 8723064 ) ) O O
11 66 68 8723064 in IN B-PP O
12 69 75 8723064 Prader NNP B-NP B-Disease
13 75 76 8723064 - HYPH I-NP I-Disease
14 76 81 8723064 Willi NNP I-NP I-Disease
15 82 90 8723064 syndrome NN I-NP I-Disease
16 91 99 8723064 detected VBN B-VP O
17 100 102 8723064 by IN B-PP O
18 103 115 8723064 fluorescence NN B-NP O
19 116 118 8723064 in FW B-NP O
20 119 123 8723064 situ FW I-NP O
21 124 137 8723064 hybridization NN I-NP O
22 137 138 8723064 : : O O
23 139 142 8723064 two CD B-NP O
24 143 147 8723064 sibs NNS I-NP O
25 148 152 8723064 with IN B-PP O
26 153 156 8723064 the DT B-NP O
27 157 164 8723064 typical JJ I-NP O
28 165 174 8723064 phenotype NN I-NP O
29 175 182 8723064 without IN B-PP O
30 183 184 8723064 a DT B-NP O
31 185 196 8723064 cytogenetic JJ I-NP O
32 197 205 8723064 deletion NN I-NP O
33 206 208 8723064 in IN B-PP O
34 209 219 8723064 chromosome NN B-NP O
35 220 223 8723064 15q NN I-NP O
36 223 224 8723064 . . O O
37 225 228 8723064 The DT B-NP O
38 229 234 8723064 small JJ I-NP O
39 235 242 8723064 nuclear JJ I-NP O
40 243 260 8723064 ribonucleoprotein NN I-NP O
41 261 272 8723064 polypeptide NN I-NP O
42 273 274 8723064 N NN I-NP O
43 275 276 8723064 ( ( O O
44 276 281 8723064 SNRPN NN B-NP O
45 281 282 8723064 ) ) O O
46 283 287 8723064 gene NN B-NP O
47 288 290 8723064 is VBZ B-VP O
48 291 299 8723064 regarded VBN I-VP O
49 300 302 8723064 as IN B-PP O
50 303 306 8723064 one CD B-NP O
51 307 309 8723064 of IN B-PP O
52 310 313 8723064 the DT B-NP O
53 314 324 8723064 candidates NNS I-NP O
54 325 328 8723064 for IN B-PP O
55 329 335 8723064 Prader NNP B-NP B-Disease
56 335 336 8723064 - HYPH I-NP I-Disease
57 336 341 8723064 Willi NNP I-NP I-Disease
58 342 350 8723064 syndrome NN I-NP I-Disease
59 351 352 8723064 ( ( O O
60 352 355 8723064 PWS NN B-NP B-Disease
61 355 356 8723064 ) ) O O
62 356 357 8723064 . . O O

1 358 360 8723064 We PRP B-NP O
2 361 369 8723064 describe VBP B-VP O
3 370 373 8723064 two CD B-NP O
4 374 378 8723064 sibs NNS I-NP O
5 379 383 8723064 with IN B-PP O
6 384 391 8723064 typical JJ B-NP O
7 392 395 8723064 PWS NN I-NP B-Disease
8 396 406 8723064 presenting VBG B-VP O
9 407 415 8723064 deletion NN B-NP O
10 416 418 8723064 of IN B-PP O
11 419 424 8723064 SNRPN NN B-NP O
12 425 433 8723064 detected VBN B-VP O
13 434 436 8723064 by IN B-PP O
14 437 449 8723064 fluorescence NN B-NP O
15 450 452 8723064 in FW B-NP O
16 453 457 8723064 situ FW I-NP O
17 458 471 8723064 hybridization NN I-NP O
18 472 473 8723064 ( ( O O
19 473 477 8723064 FISH NN B-NP O
20 477 478 8723064 ) ) O O
21 478 479 8723064 . . O O

1 480 487 8723064 Neither CC O O
2 488 489 8723064 a DT B-NP O
3 490 505 8723064 cytogenetically RB I-NP O
4 506 516 8723064 detectable JJ I-NP O
5 517 522 8723064 15q12 CD I-NP O
6 523 531 8723064 deletion NN I-NP O
7 532 535 8723064 nor CC O O
8 536 537 8723064 a DT B-NP O
9 538 546 8723064 deletion NN I-NP O
10 547 550 8723064 for IN B-PP O
11 551 554 8723064 the DT B-NP O
12 555 561 8723064 D15S11 NN I-NP O
13 561 562 8723064 , , O O
14 563 569 8723064 D15S10 NN B-NP O
15 569 570 8723064 , , O O
16 571 574 8723064 and CC O O
17 575 581 8723064 GABRB3 NN B-NP O
18 582 588 8723064 cosmid NN I-NP O
19 589 595 8723064 probes NNS I-NP O
20 596 600 8723064 were VBD B-VP O
21 601 606 8723064 found VBN I-VP O
22 607 609 8723064 in IN B-PP O
23 610 616 8723064 either DT B-NP O
24 617 624 8723064 patient NN I-NP O
25 624 625 8723064 . . O O

1 626 630 8723064 This DT B-NP O
2 631 638 8723064 implies VBZ B-VP O
3 639 640 8723064 a DT B-NP O
4 641 648 8723064 smaller JJR I-NP O
5 649 657 8723064 deletion NN I-NP O
6 658 665 8723064 limited VBN B-VP O
7 666 668 8723064 to TO B-PP O
8 669 672 8723064 the DT B-NP O
9 673 676 8723064 PWS NN I-NP B-Disease
10 677 685 8723064 critical JJ I-NP O
11 686 692 8723064 region NN I-NP O
12 692 693 8723064 . . O O

1 694 698 8723064 FISH NN B-NP O
2 699 703 8723064 with IN B-PP O
3 704 705 8723064 a DT B-NP O
4 706 711 8723064 SNRPN NN I-NP O
5 712 717 8723064 probe NN I-NP O
6 718 722 8723064 will MD B-VP O
7 723 729 8723064 permit VB I-VP O
8 730 738 8723064 analysis NN B-NP O
9 739 741 8723064 of IN B-PP O
10 742 745 8723064 PWS NN B-NP B-Disease
11 746 754 8723064 patients NNS I-NP O
12 755 759 8723064 with IN B-PP O
13 760 767 8723064 limited JJ B-NP O
14 768 777 8723064 deletions NNS I-NP O
15 778 781 8723064 not RB B-ADJP O
16 782 792 8723064 detectable JJ I-ADJP O
17 793 797 8723064 with IN B-PP O
18 798 803 8723064 other JJ B-NP O
19 804 810 8723064 probes NNS I-NP O
20 810 811 8723064 . . O O
21 811 812 8723064 . . O O

1 0 0 8931701 -DOCSTART- -X- -X- O

1 0 14 8931701 Identification NN B-NP O
2 15 17 8931701 of IN B-PP O
3 18 22 8931701 WASP NN B-NP O
4 23 32 8931701 mutations NNS I-NP O
5 32 33 8931701 , , O O
6 34 42 8931701 mutation NN B-NP O
7 43 51 8931701 hotspots NNS I-NP O
8 52 55 8931701 and CC O O
9 56 64 8931701 genotype NN B-NP O
10 64 65 8931701 - HYPH I-NP O
11 65 74 8931701 phenotype NN I-NP O
12 75 86 8931701 disparities NNS I-NP O
13 87 89 8931701 in IN B-PP O
14 90 92 8931701 24 CD B-NP O
15 93 101 8931701 patients NNS I-NP O
16 102 106 8931701 with IN B-PP O
17 107 110 8931701 the DT B-NP O
18 111 118 8931701 Wiskott NNP I-NP B-Disease
19 118 119 8931701 - HYPH I-NP I-Disease
20 119 126 8931701 Aldrich NNP I-NP I-Disease
21 127 135 8931701 syndrome NN I-NP I-Disease
22 135 136 8931701 . . O O
23 137 140 8931701 The DT B-NP O
24 141 148 8931701 Wiskott NNP I-NP B-Disease
25 148 149 8931701 - HYPH I-NP I-Disease
26 149 156 8931701 Aldrich NNP I-NP I-Disease
27 157 165 8931701 syndrome NN I-NP I-Disease
28 166 167 8931701 ( ( O O
29 167 170 8931701 WAS NN B-NP B-Disease
30 170 171 8931701 ) ) O O
31 171 172 8931701 , , O O
32 173 175 8931701 an DT B-NP O
33 176 177 8931701 X NN I-NP B-Disease
34 177 178 8931701 - HYPH B-VP I-Disease
35 178 184 8931701 linked VBN B-NP I-Disease
36 185 201 8931701 immunodeficiency NN I-NP I-Disease
37 202 209 8931701 disease NN I-NP I-Disease
38 210 216 8931701 caused VBN B-VP O
39 217 219 8931701 by IN B-PP O
40 220 228 8931701 mutation NN B-NP O
41 229 231 8931701 in IN B-PP O
42 232 235 8931701 the DT B-NP O
43 236 244 8931701 recently RB I-NP O
44 245 253 8931701 isolated VBN I-NP O
45 254 258 8931701 gene NN I-NP O
46 259 267 8931701 encoding VBG B-VP O
47 268 271 8931701 WAS NN B-NP B-Disease
48 272 279 8931701 protein NN I-NP O
49 280 281 8931701 ( ( O O
50 281 285 8931701 WASP NN B-NP O
51 285 286 8931701 ) ) O O
52 286 287 8931701 , , O O
53 288 290 8931701 is VBZ B-VP O
54 291 296 8931701 known VBN I-VP O
55 297 299 8931701 to TO I-VP O
56 300 302 8931701 be VB I-VP O
57 303 313 8931701 associated VBN I-VP O
58 314 318 8931701 with IN B-PP O
59 319 328 8931701 extensive JJ B-NP O
60 329 337 8931701 clinical JJ I-NP O
61 338 351 8931701 heterogeneity NN I-NP O
62 351 352 8931701 . . O O

1 353 363 8931701 Cumulative JJ B-NP O
2 364 372 8931701 mutation NN I-NP O
3 373 377 8931701 data NNS I-NP O
4 378 382 8931701 have VBP B-VP O
5 383 391 8931701 revealed VBN I-VP O
6 392 396 8931701 that IN B-SBAR O
7 397 401 8931701 WASP NN B-NP O
8 402 411 8931701 genotypes NNS I-NP O
9 412 415 8931701 are VBP B-VP O
10 416 420 8931701 also RB B-ADVP O
11 421 427 8931701 highly RB B-ADJP O
12 428 436 8931701 variable JJ I-ADJP O
13 437 442 8931701 among IN B-PP O
14 443 446 8931701 WAS NN B-NP B-Disease
15 447 455 8931701 patients NNS I-NP O
16 455 456 8931701 , , O O
17 457 460 8931701 but CC O O
18 461 464 8931701 the DT B-NP O
19 465 477 8931701 relationship NN I-NP O
20 478 480 8931701 of IN B-PP O
21 481 490 8931701 phenotype NN B-NP O
22 491 495 8931701 with IN B-PP O
23 496 504 8931701 genotype NN B-NP O
24 505 507 8931701 in IN B-PP O
25 508 512 8931701 this DT B-NP O
26 513 520 8931701 disease NN I-NP O
27 521 528 8931701 remains VBZ B-VP O
28 529 536 8931701 unclear JJ B-ADJP O
29 536 537 8931701 . . O O

1 538 540 8931701 To TO B-VP O
2 541 548 8931701 address VB I-VP O
3 549 553 8931701 this DT B-NP O
4 554 559 8931701 issue NN I-NP O
5 560 562 8931701 we PRP B-NP O
6 563 576 8931701 characterized VBD B-VP O
7 577 581 8931701 WASP NN B-NP O
8 582 591 8931701 mutations NNS I-NP O
9 592 594 8931701 in IN B-PP O
10 595 597 8931701 24 CD B-NP O
11 598 607 8931701 unrelated JJ I-NP O
12 608 611 8931701 WAS NN I-NP B-Disease
13 612 620 8931701 patients NNS I-NP O
14 620 621 8931701 , , O O
15 622 631 8931701 including VBG B-PP O
16 632 634 8931701 18 CD B-NP O
17 635 639 8931701 boys NNS I-NP O
18 640 644 8931701 with IN B-PP O
19 645 651 8931701 severe JJ B-NP O
20 652 661 8931701 classical JJ I-NP O
21 662 665 8931701 WAS NN I-NP B-Disease
22 666 669 8931701 and CC I-NP O
23 670 671 8931701 6 CD I-NP O
24 672 676 8931701 boys NNS I-NP O
25 677 687 8931701 expressing VBG B-VP O
26 688 692 8931701 mild JJ B-NP O
27 693 698 8931701 forms NNS I-NP O
28 699 701 8931701 of IN B-PP O
29 702 705 8931701 the DT B-NP O
30 706 713 8931701 disease NN I-NP O
31 713 714 8931701 , , O O
32 715 718 8931701 and CC O O
33 719 723 8931701 then RB B-VP O
34 724 732 8931701 examined VBD I-VP O
35 733 736 8931701 the DT B-NP O
36 737 743 8931701 degree NN I-NP O
37 744 746 8931701 of IN B-PP O
38 747 758 8931701 correlation NN B-NP O
39 759 761 8931701 of IN B-PP O
40 762 767 8931701 these DT O O
41 768 770 8931701 as RB B-CONJP O
42 771 775 8931701 well RB I-CONJP O
43 776 778 8931701 as IN I-CONJP O
44 779 782 8931701 all DT B-NP O
45 783 793 8931701 previously RB I-NP O
46 794 803 8931701 published VBN I-NP O
47 804 808 8931701 WASP NN I-NP O
48 809 818 8931701 mutations NNS I-NP O
49 819 823 8931701 with IN B-PP O
50 824 831 8931701 disease NN B-NP O
51 832 840 8931701 severity NN I-NP O
52 840 841 8931701 . . O O

1 842 844 8931701 By IN B-PP O
2 845 853 8931701 analysis NN B-NP O
3 854 856 8931701 of IN B-PP O
4 857 862 8931701 these DT B-NP O
5 863 871 8931701 compiled VBN I-NP O
6 872 880 8931701 mutation NN I-NP O
7 881 885 8931701 data NNS I-NP O
8 885 886 8931701 , , O O
9 887 889 8931701 we PRP B-NP O
10 890 902 8931701 demonstrated VBD B-VP O
11 903 913 8931701 clustering NN B-NP O
12 914 916 8931701 of IN B-PP O
13 917 921 8931701 WASP NN B-NP O
14 922 931 8931701 mutations NNS I-NP O
15 932 938 8931701 within IN B-PP O
16 939 942 8931701 the DT B-NP O
17 943 947 8931701 four CD I-NP O
18 948 952 8931701 most JJS I-NP O
19 953 954 8931701 N NN I-NP O
20 954 955 8931701 - HYPH I-NP O
21 955 963 8931701 terminal JJ I-NP O
22 964 969 8931701 exons NNS I-NP O
23 970 972 8931701 of IN B-PP O
24 973 976 8931701 the DT B-NP O
25 977 981 8931701 gene NN I-NP O
26 982 985 8931701 and CC O O
27 986 990 8931701 also RB B-ADVP O
28 991 1001 8931701 identified VBD B-VP O
29 1002 1009 8931701 several JJ B-NP O
30 1010 1015 8931701 sites NNS I-NP O
31 1016 1022 8931701 within IN B-PP O
32 1023 1027 8931701 this DT B-NP O
33 1028 1034 8931701 region NN I-NP O
34 1035 1037 8931701 as IN B-PP O
35 1038 1046 8931701 hotspots NNS B-NP O
36 1047 1050 8931701 for IN B-PP O
37 1051 1055 8931701 WASP NN B-NP O
38 1056 1064 8931701 mutation NN I-NP O
39 1064 1065 8931701 . . O O

1 1066 1071 8931701 These DT B-NP O
2 1072 1087 8931701 characteristics NNS I-NP O
3 1088 1092 8931701 were VBD B-VP O
4 1093 1101 8931701 observed VBN I-VP O
5 1101 1102 8931701 , , O O
6 1103 1110 8931701 however RB B-ADVP O
7 1110 1111 8931701 , , O O
8 1112 1114 8931701 in IN B-PP O
9 1115 1119 8931701 both CC B-NP O
10 1120 1126 8931701 severe JJ I-NP O
11 1127 1130 8931701 and CC I-NP O
12 1131 1135 8931701 mild JJ I-NP O
13 1136 1141 8931701 cases NNS I-NP O
14 1142 1144 8931701 of IN B-PP O
15 1145 1148 8931701 the DT B-NP O
16 1149 1156 8931701 disease NN I-NP O
17 1156 1157 8931701 . . O O

1 1158 1167 8931701 Similarly RB B-ADVP O
2 1167 1168 8931701 , , O O
3 1169 1174 8931701 while IN B-SBAR O
4 1175 1178 8931701 the DT B-NP O
5 1179 1189 8931701 cumulative JJ I-NP O
6 1190 1194 8931701 data NNS I-NP O
7 1195 1203 8931701 revealed VBD B-VP O
8 1204 1205 8931701 a DT B-NP O
9 1206 1218 8931701 predominance NN I-NP O
10 1219 1221 8931701 of IN B-PP O
11 1222 1230 8931701 missense JJ B-NP O
12 1231 1240 8931701 mutations NNS I-NP O
13 1241 1246 8931701 among IN B-PP O
14 1247 1250 8931701 the DT B-NP O
15 1251 1255 8931701 WASP NN I-NP O
16 1256 1260 8931701 gene NN I-NP O
17 1261 1268 8931701 lesions NNS I-NP O
18 1269 1277 8931701 observed VBN B-VP O
19 1278 1280 8931701 in IN B-PP O
20 1281 1285 8931701 boys NNS B-NP O
21 1286 1290 8931701 with IN B-PP O
22 1291 1299 8931701 isolated VBN B-NP B-Disease
23 1300 1316 8931701 thrombocytopenia NN I-NP I-Disease
24 1316 1317 8931701 , , O O
25 1318 1326 8931701 missense JJ B-NP O
26 1327 1336 8931701 mutations NNS I-NP O
27 1337 1341 8931701 were VBD B-VP O
28 1342 1345 8931701 not RB I-VP O
29 1346 1357 8931701 exclusively RB I-VP O
30 1358 1368 8931701 associated VBN I-VP O
31 1369 1373 8931701 with IN B-PP O
32 1374 1380 8931701 milder JJR B-NP O
33 1381 1384 8931701 WAS NN I-NP B-Disease
34 1385 1395 8931701 phenotypes NNS I-NP O
35 1395 1396 8931701 , , O O
36 1397 1400 8931701 but CC O O
37 1401 1405 8931701 also RB B-VP O
38 1406 1415 8931701 comprised VBD I-VP O
39 1416 1417 8931701 a DT B-NP O
40 1418 1429 8931701 substantial JJ I-NP O
41 1430 1437 8931701 portion NN I-NP O
42 1438 1439 8931701 ( ( O O
43 1439 1442 8931701 38% NN B-NP O
44 1442 1443 8931701 ) ) O O
45 1444 1446 8931701 of IN B-PP O
46 1447 1450 8931701 the DT B-NP O
47 1451 1455 8931701 WASP NN I-NP O
48 1456 1460 8931701 gene NN I-NP O
49 1461 1468 8931701 defects NNS I-NP O
50 1469 1474 8931701 found VBN B-VP O
51 1475 1477 8931701 in IN B-PP O
52 1478 1486 8931701 patients NNS B-NP O
53 1487 1491 8931701 with IN B-PP O
54 1492 1498 8931701 severe JJ B-NP O
55 1499 1506 8931701 disease NN I-NP O
56 1506 1507 8931701 . . O O

1 1508 1513 8931701 These DT B-NP O
2 1514 1522 8931701 findings NNS I-NP O
3 1522 1523 8931701 , , O O
4 1524 1526 8931701 as RB B-CONJP O
5 1527 1531 8931701 well RB I-CONJP O
6 1532 1534 8931701 as IN I-CONJP O
7 1535 1538 8931701 the DT B-NP O
8 1539 1548 8931701 detection NN I-NP O
9 1549 1551 8931701 of IN B-PP O
10 1552 1561 8931701 identical JJ B-NP O
11 1562 1566 8931701 WASP NN I-NP O
12 1567 1576 8931701 mutations NNS I-NP O
13 1577 1579 8931701 in IN B-PP O
14 1580 1588 8931701 patients NNS B-NP O
15 1589 1593 8931701 with IN B-PP O
16 1594 1603 8931701 disparate JJ B-NP O
17 1604 1614 8931701 phenotypes NNS I-NP O
18 1614 1615 8931701 , , O O
19 1616 1622 8931701 reveal VBP B-VP O
20 1623 1624 8931701 a DT B-NP O
21 1625 1629 8931701 lack NN I-NP O
22 1630 1632 8931701 of IN B-PP O
23 1633 1642 8931701 phenotype NN B-NP O
24 1643 1654 8931701 concordance NN I-NP O
25 1655 1659 8931701 with IN B-PP O
26 1660 1668 8931701 genotype NN B-NP O
27 1669 1671 8931701 in IN B-PP O
28 1672 1675 8931701 WAS NN B-NP B-Disease
29 1676 1679 8931701 and CC O O
30 1680 1684 8931701 thus RB B-VP O
31 1685 1690 8931701 imply VBP I-VP O
32 1691 1695 8931701 that IN B-SBAR O
33 1696 1706 8931701 phenotypic JJ B-NP O
34 1707 1714 8931701 outcome NN I-NP O
35 1715 1717 8931701 in IN B-PP O
36 1718 1722 8931701 this DT B-NP O
37 1723 1730 8931701 disease NN I-NP O
38 1731 1737 8931701 cannot MD B-VP O
39 1738 1740 8931701 be VB I-VP O
40 1741 1749 8931701 reliably RB I-VP O
41 1750 1759 8931701 predicted VBN I-VP O
42 1760 1766 8931701 solely RB B-ADVP O
43 1767 1769 8931701 on IN B-PP O
44 1770 1773 8931701 the DT B-NP O
45 1774 1779 8931701 basis NN I-NP O
46 1780 1782 8931701 of IN B-PP O
47 1783 1787 8931701 WASP NN B-NP O
48 1788 1797 8931701 genotypes NNS I-NP O
49 1797 1798 8931701 . . O O
50 1798 1799 8931701 . . O O

1 0 0 9069115 -DOCSTART- -X- -X- O

1 0 7 9069115 Cloning NN B-NP O
2 8 10 9069115 of IN B-PP O
3 11 14 9069115 the DT B-NP O
4 15 28 9069115 homogentisate NN I-NP O
5 29 32 9069115 1,2 CD I-NP O
6 32 33 9069115 - HYPH I-NP O
7 33 44 9069115 dioxygenase NN I-NP O
8 45 49 9069115 gene NN I-NP O
9 49 50 9069115 , , O O
10 51 54 9069115 the DT B-NP O
11 55 58 9069115 key JJ I-NP O
12 59 65 9069115 enzyme NN I-NP O
13 66 68 9069115 of IN B-PP O
14 69 81 9069115 alkaptonuria NN B-NP B-Disease
15 82 84 9069115 in IN B-PP O
16 85 90 9069115 mouse NN B-NP O
17 90 91 9069115 . . O O
18 92 94 9069115 We PRP B-NP O
19 95 105 9069115 determined VBD B-VP O
20 106 108 9069115 48 CD B-NP O
21 109 114 9069115 amino NN I-NP O
22 115 119 9069115 acid NN I-NP O
23 120 128 9069115 residues NNS I-NP O
24 129 133 9069115 from IN B-PP O
25 134 138 9069115 five CD B-NP O
26 139 147 9069115 peptides NNS I-NP O
27 148 152 9069115 from IN B-PP O
28 153 156 9069115 the DT B-NP O
29 157 168 9069115 homogeneous JJ I-NP O
30 169 176 9069115 monomer NN I-NP O
31 177 179 9069115 of IN B-PP O
32 180 193 9069115 homogentisate NN B-NP O
33 194 195 9069115 1 CD I-NP O
34 195 196 9069115 , , I-NP O
35 197 198 9069115 2 CD I-NP O
36 198 199 9069115 - HYPH I-NP O
37 199 210 9069115 dioxygenase NN B-NP O
38 211 212 9069115 ( ( O O
39 212 215 9069115 HGO NN B-NP O
40 215 216 9069115 ; : O O
41 217 218 9069115 E NN B-NP O
42 218 219 9069115 . . O O
43 220 221 9069115 C NN B-NP O
44 221 222 9069115 . . B-NP O
45 223 224 9069115 1 CD I-NP O
46 224 225 9069115 . . O O

1 226 228 9069115 13 CD B-NP O
2 228 229 9069115 . . O O

1 230 232 9069115 11 CD B-NP O
2 232 233 9069115 . . O O

1 234 236 9069115 15 CD B-NP O
2 236 237 9069115 ) ) O O
3 238 240 9069115 of IN B-PP O
4 241 246 9069115 mouse NN B-NP O
5 247 252 9069115 liver NN I-NP O
6 252 253 9069115 . . O O

1 254 259 9069115 After IN B-PP O
2 260 269 9069115 digestion NN B-NP O
3 270 274 9069115 with IN B-PP O
4 275 282 9069115 trypsin NN B-NP O
5 282 283 9069115 , , O O
6 284 292 9069115 peptides NNS B-NP O
7 293 297 9069115 were VBD B-VP O
8 298 307 9069115 separated VBN I-VP O
9 308 310 9069115 by IN B-PP O
10 311 319 9069115 reversed VBN B-NP O
11 320 325 9069115 phase NN I-NP O
12 326 340 9069115 chromatography NN I-NP O
13 341 344 9069115 and CC O O
14 345 350 9069115 amino NN B-NP O
15 351 355 9069115 acid NN I-NP O
16 356 365 9069115 sequenced VBN B-VP O
17 365 366 9069115 . . O O

1 367 370 9069115 The DT B-NP O
2 371 378 9069115 deduced VBN I-NP O
3 379 384 9069115 codon NN I-NP O
4 385 393 9069115 sequence NN I-NP O
5 394 396 9069115 of IN B-PP O
6 397 402 9069115 three CD B-NP O
7 403 411 9069115 peptides NNS I-NP O
8 412 415 9069115 was VBD B-VP O
9 416 420 9069115 used VBN I-VP O
10 421 423 9069115 to TO B-VP O
11 424 430 9069115 derive VB I-VP O
12 431 442 9069115 degenerated JJ B-NP O
13 443 453 9069115 oligomeres NNS I-NP O
14 453 454 9069115 . . O O

1 455 457 9069115 By IN B-PP O
2 458 467 9069115 combining VBG B-VP O
3 468 473 9069115 these DT B-NP O
4 474 480 9069115 oligos NNS I-NP O
5 480 481 9069115 , , O O
6 482 484 9069115 we PRP B-NP O
7 485 489 9069115 were VBD B-VP O
8 490 494 9069115 able JJ B-ADJP O
9 495 497 9069115 to TO B-VP O
10 498 505 9069115 amplify VB I-VP O
11 506 515 9069115 fragments NNS B-NP O
12 516 520 9069115 from IN B-PP O
13 521 524 9069115 100 CD B-NP O
14 525 527 9069115 to TO I-NP O
15 528 531 9069115 300 CD I-NP O
16 532 537 9069115 bases NNS I-NP O
17 538 539 9069115 ( ( O O
18 539 540 9069115 b NN B-NP O
19 540 541 9069115 ) ) O O
20 542 546 9069115 from IN B-PP O
21 547 552 9069115 mouse NN B-NP O
22 553 558 9069115 liver NN I-NP O
23 559 563 9069115 cDNA NN I-NP O
24 564 566 9069115 by IN B-PP O
25 567 577 9069115 polymerase NN B-NP O
26 578 583 9069115 chain NN I-NP O
27 584 592 9069115 reaction NN I-NP O
28 593 598 9069115 after IN B-PP O
29 599 606 9069115 reverse JJ B-NP O
30 607 620 9069115 transcription NN I-NP O
31 621 622 9069115 ( ( O O
32 622 624 9069115 RT NN B-NP O
33 624 625 9069115 - HYPH B-NP O
34 625 628 9069115 PCR NN I-NP O
35 628 629 9069115 ) ) O O
36 629 630 9069115 . . O O

1 631 632 9069115 A DT B-NP O
2 633 641 9069115 fragment NN I-NP O
3 642 644 9069115 of IN B-PP O
4 645 648 9069115 200 CD B-NP O
5 649 650 9069115 b NN I-NP O
6 651 654 9069115 was VBD B-VP O
7 655 661 9069115 cloned VBN I-VP O
8 662 665 9069115 and CC O O
9 666 670 9069115 used VBN B-VP O
10 671 673 9069115 as IN B-PP O
11 674 675 9069115 a DT B-NP O
12 676 681 9069115 probe NN I-NP O
13 682 684 9069115 to TO B-VP O
14 685 691 9069115 screen VB I-VP O
15 692 693 9069115 a DT B-NP O
16 694 699 9069115 mouse NN I-NP O
17 700 705 9069115 liver NN I-NP O
18 706 710 9069115 cDNA NN I-NP O
19 711 718 9069115 library NN I-NP O
20 718 719 9069115 . . O O

1 720 723 9069115 One CD B-NP O
2 724 729 9069115 clone NN I-NP O
3 730 734 9069115 from IN B-PP O
4 735 739 9069115 this DT B-NP O
5 740 747 9069115 library NN I-NP O
6 748 757 9069115 contained VBD B-VP O
7 758 761 9069115 the DT B-NP O
8 762 770 9069115 complete JJ I-NP O
9 771 775 9069115 cDNA NN I-NP O
10 775 776 9069115 - HYPH B-NP O
11 776 782 9069115 insert NN I-NP O
12 783 786 9069115 for IN B-PP O
13 787 790 9069115 HGO NN B-NP O
14 791 793 9069115 as IN B-SBAR O
15 794 804 9069115 determined VBN B-VP O
16 805 807 9069115 by IN B-PP O
17 808 818 9069115 sequencing NN B-NP O
18 818 819 9069115 . . O O

1 820 823 9069115 The DT B-NP O
2 824 828 9069115 cDNA NN I-NP O
3 829 836 9069115 encodes VBZ B-VP O
4 837 840 9069115 for IN B-PP O
5 841 842 9069115 a DT B-NP O
6 843 850 9069115 protein NN I-NP O
7 851 853 9069115 of IN B-PP O
8 854 856 9069115 50 CD B-NP O
9 857 860 9069115 kDa NN I-NP O
10 860 861 9069115 , , O O
11 862 864 9069115 as IN B-SBAR O
12 865 874 9069115 predicted VBN B-VP O
13 874 875 9069115 . . O O

1 876 879 9069115 The DT B-NP O
2 880 884 9069115 cDNA NN I-NP O
3 885 887 9069115 of IN B-PP O
4 888 893 9069115 mouse NN B-NP O
5 894 897 9069115 HGO NN I-NP O
6 898 901 9069115 has VBZ B-VP O
7 902 904 9069115 an DT B-NP O
8 905 912 9069115 overall JJ I-NP O
9 913 921 9069115 identity NN I-NP O
10 922 924 9069115 of IN B-PP O
11 925 928 9069115 41% NN B-NP O
12 929 931 9069115 to TO B-PP O
13 932 935 9069115 the DT B-NP O
14 936 949 9069115 corresponding VBG I-NP O
15 950 954 9069115 gene NN I-NP O
16 955 959 9069115 hmgA NN I-NP O
17 960 964 9069115 from IN B-PP O
18 965 976 9069115 Aspergillus NN B-NP O
19 976 977 9069115 . . O O

1 978 986 9069115 Sequence NN B-NP O
2 987 999 9069115 similarities NNS I-NP O
3 1000 1002 9069115 to TO B-PP O
4 1003 1008 9069115 human JJ B-NP O
5 1009 1018 9069115 expressed VBN I-NP O
6 1019 1027 9069115 sequence NN I-NP O
7 1028 1032 9069115 tags NNS I-NP O
8 1033 1034 9069115 ( ( O O
9 1034 1037 9069115 EST NN B-NP O
10 1037 1038 9069115 ) ) O O
11 1039 1045 9069115 clones NNS B-NP O
12 1046 1052 9069115 ranged VBD B-VP O
13 1053 1057 9069115 from IN B-PP O
14 1058 1061 9069115 70% CD B-NP O
15 1062 1064 9069115 to TO B-PP O
16 1065 1068 9069115 20% CD B-NP O
17 1068 1069 9069115 . . O O

1 1070 1073 9069115 The DT B-NP O
2 1074 1083 9069115 positions NNS I-NP O
3 1084 1086 9069115 of IN B-PP O
4 1087 1090 9069115 122 CD B-NP O
5 1091 1100 9069115 conserved VBN B-VP O
6 1101 1106 9069115 amino JJ B-NP O
7 1107 1112 9069115 acids NNS I-NP O
8 1113 1118 9069115 could MD B-VP O
9 1119 1121 9069115 be VB I-VP O
10 1122 1132 9069115 determined VBN I-VP O
11 1133 1135 9069115 by IN B-PP O
12 1136 1144 9069115 multiple JJ B-NP O
13 1145 1153 9069115 sequence NN I-NP O
14 1154 1163 9069115 alignment NN I-NP O
15 1163 1164 9069115 . . O O

1 1165 1167 9069115 We PRP B-NP O
2 1168 1178 9069115 identified VBD B-VP O
3 1179 1182 9069115 one CD B-NP O
4 1183 1188 9069115 first JJ I-NP O
5 1189 1195 9069115 intron NN I-NP O
6 1196 1198 9069115 of IN B-PP O
7 1199 1202 9069115 928 CD B-NP O
8 1203 1204 9069115 b NN I-NP O
9 1205 1207 9069115 in IN B-PP O
10 1208 1211 9069115 the DT B-NP O
11 1212 1217 9069115 mouse NN I-NP O
12 1218 1222 9069115 gene NN I-NP O
13 1222 1223 9069115 . . O O

1 1224 1227 9069115 The DT B-NP O
2 1228 1232 9069115 gene NN I-NP O
3 1233 1236 9069115 for IN B-PP O
4 1237 1240 9069115 HGO NN B-NP O
5 1241 1246 9069115 seems VBZ B-VP O
6 1247 1249 9069115 to TO I-VP O
7 1250 1252 9069115 be VB I-VP O
8 1253 1262 9069115 expressed VBN I-VP O
9 1263 1265 9069115 in IN B-PP O
10 1266 1273 9069115 various JJ B-NP O
11 1274 1281 9069115 tissues NNS I-NP O
12 1281 1282 9069115 , , O O
13 1283 1285 9069115 as IN B-SBAR O
14 1286 1291 9069115 shown VBN B-VP O
15 1292 1294 9069115 by IN B-PP O
16 1295 1297 9069115 RT NN B-NP O
17 1297 1298 9069115 - HYPH B-NP O
18 1298 1301 9069115 PCR NN I-NP O
19 1302 1304 9069115 on IN B-PP O
20 1305 1314 9069115 different JJ B-NP O
21 1315 1320 9069115 cDNAs NNS I-NP O
22 1320 1321 9069115 . . O O

1 1322 1326 9069115 FISH NN B-NP O
2 1327 1338 9069115 experiments NNS I-NP O
3 1339 1343 9069115 with IN B-PP O
4 1344 1347 9069115 the DT B-NP O
5 1348 1353 9069115 whole JJ I-NP O
6 1354 1360 9069115 murine JJ I-NP O
7 1361 1365 9069115 cDNA NN I-NP O
8 1366 1368 9069115 as IN B-PP O
9 1369 1374 9069115 probe NN B-NP O
10 1375 1382 9069115 clearly RB B-ADVP O
11 1383 1391 9069115 revealed VBD B-VP O
12 1392 1399 9069115 signals NNS B-NP O
13 1400 1402 9069115 at IN B-PP O
14 1403 1406 9069115 the DT B-NP O
15 1407 1412 9069115 human JJ I-NP O
16 1413 1424 9069115 chromosomal JJ I-NP O
17 1425 1429 9069115 band NN I-NP O
18 1430 1434 9069115 3q13 NN I-NP O
19 1434 1435 9069115 . . O O

1 1436 1437 9069115 3 CD B-NP O
2 1437 1438 9069115 - HYPH I-NP O
3 1438 1441 9069115 q21 NN I-NP O
4 1441 1442 9069115 . . O O

1 1443 1447 9069115 This DT B-NP O
2 1448 1459 9069115 corresponds VBZ B-VP O
3 1460 1464 9069115 well RB B-ADVP O
4 1465 1467 9069115 to TO B-PP O
5 1468 1471 9069115 the DT B-NP O
6 1472 1480 9069115 previous JJ I-NP O
7 1481 1491 9069115 assignment NN I-NP O
8 1492 1494 9069115 of IN B-PP O
9 1495 1498 9069115 the DT B-NP O
10 1499 1504 9069115 locus NN I-NP O
11 1505 1508 9069115 for IN B-PP O
12 1509 1512 9069115 the DT B-NP O
13 1513 1518 9069115 human JJ I-NP O
14 1519 1531 9069115 alkaptonuria NN I-NP B-Disease
15 1532 1536 9069115 gene NN I-NP O
16 1537 1538 9069115 ( ( O O
17 1538 1541 9069115 AKU NN B-NP O
18 1541 1542 9069115 ) ) O O
19 1543 1545 9069115 to TO B-PP O
20 1546 1549 9069115 the DT B-NP O
21 1550 1554 9069115 same JJ I-NP O
22 1555 1566 9069115 chromosomal JJ I-NP O
23 1567 1573 9069115 region NN I-NP O
24 1574 1576 9069115 by IN B-PP O
25 1577 1587 9069115 multipoint JJ B-NP O
26 1588 1595 9069115 linkage NN I-NP O
27 1596 1604 9069115 analysis NN I-NP O
28 1604 1605 9069115 . . O O

1 1606 1608 9069115 We PRP B-NP O
2 1609 1618 9069115 therefore RB B-ADVP O
3 1619 1627 9069115 conclude VBP B-VP O
4 1628 1632 9069115 that IN B-SBAR O
5 1633 1636 9069115 the DT B-NP O
6 1637 1640 9069115 HGO NN I-NP O
7 1641 1645 9069115 cDNA NN I-NP O
8 1646 1653 9069115 encodes VBZ B-VP O
9 1654 1657 9069115 the DT B-NP O
10 1658 1662 9069115 gene NN I-NP O
11 1663 1674 9069115 responsible JJ B-ADJP O
12 1675 1678 9069115 for IN B-PP O
13 1679 1691 9069115 alkaptonuria NN B-NP B-Disease
14 1691 1692 9069115 . . O O

1 0 0 8931709 -DOCSTART- -X- -X- O

1 0 8 8931709 Germline NN B-NP O
2 9 18 8931709 mutations NNS I-NP O
3 19 21 8931709 in IN B-PP O
4 22 25 8931709 the DT B-NP O
5 26 27 8931709 3 CD I-NP O
6 27 28 8931709 ' SYM I-NP O
7 29 33 8931709 part NN I-NP O
8 34 36 8931709 of IN B-PP O
9 37 40 8931709 APC NN B-NP B-Disease
10 41 45 8931709 exon NN I-NP O
11 46 48 8931709 15 CD I-NP O
12 49 51 8931709 do VBP B-VP O
13 52 55 8931709 not RB I-VP O
14 56 62 8931709 result VB I-VP O
15 63 65 8931709 in IN B-PP O
16 66 75 8931709 truncated VBN B-NP O
17 76 84 8931709 proteins NNS I-NP O
18 85 88 8931709 and CC O O
19 89 92 8931709 are VBP B-VP O
20 93 103 8931709 associated VBN I-VP O
21 104 108 8931709 with IN B-PP O
22 109 119 8931709 attenuated VBN B-NP O
23 120 131 8931709 adenomatous JJ I-NP B-Disease
24 132 141 8931709 polyposis NN I-NP I-Disease
25 142 146 8931709 coli NN I-NP I-Disease
26 146 147 8931709 . . O O
27 148 156 8931709 Familial JJ B-NP B-Disease
28 157 168 8931709 adenomatous JJ I-NP I-Disease
29 169 178 8931709 polyposis NN I-NP I-Disease
30 179 180 8931709 ( ( O O
31 180 183 8931709 FAP NN B-NP B-Disease
32 183 184 8931709 ) ) O O
33 185 187 8931709 is VBZ B-VP O
34 188 190 8931709 an DT B-NP O
35 191 200 8931709 inherited VBN I-NP O
36 201 215 8931709 predisposition NN I-NP O
37 216 218 8931709 to TO B-PP O
38 219 229 8931709 colorectal JJ B-NP B-Disease
39 230 236 8931709 cancer NN I-NP I-Disease
40 237 250 8931709 characterized VBN B-VP O
41 251 253 8931709 by IN B-PP O
42 254 257 8931709 the DT B-NP O
43 258 269 8931709 development NN I-NP O
44 270 272 8931709 of IN B-PP O
45 273 281 8931709 numerous JJ B-NP O
46 282 293 8931709 adenomatous JJ I-NP B-Disease
47 294 300 8931709 polyps NNS I-NP I-Disease
48 301 314 8931709 predominantly RB B-ADVP O
49 315 317 8931709 in IN B-PP O
50 318 321 8931709 the DT B-NP O
51 322 332 8931709 colorectal JJ I-NP O
52 333 339 8931709 region NN I-NP O
53 339 340 8931709 . . O O

1 341 349 8931709 Germline NN B-NP O
2 350 359 8931709 mutations NNS I-NP O
3 360 362 8931709 in IN B-PP O
4 363 366 8931709 the DT B-NP O
5 367 378 8931709 adenomatous JJ I-NP B-Disease
6 379 388 8931709 polyposis NN I-NP I-Disease
7 389 393 8931709 coli NN I-NP I-Disease
8 394 395 8931709 ( ( O O
9 395 398 8931709 APC NN B-NP B-Disease
10 398 399 8931709 ) ) O O
11 400 404 8931709 gene NN B-NP O
12 405 408 8931709 are VBP B-VP O
13 409 420 8931709 responsible JJ B-ADJP O
14 421 424 8931709 for IN B-PP O
15 425 429 8931709 most JJS B-NP O
16 430 435 8931709 cases NNS I-NP O
17 436 438 8931709 of IN B-PP O
18 439 442 8931709 FAP NN B-NP B-Disease
19 442 443 8931709 . . O O

1 444 453 8931709 Mutations NNS B-NP O
2 454 456 8931709 at IN B-PP O
3 457 460 8931709 the DT B-NP O
4 461 462 8931709 5 CD I-NP O
5 463 466 8931709 end NN I-NP O
6 467 469 8931709 of IN B-PP O
7 470 473 8931709 APC NN B-NP B-Disease
8 474 477 8931709 are VBP B-VP O
9 478 483 8931709 known VBN I-VP O
10 484 486 8931709 to TO I-VP O
11 487 489 8931709 be VB I-VP O
12 490 500 8931709 associated VBN I-VP O
13 501 505 8931709 with IN B-PP O
14 506 507 8931709 a DT B-NP O
15 508 518 8931709 relatively RB I-NP O
16 519 523 8931709 mild JJ I-NP O
17 524 528 8931709 form NN I-NP O
18 529 531 8931709 of IN B-PP O
19 532 535 8931709 the DT B-NP O
20 536 543 8931709 disease NN I-NP O
21 543 544 8931709 , , O O
22 545 551 8931709 called VBN B-VP O
23 552 562 8931709 attenuated VBD B-VP B-Disease
24 563 574 8931709 adenomatous JJ B-NP I-Disease
25 575 584 8931709 polyposis NN I-NP I-Disease
26 585 589 8931709 coli NN I-NP I-Disease
27 590 591 8931709 ( ( O O
28 591 595 8931709 AAPC NN B-NP B-Disease
29 595 596 8931709 ) ) O O
30 596 597 8931709 . . O O

1 598 600 8931709 We PRP B-NP O
2 601 611 8931709 identified VBD B-VP O
3 612 613 8931709 a DT B-NP O
4 614 624 8931709 frameshift NN I-NP O
5 625 633 8931709 mutation NN I-NP O
6 634 636 8931709 in IN B-PP O
7 637 640 8931709 the DT B-NP O
8 641 642 8931709 3 CD I-NP O
9 643 647 8931709 part NN I-NP O
10 648 650 8931709 of IN B-PP O
11 651 655 8931709 exon NN B-NP O
12 656 658 8931709 15 CD I-NP O
13 658 659 8931709 , , O O
14 660 669 8931709 resulting VBG B-VP O
15 670 672 8931709 in IN B-PP O
16 673 674 8931709 a DT B-NP O
17 675 679 8931709 stop NN I-NP O
18 680 685 8931709 codon NN I-NP O
19 686 688 8931709 at IN B-PP O
20 689 693 8931709 1862 CD B-NP O
21 693 694 8931709 , , O O
22 695 697 8931709 in IN B-PP O
23 698 699 8931709 a DT B-NP O
24 700 705 8931709 large JJ I-NP O
25 706 711 8931709 Dutch JJ I-NP O
26 712 719 8931709 kindred NN I-NP O
27 720 724 8931709 with IN B-PP O
28 725 729 8931709 AAPC NN B-NP B-Disease
29 729 730 8931709 . . O O

1 731 738 8931709 Western NN B-NP O
2 739 743 8931709 blot NN I-NP O
3 744 752 8931709 analysis NN I-NP O
4 753 755 8931709 of IN B-PP O
5 756 770 8931709 lymphoblastoid JJ B-NP O
6 771 775 8931709 cell NN I-NP O
7 776 781 8931709 lines NNS I-NP O
8 782 789 8931709 derived VBN B-VP O
9 790 794 8931709 from IN B-PP O
10 795 803 8931709 affected VBN B-NP O
11 804 810 8931709 family NN I-NP O
12 811 818 8931709 members NNS I-NP O
13 819 823 8931709 from IN B-PP O
14 824 828 8931709 this DT B-NP O
15 829 836 8931709 kindred NN I-NP O
16 836 837 8931709 , , O O
17 838 840 8931709 as RB B-CONJP O
18 841 845 8931709 well RB I-CONJP O
19 846 848 8931709 as IN I-CONJP O
20 849 853 8931709 from IN B-PP O
21 854 855 8931709 a DT B-NP O
22 856 866 8931709 previously RB I-NP O
23 867 875 8931709 reported VBN I-NP O
24 876 881 8931709 Swiss JJ I-NP O
25 882 888 8931709 family NN I-NP O
26 889 897 8931709 carrying VBG B-VP O
27 898 899 8931709 a DT B-NP O
28 900 910 8931709 frameshift NN I-NP O
29 911 919 8931709 mutation NN I-NP O
30 920 922 8931709 at IN B-PP O
31 923 928 8931709 codon NN B-NP O
32 929 933 8931709 1987 CD I-NP O
33 934 937 8931709 and CC O O
34 938 948 8931709 displaying VBG B-VP O
35 949 950 8931709 a DT B-NP O
36 951 958 8931709 similar JJ I-NP O
37 959 969 8931709 attenuated VBN I-NP O
38 970 979 8931709 phenotype NN I-NP O
39 979 980 8931709 , , O O
40 981 987 8931709 showed VBD B-VP O
41 988 992 8931709 only RB B-NP O
42 993 996 8931709 the DT I-NP O
43 997 1001 8931709 wild JJ I-NP O
44 1001 1002 8931709 - HYPH I-NP O
45 1002 1006 8931709 type NN I-NP O
46 1007 1010 8931709 APC NN I-NP B-Disease
47 1011 1018 8931709 protein NN I-NP O
48 1018 1019 8931709 . . O O

1 1020 1023 8931709 Our PRP$ B-NP O
2 1024 1029 8931709 study NN I-NP O
3 1030 1039 8931709 indicates VBZ B-VP O
4 1040 1044 8931709 that IN B-SBAR O
5 1045 1050 8931709 chain NN B-NP O
6 1050 1051 8931709 - HYPH O O
7 1051 1062 8931709 terminating VBG B-VP O
8 1063 1072 8931709 mutations NNS B-NP O
9 1073 1080 8931709 located VBN B-VP O
10 1081 1083 8931709 in IN B-PP O
11 1084 1087 8931709 the DT B-NP O
12 1088 1089 8931709 3 CD I-NP O
13 1090 1094 8931709 part NN I-NP O
14 1095 1097 8931709 of IN B-PP O
15 1098 1101 8931709 APC NN B-NP B-Disease
16 1102 1104 8931709 do VBP B-VP O
17 1105 1108 8931709 not RB I-VP O
18 1109 1115 8931709 result VB I-VP O
19 1116 1118 8931709 in IN B-PP O
20 1119 1129 8931709 detectable JJ B-NP O
21 1130 1139 8931709 truncated VBN I-NP O
22 1140 1152 8931709 polypeptides NNS I-NP O
23 1153 1156 8931709 and CC O O
24 1157 1159 8931709 we PRP B-NP O
25 1160 1171 8931709 hypothesize VBP B-VP O
26 1172 1176 8931709 that IN B-SBAR O
27 1177 1181 8931709 this DT B-NP O
28 1182 1184 8931709 is VBZ B-VP O
29 1185 1191 8931709 likely JJ B-ADJP O
30 1192 1194 8931709 to TO B-VP O
31 1195 1197 8931709 be VB I-VP O
32 1198 1201 8931709 the DT B-NP O
33 1202 1207 8931709 basis NN I-NP O
34 1208 1211 8931709 for IN B-PP O
35 1212 1215 8931709 the DT B-NP O
36 1216 1224 8931709 observed VBN I-NP O
37 1225 1229 8931709 AAPC NN I-NP B-Disease
38 1230 1239 8931709 phenotype NN I-NP O
39 1239 1240 8931709 . . O O
40 1240 1241 8931709 . . O O

1 0 0 8661102 -DOCSTART- -X- -X- O

1 0 14 8661102 Identification NN B-NP O
2 15 18 8661102 and CC O O
3 19 30 8661102 chromosomal JJ B-NP O
4 31 43 8661102 localization NN I-NP O
5 44 46 8661102 of IN B-PP O
6 47 50 8661102 Atm NNP B-NP O
7 50 51 8661102 , , O O
8 52 55 8661102 the DT B-NP O
9 56 61 8661102 mouse NN I-NP O
10 62 69 8661102 homolog NN I-NP O
11 70 72 8661102 of IN B-PP O
12 73 76 8661102 the DT B-NP O
13 77 83 8661102 ataxia NN I-NP B-Disease
14 83 84 8661102 - HYPH B-NP I-Disease
15 84 98 8661102 telangiectasia NN I-NP I-Disease
16 99 103 8661102 gene NN I-NP O
17 103 104 8661102 . . O O
18 105 108 8661102 Atm NNP B-NP O
19 108 109 8661102 , , O O
20 110 113 8661102 the DT B-NP O
21 114 119 8661102 mouse NN I-NP O
22 120 127 8661102 homolog NN I-NP O
23 128 130 8661102 of IN B-PP O
24 131 134 8661102 the DT B-NP O
25 135 140 8661102 human JJ I-NP O
26 141 144 8661102 ATM NN I-NP O
27 145 149 8661102 gene NN I-NP O
28 150 159 8661102 defective JJ B-ADJP O
29 160 162 8661102 in IN B-PP O
30 163 169 8661102 ataxia NN B-NP B-Disease
31 169 170 8661102 - HYPH B-NP I-Disease
32 170 184 8661102 telangiectasia NN I-NP I-Disease
33 185 186 8661102 ( ( O O
34 186 187 8661102 A NN B-NP B-Disease
35 187 188 8661102 - HYPH O I-Disease
36 188 189 8661102 T NN B-NP I-Disease
37 189 190 8661102 ) ) O O
38 190 191 8661102 , , O O
39 192 195 8661102 has VBZ B-VP O
40 196 200 8661102 been VBN I-VP O
41 201 211 8661102 identified VBN I-VP O
42 211 212 8661102 . . O O

1 213 216 8661102 The DT B-NP O
2 217 223 8661102 entire JJ I-NP O
3 224 230 8661102 coding VBG I-NP O
4 231 239 8661102 sequence NN I-NP O
5 240 242 8661102 of IN B-PP O
6 243 246 8661102 the DT B-NP O
7 247 250 8661102 Atm NNP I-NP O
8 251 261 8661102 transcript NN I-NP O
9 262 265 8661102 was VBD B-VP O
10 266 272 8661102 cloned VBN I-VP O
11 273 276 8661102 and CC O O
12 277 282 8661102 found VBN B-VP O
13 283 285 8661102 to TO I-VP O
14 286 293 8661102 contain VB I-VP O
15 294 296 8661102 an DT B-NP O
16 297 301 8661102 open JJ I-NP O
17 302 309 8661102 reading NN I-NP O
18 310 315 8661102 frame NN I-NP O
19 316 324 8661102 encoding VBG B-VP O
20 325 326 8661102 a DT B-NP O
21 327 334 8661102 protein NN I-NP O
22 335 337 8661102 of IN B-PP O
23 338 342 8661102 3066 CD B-NP O
24 343 348 8661102 amino NN I-NP O
25 349 354 8661102 acids NNS I-NP O
26 355 359 8661102 with IN B-PP O
27 360 363 8661102 84% NN B-NP O
28 364 371 8661102 overall JJ I-NP O
29 372 380 8661102 identity NN I-NP O
30 381 384 8661102 and CC O O
31 385 388 8661102 91% CD B-NP O
32 389 399 8661102 similarity NN I-NP O
33 400 402 8661102 to TO B-PP O
34 403 406 8661102 the DT B-NP O
35 407 412 8661102 human JJ I-NP O
36 413 416 8661102 ATM NN I-NP O
37 417 424 8661102 protein NN I-NP O
38 424 425 8661102 . . O O

1 426 434 8661102 Variable JJ B-NP O
2 435 441 8661102 levels NNS I-NP O
3 442 444 8661102 of IN B-PP O
4 445 455 8661102 expression NN B-NP O
5 456 458 8661102 of IN B-PP O
6 459 462 8661102 Atm NN B-NP O
7 463 467 8661102 were VBD B-VP O
8 468 476 8661102 observed VBN I-VP O
9 477 479 8661102 in IN B-PP O
10 480 489 8661102 different JJ B-NP O
11 490 497 8661102 tissues NNS I-NP O
12 497 498 8661102 . . O O

1 499 511 8661102 Fluorescence NN B-NP O
2 512 514 8661102 in FW B-NP O
3 515 519 8661102 situ FW I-NP O
4 520 533 8661102 hybridization NN I-NP O
5 534 537 8661102 and CC I-NP O
6 538 545 8661102 linkage NN I-NP O
7 546 554 8661102 analysis NN I-NP O
8 555 562 8661102 located JJ B-VP O
9 563 566 8661102 the DT B-NP O
10 567 570 8661102 Atm NN I-NP O
11 571 575 8661102 gene NN I-NP O
12 576 578 8661102 on IN B-PP O
13 579 584 8661102 mouse NN B-NP O
14 585 595 8661102 chromosome NN I-NP O
15 596 597 8661102 9 CD I-NP O
16 597 598 8661102 , , O O
17 599 603 8661102 band NN B-NP O
18 604 606 8661102 9C NN I-NP O
19 606 607 8661102 , , O O
20 608 610 8661102 in IN B-PP O
21 611 612 8661102 a DT B-NP O
22 613 619 8661102 region NN I-NP O
23 620 630 8661102 homologous JJ B-ADJP O
24 631 633 8661102 to TO B-PP O
25 634 637 8661102 the DT B-NP O
26 638 641 8661102 ATM NN I-NP O
27 642 648 8661102 region NN I-NP O
28 649 651 8661102 on IN B-PP O
29 652 657 8661102 human JJ B-NP O
30 658 668 8661102 chromosome NN I-NP O
31 669 674 8661102 11q22 NN I-NP O
32 674 675 8661102 - HYPH B-NP O
33 675 678 8661102 q23 NN I-NP O
34 678 679 8661102 . . O O
35 679 680 8661102 . . O O

1 0 0 9145677 -DOCSTART- -X- -X- O

1 0 5 9145677 BRCA1 NN B-NP O
2 6 15 9145677 mutations NNS I-NP O
3 16 18 9145677 in IN B-PP O
4 19 24 9145677 women NNS B-NP O
5 25 34 9145677 attending VBG B-VP O
6 35 42 9145677 clinics NNS B-NP O
7 43 47 9145677 that WDT B-NP O
8 48 56 9145677 evaluate VBP B-VP O
9 57 60 9145677 the DT B-NP O
10 61 65 9145677 risk NN I-NP O
11 66 68 9145677 of IN B-PP O
12 69 75 9145677 breast NN B-NP B-Disease
13 76 82 9145677 cancer NN I-NP I-Disease
14 82 83 9145677 . . I-NP O
15 84 94 9145677 BACKGROUND NN I-NP O
16 96 98 9145677 To TO B-VP O
17 99 105 9145677 define VB I-VP O
18 106 109 9145677 the DT B-NP O
19 110 119 9145677 incidence NN I-NP O
20 120 122 9145677 of IN B-PP O
21 123 128 9145677 BRCA1 NN B-NP O
22 129 138 9145677 mutations NNS I-NP O
23 139 144 9145677 among IN B-PP O
24 145 153 9145677 patients NNS B-NP O
25 154 158 9145677 seen VBN B-VP O
26 159 161 9145677 in IN B-PP O
27 162 169 9145677 clinics NNS B-NP O
28 170 174 9145677 that WDT B-NP O
29 175 183 9145677 evaluate VBP B-VP O
30 184 187 9145677 the DT B-NP O
31 188 192 9145677 risk NN I-NP O
32 193 195 9145677 of IN B-PP O
33 196 202 9145677 breast NN B-NP B-Disease
34 203 209 9145677 cancer NN I-NP I-Disease
35 209 210 9145677 , , O O
36 211 213 9145677 we PRP B-NP O
37 214 222 9145677 analyzed VBD B-VP O
38 223 226 9145677 DNA NN B-NP O
39 227 234 9145677 samples NNS I-NP O
40 235 239 9145677 from IN B-PP O
41 240 245 9145677 women NNS B-NP O
42 246 250 9145677 seen VBN B-VP O
43 251 253 9145677 in IN B-PP O
44 254 258 9145677 this DT B-NP O
45 259 266 9145677 setting VBG I-NP O
46 267 270 9145677 and CC I-NP O
47 271 282 9145677 constructed VBN I-NP O
48 283 294 9145677 probability NN I-NP O
49 295 301 9145677 tables NNS I-NP O
50 302 304 9145677 to TO B-VP O
51 305 312 9145677 provide VB I-VP O
52 313 322 9145677 estimates NNS B-NP O
53 323 325 9145677 of IN B-PP O
54 326 329 9145677 the DT B-NP O
55 330 340 9145677 likelihood NN I-NP O
56 341 343 9145677 of IN B-PP O
57 344 351 9145677 finding VBG B-VP O
58 352 353 9145677 a DT B-NP O
59 354 359 9145677 BRCA1 NN I-NP O
60 360 368 9145677 mutation NN I-NP O
61 369 371 9145677 in IN B-PP O
62 372 382 9145677 individual JJ B-NP O
63 383 391 9145677 families NNS I-NP O
64 391 392 9145677 . . O O

1 393 400 9145677 METHODS NNS B-NP O
2 402 410 9145677 Clinical JJ I-NP O
3 411 422 9145677 information NN I-NP O
4 422 423 9145677 , , O O
5 424 430 9145677 family NN B-NP O
6 431 440 9145677 histories NNS I-NP O
7 440 441 9145677 , , O O
8 442 445 9145677 and CC O O
9 446 451 9145677 blood NN B-NP O
10 452 455 9145677 for IN B-PP O
11 456 459 9145677 DNA NN B-NP O
12 460 468 9145677 analysis NN I-NP O
13 469 473 9145677 were VBD B-VP O
14 474 482 9145677 obtained VBN I-VP O
15 483 487 9145677 from IN B-PP O
16 488 491 9145677 263 CD B-NP O
17 492 497 9145677 women NNS I-NP O
18 498 502 9145677 with IN B-PP O
19 503 509 9145677 breast NN B-NP B-Disease
20 510 516 9145677 cancer NN I-NP I-Disease
21 516 517 9145677 . . O O

1 518 530 9145677 Conformation NN B-NP O
2 530 531 9145677 - HYPH I-NP O
3 531 540 9145677 sensitive JJ I-NP O
4 541 544 9145677 gel NN I-NP O
5 545 560 9145677 electrophoresis NN I-NP O
6 561 564 9145677 and CC O O
7 565 568 9145677 DNA NN B-NP O
8 569 579 9145677 sequencing NN I-NP O
9 580 584 9145677 were VBD B-VP O
10 585 589 9145677 used VBN I-VP O
11 590 592 9145677 to TO B-VP O
12 593 601 9145677 identify VB I-VP O
13 602 607 9145677 BRCA1 NN B-NP O
14 608 617 9145677 mutations NNS I-NP O
15 617 618 9145677 . . O O

1 619 626 9145677 RESULTS NNS B-NP O
2 628 633 9145677 BRCA1 NN I-NP O
3 634 643 9145677 mutations NNS I-NP O
4 644 648 9145677 were VBD B-VP O
5 649 659 9145677 identified VBN I-VP O
6 660 662 9145677 in IN B-PP O
7 663 665 9145677 16 CD B-NP O
8 666 673 9145677 percent NN I-NP O
9 674 676 9145677 of IN B-PP O
10 677 682 9145677 women NNS B-NP O
11 683 687 9145677 with IN B-PP O
12 688 689 9145677 a DT B-NP O
13 690 696 9145677 family NN I-NP O
14 697 704 9145677 history NN I-NP O
15 705 707 9145677 of IN B-PP O
16 708 714 9145677 breast NN B-NP B-Disease
17 715 721 9145677 cancer NN I-NP I-Disease
18 721 722 9145677 . . O O

1 723 727 9145677 Only RB B-NP O
2 728 729 9145677 7 CD I-NP O
3 730 737 9145677 percent NN I-NP O
4 738 740 9145677 of IN B-PP O
5 741 746 9145677 women NNS B-NP O
6 747 751 9145677 from IN B-PP O
7 752 760 9145677 families NNS B-NP O
8 761 765 9145677 with IN B-PP O
9 766 767 9145677 a DT B-NP O
10 768 775 9145677 history NN I-NP O
11 776 778 9145677 of IN B-PP O
12 779 785 9145677 breast NN B-NP B-Disease
13 786 792 9145677 cancer NN I-NP I-Disease
14 793 796 9145677 but CC B-CONJP O
15 797 800 9145677 not RB I-CONJP O
16 801 808 9145677 ovarian JJ B-NP B-Disease
17 809 815 9145677 cancer NN I-NP I-Disease
18 816 819 9145677 had VBD B-VP O
19 820 825 9145677 BRCA1 NN B-NP O
20 826 835 9145677 mutations NNS I-NP O
21 835 836 9145677 . . O O

1 837 840 9145677 The DT B-NP O
2 841 846 9145677 rates NNS I-NP O
3 847 851 9145677 were VBD B-VP O
4 852 858 9145677 higher JJR B-ADJP O
5 859 864 9145677 among IN B-PP O
6 865 870 9145677 women NNS B-NP O
7 871 875 9145677 from IN B-PP O
8 876 884 9145677 families NNS B-NP O
9 885 889 9145677 with IN B-PP O
10 890 891 9145677 a DT B-NP O
11 892 899 9145677 history NN I-NP O
12 900 902 9145677 of IN B-PP O
13 903 907 9145677 both CC O O
14 908 914 9145677 breast NN B-NP B-Disease
15 915 918 9145677 and CC O I-Disease
16 919 926 9145677 ovarian JJ B-NP I-Disease
17 927 933 9145677 cancer NN I-NP I-Disease
18 933 934 9145677 . . O O

1 935 940 9145677 Among IN B-PP O
2 941 947 9145677 family NN B-NP O
3 948 955 9145677 members NNS I-NP O
4 955 956 9145677 , , O O
5 957 959 9145677 an DT B-NP O
6 960 967 9145677 average JJ I-NP O
7 968 971 9145677 age NN I-NP O
8 972 974 9145677 of IN B-PP O
9 975 979 9145677 less JJR B-NP O
10 980 984 9145677 than IN I-NP O
11 985 987 9145677 55 CD I-NP O
12 988 993 9145677 years NNS I-NP O
13 994 996 9145677 at IN B-PP O
14 997 1000 9145677 the DT B-NP O
15 1001 1010 9145677 diagnosis NN I-NP O
16 1011 1013 9145677 of IN B-PP O
17 1014 1020 9145677 breast NN B-NP B-Disease
18 1021 1027 9145677 cancer NN I-NP I-Disease
19 1027 1028 9145677 , , O O
20 1029 1032 9145677 the DT B-NP O
21 1033 1041 9145677 presence NN I-NP O
22 1042 1044 9145677 of IN B-PP O
23 1045 1052 9145677 ovarian JJ B-NP B-Disease
24 1053 1059 9145677 cancer NN I-NP I-Disease
25 1059 1060 9145677 , , O O
26 1061 1064 9145677 the DT B-NP O
27 1065 1073 9145677 presence NN I-NP O
28 1074 1076 9145677 of IN B-PP O
29 1077 1083 9145677 breast NN B-NP B-Disease
30 1084 1087 9145677 and CC O I-Disease
31 1088 1095 9145677 ovarian JJ B-NP I-Disease
32 1096 1102 9145677 cancer NN I-NP I-Disease
33 1103 1105 9145677 in IN B-PP O
34 1106 1109 9145677 the DT B-NP O
35 1110 1114 9145677 same JJ I-NP O
36 1115 1120 9145677 woman NN I-NP O
37 1120 1121 9145677 , , O O
38 1122 1125 9145677 and CC O O
39 1126 1135 9145677 Ashkenazi NNP B-NP O
40 1136 1142 9145677 Jewish JJ I-NP O
41 1143 1151 9145677 ancestry NN I-NP O
42 1152 1156 9145677 were VBD B-VP O
43 1157 1160 9145677 all DT O O
44 1161 1171 9145677 associated VBN B-VP O
45 1172 1176 9145677 with IN B-PP O
46 1177 1179 9145677 an DT B-NP O
47 1180 1189 9145677 increased VBN I-NP O
48 1190 1194 9145677 risk NN I-NP O
49 1195 1197 9145677 of IN B-PP O
50 1198 1207 9145677 detecting VBG B-VP O
51 1208 1209 9145677 a DT B-NP O
52 1210 1215 9145677 BRCA1 NN I-NP O
53 1216 1224 9145677 mutation NN I-NP O
54 1224 1225 9145677 . . O O

1 1226 1228 9145677 No DT B-NP O
2 1229 1240 9145677 association NN I-NP O
3 1241 1244 9145677 was VBD B-VP O
4 1245 1250 9145677 found VBN I-VP O
5 1251 1258 9145677 between IN B-PP O
6 1259 1262 9145677 the DT B-NP O
7 1263 1271 9145677 presence NN I-NP O
8 1272 1274 9145677 of IN B-PP O
9 1275 1284 9145677 bilateral JJ B-NP O
10 1285 1291 9145677 breast NN I-NP B-Disease
11 1292 1298 9145677 cancer NN I-NP I-Disease
12 1299 1301 9145677 or CC O O
13 1302 1305 9145677 the DT B-NP O
14 1306 1312 9145677 number NN I-NP O
15 1313 1315 9145677 of IN B-PP O
16 1316 1322 9145677 breast NN B-NP B-Disease
17 1323 1330 9145677 cancers NNS I-NP I-Disease
18 1331 1333 9145677 in IN B-PP O
19 1334 1335 9145677 a DT B-NP O
20 1336 1342 9145677 family NN I-NP O
21 1343 1346 9145677 and CC O O
22 1347 1350 9145677 the DT B-NP O
23 1351 1360 9145677 detection NN I-NP O
24 1361 1363 9145677 of IN B-PP O
25 1364 1365 9145677 a DT B-NP O
26 1366 1371 9145677 BRCA1 NN I-NP O
27 1372 1380 9145677 mutation NN I-NP O
28 1380 1381 9145677 , , O O
29 1382 1384 9145677 or CC O O
30 1385 1392 9145677 between IN B-PP O
31 1393 1396 9145677 the DT B-NP O
32 1397 1405 9145677 position NN I-NP O
33 1406 1408 9145677 of IN B-PP O
34 1409 1412 9145677 the DT B-NP O
35 1413 1421 9145677 mutation NN I-NP O
36 1422 1424 9145677 in IN B-PP O
37 1425 1428 9145677 the DT B-NP O
38 1429 1434 9145677 BRCA1 NN I-NP O
39 1435 1439 9145677 gene NN I-NP O
40 1440 1443 9145677 and CC O O
41 1444 1447 9145677 the DT B-NP O
42 1448 1456 9145677 presence NN I-NP O
43 1457 1459 9145677 of IN B-PP O
44 1460 1467 9145677 ovarian JJ B-NP B-Disease
45 1468 1474 9145677 cancer NN I-NP I-Disease
46 1475 1477 9145677 in IN B-PP O
47 1478 1479 9145677 a DT B-NP O
48 1480 1486 9145677 family NN I-NP O
49 1486 1487 9145677 . . O O

1 1488 1499 9145677 CONCLUSIONS NNS B-NP O
2 1501 1506 9145677 Among IN B-PP O
3 1507 1512 9145677 women NNS B-NP O
4 1513 1517 9145677 with IN B-PP O
5 1518 1524 9145677 breast NN B-NP B-Disease
6 1525 1531 9145677 cancer NN I-NP I-Disease
7 1532 1535 9145677 and CC O O
8 1536 1537 9145677 a DT B-NP O
9 1538 1544 9145677 family NN I-NP O
10 1545 1552 9145677 history NN I-NP O
11 1553 1555 9145677 of IN B-PP O
12 1556 1559 9145677 the DT B-NP O
13 1560 1567 9145677 disease NN I-NP O
14 1567 1568 9145677 , , O O
15 1569 1572 9145677 the DT B-NP O
16 1573 1583 9145677 percentage NN I-NP O
17 1584 1588 9145677 with IN B-PP O
18 1589 1594 9145677 BRCA1 NN B-NP O
19 1595 1601 9145677 coding NN I-NP O
20 1601 1602 9145677 - HYPH B-NP O
21 1602 1608 9145677 region NN I-NP O
22 1609 1618 9145677 mutations NNS I-NP O
23 1619 1621 9145677 is VBZ B-VP O
24 1622 1626 9145677 less JJR B-ADJP O
25 1627 1631 9145677 than IN B-PP O
26 1632 1635 9145677 the DT B-NP O
27 1636 1638 9145677 45 CD I-NP O
28 1639 1646 9145677 percent NN I-NP O
29 1647 1656 9145677 predicted VBN B-VP O
30 1657 1659 9145677 by IN B-PP O
31 1660 1667 9145677 genetic JJ B-NP O
32 1667 1668 9145677 - HYPH I-NP O
33 1668 1675 9145677 linkage NN I-NP O
34 1676 1684 9145677 analysis NN I-NP O
35 1684 1685 9145677 . . O O

1 1686 1691 9145677 These DT B-NP O
2 1692 1699 9145677 results NNS I-NP O
3 1700 1707 9145677 suggest VBP B-VP O
4 1708 1712 9145677 that IN B-SBAR O
5 1713 1717 9145677 even RB B-PP O
6 1718 1720 9145677 in IN I-PP O
7 1721 1722 9145677 a DT B-NP O
8 1723 1731 9145677 referral JJ I-NP O
9 1732 1738 9145677 clinic NN I-NP O
10 1739 1751 9145677 specializing VBG B-VP O
11 1752 1754 9145677 in IN B-PP O
12 1755 1764 9145677 screening VBG B-VP O
13 1765 1770 9145677 women NNS B-NP O
14 1771 1775 9145677 from IN B-PP O
15 1776 1780 9145677 high JJ B-NP O
16 1780 1781 9145677 - HYPH I-NP O
17 1781 1785 9145677 risk NN I-NP O
18 1786 1794 9145677 families NNS I-NP O
19 1794 1795 9145677 , , O O
20 1796 1799 9145677 the DT B-NP O
21 1800 1808 9145677 majority NN I-NP O
22 1809 1811 9145677 of IN B-PP O
23 1812 1817 9145677 tests NNS B-NP O
24 1818 1821 9145677 for IN B-PP O
25 1822 1827 9145677 BRCA1 NN B-NP O
26 1828 1837 9145677 mutations NNS I-NP O
27 1838 1842 9145677 will MD B-VP O
28 1843 1845 9145677 be VB I-VP O
29 1846 1854 9145677 negative JJ B-ADJP O
30 1855 1858 9145677 and CC O O
31 1859 1868 9145677 therefore RB B-ADJP O
32 1869 1882 9145677 uninformative JJ I-ADJP O
33 1882 1883 9145677 . . O O
34 1883 1884 9145677 . . O O

1 0 0 8841191 -DOCSTART- -X- -X- O

1 0 9 8841191 Ashkenazi NN B-NP O
2 10 16 8841191 Jewish JJ I-NP O
3 17 27 8841191 population NN I-NP O
4 28 39 8841191 frequencies NNS I-NP O
5 40 43 8841191 for IN B-PP O
6 44 50 8841191 common JJ B-NP O
7 51 60 8841191 mutations NNS I-NP O
8 61 63 8841191 in IN B-PP O
9 64 69 8841191 BRCA1 NN B-NP O
10 70 73 8841191 and CC I-NP O
11 74 79 8841191 BRCA2 NN I-NP O
12 79 80 8841191 . . O O
13 81 86 8841191 BRCA1 NN B-NP O
14 87 90 8841191 and CC I-NP O
15 91 96 8841191 BRCA2 NN I-NP O
16 97 100 8841191 are VBP B-VP O
17 101 104 8841191 the DT B-NP O
18 105 108 8841191 two CD I-NP O
19 109 114 8841191 major JJ I-NP O
20 115 125 8841191 identified VBN I-NP O
21 126 132 8841191 causes NNS I-NP O
22 133 135 8841191 of IN B-PP O
23 136 145 8841191 inherited VBN B-NP B-Disease
24 146 152 8841191 breast NN I-NP I-Disease
25 153 159 8841191 cancer NN I-NP I-Disease
26 159 160 8841191 , , O O
27 161 165 8841191 with IN B-PP O
28 166 175 8841191 mutations NNS B-NP O
29 176 178 8841191 in IN B-PP O
30 179 185 8841191 either DT B-NP O
31 186 190 8841191 gene NN I-NP O
32 191 201 8841191 conferring VBG B-VP O
33 202 204 8841191 up IN B-NP O
34 205 207 8841191 to TO I-NP O
35 208 210 8841191 80 CD I-NP O
36 210 211 8841191 - HYPH I-NP O
37 211 214 8841191 90% CD I-NP O
38 215 223 8841191 lifetime NN I-NP O
39 224 228 8841191 risk NN I-NP O
40 229 231 8841191 of IN B-PP O
41 232 238 8841191 breast NN B-NP B-Disease
42 239 245 8841191 cancer NN I-NP I-Disease
43 246 248 8841191 in IN B-PP O
44 249 256 8841191 carrier NN B-NP O
45 257 264 8841191 females NNS I-NP O
46 264 265 8841191 . . O O

1 266 275 8841191 Mutations NNS B-NP O
2 276 278 8841191 in IN B-PP O
3 279 284 8841191 BRCA1 NN B-NP O
4 285 292 8841191 account NN I-NP O
5 293 296 8841191 for IN B-PP O
6 297 310 8841191 approximately RB B-NP O
7 311 314 8841191 45% CD I-NP O
8 315 317 8841191 of IN B-PP O
9 318 326 8841191 familial JJ B-NP B-Disease
10 327 333 8841191 breast NN I-NP I-Disease
11 334 340 8841191 cancer NN I-NP I-Disease
12 341 344 8841191 and CC O O
13 345 348 8841191 90% NN B-NP O
14 349 351 8841191 of IN B-PP O
15 352 361 8841191 inherited VBN B-NP B-Disease
16 362 368 8841191 breast NN I-NP I-Disease
17 368 369 8841191 / SYM B-NP I-Disease
18 369 376 8841191 ovarian JJ B-NP I-Disease
19 377 383 8841191 cancer NN I-NP I-Disease
20 383 384 8841191 , , O O
21 385 392 8841191 whereas IN O O
22 393 402 8841191 mutations NNS B-NP O
23 403 405 8841191 in IN B-PP O
24 406 411 8841191 BRCA2 NN B-NP O
25 412 419 8841191 account NN I-NP O
26 420 423 8841191 for IN B-PP O
27 424 425 8841191 a DT B-NP O
28 426 436 8841191 comparable JJ I-NP O
29 437 447 8841191 percentage NN I-NP O
30 448 450 8841191 of IN B-PP O
31 451 460 8841191 inherited VBN B-NP B-Disease
32 461 467 8841191 breast NN I-NP I-Disease
33 468 474 8841191 cancer NN I-NP I-Disease
34 475 480 8841191 cases NNS I-NP O
35 480 481 8841191 . . O O

1 482 486 8841191 Over IN B-PP O
2 487 489 8841191 85 CD B-NP O
3 490 498 8841191 distinct JJ I-NP O
4 499 504 8841191 BRCA1 NN I-NP O
5 505 514 8841191 mutations NNS I-NP O
6 515 518 8841191 and CC O O
7 519 520 8841191 a DT B-NP O
8 521 528 8841191 growing VBG I-NP O
9 529 533 8841191 list NN I-NP O
10 534 536 8841191 of IN B-PP O
11 537 542 8841191 BRCA2 NN B-NP O
12 543 552 8841191 mutations NNS I-NP O
13 553 557 8841191 have VBP B-VP O
14 558 562 8841191 been VBN I-VP O
15 563 573 8841191 identified VBN I-VP O
16 573 574 8841191 , , O O
17 575 579 8841191 with IN B-PP O
18 580 583 8841191 the DT B-NP O
19 584 592 8841191 majority NN I-NP O
20 593 602 8841191 resulting VBG B-VP O
21 603 605 8841191 in IN B-PP O
22 606 613 8841191 protein NN B-NP O
23 614 624 8841191 truncation NN I-NP O
24 624 625 8841191 . . O O

1 626 627 8841191 A DT B-NP O
2 628 636 8841191 specific JJ I-NP O
3 637 642 8841191 BRCA1 NN I-NP O
4 643 651 8841191 mutation NN I-NP O
5 651 652 8841191 , , O O
6 653 661 8841191 185delAG NN B-NP O
7 661 662 8841191 , , O O
8 663 666 8841191 has VBZ B-VP O
9 667 668 8841191 a DT B-NP O
10 669 677 8841191 reported VBN I-NP O
11 678 687 8841191 increased VBN I-NP O
12 688 695 8841191 carrier NN I-NP O
13 696 705 8841191 frequency NN I-NP O
14 706 708 8841191 of IN B-PP O
15 709 722 8841191 approximately RB B-NP O
16 723 724 8841191 0 CD I-NP O
17 724 725 8841191 . . O O

1 726 728 8841191 9% CD B-NP O
2 729 731 8841191 in IN B-PP O
3 732 735 8841191 the DT B-NP O
4 736 745 8841191 Ashkenazi NNP I-NP O
5 746 752 8841191 Jewish NNP I-NP O
6 753 763 8841191 population NN I-NP O
7 763 764 8841191 , , O O
8 765 768 8841191 but CC O O
9 769 771 8841191 is VBZ B-VP O
10 772 776 8841191 also RB I-VP O
11 777 782 8841191 found VBN I-VP O
12 783 785 8841191 in IN B-PP O
13 786 790 8841191 rare JJ B-NP O
14 791 794 8841191 non AFX I-NP O
15 794 795 8841191 - HYPH I-NP O
16 795 801 8841191 Jewish JJ B-NP O
17 802 810 8841191 patients NNS I-NP O
18 811 815 8841191 with IN B-PP O
19 816 817 8841191 a DT B-NP O
20 818 827 8841191 different JJ I-NP O
21 828 837 8841191 haplotype NN I-NP O
22 837 838 8841191 . . O O

1 839 842 8841191 The DT B-NP O
2 843 851 8841191 6174delT NN I-NP O
3 852 860 8841191 mutation NN I-NP O
4 861 863 8841191 in IN B-PP O
5 864 869 8841191 BRCA2 NN B-NP O
6 870 873 8841191 was VBD B-VP O
7 874 882 8841191 recently RB I-VP O
8 883 893 8841191 identified VBN I-VP O
9 894 896 8841191 as IN B-PP O
10 897 898 8841191 a DT B-NP O
11 899 907 8841191 frequent JJ I-NP O
12 908 916 8841191 mutation NN I-NP O
13 917 919 8841191 in IN B-PP O
14 920 921 8841191 8 CD B-NP O
15 922 925 8841191 out IN I-NP O
16 926 928 8841191 of IN I-NP O
17 929 932 8841191 107 CD I-NP O
18 933 942 8841191 Ashkenazi NN I-NP O
19 943 949 8841191 Jewish JJ I-NP O
20 950 955 8841191 women NNS I-NP O
21 956 965 8841191 diagnosed VBN B-VP O
22 966 970 8841191 with IN B-PP O
23 971 977 8841191 breast NN B-NP B-Disease
24 978 984 8841191 cancer NN I-NP I-Disease
25 985 987 8841191 by IN B-PP O
26 988 991 8841191 age NN B-NP O
27 992 994 8841191 50 CD I-NP O
28 995 996 8841191 ( ( O O
29 996 999 8841191 ref NN B-NP O
30 999 1000 8841191 . . O O

1 1001 1002 8841191 8 CD B-NP O
2 1002 1003 8841191 ) ) O O
3 1003 1004 8841191 , , O O
4 1005 1007 8841191 as RB B-CONJP O
5 1008 1012 8841191 well RB I-CONJP O
6 1013 1015 8841191 as IN I-CONJP O
7 1016 1018 8841191 in IN B-PP O
8 1019 1024 8841191 three CD B-NP O
9 1025 1034 8841191 Ashkenazi NNP I-NP O
10 1035 1039 8841191 male JJ I-NP B-Disease
11 1040 1046 8841191 breast NN I-NP I-Disease
12 1047 1053 8841191 cancer NN I-NP I-Disease
13 1054 1062 8841191 patients NNS I-NP O
14 1062 1063 8841191 . . O O

1 1064 1066 8841191 We PRP B-NP O
2 1067 1071 8841191 have VBP B-VP O
3 1072 1081 8841191 conducted VBN I-VP O
4 1082 1083 8841191 a DT B-NP O
5 1084 1089 8841191 large JJ I-NP O
6 1089 1090 8841191 - HYPH I-NP O
7 1090 1095 8841191 scale NN I-NP O
8 1096 1106 8841191 population NN I-NP O
9 1107 1112 8841191 study NN I-NP O
10 1113 1115 8841191 to TO B-VP O
11 1116 1127 8841191 investigate VB I-VP O
12 1128 1131 8841191 the DT B-NP O
13 1132 1142 8841191 prevalence NN I-NP O
14 1143 1145 8841191 of IN B-PP O
15 1146 1154 8841191 specific JJ B-NP O
16 1155 1160 8841191 BRCA1 NN I-NP O
17 1161 1164 8841191 and CC I-NP O
18 1165 1170 8841191 BRCA2 NN I-NP O
19 1171 1180 8841191 mutations NNS I-NP O
20 1181 1183 8841191 in IN B-PP O
21 1184 1193 8841191 Ashkenazi NNP B-NP O
22 1194 1200 8841191 Jewish JJ I-NP O
23 1201 1212 8841191 individuals NNS I-NP O
24 1213 1216 8841191 who WP B-NP O
25 1217 1221 8841191 were VBD B-VP O
26 1222 1232 8841191 unselected VBN I-VP O
27 1233 1236 8841191 for IN B-PP O
28 1237 1243 8841191 breast NN B-NP B-Disease
29 1244 1250 8841191 cancer NN I-NP I-Disease
30 1250 1251 8841191 . . O O

1 1252 1257 8841191 BRCA1 NN B-NP O
2 1258 1266 8841191 mutation NN I-NP O
3 1267 1276 8841191 screening NN I-NP O
4 1277 1279 8841191 on IN B-PP O
5 1280 1293 8841191 approximately RB B-NP O
6 1294 1295 8841191 3 CD I-NP O
7 1295 1296 8841191 , , I-NP O
8 1297 1300 8841191 000 CD I-NP O
9 1301 1310 8841191 Ashkenazi NNP I-NP O
10 1311 1317 8841191 Jewish NNP I-NP O
11 1318 1325 8841191 samples NNS I-NP O
12 1326 1336 8841191 determined VBD B-VP O
13 1337 1338 8841191 a DT B-NP O
14 1339 1346 8841191 carrier NN I-NP O
15 1347 1356 8841191 frequency NN I-NP O
16 1357 1359 8841191 of IN B-PP O
17 1360 1361 8841191 1 CD B-NP O
18 1361 1362 8841191 . . O O

1 1363 1366 8841191 09% CD B-NP O
2 1367 1370 8841191 for IN B-PP O
3 1371 1374 8841191 the DT B-NP O
4 1375 1383 8841191 185delAG NN I-NP O
5 1384 1392 8841191 mutation NN I-NP O
6 1393 1396 8841191 and CC O O
7 1397 1398 8841191 0 CD B-NP O
8 1398 1399 8841191 . . O O

1 1400 1403 8841191 13% CD B-NP O
2 1404 1407 8841191 for IN B-PP O
3 1408 1411 8841191 the DT B-NP O
4 1412 1420 8841191 5382insC NN I-NP O
5 1421 1429 8841191 mutation NN I-NP O
6 1429 1430 8841191 . . O O

1 1431 1436 8841191 BRCA2 NN B-NP O
2 1437 1445 8841191 analysis NN I-NP O
3 1446 1448 8841191 on IN B-PP O
4 1449 1450 8841191 3 CD B-NP O
5 1450 1451 8841191 , , O O
6 1452 1455 8841191 085 CD B-NP O
7 1456 1467 8841191 individuals NNS I-NP O
8 1468 1472 8841191 from IN B-PP O
9 1473 1476 8841191 the DT B-NP O
10 1477 1481 8841191 same JJ I-NP O
11 1482 1492 8841191 population NN I-NP O
12 1493 1499 8841191 showed VBD B-VP O
13 1500 1501 8841191 a DT B-NP O
14 1502 1509 8841191 carrier NN I-NP O
15 1510 1519 8841191 frequency NN I-NP O
16 1520 1522 8841191 of IN B-PP O
17 1523 1524 8841191 1 CD B-NP O
18 1524 1525 8841191 . . O O

1 1526 1529 8841191 52% LS B-LST O
2 1530 1533 8841191 for IN B-PP O
3 1534 1537 8841191 the DT B-NP O
4 1538 1546 8841191 6174delT NN I-NP O
5 1547 1555 8841191 mutation NN I-NP O
6 1555 1556 8841191 . . O O

1 1557 1561 8841191 This DT B-NP O
2 1562 1570 8841191 expanded VBN I-NP O
3 1571 1581 8841191 population NN I-NP O
4 1581 1582 8841191 - HYPH O O
5 1582 1587 8841191 based VBN B-NP O
6 1588 1593 8841191 study NN I-NP O
7 1594 1602 8841191 confirms VBZ B-VP O
8 1603 1607 8841191 that IN B-SBAR O
9 1608 1611 8841191 the DT B-NP O
10 1612 1617 8841191 BRCA1 NN I-NP O
11 1618 1626 8841191 185delAG NN I-NP O
12 1627 1635 8841191 mutation NN I-NP O
13 1636 1639 8841191 and CC O O
14 1640 1643 8841191 the DT B-NP O
15 1644 1649 8841191 BRCA2 NN I-NP O
16 1650 1658 8841191 6174delT NN I-NP O
17 1659 1667 8841191 mutation NN I-NP O
18 1668 1678 8841191 constitute VBP B-VP O
19 1679 1682 8841191 the DT B-NP O
20 1683 1686 8841191 two CD I-NP O
21 1687 1691 8841191 most RBS I-NP O
22 1692 1700 8841191 frequent JJ I-NP O
23 1701 1709 8841191 mutation NN I-NP O
24 1710 1717 8841191 alleles NNS I-NP O
25 1718 1730 8841191 predisposing VBG B-VP O
26 1731 1733 8841191 to TO B-PP O
27 1734 1744 8841191 hereditary JJ B-NP B-Disease
28 1745 1751 8841191 breast NN I-NP I-Disease
29 1752 1758 8841191 cancer NN I-NP I-Disease
30 1759 1764 8841191 among IN B-PP O
31 1765 1768 8841191 the DT B-NP O
32 1769 1779 8841191 Ashkenazim NNP I-NP O
33 1779 1780 8841191 , , O O
34 1781 1784 8841191 and CC O O
35 1785 1793 8841191 suggests VBZ B-VP O
36 1794 1795 8841191 a DT B-NP O
37 1796 1806 8841191 relatively RB I-NP O
38 1807 1812 8841191 lower JJR I-NP O
39 1813 1823 8841191 penetrance NN I-NP O
40 1824 1827 8841191 for IN B-PP O
41 1828 1831 8841191 the DT B-NP O
42 1832 1840 8841191 6174delT NN I-NP O
43 1841 1849 8841191 mutation NN I-NP O
44 1850 1852 8841191 in IN B-PP O
45 1853 1858 8841191 BRCA2 NN B-NP O

1 0 0 8605116 -DOCSTART- -X- -X- O

1 0 8 8605116 Germline NN B-NP O
2 9 18 8605116 mutations NNS I-NP O
3 19 21 8605116 in IN B-PP O
4 22 25 8605116 the DT B-NP O
5 26 29 8605116 RB1 NN I-NP O
6 30 34 8605116 gene NN I-NP O
7 35 37 8605116 in IN B-PP O
8 38 46 8605116 patients NNS B-NP O
9 47 51 8605116 with IN B-PP O
10 52 62 8605116 hereditary JJ B-NP B-Disease
11 63 77 8605116 retinoblastoma NN I-NP I-Disease
12 77 78 8605116 . . O O
13 79 81 8605116 We PRP B-NP O
14 82 86 8605116 have VBP B-VP O
15 87 95 8605116 analyzed VBN I-VP O
16 96 99 8605116 the DT B-NP O
17 100 102 8605116 27 CD I-NP O
18 103 108 8605116 exons NNS I-NP O
19 109 112 8605116 and CC O O
20 113 116 8605116 the DT B-NP O
21 117 125 8605116 promoter NN I-NP O
22 126 132 8605116 region NN I-NP O
23 133 135 8605116 of IN B-PP O
24 136 139 8605116 the DT B-NP O
25 140 143 8605116 RB1 NN I-NP O
26 144 148 8605116 gene NN I-NP O
27 149 151 8605116 in IN B-PP O
28 152 160 8605116 familial JJ B-NP B-Disease
29 161 163 8605116 or CC I-NP I-Disease
30 164 172 8605116 sporadic JJ I-NP I-Disease
31 173 182 8605116 bilateral JJ I-NP I-Disease
32 183 197 8605116 retinoblastoma NN I-NP I-Disease
33 198 200 8605116 by IN B-PP O
34 201 206 8605116 using VBG B-VP O
35 207 213 8605116 single JJ B-NP O
36 213 214 8605116 - HYPH I-NP O
37 214 220 8605116 strand NN I-NP O
38 221 233 8605116 conformation NN I-NP O
39 234 246 8605116 polymorphism NN I-NP O
40 247 255 8605116 analysis NN I-NP O
41 255 256 8605116 . . O O

1 257 260 8605116 For IN B-PP O
2 261 272 8605116 improvement NN B-NP O
3 273 277 8605116 over IN B-PP O
4 278 286 8605116 previous JJ B-NP O
5 287 294 8605116 studies NNS I-NP O
6 294 295 8605116 , , O O
7 296 297 8605116 a DT B-NP O
8 298 301 8605116 new JJ I-NP O
9 302 305 8605116 set NN I-NP O
10 306 308 8605116 of IN B-PP O
11 309 316 8605116 primers NNS B-NP O
12 317 320 8605116 has VBZ B-VP O
13 321 325 8605116 been VBN I-VP O
14 326 334 8605116 designed VBN I-VP O
15 334 335 8605116 , , O O
16 336 341 8605116 which WDT B-NP O
17 342 347 8605116 allow VBP B-VP O
18 348 351 8605116 for IN B-PP O
19 352 365 8605116 amplification NN B-NP O
20 366 368 8605116 of IN B-PP O
21 369 372 8605116 the DT B-NP O
22 373 379 8605116 coding NN I-NP O
23 380 383 8605116 and CC I-NP O
24 384 392 8605116 splicing NN I-NP O
25 393 402 8605116 sequences NNS I-NP O
26 403 407 8605116 only RB B-ADVP O
27 407 408 8605116 . . O O

1 409 412 8605116 The DT B-NP O
2 413 424 8605116 positioning NN I-NP O
3 425 427 8605116 of IN B-PP O
4 428 431 8605116 the DT B-NP O
5 432 442 8605116 polymerase NN I-NP O
6 443 448 8605116 chain NN I-NP O
7 449 457 8605116 reaction NN I-NP O
8 458 459 8605116 ( ( O O
9 459 462 8605116 PCR NN B-NP O
10 462 463 8605116 ) ) O O
11 464 471 8605116 primers NNS B-NP O
12 472 475 8605116 was VBD B-VP O
13 476 480 8605116 such JJ B-ADJP O
14 481 485 8605116 that IN B-SBAR O
15 486 489 8605116 the DT B-NP O
16 490 499 8605116 resulting VBG I-NP O
17 500 503 8605116 PCR NN I-NP O
18 504 512 8605116 products NNS I-NP O
19 513 517 8605116 were VBD B-VP O
20 518 520 8605116 of IN B-PP O
21 521 530 8605116 different JJ B-NP O
22 531 536 8605116 sizes NNS I-NP O
23 536 537 8605116 , , O O
24 538 543 8605116 which WDT B-NP O
25 544 551 8605116 enabled VBD B-VP O
26 552 554 8605116 us PRP B-NP O
27 555 557 8605116 to TO B-VP O
28 558 565 8605116 analyze VB I-VP O
29 566 569 8605116 two CD B-NP O
30 570 579 8605116 different JJ I-NP O
31 580 585 8605116 exons NNS I-NP O
32 586 600 8605116 simultaneously RB B-ADVP O
33 601 604 8605116 and CC O O
34 605 610 8605116 still RB B-ADJP O
35 611 622 8605116 distinguish JJ I-ADJP O
36 623 630 8605116 between IN B-PP O
37 631 634 8605116 the DT B-NP O
38 635 642 8605116 banding NN I-NP O
39 643 651 8605116 profiles NNS I-NP O
40 652 655 8605116 for IN B-PP O
41 656 660 8605116 both DT B-NP O
42 661 662 8605116 ( ( O O
43 662 668 8605116 biplex NN B-NP O
44 669 677 8605116 analysis NN I-NP O
45 677 678 8605116 ) ) O O
46 678 679 8605116 . . O O

1 680 682 8605116 By IN B-PP O
2 683 688 8605116 using VBG B-VP O
3 689 693 8605116 this DT B-NP O
4 694 702 8605116 approach NN I-NP O
5 702 703 8605116 , , O O
6 704 706 8605116 we PRP B-NP O
7 707 711 8605116 were VBD B-VP O
8 712 716 8605116 able JJ B-ADJP O
9 717 719 8605116 to TO B-VP O
10 720 728 8605116 identify VB I-VP O
11 729 737 8605116 mutation NN B-NP O
12 738 740 8605116 in IN B-PP O
13 741 743 8605116 22 CD B-NP O
14 744 747 8605116 new JJ I-NP O
15 748 756 8605116 patients NNS I-NP O
16 756 757 8605116 , , O O
17 758 761 8605116 but CC O O
18 762 765 8605116 the DT B-NP O
19 766 773 8605116 overall JJ I-NP O
20 774 784 8605116 efficiency NN I-NP O
21 785 787 8605116 of IN B-PP O
22 788 791 8605116 the DT B-NP O
23 792 801 8605116 procedure NN I-NP O
24 802 806 8605116 when WRB B-ADVP O
25 807 809 8605116 we PRP B-NP O
26 810 814 8605116 used VBD B-VP O
27 815 816 8605116 a DT B-NP O
28 817 823 8605116 single JJ I-NP O
29 823 824 8605116 - HYPH I-NP O
30 824 828 8605116 pass NN I-NP O
31 829 836 8605116 regimen NN I-NP O
32 837 840 8605116 was VBD B-VP O
33 841 845 8605116 only RB B-NP O
34 846 849 8605116 48% CD I-NP O
35 849 850 8605116 . . O O

1 851 854 8605116 The DT B-NP O
2 855 864 8605116 mutations NNS I-NP O
3 865 869 8605116 were VBD B-VP O
4 870 875 8605116 small JJ B-NP O
5 876 886 8605116 insertions NNS I-NP O
6 887 890 8605116 and CC I-NP O
7 891 900 8605116 deletions NNS I-NP O
8 901 904 8605116 and CC O O
9 905 910 8605116 point NN B-NP O
10 911 920 8605116 mutations NNS I-NP O
11 921 923 8605116 in IN B-PP O
12 924 931 8605116 roughly RB B-NP O
13 932 937 8605116 equal JJ I-NP O
14 938 949 8605116 proportions NNS I-NP O
15 949 950 8605116 . . O O
16 950 951 8605116 . . O O

1 0 0 8968716 -DOCSTART- -X- -X- O

1 0 5 8968716 BRCA1 NN B-NP O
2 6 11 8968716 R841W NN I-NP O
3 11 12 8968716 : : O O
4 13 14 8968716 a DT B-NP O
5 15 21 8968716 strong JJ I-NP O
6 22 31 8968716 candidate NN I-NP O
7 32 35 8968716 for IN B-PP O
8 36 37 8968716 a DT B-NP O
9 38 44 8968716 common JJ I-NP O
10 45 53 8968716 mutation NN I-NP O
11 54 58 8968716 with IN B-PP O
12 59 67 8968716 moderate JJ B-NP O
13 68 77 8968716 phenotype NN I-NP O
14 77 78 8968716 . . O O
15 79 84 8968716 BRCA1 NN B-NP O
16 85 94 8968716 mutations NNS I-NP O
17 95 100 8968716 cause VBP B-VP O
18 101 110 8968716 increased VBN B-NP O
19 111 115 8968716 risk NN I-NP O
20 116 119 8968716 for IN B-PP O
21 120 126 8968716 breast NN B-NP B-Disease
22 127 130 8968716 and CC O I-Disease
23 131 138 8968716 ovarian JJ B-NP I-Disease
24 139 145 8968716 cancer NN I-NP I-Disease
25 145 146 8968716 , , O O
26 147 157 8968716 frequently RB B-ADVP O
27 158 160 8968716 of IN B-PP O
28 161 166 8968716 early JJ B-NP O
29 167 172 8968716 onset NN I-NP O
30 172 173 8968716 . . O O

1 174 178 8968716 Many JJ B-NP O
2 179 188 8968716 different JJ I-NP O
3 189 198 8968716 mutations NNS I-NP O
4 199 204 8968716 occur VBP B-VP O
5 205 207 8968716 in IN B-PP O
6 208 213 8968716 BRCA1 NN B-NP O
7 213 214 8968716 , , O O
8 215 224 8968716 including VBG B-PP O
9 225 232 8968716 several JJ B-NP O
10 233 241 8968716 examples NNS I-NP O
11 242 244 8968716 of IN B-PP O
12 245 254 8968716 recurrent JJ B-NP O
13 255 264 8968716 mutations NNS I-NP O
14 264 265 8968716 , , O O
15 266 270 8968716 each DT B-NP O
16 271 273 8968716 of IN B-PP O
17 274 279 8968716 which WDT B-NP O
18 280 288 8968716 accounts VBZ B-VP O
19 289 292 8968716 for IN B-PP O
20 293 294 8968716 a DT B-NP O
21 295 306 8968716 significant JJ I-NP O
22 307 313 8968716 number NN I-NP O
23 314 316 8968716 of IN B-PP O
24 317 325 8968716 families NNS B-NP O
25 326 330 8968716 with IN B-PP O
26 331 340 8968716 heritable JJ B-NP O
27 341 347 8968716 cancer NN I-NP B-Disease
28 348 362 8968716 predisposition NN I-NP O
29 362 363 8968716 . . O O

1 364 369 8968716 These DT B-NP O
2 370 376 8968716 common JJ I-NP O
3 377 386 8968716 mutations NNS I-NP O
4 387 391 8968716 have VBP B-VP O
5 392 394 8968716 an DT B-NP O
6 395 406 8968716 etiological JJ I-NP O
7 407 411 8968716 role NN I-NP O
8 412 414 8968716 in IN B-PP O
9 415 419 8968716 many JJ B-NP O
10 420 426 8968716 breast NN I-NP B-Disease
11 427 430 8968716 and CC I-NP I-Disease
12 431 438 8968716 ovarian JJ I-NP I-Disease
13 439 445 8968716 cancer NN I-NP I-Disease
14 446 451 8968716 cases NNS I-NP O
15 452 455 8968716 and CC O O
16 456 463 8968716 provide VBP B-VP O
17 464 467 8968716 the DT B-NP O
18 468 479 8968716 opportunity NN I-NP O
19 480 482 8968716 to TO B-VP O
20 483 490 8968716 examine VB I-VP O
21 491 499 8968716 genotype NN B-NP O
22 499 500 8968716 - HYPH B-NP O
23 500 509 8968716 phenotype NN I-NP O
24 510 522 8968716 correlations NNS I-NP O
25 523 526 8968716 and CC O O
26 527 535 8968716 genotype NN B-NP O
27 535 536 8968716 - HYPH I-NP O
28 536 547 8968716 environment NN I-NP O
29 548 560 8968716 interactions NNS I-NP O
30 561 563 8968716 in IN B-PP O
31 564 575 8968716 individuals NNS B-NP O
32 576 580 8968716 with IN B-PP O
33 581 584 8968716 the DT B-NP O
34 585 594 8968716 identical JJ I-NP O
35 595 600 8968716 BRCA1 NN I-NP O
36 601 607 8968716 lesion NN I-NP O
37 607 608 8968716 . . O O

1 609 611 8968716 We PRP B-NP O
2 612 618 8968716 report VBP B-VP O
3 619 620 8968716 a DT B-NP O
4 621 626 8968716 novel JJ I-NP O
5 627 635 8968716 missense JJ I-NP O
6 636 642 8968716 change NN I-NP O
7 643 645 8968716 in IN B-PP O
8 646 651 8968716 BRCA1 NN B-NP O
9 651 652 8968716 , , O O
10 653 657 8968716 2640 CD B-NP O
11 658 659 8968716 C JJ I-NP O
12 659 660 8968716 - SYM O O
13 660 661 8968716 - HYPH O O
14 662 663 8968716 > SYM O O
15 664 665 8968716 T NN B-NP O
16 666 667 8968716 ( ( O O
17 667 672 8968716 R841W NN B-NP O
18 672 673 8968716 ) ) O O
19 673 674 8968716 , , O O
20 675 680 8968716 found VBN B-VP O
21 681 683 8968716 in IN B-PP O
22 684 685 8968716 3 CD B-NP O
23 686 691 8968716 cases NNS I-NP O
24 692 696 8968716 from IN B-PP O
25 697 698 8968716 a DT B-NP O
26 699 706 8968716 subject JJ I-NP O
27 707 712 8968716 group NN I-NP O
28 713 715 8968716 of IN B-PP O
29 716 719 8968716 305 CD B-NP O
30 720 726 8968716 breast NN I-NP B-Disease
31 727 730 8968716 and CC O I-Disease
32 731 733 8968716 79 CD B-NP I-Disease
33 734 741 8968716 ovarian JJ I-NP I-Disease
34 742 748 8968716 cancer NN I-NP I-Disease
35 749 754 8968716 cases NNS I-NP O
36 755 759 8968716 from IN B-PP O
37 760 766 8968716 Orange NNP B-NP O
38 767 773 8968716 County NNP I-NP O
39 773 774 8968716 , , O O
40 775 778 8968716 CA. NNP B-NP O

1 779 784 8968716 These DT B-NP O
2 785 788 8968716 are VBP B-VP O
3 789 800 8968716 consecutive JJ B-ADJP O
4 800 801 8968716 , , O O
5 802 812 8968716 population NN B-NP O
6 812 813 8968716 - HYPH B-NP O
7 813 818 8968716 based VBN I-NP O
8 819 824 8968716 cases NNS I-NP O
9 825 828 8968716 not RB B-VP O
10 829 837 8968716 selected VBN I-VP O
11 838 841 8968716 for IN B-PP O
12 842 845 8968716 age NN B-NP O
13 846 848 8968716 or CC I-NP O
14 849 855 8968716 family NN I-NP O
15 856 863 8968716 history NN I-NP O
16 863 864 8968716 . . O O

1 865 867 8968716 In IN B-PP O
2 868 871 8968716 all DT B-NP O
3 872 877 8968716 three CD I-NP O
4 878 883 8968716 cases NNS I-NP O
5 883 884 8968716 , , O O
6 885 890 8968716 there EX B-NP O
7 891 893 8968716 is VBZ B-VP O
8 894 895 8968716 a DT B-NP O
9 896 902 8968716 strong JJ I-NP O
10 903 909 8968716 family NN I-NP O
11 910 917 8968716 history NN I-NP O
12 918 920 8968716 of IN B-PP O
13 921 927 8968716 breast NN B-NP B-Disease
14 927 928 8968716 , , O I-Disease
15 929 936 8968716 ovarian JJ B-ADJP I-Disease
16 936 937 8968716 , , O I-Disease
17 938 940 8968716 or CC O I-Disease
18 941 946 8968716 other JJ B-NP I-Disease
19 947 954 8968716 cancers NNS I-NP I-Disease
20 955 963 8968716 possibly RB B-ADJP O
21 964 971 8968716 related JJ I-ADJP O
22 972 974 8968716 to TO B-PP O
23 975 976 8968716 a DT B-NP O
24 977 982 8968716 BRCA1 NN I-NP O
25 983 989 8968716 defect NN I-NP O
26 990 993 8968716 and CC I-NP O
27 994 1000 8968716 family NN I-NP O
28 1001 1008 8968716 members NNS I-NP O
29 1009 1015 8968716 showed VBD B-VP O
30 1016 1017 8968716 a DT B-NP O
31 1018 1022 8968716 high JJ I-NP O
32 1023 1034 8968716 concordance NN I-NP O
33 1035 1037 8968716 of IN B-PP O
34 1038 1044 8968716 cancer NN B-NP B-Disease
35 1045 1054 8968716 incidence NN I-NP O
36 1055 1059 8968716 with IN B-PP O
37 1060 1063 8968716 the DT B-NP O
38 1064 1072 8968716 presence NN I-NP O
39 1073 1075 8968716 of IN B-PP O
40 1076 1081 8968716 R841W NN B-NP O
41 1081 1082 8968716 . . O O

1 1083 1086 8968716 The DT B-NP O
2 1087 1090 8968716 age NN I-NP O
3 1091 1093 8968716 of IN B-PP O
4 1094 1100 8968716 cancer NN B-NP B-Disease
5 1101 1106 8968716 onset NN I-NP O
6 1107 1110 8968716 was VBD B-VP O
7 1111 1114 8968716 not RB O O
8 1115 1121 8968716 always RB B-ADVP O
9 1122 1130 8968716 distinct JJ B-ADJP O
10 1131 1135 8968716 from IN B-PP O
11 1136 1143 8968716 typical JJ B-NP O
12 1144 1152 8968716 sporadic JJ I-NP O
13 1153 1158 8968716 cases NNS I-NP O
14 1158 1159 8968716 . . O O

1 1160 1167 8968716 Testing NN B-NP O
2 1168 1170 8968716 of IN B-PP O
3 1171 1172 8968716 a DT B-NP O
4 1173 1179 8968716 sample NN I-NP O
5 1180 1182 8968716 of IN B-PP O
6 1183 1186 8968716 413 CD B-NP O
7 1187 1196 8968716 unrelated JJ I-NP O
8 1197 1208 8968716 individuals NNS I-NP O
9 1209 1211 8968716 to TO B-VP O
10 1212 1219 8968716 examine VB I-VP O
11 1220 1223 8968716 the DT B-NP O
12 1224 1234 8968716 hypothesis NN I-NP O
13 1235 1239 8968716 that IN B-SBAR O
14 1240 1245 8968716 R841W NN B-NP O
15 1246 1251 8968716 might MD B-VP O
16 1252 1254 8968716 be VB I-VP O
17 1255 1256 8968716 a DT B-NP O
18 1257 1261 8968716 rare JJ I-NP O
19 1262 1274 8968716 polymorphism NN I-NP O
20 1275 1283 8968716 detected VBD B-VP O
21 1284 1287 8968716 one CD B-NP O
22 1288 1298 8968716 additional JJ I-NP O
23 1299 1307 8968716 instance NN I-NP O
24 1308 1310 8968716 in IN B-PP O
25 1311 1312 8968716 a DT B-NP O
26 1313 1318 8968716 woman NN I-NP O
27 1319 1323 8968716 with IN B-PP O
28 1324 1330 8968716 breast NN B-NP B-Disease
29 1331 1337 8968716 cancer NN I-NP I-Disease
30 1338 1347 8968716 diagnosed VBN B-VP O
31 1348 1350 8968716 at IN B-PP O
32 1351 1354 8968716 age NN B-NP O
33 1355 1357 8968716 77 CD B-NP O
34 1358 1363 8968716 years NNS I-NP O
35 1363 1364 8968716 , , O O
36 1365 1368 8968716 and CC O O
37 1369 1375 8968716 cancer NN B-NP B-Disease
38 1376 1378 8968716 in IN B-PP O
39 1379 1382 8968716 one CD B-NP O
40 1383 1389 8968716 parent NN I-NP O
41 1389 1390 8968716 . . O O

1 1391 1396 8968716 R841W NN B-NP O
2 1397 1399 8968716 is VBZ B-VP O
3 1400 1406 8968716 likely JJ B-ADJP O
4 1407 1409 8968716 to TO B-VP O
5 1410 1412 8968716 be VB I-VP O
6 1413 1415 8968716 an DT B-NP O
7 1416 1429 8968716 etiologically RB I-NP O
8 1430 1441 8968716 significant JJ I-NP O
9 1442 1448 8968716 lesion NN I-NP O
10 1449 1453 8968716 with IN B-PP O
11 1454 1465 8968716 involvement NN B-NP O
12 1466 1468 8968716 in IN B-PP O
13 1469 1474 8968716 close JJ B-ADJP O
14 1475 1477 8968716 to TO B-PP O
15 1478 1480 8968716 1% NN B-NP O
16 1481 1482 8968716 ( ( O O
17 1482 1485 8968716 95% CD B-NP O
18 1486 1496 8968716 confidence NN I-NP O
19 1497 1505 8968716 interval NN I-NP O
20 1506 1508 8968716 of IN B-PP O
21 1509 1510 8968716 0 CD B-NP O
22 1510 1511 8968716 - HYPH I-NP O
23 1511 1512 8968716 1 CD I-NP O
24 1512 1513 8968716 . . O O

1 1514 1516 8968716 7% LS B-LST O
2 1516 1517 8968716 ) ) O O
3 1518 1520 8968716 of IN B-PP O
4 1521 1524 8968716 all DT B-NP O
5 1525 1531 8968716 breast NN I-NP B-Disease
6 1532 1535 8968716 and CC I-NP I-Disease
7 1536 1543 8968716 ovarian JJ I-NP I-Disease
8 1544 1551 8968716 cancers NNS I-NP I-Disease
9 1552 1554 8968716 in IN B-PP O
10 1555 1559 8968716 this DT B-NP O
11 1560 1570 8968716 population NN I-NP O
12 1570 1571 8968716 . . O O

1 0 0 8659549 -DOCSTART- -X- -X- O

1 0 14 8659549 Identification NN B-NP O
2 15 18 8659549 and CC I-NP O
3 19 29 8659549 expression NN I-NP O
4 30 32 8659549 of IN B-PP O
5 33 38 8659549 eight CD B-NP O
6 39 44 8659549 novel JJ I-NP O
7 45 54 8659549 mutations NNS I-NP O
8 55 60 8659549 among IN B-PP O
9 61 64 8659549 non AFX B-NP O
10 64 65 8659549 - HYPH I-NP O
11 65 71 8659549 Jewish JJ B-NP O
12 72 80 8659549 patients NNS I-NP O
13 81 85 8659549 with IN B-PP O
14 86 93 8659549 Canavan NN B-NP B-Disease
15 94 101 8659549 disease NN I-NP I-Disease
16 101 102 8659549 . . O O
17 103 110 8659549 Canavan NNP B-NP B-Disease
18 111 118 8659549 disease NN I-NP I-Disease
19 119 121 8659549 is VBZ B-VP O
20 122 131 8659549 inherited VBN I-VP O
21 132 134 8659549 as IN B-PP O
22 135 137 8659549 an DT B-NP O
23 138 147 8659549 autosomal JJ I-NP O
24 148 157 8659549 recessive JJ I-NP O
25 158 163 8659549 trait NN I-NP O
26 164 168 8659549 that WDT B-NP O
27 169 171 8659549 is VBZ B-VP O
28 172 178 8659549 caused VBN I-VP O
29 179 181 8659549 by IN B-PP O
30 182 185 8659549 the DT B-NP O
31 186 196 8659549 deficiency NN I-NP B-Disease
32 197 199 8659549 of IN B-PP I-Disease
33 200 214 8659549 aspartoacylase NN B-NP I-Disease
34 215 216 8659549 ( ( O O
35 216 220 8659549 ASPA NN B-NP O
36 220 221 8659549 ) ) O O
37 221 222 8659549 . . O O

1 223 226 8659549 The DT B-NP O
2 227 235 8659549 majority NN I-NP O
3 236 238 8659549 of IN B-PP O
4 239 247 8659549 patients NNS B-NP O
5 248 252 8659549 with IN B-PP O
6 253 260 8659549 Canavan NNP B-NP B-Disease
7 261 268 8659549 disease NN I-NP I-Disease
8 269 272 8659549 are VBP B-VP O
9 273 277 8659549 from IN B-PP O
10 278 280 8659549 an DT B-NP O
11 281 290 8659549 Ashkenazi NNP I-NP O
12 291 297 8659549 Jewish JJ I-NP O
13 298 308 8659549 background NN I-NP O
14 308 309 8659549 . . O O

1 310 319 8659549 Mutations NNS B-NP O
2 320 322 8659549 in IN B-PP O
3 323 327 8659549 ASPA NN B-NP O
4 328 332 8659549 that WDT B-NP O
5 333 337 8659549 lead VBP B-VP O
6 338 340 8659549 to TO B-PP O
7 341 345 8659549 loss NN B-NP O
8 346 348 8659549 of IN B-PP O
9 349 358 8659549 enzymatic JJ B-NP O
10 359 367 8659549 activity NN I-NP O
11 368 372 8659549 have VBP B-VP O
12 373 377 8659549 been VBN I-VP O
13 378 388 8659549 identified VBN I-VP O
14 388 389 8659549 , , O O
15 390 393 8659549 and CC O O
16 394 399 8659549 E285A NN B-NP O
17 400 403 8659549 and CC I-NP O
18 404 409 8659549 Y231X NN I-NP O
19 410 413 8659549 are VBP B-VP O
20 414 417 8659549 the DT B-NP O
21 418 421 8659549 two CD I-NP O
22 422 433 8659549 predominant JJ I-NP O
23 434 443 8659549 mutations NNS I-NP O
24 444 448 8659549 that WDT B-NP O
25 449 456 8659549 account VBP B-VP O
26 457 460 8659549 for IN B-PP O
27 461 464 8659549 97% CD B-NP O
28 465 467 8659549 of IN B-PP O
29 468 471 8659549 the DT B-NP O
30 472 478 8659549 mutant JJ I-NP O
31 479 490 8659549 chromosomes NNS I-NP O
32 491 493 8659549 in IN B-PP O
33 494 503 8659549 Ashkenazi NNP B-NP O
34 504 510 8659549 Jewish JJ I-NP O
35 511 519 8659549 patients NNS I-NP O
36 519 520 8659549 . . O O

1 521 524 8659549 The DT B-NP O
2 525 532 8659549 current JJ I-NP O
3 533 538 8659549 study NN I-NP O
4 539 542 8659549 was VBD B-VP O
5 543 548 8659549 aimed VBN I-VP O
6 549 551 8659549 at IN B-PP O
7 552 559 8659549 finding VBG B-VP O
8 560 563 8659549 the DT B-NP O
9 564 573 8659549 molecular JJ I-NP O
10 574 579 8659549 basis NN I-NP O
11 580 582 8659549 of IN B-PP O
12 583 590 8659549 Canavan NNP B-NP B-Disease
13 591 598 8659549 disease NN I-NP I-Disease
14 599 601 8659549 in IN B-PP O
15 602 604 8659549 25 CD B-NP O
16 605 616 8659549 independent JJ I-NP O
17 617 625 8659549 patients NNS I-NP O
18 626 628 8659549 of IN B-PP O
19 629 632 8659549 non AFX B-NP O
20 632 633 8659549 - HYPH I-NP O
21 633 639 8659549 Jewish JJ I-NP O
22 640 650 8659549 background NN I-NP O
23 650 651 8659549 . . O O

1 652 657 8659549 Eight CD B-NP O
2 658 663 8659549 novel JJ I-NP O
3 664 667 8659549 and CC I-NP O
4 668 673 8659549 three CD I-NP O
5 674 684 8659549 previously RB I-NP O
6 685 698 8659549 characterized VBN I-NP O
7 699 708 8659549 mutations NNS I-NP O
8 709 718 8659549 accounted VBD B-VP O
9 719 722 8659549 for IN B-PP O
10 723 726 8659549 80% CD B-NP O
11 727 728 8659549 ( ( O O
12 728 730 8659549 40 CD B-NP O
13 730 731 8659549 / SYM I-NP O
14 731 733 8659549 50 CD I-NP O
15 733 734 8659549 ) ) O O
16 735 737 8659549 of IN B-PP O
17 738 744 8659549 mutant JJ B-NP O
18 745 756 8659549 chromosomes NNS I-NP O
19 756 757 8659549 . . O O

1 758 761 8659549 The DT B-NP O
2 762 767 8659549 A305E NN I-NP O
3 768 776 8659549 missense JJ I-NP O
4 777 785 8659549 mutation NN I-NP O
5 786 795 8659549 accounted VBD B-VP O
6 796 799 8659549 for IN B-PP O
7 800 803 8659549 48% CD B-NP O
8 804 805 8659549 ( ( O O
9 805 807 8659549 24 CD B-NP O
10 807 808 8659549 / SYM O O
11 808 810 8659549 50 CD B-NP O
12 810 811 8659549 ) ) O O
13 812 814 8659549 of IN B-PP O
14 815 821 8659549 mutant JJ B-NP O
15 822 833 8659549 chromosomes NNS I-NP O
16 834 836 8659549 in IN B-PP O
17 837 845 8659549 patients NNS B-NP O
18 846 848 8659549 of IN B-PP O
19 849 856 8659549 western JJ B-NP O
20 857 865 8659549 European JJ I-NP O
21 866 873 8659549 descent NN I-NP O
22 873 874 8659549 , , O O
23 875 880 8659549 while IN B-SBAR O
24 881 884 8659549 the DT B-NP O
25 885 888 8659549 two CD I-NP O
26 889 900 8659549 predominant JJ I-NP O
27 901 907 8659549 Jewish JJ I-NP O
28 908 917 8659549 mutations NNS I-NP O
29 918 922 8659549 each DT O O
30 923 932 8659549 accounted VBD B-VP O
31 933 936 8659549 for IN B-PP O
32 937 938 8659549 a DT B-NP O
33 939 945 8659549 single JJ I-NP O
34 946 952 8659549 mutant JJ I-NP O
35 953 963 8659549 chromosome NN I-NP O
36 963 964 8659549 . . O O

1 965 968 8659549 The DT B-NP O
2 969 974 8659549 eight CD I-NP O
3 975 980 8659549 novel JJ I-NP O
4 981 990 8659549 mutations NNS I-NP O
5 991 1001 8659549 identified VBN B-VP O
6 1002 1010 8659549 included VBD B-VP O
7 1011 1012 8659549 1 CD B-NP O
8 1012 1013 8659549 - HYPH B-NP O
9 1014 1017 8659549 and CC I-NP O
10 1018 1019 8659549 4 CD I-NP O
11 1019 1020 8659549 - HYPH I-NP O
12 1020 1022 8659549 bp NN I-NP O
13 1023 1032 8659549 deletions NNS I-NP O
14 1033 1034 8659549 ( ( O O
15 1034 1036 8659549 32 CD B-NP O
16 1037 1043 8659549 deltaT NN I-NP O
17 1044 1047 8659549 and CC O O
18 1048 1051 8659549 876 CD B-NP O
19 1052 1061 8659549 deltaAGAA NN I-NP O
20 1061 1062 8659549 , , O O
21 1063 1075 8659549 respectively RB B-ADVP O
22 1075 1076 8659549 ) ) O O
23 1077 1080 8659549 and CC O O
24 1081 1085 8659549 I16T NN B-NP O
25 1085 1086 8659549 , , O O
26 1087 1091 8659549 G27R NN B-NP O
27 1091 1092 8659549 , , O O
28 1093 1098 8659549 D114E NN B-NP O
29 1098 1099 8659549 , , O O
30 1100 1105 8659549 G123E NN B-NP O
31 1105 1106 8659549 , , O O
32 1107 1112 8659549 C152Y NN B-NP O
33 1112 1113 8659549 , , O O
34 1114 1117 8659549 and CC O O
35 1118 1123 8659549 R168C NN B-NP O
36 1124 1132 8659549 missense JJ I-NP O
37 1133 1142 8659549 mutations NNS I-NP O
38 1142 1143 8659549 . . O O

1 1144 1147 8659549 The DT B-NP O
2 1148 1158 8659549 homozygous JJ I-NP O
3 1159 1161 8659549 32 CD I-NP O
4 1162 1168 8659549 deltaT NN I-NP O
5 1169 1177 8659549 deletion NN I-NP O
6 1178 1181 8659549 was VBD B-VP O
7 1182 1192 8659549 identified VBN I-VP O
8 1193 1195 8659549 in IN B-PP O
9 1196 1199 8659549 the DT B-NP O
10 1200 1204 8659549 only JJ I-NP O
11 1205 1210 8659549 known JJ I-NP O
12 1211 1218 8659549 patient NN I-NP O
13 1219 1221 8659549 of IN B-PP O
14 1222 1229 8659549 African JJ B-NP O
15 1229 1230 8659549 - HYPH I-NP O
16 1230 1238 8659549 American JJ I-NP O
17 1239 1245 8659549 origin NN I-NP O
18 1246 1250 8659549 with IN B-PP O
19 1251 1258 8659549 Canavan NNP B-NP B-Disease
20 1259 1266 8659549 disease NN I-NP I-Disease
21 1266 1267 8659549 . . O O

1 1268 1271 8659549 The DT B-NP O
2 1272 1286 8659549 heterozygosity NN I-NP O
3 1287 1290 8659549 for IN B-PP O
4 1291 1294 8659549 876 CD B-NP O
5 1295 1304 8659549 deltaAGAA NN I-NP O
6 1305 1313 8659549 mutation NN I-NP O
7 1314 1317 8659549 was VBD B-VP O
8 1318 1328 8659549 identified VBN I-VP O
9 1329 1331 8659549 in IN B-PP O
10 1332 1337 8659549 three CD B-NP O
11 1338 1349 8659549 independent JJ I-NP O
12 1350 1358 8659549 patients NNS I-NP O
13 1359 1363 8659549 from IN B-PP O
14 1364 1371 8659549 England NNP B-NP O
15 1371 1372 8659549 . . O O

1 1373 1376 8659549 Six CD B-NP O
2 1377 1383 8659549 single JJ I-NP O
3 1383 1384 8659549 - HYPH I-NP O
4 1384 1388 8659549 base NN I-NP O
5 1389 1396 8659549 changes NNS I-NP O
6 1397 1404 8659549 leading VBG B-VP O
7 1405 1407 8659549 to TO B-PP O
8 1408 1416 8659549 missense JJ B-NP O
9 1417 1426 8659549 mutations NNS I-NP O
10 1427 1431 8659549 were VBD B-VP O
11 1432 1442 8659549 identified VBN I-VP O
12 1443 1445 8659549 in IN B-PP O
13 1446 1454 8659549 patients NNS B-NP O
14 1455 1459 8659549 from IN B-PP O
15 1460 1466 8659549 Turkey NNP B-NP O
16 1467 1468 8659549 ( ( O O
17 1468 1473 8659549 D114E NN B-NP O
18 1473 1474 8659549 , , O O
19 1475 1480 8659549 R168C NN B-NP O
20 1480 1481 8659549 ) ) O O
21 1481 1482 8659549 , , O O
22 1483 1486 8659549 The DT B-NP O
23 1487 1498 8659549 Netherlands NNP I-NP O
24 1499 1500 8659549 ( ( O O
25 1500 1504 8659549 I16T NN B-NP O
26 1504 1505 8659549 ) ) O O
27 1505 1506 8659549 , , O O
28 1507 1514 8659549 Germany NNP B-NP O
29 1515 1516 8659549 ( ( O O
30 1516 1520 8659549 G27R NN B-NP O
31 1520 1521 8659549 ) ) O O
32 1521 1522 8659549 , , O O
33 1523 1530 8659549 Ireland NN B-NP O
34 1531 1532 8659549 ( ( O O
35 1532 1537 8659549 C152Y NN B-NP O
36 1537 1538 8659549 ) ) O O
37 1538 1539 8659549 , , O O
38 1540 1543 8659549 and CC O O
39 1544 1550 8659549 Canada NNP B-NP O
40 1551 1552 8659549 ( ( O O
41 1552 1557 8659549 G123E NN B-NP O
42 1557 1558 8659549 ) ) O O
43 1558 1559 8659549 . . O O

1 1560 1561 8659549 A DT B-NP O
2 1562 1565 8659549 PCR NN I-NP O
3 1565 1566 8659549 - HYPH B-VP O
4 1566 1571 8659549 based VBN B-NP O
5 1572 1580 8659549 protocol NN I-NP O
6 1581 1583 8659549 is VBZ B-VP O
7 1584 1593 8659549 described VBN I-VP O
8 1594 1598 8659549 that WDT B-NP O
9 1599 1602 8659549 was VBD B-VP O
10 1603 1607 8659549 used VBN I-VP O
11 1608 1610 8659549 to TO B-VP O
12 1611 1620 8659549 introduce VB I-VP O
13 1621 1630 8659549 mutations NNS B-NP O
14 1631 1633 8659549 in IN B-PP O
15 1634 1638 8659549 wild JJ B-NP O
16 1638 1639 8659549 - HYPH I-NP O
17 1639 1643 8659549 type NN I-NP O
18 1644 1648 8659549 cDNA NN I-NP O
19 1648 1649 8659549 . . O O

1 1650 1652 8659549 In FW B-NP O
2 1653 1658 8659549 vitro FW I-NP O
3 1659 1669 8659549 expression NN I-NP O
4 1670 1672 8659549 of IN B-PP O
5 1673 1679 8659549 mutant JJ B-NP O
6 1680 1684 8659549 cDNA NN I-NP O
7 1685 1691 8659549 clones NNS I-NP O
8 1692 1704 8659549 demonstrated VBD B-VP O
9 1705 1709 8659549 that IN B-SBAR O
10 1710 1713 8659549 all DT B-NP O
11 1714 1716 8659549 of IN B-PP O
12 1717 1722 8659549 these DT B-NP O
13 1723 1732 8659549 mutations NNS I-NP O
14 1733 1736 8659549 led VBD B-VP O
15 1737 1739 8659549 to TO B-PP O
16 1740 1741 8659549 a DT B-NP O
17 1742 1752 8659549 deficiency NN I-NP B-Disease
18 1753 1755 8659549 of IN B-PP I-Disease
19 1756 1760 8659549 ASPA NN B-NP I-Disease
20 1761 1764 8659549 and CC O O
21 1765 1771 8659549 should MD B-VP O
22 1772 1781 8659549 therefore RB I-VP O
23 1782 1788 8659549 result VB I-VP O
24 1789 1791 8659549 in IN B-PP O
25 1792 1799 8659549 Canavan NNP B-NP B-Disease
26 1800 1807 8659549 disease NN I-NP I-Disease
27 1807 1808 8659549 . . O O
28 1808 1809 8659549 . . O O

1 0 0 8637912 -DOCSTART- -X- -X- O

1 0 5 8637912 Tumor NN B-NP B-Disease
2 6 17 8637912 suppression NN I-NP O
3 18 21 8637912 and CC O O
4 22 31 8637912 apoptosis NN B-NP O
5 32 34 8637912 of IN B-PP O
6 35 40 8637912 human JJ B-NP O
7 41 49 8637912 prostate NN I-NP B-Disease
8 50 59 8637912 carcinoma NN I-NP I-Disease
9 60 68 8637912 mediated VBN B-VP O
10 69 71 8637912 by IN B-PP O
11 72 73 8637912 a DT B-NP O
12 74 81 8637912 genetic JJ I-NP O
13 82 87 8637912 locus NN I-NP O
14 88 94 8637912 within IN B-PP O
15 95 100 8637912 human JJ B-NP O
16 101 111 8637912 chromosome NN I-NP O
17 112 118 8637912 10pter NN I-NP O
18 118 119 8637912 - HYPH B-NP O
19 119 122 8637912 q11 NN I-NP O
20 122 123 8637912 . . O O
21 124 132 8637912 Prostate NN B-NP B-Disease
22 133 139 8637912 cancer NN I-NP I-Disease
23 140 142 8637912 is VBZ B-VP O
24 143 146 8637912 the DT B-NP O
25 147 153 8637912 second JJ I-NP O
26 154 161 8637912 leading VBG I-NP O
27 162 167 8637912 cause NN I-NP O
28 168 170 8637912 of IN B-PP O
29 171 175 8637912 male JJ B-NP O
30 176 182 8637912 cancer NN I-NP B-Disease
31 183 189 8637912 deaths NNS I-NP O
32 190 192 8637912 in IN B-PP O
33 193 196 8637912 the DT B-NP O
34 197 203 8637912 United NNP I-NP O
35 204 210 8637912 States NNPS I-NP O
36 210 211 8637912 . . O O

1 212 215 8637912 Yet RB B-ADVP O
2 215 216 8637912 , , O O
3 217 224 8637912 despite IN B-PP O
4 225 226 8637912 a DT B-NP O
5 227 232 8637912 large JJ I-NP O
6 233 246 8637912 international JJ I-NP O
7 247 253 8637912 effort NN I-NP O
8 253 254 8637912 , , O O
9 255 261 8637912 little JJ B-NP O
10 262 264 8637912 is VBZ B-VP O
11 265 270 8637912 known VBN I-VP O
12 271 276 8637912 about IN B-PP O
13 277 280 8637912 the DT B-NP O
14 281 290 8637912 molecular JJ I-NP O
15 291 301 8637912 mechanisms NNS I-NP O
16 302 306 8637912 that WDT B-NP O
17 307 315 8637912 underlie VBP B-VP O
18 316 320 8637912 this DT B-NP O
19 321 332 8637912 devastating VBG I-NP O
20 333 340 8637912 disease NN I-NP O
21 340 341 8637912 . . O O

1 342 350 8637912 Prostate NN B-NP O
2 351 360 8637912 secretory JJ I-NP O
3 361 371 8637912 epithelial JJ I-NP O
4 372 377 8637912 cells NNS I-NP O
5 378 381 8637912 and CC O O
6 382 390 8637912 androgen NN B-NP O
7 390 391 8637912 - HYPH B-NP O
8 391 400 8637912 dependent JJ I-NP O
9 401 409 8637912 prostate NN I-NP B-Disease
10 410 420 8637912 carcinomas NNS I-NP I-Disease
11 421 428 8637912 undergo VBP B-VP O
12 429 438 8637912 apoptosis NN B-NP O
13 439 441 8637912 in IN B-PP O
14 442 450 8637912 response NN B-NP O
15 451 453 8637912 to TO B-PP O
16 454 462 8637912 androgen NN B-NP O
17 463 474 8637912 deprivation NN I-NP O
18 475 478 8637912 and CC O O
19 478 479 8637912 , , O O
20 480 491 8637912 furthermore RB B-ADVP O
21 491 492 8637912 , , O O
22 493 497 8637912 most JJS B-NP O
23 498 506 8637912 prostate NN I-NP B-Disease
24 507 517 8637912 carcinomas NNS I-NP I-Disease
25 518 524 8637912 become VBP B-VP O
26 525 533 8637912 androgen NN B-NP O
27 534 545 8637912 independent JJ B-ADJP O
28 546 549 8637912 and CC I-ADJP O
29 550 560 8637912 refractory JJ I-ADJP O
30 561 563 8637912 to TO B-PP O
31 564 571 8637912 further JJ B-NP O
32 572 583 8637912 therapeutic JJ I-NP O
33 584 597 8637912 manipulations NNS I-NP O
34 598 604 8637912 during IN B-PP O
35 605 612 8637912 disease NN B-NP O
36 613 624 8637912 progression NN I-NP O
37 624 625 8637912 . . O O

1 626 636 8637912 Definition NN B-NP O
2 637 639 8637912 of IN B-PP O
3 640 643 8637912 the DT B-NP O
4 644 651 8637912 genetic JJ I-NP O
5 652 658 8637912 events NNS I-NP O
6 659 663 8637912 that WDT B-NP O
7 664 671 8637912 trigger VBP B-VP O
8 672 681 8637912 apoptosis NN B-NP O
9 682 684 8637912 in IN B-PP O
10 685 688 8637912 the DT B-NP O
11 689 697 8637912 prostate NN I-NP O
12 698 703 8637912 could MD B-VP O
13 704 711 8637912 provide VB I-VP O
14 712 721 8637912 important JJ B-NP O
15 722 730 8637912 insights NNS I-NP O
16 731 735 8637912 into IN B-PP O
17 736 744 8637912 critical JJ B-NP O
18 745 753 8637912 pathways NNS I-NP O
19 754 756 8637912 in IN B-PP O
20 757 763 8637912 normal JJ B-NP O
21 764 775 8637912 development NN I-NP O
22 776 778 8637912 as RB B-CONJP O
23 779 783 8637912 well RB I-CONJP O
24 784 786 8637912 as IN I-CONJP O
25 787 796 8637912 elucidate VB B-VP O
26 797 800 8637912 the DT B-NP O
27 801 814 8637912 perturbations NNS I-NP O
28 815 817 8637912 of IN B-PP O
29 818 823 8637912 those DT B-NP O
30 824 827 8637912 key JJ I-NP O
31 828 836 8637912 pathways NNS I-NP O
32 837 839 8637912 in IN B-PP O
33 840 850 8637912 neoplastic JJ B-NP O
34 851 865 8637912 transformation NN I-NP O
35 865 866 8637912 . . O O

1 867 869 8637912 We PRP B-NP O
2 870 876 8637912 report VBP B-VP O
3 877 880 8637912 the DT B-NP O
4 881 891 8637912 functional JJ I-NP O
5 892 902 8637912 definition NN I-NP O
6 903 905 8637912 of IN B-PP O
7 906 907 8637912 a DT B-NP O
8 908 913 8637912 novel JJ I-NP O
9 914 921 8637912 genetic JJ I-NP O
10 922 927 8637912 locus NN I-NP O
11 928 934 8637912 within IN B-PP O
12 935 940 8637912 human JJ B-NP O
13 941 951 8637912 chromosome NN I-NP O
14 952 958 8637912 10pter NN I-NP O
15 958 959 8637912 - HYPH B-NP O
16 959 962 8637912 q11 NN I-NP O
17 963 967 8637912 that WDT B-NP O
18 968 976 8637912 mediates VBZ B-VP O
19 977 981 8637912 both CC O O
20 982 984 8637912 in FW B-NP O
21 985 989 8637912 vivo FW I-NP O
22 990 995 8637912 tumor NN I-NP O
23 996 1007 8637912 suppression NN I-NP O
24 1008 1011 8637912 and CC O O
25 1012 1014 8637912 in FW B-NP O
26 1015 1020 8637912 vitro FW I-NP O
27 1021 1030 8637912 apoptosis NN I-NP O
28 1031 1033 8637912 of IN B-PP O
29 1034 1043 8637912 prostatic JJ B-NP B-Disease
30 1044 1058 8637912 adenocarcinoma NN I-NP I-Disease
31 1059 1064 8637912 cells NNS I-NP O
32 1064 1065 8637912 . . O O

1 1066 1067 8637912 A DT B-NP O
2 1068 1075 8637912 defined VBN I-NP O
3 1076 1084 8637912 fragment NN I-NP O
4 1085 1087 8637912 of IN B-PP O
5 1088 1093 8637912 human JJ B-NP O
6 1094 1104 8637912 chromosome NN I-NP O
7 1105 1107 8637912 10 CD I-NP O
8 1108 1111 8637912 was VBD B-VP O
9 1112 1123 8637912 transferred VBN I-VP O
10 1124 1127 8637912 via IN B-PP O
11 1128 1137 8637912 microcell NN B-NP O
12 1138 1144 8637912 fusion NN I-NP O
13 1145 1149 8637912 into IN B-PP O
14 1150 1151 8637912 a DT B-NP O
15 1152 1160 8637912 prostate NN I-NP B-Disease
16 1161 1175 8637912 adenocarcinoma NN I-NP I-Disease
17 1176 1180 8637912 cell NN I-NP O
18 1181 1185 8637912 line NN I-NP O
19 1185 1186 8637912 . . O O

1 1187 1196 8637912 Microcell NN B-NP O
2 1197 1204 8637912 hybrids NNS I-NP O
3 1205 1215 8637912 containing VBG B-VP O
4 1216 1220 8637912 only RB B-ADVP O
5 1221 1224 8637912 the DT B-NP O
6 1225 1231 8637912 region NN I-NP O
7 1232 1238 8637912 10pter NN I-NP O
8 1238 1239 8637912 - HYPH B-NP O
9 1239 1242 8637912 q11 NN I-NP O
10 1243 1247 8637912 were VBD B-VP O
11 1248 1258 8637912 suppressed VBN I-VP O
12 1259 1262 8637912 for IN B-PP O
13 1263 1277 8637912 tumorigenicity NN B-NP O
14 1278 1287 8637912 following VBG B-PP O
15 1288 1297 8637912 injection NN B-NP O
16 1298 1300 8637912 of IN B-PP O
17 1301 1310 8637912 microcell NN B-NP O
18 1311 1318 8637912 hybrids NNS I-NP O
19 1319 1323 8637912 into IN B-PP O
20 1324 1328 8637912 nude JJ B-NP O
21 1329 1333 8637912 mice NNS I-NP O
22 1333 1334 8637912 . . O O

1 1335 1346 8637912 Furthermore RB B-ADVP O
2 1346 1347 8637912 , , O O
3 1348 1351 8637912 the DT B-NP O
4 1352 1364 8637912 complemented VBN I-NP O
5 1365 1372 8637912 hybrids NNS I-NP O
6 1373 1380 8637912 undergo VBP B-VP O
7 1381 1391 8637912 programmed VBN I-VP O
8 1392 1396 8637912 cell NN B-NP O
9 1397 1402 8637912 death NN I-NP O
10 1403 1405 8637912 in FW B-ADVP O
11 1406 1411 8637912 vitro FW I-ADVP O
12 1412 1415 8637912 via IN B-PP O
13 1416 1417 8637912 a DT B-NP O
14 1418 1427 8637912 mechanism NN I-NP O
15 1428 1432 8637912 that WDT B-NP O
16 1433 1437 8637912 does VBZ B-VP O
17 1438 1441 8637912 not RB I-VP O
18 1442 1449 8637912 require VB I-VP O
19 1450 1457 8637912 nuclear JJ B-NP O
20 1458 1470 8637912 localization NN I-NP O
21 1471 1473 8637912 of IN B-PP O
22 1474 1477 8637912 p53 NN B-NP O
23 1477 1478 8637912 . . O O

1 1479 1484 8637912 These DT B-NP O
2 1485 1489 8637912 data NNS I-NP O
3 1490 1502 8637912 functionally RB B-ADVP O
4 1503 1509 8637912 define VBP B-VP O
5 1510 1511 8637912 a DT B-NP O
6 1512 1517 8637912 novel JJ I-NP O
7 1518 1525 8637912 genetic JJ I-NP O
8 1526 1531 8637912 locus NN I-NP O
9 1531 1532 8637912 , , O O
10 1533 1543 8637912 designated VBN B-VP O
11 1544 1548 8637912 PAC1 NN B-NP O
12 1548 1549 8637912 , , O O
13 1550 1553 8637912 for IN B-PP O
14 1554 1562 8637912 prostate NN B-NP O
15 1563 1577 8637912 adenocarcinoma NN I-NP O
16 1578 1579 8637912 1 CD I-NP O
17 1579 1580 8637912 , , O O
18 1581 1589 8637912 involved VBN B-VP O
19 1590 1592 8637912 in IN B-PP O
20 1593 1598 8637912 tumor NN B-NP O
21 1599 1610 8637912 suppression NN I-NP O
22 1611 1613 8637912 of IN B-PP O
23 1614 1619 8637912 human JJ B-NP O
24 1620 1628 8637912 prostate NN I-NP B-Disease
25 1629 1638 8637912 carcinoma NN I-NP I-Disease
26 1639 1642 8637912 and CC O O
27 1643 1654 8637912 furthermore RB B-VP O
28 1655 1663 8637912 strongly RB I-VP O
29 1664 1671 8637912 suggest VBP I-VP O
30 1672 1676 8637912 that IN B-SBAR O
31 1677 1680 8637912 the DT B-NP O
32 1681 1685 8637912 cell NN I-NP O
33 1686 1691 8637912 death NN I-NP O
34 1692 1699 8637912 pathway NN I-NP O
35 1700 1703 8637912 can MD B-VP O
36 1704 1706 8637912 be VB I-VP O
37 1707 1719 8637912 functionally RB I-VP O
38 1720 1728 8637912 restored VBN I-VP O
39 1729 1731 8637912 in IN B-PP O
40 1732 1741 8637912 prostatic JJ B-NP B-Disease
41 1742 1756 8637912 adenocarcinoma NN I-NP I-Disease
42 1756 1757 8637912 . . O O
43 1757 1758 8637912 . . O O

1 0 0 8786135 -DOCSTART- -X- -X- O

1 0 11 8786135 Comparative JJ B-NP O
2 12 18 8786135 genome NN I-NP O
3 19 26 8786135 mapping NN I-NP O
4 27 29 8786135 of IN B-PP O
5 30 33 8786135 the DT B-NP O
6 34 40 8786135 ataxia NN I-NP B-Disease
7 40 41 8786135 - HYPH B-NP I-Disease
8 41 55 8786135 telangiectasia NN I-NP I-Disease
9 56 62 8786135 region NN I-NP O
10 63 65 8786135 in IN B-PP O
11 66 71 8786135 mouse NN B-NP O
12 71 72 8786135 , , O O
13 73 76 8786135 rat NN B-NP O
14 76 77 8786135 , , O O
15 78 81 8786135 and CC O O
16 82 88 8786135 Syrian JJ B-NP O
17 89 96 8786135 hamster NN I-NP O
18 96 97 8786135 . . O O
19 98 109 8786135 Chromosomal JJ B-NP O
20 110 119 8786135 locations NNS I-NP O
21 120 122 8786135 of IN B-PP O
22 123 126 8786135 the DT B-NP O
23 127 130 8786135 Atm NN I-NP O
24 131 132 8786135 ( ( O O
25 132 138 8786135 ataxia NN B-NP B-Disease
26 138 139 8786135 - HYPH O I-Disease
27 139 153 8786135 telangiectasia NN B-NP I-Disease
28 154 155 8786135 ( ( O O
29 155 157 8786135 AT NN B-NP B-Disease
30 157 158 8786135 ) ) O O
31 159 160 8786135 - HYPH B-VP O
32 160 167 8786135 mutated VBN I-VP O
33 167 168 8786135 ) ) O O
34 169 172 8786135 and CC O O
35 173 178 8786135 Acat1 NN B-NP O
36 179 180 8786135 ( ( O O
37 180 193 8786135 mitochondrial JJ B-NP O
38 194 205 8786135 acetoacetyl NN I-NP O
39 205 206 8786135 - HYPH B-NP O
40 206 209 8786135 CoA NN I-NP O
41 210 218 8786135 thiolase NN I-NP O
42 218 219 8786135 ) ) O O
43 220 225 8786135 genes NNS B-NP O
44 226 228 8786135 in IN B-PP O
45 229 234 8786135 mouse NN B-NP O
46 234 235 8786135 , , O O
47 236 239 8786135 rat NN B-NP O
48 239 240 8786135 , , O O
49 241 244 8786135 and CC O O
50 245 251 8786135 Syrian JJ B-NP O
51 252 259 8786135 hamster NN I-NP O
52 260 264 8786135 were VBD B-VP O
53 265 275 8786135 determined VBN I-VP O
54 276 278 8786135 by IN B-PP O
55 279 285 8786135 direct JJ B-NP O
56 286 287 8786135 R NN I-NP O
57 287 288 8786135 - HYPH O O
58 288 295 8786135 banding VBG B-VP O
59 296 300 8786135 FISH NN B-NP O
60 300 301 8786135 . . O O

1 302 306 8786135 Both DT B-NP O
2 307 312 8786135 genes NNS I-NP O
3 313 317 8786135 were VBD B-VP O
4 318 329 8786135 colocalized VBN I-VP O
5 330 332 8786135 to TO B-PP O
6 333 336 8786135 the DT B-NP O
7 337 338 8786135 C NN I-NP O
8 338 339 8786135 - HYPH B-NP O
9 339 340 8786135 D NN I-NP O
10 341 345 8786135 band NN I-NP O
11 346 348 8786135 of IN B-PP O
12 349 354 8786135 mouse NN B-NP O
13 355 365 8786135 chromosome NN I-NP O
14 366 367 8786135 9 CD I-NP O
15 367 368 8786135 , , O O
16 369 372 8786135 the DT B-NP O
17 373 381 8786135 proximal JJ I-NP O
18 382 385 8786135 end NN I-NP O
19 386 388 8786135 of IN B-PP O
20 389 392 8786135 q24 NN B-NP O
21 392 393 8786135 . . O O

1 394 395 8786135 1 CD B-NP O
2 396 398 8786135 of IN B-PP O
3 399 402 8786135 rat NN B-NP O
4 403 413 8786135 chromosome NN I-NP O
5 414 415 8786135 8 CD I-NP O
6 415 416 8786135 , , O O
7 417 420 8786135 and CC O O
8 421 424 8786135 qa4 NN B-NP O
9 424 425 8786135 - HYPH I-NP O
10 425 428 8786135 qa5 NN I-NP O
11 429 431 8786135 of IN B-PP O
12 432 438 8786135 Syrian JJ B-NP O
13 439 446 8786135 hamster NN I-NP O
14 447 457 8786135 chromosome NN I-NP O
15 458 460 8786135 12 CD I-NP O
16 460 461 8786135 . . O O

1 462 465 8786135 The DT B-NP O
2 466 473 8786135 regions NNS I-NP O
3 474 476 8786135 in IN B-PP O
4 477 480 8786135 the DT B-NP O
5 481 486 8786135 mouse NN I-NP O
6 487 490 8786135 and CC O O
7 491 494 8786135 rat NN B-NP O
8 495 499 8786135 were VBD B-VP O
9 500 510 8786135 homologous JJ B-ADJP O
10 511 513 8786135 to TO B-PP O
11 514 519 8786135 human JJ B-NP O
12 520 530 8786135 chromosome NN I-NP O
13 531 534 8786135 11q NN I-NP O
14 534 535 8786135 . . O O

1 536 540 8786135 Fine JJ B-NP O
2 541 548 8786135 genetic JJ I-NP O
3 549 556 8786135 linkage NN I-NP O
4 557 564 8786135 mapping NN I-NP O
5 565 567 8786135 of IN B-PP O
6 568 571 8786135 the DT B-NP O
7 572 577 8786135 mouse NN I-NP O
8 578 580 8786135 AT NN I-NP B-Disease
9 581 587 8786135 region NN I-NP O
10 588 591 8786135 was VBD B-VP O
11 592 601 8786135 performed VBN I-VP O
12 602 607 8786135 using VBG B-VP O
13 608 611 8786135 the DT B-NP O
14 612 625 8786135 interspecific JJ I-NP O
15 626 635 8786135 backcross NN I-NP O
16 636 640 8786135 mice NNS I-NP O
17 640 641 8786135 . . O O

1 642 645 8786135 Atm NN B-NP O
2 645 646 8786135 , , O O
3 647 652 8786135 Acat1 NN B-NP O
4 652 653 8786135 , , O O
5 654 657 8786135 and CC O O
6 658 662 8786135 Npat NN B-NP O
7 662 663 8786135 , , O O
8 664 669 8786135 which WDT B-NP O
9 670 672 8786135 is VBZ B-VP O
10 673 674 8786135 a DT B-NP O
11 675 678 8786135 new JJ I-NP O
12 679 683 8786135 gene NN I-NP O
13 684 692 8786135 isolated VBN B-VP O
14 693 697 8786135 from IN B-PP O
15 698 701 8786135 the DT B-NP O
16 702 704 8786135 AT NN I-NP O
17 705 711 8786135 region NN I-NP O
18 711 712 8786135 , , O O
19 713 716 8786135 and CC O O
20 717 719 8786135 12 CD B-NP O
21 720 728 8786135 flanking NN I-NP O
22 729 743 8786135 microsatellite NN I-NP O
23 744 747 8786135 DNA NN I-NP O
24 748 755 8786135 markers NNS I-NP O
25 756 760 8786135 were VBD B-VP O
26 761 769 8786135 examined VBN I-VP O
27 769 770 8786135 . . O O

1 771 773 8786135 No DT B-NP O
2 774 788 8786135 recombinations NNS I-NP O
3 789 793 8786135 were VBD B-VP O
4 794 799 8786135 found VBN I-VP O
5 800 805 8786135 among IN B-PP O
6 806 809 8786135 the DT B-NP O
7 810 813 8786135 Atm NN I-NP O
8 813 814 8786135 , , O O
9 815 819 8786135 Npat NN B-NP O
10 819 820 8786135 , , O O
11 821 826 8786135 Acat1 NN B-NP O
12 826 827 8786135 , , O O
13 828 831 8786135 and CC O O
14 832 838 8786135 D9Mit6 NN B-NP O
15 839 843 8786135 loci NNS I-NP O
16 843 844 8786135 , , O O
17 845 848 8786135 and CC O O
18 849 854 8786135 these DT B-NP O
19 855 859 8786135 loci NNS I-NP O
20 860 864 8786135 were VBD B-VP O
21 865 871 8786135 mapped VBN I-VP O
22 872 873 8786135 2 CD B-NP O
23 873 874 8786135 . . O O
24 875 876 8786135 0 CD B-NP O
25 877 879 8786135 cM NN I-NP O
26 880 886 8786135 distal JJ B-ADJP O
27 887 889 8786135 to TO B-PP O
28 890 897 8786135 D9Mit99 NN B-NP O
29 898 901 8786135 and CC O O
30 902 903 8786135 1 CD B-NP O
31 903 904 8786135 . . O O

1 905 906 8786135 3 CD B-NP O
2 907 909 8786135 cM NN I-NP O
3 910 918 8786135 proximal JJ B-ADJP O
4 919 921 8786135 to TO B-PP O
5 922 930 8786135 D9Mit102 NN B-NP O
6 930 931 8786135 . . O O

1 932 942 8786135 Comparison NN B-NP O
2 943 945 8786135 of IN B-PP O
3 946 949 8786135 the DT B-NP O
4 950 957 8786135 linkage NN I-NP O
5 958 961 8786135 map NN I-NP O
6 962 964 8786135 of IN B-PP O
7 965 970 8786135 mouse NN B-NP O
8 971 981 8786135 chromosome NN I-NP O
9 982 983 8786135 9 CD I-NP O
10 984 985 8786135 ( ( O O
11 985 989 8786135 MMU9 NN B-NP O
12 989 990 8786135 ) ) O O
13 991 994 8786135 and CC O O
14 995 999 8786135 that DT B-NP O
15 1000 1002 8786135 of IN B-PP O
16 1003 1008 8786135 human JJ B-NP O
17 1009 1019 8786135 chromosome NN I-NP O
18 1020 1022 8786135 11 CD I-NP O
19 1023 1024 8786135 ( ( O O
20 1024 1029 8786135 HSA11 NN B-NP O
21 1029 1030 8786135 ) ) O O
22 1031 1040 8786135 indicates VBZ B-VP O
23 1041 1045 8786135 that IN B-SBAR O
24 1046 1051 8786135 there EX B-NP O
25 1052 1054 8786135 is VBZ B-VP O
26 1055 1056 8786135 a DT B-NP O
27 1057 1068 8786135 chromosomal JJ I-NP O
28 1069 1082 8786135 rearrangement NN I-NP O
29 1083 1086 8786135 due JJ B-PP O
30 1087 1089 8786135 to TO B-PP O
31 1090 1092 8786135 an DT B-NP O
32 1093 1102 8786135 inversion NN I-NP O
33 1103 1110 8786135 between IN B-PP O
34 1111 1115 8786135 Ets1 NN B-NP O
35 1116 1119 8786135 and CC I-NP O
36 1120 1123 8786135 Atm NN I-NP O
37 1123 1124 8786135 - HYPH B-NP O
38 1124 1128 8786135 Npat NN I-NP O
39 1128 1129 8786135 - HYPH B-NP O
40 1129 1134 8786135 Acat1 NN I-NP O
41 1135 1138 8786135 and CC O O
42 1139 1143 8786135 that IN B-SBAR O
43 1144 1147 8786135 the DT B-NP O
44 1148 1157 8786135 inversion NN I-NP O
45 1158 1160 8786135 of IN B-PP O
46 1161 1165 8786135 MMU9 NN B-NP O
47 1166 1176 8786135 originated VBN B-VP O
48 1177 1181 8786135 from IN B-PP O
49 1182 1185 8786135 the DT B-NP O
50 1186 1197 8786135 chromosomal JJ I-NP O
51 1198 1206 8786135 breakage NN I-NP O
52 1207 1209 8786135 at IN B-PP O
53 1210 1213 8786135 the DT B-NP O
54 1214 1222 8786135 boundary NN I-NP O
55 1223 1230 8786135 between IN B-PP O
56 1231 1236 8786135 Gria4 NN B-NP O
57 1237 1240 8786135 and CC I-NP O
58 1241 1244 8786135 Atm NN I-NP O
59 1244 1245 8786135 - HYPH B-NP O
60 1245 1249 8786135 Npat NN I-NP O
61 1249 1250 8786135 - HYPH B-NP O
62 1250 1255 8786135 Acat1 NN I-NP O
63 1256 1258 8786135 on IN B-PP O
64 1259 1264 8786135 HSA11 NN B-NP O
65 1264 1265 8786135 . . O O

1 1266 1270 8786135 This DT B-NP O
2 1271 1275 8786135 type NN I-NP O
3 1276 1278 8786135 of IN B-PP O
4 1279 1288 8786135 inversion NN B-NP O
5 1289 1297 8786135 appeared VBD B-VP O
6 1298 1300 8786135 to TO I-VP O
7 1301 1303 8786135 be VB I-VP O
8 1304 1313 8786135 conserved VBN I-VP O
9 1314 1316 8786135 in IN B-PP O
10 1317 1320 8786135 the DT B-NP O
11 1321 1326 8786135 three CD I-NP O
12 1327 1333 8786135 rodent NN I-NP O
13 1334 1341 8786135 species NNS I-NP O
14 1341 1342 8786135 , , O O
15 1343 1348 8786135 mouse NN B-NP O
16 1348 1349 8786135 , , O O
17 1350 1353 8786135 rat NN B-NP O
18 1353 1354 8786135 , , O O
19 1355 1358 8786135 and CC O O
20 1359 1365 8786135 Syrian JJ B-NP O
21 1366 1373 8786135 hamster NN I-NP O
22 1373 1374 8786135 , , O O
23 1375 1380 8786135 using VBG B-VP O
24 1381 1391 8786135 additional JJ B-NP O
25 1392 1403 8786135 comparative JJ I-NP O
26 1404 1411 8786135 mapping NN I-NP O
27 1412 1416 8786135 data NNS I-NP O
28 1417 1421 8786135 with IN B-PP O
29 1422 1425 8786135 the DT B-NP O
30 1426 1429 8786135 Rck NN I-NP O
31 1430 1434 8786135 gene NN I-NP O

1 0 0 9218625 -DOCSTART- -X- -X- O

1 0 9 9218625 Molecular JJ B-NP O
2 10 15 9218625 bases NNS I-NP O
3 16 18 9218625 of IN B-PP O
4 19 21 9218625 C7 NN B-NP B-Disease
5 22 32 9218625 deficiency NN I-NP I-Disease
6 32 33 9218625 : : O O
7 34 39 9218625 three CD B-NP O
8 40 49 9218625 different JJ I-NP O
9 50 57 9218625 defects NNS I-NP O
10 57 58 9218625 . . O O
11 59 62 9218625 The DT B-NP O
12 63 72 9218625 molecular JJ I-NP O
13 73 78 9218625 basis NN I-NP O
14 79 81 9218625 of IN B-PP O
15 82 84 9218625 C7 NN B-NP B-Disease
16 85 95 9218625 deficiency NN I-NP I-Disease
17 96 99 9218625 has VBZ B-VP O
18 100 104 9218625 been VBN I-VP O
19 105 117 9218625 investigated VBN I-VP O
20 118 120 9218625 in IN B-PP O
21 121 124 9218625 two CD B-NP O
22 125 130 9218625 Irish JJ I-NP O
23 131 139 9218625 families NNS I-NP O
24 140 143 9218625 and CC O O
25 144 145 9218625 a DT B-NP O
26 146 152 9218625 number NN I-NP O
27 153 155 9218625 of IN B-PP O
28 156 163 9218625 Israeli JJ B-NP O
29 164 172 9218625 families NNS I-NP O
30 173 175 9218625 of IN B-PP O
31 176 184 9218625 Moroccan NNP B-NP O
32 185 194 9218625 Sephardic NNP I-NP O
33 195 201 9218625 Jewish NNP I-NP O
34 202 208 9218625 origin NN I-NP O
35 208 209 9218625 . . O O

1 210 214 9218625 Exon NN B-NP O
2 215 218 9218625 PCR NN I-NP O
3 219 222 9218625 and CC I-NP O
4 223 233 9218625 sequencing NN I-NP O
5 234 242 9218625 revealed VBD B-VP O
6 243 244 9218625 a DT B-NP O
7 245 257 9218625 heterozygous JJ I-NP O
8 258 263 9218625 point NN I-NP O
9 264 272 9218625 mutation NN I-NP O
10 273 275 9218625 at IN B-PP O
11 276 279 9218625 the DT B-NP O
12 280 281 9218625 3 CD I-NP O
13 282 288 9218625 splice NN I-NP O
14 289 297 9218625 acceptor NN I-NP O
15 298 302 9218625 site NN I-NP O
16 303 305 9218625 of IN B-PP O
17 306 312 9218625 intron NN B-NP O
18 313 314 9218625 1 CD I-NP O
19 315 317 9218625 in IN B-PP O
20 318 321 9218625 one CD B-NP O
21 322 327 9218625 Irish JJ I-NP O
22 328 334 9218625 family NN I-NP O
23 334 335 9218625 . . O O

1 336 338 9218625 In IN B-PP O
2 339 342 9218625 the DT B-NP O
3 343 348 9218625 other JJ I-NP O
4 349 354 9218625 Irish JJ I-NP O
5 355 361 9218625 family NN I-NP O
6 361 362 9218625 , , O O
7 363 368 9218625 exons NNS B-NP O
8 369 370 9218625 7 CD B-NP O
9 371 374 9218625 and CC I-NP O
10 375 376 9218625 8 CD I-NP O
11 377 383 9218625 failed VBD B-VP O
12 384 386 9218625 to TO I-VP O
13 387 394 9218625 amplify VB I-VP O
14 395 398 9218625 and CC O O
15 399 403 9218625 they PRP B-NP O
16 404 408 9218625 were VBD B-VP O
17 409 414 9218625 shown VBN I-VP O
18 415 417 9218625 to TO I-VP O
19 418 420 9218625 be VB I-VP O
20 421 428 9218625 deleted VBN I-VP O
21 428 429 9218625 . . O O

1 430 436 9218625 Marker NN B-NP O
2 437 446 9218625 haplotype NN I-NP O
3 447 454 9218625 studies NNS I-NP O
4 455 457 9218625 of IN B-PP O
5 458 461 9218625 the DT B-NP O
6 462 464 9218625 C6 NN I-NP O
7 465 468 9218625 and CC I-NP O
8 469 471 9218625 C7 NN I-NP O
9 472 476 9218625 gene NN I-NP O
10 477 483 9218625 region NN I-NP O
11 484 487 9218625 and CC O O
12 488 496 9218625 Southern JJ B-NP O
13 497 502 9218625 blots NNS I-NP O
14 503 507 9218625 show VBP B-VP O
15 508 512 9218625 that IN B-SBAR O
16 513 516 9218625 the DT B-NP O
17 517 522 9218625 Irish JJ I-NP O
18 523 529 9218625 family NN I-NP O
19 530 534 9218625 with IN B-PP O
20 535 538 9218625 the DT B-NP O
21 539 545 9218625 splice NN I-NP O
22 546 552 9218625 defect NN I-NP O
23 553 557 9218625 also RB B-ADVP O
24 558 567 9218625 segregate VBP B-VP O
25 568 571 9218625 for IN B-PP O
26 572 575 9218625 the DT B-NP O
27 576 584 9218625 deletion NN I-NP O
28 584 585 9218625 , , O O
29 586 591 9218625 which WDT B-NP O
30 592 594 9218625 is VBZ B-VP O
31 595 598 9218625 not RB I-VP O
32 599 605 9218625 easily RB I-VP O
33 606 614 9218625 detected VBN I-VP O
34 615 617 9218625 in IN B-PP O
35 618 631 9218625 heterozygotes NNS B-NP O
36 631 632 9218625 . . O O

1 633 636 9218625 The DT B-NP O
2 637 644 9218625 Israeli JJ I-NP O
3 645 647 9218625 C7 NN I-NP B-Disease
4 647 648 9218625 - HYPH O I-Disease
5 648 657 9218625 deficient JJ B-NP I-Disease
6 658 663 9218625 cases NNS I-NP O
7 664 667 9218625 all DT B-ADVP O
8 668 673 9218625 share VBP B-VP O
9 674 675 9218625 a DT B-NP O
10 676 678 9218625 C7 NN I-NP O
11 679 688 9218625 haplotype NN I-NP O
12 689 692 9218625 and CC O O
13 693 696 9218625 are VBP B-VP O
14 697 707 9218625 homozygous JJ B-ADJP O
15 708 711 9218625 for IN B-PP O
16 712 713 9218625 a DT B-NP O
17 714 717 9218625 mis AFX I-NP O
18 717 718 9218625 - HYPH I-NP O
19 718 723 9218625 sense NN I-NP O
20 724 732 9218625 mutation NN I-NP O
21 733 735 9218625 in IN B-PP O
22 736 740 9218625 exon NN B-NP O
23 741 742 9218625 9 CD I-NP O
24 742 743 9218625 . . O O

1 744 751 9218625 However RB B-ADVP O
2 751 752 9218625 , , O O
3 753 756 9218625 one CD B-NP O
4 757 767 9218625 individual NN I-NP O
5 768 770 9218625 is VBZ B-VP O
6 771 783 9218625 heterozygous JJ B-ADJP O
7 784 787 9218625 for IN B-PP O
8 788 795 9218625 markers NNS B-NP O
9 796 798 9218625 at IN B-PP O
10 799 807 9218625 adjacent JJ B-NP O
11 808 810 9218625 C6 NN I-NP O
12 811 815 9218625 loci NNS I-NP O
13 815 816 9218625 , , O O
14 817 824 9218625 showing VBG B-VP O
15 825 829 9218625 that IN B-SBAR O
16 830 835 9218625 there EX B-NP O
17 836 839 9218625 has VBZ B-VP O
18 840 844 9218625 been VBN I-VP O
19 845 847 9218625 an DT B-NP O
20 848 858 9218625 intergenic JJ I-NP O
21 859 872 9218625 recombination NN I-NP O
22 873 876 9218625 and CC O O
23 877 887 9218625 suggesting VBG B-VP O
24 888 892 9218625 that IN B-SBAR O
25 893 896 9218625 the DT B-NP O
26 897 907 9218625 deficiency NN I-NP O
27 908 916 9218625 mutation NN I-NP O
28 917 919 9218625 is VBZ B-VP O
29 920 922 9218625 of IN B-PP O
30 923 934 9218625 appreciable JJ B-NP O
31 935 944 9218625 antiquity NN I-NP O
32 944 945 9218625 . . O O
33 945 946 9218625 . . O O

1 0 0 8892662 -DOCSTART- -X- -X- O

1 0 7 8892662 Genetic JJ B-NP O
2 8 13 8892662 bases NNS I-NP O
3 14 16 8892662 of IN B-PP O
4 17 22 8892662 human JJ B-NP O
5 23 33 8892662 complement NN I-NP B-Disease
6 34 36 8892662 C7 NN I-NP I-Disease
7 37 47 8892662 deficiency NN I-NP I-Disease
8 47 48 8892662 . . O O
9 49 59 8892662 Complement NN B-NP B-Disease
10 60 62 8892662 C7 NN I-NP I-Disease
11 63 73 8892662 deficiency NN I-NP I-Disease
12 74 75 8892662 ( ( O O
13 75 78 8892662 C7D NN B-NP B-Disease
14 78 79 8892662 ) ) O O
15 80 82 8892662 is VBZ B-VP O
16 83 93 8892662 associated VBN I-VP O
17 94 104 8892662 frequently RB B-ADVP O
18 105 109 8892662 with IN B-PP O
19 110 119 8892662 recurrent JJ B-NP O
20 120 129 8892662 bacterial JJ I-NP B-Disease
21 130 140 8892662 infections NNS I-NP I-Disease
22 140 141 8892662 , , O O
23 142 152 8892662 especially RB B-NP O
24 153 163 8892662 meningitis NN I-NP B-Disease
25 164 170 8892662 caused VBN B-VP O
26 171 173 8892662 by IN B-PP O
27 174 183 8892662 Neisseria NNP B-NP B-Disease
28 184 196 8892662 meningitidis NNP I-NP I-Disease
29 196 197 8892662 . . O O

1 198 200 8892662 We PRP B-NP O
2 201 207 8892662 report VBP B-VP O
3 208 210 8892662 in IN B-PP O
4 211 215 8892662 this DT B-NP O
5 216 220 8892662 work NN I-NP O
6 221 224 8892662 the DT B-NP O
7 225 234 8892662 molecular JJ I-NP O
8 235 240 8892662 bases NNS I-NP O
9 241 243 8892662 of IN B-PP O
10 244 247 8892662 C7D NN B-NP B-Disease
11 248 250 8892662 in IN B-PP O
12 251 254 8892662 two CD B-NP O
13 255 264 8892662 unrelated JJ I-NP O
14 265 273 8892662 Japanese JJ I-NP O
15 274 279 8892662 males NNS I-NP O
16 279 280 8892662 . . O O

1 281 283 8892662 We PRP B-NP O
2 284 288 8892662 used VBD B-VP O
3 289 293 8892662 exon NN B-NP O
4 293 294 8892662 - HYPH B-NP O
5 294 302 8892662 specific JJ I-NP O
6 303 306 8892662 PCR NN I-NP O
7 306 307 8892662 / SYM B-NP O
8 307 313 8892662 single JJ I-NP O
9 313 314 8892662 - HYPH I-NP O
10 314 320 8892662 strand NN I-NP O
11 321 333 8892662 conformation NN I-NP O
12 334 346 8892662 polymorphism NN I-NP O
13 347 355 8892662 analysis NN I-NP O
14 356 358 8892662 as IN B-PP O
15 359 360 8892662 a DT B-NP O
16 361 370 8892662 screening NN I-NP O
17 371 375 8892662 step NN I-NP O
18 376 379 8892662 for IN B-PP O
19 380 389 8892662 mutations NNS B-NP O
20 389 390 8892662 . . O O

1 391 401 8892662 Subsequent JJ B-NP O
2 402 408 8892662 direct JJ I-NP O
3 409 419 8892662 sequencing NN I-NP O
4 420 422 8892662 of IN B-PP O
5 423 426 8892662 the DT B-NP O
6 427 433 8892662 target NN I-NP O
7 434 439 8892662 exons NNS I-NP O
8 440 450 8892662 identified VBD B-VP O
9 451 461 8892662 homozygous JJ B-NP O
10 462 471 8892662 mutations NNS I-NP O
11 472 474 8892662 in IN B-PP O
12 475 479 8892662 exon NN B-NP O
13 480 482 8892662 16 CD I-NP O
14 483 485 8892662 of IN B-PP O
15 486 490 8892662 case NN B-NP O
16 491 492 8892662 1 CD I-NP O
17 493 496 8892662 and CC O O
18 497 499 8892662 in IN B-PP O
19 500 504 8892662 exon NN B-NP O
20 505 507 8892662 15 CD I-NP O
21 508 510 8892662 of IN B-PP O
22 511 515 8892662 case NN B-NP O
23 516 517 8892662 2 CD I-NP O
24 517 518 8892662 . . O O

1 519 522 8892662 The DT B-NP O
2 523 531 8892662 mutation NN I-NP O
3 532 534 8892662 of IN B-PP O
4 535 539 8892662 case NN B-NP O
5 540 541 8892662 1 CD I-NP O
6 542 545 8892662 was VBD B-VP O
7 546 547 8892662 a DT B-NP O
8 548 558 8892662 homozygous JJ I-NP O
9 559 560 8892662 T NN I-NP O
10 561 563 8892662 to TO B-PP O
11 564 565 8892662 A NN B-NP O
12 566 578 8892662 transversion NN I-NP O
13 579 581 8892662 at IN B-PP O
14 582 592 8892662 nucleotide NN B-NP O
15 593 597 8892662 2250 CD I-NP O
16 597 598 8892662 , , O O
17 599 602 8892662 the DT B-NP O
18 603 608 8892662 third JJ I-NP O
19 609 619 8892662 nucleotide NN I-NP O
20 620 622 8892662 of IN B-PP O
21 623 626 8892662 the DT B-NP O
22 627 632 8892662 codon NN I-NP O
23 633 636 8892662 TGT NN I-NP O
24 637 640 8892662 for IN B-PP O
25 641 647 8892662 Cys728 NN B-NP O
26 647 648 8892662 , , O O
27 649 656 8892662 leading VBG B-VP O
28 657 659 8892662 to TO B-PP O
29 660 661 8892662 a DT B-NP O
30 662 666 8892662 stop NN I-NP O
31 667 672 8892662 codon NN I-NP O
32 673 676 8892662 TGA NN I-NP O
33 677 678 8892662 ( ( O O
34 678 683 8892662 C728X NN B-NP O
35 683 684 8892662 ) ) O O
36 684 685 8892662 . . O O

1 686 688 8892662 In IN B-SBAR O
2 689 693 8892662 case NN O O
3 694 695 8892662 2 CD B-NP O
4 695 696 8892662 , , O O
5 697 698 8892662 a DT B-NP O
6 699 709 8892662 homozygous JJ I-NP O
7 710 711 8892662 2 CD I-NP O
8 711 712 8892662 - HYPH I-NP O
9 712 714 8892662 bp NN I-NP O
10 715 723 8892662 deletion NN I-NP O
11 724 725 8892662 ( ( O O
12 725 734 8892662 2137delTG NN B-NP O
13 734 735 8892662 / SYM B-NP O
14 735 744 8892662 2138delGT NN I-NP O
15 744 745 8892662 / SYM I-NP O
16 745 754 8892662 2139delTG NN I-NP O
17 754 755 8892662 ) ) O O
18 756 762 8892662 caused VBD B-VP O
19 763 764 8892662 a DT B-NP O
20 765 775 8892662 frameshift NN I-NP O
21 775 776 8892662 , , O O
22 777 787 8892662 generating VBG B-VP O
23 788 789 8892662 a DT B-NP O
24 790 799 8892662 premature JJ I-NP O
25 800 811 8892662 termination NN I-NP O
26 812 817 8892662 codon NN I-NP O
27 818 819 8892662 4 CD B-NP O
28 820 822 8892662 to TO I-NP O
29 823 824 8892662 6 CD I-NP O
30 825 836 8892662 nucleotides NNS I-NP O
31 837 847 8892662 downstream RB B-ADVP O
32 847 848 8892662 . . O O

1 849 855 8892662 Family RB B-NP O
2 856 861 8892662 study NN I-NP O
3 862 864 8892662 in IN B-PP O
4 865 869 8892662 case NN B-NP O
5 870 871 8892662 1 CD I-NP O
6 872 881 8892662 confirmed VBD B-VP O
7 882 885 8892662 the DT B-NP O
8 886 893 8892662 genetic JJ I-NP O
9 894 900 8892662 nature NN I-NP O
10 901 903 8892662 of IN B-PP O
11 904 907 8892662 the DT B-NP O
12 908 914 8892662 defect NN I-NP O
13 914 915 8892662 . . O O

1 916 924 8892662 Moreover RB B-ADVP O
2 924 925 8892662 , , O O
3 926 928 8892662 we PRP B-NP O
4 929 937 8892662 detected VBD B-VP O
5 938 939 8892662 a DT B-NP O
6 940 945 8892662 novel JJ I-NP O
7 946 958 8892662 polymorphism NN I-NP O
8 959 961 8892662 in IN B-PP O
9 962 968 8892662 intron NN B-NP O
10 969 971 8892662 11 CD I-NP O
11 972 976 8892662 that WDT B-NP O
12 977 987 8892662 presumably RB B-ADVP O
13 988 990 8892662 is VBZ B-VP O
14 991 997 8892662 linked VBN I-VP O
15 998 1000 8892662 to TO B-PP O
16 1001 1004 8892662 the DT B-NP O
17 1005 1013 8892662 mutation NN I-NP O
18 1014 1025 8892662 responsible JJ B-ADJP O
19 1026 1029 8892662 for IN B-PP O
20 1030 1033 8892662 C7D NN B-NP B-Disease
21 1034 1036 8892662 in IN B-PP O
22 1037 1041 8892662 case NN B-NP O
23 1042 1043 8892662 1 CD I-NP O
24 1043 1044 8892662 . . O O

1 1045 1048 8892662 Our PRP$ B-NP O
2 1049 1056 8892662 results NNS I-NP O
3 1057 1065 8892662 indicate VBP B-VP O
4 1066 1070 8892662 that IN B-SBAR O
5 1071 1074 8892662 the DT B-NP O
6 1075 1087 8892662 pathogenesis NN I-NP O
7 1088 1090 8892662 of IN B-PP O
8 1091 1094 8892662 C7D NN B-NP B-Disease
9 1095 1097 8892662 is VBZ B-VP O
10 1098 1111 8892662 heterogeneous JJ B-ADJP O
11 1112 1116 8892662 like IN B-PP O
12 1117 1121 8892662 most JJS B-NP O
13 1122 1124 8892662 of IN B-PP O
14 1125 1128 8892662 the DT B-NP O
15 1129 1134 8892662 other JJ I-NP O
16 1135 1147 8892662 deficiencies NNS I-NP B-Disease
17 1148 1150 8892662 of IN B-PP I-Disease
18 1151 1161 8892662 complement NN B-NP I-Disease
19 1162 1172 8892662 components NNS I-NP I-Disease
20 1172 1173 8892662 . . O O
21 1173 1174 8892662 . . O O

1 0 0 8845838 -DOCSTART- -X- -X- O

1 0 7 8845838 Cloning NN B-NP O
2 8 11 8845838 and CC I-NP O
3 12 28 8845838 characterization NN I-NP O
4 29 31 8845838 of IN B-PP O
5 32 37 8845838 human JJ B-NP O
6 38 42 8845838 very RB I-NP O
7 42 43 8845838 - HYPH I-NP O
8 43 47 8845838 long JJ I-NP O
9 47 48 8845838 - HYPH I-NP O
10 48 53 8845838 chain NN I-NP O
11 54 58 8845838 acyl NN I-NP O
12 58 59 8845838 - HYPH B-NP O
13 59 62 8845838 CoA NN I-NP O
14 63 76 8845838 dehydrogenase NN I-NP O
15 77 81 8845838 cDNA NN I-NP O
16 81 82 8845838 , , O O
17 83 94 8845838 chromosomal JJ B-NP O
18 95 105 8845838 assignment NN I-NP O
19 106 108 8845838 of IN B-PP O
20 109 112 8845838 the DT B-NP O
21 113 117 8845838 gene NN I-NP O
22 118 121 8845838 and CC I-NP O
23 122 136 8845838 identification NN I-NP O
24 137 139 8845838 in IN B-PP O
25 140 144 8845838 four CD B-NP O
26 145 153 8845838 patients NNS I-NP O
27 154 156 8845838 of IN B-PP O
28 157 161 8845838 nine CD B-NP O
29 162 171 8845838 different JJ I-NP O
30 172 181 8845838 mutations NNS I-NP O
31 182 188 8845838 within IN B-PP O
32 189 192 8845838 the DT B-NP O
33 193 198 8845838 VLCAD NN I-NP O
34 199 203 8845838 gene NN I-NP O
35 203 204 8845838 . . B-NP O
36 205 209 8845838 Very NN I-NP O
37 209 210 8845838 - HYPH B-NP O
38 210 214 8845838 long JJ I-NP O
39 214 215 8845838 - HYPH I-NP O
40 215 220 8845838 chain NN I-NP O
41 221 225 8845838 acyl NN I-NP O
42 225 226 8845838 - HYPH O O
43 226 229 8845838 CoA NN B-NP O
44 230 243 8845838 dehydrogenase NN I-NP O
45 244 245 8845838 ( ( O O
46 245 250 8845838 VLCAD NN B-NP O
47 250 251 8845838 ) ) O O
48 252 254 8845838 is VBZ B-VP O
49 255 258 8845838 one CD B-NP O
50 259 261 8845838 of IN B-PP O
51 262 266 8845838 four CD B-NP O
52 267 275 8845838 straight JJ I-NP O
53 275 276 8845838 - HYPH I-NP O
54 276 281 8845838 chain NN I-NP O
55 282 286 8845838 acyl NN I-NP O
56 286 287 8845838 - HYPH O O
57 287 290 8845838 CoA NN B-NP O
58 291 304 8845838 dehydrogenase NN I-NP O
59 305 306 8845838 ( ( O O
60 306 309 8845838 ACD NN B-NP O
61 309 310 8845838 ) ) O O
62 311 318 8845838 enzymes NNS B-NP O
63 318 319 8845838 , , O O
64 320 325 8845838 which WDT B-NP O
65 326 329 8845838 are VBP B-VP O
66 330 333 8845838 all DT B-NP O
67 334 341 8845838 nuclear JJ I-NP O
68 342 349 8845838 encoded VBN I-NP O
69 350 363 8845838 mitochondrial JJ I-NP O
70 364 377 8845838 flavoproteins NNS I-NP O
71 378 388 8845838 catalyzing VBG B-VP O
72 389 392 8845838 the DT B-NP O
73 393 400 8845838 initial JJ I-NP O
74 401 405 8845838 step NN I-NP O
75 406 408 8845838 in IN B-PP O
76 409 414 8845838 fatty JJ B-NP O
77 415 419 8845838 acid NN I-NP O
78 420 424 8845838 beta SYM B-VP O
79 424 425 8845838 - HYPH O O
80 425 434 8845838 oxidation NN B-NP O
81 434 435 8845838 . . O O

1 436 438 8845838 We PRP B-NP O
2 439 443 8845838 have VBP B-VP O
3 444 448 8845838 used VBN I-VP O
4 449 452 8845838 the DT B-NP O
5 453 457 8845838 very RB I-NP O
6 458 462 8845838 fast JJ I-NP O
7 462 463 8845838 , , I-NP O
8 464 469 8845838 Rapid JJ I-NP O
9 470 483 8845838 Amplification NN I-NP O
10 484 486 8845838 of IN B-PP O
11 487 491 8845838 cDNA NN B-NP O
12 492 496 8845838 Ends NNS I-NP O
13 497 498 8845838 ( ( O O
14 498 502 8845838 RACE NN B-NP O
15 502 503 8845838 ) ) O O
16 504 509 8845838 based JJ B-NP O
17 510 518 8845838 strategy NN I-NP O
18 519 521 8845838 to TO B-VP O
19 522 528 8845838 obtain VB I-VP O
20 529 532 8845838 the DT B-NP O
21 533 541 8845838 sequence NN I-NP O
22 542 544 8845838 of IN B-PP O
23 545 550 8845838 cDNAs NNS B-NP O
24 551 559 8845838 encoding VBG B-VP O
25 560 565 8845838 human JJ B-NP O
26 566 571 8845838 VLCAD NN I-NP O
27 572 576 8845838 from IN B-PP O
28 577 585 8845838 placenta NN B-NP O
29 586 589 8845838 and CC I-NP O
30 590 601 8845838 fibroblasts NNS I-NP O
31 601 602 8845838 . . O O

1 603 612 8845838 Alignment NN B-NP O
2 613 615 8845838 of IN B-PP O
3 616 619 8845838 the DT B-NP O
4 620 629 8845838 predicted VBN I-NP O
5 630 635 8845838 amino NN I-NP O
6 636 640 8845838 acid NN I-NP O
7 641 649 8845838 sequence NN I-NP O
8 650 652 8845838 of IN B-PP O
9 653 658 8845838 human JJ B-NP O
10 659 664 8845838 VLCAD NN I-NP O
11 665 669 8845838 with IN B-PP O
12 670 675 8845838 those DT B-NP O
13 676 678 8845838 of IN B-PP O
14 679 682 8845838 the DT B-NP O
15 683 688 8845838 other JJ I-NP O
16 689 694 8845838 human JJ I-NP O
17 695 698 8845838 ACD NN I-NP O
18 699 706 8845838 enzymes NNS I-NP O
19 707 715 8845838 revealed VBD B-VP O
20 716 725 8845838 extensive JJ B-NP O
21 726 734 8845838 sequence NN I-NP O
22 735 743 8845838 homology NN I-NP O
23 743 744 8845838 . . O O

1 745 753 8845838 Moreover RB B-ADVP O
2 753 754 8845838 , , O O
3 755 760 8845838 human JJ B-NP O
4 761 766 8845838 VLCAD NN I-NP O
5 767 770 8845838 and CC O O
6 771 776 8845838 human JJ B-NP O
7 777 781 8845838 acyl NN I-NP O
8 781 782 8845838 - HYPH B-NP O
9 782 785 8845838 CoA NN I-NP O
10 786 793 8845838 oxidase NN I-NP O
11 794 800 8845838 showed VBD B-VP O
12 801 810 8845838 extensive JJ B-NP O
13 811 819 8845838 sequence NN I-NP O
14 820 828 8845838 homology NN I-NP O
15 829 842 8845838 corroborating VBG B-VP O
16 843 846 8845838 the DT B-NP O
17 847 853 8845838 notion NN I-NP O
18 854 858 8845838 that IN B-SBAR O
19 859 864 8845838 these DT B-NP O
20 865 870 8845838 genes NNS I-NP O
21 871 874 8845838 are VBP B-VP O
22 875 889 8845838 evolutionarily RB B-ADJP O
23 890 897 8845838 related VBN I-ADJP O
24 897 898 8845838 . . O O

1 899 907 8845838 Southern NN B-NP O
2 908 912 8845838 blot NN I-NP O
3 913 921 8845838 analysis NN I-NP O
4 922 924 8845838 of IN B-PP O
5 925 932 8845838 genomic JJ B-NP O
6 933 936 8845838 DNA NN I-NP O
7 937 941 8845838 from IN B-PP O
8 942 948 8845838 hybrid JJ B-NP O
9 949 953 8845838 cell NN I-NP O
10 954 959 8845838 lines NNS I-NP O
11 960 963 8845838 was VBD B-VP O
12 964 968 8845838 used VBN I-VP O
13 969 971 8845838 to TO B-VP O
14 972 980 8845838 localize VB I-VP O
15 981 984 8845838 the DT B-NP O
16 985 990 8845838 VLCAD NN I-NP O
17 991 995 8845838 gene NN I-NP O
18 996 998 8845838 to TO B-PP O
19 999 1004 8845838 human JJ B-NP O
20 1005 1015 8845838 chromosome NN I-NP O
21 1016 1021 8845838 17p11 NN I-NP O
22 1021 1022 8845838 . . O O

1 1023 1024 8845838 2 CD B-NP O
2 1024 1025 8845838 - HYPH I-NP O
3 1025 1028 8845838 p11 NN I-NP O
4 1028 1029 8845838 . . O O

1 1030 1035 8845838 13105 CD B-NP O
2 1035 1036 8845838 . . O O

1 1037 1042 8845838 Using VBG B-VP O
2 1043 1051 8845838 Northern JJ B-NP O
3 1052 1055 8845838 and CC I-NP O
4 1056 1063 8845838 Western JJ I-NP O
5 1064 1068 8845838 blot NN I-NP O
6 1069 1077 8845838 analysis NN I-NP O
7 1078 1080 8845838 to TO B-VP O
8 1081 1092 8845838 investigate VB I-VP O
9 1093 1096 8845838 the DT B-NP O
10 1097 1103 8845838 tissue NN I-NP O
11 1104 1112 8845838 specific JJ I-NP O
12 1113 1125 8845838 distribution NN I-NP O
13 1126 1128 8845838 of IN B-PP O
14 1129 1134 8845838 VLCAD NN B-NP O
15 1135 1139 8845838 mRNA NN I-NP O
16 1140 1143 8845838 and CC I-NP O
17 1144 1151 8845838 protein NN I-NP O
18 1152 1154 8845838 in IN B-PP O
19 1155 1162 8845838 several JJ B-NP O
20 1163 1168 8845838 human JJ I-NP O
21 1169 1176 8845838 tissues NNS I-NP O
22 1177 1179 8845838 we PRP B-NP O
23 1180 1186 8845838 showed VBD B-VP O
24 1187 1191 8845838 that IN B-SBAR O
25 1192 1197 8845838 VLCAD NN B-NP O
26 1198 1200 8845838 is VBZ B-VP O
27 1201 1205 8845838 most RBS B-ADJP O
28 1206 1214 8845838 abundant JJ I-ADJP O
29 1215 1217 8845838 in IN B-PP O
30 1218 1223 8845838 heart NN B-NP O
31 1224 1227 8845838 and CC O O
32 1228 1236 8845838 skeletal JJ B-NP O
33 1237 1243 8845838 muscle NN I-NP O
34 1243 1244 8845838 . . O O

1 1245 1249 8845838 This DT B-NP O
2 1250 1256 8845838 agrees VBZ B-VP O
3 1257 1261 8845838 well RB B-ADVP O
4 1262 1266 8845838 with IN B-PP O
5 1267 1270 8845838 the DT B-NP O
6 1271 1275 8845838 fact NN I-NP O
7 1276 1280 8845838 that IN B-SBAR O
8 1281 1288 8845838 cardiac JJ B-NP O
9 1289 1292 8845838 and CC I-NP O
10 1293 1299 8845838 muscle NN I-NP O
11 1300 1308 8845838 symptoms NNS I-NP O
12 1309 1312 8845838 are VBP B-VP O
13 1313 1327 8845838 characteristic JJ B-ADJP O
14 1328 1331 8845838 for IN B-PP O
15 1332 1340 8845838 patients NNS B-NP O
16 1341 1345 8845838 with IN B-PP O
17 1346 1351 8845838 VLCAD NN B-NP B-Disease
18 1352 1362 8845838 deficiency NN I-NP I-Disease
19 1362 1363 8845838 . . O O

1 1364 1372 8845838 Northern NN B-NP O
2 1373 1377 8845838 blot NN I-NP O
3 1378 1386 8845838 analysis NN I-NP O
4 1387 1390 8845838 and CC I-NP O
5 1391 1401 8845838 sequencing NN I-NP O
6 1402 1404 8845838 of IN B-PP O
7 1405 1411 8845838 cloned VBN B-NP O
8 1412 1415 8845838 PCR NN I-NP O
9 1416 1425 8845838 amplified VBN I-NP O
10 1426 1431 8845838 VLCAD NN I-NP O
11 1432 1436 8845838 cDNA NN I-NP O
12 1437 1441 8845838 from IN B-PP O
13 1442 1446 8845838 four CD B-NP O
14 1447 1456 8845838 unrelated JJ I-NP O
15 1457 1465 8845838 patients NNS I-NP O
16 1466 1470 8845838 with IN B-PP O
17 1471 1476 8845838 VLCAD NN B-NP B-Disease
18 1477 1487 8845838 deficiency NN I-NP I-Disease
19 1488 1494 8845838 showed VBD B-VP O
20 1495 1499 8845838 that IN B-SBAR O
21 1500 1505 8845838 VLCAD NN B-NP O
22 1506 1510 8845838 mRNA NN I-NP O
23 1511 1514 8845838 was VBD B-VP O
24 1515 1527 8845838 undetectable JJ B-ADJP O
25 1528 1530 8845838 in IN B-PP O
26 1531 1534 8845838 one CD B-NP O
27 1535 1542 8845838 patient NN I-NP O
28 1543 1546 8845838 and CC O O
29 1547 1551 8845838 that IN B-SBAR O
30 1552 1555 8845838 the DT B-NP O
31 1556 1561 8845838 other JJ I-NP O
32 1562 1567 8845838 three CD I-NP O
33 1568 1572 8845838 have VBP B-VP O
34 1573 1582 8845838 mutations NNS B-NP O
35 1583 1585 8845838 in IN B-PP O
36 1586 1590 8845838 both DT B-NP O
37 1591 1596 8845838 VLCAD NN I-NP O
38 1597 1604 8845838 alleles NNS I-NP O
39 1604 1605 8845838 . . O O

1 1606 1613 8845838 Western NN B-NP O
2 1614 1618 8845838 blot NN I-NP O
3 1619 1627 8845838 analysis NN I-NP O
4 1628 1630 8845838 of IN B-PP O
5 1631 1638 8845838 patient NN B-NP O
6 1639 1650 8845838 fibroblasts NNS I-NP O
7 1651 1657 8845838 showed VBD B-VP O
8 1658 1662 8845838 that IN B-SBAR O
9 1663 1666 8845838 the DT B-NP O
10 1667 1677 8845838 identified VBN I-NP O
11 1678 1687 8845838 mutations NNS I-NP O
12 1688 1694 8845838 result VBP B-VP O
13 1695 1697 8845838 in IN B-PP O
14 1698 1706 8845838 severely RB B-NP O
15 1707 1714 8845838 reduced VBN I-NP O
16 1715 1722 8845838 amounts NNS I-NP O
17 1723 1725 8845838 of IN B-PP O
18 1726 1731 8845838 VLCAD NN B-NP O
19 1732 1739 8845838 protein NN I-NP O
20 1739 1740 8845838 . . O O

1 0 0 9122265 -DOCSTART- -X- -X- O

1 0 1 9122265 A DT B-NP O
2 2 10 9122265 mutation NN I-NP O
3 11 13 9122265 in IN B-PP O
4 14 23 9122265 autosomal JJ B-NP B-Disease
5 24 32 9122265 dominant JJ I-NP I-Disease
6 33 41 9122265 myotonia NN I-NP I-Disease
7 42 51 9122265 congenita NN I-NP I-Disease
8 52 59 9122265 affects VBZ B-VP O
9 60 64 9122265 pore NN B-NP O
10 65 75 9122265 properties NNS I-NP O
11 76 78 9122265 of IN B-PP O
12 79 82 9122265 the DT B-NP O
13 83 89 9122265 muscle NN I-NP O
14 90 98 9122265 chloride NN I-NP O
15 99 106 9122265 channel NN I-NP O
16 106 107 9122265 . . O O
17 108 117 9122265 Autosomal JJ B-NP B-Disease
18 118 126 9122265 dominant JJ I-NP I-Disease
19 127 135 9122265 myotonia NN I-NP I-Disease
20 136 145 9122265 congenita NN I-NP I-Disease
21 146 148 9122265 is VBZ B-VP O
22 149 151 9122265 an DT B-NP O
23 152 161 9122265 inherited VBN I-NP B-Disease
24 162 170 9122265 disorder NN I-NP I-Disease
25 171 173 9122265 of IN B-PP I-Disease
26 174 182 9122265 skeletal JJ B-NP I-Disease
27 183 189 9122265 muscle NN I-NP I-Disease
28 190 196 9122265 caused VBN B-VP O
29 197 199 9122265 by IN B-PP O
30 200 209 9122265 mutations NNS B-NP O
31 210 212 9122265 in IN B-PP O
32 213 214 9122265 a DT B-NP O
33 215 222 9122265 voltage NN I-NP O
34 222 223 9122265 - HYPH O O
35 223 228 9122265 gated VBN B-NP O
36 229 231 9122265 Cl NN I-NP O
37 231 232 9122265 - HYPH B-NP O
38 233 240 9122265 channel NN I-NP O
39 241 245 9122265 gene NN I-NP O
40 246 247 9122265 ( ( O O
41 247 252 9122265 CLCN1 NN B-NP O
42 252 253 9122265 , , O O
43 254 258 9122265 7q35 CD B-NP O
44 258 259 9122265 ) ) O O
45 259 260 9122265 . . O O

1 261 265 9122265 Here RB B-ADVP O
2 265 266 9122265 , , O O
3 267 269 9122265 we PRP B-NP O
4 270 276 9122265 report VBP B-VP O
5 277 281 9122265 that IN B-SBAR O
6 282 283 9122265 a DT B-NP O
7 284 292 9122265 mutation NN I-NP O
8 293 303 9122265 predicting VBG B-VP O
9 304 307 9122265 the DT B-NP O
10 308 320 9122265 substitution NN I-NP O
11 321 323 9122265 of IN B-PP O
12 324 327 9122265 Gly NN B-NP O
13 328 331 9122265 230 CD I-NP O
14 332 334 9122265 by IN B-PP O
15 335 343 9122265 glutamic JJ B-NP O
16 344 348 9122265 acid NN I-NP O
17 349 350 9122265 ( ( O O
18 350 355 9122265 G230E NN B-NP O
19 355 356 9122265 ) ) O O
20 357 364 9122265 between IN B-PP O
21 365 373 9122265 segments NNS B-NP O
22 374 376 9122265 D3 NN I-NP O
23 377 380 9122265 and CC I-NP O
24 381 383 9122265 D4 NN I-NP O
25 384 396 9122265 dramatically RB B-ADVP O
26 397 403 9122265 alters VBZ B-VP O
27 404 407 9122265 the DT B-NP O
28 408 412 9122265 pore NN I-NP O
29 413 423 9122265 properties NNS I-NP O
30 424 426 9122265 of IN B-PP O
31 427 428 9122265 a DT B-NP O
32 429 440 9122265 recombinant JJ I-NP O
33 441 446 9122265 human JJ I-NP O
34 447 453 9122265 muscle NN I-NP O
35 454 456 9122265 Cl NN I-NP O
36 456 457 9122265 - HYPH B-NP O
37 458 465 9122265 channel NN I-NP O
38 466 467 9122265 ( ( O O
39 467 471 9122265 hCIC NN B-NP O
40 471 472 9122265 - HYPH B-NP O
41 472 473 9122265 1 CD I-NP O
42 473 474 9122265 ) ) O O
43 475 484 9122265 expressed VBN B-VP O
44 485 487 9122265 in IN B-PP O
45 488 489 9122265 a DT B-NP O
46 490 499 9122265 mammalian JJ I-NP O
47 500 504 9122265 cell NN I-NP O
48 505 509 9122265 line NN I-NP O
49 510 511 9122265 ( ( O O
50 511 517 9122265 tsA201 NN B-NP O
51 517 518 9122265 ) ) O O
52 518 519 9122265 . . O O

1 520 523 9122265 The DT B-NP O
2 524 529 9122265 G230E NN I-NP O
3 530 538 9122265 mutation NN I-NP O
4 539 545 9122265 causes VBZ B-VP O
5 546 557 9122265 substantial JJ B-NP O
6 558 565 9122265 changes NNS I-NP O
7 566 568 9122265 in IN B-PP O
8 569 574 9122265 anion NN B-NP O
9 575 578 9122265 and CC I-NP O
10 579 585 9122265 cation NN I-NP O
11 586 597 9122265 selectivity NN I-NP O
12 598 600 9122265 as RB B-CONJP O
13 601 605 9122265 well RB I-CONJP O
14 606 608 9122265 as IN I-CONJP O
15 609 610 9122265 a DT B-NP O
16 611 622 9122265 fundamental JJ I-NP O
17 623 629 9122265 change NN I-NP O
18 630 632 9122265 in IN B-PP O
19 633 646 9122265 rectification NN B-NP O
20 647 649 9122265 of IN B-PP O
21 650 653 9122265 the DT B-NP O
22 654 661 9122265 current JJ I-NP O
23 661 662 9122265 - HYPH I-NP O
24 662 669 9122265 voltage NN I-NP O
25 670 682 9122265 relationship NN I-NP O
26 682 683 9122265 . . O O

1 684 691 9122265 Whereas IN B-PP O
2 692 696 9122265 wild JJ B-NP O
3 696 697 9122265 - HYPH I-NP O
4 697 701 9122265 type NN I-NP O
5 702 710 9122265 channels NNS I-NP O
6 711 714 9122265 are VBP B-VP O
7 715 728 9122265 characterized VBN I-VP O
8 729 731 9122265 by IN B-PP O
9 732 742 9122265 pronounced JJ B-NP O
10 743 749 9122265 inward JJ I-NP O
11 750 763 9122265 rectification NN I-NP O
12 764 767 9122265 and CC O O
13 768 769 9122265 a DT B-NP O
14 770 772 9122265 Cl NN I-NP O
15 773 774 9122265 > SYM B-NP O
16 775 786 9122265 thiocyanate NN I-NP O
17 787 788 9122265 > SYM I-NP O
18 789 791 9122265 Br NN I-NP O
19 792 793 9122265 > SYM B-NP O
20 794 796 9122265 NO NN I-NP O
21 797 798 9122265 ( ( O O
22 798 799 9122265 3 CD B-NP O
23 799 800 9122265 ) ) O O
24 801 802 9122265 > SYM B-NP O
25 803 804 9122265 I NN I-NP O
26 805 806 9122265 > SYM B-NP O
27 807 809 9122265 CH NN I-NP O
28 810 811 9122265 ( ( B-LST O
29 811 812 9122265 3 LS I-LST O
30 812 813 9122265 ) ) O O
31 814 816 9122265 SO NN B-NP O
32 817 818 9122265 ( ( O O
33 818 819 9122265 3 CD B-NP O
34 819 820 9122265 ) ) O O
35 821 832 9122265 selectivity NN B-NP O
36 832 833 9122265 , , O O
37 834 839 9122265 G230E NN B-NP O
38 840 848 9122265 exhibits VBZ B-VP O
39 849 856 9122265 outward JJ B-NP O
40 857 870 9122265 rectification NN I-NP O
41 871 873 9122265 at IN B-PP O
42 874 882 9122265 positive JJ B-NP O
43 883 893 9122265 potentials NNS I-NP O
44 894 897 9122265 and CC O O
45 898 899 9122265 a DT B-NP O
46 900 911 9122265 thiocyanate NN I-NP O
47 912 913 9122265 > SYM O O
48 914 916 9122265 NO NN B-NP O
49 917 918 9122265 ( ( O O
50 918 919 9122265 3 CD B-NP O
51 919 920 9122265 ) ) O O
52 921 922 9122265 > SYM B-NP O
53 923 924 9122265 I NN I-NP O
54 925 926 9122265 > SYM B-NP O
55 927 929 9122265 Br NN I-NP O
56 930 931 9122265 > SYM I-NP O
57 932 934 9122265 Cl NN I-NP O
58 935 936 9122265 > SYM B-NP O
59 937 939 9122265 CH NN I-NP O
60 940 941 9122265 ( ( O O
61 941 942 9122265 3 CD B-NP O
62 942 943 9122265 ) ) O O
63 944 946 9122265 SO NN B-NP O
64 947 948 9122265 ( ( O O
65 948 949 9122265 3 CD B-NP O
66 949 950 9122265 ) ) O O
67 951 962 9122265 selectivity NN B-NP O
68 962 963 9122265 . . O O

1 964 975 9122265 Furthermore RB B-ADVP O
2 975 976 9122265 , , O O
3 977 980 9122265 the DT B-NP O
4 981 987 9122265 cation NN I-NP O
5 987 988 9122265 - HYPH B-ADJP O
6 988 990 9122265 to TO B-PP O
7 990 991 9122265 - HYPH B-NP O
8 991 996 9122265 anion NN I-NP O
9 997 1009 9122265 permeability NN I-NP O
10 1010 1015 9122265 ratio NN I-NP O
11 1016 1018 9122265 of IN B-PP O
12 1019 1022 9122265 the DT B-NP O
13 1023 1029 9122265 mutant NN I-NP O
14 1030 1032 9122265 is VBZ B-VP O
15 1033 1037 9122265 much RB B-ADJP O
16 1038 1045 9122265 greater JJR I-ADJP O
17 1046 1050 9122265 than IN B-PP O
18 1051 1055 9122265 that DT B-NP O
19 1056 1058 9122265 of IN B-PP O
20 1059 1062 9122265 the DT B-NP O
21 1063 1067 9122265 wild JJ I-NP O
22 1067 1068 9122265 - HYPH I-NP O
23 1068 1072 9122265 type NN I-NP O
24 1073 1080 9122265 channel NN I-NP O
25 1080 1081 9122265 . . O O

1 1082 1089 9122265 Voltage NN B-NP O
2 1089 1090 9122265 - HYPH I-NP O
3 1090 1099 9122265 dependent JJ I-NP O
4 1100 1106 9122265 blocks NNS I-NP O
5 1107 1109 9122265 by IN B-PP O
6 1110 1123 9122265 intracellular JJ B-NP O
7 1124 1127 9122265 and CC I-NP O
8 1128 1141 9122265 extracellular JJ I-NP O
9 1142 1148 9122265 iodide NN I-NP O
10 1149 1153 9122265 help NN I-NP O
11 1154 1156 9122265 to TO B-VP O
12 1157 1168 9122265 distinguish VB I-VP O
13 1169 1172 9122265 two CD B-NP O
14 1173 1181 9122265 distinct JJ I-NP O
15 1182 1185 9122265 ion NN I-NP O
16 1186 1193 9122265 binding NN I-NP O
17 1194 1199 9122265 sites NNS I-NP O
18 1200 1206 9122265 within IN B-PP O
19 1207 1210 9122265 the DT B-NP O
20 1211 1215 9122265 hClC NN I-NP O
21 1215 1216 9122265 - HYPH B-NP O
22 1216 1217 9122265 1 CD I-NP O
23 1218 1228 9122265 conduction NN I-NP O
24 1229 1236 9122265 pathway NN I-NP O
25 1236 1237 9122265 . . O O

1 1238 1242 9122265 Both DT B-NP O
2 1243 1250 9122265 binding NN I-NP O
3 1251 1256 9122265 sites NNS I-NP O
4 1257 1260 9122265 are VBP B-VP O
5 1261 1270 9122265 preserved VBN I-VP O
6 1271 1273 9122265 in IN B-PP O
7 1274 1277 9122265 the DT B-NP O
8 1278 1284 9122265 mutant NN I-NP O
9 1285 1288 9122265 but CC O O
10 1289 1293 9122265 have VBP B-VP O
11 1294 1303 9122265 decreased VBN I-VP O
12 1304 1314 9122265 affinities NNS B-NP O
13 1315 1318 9122265 for IN B-PP O
14 1319 1325 9122265 iodide NN B-NP O
15 1325 1326 9122265 . . O O

1 1327 1332 9122265 These DT B-NP O
2 1333 1341 9122265 findings NNS I-NP O
3 1342 1349 9122265 suggest VBP B-VP O
4 1350 1354 9122265 that IN B-SBAR O
5 1355 1358 9122265 Gly NN B-NP O
6 1359 1362 9122265 230 CD I-NP O
7 1363 1365 9122265 is VBZ B-VP O
8 1366 1374 9122265 critical JJ B-ADJP O
9 1375 1378 9122265 for IN B-PP O
10 1379 1385 9122265 normal JJ B-NP O
11 1386 1389 9122265 ion NN I-NP O
12 1390 1401 9122265 conductance NN I-NP O
13 1402 1404 9122265 in IN B-PP O
14 1405 1409 9122265 hClC NN B-NP O
15 1409 1410 9122265 - HYPH B-NP O
16 1410 1411 9122265 1 CD I-NP O
17 1412 1415 9122265 and CC O O
18 1416 1420 9122265 that IN B-SBAR O
19 1421 1425 9122265 this DT B-NP O
20 1426 1433 9122265 residue NN I-NP O
21 1434 1441 9122265 resides VBZ B-VP O
22 1442 1448 9122265 within IN B-PP O
23 1449 1452 9122265 the DT B-NP O
24 1453 1460 9122265 channel NN I-NP O
25 1461 1465 9122265 pore NN I-NP O
26 1465 1466 9122265 . . O O
27 1466 1467 9122265 . . O O

1 0 0 8636252 -DOCSTART- -X- -X- O

1 0 1 8636252 X NN B-NP B-Disease
2 1 2 8636252 - HYPH B-PP I-Disease
3 2 8 8636252 linked VBN B-NP I-Disease
4 9 29 8636252 adrenoleukodystrophy NN I-NP I-Disease
5 30 32 8636252 is VBZ B-VP O
6 33 34 8636252 a DT B-NP O
7 35 43 8636252 frequent JJ I-NP O
8 44 49 8636252 cause NN I-NP O
9 50 52 8636252 of IN B-PP O
10 53 63 8636252 idiopathic JJ B-NP O
11 64 73 8636252 Addison's NNS I-NP B-Disease
12 74 81 8636252 disease NN I-NP I-Disease
13 82 84 8636252 in IN B-PP O
14 85 90 8636252 young JJ B-NP O
15 91 96 8636252 adult JJ I-NP O
16 97 101 8636252 male JJ I-NP O
17 102 110 8636252 patients NNS I-NP O
18 110 111 8636252 . . O O
19 112 113 8636252 X NN B-NP B-Disease
20 113 114 8636252 - HYPH O I-Disease
21 114 120 8636252 Linked VBN B-VP I-Disease
22 121 141 8636252 adrenoleukodystrophy NN B-NP I-Disease
23 142 143 8636252 ( ( O O
24 143 146 8636252 ALD NN B-NP B-Disease
25 146 147 8636252 ) ) O O
26 148 150 8636252 is VBZ B-VP O
27 151 152 8636252 a DT B-NP O
28 153 160 8636252 genetic JJ I-NP B-Disease
29 161 168 8636252 disease NN I-NP I-Disease
30 169 179 8636252 associated VBN B-VP O
31 180 184 8636252 with IN B-PP O
32 185 198 8636252 demyelination NN B-NP B-Disease
33 199 201 8636252 of IN B-PP I-Disease
34 202 205 8636252 the DT B-NP I-Disease
35 206 213 8636252 central JJ I-NP I-Disease
36 214 221 8636252 nervous JJ I-NP I-Disease
37 222 228 8636252 system NN I-NP I-Disease
38 228 229 8636252 , , O O
39 230 237 8636252 adrenal JJ B-NP B-Disease
40 238 251 8636252 insufficiency NN I-NP I-Disease
41 251 252 8636252 , , O O
42 253 256 8636252 and CC O O
43 257 269 8636252 accumulation NN B-NP O
44 270 272 8636252 of IN B-PP O
45 273 277 8636252 very RB B-NP O
46 278 282 8636252 long JJ I-NP O
47 283 288 8636252 chain NN I-NP O
48 289 294 8636252 fatty JJ I-NP O
49 295 300 8636252 acids NNS I-NP O
50 301 303 8636252 in IN B-PP O
51 304 310 8636252 tissue NN B-NP O
52 311 314 8636252 and CC I-NP O
53 315 319 8636252 body NN I-NP O
54 320 326 8636252 fluids NNS I-NP O
55 326 327 8636252 . . O O

1 328 331 8636252 ALD NN B-NP B-Disease
2 332 334 8636252 is VBZ B-VP O
3 335 338 8636252 due IN B-PP O
4 339 341 8636252 to TO I-PP O
5 342 350 8636252 mutation NN B-NP O
6 351 353 8636252 of IN B-PP O
7 354 355 8636252 a DT B-NP O
8 356 360 8636252 gene NN I-NP O
9 361 368 8636252 located VBN B-VP O
10 369 371 8636252 in IN B-PP O
11 372 376 8636252 Xq28 NN B-NP O
12 377 381 8636252 that WDT B-NP O
13 382 389 8636252 encodes VBZ B-VP O
14 390 391 8636252 a DT B-NP O
15 392 403 8636252 peroxisomal JJ I-NP O
16 404 415 8636252 transporter NN I-NP O
17 416 423 8636252 protein NN I-NP O
18 424 426 8636252 of IN B-PP O
19 427 434 8636252 unknown JJ B-NP O
20 435 443 8636252 function NN I-NP O
21 443 444 8636252 . . O O

1 445 448 8636252 The DT B-NP O
2 449 453 8636252 most RBS I-NP O
3 454 460 8636252 common JJ I-NP O
4 461 470 8636252 phenotype NN I-NP O
5 471 473 8636252 of IN B-PP O
6 474 477 8636252 ALD NN B-NP B-Disease
7 478 480 8636252 is VBZ B-VP O
8 481 484 8636252 the DT B-NP O
9 485 493 8636252 cerebral JJ I-NP O
10 494 498 8636252 form NN I-NP O
11 499 500 8636252 ( ( O O
12 500 503 8636252 45% NN B-NP O
13 503 504 8636252 ) ) O O
14 505 509 8636252 that WDT B-NP O
15 510 518 8636252 develops VBZ B-VP O
16 519 521 8636252 in IN B-PP O
17 522 526 8636252 boys NNS B-NP O
18 527 534 8636252 between IN B-PP O
19 535 536 8636252 5 CD B-NP O
20 536 537 8636252 - HYPH I-NP O
21 537 539 8636252 12 CD I-NP O
22 540 542 8636252 yr NN I-NP O
23 542 543 8636252 . . O O

1 544 565 8636252 Adrenomyeloneuropathy NN B-NP B-Disease
2 566 567 8636252 ( ( O O
3 567 570 8636252 AMN NN B-NP B-Disease
4 570 571 8636252 ) ) O O
5 572 580 8636252 involves VBZ B-VP O
6 581 584 8636252 the DT B-NP O
7 585 591 8636252 spinal JJ I-NP O
8 592 596 8636252 cord NN I-NP O
9 597 600 8636252 and CC O O
10 601 611 8636252 peripheral JJ B-NP O
11 612 618 8636252 nerves NNS I-NP O
12 619 621 8636252 in IN B-PP O
13 622 627 8636252 young JJ B-NP O
14 628 634 8636252 adults NNS I-NP O
15 635 636 8636252 ( ( O O
16 636 639 8636252 35% CD B-NP O
17 639 640 8636252 ) ) O O
18 640 641 8636252 . . O O

1 642 649 8636252 Adrenal JJ B-NP B-Disease
2 650 663 8636252 insufficiency NN I-NP I-Disease
3 664 665 8636252 ( ( O O
4 665 673 8636252 Addisons NNS B-NP B-Disease
5 674 681 8636252 disease NN I-NP I-Disease
6 681 682 8636252 ) ) O O
7 683 685 8636252 is VBZ B-VP O
8 686 696 8636252 frequently RB I-VP O
9 697 707 8636252 associated VBN I-VP O
10 708 712 8636252 with IN B-PP O
11 713 716 8636252 AMN NN B-NP B-Disease
12 717 719 8636252 or CC O O
13 720 728 8636252 cerebral JJ B-NP B-Disease
14 729 732 8636252 ALD NN I-NP I-Disease
15 733 736 8636252 and CC O O
16 737 740 8636252 may MD B-VP O
17 741 747 8636252 remain VB I-VP O
18 748 751 8636252 the DT B-NP O
19 752 756 8636252 only RB I-NP O
20 757 765 8636252 clinical JJ I-NP O
21 766 776 8636252 expression NN I-NP O
22 777 779 8636252 of IN B-PP O
23 780 783 8636252 ALD NN B-NP B-Disease
24 784 785 8636252 ( ( O O
25 785 787 8636252 8% CD B-NP O
26 788 790 8636252 of IN B-PP O
27 791 796 8636252 cases NNS B-NP O
28 796 797 8636252 ) ) O O
29 797 798 8636252 . . O O

1 799 802 8636252 The DT B-NP O
2 803 813 8636252 prevalence NN I-NP O
3 814 816 8636252 of IN B-PP O
4 817 820 8636252 ALD NN B-NP B-Disease
5 821 826 8636252 among IN B-PP O
6 827 833 8636252 adults NNS B-NP O
7 834 838 8636252 with IN B-PP O
8 839 847 8636252 Addisons NNS B-NP B-Disease
9 848 855 8636252 disease NN I-NP I-Disease
10 856 863 8636252 remains VBZ B-VP O
11 864 871 8636252 unknown JJ B-ADJP O
12 871 872 8636252 . . O O

1 873 875 8636252 To TO B-VP O
2 876 884 8636252 evaluate VB I-VP O
3 885 889 8636252 this DT B-NP O
4 890 900 8636252 prevalence NN I-NP O
5 900 901 8636252 , , O O
6 902 904 8636252 we PRP B-NP O
7 905 914 8636252 performed VBD B-VP O
8 915 926 8636252 biochemical JJ B-NP O
9 927 935 8636252 analysis NN I-NP O
10 936 938 8636252 of IN B-PP O
11 939 943 8636252 very RB B-NP O
12 944 948 8636252 long JJ I-NP O
13 949 954 8636252 chain NN I-NP O
14 955 960 8636252 fatty JJ I-NP O
15 961 966 8636252 acids NNS I-NP O
16 967 969 8636252 in IN B-PP O
17 970 972 8636252 14 CD B-NP O
18 973 977 8636252 male JJ I-NP O
19 978 986 8636252 patients NNS I-NP O
20 987 988 8636252 ( ( O O
21 988 991 8636252 age NN B-NP O
22 992 999 8636252 ranging VBG B-VP O
23 1000 1004 8636252 from IN B-PP O
24 1005 1007 8636252 12 CD B-NP O
25 1007 1008 8636252 - HYPH I-NP O
26 1008 1010 8636252 45 CD I-NP O
27 1011 1013 8636252 yr NN I-NP O
28 1014 1016 8636252 at IN B-PP O
29 1017 1026 8636252 diagnosis NN B-NP O
30 1026 1027 8636252 ) ) O O
31 1028 1038 8636252 previously RB B-VP O
32 1039 1048 8636252 diagnosed VBN I-VP O
33 1049 1051 8636252 as IN B-PP O
34 1052 1058 8636252 having VBG B-VP O
35 1059 1066 8636252 primary JJ B-NP O
36 1067 1077 8636252 idiopathic JJ I-NP O
37 1078 1092 8636252 adrenocortical JJ I-NP B-Disease
38 1093 1106 8636252 insufficiency NN I-NP I-Disease
39 1106 1107 8636252 . . O O

1 1108 1110 8636252 In IN B-PP O
2 1111 1112 8636252 5 CD B-NP O
3 1113 1115 8636252 of IN B-PP O
4 1116 1118 8636252 14 CD B-NP O
5 1119 1127 8636252 patients NNS I-NP O
6 1128 1129 8636252 ( ( O O
7 1129 1132 8636252 35% NN B-NP O
8 1132 1133 8636252 ) ) O O
9 1133 1134 8636252 , , O O
10 1135 1143 8636252 elevated VBN B-NP O
11 1144 1150 8636252 plasma NN I-NP O
12 1151 1165 8636252 concentrations NNS I-NP O
13 1166 1168 8636252 of IN B-PP O
14 1169 1173 8636252 very RB B-NP O
15 1174 1178 8636252 long JJ I-NP O
16 1179 1184 8636252 chain NN I-NP O
17 1185 1190 8636252 fatty JJ I-NP O
18 1191 1196 8636252 acids NNS I-NP O
19 1197 1201 8636252 were VBD B-VP O
20 1202 1210 8636252 detected VBN I-VP O
21 1210 1211 8636252 . . O O

1 1212 1216 8636252 None NN B-NP O
2 1217 1219 8636252 of IN B-PP O
3 1220 1225 8636252 these DT B-NP O
4 1226 1234 8636252 patients NNS I-NP O
5 1235 1238 8636252 had VBD B-VP O
6 1239 1253 8636252 adrenocortical JJ B-NP O
7 1254 1264 8636252 antibodies NNS I-NP O
8 1264 1265 8636252 . . O O

1 1266 1268 8636252 By IN B-PP O
2 1269 1289 8636252 electrophysiological JJ B-NP O
3 1290 1295 8636252 tests NNS I-NP O
4 1296 1299 8636252 and CC O O
5 1300 1308 8636252 magnetic JJ B-NP O
6 1309 1318 8636252 resonance NN I-NP O
7 1319 1326 8636252 imaging VBG B-VP O
8 1327 1329 8636252 it PRP B-NP O
9 1330 1333 8636252 was VBD B-VP O
10 1334 1344 8636252 determined VBN I-VP O
11 1345 1349 8636252 that IN B-SBAR O
12 1350 1353 8636252 two CD B-NP O
13 1354 1362 8636252 patients NNS I-NP O
14 1363 1366 8636252 had VBD B-VP O
15 1367 1375 8636252 cerebral JJ B-NP B-Disease
16 1376 1379 8636252 ALD NN I-NP I-Disease
17 1379 1380 8636252 , , O O
18 1381 1384 8636252 one CD B-NP O
19 1385 1388 8636252 had VBD B-VP O
20 1389 1410 8636252 adrenomyeloneuropathy NN B-NP B-Disease
21 1411 1415 8636252 with IN B-PP O
22 1416 1424 8636252 cerebral JJ B-NP O
23 1425 1436 8636252 involvement NN I-NP O
24 1436 1437 8636252 , , O O
25 1438 1441 8636252 and CC O O
26 1442 1445 8636252 two CD B-NP O
27 1446 1449 8636252 had VBD B-VP O
28 1450 1461 8636252 preclinical JJ B-NP O
29 1462 1465 8636252 AMN NN I-NP B-Disease
30 1465 1466 8636252 . . O O

1 1467 1470 8636252 Our PRP$ B-NP O
2 1471 1475 8636252 data NNS I-NP O
3 1476 1483 8636252 support VBP B-VP O
4 1484 1487 8636252 the DT B-NP O
5 1488 1498 8636252 hypothesis NN I-NP O
6 1499 1503 8636252 that IN B-SBAR O
7 1504 1507 8636252 ALD NN B-NP B-Disease
8 1508 1510 8636252 is VBZ B-VP O
9 1511 1512 8636252 a DT B-NP O
10 1513 1521 8636252 frequent JJ I-NP O
11 1522 1527 8636252 cause NN I-NP O
12 1528 1530 8636252 of IN B-PP O
13 1531 1541 8636252 idiopathic JJ B-NP O
14 1542 1550 8636252 Addisons NNS I-NP B-Disease
15 1551 1558 8636252 disease NN I-NP I-Disease
16 1559 1561 8636252 in IN B-PP O
17 1562 1570 8636252 children NNS B-NP O
18 1571 1574 8636252 and CC I-NP O
19 1575 1581 8636252 adults NNS I-NP O
20 1581 1582 8636252 . . O O
21 1582 1583 8636252 . . O O

1 0 0 8758207 -DOCSTART- -X- -X- O

1 0 8 8758207 Mutation NN B-NP O
2 9 11 8758207 of IN B-PP O
3 12 15 8758207 the DT B-NP O
4 16 19 8758207 VHL NN I-NP O
5 20 24 8758207 gene NN I-NP O
6 25 27 8758207 is VBZ B-VP O
7 28 38 8758207 associated VBN I-VP O
8 39 50 8758207 exclusively RB B-ADVP O
9 51 55 8758207 with IN B-PP O
10 56 59 8758207 the DT B-NP O
11 60 71 8758207 development NN I-NP O
12 72 74 8758207 of IN B-PP O
13 75 78 8758207 non AFX B-NP B-Disease
14 78 79 8758207 - HYPH I-NP I-Disease
15 79 88 8758207 papillary JJ I-NP I-Disease
16 89 94 8758207 renal JJ I-NP I-Disease
17 95 99 8758207 cell NN I-NP I-Disease
18 100 110 8758207 carcinomas NNS I-NP I-Disease
19 110 111 8758207 . . O O
20 112 114 8758207 To TO B-VP O
21 115 121 8758207 define VB I-VP O
22 122 125 8758207 the DT B-NP O
23 126 134 8758207 possible JJ I-NP O
24 135 139 8758207 role NN I-NP O
25 140 142 8758207 of IN B-PP O
26 143 146 8758207 the DT B-NP O
27 147 150 8758207 VHL NN I-NP B-Disease
28 151 155 8758207 gene NN I-NP O
29 156 158 8758207 in IN B-PP O
30 159 162 8758207 the DT B-NP O
31 163 174 8758207 development NN I-NP O
32 175 177 8758207 of IN B-PP O
33 178 186 8758207 sporadic JJ B-NP B-Disease
34 187 192 8758207 renal JJ I-NP I-Disease
35 193 197 8758207 cell NN I-NP I-Disease
36 198 208 8758207 carcinomas NNS I-NP I-Disease
37 208 209 8758207 , , O O
38 210 212 8758207 91 CD B-NP O
39 213 222 8758207 different JJ I-NP O
40 223 234 8758207 parenchymal JJ I-NP B-Disease
41 235 242 8758207 tumours NNS I-NP I-Disease
42 243 245 8758207 of IN B-PP I-Disease
43 246 249 8758207 the DT B-NP I-Disease
44 250 256 8758207 kidney NN I-NP I-Disease
45 257 261 8758207 have VBP B-VP O
46 262 266 8758207 been VBN I-VP O
47 267 279 8758207 investigated VBN I-VP O
48 280 283 8758207 for IN B-PP O
49 284 292 8758207 mutation NN B-NP O
50 293 295 8758207 of IN B-PP O
51 296 299 8758207 the DT B-NP O
52 300 303 8758207 VHL NN I-NP B-Disease
53 304 308 8758207 gene NN I-NP O
54 309 311 8758207 by IN B-PP O
55 312 318 8758207 single JJ B-NP O
56 319 325 8758207 strand NN I-NP O
57 326 338 8758207 conformation NN I-NP O
58 339 351 8758207 polymorphism NN I-NP O
59 352 353 8758207 ( ( O O
60 353 357 8758207 SSCP NN B-NP O
61 357 358 8758207 ) ) O O
62 359 362 8758207 and CC O O
63 362 363 8758207 / SYM B-NP O
64 363 365 8758207 or CC O O
65 366 378 8758207 heteroduplex NN B-NP O
66 379 380 8758207 ( ( O O
67 380 382 8758207 HD NN B-NP O
68 382 383 8758207 ) ) O O
69 384 394 8758207 techniques NNS B-NP O
70 394 395 8758207 . . O O

1 396 406 8758207 Chromosome NN B-NP O
2 407 409 8758207 3p NN I-NP O
3 410 418 8758207 deletion NN I-NP O
4 419 422 8758207 was VBD B-VP O
5 423 431 8758207 detected VBN I-VP O
6 432 434 8758207 in IN B-PP O
7 435 437 8758207 98 CD B-NP O
8 438 441 8758207 per IN B-PP O
9 442 446 8758207 cent NN B-NP O
10 447 449 8758207 of IN B-PP O
11 450 453 8758207 non AFX B-NP B-Disease
12 453 454 8758207 - HYPH I-NP I-Disease
13 454 463 8758207 papillary JJ I-NP I-Disease
14 464 469 8758207 renal JJ I-NP I-Disease
15 470 474 8758207 cell NN I-NP I-Disease
16 475 485 8758207 carcinomas NNS I-NP I-Disease
17 486 489 8758207 and CC O O
18 490 492 8758207 in IN B-PP O
19 493 495 8758207 25 CD B-NP O
20 496 499 8758207 per IN B-PP O
21 500 504 8758207 cent NN B-NP O
22 505 507 8758207 of IN B-PP O
23 508 519 8758207 chromophobe NN B-NP O
24 520 525 8758207 renal JJ I-NP B-Disease
25 526 530 8758207 cell NN I-NP I-Disease
26 531 541 8758207 carcinomas NNS I-NP I-Disease
27 541 542 8758207 . . O O

1 543 545 8758207 In IN B-PP O
2 546 548 8758207 22 CD B-NP O
3 549 551 8758207 of IN B-PP O
4 552 555 8758207 the DT B-NP O
5 556 558 8758207 43 CD I-NP O
6 559 562 8758207 non AFX I-NP B-Disease
7 562 563 8758207 - HYPH I-NP I-Disease
8 563 572 8758207 papillary JJ I-NP I-Disease
9 573 578 8758207 renal JJ I-NP I-Disease
10 579 583 8758207 cell NN I-NP I-Disease
11 584 594 8758207 carcinomas NNS I-NP I-Disease
12 594 595 8758207 , , O O
13 596 606 8758207 abnormally RB B-VP O
14 607 616 8758207 migrating VBG I-VP O
15 617 620 8758207 DNA NN B-NP O
16 621 626 8758207 bands NNS I-NP O
17 627 631 8758207 were VBD B-VP O
18 632 640 8758207 detected VBN I-VP O
19 641 643 8758207 by IN B-PP O
20 644 648 8758207 SSCP NN B-NP O
21 649 652 8758207 and CC O O
22 652 653 8758207 / SYM B-NP O
23 653 655 8758207 or CC O O
24 656 658 8758207 HD NN B-NP O
25 659 667 8758207 analysis NN I-NP O
26 667 668 8758207 . . O O

1 669 671 8758207 No DT B-NP O
2 672 680 8758207 mobility NN I-NP O
3 681 686 8758207 shift NN I-NP O
4 687 690 8758207 was VBD B-VP O
5 691 695 8758207 seen VBN I-VP O
6 696 698 8758207 in IN B-PP O
7 699 702 8758207 any DT B-NP O
8 703 705 8758207 of IN B-PP O
9 706 709 8758207 the DT B-NP O
10 710 712 8758207 23 CD I-NP O
11 713 724 8758207 chromophobe NN I-NP O
12 725 730 8758207 renal JJ I-NP B-Disease
13 731 735 8758207 cell NN I-NP I-Disease
14 736 746 8758207 carcinomas NNS I-NP I-Disease
15 746 747 8758207 . . O O

1 748 750 8758207 In IN B-PP O
2 751 759 8758207 addition NN B-NP O
3 759 760 8758207 , , O O
4 761 763 8758207 15 CD B-NP O
5 764 773 8758207 papillary JJ I-NP B-Disease
6 774 779 8758207 renal JJ I-NP I-Disease
7 780 784 8758207 cell NN I-NP I-Disease
8 785 792 8758207 tumours NNS I-NP I-Disease
9 793 796 8758207 and CC O O
10 797 800 8758207 ten CD B-NP O
11 801 806 8758207 renal JJ I-NP B-Disease
12 807 818 8758207 oncocytomas NNS I-NP I-Disease
13 818 819 8758207 , , O O
14 820 825 8758207 which WDT B-NP O
15 826 829 8758207 are VBP B-VP O
16 830 843 8758207 characterized VBN I-VP O
17 844 846 8758207 by IN B-PP O
18 847 854 8758207 genetic JJ B-NP O
19 855 862 8758207 changes NNS I-NP O
20 863 868 8758207 other JJ B-ADJP O
21 869 873 8758207 than IN B-PP O
22 874 878 8758207 loss NN B-NP O
23 879 881 8758207 of IN B-PP O
24 882 892 8758207 chromosome NN B-NP O
25 893 895 8758207 3p NN I-NP O
26 896 905 8758207 sequences NNS I-NP O
27 905 906 8758207 , , O O
28 907 911 8758207 were VBD B-VP O
29 912 920 8758207 analysed VBN I-VP O
30 921 924 8758207 for IN B-PP O
31 925 933 8758207 mutation NN B-NP O
32 934 936 8758207 of IN B-PP O
33 937 940 8758207 the DT B-NP O
34 941 944 8758207 VHL NN I-NP B-Disease
35 945 949 8758207 gene NN I-NP O
36 949 950 8758207 . . O O

1 951 955 8758207 None NN B-NP O
2 956 958 8758207 of IN B-PP O
3 959 964 8758207 these DT B-NP O
4 965 972 8758207 tumours NNS I-NP B-Disease
5 973 979 8758207 showed VBD B-VP O
6 980 988 8758207 abnormal JJ B-NP O
7 989 998 8758207 migration NN I-NP O
8 999 1007 8758207 patterns NNS I-NP O
9 1007 1008 8758207 . . O O

1 1009 1012 8758207 The DT B-NP O
2 1013 1020 8758207 results NNS I-NP O
3 1021 1029 8758207 indicate VBP B-VP O
4 1030 1034 8758207 that IN B-SBAR O
5 1035 1043 8758207 mutation NN B-NP O
6 1044 1046 8758207 of IN B-PP O
7 1047 1050 8758207 the DT B-NP O
8 1051 1054 8758207 VHL NN I-NP B-Disease
9 1055 1059 8758207 gene NN I-NP O
10 1060 1062 8758207 is VBZ B-VP O
11 1063 1073 8758207 associated VBN I-VP O
12 1074 1085 8758207 exclusively RB B-ADVP O
13 1086 1090 8758207 with IN B-PP O
14 1091 1094 8758207 the DT B-NP O
15 1095 1106 8758207 development NN I-NP O
16 1107 1109 8758207 of IN B-PP O
17 1110 1113 8758207 non AFX B-NP B-Disease
18 1113 1114 8758207 - HYPH I-NP I-Disease
19 1114 1123 8758207 papillary JJ I-NP I-Disease
20 1124 1129 8758207 renal JJ I-NP I-Disease
21 1130 1134 8758207 cell NN I-NP I-Disease
22 1135 1144 8758207 carcinoma NN I-NP I-Disease
23 1144 1145 8758207 . . O O
24 1145 1146 8758207 . . O O

1 0 0 9019400 -DOCSTART- -X- -X- O

1 0 3 9019400 The DT B-NP O
2 4 10 9019400 TSG101 NN I-NP O
3 11 16 9019400 tumor NN I-NP B-Disease
4 17 31 9019400 susceptibility NN I-NP O
5 32 36 9019400 gene NN I-NP O
6 37 39 9019400 is VBZ B-VP O
7 40 47 9019400 located JJ B-ADJP O
8 48 50 9019400 in IN B-PP O
9 51 61 9019400 chromosome NN B-NP O
10 62 64 9019400 11 CD I-NP O
11 65 69 9019400 band NN I-NP O
12 70 73 9019400 p15 NN I-NP O
13 74 77 9019400 and CC O O
14 78 80 9019400 is VBZ B-VP O
15 81 88 9019400 mutated VBN I-VP O
16 89 91 9019400 in IN B-PP O
17 92 97 9019400 human JJ B-NP O
18 98 104 9019400 breast NN I-NP B-Disease
19 105 111 9019400 cancer NN I-NP I-Disease
20 111 112 9019400 . . O O
21 113 119 9019400 Recent JJ B-NP O
22 120 124 9019400 work NN I-NP O
23 125 128 9019400 has VBZ B-VP O
24 129 139 9019400 identified VBN I-VP O
25 140 141 9019400 a DT B-NP O
26 142 147 9019400 mouse NN I-NP O
27 148 152 9019400 gene NN I-NP O
28 153 154 9019400 ( ( O O
29 154 160 9019400 tsg101 NN B-NP O
30 160 161 9019400 ) ) O O
31 162 167 9019400 whose WP$ B-NP O
32 168 180 9019400 inactivation NN I-NP O
33 181 183 9019400 in IN B-PP O
34 184 195 9019400 fibroblasts NNS B-NP O
35 196 203 9019400 results VBZ B-VP O
36 204 206 9019400 in IN B-PP O
37 207 215 9019400 cellular JJ B-NP O
38 216 230 9019400 transformation NN I-NP O
39 231 234 9019400 and CC O O
40 235 238 9019400 the DT B-NP O
41 239 246 9019400 ability NN I-NP O
42 247 249 9019400 to TO B-VP O
43 250 257 9019400 produce VB I-VP O
44 258 268 9019400 metastatic JJ B-NP B-Disease
45 269 275 9019400 tumors NNS I-NP I-Disease
46 276 278 9019400 in IN B-PP O
47 279 283 9019400 nude JJ B-NP O
48 284 288 9019400 mice NNS I-NP O
49 288 289 9019400 . . O O

1 290 294 9019400 Here RB B-ADVP O
2 294 295 9019400 , , O O
3 296 298 9019400 we PRP B-NP O
4 299 305 9019400 report VBP B-VP O
5 306 310 9019400 that IN B-SBAR O
6 311 314 9019400 the DT B-NP O
7 315 320 9019400 human JJ I-NP O
8 321 328 9019400 homolog NN I-NP O
9 328 329 9019400 , , O O
10 330 336 9019400 TSG101 NN B-NP O
11 336 337 9019400 , , O O
12 338 343 9019400 which WDT B-NP O
13 344 346 9019400 we PRP B-NP O
14 347 355 9019400 isolated VBD B-VP O
15 356 359 9019400 and CC O O
16 360 366 9019400 mapped VBD B-VP O
17 367 369 9019400 to TO B-PP O
18 370 380 9019400 chromosome NN B-NP O
19 381 383 9019400 11 CD I-NP O
20 383 384 9019400 , , O O
21 385 390 9019400 bands NNS B-NP O
22 391 393 9019400 15 CD B-NP O
23 393 394 9019400 . . O O

1 395 396 9019400 1 CD B-NP O
2 396 397 9019400 - HYPH I-NP O
3 397 399 9019400 15 CD B-NP O
4 400 401 9019400 1 CD I-NP O
5 401 402 9019400 - HYPH I-NP O
6 402 404 9019400 15 CD I-NP O
7 404 405 9019400 . . O O

1 406 407 9019400 2 CD B-NP O
2 407 408 9019400 , , O O
3 409 410 9019400 a DT B-NP O
4 411 417 9019400 region NN I-NP O
5 418 426 9019400 proposed VBN B-VP O
6 427 429 9019400 to TO I-VP O
7 430 437 9019400 contain VB I-VP O
8 438 443 9019400 tumor NN B-NP B-Disease
9 444 454 9019400 suppressor NN I-NP O
10 455 459 9019400 gene NN I-NP O
11 460 461 9019400 ( ( I-NP O
12 461 462 9019400 s NNS I-NP O
13 462 463 9019400 ) ) O O
14 463 464 9019400 , , O O
15 465 467 9019400 is VBZ B-VP O
16 468 475 9019400 mutated VBN I-VP O
17 476 478 9019400 at IN B-PP O
18 479 483 9019400 high JJ B-NP O
19 484 493 9019400 frequency NN I-NP O
20 494 496 9019400 in IN B-PP O
21 497 502 9019400 human JJ B-NP O
22 503 509 9019400 breast NN I-NP B-Disease
23 510 516 9019400 cancer NN I-NP I-Disease
24 516 517 9019400 . . O O

1 518 520 9019400 In IN B-PP O
2 521 522 9019400 7 CD B-NP O
3 523 525 9019400 of IN B-PP O
4 526 528 9019400 15 CD B-NP O
5 529 539 9019400 uncultured JJ I-NP O
6 540 547 9019400 primary JJ I-NP O
7 548 553 9019400 human JJ I-NP O
8 554 560 9019400 breast NN I-NP B-Disease
9 561 571 9019400 carcinomas NNS I-NP I-Disease
10 571 572 9019400 , , O O
11 573 583 9019400 intragenic JJ B-NP O
12 584 593 9019400 deletions NNS I-NP O
13 594 598 9019400 were VBD B-VP O
14 599 604 9019400 shown VBN I-VP O
15 605 607 9019400 in IN B-PP O
16 608 614 9019400 TSG101 NN B-NP O
17 615 622 9019400 genomic JJ I-NP O
18 623 626 9019400 DNA NN I-NP O
19 627 630 9019400 and CC O O
20 631 642 9019400 transcripts NNS B-NP O
21 643 645 9019400 by IN B-PP O
22 646 649 9019400 gel NN B-NP O
23 650 653 9019400 and CC O O
24 654 662 9019400 sequence NN B-NP O
25 663 671 9019400 analysis NN I-NP O
26 671 672 9019400 , , O O
27 673 676 9019400 and CC O O
28 677 686 9019400 mutations NNS B-NP O
29 687 696 9019400 affecting VBG B-VP O
30 697 700 9019400 two CD B-NP O
31 701 707 9019400 TSG101 NN I-NP O
32 708 715 9019400 alleles NNS I-NP O
33 716 720 9019400 were VBD B-VP O
34 721 731 9019400 identified VBN I-VP O
35 732 734 9019400 in IN B-PP O
36 735 739 9019400 four CD B-NP O
37 740 742 9019400 of IN B-PP O
38 743 748 9019400 these DT B-NP O
39 749 756 9019400 cancers NNS I-NP B-Disease
40 756 757 9019400 . . O O

1 758 760 9019400 No DT B-NP O
2 761 767 9019400 TSG101 NN I-NP O
3 768 775 9019400 defects NNS I-NP O
4 776 780 9019400 were VBD B-VP O
5 781 786 9019400 found VBN I-VP O
6 787 789 9019400 in IN B-PP O
7 790 797 9019400 matched VBN B-NP O
8 798 804 9019400 normal JJ I-NP O
9 805 811 9019400 breast NN I-NP O
10 812 818 9019400 tissue NN I-NP O
11 819 823 9019400 from IN B-PP O
12 824 827 9019400 the DT B-NP O
13 828 834 9019400 breast NN I-NP B-Disease
14 835 841 9019400 cancer NN I-NP I-Disease
15 842 850 9019400 patients NNS I-NP O
16 850 851 9019400 . . O O

1 852 857 9019400 These DT B-NP O
2 858 866 9019400 findings NNS I-NP O
3 867 875 9019400 strongly RB B-VP O
4 876 885 9019400 implicate VBP I-VP O
5 886 892 9019400 TSG101 NN B-NP O
6 893 902 9019400 mutations NNS I-NP O
7 903 905 9019400 in IN B-PP O
8 906 911 9019400 human JJ B-NP O
9 912 918 9019400 breast NN I-NP B-Disease
10 919 925 9019400 cancer NN I-NP I-Disease

1 0 0 8640236 -DOCSTART- -X- -X- O

1 0 3 8640236 Low JJ B-NP O
2 4 13 8640236 incidence NN I-NP O
3 14 16 8640236 of IN B-PP O
4 17 22 8640236 BRCA2 NN B-NP O
5 23 32 8640236 mutations NNS I-NP O
6 33 35 8640236 in IN B-PP O
7 36 42 8640236 breast NN B-NP B-Disease
8 43 52 8640236 carcinoma NN I-NP I-Disease
9 53 56 8640236 and CC O O
10 57 62 8640236 other JJ B-NP O
11 63 70 8640236 cancers NNS I-NP B-Disease
12 70 71 8640236 . . O O
13 72 81 8640236 Inherited VBN B-VP O
14 82 88 8640236 mutant JJ B-NP O
15 89 96 8640236 alleles NNS I-NP O
16 97 99 8640236 of IN B-PP O
17 100 108 8640236 familial JJ B-NP O
18 109 115 8640236 tumour NN I-NP B-Disease
19 116 126 8640236 suppressor NN I-NP O
20 127 132 8640236 genes NNS I-NP O
21 133 143 8640236 predispose VBP B-VP O
22 144 155 8640236 individuals NNS B-NP O
23 156 158 8640236 to TO B-PP O
24 159 169 8640236 particular JJ B-NP O
25 170 175 8640236 types NNS I-NP O
26 176 178 8640236 of IN B-PP O
27 179 185 8640236 cancer NN B-NP B-Disease
28 185 186 8640236 . . O O

1 187 189 8640236 In IN B-PP O
2 190 198 8640236 addition NN B-NP O
3 199 201 8640236 to TO B-PP O
4 202 204 8640236 an DT B-NP O
5 205 216 8640236 involvement NN I-NP O
6 217 219 8640236 in IN B-PP O
7 220 229 8640236 inherited VBN B-NP O
8 230 244 8640236 susceptibility NN I-NP O
9 245 247 8640236 to TO B-PP O
10 248 254 8640236 cancer NN B-NP B-Disease
11 254 255 8640236 , , O O
12 256 261 8640236 these DT B-NP O
13 262 268 8640236 tumour NN I-NP B-Disease
14 269 279 8640236 suppressor NN I-NP O
15 280 285 8640236 genes NNS I-NP O
16 286 289 8640236 are VBP B-VP O
17 290 297 8640236 targets NNS B-NP O
18 298 301 8640236 for IN B-PP O
19 302 309 8640236 somatic JJ B-NP O
20 310 319 8640236 mutations NNS I-NP O
21 320 322 8640236 in IN B-PP O
22 323 331 8640236 sporadic JJ B-NP B-Disease
23 332 339 8640236 cancers NNS I-NP I-Disease
24 340 342 8640236 of IN B-PP O
25 343 346 8640236 the DT B-NP O
26 347 351 8640236 same JJ I-NP O
27 352 356 8640236 type NN I-NP O
28 357 362 8640236 found VBN B-VP O
29 363 365 8640236 in IN B-PP O
30 366 369 8640236 the DT B-NP O
31 370 378 8640236 familial JJ I-NP O
32 379 384 8640236 forms NNS I-NP O
33 384 385 8640236 . . O O

1 386 388 8640236 An DT B-NP O
2 389 398 8640236 exception NN I-NP O
3 399 401 8640236 is VBZ B-VP O
4 402 407 8640236 BRCA1 NN B-NP O
5 407 408 8640236 , , O O
6 409 414 8640236 which WDT B-NP O
7 415 426 8640236 contributes VBZ B-VP O
8 427 429 8640236 to TO B-PP O
9 430 431 8640236 a DT B-NP O
10 432 443 8640236 significant JJ I-NP O
11 444 452 8640236 fraction NN I-NP O
12 453 455 8640236 of IN B-PP O
13 456 464 8640236 familial JJ B-NP B-Disease
14 465 471 8640236 breast NN I-NP I-Disease
15 472 475 8640236 and CC O I-Disease
16 476 483 8640236 ovarian JJ B-NP I-Disease
17 484 490 8640236 cancer NN I-NP I-Disease
18 490 491 8640236 , , O O
19 492 495 8640236 but CC O O
20 496 505 8640236 undergoes VBZ B-VP O
21 506 514 8640236 mutation NN B-NP O
22 515 517 8640236 at IN B-PP O
23 518 522 8640236 very RB B-NP O
24 523 526 8640236 low JJ I-NP O
25 527 532 8640236 rates NNS I-NP O
26 533 535 8640236 in IN B-PP O
27 536 544 8640236 sporadic JJ B-NP B-Disease
28 545 551 8640236 breast NN I-NP I-Disease
29 552 555 8640236 and CC O I-Disease
30 556 563 8640236 ovarian JJ B-NP I-Disease
31 564 571 8640236 cancers NNS I-NP I-Disease
32 571 572 8640236 . . O O

1 573 577 8640236 This DT B-NP O
2 578 585 8640236 finding NN I-NP O
3 586 594 8640236 suggests VBZ B-VP O
4 595 599 8640236 that IN B-SBAR O
5 600 605 8640236 other JJ B-NP O
6 606 611 8640236 genes NNS I-NP O
7 612 615 8640236 may MD B-VP O
8 616 618 8640236 be VB I-VP O
9 619 622 8640236 the DT B-NP O
10 623 632 8640236 principal JJ I-NP O
11 633 640 8640236 targets NNS I-NP O
12 641 644 8640236 for IN B-PP O
13 645 652 8640236 somatic JJ B-NP O
14 653 661 8640236 mutation NN I-NP O
15 662 664 8640236 in IN B-PP O
16 665 671 8640236 breast NN B-NP B-Disease
17 672 681 8640236 carcinoma NN I-NP I-Disease
18 681 682 8640236 . . O O

1 683 684 8640236 A DT B-NP O
2 685 691 8640236 second JJ I-NP O
3 691 692 8640236 , , O O
4 693 701 8640236 recently RB B-ADVP O
5 702 712 8640236 identified VBD B-VP O
6 713 721 8640236 familial JJ B-NP B-Disease
7 722 728 8640236 breast NN I-NP I-Disease
8 729 735 8640236 cancer NN I-NP I-Disease
9 736 740 8640236 gene NN I-NP O
10 740 741 8640236 , , O O
11 742 747 8640236 BRCA2 NN B-NP O
12 748 749 8640236 ( ( O O
13 749 753 8640236 refs NNS B-NP O
14 754 755 8640236 5 CD B-NP O
15 755 756 8640236 - HYPH I-NP O
16 756 757 8640236 8 CD I-NP O
17 757 758 8640236 ) ) O O
18 758 759 8640236 , , O O
19 760 768 8640236 accounts VBZ B-VP O
20 769 772 8640236 for IN B-PP O
21 773 774 8640236 a DT B-NP O
22 775 785 8640236 proportion NN I-NP O
23 786 788 8640236 of IN B-PP O
24 789 795 8640236 breast NN B-NP B-Disease
25 796 802 8640236 cancer NN I-NP I-Disease
26 803 810 8640236 roughly RB B-ADJP O
27 811 816 8640236 equal JJ I-ADJP O
28 817 819 8640236 to TO B-PP O
29 820 825 8640236 BRCA1 NN B-NP O
30 825 826 8640236 . . O O

1 827 831 8640236 Like IN B-PP O
2 832 837 8640236 BRCA1 NN B-NP O
3 837 838 8640236 , , O O
4 839 844 8640236 BRCA2 NN B-NP O
5 845 852 8640236 behaves VBZ B-VP O
6 853 855 8640236 as IN B-PP O
7 856 857 8640236 a DT B-NP O
8 858 868 8640236 dominantly RB I-NP O
9 869 878 8640236 inherited VBN I-NP O
10 879 885 8640236 tumour NN I-NP B-Disease
11 886 896 8640236 suppressor NN I-NP O
12 897 901 8640236 gene NN I-NP O
13 901 902 8640236 . . O O

1 903 914 8640236 Individuals NNS B-NP O
2 915 918 8640236 who WP B-NP O
3 919 926 8640236 inherit VBP B-VP O
4 927 930 8640236 one CD B-NP O
5 931 937 8640236 mutant JJ I-NP O
6 938 944 8640236 allele NN I-NP O
7 945 948 8640236 are VBP B-VP O
8 949 951 8640236 at IN B-PP O
9 952 961 8640236 increased VBN B-NP O
10 962 966 8640236 risk NN I-NP O
11 967 970 8640236 for IN B-PP O
12 971 977 8640236 breast NN B-NP B-Disease
13 978 984 8640236 cancer NN I-NP I-Disease
14 984 985 8640236 , , O O
15 986 989 8640236 and CC O O
16 990 993 8640236 the DT B-NP O
17 994 1001 8640236 tumours NNS I-NP B-Disease
18 1002 1006 8640236 they PRP B-NP O
19 1007 1014 8640236 develop VBP B-VP O
20 1015 1019 8640236 lose VB I-VP O
21 1020 1023 8640236 the DT B-NP O
22 1024 1028 8640236 wild JJ I-NP O
23 1028 1029 8640236 - HYPH I-NP O
24 1029 1033 8640236 type NN I-NP O
25 1034 1040 8640236 allele NN I-NP O
26 1041 1043 8640236 by IN B-PP O
27 1044 1056 8640236 heterozygous JJ B-NP O
28 1057 1065 8640236 deletion NN I-NP O
29 1065 1066 8640236 . . O O

1 1067 1070 8640236 The DT B-NP O
2 1071 1076 8640236 BRCA2 NN I-NP O
3 1077 1083 8640236 coding NN I-NP O
4 1084 1092 8640236 sequence NN I-NP O
5 1093 1095 8640236 is VBZ B-VP O
6 1096 1100 8640236 huge JJ B-ADJP O
7 1100 1101 8640236 , , O O
8 1102 1110 8640236 composed VBN B-VP O
9 1111 1113 8640236 of IN B-PP O
10 1114 1116 8640236 26 CD B-NP O
11 1117 1122 8640236 exons NNS I-NP O
12 1123 1127 8640236 that WDT B-NP O
13 1128 1132 8640236 span VBP B-VP O
14 1133 1135 8640236 10 CD B-NP O
15 1135 1136 8640236 , , I-NP O
16 1137 1140 8640236 443 CD I-NP O
17 1141 1143 8640236 bp NN I-NP O
18 1143 1144 8640236 . . O O

1 1145 1149 8640236 Here RB B-ADVP O
2 1150 1152 8640236 we PRP B-NP O
3 1153 1164 8640236 investigate VBP B-VP O
4 1165 1168 8640236 the DT B-NP O
5 1169 1173 8640236 rate NN I-NP O
6 1174 1176 8640236 of IN B-PP O
7 1177 1182 8640236 BRCA2 NN B-NP O
8 1183 1191 8640236 mutation NN I-NP O
9 1192 1194 8640236 in IN B-PP O
10 1195 1203 8640236 sporadic JJ B-NP B-Disease
11 1204 1210 8640236 breast NN I-NP I-Disease
12 1211 1218 8640236 cancers NNS I-NP I-Disease
13 1219 1222 8640236 and CC B-PP O
14 1223 1225 8640236 in IN B-PP O
15 1226 1227 8640236 a DT B-NP O
16 1228 1231 8640236 set NN I-NP O
17 1232 1234 8640236 of IN B-PP O
18 1235 1239 8640236 cell NN B-NP O
19 1240 1245 8640236 lines NNS I-NP O
20 1246 1250 8640236 that WDT B-NP O
21 1251 1260 8640236 represent VBP B-VP O
22 1261 1267 8640236 twelve CD B-NP O
23 1268 1273 8640236 other JJ I-NP O
24 1274 1280 8640236 tumour NN I-NP B-Disease
25 1281 1286 8640236 types NNS I-NP O
26 1286 1287 8640236 . . O O

1 1288 1300 8640236 Surprisingly RB B-ADVP O
2 1300 1301 8640236 , , O O
3 1302 1311 8640236 mutations NNS B-NP O
4 1312 1314 8640236 in IN B-PP O
5 1315 1320 8640236 BRCA2 NN B-NP O
6 1321 1324 8640236 are VBP B-VP O
7 1325 1335 8640236 infrequent JJ B-ADJP O
8 1336 1338 8640236 in IN B-PP O
9 1339 1346 8640236 cancers NNS B-NP B-Disease
10 1347 1356 8640236 including VBG B-PP O
11 1357 1363 8640236 breast NN B-NP B-Disease
12 1364 1373 8640236 carcinoma NN I-NP I-Disease
13 1373 1374 8640236 . . O O

1 1375 1382 8640236 However RB B-ADVP O
2 1382 1383 8640236 , , O O
3 1384 1385 8640236 a DT B-NP O
4 1386 1394 8640236 probable JJ I-NP O
5 1395 1403 8640236 germline NN I-NP O
6 1404 1412 8640236 mutation NN I-NP O
7 1413 1415 8640236 in IN B-PP O
8 1416 1417 8640236 a DT B-NP O
9 1418 1428 8640236 pancreatic JJ I-NP B-Disease
10 1429 1435 8640236 tumour NN I-NP I-Disease
11 1436 1440 8640236 cell NN I-NP O
12 1441 1445 8640236 line NN I-NP O
13 1446 1454 8640236 suggests VBZ B-VP O
14 1455 1456 8640236 a DT B-NP O
15 1457 1461 8640236 role NN I-NP O
16 1462 1465 8640236 for IN B-PP O
17 1466 1471 8640236 BRCA2 NN B-NP O
18 1472 1474 8640236 in IN B-PP O
19 1475 1489 8640236 susceptibility NN B-NP O
20 1490 1492 8640236 to TO B-PP O
21 1493 1503 8640236 pancreatic JJ B-NP B-Disease
22 1504 1510 8640236 cancer NN I-NP I-Disease
23 1510 1511 8640236 . . O O
24 1511 1512 8640236 . . O O

1 0 0 8700509 -DOCSTART- -X- -X- O

1 0 3 8700509 The DT B-NP O
2 4 5 8700509 5 CD I-NP O
3 5 6 8700509 ' SYM I-NP O
4 7 10 8700509 end NN I-NP O
5 11 13 8700509 of IN B-PP O
6 14 17 8700509 the DT B-NP O
7 18 23 8700509 BRCA1 NN I-NP O
8 24 28 8700509 gene NN I-NP O
9 29 33 8700509 lies VBZ B-VP O
10 34 40 8700509 within IN B-PP O
11 41 42 8700509 a DT B-NP O
12 43 53 8700509 duplicated JJ I-NP O
13 54 60 8700509 region NN I-NP O
14 61 63 8700509 of IN B-PP O
15 64 69 8700509 human JJ B-NP O
16 70 80 8700509 chromosome NN I-NP O
17 81 86 8700509 17q21 NN I-NP O
18 86 87 8700509 . . O O
19 88 90 8700509 To TO B-VP O
20 91 96 8700509 begin VB I-VP O
21 97 99 8700509 to TO I-VP O
22 100 107 8700509 address VB I-VP O
23 108 111 8700509 the DT B-NP O
24 112 122 8700509 hypothesis NN I-NP O
25 123 127 8700509 that IN B-SBAR O
26 128 136 8700509 abnormal JJ B-NP O
27 137 147 8700509 regulation NN I-NP O
28 148 150 8700509 of IN B-PP O
29 151 154 8700509 the DT B-NP O
30 155 161 8700509 breast NN I-NP B-Disease
31 161 162 8700509 / SYM B-NP I-Disease
32 162 169 8700509 ovarian JJ I-NP I-Disease
33 170 176 8700509 cancer NN I-NP I-Disease
34 177 191 8700509 susceptibility NN I-NP O
35 192 196 8700509 gene NN I-NP O
36 197 202 8700509 BRCA1 NN I-NP O
37 203 205 8700509 is VBZ B-VP O
38 206 207 8700509 a DT B-NP O
39 208 216 8700509 critical JJ I-NP O
40 217 221 8700509 step NN I-NP O
41 222 224 8700509 in IN B-PP O
42 225 233 8700509 sporadic JJ B-NP O
43 234 240 8700509 breast NN I-NP O
44 240 241 8700509 / SYM B-NP O
45 241 248 8700509 ovarian JJ I-NP O
46 249 262 8700509 tumorigenesis NN I-NP O
47 262 263 8700509 , , O O
48 264 266 8700509 we PRP B-NP O
49 267 271 8700509 have VBP B-VP O
50 272 282 8700509 determined VBN I-VP O
51 283 286 8700509 the DT B-NP O
52 287 295 8700509 detailed JJ I-NP O
53 296 305 8700509 structure NN I-NP O
54 306 308 8700509 of IN B-PP O
55 309 312 8700509 the DT B-NP O
56 313 318 8700509 BRCA1 NN I-NP O
57 319 326 8700509 genomic JJ I-NP O
58 327 333 8700509 region NN I-NP O
59 333 334 8700509 . . O O

1 335 337 8700509 We PRP B-NP O
2 338 342 8700509 show VBP B-VP O
3 343 347 8700509 that IN B-SBAR O
4 348 352 8700509 this DT B-NP O
5 353 359 8700509 region NN I-NP O
6 360 362 8700509 of IN B-PP O
7 363 366 8700509 the DT B-NP O
8 367 373 8700509 genome NN I-NP O
9 374 382 8700509 contains VBZ B-VP O
10 383 384 8700509 a DT B-NP O
11 385 391 8700509 tandem JJ I-NP O
12 392 403 8700509 duplication NN I-NP O
13 404 406 8700509 of IN B-PP O
14 407 420 8700509 approximately RB B-NP O
15 421 423 8700509 30 CD I-NP O
16 424 433 8700509 kilobases NNS I-NP O
17 433 434 8700509 , , O O
18 435 440 8700509 which WDT B-NP O
19 441 448 8700509 results VBZ B-VP O
20 449 451 8700509 in IN B-PP O
21 452 455 8700509 two CD B-NP O
22 456 462 8700509 copies NNS I-NP O
23 463 465 8700509 of IN B-PP O
24 466 471 8700509 BRCA1 NN B-NP O
25 472 477 8700509 exons NNS I-NP O
26 478 479 8700509 1 CD B-NP O
27 480 483 8700509 and CC I-NP O
28 484 485 8700509 2 CD I-NP O
29 485 486 8700509 , , O O
30 487 489 8700509 of IN B-PP O
31 490 495 8700509 exons NNS B-NP O
32 496 497 8700509 1 CD I-NP O
33 498 501 8700509 and CC I-NP O
34 502 503 8700509 3 CD I-NP O
35 504 506 8700509 of IN B-PP O
36 507 510 8700509 the DT B-NP O
37 511 519 8700509 adjacent JJ I-NP O
38 520 523 8700509 1A1 NN I-NP O
39 523 524 8700509 - HYPH B-NP O
40 524 526 8700509 3B NN I-NP O
41 527 531 8700509 gene NN I-NP O
42 532 535 8700509 and CC B-PP O
43 536 538 8700509 of IN B-PP O
44 539 542 8700509 the DT B-NP O
45 543 553 8700509 previously RB I-NP O
46 554 562 8700509 reported VBN I-NP O
47 563 566 8700509 295 CD I-NP O
48 567 571 8700509 base NN I-NP O
49 572 576 8700509 pair NN I-NP O
50 577 587 8700509 intergenic JJ I-NP O
51 588 594 8700509 region NN I-NP O
52 594 595 8700509 . . O O

1 596 604 8700509 Sequence NN B-NP O
2 605 613 8700509 analysis NN I-NP O
3 614 616 8700509 of IN B-PP O
4 617 620 8700509 the DT B-NP O
5 621 631 8700509 duplicated VBN I-NP O
6 632 637 8700509 exons NNS I-NP O
7 638 640 8700509 of IN B-PP O
8 641 646 8700509 BRCA1 NN B-NP O
9 647 650 8700509 and CC I-NP O
10 651 654 8700509 1A1 NN I-NP O
11 654 655 8700509 - HYPH B-NP O
12 655 657 8700509 3B NN I-NP O
13 658 661 8700509 and CC O O
14 662 670 8700509 flanking NN B-NP O
15 671 678 8700509 genomic JJ I-NP O
16 679 682 8700509 DNA NN I-NP O
17 683 690 8700509 reveals VBZ B-VP O
18 691 702 8700509 maintenance NN B-NP O
19 703 705 8700509 of IN B-PP O
20 706 709 8700509 the DT B-NP O
21 710 716 8700509 intron NN I-NP O
22 716 717 8700509 - HYPH B-NP O
23 717 721 8700509 exon NN I-NP O
24 722 731 8700509 structure NN I-NP O
25 732 735 8700509 and CC O O
26 736 737 8700509 a DT B-NP O
27 738 742 8700509 high JJ I-NP O
28 743 749 8700509 degree NN I-NP O
29 750 752 8700509 of IN B-PP O
30 753 763 8700509 nucleotide NN B-NP O
31 764 772 8700509 sequence NN I-NP O
32 773 781 8700509 identity NN I-NP O
33 781 782 8700509 , , O O
34 783 793 8700509 suggesting VBG B-VP O
35 794 798 8700509 that IN B-SBAR O
36 799 804 8700509 these DT B-NP O
37 805 808 8700509 are VBP B-VP O
38 809 812 8700509 non AFX O O
39 812 813 8700509 - HYPH O O
40 813 822 8700509 processed VBN B-NP O
41 823 834 8700509 pseudogenes NNS I-NP O
42 835 838 8700509 and CC O O
43 839 843 8700509 that IN B-SBAR O
44 844 847 8700509 the DT B-NP O
45 848 859 8700509 duplication NN I-NP O
46 860 862 8700509 is VBZ B-VP O
47 863 864 8700509 a DT B-NP O
48 865 871 8700509 recent JJ I-NP O
49 872 877 8700509 event NN I-NP O
50 878 880 8700509 in IN B-PP O
51 881 893 8700509 evolutionary JJ B-NP O
52 894 899 8700509 terms NNS I-NP O
53 899 900 8700509 . . O O

1 901 903 8700509 We PRP B-NP O
2 904 908 8700509 also RB B-ADVP O
3 909 913 8700509 show VBP B-VP O
4 914 918 8700509 that IN B-SBAR O
5 919 920 8700509 a DT B-NP O
6 921 930 8700509 processed VBN I-NP O
7 931 941 8700509 pseudogene NN I-NP O
8 942 944 8700509 of IN B-PP O
9 945 948 8700509 the DT B-NP O
10 949 955 8700509 acidic JJ I-NP O
11 956 965 8700509 ribosomal JJ I-NP O
12 966 980 8700509 phosphoprotein NN I-NP O
13 981 983 8700509 P1 NN I-NP O
14 984 985 8700509 ( ( O O
15 985 990 8700509 ARPP1 NN B-NP O
16 990 991 8700509 ) ) O O
17 992 994 8700509 is VBZ B-VP O
18 995 1003 8700509 inserted VBN I-VP O
19 1004 1012 8700509 directly RB B-ADVP O
20 1013 1021 8700509 upstream RB B-ADVP O
21 1022 1024 8700509 of IN B-PP O
22 1025 1031 8700509 pseudo AFX B-NP O
23 1031 1032 8700509 - HYPH I-NP O
24 1032 1037 8700509 BRCA1 NN I-NP O
25 1038 1042 8700509 exon NN I-NP O
26 1043 1045 8700509 1A NN I-NP O
27 1045 1046 8700509 . . O O

1 1047 1049 8700509 We PRP B-NP O
2 1050 1057 8700509 believe VBP B-VP O
3 1058 1062 8700509 that IN B-SBAR O
4 1063 1068 8700509 these DT B-NP O
5 1069 1077 8700509 findings NNS I-NP O
6 1078 1083 8700509 could MD B-VP O
7 1084 1087 8700509 not RB I-VP O
8 1088 1092 8700509 only RB I-VP O
9 1093 1101 8700509 confound VB I-VP O
10 1102 1107 8700509 BRCA1 NN B-NP O
11 1108 1116 8700509 mutation NN I-NP O
12 1117 1125 8700509 analysis NN I-NP O
13 1125 1126 8700509 , , O O
14 1127 1130 8700509 but CC O O
15 1131 1136 8700509 could MD B-VP O
16 1137 1141 8700509 have VB I-VP O
17 1142 1154 8700509 implications NNS B-NP O
18 1155 1158 8700509 for IN B-PP O
19 1159 1162 8700509 the DT B-NP O
20 1163 1169 8700509 normal JJ I-NP O
21 1170 1173 8700509 and CC I-NP O
22 1174 1182 8700509 abnormal JJ I-NP O
23 1183 1193 8700509 regulation NN I-NP O
24 1194 1196 8700509 of IN B-PP O
25 1197 1202 8700509 BRCA1 NN B-NP O
26 1203 1216 8700509 transcription NN I-NP O
27 1216 1217 8700509 , , O O
28 1218 1229 8700509 translation NN B-NP O
29 1230 1233 8700509 and CC I-NP O
30 1234 1242 8700509 function NN I-NP O
31 1242 1243 8700509 . . O O
32 1243 1244 8700509 . . O O

1 0 0 8625410 -DOCSTART- -X- -X- O

1 0 7 8625410 Wiskott NNP B-NP B-Disease
2 7 8 8625410 - HYPH I-NP I-Disease
3 8 15 8625410 Aldrich NNP I-NP I-Disease
4 16 24 8625410 syndrome NN I-NP I-Disease
5 25 32 8625410 protein NN I-NP O
6 32 33 8625410 , , O O
7 34 35 8625410 a DT B-NP O
8 36 41 8625410 novel JJ I-NP O
9 42 50 8625410 effector NN I-NP O
10 51 54 8625410 for IN B-PP O
11 55 58 8625410 the DT B-NP O
12 59 65 8625410 GTPase NN I-NP O
13 66 73 8625410 CDC42Hs NNS I-NP O
14 73 74 8625410 , , O O
15 75 77 8625410 is VBZ B-VP O
16 78 88 8625410 implicated VBN I-VP O
17 89 91 8625410 in IN B-PP O
18 92 97 8625410 actin NN B-NP O
19 98 112 8625410 polymerization NN I-NP O
20 112 113 8625410 . . O O
21 114 117 8625410 The DT B-NP O
22 118 121 8625410 Rho NNP I-NP O
23 122 128 8625410 family NN I-NP O
24 129 131 8625410 of IN B-PP O
25 132 139 8625410 GTPases NNS B-NP O
26 140 147 8625410 control VBP B-VP O
27 148 155 8625410 diverse JJ B-NP O
28 156 166 8625410 biological JJ I-NP O
29 167 176 8625410 processes NNS I-NP O
30 176 177 8625410 , , O O
31 178 187 8625410 including VBG B-PP O
32 188 192 8625410 cell NN B-NP O
33 193 203 8625410 morphology NN I-NP O
34 204 207 8625410 and CC O O
35 208 219 8625410 mitogenesis NN B-NP O
36 219 220 8625410 . . O O

1 221 223 8625410 We PRP B-NP O
2 224 228 8625410 have VBP B-VP O
3 229 239 8625410 identified VBN I-VP O
4 240 244 8625410 WASP NN B-NP O
5 244 245 8625410 , , O O
6 246 249 8625410 the DT B-NP O
7 250 257 8625410 protein NN I-NP O
8 258 262 8625410 that WDT B-NP O
9 263 265 8625410 is VBZ B-VP O
10 266 275 8625410 defective JJ B-ADJP O
11 276 278 8625410 in IN B-PP O
12 279 286 8625410 Wiskott NNP B-NP B-Disease
13 286 287 8625410 - HYPH B-NP I-Disease
14 287 294 8625410 Aldrich NNP I-NP I-Disease
15 295 303 8625410 syndrome NN I-NP I-Disease
16 304 305 8625410 ( ( O O
17 305 308 8625410 WAS NN B-NP B-Disease
18 308 309 8625410 ) ) O O
19 309 310 8625410 , , O O
20 311 313 8625410 as IN B-PP O
21 314 315 8625410 a DT B-NP O
22 316 321 8625410 novel JJ I-NP O
23 322 330 8625410 effector NN I-NP O
24 331 334 8625410 for IN B-PP O
25 335 342 8625410 CDC42Hs NNS B-NP O
26 342 343 8625410 , , O O
27 344 347 8625410 but CC O O
28 348 351 8625410 not RB O O
29 352 355 8625410 for IN B-PP O
30 356 359 8625410 the DT B-NP O
31 360 365 8625410 other JJ I-NP O
32 366 369 8625410 Rho NN I-NP O
33 370 376 8625410 family NN I-NP O
34 377 384 8625410 members NNS I-NP O
35 384 385 8625410 , , O O
36 386 389 8625410 Rac NN B-NP O
37 390 393 8625410 and CC I-NP O
38 394 397 8625410 Rho NN I-NP O
39 397 398 8625410 . . O O

1 399 403 8625410 This DT B-NP O
2 404 415 8625410 interaction NN I-NP O
3 416 418 8625410 is VBZ B-VP O
4 419 428 8625410 dependent JJ B-ADJP O
5 429 431 8625410 on IN B-PP O
6 432 435 8625410 the DT B-NP O
7 436 444 8625410 presence NN I-NP O
8 445 447 8625410 of IN B-PP O
9 448 451 8625410 the DT B-NP O
10 452 453 8625410 G NN I-NP O
11 454 461 8625410 protein NN I-NP O
12 461 462 8625410 - HYPH O O
13 462 469 8625410 binding VBG B-NP O
14 470 476 8625410 domain NN I-NP O
15 476 477 8625410 . . O O

1 478 486 8625410 Cellular JJ B-NP O
2 487 497 8625410 expression NN I-NP O
3 498 500 8625410 of IN B-PP O
4 501 508 8625410 epitope NN B-NP O
5 508 509 8625410 - HYPH B-NP O
6 509 515 8625410 tagged VBN I-NP O
7 516 520 8625410 WASP NN I-NP O
8 521 529 8625410 produces VBZ B-VP O
9 530 538 8625410 clusters NNS B-NP O
10 539 541 8625410 of IN B-PP O
11 542 546 8625410 WASP NN B-NP O
12 547 551 8625410 that WDT B-NP O
13 552 555 8625410 are VBP B-VP O
14 556 562 8625410 highly RB I-VP O
15 563 571 8625410 enriched VBN I-VP O
16 572 574 8625410 in IN B-PP O
17 575 586 8625410 polymerized JJ B-NP O
18 587 592 8625410 actin NN I-NP O
19 592 593 8625410 . . O O

1 594 598 8625410 This DT B-NP O
2 599 609 8625410 clustering NN I-NP O
3 610 612 8625410 is VBZ B-VP O
4 613 616 8625410 not RB I-VP O
5 617 625 8625410 observed VBN I-VP O
6 626 630 8625410 with IN B-PP O
7 631 632 8625410 a DT B-NP O
8 633 634 8625410 C NN I-NP O
9 634 635 8625410 - HYPH B-VP O
10 635 645 8625410 terminally RB B-NP O
11 646 653 8625410 deleted VBN I-NP O
12 654 658 8625410 WASP NN I-NP O
13 659 662 8625410 and CC O O
14 663 665 8625410 is VBZ B-VP O
15 666 675 8625410 inhibited VBN I-VP O
16 676 678 8625410 by IN B-PP O
17 679 691 8625410 coexpression NN B-NP O
18 692 696 8625410 with IN B-PP O
19 697 705 8625410 dominant JJ B-NP O
20 706 714 8625410 negative JJ I-NP O
21 715 722 8625410 CDC42Hs NNS I-NP O
22 722 723 8625410 - HYPH B-NP O
23 723 726 8625410 N17 NN I-NP O
24 726 727 8625410 , , O O
25 728 731 8625410 but CC O O
26 732 735 8625410 not RB O O
27 736 740 8625410 with IN B-PP O
28 741 749 8625410 dominant JJ B-NP O
29 750 758 8625410 negative JJ I-NP O
30 759 764 8625410 forms NNS I-NP O
31 765 767 8625410 of IN B-PP O
32 768 771 8625410 Rac NN B-NP O
33 772 774 8625410 or CC I-NP O
34 775 778 8625410 Rho NN I-NP O
35 778 779 8625410 . . O O

1 780 784 8625410 Thus RB B-ADVP O
2 784 785 8625410 , , O O
3 786 790 8625410 WASP NN B-NP O
4 791 799 8625410 provides VBZ B-VP O
5 800 801 8625410 a DT B-NP O
6 802 807 8625410 novel JJ I-NP O
7 808 812 8625410 link NN I-NP O
8 813 820 8625410 between IN B-PP O
9 821 828 8625410 CDC42Hs NNS B-NP O
10 829 832 8625410 and CC O O
11 833 836 8625410 the DT B-NP O
12 837 842 8625410 actin NN I-NP O
13 843 855 8625410 cytoskeleton NN I-NP O
14 855 856 8625410 , , O O
15 857 862 8625410 which WDT B-NP O
16 863 871 8625410 suggests VBZ B-VP O
17 872 873 8625410 a DT B-NP O
18 874 883 8625410 molecular JJ I-NP O
19 884 893 8625410 mechanism NN I-NP O
20 894 897 8625410 for IN B-PP O
21 898 902 8625410 many JJ B-NP O
22 903 905 8625410 of IN B-PP O
23 906 909 8625410 the DT B-NP O
24 910 918 8625410 cellular JJ I-NP O
25 919 932 8625410 abnormalities NNS I-NP O
26 933 935 8625410 in IN B-PP O
27 936 939 8625410 WAS NNP B-NP B-Disease
28 939 940 8625410 . . O O

1 941 944 8625410 The DT B-NP O
2 945 949 8625410 WASP NN I-NP O
3 950 958 8625410 sequence NN I-NP O
4 959 967 8625410 contains VBZ B-VP O
5 968 971 8625410 two CD B-NP O
6 972 977 8625410 novel JJ I-NP O
7 978 985 8625410 domains NNS I-NP O
8 986 990 8625410 that WDT B-NP O
9 991 994 8625410 are VBP B-VP O
10 995 1005 8625410 homologous JJ B-ADJP O
11 1006 1008 8625410 to TO B-PP O
12 1009 1014 8625410 other JJ B-NP O
13 1015 1023 8625410 proteins NNS I-NP O
14 1024 1032 8625410 involved VBN B-VP O
15 1033 1035 8625410 in IN B-PP O
16 1036 1042 8625410 action NN B-NP O
17 1043 1055 8625410 organization NN I-NP O
18 1055 1056 8625410 . . O O
19 1056 1057 8625410 . . O O

1 0 0 8621452 -DOCSTART- -X- -X- O

1 0 4 8621452 Type NN B-NP B-Disease
2 5 7 8621452 II CD I-NP I-Disease
3 8 13 8621452 human JJ I-NP I-Disease
4 14 24 8621452 complement NN I-NP I-Disease
5 25 27 8621452 C2 NN I-NP I-Disease
6 28 38 8621452 deficiency NN I-NP I-Disease
7 38 39 8621452 . . O O

1 40 46 8621452 Allele NN B-NP O
2 46 47 8621452 - HYPH I-NP O
3 47 55 8621452 specific JJ I-NP O
4 56 61 8621452 amino NN I-NP O
5 62 66 8621452 acid NN I-NP O
6 67 80 8621452 substitutions NNS I-NP O
7 81 82 8621452 ( ( O O
8 82 88 8621452 Ser189 NN B-NP O
9 89 90 8621452 - SYM O O
10 90 91 8621452 - HYPH O O
11 91 92 8621452 > SYM O O
12 93 96 8621452 Phe NN B-NP O
13 96 97 8621452 ; : O O
14 98 104 8621452 Gly444 NN B-NP O
15 105 106 8621452 - SYM B-NP O
16 106 107 8621452 - HYPH B-NP O
17 107 108 8621452 > SYM I-NP O
18 109 112 8621452 Arg NN I-NP O
19 112 113 8621452 ) ) O O
20 114 119 8621452 cause VBP B-VP O
21 120 128 8621452 impaired JJ B-NP O
22 129 131 8621452 C2 NN I-NP O
23 132 141 8621452 secretion NN I-NP O
24 141 142 8621452 . . O O
25 143 147 8621452 Type NN B-NP B-Disease
26 148 150 8621452 II CD I-NP I-Disease
27 151 161 8621452 complement NN I-NP I-Disease
28 162 169 8621452 protein NN I-NP I-Disease
29 170 172 8621452 C2 NN I-NP I-Disease
30 173 183 8621452 deficiency NN I-NP I-Disease
31 184 186 8621452 is VBZ B-VP O
32 187 200 8621452 characterized VBN I-VP O
33 201 203 8621452 by IN B-PP O
34 204 205 8621452 a DT B-NP O
35 206 215 8621452 selective JJ I-NP O
36 216 221 8621452 block NN I-NP O
37 222 224 8621452 in IN B-PP O
38 225 227 8621452 C2 NN B-NP O
39 228 237 8621452 secretion NN I-NP O
40 237 238 8621452 . . O O

1 239 242 8621452 The DT B-NP O
2 243 247 8621452 Type NN I-NP O
3 248 250 8621452 II CD I-NP O
4 251 253 8621452 C2 NN I-NP O
5 254 258 8621452 null JJ I-NP O
6 259 265 8621452 allele NN I-NP O
7 266 267 8621452 ( ( O O
8 267 271 8621452 C2Q0 NN B-NP O
9 271 272 8621452 ) ) O O
10 273 275 8621452 is VBZ B-VP O
11 276 282 8621452 linked VBN I-VP O
12 283 285 8621452 to TO B-PP O
13 286 289 8621452 two CD B-NP O
14 290 295 8621452 major JJ I-NP O
15 296 314 8621452 histocompatibility NN I-NP O
16 315 325 8621452 haplotypes NNS I-NP O
17 326 327 8621452 ( ( O O
18 327 330 8621452 MHC NN B-NP O
19 330 331 8621452 ) ) O O
20 332 336 8621452 that WDT B-NP O
21 337 343 8621452 differ VBP B-VP O
22 344 348 8621452 from IN B-PP O
23 349 352 8621452 the DT B-NP O
24 353 356 8621452 MHC NN I-NP O
25 357 359 8621452 of IN B-PP O
26 360 363 8621452 the DT B-NP O
27 364 368 8621452 more RBR I-NP O
28 369 375 8621452 common JJ I-NP O
29 376 380 8621452 Type NN I-NP B-Disease
30 381 382 8621452 I CD I-NP I-Disease
31 383 385 8621452 C2 NN I-NP I-Disease
32 386 396 8621452 deficiency NN I-NP I-Disease
33 396 397 8621452 . . O O

1 398 400 8621452 To TO B-VP O
2 401 410 8621452 determine VB I-VP O
3 411 414 8621452 the DT B-NP O
4 415 424 8621452 molecular JJ I-NP O
5 425 430 8621452 basis NN I-NP O
6 431 433 8621452 of IN B-PP O
7 434 438 8621452 Type NN B-NP B-Disease
8 439 441 8621452 II CD I-NP I-Disease
9 442 452 8621452 deficiency NN I-NP I-Disease
10 453 456 8621452 the DT B-NP O
11 457 460 8621452 two CD I-NP O
12 461 465 8621452 Type NN I-NP O
13 466 468 8621452 II CD I-NP O
14 469 473 8621452 C2Q0 NN I-NP O
15 474 479 8621452 genes NNS I-NP O
16 480 484 8621452 were VBD B-VP O
17 485 493 8621452 isolated VBN I-VP O
18 494 497 8621452 and CC O O
19 498 509 8621452 transfected VBN B-VP O
20 510 520 8621452 separately RB B-ADVP O
21 521 525 8621452 into IN B-PP O
22 526 527 8621452 L NN B-NP O
23 527 528 8621452 - HYPH B-VP O
24 528 533 8621452 cells NNS B-NP O
25 533 534 8621452 . . O O

1 535 545 8621452 Subsequent JJ B-NP O
2 546 555 8621452 molecular JJ I-NP O
3 556 563 8621452 biology NN I-NP O
4 563 564 8621452 , , O O
5 565 577 8621452 biosynthetic JJ B-ADJP O
6 577 578 8621452 , , O O
7 579 582 8621452 and CC O O
8 583 601 8621452 immunofluorescence NN B-NP O
9 602 609 8621452 studies NNS I-NP O
10 610 622 8621452 demonstrated VBD B-VP O
11 623 627 8621452 that IN B-SBAR O
12 628 630 8621452 C2 NN B-NP O
13 631 640 8621452 secretion NN I-NP O
14 641 643 8621452 is VBZ B-VP O
15 644 652 8621452 impaired JJ B-ADJP O
16 653 655 8621452 in IN B-PP O
17 656 660 8621452 Type NN B-NP B-Disease
18 661 663 8621452 II CD I-NP I-Disease
19 664 666 8621452 C2 NN I-NP I-Disease
20 667 677 8621452 deficiency NN I-NP I-Disease
21 678 685 8621452 because IN B-PP O
22 686 688 8621452 of IN I-PP O
23 689 698 8621452 different JJ B-NP O
24 699 707 8621452 missense JJ I-NP O
25 708 717 8621452 mutations NNS I-NP O
26 718 720 8621452 at IN B-PP O
27 721 727 8621452 highly RB B-NP O
28 728 737 8621452 conserved VBN I-NP O
29 738 746 8621452 residues NNS I-NP O
30 747 749 8621452 in IN B-PP O
31 750 754 8621452 each DT B-NP O
32 755 757 8621452 of IN B-PP O
33 758 761 8621452 the DT B-NP O
34 762 766 8621452 C2Q0 NN I-NP O
35 767 774 8621452 alleles NNS I-NP O
36 774 775 8621452 . . O O

1 776 779 8621452 One CD B-NP O
2 780 782 8621452 is VBZ B-VP O
3 783 785 8621452 in IN B-PP O
4 786 790 8621452 exon NN B-NP O
5 791 792 8621452 5 CD I-NP O
6 793 794 8621452 ( ( O O
7 794 804 8621452 nucleotide NN B-NP O
8 805 809 8621452 C566 NN I-NP O
9 810 811 8621452 - SYM O O
10 811 812 8621452 - HYPH O O
11 813 814 8621452 > SYM O O
12 815 816 8621452 T NN B-NP O
13 816 817 8621452 ; : O O
14 818 824 8621452 Ser189 NN B-NP O
15 825 826 8621452 - SYM B-NP O
16 826 827 8621452 - HYPH B-NP O
17 828 829 8621452 > SYM I-NP O
18 830 833 8621452 Phe NN I-NP O
19 833 834 8621452 ) ) O O
20 835 837 8621452 of IN B-PP O
21 838 841 8621452 the DT B-NP O
22 842 846 8621452 C2Q0 NN I-NP O
23 847 851 8621452 gene NN I-NP O
24 852 858 8621452 linked VBN B-VP O
25 859 861 8621452 to TO B-PP O
26 862 865 8621452 the DT B-NP O
27 866 869 8621452 MHC NN I-NP O
28 870 879 8621452 haplotype NN I-NP O
29 880 883 8621452 A11 NN I-NP O
30 883 884 8621452 , , O O
31 885 888 8621452 B35 NN B-NP O
32 888 889 8621452 , , O O
33 890 894 8621452 DRw1 NN B-NP O
34 894 895 8621452 , , O O
35 896 899 8621452 BFS NN B-NP O
36 899 900 8621452 , , O O
37 901 907 8621452 C4A0B1 NN B-NP O
38 907 908 8621452 . . O O

1 909 912 8621452 The DT B-NP O
2 913 918 8621452 other JJ I-NP O
3 919 921 8621452 is VBZ B-VP O
4 922 924 8621452 in IN B-PP O
5 925 929 8621452 exon NN B-NP O
6 930 932 8621452 11 CD I-NP O
7 933 934 8621452 ( ( O O
8 934 939 8621452 G1930 NN B-NP O
9 940 941 8621452 - SYM O O
10 941 942 8621452 - HYPH B-NP O
11 943 944 8621452 > SYM I-NP O
12 945 946 8621452 A NN I-NP O
13 946 947 8621452 ; : O O
14 948 954 8621452 Gly444 NN B-NP O
15 955 956 8621452 - SYM B-NP O
16 956 957 8621452 - HYPH B-NP O
17 958 959 8621452 > SYM I-NP O
18 960 963 8621452 Arg NN I-NP O
19 963 964 8621452 ) ) O O
20 965 967 8621452 of IN B-PP O
21 968 971 8621452 the DT B-NP O
22 972 976 8621452 C2Q0 NN I-NP O
23 977 981 8621452 gene NN I-NP O
24 982 988 8621452 linked VBN B-VP O
25 989 991 8621452 to TO B-PP O
26 992 995 8621452 the DT B-NP O
27 996 999 8621452 MHC NN I-NP O
28 1000 1009 8621452 haplotype NN I-NP O
29 1010 1012 8621452 A2 NN I-NP O
30 1012 1013 8621452 , , O O
31 1014 1016 8621452 B5 NN B-NP O
32 1016 1017 8621452 , , O O
33 1018 1022 8621452 DRw4 NN B-NP O
34 1022 1023 8621452 , , O O
35 1024 1027 8621452 BFS NN B-NP O
36 1027 1028 8621452 , , O O
37 1029 1035 8621452 C4A3B1 NN B-NP O
38 1035 1036 8621452 . . O O

1 1037 1041 8621452 Each DT B-NP O
2 1042 1048 8621452 mutant JJ I-NP O
3 1049 1051 8621452 C2 NN I-NP O
4 1052 1056 8621452 gene NN I-NP O
5 1057 1064 8621452 product NN I-NP O
6 1065 1067 8621452 is VBZ B-VP O
7 1068 1076 8621452 retained VBN I-VP O
8 1077 1082 8621452 early RB B-ADVP O
9 1083 1085 8621452 in IN B-PP O
10 1086 1089 8621452 the DT B-NP O
11 1090 1099 8621452 secretory JJ I-NP O
12 1100 1107 8621452 pathway NN I-NP O
13 1107 1108 8621452 . . O O

1 1109 1114 8621452 These DT B-NP O
2 1115 1122 8621452 mutants NNS I-NP O
3 1123 1130 8621452 provide VBP B-VP O
4 1131 1137 8621452 models NNS B-NP O
5 1138 1141 8621452 for IN B-PP O
6 1142 1153 8621452 elucidating VBG B-VP O
7 1154 1157 8621452 the DT B-NP O
8 1158 1160 8621452 C2 NN I-NP O
9 1161 1170 8621452 secretory NN I-NP O
10 1171 1178 8621452 pathway NN I-NP O
11 1178 1179 8621452 . . O O
12 1179 1180 8621452 . . O O

1 0 0 9056547 -DOCSTART- -X- -X- O

1 0 8 9056547 Nonsense NN B-NP O
2 9 17 9056547 mutation NN I-NP O
3 18 20 9056547 in IN B-PP O
4 21 25 9056547 exon NN B-NP O
5 26 27 9056547 3 CD I-NP O
6 28 30 9056547 of IN B-PP O
7 31 34 9056547 the DT B-NP O
8 35 46 9056547 proteolipid NN I-NP O
9 47 54 9056547 protein NN I-NP O
10 55 59 9056547 gene NN I-NP O
11 60 61 9056547 ( ( O O
12 61 64 9056547 PLP NN B-NP O
13 64 65 9056547 ) ) O O
14 66 68 9056547 in IN B-PP O
15 69 70 9056547 a DT B-NP O
16 71 77 9056547 family NN I-NP O
17 78 82 9056547 with IN B-PP O
18 83 85 9056547 an DT B-NP O
19 86 93 9056547 unusual JJ I-NP O
20 94 98 9056547 form NN I-NP O
21 99 101 9056547 of IN B-PP O
22 102 111 9056547 Pelizaeus NNP B-NP B-Disease
23 111 112 9056547 - HYPH I-NP I-Disease
24 112 122 9056547 Merzbacher NNP I-NP I-Disease
25 123 130 9056547 disease NN I-NP I-Disease
26 130 131 9056547 . . O O
27 132 134 9056547 We PRP B-NP O
28 135 141 9056547 report VBP B-VP O
29 142 143 9056547 a DT B-NP O
30 144 145 9056547 G NN I-NP O
31 145 146 9056547 - SYM B-NP O
32 146 147 9056547 - HYPH B-NP O
33 148 149 9056547 > SYM I-NP O
34 150 151 9056547 A NN I-NP O
35 152 162 9056547 transition NN I-NP O
36 163 165 9056547 at IN B-PP O
37 166 176 9056547 nucleotide NN B-NP O
38 177 180 9056547 431 CD I-NP O
39 181 183 9056547 of IN B-PP O
40 184 187 9056547 the DT B-NP O
41 188 199 9056547 proteolipid NN I-NP O
42 200 207 9056547 protein NN I-NP O
43 208 212 9056547 gene NN I-NP O
44 213 214 9056547 ( ( O O
45 214 217 9056547 PLP NN B-NP O
46 217 218 9056547 ) ) O O
47 219 226 9056547 results VBZ B-VP O
48 227 229 9056547 in IN B-PP O
49 230 231 9056547 a DT B-NP O
50 232 240 9056547 nonsense JJ I-NP O
51 241 246 9056547 codon NN I-NP O
52 247 249 9056547 in IN B-PP O
53 250 251 9056547 a DT B-NP O
54 252 258 9056547 family NN I-NP O
55 259 263 9056547 with IN B-PP O
56 264 266 9056547 an DT B-NP O
57 267 274 9056547 unusual JJ I-NP O
58 275 279 9056547 form NN I-NP O
59 280 282 9056547 of IN B-PP O
60 283 292 9056547 Pelizaeus NNP B-NP B-Disease
61 292 293 9056547 - HYPH I-NP I-Disease
62 293 303 9056547 Merzbacher NNP I-NP I-Disease
63 304 311 9056547 disease NN I-NP I-Disease
64 312 313 9056547 ( ( O O
65 313 316 9056547 PMD NN B-NP B-Disease
66 316 317 9056547 ) ) O O
67 317 318 9056547 . . O O

1 319 322 9056547 The DT B-NP O
2 323 331 9056547 mutation NN I-NP O
3 331 332 9056547 , , O O
4 333 338 9056547 which WDT B-NP O
5 339 346 9056547 creates VBZ B-VP O
6 347 348 9056547 a DT B-NP O
7 349 355 9056547 second JJ I-NP O
8 356 360 9056547 AluI NN I-NP O
9 361 372 9056547 restriction NN I-NP O
10 373 377 9056547 site NN I-NP O
11 377 378 9056547 , , O O
12 379 386 9056547 results VBZ B-VP O
13 387 389 9056547 in IN B-PP O
14 390 391 9056547 a DT B-NP O
15 392 400 9056547 nonsense JJ I-NP O
16 401 409 9056547 mutation NN I-NP O
17 410 412 9056547 in IN B-PP O
18 413 416 9056547 PLP NN B-NP O
19 416 417 9056547 . . O O

1 418 421 9056547 The DT B-NP O
2 422 430 9056547 clinical JJ I-NP O
3 431 438 9056547 picture NN I-NP O
4 439 448 9056547 resembles VBZ B-VP O
5 449 457 9056547 somewhat RB B-NP O
6 458 462 9056547 that DT I-NP O
7 463 465 9056547 of IN B-PP O
8 466 467 9056547 X NN B-NP B-Disease
9 467 468 9056547 - HYPH O I-Disease
10 468 474 9056547 linked VBN B-VP I-Disease
11 475 482 9056547 spastic JJ B-NP I-Disease
12 483 493 9056547 paraplegia NN I-NP I-Disease
13 494 495 9056547 ( ( O O
14 495 498 9056547 SPG NN B-NP B-Disease
15 498 499 9056547 ) ) O O
16 499 500 9056547 . . O O

1 501 503 9056547 It PRP B-NP O
2 504 511 9056547 differs VBZ B-VP O
3 512 516 9056547 from IN B-PP O
4 517 521 9056547 this DT B-NP O
5 522 525 9056547 and CC O O
6 526 530 9056547 both CC O O
7 531 534 9056547 the DT B-NP O
8 535 544 9056547 classical JJ I-NP O
9 545 548 9056547 and CC I-NP O
10 549 557 9056547 connatal JJ I-NP O
11 558 563 9056547 forms NNS I-NP O
12 564 566 9056547 of IN B-PP O
13 567 570 9056547 PMD NN B-NP B-Disease
14 571 573 9056547 in IN B-PP O
15 574 578 9056547 that IN B-NP O
16 579 581 9056547 it PRP B-NP O
17 582 584 9056547 is VBZ B-VP O
18 585 595 9056547 relatively RB B-ADJP O
19 596 600 9056547 mild JJ I-ADJP O
20 601 603 9056547 in IN B-PP O
21 604 608 9056547 form NN B-NP O
22 608 609 9056547 , , O O
23 610 615 9056547 onset NN B-NP O
24 616 618 9056547 is VBZ B-VP O
25 619 626 9056547 delayed VBN I-VP O
26 627 633 9056547 beyond IN B-PP O
27 634 637 9056547 age NN B-NP O
28 638 639 9056547 2 CD B-NP O
29 640 645 9056547 years NNS I-NP O
30 645 646 9056547 , , O O
31 647 656 9056547 nystagmus NN B-NP B-Disease
32 657 659 9056547 is VBZ B-VP O
33 660 666 9056547 absent JJ B-ADJP O
34 666 667 9056547 , , O O
35 668 675 9056547 tremors NNS B-NP B-Disease
36 676 679 9056547 are VBP B-VP O
37 680 689 9056547 prominent JJ B-NP O
38 689 690 9056547 , , I-NP O
39 691 697 9056547 mental JJ I-NP B-Disease
40 698 709 9056547 retardation NN I-NP I-Disease
41 710 712 9056547 is VBZ B-VP O
42 713 716 9056547 not RB O O
43 717 723 9056547 severe JJ B-ADJP O
44 723 724 9056547 , , O O
45 725 729 9056547 some DT B-NP O
46 730 738 9056547 patients NNS I-NP O
47 739 743 9056547 show VBP B-VP O
48 744 752 9056547 dementia NN B-NP B-Disease
49 753 755 9056547 or CC I-NP O
50 756 767 9056547 personality NN I-NP B-Disease
51 768 777 9056547 disorders NNS I-NP I-Disease
52 777 778 9056547 , , O O
53 779 782 9056547 the DT B-NP O
54 783 790 9056547 disease NN I-NP O
55 791 793 9056547 is VBZ B-VP O
56 794 805 9056547 progressive JJ B-ADJP O
57 806 812 9056547 rather RB B-PP O
58 813 817 9056547 than IN I-PP O
59 818 824 9056547 static JJ B-ADJP O
60 825 827 9056547 in IN B-PP O
61 828 832 9056547 some DT B-NP O
62 832 833 9056547 , , O O
63 834 837 9056547 and CC O O
64 838 845 9056547 several JJ B-NP O
65 846 853 9056547 females NNS I-NP O
66 854 858 9056547 show VBP B-VP O
67 859 864 9056547 signs NNS B-NP O
68 865 867 9056547 of IN B-PP O
69 868 875 9056547 disease NN B-NP O
70 875 876 9056547 . . O O

1 877 880 9056547 The DT B-NP O
2 881 889 9056547 nonsense JJ I-NP O
3 890 898 9056547 mutation NN I-NP O
4 898 899 9056547 , , O O
5 900 905 9056547 which WDT B-NP O
6 906 908 9056547 is VBZ B-VP O
7 909 911 9056547 in IN B-PP O
8 912 916 9056547 exon NN B-NP O
9 917 919 9056547 3B NN I-NP O
10 919 920 9056547 , , O O
11 921 927 9056547 should MD B-VP O
12 928 933 9056547 block VB I-VP O
13 934 937 9056547 the DT B-NP O
14 938 947 9056547 synthesis NN I-NP O
15 948 950 9056547 of IN B-PP O
16 951 957 9056547 normal JJ B-NP O
17 958 961 9056547 PLP NN I-NP O
18 962 965 9056547 but CC O O
19 966 971 9056547 spare JJ B-NP O
20 972 976 9056547 DM20 NN I-NP O
21 976 977 9056547 , , O O
22 978 981 9056547 the DT B-NP O
23 982 989 9056547 isoform NN I-NP O
24 990 995 9056547 whose WP$ B-NP O
25 996 1007 9056547 persistence NN I-NP O
26 1008 1011 9056547 has VBZ B-VP O
27 1012 1016 9056547 been VBN I-VP O
28 1017 1027 9056547 associated VBN I-VP O
29 1028 1032 9056547 with IN B-PP O
30 1033 1037 9056547 mild JJ B-NP O
31 1038 1043 9056547 forms NNS I-NP O
32 1044 1046 9056547 of IN B-PP O
33 1047 1050 9056547 PLP NN B-NP B-Disease
34 1050 1051 9056547 - HYPH B-NP I-Disease
35 1051 1061 9056547 associated VBN I-NP I-Disease
36 1062 1069 9056547 disease NN I-NP I-Disease
37 1070 1072 9056547 in IN B-PP O
38 1073 1077 9056547 both CC B-NP O
39 1078 1084 9056547 humans NNS I-NP O
40 1085 1088 9056547 and CC I-NP O
41 1089 1093 9056547 mice NNS I-NP O
42 1093 1094 9056547 . . O O
43 1094 1095 9056547 . . O O

1 0 0 9271438 -DOCSTART- -X- -X- O

1 0 3 9271438 The DT B-NP O
2 4 7 9271438 von NNP I-NP B-Disease
3 8 14 9271438 Hippel NNP I-NP I-Disease
4 14 15 9271438 - HYPH I-NP I-Disease
5 15 21 9271438 Lindau NNP I-NP I-Disease
6 22 27 9271438 tumor NN I-NP I-Disease
7 28 38 9271438 suppressor NN I-NP O
8 39 43 9271438 gene NN I-NP O
9 44 51 9271438 product NN I-NP O
10 52 61 9271438 interacts VBZ B-VP O
11 62 66 9271438 with IN B-PP O
12 67 70 9271438 Sp1 NN B-NP O
13 71 73 9271438 to TO B-VP O
14 74 81 9271438 repress VB I-VP O
15 82 90 9271438 vascular JJ B-NP O
16 91 102 9271438 endothelial JJ I-NP O
17 103 109 9271438 growth NN I-NP O
18 110 116 9271438 factor NN I-NP O
19 117 125 9271438 promoter NN I-NP O
20 126 134 9271438 activity NN I-NP O
21 134 135 9271438 . . O O
22 136 139 9271438 The DT B-NP O
23 140 143 9271438 von NNP I-NP B-Disease
24 144 150 9271438 Hippel NNP I-NP I-Disease
25 150 151 9271438 - HYPH I-NP I-Disease
26 151 157 9271438 Lindau NNP I-NP I-Disease
27 158 163 9271438 tumor NN I-NP I-Disease
28 164 174 9271438 suppressor NN I-NP O
29 175 179 9271438 gene NN I-NP O
30 180 181 9271438 ( ( O O
31 181 184 9271438 VHL NN B-NP O
32 184 185 9271438 ) ) O O
33 186 189 9271438 has VBZ B-VP O
34 190 191 9271438 a DT B-NP O
35 192 200 9271438 critical JJ I-NP O
36 201 205 9271438 role NN I-NP O
37 206 208 9271438 in IN B-PP O
38 209 212 9271438 the DT B-NP O
39 213 225 9271438 pathogenesis NN I-NP O
40 226 228 9271438 of IN B-PP O
41 229 234 9271438 clear JJ B-NP B-Disease
42 234 235 9271438 - HYPH I-NP I-Disease
43 235 239 9271438 cell NN I-NP I-Disease
44 240 245 9271438 renal JJ I-NP I-Disease
45 246 250 9271438 cell NN I-NP I-Disease
46 251 260 9271438 carcinoma NN I-NP I-Disease
47 261 262 9271438 ( ( O O
48 262 265 9271438 RCC NN B-NP B-Disease
49 265 266 9271438 ) ) O O
50 266 267 9271438 , , O O
51 268 270 9271438 as IN B-SBAR O
52 271 274 9271438 VHL NN B-NP O
53 275 284 9271438 mutations NNS I-NP O
54 285 289 9271438 have VBP B-VP O
55 290 294 9271438 been VBN I-VP O
56 295 300 9271438 found VBN I-VP O
57 301 303 9271438 in IN B-PP O
58 304 308 9271438 both DT B-NP O
59 309 312 9271438 von NNP B-NP B-Disease
60 313 319 9271438 Hippel NNP I-NP I-Disease
61 319 320 9271438 - HYPH B-NP I-Disease
62 320 326 9271438 Lindau NNP I-NP I-Disease
63 327 334 9271438 disease NN I-NP I-Disease
64 334 335 9271438 - HYPH B-VP I-Disease
65 335 345 9271438 associated VBN B-NP I-Disease
66 346 349 9271438 and CC I-NP I-Disease
67 350 358 9271438 sporadic JJ I-NP I-Disease
68 359 363 9271438 RCCs NNS I-NP I-Disease
69 363 364 9271438 . . O O

1 365 371 9271438 Recent JJ B-NP O
2 372 379 9271438 studies NNS I-NP O
3 380 387 9271438 suggest VBP B-VP O
4 388 392 9271438 that IN B-SBAR O
5 393 401 9271438 vascular JJ B-NP O
6 402 413 9271438 endothelial JJ I-NP O
7 414 420 9271438 growth NN I-NP O
8 421 427 9271438 factor NN I-NP O
9 428 429 9271438 ( ( O O
10 429 433 9271438 VEGF NN B-NP O
11 433 434 9271438 ) ) O O
12 435 439 9271438 mRNA NN B-NP O
13 440 442 9271438 is VBZ B-VP O
14 443 454 9271438 upregulated VBN I-VP O
15 455 457 9271438 in IN B-PP O
16 458 461 9271438 RCC NN B-NP B-Disease
17 461 462 9271438 - HYPH O I-Disease
18 463 466 9271438 and CC O I-Disease
19 467 470 9271438 von NNP B-NP I-Disease
20 471 477 9271438 Hippel NNP I-NP I-Disease
21 477 478 9271438 - HYPH B-NP I-Disease
22 478 484 9271438 Lindau NNP I-NP I-Disease
23 485 492 9271438 disease NN I-NP I-Disease
24 492 493 9271438 - HYPH B-NP I-Disease
25 493 503 9271438 associated VBN I-NP I-Disease
26 504 510 9271438 tumors NNS I-NP I-Disease
27 510 511 9271438 . . O O

1 512 514 9271438 We PRP B-NP O
2 515 519 9271438 have VBP B-VP O
3 520 529 9271438 therefore RB I-VP O
4 530 538 9271438 assessed VBN I-VP O
5 539 542 9271438 the DT B-NP O
6 543 549 9271438 effect NN I-NP O
7 550 552 9271438 of IN B-PP O
8 553 556 9271438 the DT B-NP O
9 557 560 9271438 VHL NN I-NP O
10 561 565 9271438 gene NN I-NP O
11 566 573 9271438 product NN I-NP O
12 574 576 9271438 on IN B-PP O
13 577 581 9271438 VEGF NN B-NP O
14 582 592 9271438 expression NN I-NP O
15 592 593 9271438 . . O O

1 594 598 9271438 VEGF NN B-NP O
2 599 607 9271438 promoter NN I-NP O
3 607 608 9271438 - HYPH B-NP O
4 608 618 9271438 luciferase NN I-NP O
5 619 629 9271438 constructs NNS I-NP O
6 630 634 9271438 were VBD B-VP O
7 635 646 9271438 transiently RB I-VP O
8 647 660 9271438 cotransfected VBN I-VP O
9 661 665 9271438 with IN B-PP O
10 666 667 9271438 a DT B-NP O
11 668 672 9271438 wild JJ I-NP O
12 672 673 9271438 - HYPH I-NP O
13 673 677 9271438 type NN I-NP O
14 678 681 9271438 VHL NN I-NP O
15 682 683 9271438 ( ( O O
16 683 685 9271438 wt NN B-NP O
17 685 686 9271438 - HYPH B-NP O
18 686 689 9271438 VHL NN I-NP O
19 689 690 9271438 ) ) O O
20 691 697 9271438 vector NN B-NP O
21 698 700 9271438 in IN B-PP O
22 701 708 9271438 several JJ B-NP O
23 709 713 9271438 cell NN I-NP O
24 714 719 9271438 lines NNS I-NP O
25 719 720 9271438 , , O O
26 721 730 9271438 including VBG B-PP O
27 731 734 9271438 293 CD B-NP O
28 735 744 9271438 embryonic JJ I-NP O
29 745 751 9271438 kidney NN I-NP O
30 752 755 9271438 and CC I-NP O
31 756 759 9271438 RCC NN I-NP B-Disease
32 760 764 9271438 cell NN I-NP O
33 765 770 9271438 lines NNS I-NP O
34 770 771 9271438 . . O O

1 772 774 9271438 wt AFX B-NP O
2 774 775 9271438 - HYPH I-NP O
3 775 778 9271438 VHL NN I-NP O
4 779 786 9271438 protein NN I-NP O
5 787 796 9271438 inhibited VBD B-VP O
6 797 801 9271438 VEGF NN B-NP O
7 802 810 9271438 promoter NN I-NP O
8 811 819 9271438 activity NN I-NP O
9 820 822 9271438 in IN B-PP O
10 823 824 9271438 a DT B-NP O
11 825 829 9271438 dose NN I-NP O
12 829 830 9271438 - HYPH B-NP O
13 830 839 9271438 dependent JJ I-NP O
14 840 846 9271438 manner NN I-NP O
15 847 849 9271438 up IN B-NP O
16 850 852 9271438 to TO I-NP O
17 853 854 9271438 5 CD I-NP O
18 854 855 9271438 - HYPH I-NP O
19 856 858 9271438 to TO B-PP O
20 859 861 9271438 10 CD B-NP O
21 861 862 9271438 - HYPH O O
22 862 866 9271438 fold RB B-ADVP O
23 866 867 9271438 . . O O

1 868 876 9271438 Deletion NN B-NP O
2 877 885 9271438 analysis NN I-NP O
3 886 893 9271438 defined VBD B-VP O
4 894 895 9271438 a DT B-NP O
5 896 899 9271438 144 CD I-NP O
6 899 900 9271438 - HYPH I-NP O
7 900 902 9271438 bp NN I-NP O
8 903 909 9271438 region NN I-NP O
9 910 912 9271438 of IN B-PP O
10 913 916 9271438 the DT B-NP O
11 917 921 9271438 VEGF NN I-NP O
12 922 930 9271438 promoter NN I-NP O
13 931 940 9271438 necessary JJ B-ADJP O
14 941 944 9271438 for IN B-PP O
15 945 948 9271438 VHL NN B-NP O
16 949 959 9271438 repression NN I-NP O
17 959 960 9271438 . . O O

1 961 965 9271438 This DT B-NP O
2 966 969 9271438 VHL NN I-NP O
3 969 970 9271438 - HYPH B-NP O
4 970 980 9271438 responsive JJ I-NP O
5 981 988 9271438 element NN I-NP O
6 989 991 9271438 is VBZ B-VP O
7 992 994 9271438 GC NN B-NP O
8 995 999 9271438 rich JJ B-ADJP O
9 1000 1003 9271438 and CC O O
10 1004 1016 9271438 specifically RB B-VP O
11 1017 1022 9271438 binds VBZ I-VP O
12 1023 1026 9271438 the DT B-NP O
13 1027 1040 9271438 transcription NN I-NP O
14 1041 1047 9271438 factor NN I-NP O
15 1048 1051 9271438 Sp1 NN I-NP O
16 1052 1054 9271438 in IN B-PP O
17 1055 1060 9271438 crude JJ B-NP O
18 1061 1068 9271438 nuclear JJ I-NP O
19 1069 1077 9271438 extracts NNS I-NP O
20 1077 1078 9271438 . . O O

1 1079 1081 9271438 In IN B-PP O
2 1082 1092 9271438 Drosophila NN B-NP O
3 1093 1098 9271438 cells NNS I-NP O
4 1098 1099 9271438 , , O O
5 1100 1113 9271438 cotransfected VBN B-NP O
6 1114 1117 9271438 VHL NN I-NP O
7 1118 1127 9271438 represses VBZ B-VP O
8 1128 1131 9271438 Sp1 NN B-NP O
9 1131 1132 9271438 - HYPH O O
10 1132 1140 9271438 mediated VBN B-NP O
11 1141 1151 9271438 activation NN I-NP O
12 1152 1155 9271438 but CC B-CONJP O
13 1156 1159 9271438 not RB I-CONJP O
14 1160 1165 9271438 basal JJ B-NP O
15 1166 1174 9271438 activity NN I-NP O
16 1175 1177 9271438 of IN B-PP O
17 1178 1181 9271438 the DT B-NP O
18 1182 1186 9271438 VEGF NN I-NP O
19 1187 1195 9271438 promoter NN I-NP O
20 1195 1196 9271438 . . O O

1 1197 1199 9271438 We PRP B-NP O
2 1200 1204 9271438 next RB B-ADVP O
3 1205 1217 9271438 demonstrated VBD B-VP O
4 1218 1220 9271438 in IN B-PP O
5 1221 1241 9271438 coimmunoprecipitates NNS B-NP O
6 1242 1246 9271438 that IN B-SBAR O
7 1247 1250 9271438 VHL NN B-NP O
8 1251 1254 9271438 and CC I-NP O
9 1255 1258 9271438 Sp1 NN I-NP O
10 1259 1263 9271438 were VBD B-VP O
11 1264 1268 9271438 part NN B-NP O
12 1269 1271 9271438 of IN B-PP O
13 1272 1275 9271438 the DT B-NP O
14 1276 1280 9271438 same JJ I-NP O
15 1281 1288 9271438 complex NN I-NP O
16 1289 1292 9271438 and CC O O
17 1292 1293 9271438 , , O O
18 1294 1296 9271438 by IN B-PP O
19 1297 1302 9271438 using VBG B-VP O
20 1303 1304 9271438 a DT B-NP O
21 1305 1316 9271438 glutathione NN I-NP O
22 1316 1317 9271438 - HYPH I-NP O
23 1317 1318 9271438 S NN I-NP O
24 1318 1319 9271438 - HYPH I-NP O
25 1319 1330 9271438 transferase NN I-NP O
26 1330 1331 9271438 - HYPH I-NP O
27 1331 1334 9271438 VHL NN I-NP O
28 1335 1341 9271438 fusion NN I-NP O
29 1342 1349 9271438 protein NN I-NP O
30 1350 1353 9271438 and CC O O
31 1354 1362 9271438 purified VBN B-NP O
32 1363 1366 9271438 Sp1 NN I-NP O
33 1366 1367 9271438 , , O O
34 1368 1372 9271438 that IN B-SBAR O
35 1373 1376 9271438 VHL NN B-NP O
36 1377 1380 9271438 and CC I-NP O
37 1381 1384 9271438 Sp1 NN I-NP O
38 1385 1393 9271438 directly RB B-ADVP O
39 1394 1402 9271438 interact VBP B-VP O
40 1402 1403 9271438 . . O O

1 1404 1415 9271438 Furthermore RB B-ADVP O
2 1415 1416 9271438 , , O O
3 1417 1427 9271438 endogenous JJ B-NP O
4 1428 1432 9271438 VEGF NN I-NP O
5 1433 1437 9271438 mRNA NN I-NP O
6 1438 1444 9271438 levels NNS I-NP O
7 1445 1449 9271438 were VBD B-VP O
8 1450 1460 9271438 suppressed VBN I-VP O
9 1461 1463 9271438 in IN B-PP O
10 1464 1473 9271438 permanent JJ B-NP O
11 1474 1477 9271438 RCC NN I-NP B-Disease
12 1478 1482 9271438 cell NN I-NP O
13 1483 1488 9271438 lines NNS I-NP O
14 1489 1499 9271438 expressing VBG B-VP O
15 1500 1502 9271438 wt NN B-NP O
16 1502 1503 9271438 - HYPH B-NP O
17 1503 1506 9271438 VHL NN I-NP O
18 1506 1507 9271438 , , O O
19 1508 1511 9271438 and CC O O
20 1512 1519 9271438 nuclear JJ B-NP O
21 1520 1523 9271438 run NN I-NP O
22 1523 1524 9271438 - HYPH B-ADVP O
23 1524 1526 9271438 on IN B-PP O
24 1527 1534 9271438 studies NNS B-NP O
25 1535 1544 9271438 indicated VBD B-VP O
26 1545 1549 9271438 that IN B-SBAR O
27 1550 1553 9271438 VHL NN B-NP O
28 1554 1564 9271438 regulation NN I-NP O
29 1565 1567 9271438 of IN B-PP O
30 1568 1572 9271438 VEGF NN B-NP O
31 1573 1579 9271438 occurs VBZ B-VP O
32 1580 1582 9271438 at IN B-ADVP O
33 1583 1588 9271438 least JJS I-ADVP O
34 1589 1595 9271438 partly RB B-ADVP O
35 1596 1598 9271438 at IN B-PP O
36 1599 1602 9271438 the DT B-NP O
37 1603 1618 9271438 transcriptional JJ I-NP O
38 1619 1624 9271438 level NN I-NP O
39 1624 1625 9271438 . . O O

1 1626 1631 9271438 These DT B-NP O
2 1632 1644 9271438 observations NNS I-NP O
3 1645 1652 9271438 support VBP B-VP O
4 1653 1654 9271438 a DT B-NP O
5 1655 1658 9271438 new JJ I-NP O
6 1659 1668 9271438 mechanism NN I-NP O
7 1669 1672 9271438 for IN B-PP O
8 1673 1676 9271438 VHL NN B-NP O
9 1676 1677 9271438 - HYPH O O
10 1677 1685 9271438 mediated VBN B-VP O
11 1686 1701 9271438 transcriptional JJ B-NP O
12 1702 1712 9271438 repression NN I-NP O
13 1713 1716 9271438 via IN B-PP O
14 1717 1718 9271438 a DT B-NP O
15 1719 1725 9271438 direct JJ I-NP O
16 1726 1736 9271438 inhibitory JJ I-NP O
17 1737 1743 9271438 action NN I-NP O
18 1744 1746 9271438 on IN B-PP O
19 1747 1750 9271438 Sp1 NN B-NP O
20 1751 1754 9271438 and CC O O
21 1755 1762 9271438 suggest VBP B-VP O
22 1763 1767 9271438 that IN B-SBAR O
23 1768 1772 9271438 loss NN B-NP O
24 1773 1775 9271438 of IN B-PP O
25 1776 1779 9271438 Sp1 NN B-NP O
26 1780 1790 9271438 inhibition NN I-NP O
27 1791 1794 9271438 may MD B-VP O
28 1795 1797 9271438 be VB I-VP O
29 1798 1807 9271438 important JJ B-ADJP O
30 1808 1810 9271438 in IN B-PP O
31 1811 1814 9271438 the DT B-NP O
32 1815 1827 9271438 pathogenesis NN I-NP O
33 1828 1830 9271438 of IN B-PP O
34 1831 1834 9271438 von NNP B-NP B-Disease
35 1835 1841 9271438 Hippel NNP I-NP I-Disease
36 1841 1842 9271438 - HYPH B-NP I-Disease
37 1842 1848 9271438 Lindau NNP I-NP I-Disease
38 1849 1856 9271438 disease NN I-NP I-Disease
39 1857 1860 9271438 and CC I-NP O
40 1861 1864 9271438 RCC NN I-NP B-Disease
41 1864 1865 9271438 . . O O
42 1865 1866 9271438 . . O O

1 0 0 8678979 -DOCSTART- -X- -X- O

1 0 7 8678979 Mapping VBG B-VP O
2 8 11 8678979 the DT B-NP O
3 12 19 8678979 homolog NN I-NP O
4 20 22 8678979 of IN B-PP O
5 23 26 8678979 the DT B-NP O
6 27 32 8678979 human JJ I-NP O
7 33 36 8678979 Rb1 NN I-NP O
8 37 41 8678979 gene NN I-NP O
9 42 44 8678979 to TO B-PP O
10 45 55 8678979 chromosome NN B-NP O
11 56 58 8678979 14 CD I-NP O
12 59 61 8678979 of IN B-PP O
13 62 68 8678979 higher JJR B-NP O
14 69 77 8678979 primates NNS I-NP O
15 77 78 8678979 . . O O
16 79 82 8678979 The DT B-NP O
17 83 86 8678979 Rb1 NN I-NP O
18 87 91 8678979 gene NN I-NP O
19 92 95 8678979 has VBZ B-VP O
20 96 100 8678979 been VBN I-VP O
21 101 111 8678979 implicated VBN I-VP O
22 112 116 8678979 with IN B-PP O
23 117 131 8678979 retinoblastoma NN B-NP B-Disease
24 132 135 8678979 and CC O O
25 136 138 8678979 is VBZ B-VP O
26 139 146 8678979 located JJ B-ADJP O
27 147 149 8678979 on IN B-PP O
28 150 155 8678979 human JJ B-NP O
29 156 166 8678979 Chromosome NN I-NP O
30 167 168 8678979 ( ( O O
31 168 171 8678979 Chr NN B-NP O
32 171 172 8678979 ) ) O O
33 173 178 8678979 13q14 CD B-NP O
34 178 179 8678979 . . O O

1 180 181 8678979 2 CD B-NP O
2 182 183 8678979 2 CD I-NP O
3 183 184 8678979 . . O O

1 185 186 8678979 A DT B-NP O
2 187 193 8678979 unique JJ I-NP O
3 194 202 8678979 sequence NN I-NP O
4 203 208 8678979 human JJ I-NP O
5 209 212 8678979 Rb1 NN I-NP O
6 213 219 8678979 cosmid NN I-NP O
7 220 223 8678979 DNA NN I-NP O
8 224 229 8678979 probe NN I-NP O
9 230 233 8678979 has VBZ B-VP O
10 234 238 8678979 been VBN I-VP O
11 239 243 8678979 used VBN I-VP O
12 244 246 8678979 to TO I-VP O
13 247 255 8678979 localize VB I-VP O
14 256 260 8678979 this DT B-NP O
15 261 267 8678979 region NN I-NP O
16 268 270 8678979 on IN B-PP O
17 271 275 8678979 apes NNS B-NP O
18 276 279 8678979 Chr NN B-NP O
19 280 282 8678979 14 CD I-NP O
20 283 285 8678979 by IN B-PP O
21 286 289 8678979 the DT B-NP O
22 290 294 8678979 FISH NN I-NP O
23 295 304 8678979 technique NN I-NP O
24 304 305 8678979 . . O O

1 306 309 8678979 The DT B-NP O
2 310 322 8678979 conservation NN I-NP O
3 323 325 8678979 of IN B-PP O
4 326 329 8678979 the DT B-NP O
5 330 333 8678979 Rb1 NN I-NP O
6 334 338 8678979 gene NN I-NP O
7 339 341 8678979 in IN B-PP O
8 342 348 8678979 higher JJR B-NP O
9 349 357 8678979 primates NNS I-NP O
10 358 360 8678979 at IN B-PP O
11 361 364 8678979 the DT B-NP O
12 365 378 8678979 corresponding VBG I-NP O
13 379 389 8678979 equivalent JJ I-NP O
14 390 400 8678979 chromosome NN I-NP O
15 401 406 8678979 locus NN I-NP O
16 407 408 8678979 ( ( O O
17 408 413 8678979 14q14 CD B-NP O
18 413 414 8678979 ) ) O O
19 415 417 8678979 of IN B-PP O
20 418 421 8678979 the DT B-NP O
21 422 427 8678979 human NN I-NP O
22 428 431 8678979 may MD B-VP O
23 432 437 8678979 serve VB I-VP O
24 438 440 8678979 as IN B-PP O
25 441 442 8678979 a DT B-NP O
26 443 455 8678979 phylogenetic JJ I-NP O
27 456 462 8678979 marker NN I-NP O
28 463 465 8678979 to TO B-VP O
29 466 473 8678979 further RB I-VP O
30 474 479 8678979 trace VB I-VP O
31 480 483 8678979 the DT B-NP O
32 484 496 8678979 evolutionary JJ I-NP O
33 497 504 8678979 pathway NN I-NP O
34 505 507 8678979 of IN B-PP O
35 508 513 8678979 human JJ B-NP O
36 514 521 8678979 descent NN I-NP O
37 521 522 8678979 . . O O

1 0 0 8670333 -DOCSTART- -X- -X- O

1 0 10 8670333 Colchicine NN B-NP O
2 11 13 8670333 in IN B-PP O
3 14 20 8670333 breast NN B-NP O
4 21 25 8670333 milk NN I-NP O
5 26 28 8670333 of IN B-PP O
6 29 37 8670333 patients NNS B-NP O
7 38 42 8670333 with IN B-PP O
8 43 51 8670333 familial JJ B-NP B-Disease
9 52 65 8670333 Mediterranean JJ I-NP I-Disease
10 66 71 8670333 fever NN I-NP I-Disease
11 71 72 8670333 . . I-NP O
12 73 82 8670333 OBJECTIVE NN I-NP O
13 82 83 8670333 . . O O

1 84 86 8670333 To TO B-VP O
2 87 94 8670333 clarify VB I-VP O
3 95 102 8670333 whether IN B-SBAR O
4 103 113 8670333 colchicine NN B-NP O
5 114 116 8670333 is VBZ B-VP O
6 117 125 8670333 excreted VBN I-VP O
7 126 128 8670333 in IN B-PP O
8 129 135 8670333 breast NN B-NP O
9 136 140 8670333 milk NN I-NP O
10 140 141 8670333 , , O O
11 142 145 8670333 and CC O O
12 146 148 8670333 to TO B-VP O
13 149 156 8670333 compare VB I-VP O
14 157 160 8670333 its PRP$ B-NP O
15 161 175 8670333 concentrations NNS I-NP O
16 176 178 8670333 in IN B-PP O
17 179 182 8670333 the DT B-NP O
18 183 188 8670333 serum NN I-NP O
19 189 192 8670333 and CC I-NP O
20 193 199 8670333 breast NN I-NP O
21 200 204 8670333 milk NN I-NP O
22 205 207 8670333 of IN B-PP O
23 208 217 8670333 lactating VBG B-NP O
24 218 223 8670333 women NNS I-NP O
25 224 227 8670333 who WP B-NP O
26 228 232 8670333 have VBP B-VP O
27 233 241 8670333 familial JJ B-NP B-Disease
28 242 255 8670333 Mediterranean JJ I-NP I-Disease
29 256 261 8670333 fever NN I-NP I-Disease
30 262 263 8670333 ( ( O O
31 263 266 8670333 FMF NN B-NP B-Disease
32 266 267 8670333 ) ) O O
33 267 268 8670333 . . O O

1 269 276 8670333 METHODS NNS B-NP O
2 276 277 8670333 . . O O

1 278 283 8670333 Using VBG B-VP O
2 284 285 8670333 a DT B-NP O
3 286 294 8670333 specific JJ I-NP O
4 295 311 8670333 radioimmunoassay NN I-NP O
5 311 312 8670333 , , O O
6 313 315 8670333 we PRP B-NP O
7 316 326 8670333 determined VBD B-VP O
8 327 337 8670333 colchicine NN B-NP O
9 338 352 8670333 concentrations NNS I-NP O
10 353 355 8670333 in IN B-PP O
11 356 359 8670333 the DT B-NP O
12 360 365 8670333 serum NN I-NP O
13 366 369 8670333 and CC I-NP O
14 370 376 8670333 breast NN I-NP O
15 377 381 8670333 milk NN I-NP O
16 382 384 8670333 of IN B-PP O
17 385 386 8670333 4 CD B-NP O
18 387 395 8670333 patients NNS I-NP O
19 396 398 8670333 at IN B-PP O
20 399 406 8670333 various JJ B-NP O
21 407 411 8670333 time NN I-NP O
22 412 418 8670333 points NNS I-NP O
23 418 419 8670333 , , O O
24 420 429 8670333 following VBG B-PP O
25 430 434 8670333 oral JJ B-NP O
26 435 449 8670333 administration NN I-NP O
27 450 452 8670333 of IN B-PP O
28 453 456 8670333 the DT B-NP O
29 457 461 8670333 drug NN I-NP O
30 461 462 8670333 . . O O

1 463 466 8670333 The DT B-NP O
2 467 472 8670333 study NN I-NP O
3 473 482 8670333 evaluated VBD B-VP O
4 483 484 8670333 4 CD B-NP O
5 485 493 8670333 patients NNS I-NP O
6 494 498 8670333 with IN B-PP O
7 499 502 8670333 FMF NN B-NP B-Disease
8 503 506 8670333 who WP B-NP O
9 507 510 8670333 had VBD B-VP O
10 511 515 8670333 been VBN I-VP O
11 516 522 8670333 taking VBG I-VP O
12 523 533 8670333 colchicine NN B-NP O
13 534 536 8670333 on IN B-PP O
14 537 538 8670333 a DT B-NP O
15 539 543 8670333 long JJ I-NP O
16 543 544 8670333 - HYPH I-NP O
17 544 548 8670333 term NN I-NP O
18 549 554 8670333 basis NN I-NP O
19 554 555 8670333 . . O O

1 556 563 8670333 RESULTS NNS B-NP O
2 563 564 8670333 . . O O

1 565 575 8670333 Colchicine NN B-NP O
2 576 579 8670333 was VBD B-VP O
3 580 585 8670333 found VBN I-VP O
4 586 588 8670333 to TO I-VP O
5 589 591 8670333 be VB I-VP O
6 592 600 8670333 excreted VBN I-VP O
7 601 603 8670333 in IN B-PP O
8 604 610 8670333 breast NN B-NP O
9 611 615 8670333 milk NN I-NP O
10 615 616 8670333 . . O O

1 617 620 8670333 Its PRP$ B-NP O
2 621 627 8670333 levels NNS I-NP O
3 628 634 8670333 ranged VBD B-VP O
4 635 642 8670333 between IN B-PP O
5 643 644 8670333 1 CD B-NP O
6 644 645 8670333 . . O O

1 646 647 8670333 9 CD B-NP O
2 648 651 8670333 and CC I-NP O
3 652 653 8670333 8 CD I-NP O
4 653 654 8670333 . . O O

1 655 656 8670333 6 CD B-NP O
2 657 659 8670333 ng NN I-NP O
3 659 660 8670333 / SYM I-NP O
4 660 662 8670333 ml NN I-NP O
5 662 663 8670333 , , O O
6 664 669 8670333 which WDT B-NP O
7 670 674 8670333 were VBD B-VP O
8 675 682 8670333 similar JJ B-ADJP O
9 683 685 8670333 to TO B-PP O
10 686 691 8670333 those DT B-NP O
11 692 697 8670333 found VBN B-VP O
12 698 700 8670333 in IN B-PP O
13 701 704 8670333 the DT B-NP O
14 705 710 8670333 serum NN I-NP O
15 711 712 8670333 ( ( O O
16 712 720 8670333 parallel JJ B-NP O
17 721 734 8670333 concentration NN I-NP O
18 735 739 8670333 time NN I-NP O
19 740 746 8670333 curves NNS I-NP O
20 746 747 8670333 ) ) O O
21 747 748 8670333 . . O O

1 749 756 8670333 However RB B-ADVP O
2 756 757 8670333 , , O O
3 758 763 8670333 there EX B-NP O
4 764 772 8670333 appeared VBD B-VP O
5 773 775 8670333 to TO I-VP O
6 776 778 8670333 be VB I-VP O
7 779 780 8670333 a DT B-NP O
8 781 793 8670333 considerable JJ I-NP O
9 794 803 8670333 variation NN I-NP O
10 804 806 8670333 in IN B-PP O
11 807 817 8670333 colchicine NN B-NP O
12 818 822 8670333 milk NN I-NP O
13 823 836 8670333 concentration NN I-NP O
14 837 842 8670333 among IN B-PP O
15 843 846 8670333 the DT B-NP O
16 847 856 8670333 different JJ I-NP O
17 857 865 8670333 patients NNS I-NP O
18 865 866 8670333 , , O O
19 867 872 8670333 which WDT B-NP O
20 873 878 8670333 might MD B-VP O
21 879 881 8670333 be VB I-VP O
22 882 889 8670333 related JJ B-ADJP O
23 890 892 8670333 to TO B-PP O
24 893 903 8670333 individual JJ B-NP O
25 904 910 8670333 breast NN I-NP O
26 911 915 8670333 milk NN I-NP O
27 916 927 8670333 composition NN I-NP O
28 928 931 8670333 and CC O O
29 931 932 8670333 , , O O
30 933 941 8670333 possibly RB B-ADVP O
31 941 942 8670333 , , O O
32 943 945 8670333 to TO B-PP O
33 946 951 8670333 other JJ B-NP O
34 952 963 8670333 nutritional JJ I-NP O
35 964 966 8670333 or CC I-NP O
36 967 976 8670333 metabolic JJ I-NP O
37 977 984 8670333 factors NNS I-NP O
38 984 985 8670333 . . O O

1 986 996 8670333 CONCLUSION NN B-NP O
2 996 997 8670333 . . O O

1 998 1001 8670333 The DT B-NP O
2 1002 1011 8670333 extensive JJ I-NP O
3 1012 1022 8670333 peripheral JJ I-NP O
4 1023 1029 8670333 tissue NN I-NP O
5 1030 1037 8670333 binding NN I-NP O
6 1038 1041 8670333 and CC O O
7 1042 1052 8670333 relatively RB B-NP O
8 1053 1056 8670333 low JJ I-NP O
9 1057 1070 8670333 concentration NN I-NP O
10 1071 1073 8670333 of IN B-PP O
11 1074 1084 8670333 colchicine NN B-NP O
12 1085 1087 8670333 in IN B-PP O
13 1088 1094 8670333 breast NN B-NP O
14 1095 1099 8670333 milk NN I-NP O
15 1100 1108 8670333 suggests VBZ B-VP O
16 1109 1113 8670333 that IN B-SBAR O
17 1114 1117 8670333 the DT B-NP O
18 1118 1124 8670333 amount NN I-NP O
19 1125 1133 8670333 ingested VBN B-VP O
20 1134 1136 8670333 by IN B-PP O
21 1137 1140 8670333 the DT B-NP O
22 1141 1147 8670333 infant NN I-NP O
23 1148 1150 8670333 is VBZ B-VP O
24 1151 1156 8670333 small JJ B-ADJP O
25 1156 1157 8670333 . . O O

1 1158 1169 8670333 Furthermore RB B-ADVP O
2 1169 1170 8670333 , , O O
3 1171 1176 8670333 based VBN B-PP O
4 1177 1179 8670333 on IN B-PP O
5 1180 1183 8670333 our PRP$ B-NP O
6 1184 1192 8670333 clinical JJ I-NP O
7 1193 1203 8670333 experience NN I-NP O
8 1203 1204 8670333 , , O O
9 1205 1212 8670333 nursing NN B-NP O
10 1213 1220 8670333 appears VBZ B-VP O
11 1221 1223 8670333 to TO I-VP O
12 1224 1226 8670333 be VB I-VP O
13 1227 1231 8670333 safe JJ B-ADJP O
14 1232 1235 8670333 for IN B-PP O
15 1236 1245 8670333 lactating VBG B-VP O
16 1246 1251 8670333 women NNS B-NP O
17 1252 1256 8670333 with IN B-PP O
18 1257 1260 8670333 FMF NNP B-NP B-Disease
19 1261 1264 8670333 who WP B-NP O
20 1265 1273 8670333 continue VBP B-VP O
21 1274 1276 8670333 to TO I-VP O
22 1277 1281 8670333 take VB I-VP O
23 1282 1292 8670333 colchicine NN B-NP O
24 1292 1293 8670333 . . O O

1 0 0 8651278 -DOCSTART- -X- -X- O

1 0 3 8651278 The DT B-NP O
2 4 12 8651278 spectrum NN I-NP O
3 13 15 8651278 of IN B-PP O
4 16 19 8651278 RB1 NN B-NP O
5 20 24 8651278 germ NN I-NP O
6 24 25 8651278 - HYPH B-NP O
7 25 29 8651278 line NN I-NP O
8 30 39 8651278 mutations NNS I-NP O
9 40 42 8651278 in IN B-PP O
10 43 53 8651278 hereditary JJ B-NP B-Disease
11 54 68 8651278 retinoblastoma NN I-NP I-Disease
12 68 69 8651278 . . O O
13 70 72 8651278 We PRP B-NP O
14 73 77 8651278 have VBP B-VP O
15 78 86 8651278 searched VBN I-VP O
16 87 90 8651278 for IN B-PP O
17 91 95 8651278 germ NN B-NP O
18 95 96 8651278 - HYPH I-NP O
19 96 100 8651278 line NN I-NP O
20 101 104 8651278 RB1 NN I-NP O
21 105 114 8651278 mutations NNS I-NP O
22 115 117 8651278 in IN B-PP O
23 118 121 8651278 119 CD B-NP O
24 122 130 8651278 patients NNS I-NP O
25 131 135 8651278 with IN B-PP O
26 136 146 8651278 hereditary JJ B-NP B-Disease
27 147 161 8651278 retinoblastoma NN I-NP I-Disease
28 161 162 8651278 . . O O

1 163 171 8651278 Previous JJ B-NP O
2 172 186 8651278 investigations NNS I-NP O
3 187 189 8651278 by IN B-PP O
4 190 198 8651278 Southern JJ B-NP O
5 199 203 8651278 blot NN I-NP O
6 204 217 8651278 hybridization NN I-NP O
7 218 221 8651278 and CC O O
8 222 225 8651278 PCR NN B-NP O
9 226 234 8651278 fragment NN I-NP O
10 234 235 8651278 - HYPH B-NP O
11 235 241 8651278 length NN I-NP O
12 242 250 8651278 analysis NN I-NP O
13 251 254 8651278 had VBD B-VP O
14 255 263 8651278 revealed VBN I-VP O
15 264 273 8651278 mutations NNS B-NP O
16 274 276 8651278 in IN B-PP O
17 277 279 8651278 48 CD B-NP O
18 280 288 8651278 patients NNS I-NP O
19 288 289 8651278 . . O O

1 290 294 8651278 Here RB B-ADVP O
2 295 297 8651278 we PRP B-NP O
3 298 304 8651278 report VBP B-VP O
4 305 307 8651278 on IN B-PP O
5 308 311 8651278 the DT B-NP O
6 312 320 8651278 analysis NN I-NP O
7 321 323 8651278 of IN B-PP O
8 324 327 8651278 the DT B-NP O
9 328 337 8651278 remaining VBG I-NP O
10 338 340 8651278 71 CD I-NP O
11 341 349 8651278 patients NNS I-NP O
12 349 350 8651278 . . O O

1 351 353 8651278 By IN B-PP O
2 354 362 8651278 applying VBG B-VP O
3 363 375 8651278 heteroduplex NN B-NP O
4 376 384 8651278 analysis NN I-NP O
5 384 385 8651278 , , O O
6 386 397 8651278 nonisotopic JJ B-NP O
7 398 402 8651278 SSCP NN I-NP O
8 402 403 8651278 , , O O
9 404 407 8651278 and CC O O
10 408 414 8651278 direct JJ B-NP O
11 415 425 8651278 sequencing NN I-NP O
12 425 426 8651278 , , O O
13 427 429 8651278 we PRP B-NP O
14 430 438 8651278 detected VBD B-VP O
15 439 443 8651278 germ NN B-NP O
16 443 444 8651278 - HYPH B-NP O
17 444 448 8651278 line NN I-NP O
18 449 458 8651278 mutations NNS I-NP O
19 459 468 8651278 resulting VBG B-VP O
20 469 471 8651278 in IN B-PP O
21 472 481 8651278 premature JJ B-NP O
22 482 493 8651278 termination NN I-NP O
23 494 500 8651278 codons NNS I-NP O
24 501 503 8651278 or CC O O
25 504 514 8651278 disruption NN B-NP O
26 515 517 8651278 of IN B-PP O
27 518 524 8651278 splice NN B-NP O
28 525 532 8651278 signals NNS I-NP O
29 533 535 8651278 in IN B-PP O
30 536 538 8651278 51 CD B-NP O
31 539 540 8651278 ( ( O O
32 540 543 8651278 72% NN B-NP O
33 543 544 8651278 ) ) O O
34 545 547 8651278 of IN B-PP O
35 548 551 8651278 the DT B-NP O
36 552 554 8651278 71 CD I-NP O
37 555 563 8651278 patients NNS I-NP O
38 563 564 8651278 . . O O

1 565 569 8651278 Four CD B-NP O
2 570 578 8651278 patients NNS I-NP O
3 579 583 8651278 also RB B-ADVP O
4 584 590 8651278 showed VBD B-VP O
5 591 595 8651278 rare JJ B-NP O
6 596 604 8651278 sequence NN I-NP O
7 605 613 8651278 variants NNS I-NP O
8 613 614 8651278 . . O O

1 615 617 8651278 No DT B-NP O
2 618 624 8651278 region NN I-NP O
3 625 627 8651278 of IN B-PP O
4 628 631 8651278 the DT B-NP O
5 632 635 8651278 RB1 NN I-NP O
6 636 640 8651278 gene NN I-NP O
7 641 644 8651278 was VBD B-VP O
8 645 659 8651278 preferentially RB I-VP O
9 660 668 8651278 involved VBN I-VP O
10 669 671 8651278 in IN B-PP O
11 672 678 8651278 single JJ B-NP O
12 679 683 8651278 base NN I-NP O
13 684 697 8651278 substitutions NNS I-NP O
14 697 698 8651278 . . O O

1 699 708 8651278 Recurrent JJ B-NP O
2 709 720 8651278 transitions NNS I-NP O
3 721 725 8651278 were VBD B-VP O
4 726 734 8651278 observed VBN I-VP O
5 735 737 8651278 at IN B-PP O
6 738 742 8651278 most JJS B-NP O
7 743 745 8651278 of IN B-PP O
8 746 749 8651278 the DT B-NP O
9 750 752 8651278 14 CD I-NP O
10 753 759 8651278 codons NNS I-NP O
11 760 766 8651278 within IN B-PP O
12 767 770 8651278 the DT B-NP O
13 771 774 8651278 RB1 NN I-NP O
14 774 775 8651278 . . O O

1 776 778 8651278 No DT B-NP O
2 779 787 8651278 mutation NN I-NP O
3 788 791 8651278 was VBD B-VP O
4 792 800 8651278 observed VBN I-VP O
5 801 803 8651278 in IN B-PP O
6 804 809 8651278 exons NNS B-NP O
7 810 812 8651278 25 CD B-NP O
8 812 813 8651278 - HYPH I-NP O
9 813 815 8651278 27 CD I-NP O
10 815 816 8651278 , , O O
11 817 825 8651278 although IN B-SBAR O
12 826 830 8651278 this DT B-NP O
13 831 837 8651278 region NN I-NP O
14 838 846 8651278 contains VBZ B-VP O
15 847 850 8651278 two CD B-NP O
16 851 854 8651278 CGA NN I-NP O
17 855 861 8651278 codons NNS I-NP O
18 861 862 8651278 . . O O

1 863 867 8651278 This DT B-NP O
2 868 876 8651278 suggests VBZ B-VP O
3 877 881 8651278 that IN B-SBAR O
4 882 891 8651278 mutations NNS B-NP O
5 892 898 8651278 within IN B-PP O
6 899 902 8651278 the DT B-NP O
7 903 904 8651278 3 CD I-NP O
8 904 905 8651278 - HYPH I-NP O
9 905 913 8651278 terminal JJ I-NP O
10 914 920 8651278 region NN I-NP O
11 921 923 8651278 of IN B-PP O
12 924 927 8651278 the DT B-NP O
13 928 931 8651278 RB1 NN I-NP O
14 932 936 8651278 gene NN I-NP O
15 937 940 8651278 may MD B-VP O
16 941 944 8651278 not RB I-VP O
17 945 947 8651278 be VB I-VP O
18 948 957 8651278 oncogenic JJ B-ADJP O
19 957 958 8651278 . . O O

1 959 963 8651278 When WRB B-ADVP O
2 964 969 8651278 these DT B-NP O
3 970 974 8651278 data NNS I-NP O
4 975 979 8651278 were VBD B-VP O
5 980 988 8651278 combined VBN I-VP O
6 989 993 8651278 with IN B-PP O
7 994 997 8651278 the DT B-NP O
8 998 1005 8651278 results NNS I-NP O
9 1006 1008 8651278 of IN B-PP O
10 1009 1012 8651278 our PRP$ B-NP O
11 1013 1021 8651278 previous JJ I-NP O
12 1022 1036 8651278 investigations NNS I-NP O
13 1036 1037 8651278 , , O O
14 1038 1047 8651278 mutations NNS B-NP O
15 1048 1052 8651278 were VBD B-VP O
16 1053 1063 8651278 identified VBN I-VP O
17 1064 1066 8651278 in IN B-PP O
18 1067 1068 8651278 a DT B-NP O
19 1069 1074 8651278 total NN I-NP O
20 1075 1077 8651278 of IN B-PP O
21 1078 1080 8651278 99 CD B-NP O
22 1081 1082 8651278 ( ( O O
23 1082 1085 8651278 83% NN B-NP O
24 1085 1086 8651278 ) ) O O
25 1087 1089 8651278 of IN B-PP O
26 1090 1093 8651278 119 CD B-NP O
27 1094 1102 8651278 patients NNS I-NP O
28 1102 1103 8651278 . . O O

1 1104 1107 8651278 The DT B-NP O
2 1108 1116 8651278 spectrum NN I-NP O
3 1117 1126 8651278 comprises VBZ B-VP O
4 1127 1130 8651278 15% CD B-NP O
5 1131 1136 8651278 large JJ I-NP O
6 1137 1146 8651278 deletions NNS I-NP O
7 1146 1147 8651278 , , O O
8 1148 1151 8651278 26% CD B-NP O
9 1152 1157 8651278 small JJ I-NP O
10 1158 1164 8651278 length NN I-NP O
11 1165 1176 8651278 alterations NNS I-NP O
12 1176 1177 8651278 , , O O
13 1178 1181 8651278 and CC O O
14 1182 1185 8651278 42% NN B-NP O
15 1186 1190 8651278 base NN I-NP O
16 1191 1204 8651278 substitutions NNS I-NP O
17 1204 1205 8651278 . . O O

1 1206 1208 8651278 No DT B-NP O
2 1209 1220 8651278 correlation NN I-NP O
3 1221 1228 8651278 between IN B-PP O
4 1229 1232 8651278 the DT B-NP O
5 1233 1241 8651278 location NN I-NP O
6 1242 1244 8651278 of IN B-PP O
7 1245 1255 8651278 frameshift NN B-NP O
8 1256 1258 8651278 or CC O O
9 1259 1267 8651278 nonsense JJ B-NP O
10 1268 1277 8651278 mutations NNS I-NP O
11 1278 1281 8651278 and CC O O
12 1282 1292 8651278 phenotypic JJ B-NP O
13 1293 1301 8651278 features NNS I-NP O
14 1301 1302 8651278 , , O O
15 1303 1312 8651278 including VBG B-PP O
16 1313 1316 8651278 age NN B-NP O
17 1317 1319 8651278 at IN B-PP O
18 1320 1329 8651278 diagnosis NN B-NP O
19 1329 1330 8651278 , , O O
20 1331 1334 8651278 the DT B-NP O
21 1335 1341 8651278 number NN I-NP O
22 1342 1344 8651278 of IN B-PP O
23 1345 1350 8651278 tumor NN B-NP B-Disease
24 1351 1355 8651278 foci NNS I-NP O
25 1355 1356 8651278 , , O O
26 1357 1360 8651278 and CC O O
27 1361 1374 8651278 manifestation NN B-NP O
28 1375 1377 8651278 of IN B-PP O
29 1378 1387 8651278 nonocular JJ B-NP B-Disease
30 1388 1394 8651278 tumors NNS I-NP I-Disease
31 1395 1398 8651278 was VBD B-VP O
32 1399 1407 8651278 observed VBN I-VP O
33 1407 1408 8651278 . . O O
34 1408 1409 8651278 . . O O

1 0 0 9174057 -DOCSTART- -X- -X- O

1 0 9 9174057 Mutations NNS B-NP O
2 10 12 9174057 in IN B-PP O
3 13 16 9174057 the DT B-NP O
4 17 25 9174057 arginine NN I-NP O
5 25 26 9174057 - HYPH B-NP O
6 26 30 9174057 rich JJ I-NP O
7 31 38 9174057 protein NN I-NP O
8 39 43 9174057 gene NN I-NP O
9 44 45 9174057 ( ( O O
10 45 48 9174057 ARP NN B-NP O
11 48 49 9174057 ) ) O O
12 50 52 9174057 in IN B-PP O
13 53 63 9174057 pancreatic JJ B-NP B-Disease
14 64 70 9174057 cancer NN I-NP I-Disease
15 70 71 9174057 . . O O
16 72 75 9174057 The DT B-NP O
17 76 79 9174057 ARP NN I-NP O
18 80 84 9174057 gene NN I-NP O
19 85 92 9174057 encodes VBZ B-VP O
20 93 94 9174057 a DT B-NP O
21 95 101 9174057 highly RB I-NP O
22 102 111 9174057 conserved VBN I-NP O
23 112 120 9174057 arginine NN I-NP O
24 120 121 9174057 - HYPH I-NP O
25 121 125 9174057 rich JJ I-NP O
26 126 133 9174057 protein NN I-NP O
27 134 138 9174057 from IN B-PP O
28 139 150 9174057 chromosomal JJ B-NP O
29 151 155 9174057 band NN I-NP O
30 156 160 9174057 3p21 NN I-NP O
31 160 161 9174057 . . O O

1 162 163 9174057 1 CD B-NP O
2 164 165 9174057 1 CD I-NP O
3 165 166 9174057 . . O O

1 167 169 9174057 At IN B-PP O
2 170 173 9174057 the DT B-NP O
3 174 185 9174057 cytogenetic JJ I-NP O
4 186 191 9174057 level NN I-NP O
5 192 196 9174057 this DT B-NP O
6 197 203 9174057 region NN I-NP O
7 204 206 9174057 is VBZ B-VP O
8 207 217 9174057 frequently RB I-VP O
9 218 225 9174057 deleted VBN I-VP O
10 226 228 9174057 in IN B-PP O
11 229 230 9174057 a DT B-NP O
12 231 238 9174057 variety NN I-NP O
13 239 241 9174057 of IN B-PP O
14 242 251 9174057 different JJ B-NP O
15 252 257 9174057 solid JJ I-NP B-Disease
16 258 264 9174057 tumors NNS I-NP I-Disease
17 264 265 9174057 , , O O
18 266 274 9174057 although IN B-SBAR O
19 275 278 9174057 not RB O O
20 279 281 9174057 in IN B-PP O
21 282 292 9174057 pancreatic JJ B-NP B-Disease
22 293 299 9174057 cancer NN I-NP I-Disease
23 299 300 9174057 . . O O

1 301 303 9174057 We PRP B-NP O
2 304 308 9174057 have VBP B-VP O
3 309 317 9174057 reported VBN I-VP O
4 318 321 9174057 the DT B-NP O
5 322 330 9174057 presence NN I-NP O
6 331 333 9174057 of IN B-PP O
7 334 335 9174057 a DT B-NP O
8 336 344 9174057 specific JJ I-NP O
9 345 353 9174057 mutation NN I-NP O
10 354 355 9174057 ( ( O O
11 355 360 9174057 ATG50 NN B-NP O
12 360 361 9174057 - SYM O O
13 361 362 9174057 - HYPH B-NP O
14 363 364 9174057 > SYM I-NP O
15 365 368 9174057 AGG NN I-NP O
16 368 369 9174057 ) ) O O
17 370 372 9174057 or CC O O
18 373 381 9174057 deletion NN B-NP O
19 382 384 9174057 of IN B-PP O
20 385 390 9174057 codon NN B-NP O
21 391 393 9174057 50 CD I-NP O
22 394 396 9174057 of IN B-PP O
23 397 400 9174057 the DT B-NP O
24 401 404 9174057 ARP NN I-NP O
25 405 409 9174057 gene NN I-NP O
26 410 412 9174057 in IN B-PP O
27 413 422 9174057 different JJ B-NP O
28 423 428 9174057 tumor NN I-NP B-Disease
29 429 434 9174057 types NNS I-NP I-Disease
30 435 436 9174057 ( ( O O
31 436 444 9174057 Shridhar NNP B-NP O
32 445 447 9174057 et FW I-NP O
33 448 451 9174057 al. FW I-NP O
34 451 452 9174057 , , O O
35 453 457 9174057 1996 CD B-NP O
36 457 458 9174057 , , I-NP O
37 459 464 9174057 1996a CD I-NP O
38 464 465 9174057 ) ) O O
39 465 466 9174057 . . O O

1 467 469 9174057 In IN B-PP O
2 470 473 9174057 the DT B-NP O
3 474 481 9174057 present JJ I-NP O
4 482 487 9174057 study NN I-NP O
5 487 488 9174057 , , O O
6 489 491 9174057 we PRP B-NP O
7 492 496 9174057 have VBP B-VP O
8 497 505 9174057 observed VBN I-VP O
9 506 515 9174057 mutations NNS B-NP O
10 516 525 9174057 involving VBG B-VP O
11 526 531 9174057 codon NN B-NP O
12 532 534 9174057 50 CD I-NP O
13 535 537 9174057 in IN B-PP O
14 538 540 9174057 11 CD B-NP O
15 541 543 9174057 of IN B-PP O
16 544 546 9174057 37 CD B-NP O
17 547 557 9174057 pancreatic JJ I-NP B-Disease
18 558 564 9174057 tumors NNS I-NP I-Disease
19 564 565 9174057 . . O O

1 566 569 9174057 The DT B-NP O
2 570 579 9174057 frequency NN I-NP O
3 580 582 9174057 of IN B-PP O
4 583 588 9174057 codon NN B-NP O
5 589 591 9174057 50 CD I-NP O
6 592 600 9174057 mutation NN I-NP O
7 601 603 9174057 is VBZ B-VP O
8 604 611 9174057 roughly RB B-NP O
9 612 615 9174057 the DT I-NP O
10 616 620 9174057 same JJ I-NP O
11 621 623 9174057 in IN B-PP O
12 624 634 9174057 pancreatic JJ B-NP B-Disease
13 635 641 9174057 tumors NNS I-NP I-Disease
14 642 644 9174057 as IN B-PP O
15 645 647 9174057 in IN B-PP O
16 648 651 9174057 the DT B-NP O
17 652 657 9174057 other JJ I-NP O
18 658 663 9174057 types NNS I-NP O
19 664 666 9174057 of IN B-PP O
20 667 673 9174057 tumors NNS B-NP B-Disease
21 674 684 9174057 previously RB B-VP O
22 685 693 9174057 examined VBN I-VP O
23 693 694 9174057 . . O O

1 695 697 9174057 In IN B-PP O
2 698 706 9174057 addition NN B-NP O
3 706 707 9174057 , , O O
4 708 710 9174057 we PRP B-NP O
5 711 715 9174057 have VBP B-VP O
6 716 724 9174057 detected VBN I-VP O
7 725 734 9174057 mutations NNS B-NP O
8 735 737 9174057 at IN B-PP O
9 738 743 9174057 codon NN B-NP O
10 744 746 9174057 51 CD I-NP O
11 747 749 9174057 in IN B-PP O
12 750 758 9174057 multiple JJ B-NP O
13 759 762 9174057 PCR NN I-NP O
14 763 772 9174057 subclones NNS I-NP O
15 773 775 9174057 in IN B-PP O
16 776 779 9174057 two CD B-NP O
17 780 785 9174057 other JJ I-NP O
18 786 796 9174057 pancreatic JJ I-NP B-Disease
19 797 803 9174057 tumors NNS I-NP I-Disease
20 803 804 9174057 . . O O

1 805 814 9174057 Mutations NNS B-NP O
2 815 817 9174057 in IN B-PP O
3 818 821 9174057 the DT B-NP O
4 822 825 9174057 ARP NN I-NP O
5 826 830 9174057 gene NN I-NP O
6 831 834 9174057 are VBP B-VP O
7 835 839 9174057 thus RB I-VP O
8 840 848 9174057 commonly RB I-VP O
9 849 857 9174057 observed VBN I-VP O
10 858 860 9174057 in IN B-PP O
11 861 871 9174057 pancreatic JJ B-NP B-Disease
12 872 878 9174057 cancer NN I-NP I-Disease
13 878 879 9174057 , , O O
14 880 882 9174057 as RB B-CONJP O
15 883 887 9174057 well RB I-CONJP O
16 888 890 9174057 as IN I-CONJP O
17 891 895 9174057 many JJ B-NP O
18 896 901 9174057 other JJ I-NP O
19 902 909 9174057 cancers NNS I-NP B-Disease
20 909 910 9174057 . . O O

1 0 0 8782829 -DOCSTART- -X- -X- O

1 0 8 8782829 Mutation NN B-NP O
2 9 11 8782829 of IN B-PP O
3 12 16 8782829 MSH3 NN B-NP O
4 17 19 8782829 in IN B-PP O
5 20 31 8782829 endometrial JJ B-NP B-Disease
6 32 38 8782829 cancer NN I-NP I-Disease
7 39 42 8782829 and CC I-NP O
8 43 51 8782829 evidence NN I-NP O
9 52 55 8782829 for IN B-PP O
10 56 59 8782829 its PRP$ B-NP O
11 60 70 8782829 functional JJ I-NP O
12 71 75 8782829 role NN I-NP O
13 76 78 8782829 in IN B-PP O
14 79 91 8782829 heteroduplex NN B-NP O
15 92 98 8782829 repair NN I-NP O
16 98 99 8782829 . . O O
17 100 104 8782829 Many JJ B-NP O
18 105 110 8782829 human JJ I-NP O
19 111 118 8782829 tumours NNS I-NP B-Disease
20 119 123 8782829 have VBP B-VP O
21 124 130 8782829 length NN B-NP O
22 131 142 8782829 alterations NNS I-NP O
23 143 145 8782829 in IN B-PP O
24 146 156 8782829 repetitive JJ B-NP O
25 157 165 8782829 sequence NN I-NP O
26 166 174 8782829 elements NNS I-NP O
27 174 175 8782829 . . O O

1 176 184 8782829 Although IN B-SBAR O
2 185 189 8782829 this DT B-NP O
3 190 204 8782829 microsatellite NN I-NP B-Disease
4 205 216 8782829 instability NN I-NP I-Disease
5 217 220 8782829 has VBZ B-VP O
6 221 225 8782829 been VBN I-VP O
7 226 236 8782829 attributed VBN I-VP O
8 237 239 8782829 to TO B-PP O
9 240 249 8782829 mutations NNS B-NP O
10 250 252 8782829 in IN B-PP O
11 253 257 8782829 four CD B-NP O
12 258 261 8782829 DNA NN I-NP O
13 262 270 8782829 mismatch NN I-NP O
14 271 277 8782829 repair NN I-NP O
15 278 283 8782829 genes NNS I-NP O
16 284 286 8782829 in IN B-PP O
17 287 297 8782829 hereditary JJ B-NP B-Disease
18 298 310 8782829 nonpolyposis NN I-NP I-Disease
19 311 321 8782829 colorectal JJ I-NP I-Disease
20 322 328 8782829 cancer NN I-NP I-Disease
21 329 330 8782829 ( ( O O
22 330 335 8782829 HNPCC NN B-NP B-Disease
23 335 336 8782829 ) ) O O
24 337 345 8782829 kindreds NNS B-NP O
25 345 346 8782829 , , O O
26 347 351 8782829 many JJ B-NP O
27 352 360 8782829 sporadic JJ I-NP B-Disease
28 361 368 8782829 tumours NNS I-NP I-Disease
29 369 376 8782829 exhibit VBP B-VP O
30 377 388 8782829 instability NN B-NP O
31 389 392 8782829 but CC O O
32 393 395 8782829 no DT B-NP O
33 396 406 8782829 detectable JJ I-NP O
34 407 416 8782829 mutations NNS I-NP O
35 417 419 8782829 in IN B-PP O
36 420 425 8782829 these DT B-NP O
37 426 431 8782829 genes NNS I-NP O
38 431 432 8782829 . . O O

1 433 435 8782829 It PRP B-NP O
2 436 438 8782829 is VBZ B-VP O
3 439 448 8782829 therefore RB B-ADVP O
4 449 451 8782829 of IN B-PP O
5 452 460 8782829 interest NN B-NP O
6 461 463 8782829 to TO B-VP O
7 464 472 8782829 identify VB I-VP O
8 473 478 8782829 other JJ B-NP O
9 479 484 8782829 genes NNS I-NP O
10 485 489 8782829 that WDT B-NP O
11 490 500 8782829 contribute VBP B-VP O
12 501 503 8782829 to TO B-PP O
13 504 508 8782829 this DT B-NP O
14 509 520 8782829 instability NN I-NP O
15 520 521 8782829 . . O O

1 522 524 8782829 In IN B-PP O
2 525 530 8782829 yeast NN B-NP O
3 530 531 8782829 , , O O
4 532 541 8782829 mutations NNS B-NP O
5 542 544 8782829 in IN B-PP O
6 545 552 8782829 several JJ B-NP O
7 553 558 8782829 genes NNS I-NP O
8 558 559 8782829 , , O O
9 560 569 8782829 including VBG B-PP O
10 570 573 8782829 RTH NN B-NP O
11 574 577 8782829 and CC I-NP O
12 578 582 8782829 MSH3 NN I-NP O
13 582 583 8782829 , , O O
14 584 589 8782829 cause VBP B-VP O
15 590 604 8782829 microsatellite NN B-NP O
16 605 616 8782829 instability NN I-NP O
17 616 617 8782829 . . O O

1 618 622 8782829 Thus RB B-ADVP O
2 622 623 8782829 , , O O
3 624 626 8782829 we PRP B-NP O
4 627 635 8782829 screened VBD B-VP O
5 636 638 8782829 16 CD B-NP O
6 639 650 8782829 endometrial JJ I-NP B-Disease
7 651 661 8782829 carcinomas NNS I-NP I-Disease
8 662 666 8782829 with IN B-PP O
9 667 681 8782829 microsatellite NN B-NP O
10 682 693 8782829 instability NN I-NP O
11 694 697 8782829 for IN B-PP O
12 698 709 8782829 alterations NNS B-NP O
13 710 712 8782829 in IN B-PP O
14 713 717 8782829 FEN1 NN B-NP O
15 718 719 8782829 ( ( O O
16 719 722 8782829 the DT B-NP O
17 723 728 8782829 human JJ I-NP O
18 729 736 8782829 homolog NN I-NP O
19 737 739 8782829 of IN B-PP O
20 740 743 8782829 RTH NN B-NP O
21 743 744 8782829 ) ) O O
22 745 748 8782829 and CC O O
23 749 751 8782829 in IN B-PP O
24 752 756 8782829 MSH3 NN B-NP O
25 757 758 8782829 ( ( O O
26 758 762 8782829 refs NNS B-NP O
27 763 765 8782829 12 CD B-NP O
28 765 766 8782829 - HYPH I-NP O
29 766 768 8782829 14 CD I-NP O
30 768 769 8782829 ) ) O O
31 769 770 8782829 . . O O

1 771 779 8782829 Although IN B-SBAR O
2 780 782 8782829 we PRP B-NP O
3 783 788 8782829 found VBD B-VP O
4 789 791 8782829 no DT B-NP O
5 792 796 8782829 FEN1 NN I-NP O
6 797 806 8782829 mutations NNS I-NP O
7 806 807 8782829 , , O O
8 808 809 8782829 a DT B-NP O
9 810 820 8782829 frameshift NN I-NP O
10 821 829 8782829 mutation NN I-NP O
11 830 832 8782829 in IN B-PP O
12 833 837 8782829 MSH3 NN B-NP O
13 838 841 8782829 was VBD B-VP O
14 842 850 8782829 observed VBN I-VP O
15 851 853 8782829 in IN B-PP O
16 854 856 8782829 an DT B-NP O
17 857 868 8782829 endometrial JJ I-NP B-Disease
18 869 878 8782829 carcinoma NN I-NP I-Disease
19 879 882 8782829 and CC B-PP O
20 883 885 8782829 in IN B-PP O
21 886 888 8782829 an DT B-NP O
22 889 900 8782829 endometrial JJ I-NP B-Disease
23 901 910 8782829 carcinoma NN I-NP I-Disease
24 911 915 8782829 cell NN I-NP O
25 916 920 8782829 line NN I-NP O
26 920 921 8782829 . . O O

1 922 930 8782829 Extracts NNS B-NP O
2 931 933 8782829 of IN B-PP O
3 934 937 8782829 the DT B-NP O
4 938 942 8782829 cell NN I-NP O
5 943 947 8782829 line NN I-NP O
6 948 952 8782829 were VBD B-VP O
7 953 962 8782829 deficient JJ B-ADJP O
8 963 965 8782829 in IN B-PP O
9 966 972 8782829 repair NN B-NP O
10 973 975 8782829 of IN B-PP O
11 976 979 8782829 DNA NN B-NP O
12 980 990 8782829 substrates NNS I-NP O
13 991 1001 8782829 containing VBG B-VP O
14 1002 1012 8782829 mismatches NNS B-NP O
15 1013 1015 8782829 or CC O O
16 1016 1021 8782829 extra JJ B-NP O
17 1022 1033 8782829 nucleotides NNS I-NP O
18 1033 1034 8782829 . . O O

1 1035 1046 8782829 Introducing VBG B-VP O
2 1047 1057 8782829 chromosome NN B-NP O
3 1058 1059 8782829 5 CD I-NP O
4 1059 1060 8782829 , , O O
5 1061 1069 8782829 encoding VBG B-VP O
6 1070 1073 8782829 the DT B-NP O
7 1074 1078 8782829 MSH3 NN I-NP O
8 1079 1083 8782829 gene NN I-NP O
9 1083 1084 8782829 , , O O
10 1085 1089 8782829 into IN B-PP O
11 1090 1093 8782829 the DT B-NP O
12 1094 1100 8782829 mutant JJ I-NP O
13 1101 1105 8782829 cell NN I-NP O
14 1106 1110 8782829 line NN I-NP O
15 1111 1120 8782829 increased VBD B-VP O
16 1121 1124 8782829 the DT B-NP O
17 1125 1134 8782829 stability NN I-NP O
18 1135 1137 8782829 of IN B-PP O
19 1138 1142 8782829 some DT B-NP O
20 1143 1146 8782829 but CC I-NP O
21 1147 1150 8782829 not RB I-NP O
22 1151 1154 8782829 all DT B-NP O
23 1155 1170 8782829 microsatellites NNS I-NP O
24 1170 1171 8782829 . . O O

1 1172 1180 8782829 Extracts NNS B-NP O
2 1181 1183 8782829 of IN B-PP O
3 1184 1189 8782829 these DT B-NP O
4 1190 1195 8782829 cells NNS I-NP O
5 1196 1204 8782829 repaired VBD B-VP O
6 1205 1212 8782829 certain JJ B-NP O
7 1213 1223 8782829 substrates NNS I-NP O
8 1224 1234 8782829 containing VBG B-VP O
9 1235 1240 8782829 extra JJ B-NP O
10 1241 1252 8782829 nucleotides NNS I-NP O
11 1252 1253 8782829 , , O O
12 1254 1257 8782829 but CC O O
13 1258 1262 8782829 were VBD B-VP O
14 1263 1272 8782829 deficient JJ B-ADJP O
15 1273 1275 8782829 in IN B-PP O
16 1276 1282 8782829 repair NN B-NP O
17 1283 1285 8782829 of IN B-PP O
18 1286 1291 8782829 those DT B-NP O
19 1292 1302 8782829 containing VBG I-NP O
20 1303 1313 8782829 mismatches NNS I-NP O
21 1314 1316 8782829 or CC O O
22 1317 1322 8782829 other JJ B-NP O
23 1323 1328 8782829 extra JJ I-NP O
24 1329 1340 8782829 nucleotides NNS I-NP O
25 1340 1341 8782829 . . O O

1 1342 1343 8782829 A DT B-NP O
2 1344 1354 8782829 subsequent JJ I-NP O
3 1355 1361 8782829 search NN I-NP O
4 1362 1370 8782829 revealed VBD B-VP O
5 1371 1372 8782829 a DT B-NP O
6 1373 1379 8782829 second JJ I-NP O
7 1380 1384 8782829 gene NN I-NP O
8 1385 1393 8782829 mutation NN I-NP O
9 1394 1396 8782829 in IN B-PP O
10 1397 1401 8782829 HHUA NN B-NP O
11 1402 1407 8782829 cells NNS I-NP O
12 1407 1408 8782829 , , O O
13 1409 1410 8782829 a DT B-NP O
14 1411 1419 8782829 missense JJ I-NP O
15 1420 1428 8782829 mutation NN I-NP O
16 1429 1431 8782829 in IN B-PP O
17 1432 1435 8782829 the DT B-NP O
18 1436 1440 8782829 MSH6 NN I-NP O
19 1441 1445 8782829 gene NN I-NP O
20 1445 1446 8782829 . . O O

1 1447 1455 8782829 Together RB B-ADVP O
2 1456 1459 8782829 the DT B-NP O
3 1460 1464 8782829 data NNS I-NP O
4 1465 1472 8782829 suggest VBP B-VP O
5 1473 1477 8782829 that IN B-SBAR O
6 1478 1481 8782829 the DT B-NP O
7 1482 1486 8782829 MSH3 NN I-NP O
8 1487 1491 8782829 gene NN I-NP O
9 1492 1499 8782829 encodes VBZ B-VP O
10 1500 1501 8782829 a DT B-NP O
11 1502 1509 8782829 product NN I-NP O
12 1510 1514 8782829 that WDT B-NP O
13 1515 1524 8782829 functions VBZ B-VP O
14 1525 1527 8782829 in IN B-PP O
15 1528 1534 8782829 repair NN B-NP O
16 1535 1537 8782829 of IN B-PP O
17 1538 1542 8782829 some DT B-NP O
18 1543 1546 8782829 but CC I-NP O
19 1547 1550 8782829 not RB I-NP O
20 1551 1554 8782829 all DT B-NP O
21 1555 1558 8782829 pre AFX B-NP O
22 1558 1559 8782829 - HYPH I-NP O
23 1559 1569 8782829 mutational JJ I-NP O
24 1570 1583 8782829 intermediates NNS I-NP O
25 1583 1584 8782829 , , O O
26 1585 1588 8782829 its PRP$ B-NP O
27 1589 1597 8782829 mutation NN I-NP O
28 1598 1600 8782829 in IN B-PP O
29 1601 1608 8782829 tumours NNS B-NP B-Disease
30 1609 1612 8782829 can MD B-VP O
31 1613 1619 8782829 result VB I-VP O
32 1620 1622 8782829 in IN B-PP O
33 1623 1630 8782829 genomic JJ B-NP O
34 1631 1642 8782829 instability NN I-NP O
35 1643 1646 8782829 and CC O O
36 1646 1647 8782829 , , O O
37 1648 1650 8782829 as IN B-PP O
38 1651 1653 8782829 in IN B-PP O
39 1654 1659 8782829 yeast NN B-NP O
40 1659 1660 8782829 , , O O
41 1661 1665 8782829 MSH3 NN B-NP O
42 1666 1669 8782829 and CC I-NP O
43 1670 1674 8782829 MSH6 NN I-NP O
44 1675 1678 8782829 are VBP B-VP O
45 1679 1688 8782829 partially RB B-ADJP O
46 1689 1698 8782829 redundant JJ I-ADJP O
47 1699 1702 8782829 for IN B-PP O
48 1703 1711 8782829 mismatch NN B-NP O
49 1712 1718 8782829 repair NN I-NP O
50 1718 1719 8782829 . . O O
51 1719 1720 8782829 . . O O

1 0 0 8755645 -DOCSTART- -X- -X- O

1 0 2 8755645 An DT B-NP O
2 3 11 8755645 intronic JJ I-NP O
3 12 20 8755645 mutation NN I-NP O
4 21 23 8755645 in IN B-PP O
5 24 25 8755645 a DT B-NP O
6 26 32 8755645 lariat NN I-NP O
7 33 44 8755645 branchpoint NN I-NP O
8 45 53 8755645 sequence NN I-NP O
9 54 56 8755645 is VBZ B-VP O
10 57 58 8755645 a DT B-NP O
11 59 65 8755645 direct JJ I-NP O
12 66 71 8755645 cause NN I-NP O
13 72 74 8755645 of IN B-PP O
14 75 77 8755645 an DT B-NP O
15 78 87 8755645 inherited VBN I-NP B-Disease
16 88 93 8755645 human JJ I-NP I-Disease
17 94 102 8755645 disorder NN I-NP I-Disease
18 103 104 8755645 ( ( O O
19 104 108 8755645 fish NN B-NP B-Disease
20 108 109 8755645 - HYPH B-NP I-Disease
21 109 112 8755645 eye NN I-NP I-Disease
22 113 120 8755645 disease NN I-NP I-Disease
23 120 121 8755645 ) ) O O
24 121 122 8755645 . . O O
25 123 126 8755645 The DT B-NP O
26 127 132 8755645 first JJ I-NP O
27 133 137 8755645 step NN I-NP O
28 138 140 8755645 in IN B-PP O
29 141 144 8755645 the DT B-NP O
30 145 153 8755645 splicing NN I-NP O
31 154 156 8755645 of IN B-PP O
32 157 159 8755645 an DT B-NP O
33 160 166 8755645 intron NN I-NP O
34 167 171 8755645 from IN B-PP O
35 172 179 8755645 nuclear JJ B-NP O
36 180 190 8755645 precursors NNS I-NP O
37 191 193 8755645 of IN B-PP O
38 194 198 8755645 mRNA NN B-NP O
39 199 206 8755645 results VBZ B-VP O
40 207 209 8755645 in IN B-PP O
41 210 213 8755645 the DT B-NP O
42 214 223 8755645 formation NN I-NP O
43 224 226 8755645 of IN B-PP O
44 227 228 8755645 a DT B-NP O
45 229 235 8755645 lariat NN I-NP O
46 236 245 8755645 structure NN I-NP O
47 245 246 8755645 . . O O

1 247 248 8755645 A DT B-NP O
2 249 257 8755645 distinct JJ I-NP O
3 258 266 8755645 intronic JJ I-NP O
4 267 277 8755645 nucleotide NN I-NP O
5 278 286 8755645 sequence NN I-NP O
6 286 287 8755645 , , O O
7 288 293 8755645 known VBN B-VP O
8 294 296 8755645 as IN B-PP O
9 297 300 8755645 the DT B-NP O
10 301 312 8755645 branchpoint NN I-NP O
11 313 319 8755645 region NN I-NP O
12 319 320 8755645 , , O O
13 321 326 8755645 plays VBZ B-VP O
14 327 328 8755645 a DT B-NP O
15 329 336 8755645 central JJ I-NP O
16 337 341 8755645 role NN I-NP O
17 342 344 8755645 in IN B-PP O
18 345 349 8755645 this DT B-NP O
19 350 357 8755645 process NN I-NP O
20 357 358 8755645 . . O O

1 359 361 8755645 We PRP B-NP O
2 362 366 8755645 here RB B-ADVP O
3 367 375 8755645 describe VBP B-VP O
4 376 377 8755645 a DT B-NP O
5 378 383 8755645 point NN I-NP O
6 384 392 8755645 mutation NN I-NP O
7 393 395 8755645 in IN B-PP O
8 396 400 8755645 such JJ B-NP O
9 401 402 8755645 a DT I-NP O
10 403 411 8755645 sequence NN I-NP O
11 411 412 8755645 . . O O

1 413 418 8755645 Three CD B-NP O
2 419 426 8755645 sisters NNS I-NP O
3 427 431 8755645 were VBD B-VP O
4 432 437 8755645 shown VBN I-VP O
5 438 440 8755645 to TO I-VP O
6 441 447 8755645 suffer VB I-VP O
7 448 452 8755645 from IN B-PP O
8 453 457 8755645 fish NN B-NP B-Disease
9 457 458 8755645 - HYPH B-NP I-Disease
10 458 461 8755645 eye NN I-NP I-Disease
11 462 469 8755645 disease NN I-NP I-Disease
12 470 471 8755645 ( ( O O
13 471 474 8755645 FED VBN B-VP B-Disease
14 474 475 8755645 ) ) O O
15 475 476 8755645 , , O O
16 477 478 8755645 a DT B-NP O
17 479 487 8755645 disorder NN I-NP O
18 488 493 8755645 which WDT B-NP O
19 494 496 8755645 is VBZ B-VP O
20 497 503 8755645 caused VBN I-VP O
21 504 506 8755645 by IN B-PP O
22 507 516 8755645 mutations NNS B-NP O
23 517 519 8755645 in IN B-PP O
24 520 523 8755645 the DT B-NP O
25 524 528 8755645 gene NN I-NP O
26 529 535 8755645 coding VBG B-VP O
27 536 539 8755645 for IN B-PP O
28 540 548 8755645 lecithin JJ B-NP O
29 550 561 8755645 cholesterol NN I-NP O
30 562 577 8755645 acyltransferase NN I-NP O
31 578 579 8755645 ( ( O O
32 579 583 8755645 LCAT NN B-NP O
33 583 584 8755645 ) ) O O
34 584 585 8755645 . . O O

1 586 596 8755645 Sequencing NN B-NP O
2 597 599 8755645 of IN B-PP O
3 600 603 8755645 the DT B-NP O
4 604 608 8755645 LCAT NN I-NP O
5 609 613 8755645 gene NN I-NP O
6 614 616 8755645 of IN B-PP O
7 617 620 8755645 all DT B-NP O
8 621 626 8755645 three CD I-NP O
9 627 635 8755645 probands NNS I-NP O
10 636 644 8755645 revealed VBD B-VP O
11 645 653 8755645 compound NN B-NP O
12 654 668 8755645 heterozygosity NN I-NP O
13 669 672 8755645 for IN B-PP O
14 673 674 8755645 a DT B-NP O
15 675 683 8755645 missense JJ I-NP O
16 684 692 8755645 mutation NN I-NP O
17 693 695 8755645 in IN B-PP O
18 696 700 8755645 exon NN B-NP O
19 701 702 8755645 4 CD I-NP O
20 703 708 8755645 which WDT B-NP O
21 709 711 8755645 is VBZ B-VP O
22 712 720 8755645 reported VBN I-VP O
23 721 723 8755645 to TO I-VP O
24 724 732 8755645 underlie VB I-VP O
25 733 736 8755645 the DT B-NP O
26 737 740 8755645 FED JJ I-NP B-Disease
27 741 750 8755645 phenotype NN I-NP O
28 750 751 8755645 , , O O
29 752 755 8755645 and CC O O
30 756 757 8755645 a DT B-NP O
31 758 763 8755645 point NN I-NP O
32 764 772 8755645 mutation NN I-NP O
33 773 780 8755645 located VBN B-VP O
34 781 783 8755645 in IN B-PP O
35 784 790 8755645 intron NN B-NP O
36 791 792 8755645 4 CD I-NP O
37 793 794 8755645 ( ( O O
38 794 798 8755645 IVS4 CD B-NP O
39 800 801 8755645 T NN I-NP O
40 801 802 8755645 - HYPH B-NP O
41 802 805 8755645 22C NN I-NP O
42 805 806 8755645 ) ) O O
43 806 807 8755645 . . O O

1 808 810 8755645 By IN B-PP O
2 811 821 8755645 performing VBG B-VP O
3 822 824 8755645 in FW B-NP O
4 825 830 8755645 vitro FW I-NP O
5 831 841 8755645 expression NN I-NP O
6 842 844 8755645 of IN B-PP O
7 845 849 8755645 LCAT NN B-NP O
8 850 859 8755645 minigenes NNS I-NP O
9 860 863 8755645 and CC O O
10 864 871 8755645 reverse JJ B-NP O
11 872 885 8755645 transcriptase NN I-NP O
12 886 889 8755645 PCR NN I-NP O
13 890 892 8755645 on IN B-PP O
14 893 897 8755645 mRNA NN B-NP O
15 898 906 8755645 isolated VBN B-VP O
16 907 911 8755645 from IN B-PP O
17 912 922 8755645 leukocytes NNS B-NP O
18 923 925 8755645 of IN B-PP O
19 926 929 8755645 the DT B-NP O
20 930 937 8755645 patient NN I-NP O
21 937 938 8755645 , , O O
22 939 943 8755645 this DT B-NP O
23 944 948 8755645 gene NN I-NP O
24 949 955 8755645 defect NN I-NP O
25 956 959 8755645 was VBD B-VP O
26 960 965 8755645 shown VBN I-VP O
27 966 968 8755645 to TO I-VP O
28 969 974 8755645 cause VB I-VP O
29 975 976 8755645 a DT B-NP O
30 977 981 8755645 null JJ I-NP O
31 982 988 8755645 allele NN I-NP O
32 989 991 8755645 as IN B-PP O
33 992 995 8755645 the DT B-NP O
34 996 1002 8755645 result NN I-NP O
35 1003 1005 8755645 of IN B-PP O
36 1006 1014 8755645 complete JJ B-NP O
37 1015 1021 8755645 intron NN I-NP O
38 1022 1031 8755645 retention NN I-NP O
39 1031 1032 8755645 . . O O

1 1033 1035 8755645 In IN B-PP O
2 1036 1046 8755645 conclusion NN B-NP O
3 1046 1047 8755645 , , O O
4 1048 1050 8755645 we PRP B-NP O
5 1051 1063 8755645 demonstrated VBD B-VP O
6 1064 1068 8755645 that IN B-SBAR O
7 1069 1070 8755645 a DT B-NP O
8 1071 1076 8755645 point NN I-NP O
9 1077 1085 8755645 mutation NN I-NP O
10 1086 1088 8755645 in IN B-PP O
11 1089 1090 8755645 a DT B-NP O
12 1091 1097 8755645 lariat NN I-NP O
13 1098 1109 8755645 branchpoint NN I-NP O
14 1110 1119 8755645 consensus NN I-NP O
15 1120 1128 8755645 sequence NN I-NP O
16 1129 1135 8755645 causes VBZ B-VP O
17 1136 1137 8755645 a DT B-NP O
18 1138 1142 8755645 null JJ I-NP O
19 1143 1149 8755645 allele NN I-NP O
20 1150 1152 8755645 in IN B-PP O
21 1153 1154 8755645 a DT B-NP O
22 1155 1162 8755645 patient NN I-NP O
23 1163 1167 8755645 with IN B-PP O
24 1168 1171 8755645 FED NNP B-NP B-Disease
25 1171 1172 8755645 . . O O

1 1173 1175 8755645 In IN B-PP O
2 1176 1184 8755645 addition NN B-NP O
3 1184 1185 8755645 , , O O
4 1186 1189 8755645 our PRP$ B-NP O
5 1190 1197 8755645 finding NN I-NP O
6 1198 1209 8755645 illustrates VBZ B-VP O
7 1210 1213 8755645 the DT B-NP O
8 1214 1224 8755645 importance NN I-NP O
9 1225 1227 8755645 of IN B-PP O
10 1228 1232 8755645 this DT B-NP O
11 1233 1241 8755645 sequence NN I-NP O
12 1242 1245 8755645 for IN B-PP O
13 1246 1252 8755645 normal JJ B-NP O
14 1253 1258 8755645 human JJ I-NP O
15 1259 1263 8755645 mRNA NN I-NP O
16 1264 1274 8755645 processing NN I-NP O
17 1274 1275 8755645 . . O O

1 1276 1283 8755645 Finally RB B-ADVP O
2 1283 1284 8755645 , , O O
3 1285 1289 8755645 this DT B-NP O
4 1290 1296 8755645 report NN I-NP O
5 1297 1305 8755645 provides VBZ B-VP O
6 1306 1307 8755645 a DT B-NP O
7 1308 1314 8755645 widely RB I-NP O
8 1315 1325 8755645 applicable JJ I-NP O
9 1326 1334 8755645 strategy NN I-NP O
10 1335 1340 8755645 which WDT B-NP O
11 1341 1348 8755645 ensures VBZ B-VP O
12 1349 1353 8755645 fast JJ B-NP O
13 1354 1357 8755645 and CC I-NP O
14 1358 1367 8755645 effective JJ I-NP O
15 1368 1377 8755645 screening NN I-NP O
16 1378 1381 8755645 for IN B-PP O
17 1382 1390 8755645 intronic JJ B-NP O
18 1391 1398 8755645 defects NNS I-NP O
19 1399 1403 8755645 that WDT B-NP O
20 1404 1412 8755645 underlie VBP B-VP O
21 1413 1425 8755645 differential JJ B-NP O
22 1426 1430 8755645 gene NN I-NP O
23 1431 1441 8755645 expression NN I-NP O
24 1441 1442 8755645 . . O O
25 1442 1443 8755645 . . O O

1 0 0 8589722 -DOCSTART- -X- -X- O

1 0 5 8589722 BRCA1 NN B-NP O
2 6 8 8589722 is VBZ B-VP O
3 9 17 8589722 secreted VBN I-VP O
4 18 21 8589722 and CC O O
5 22 30 8589722 exhibits VBZ B-VP O
6 31 41 8589722 properties NNS B-NP O
7 42 44 8589722 of IN B-PP O
8 45 46 8589722 a DT B-NP O
9 47 53 8589722 granin NN I-NP O
10 53 54 8589722 . . O O
11 55 63 8589722 Germline NN B-NP O
12 64 73 8589722 mutations NNS I-NP O
13 74 76 8589722 in IN B-PP O
14 77 82 8589722 BRCA1 NN B-NP O
15 83 86 8589722 are VBP B-VP O
16 87 98 8589722 responsible JJ B-ADJP O
17 99 102 8589722 for IN B-PP O
18 103 107 8589722 most JJS B-NP O
19 108 113 8589722 cases NNS I-NP O
20 114 116 8589722 of IN B-PP O
21 117 126 8589722 inherited VBN B-NP B-Disease
22 127 133 8589722 breast NN I-NP I-Disease
23 134 137 8589722 and CC O I-Disease
24 138 145 8589722 ovarian JJ B-NP I-Disease
25 146 152 8589722 cancer NN I-NP I-Disease
26 153 154 8589722 . . O O
27 155 162 8589722 However RB B-ADVP O
28 162 163 8589722 , , O O
29 164 167 8589722 the DT B-NP O
30 168 176 8589722 function NN I-NP O
31 177 179 8589722 of IN B-PP O
32 180 183 8589722 the DT B-NP O
33 184 189 8589722 BRCA1 NN I-NP O
34 190 197 8589722 protein NN I-NP O
35 198 201 8589722 has VBZ B-VP O
36 202 210 8589722 remained VBN I-VP O
37 211 218 8589722 elusive JJ B-ADJP O
38 218 219 8589722 . . O O

1 220 222 8589722 We PRP B-NP O
2 223 226 8589722 now RB B-ADVP O
3 227 231 8589722 show VBP B-VP O
4 232 236 8589722 that IN B-SBAR O
5 237 242 8589722 BRCA1 NN B-NP O
6 243 250 8589722 encodes VBZ B-VP O
7 251 252 8589722 a DT B-NP O
8 253 256 8589722 190 CD I-NP O
9 256 257 8589722 - HYPH I-NP O
10 257 259 8589722 kD NN I-NP O
11 260 267 8589722 protein NN I-NP O
12 268 272 8589722 with IN B-PP O
13 273 281 8589722 sequence NN B-NP O
14 282 290 8589722 homology NN I-NP O
15 291 294 8589722 and CC O O
16 295 306 8589722 biochemical JJ B-NP O
17 307 314 8589722 analogy NN I-NP O
18 315 317 8589722 to TO B-PP O
19 318 321 8589722 the DT B-NP O
20 322 328 8589722 granin NN I-NP O
21 329 336 8589722 protein NN I-NP O
22 337 343 8589722 family NN I-NP O
23 343 344 8589722 . . O O

1 345 358 8589722 Interestingly RB B-ADVP O
2 358 359 8589722 , , O O
3 360 365 8589722 BRCA2 NN B-NP O
4 366 370 8589722 also RB B-ADVP O
5 371 379 8589722 includes VBZ B-VP O
6 380 381 8589722 a DT B-NP O
7 382 387 8589722 motif NN I-NP O
8 388 395 8589722 similar JJ B-ADJP O
9 396 398 8589722 to TO B-PP O
10 399 402 8589722 the DT B-NP O
11 403 409 8589722 granin NN I-NP O
12 410 419 8589722 consensus NN I-NP O
13 420 422 8589722 at IN B-PP O
14 423 426 8589722 the DT B-NP O
15 427 428 8589722 C NN I-NP O
16 429 437 8589722 terminus NN I-NP O
17 438 440 8589722 of IN B-PP O
18 441 444 8589722 the DT B-NP O
19 445 452 8589722 protein NN I-NP O
20 452 453 8589722 . . O O

1 454 458 8589722 Both CC O O
2 459 464 8589722 BRCA1 NN B-NP O
3 465 468 8589722 and CC O O
4 469 472 8589722 the DT B-NP O
5 473 480 8589722 granins NNS I-NP O
6 481 489 8589722 localize VBP B-VP O
7 490 492 8589722 to TO B-PP O
8 493 502 8589722 secretory JJ B-NP O
9 503 511 8589722 vesicles NNS I-NP O
10 511 512 8589722 , , O O
11 513 516 8589722 are VBP B-VP O
12 517 525 8589722 secreted VBN I-VP O
13 526 528 8589722 by IN B-PP O
14 529 530 8589722 a DT B-NP O
15 531 540 8589722 regulated VBN I-NP O
16 541 548 8589722 pathway NN I-NP O
17 548 549 8589722 , , O O
18 550 553 8589722 are VBP B-VP O
19 554 558 8589722 post AFX B-ADVP O
20 558 559 8589722 - HYPH B-NP O
21 559 574 8589722 translationally RB B-VP O
22 575 587 8589722 glycosylated VBN I-VP O
23 588 591 8589722 and CC O O
24 592 595 8589722 are VBP B-VP O
25 596 606 8589722 responsive JJ B-ADJP O
26 607 609 8589722 to TO B-PP O
27 610 618 8589722 hormones NNS B-NP O
28 618 619 8589722 . . O O

1 620 622 8589722 As IN B-PP O
2 623 624 8589722 a DT B-NP O
3 625 634 8589722 regulated VBN I-NP O
4 635 644 8589722 secretory JJ I-NP O
5 645 652 8589722 protein NN I-NP O
6 652 653 8589722 , , O O
7 654 659 8589722 BRCA1 NN B-NP O
8 660 667 8589722 appears VBZ B-VP O
9 668 670 8589722 to TO I-VP O
10 671 679 8589722 function VB I-VP O
11 680 682 8589722 by IN B-PP O
12 683 684 8589722 a DT B-NP O
13 685 694 8589722 mechanism NN I-NP O
14 695 698 8589722 not RB O O
15 699 709 8589722 previously RB B-VP O
16 710 719 8589722 described VBN I-VP O
17 720 723 8589722 for IN B-PP O
18 724 730 8589722 tumour NN B-NP B-Disease
19 731 741 8589722 suppressor NN I-NP O
20 742 746 8589722 gene NN I-NP O
21 747 755 8589722 products NNS I-NP O
22 755 756 8589722 . . O O
23 756 757 8589722 . . O O

1 0 0 8589723 -DOCSTART- -X- -X- O

1 0 7 8589723 Ovarian JJ B-NP B-Disease
2 8 14 8589723 cancer NN I-NP I-Disease
3 15 19 8589723 risk NN I-NP O
4 20 22 8589723 in IN B-PP O
5 23 28 8589723 BRCA1 NN B-NP O
6 29 37 8589723 carriers NNS I-NP O
7 38 40 8589723 is VBZ B-VP O
8 41 49 8589723 modified VBN I-VP O
9 50 52 8589723 by IN B-PP O
10 53 56 8589723 the DT B-NP O
11 57 62 8589723 HRAS1 NN I-NP O
12 63 71 8589723 variable JJ I-NP O
13 72 78 8589723 number NN I-NP O
14 79 81 8589723 of IN B-PP O
15 82 88 8589723 tandem JJ B-NP O
16 89 95 8589723 repeat NN I-NP O
17 96 97 8589723 ( ( O O
18 97 101 8589723 VNTR NN B-NP O
19 101 102 8589723 ) ) O O
20 103 108 8589723 locus NN B-NP O
21 108 109 8589723 . . I-NP O
22 110 115 8589723 Women NNS I-NP O
23 116 119 8589723 who WP B-NP O
24 120 125 8589723 carry VBP B-VP O
25 126 127 8589723 a DT B-NP O
26 128 136 8589723 mutation NN I-NP O
27 137 139 8589723 in IN B-PP O
28 140 143 8589723 the DT B-NP O
29 144 149 8589723 BRCA1 NN I-NP O
30 150 154 8589723 gene NN I-NP O
31 155 156 8589723 ( ( O O
32 156 158 8589723 on IN B-PP O
33 159 169 8589723 chromosome NN B-NP O
34 170 175 8589723 17q21 NN I-NP O
35 175 176 8589723 ) ) O O
36 176 177 8589723 , , O O
37 178 182 8589723 have VBP B-VP O
38 183 185 8589723 an DT B-NP O
39 186 189 8589723 80% JJ I-NP O
40 190 194 8589723 risk NN I-NP O
41 195 197 8589723 of IN B-PP O
42 198 204 8589723 breast NN B-NP B-Disease
43 205 211 8589723 cancer NN I-NP I-Disease
44 212 215 8589723 and CC O O
45 216 217 8589723 a DT B-NP O
46 218 221 8589723 40% JJ I-NP O
47 222 226 8589723 risk NN I-NP O
48 227 229 8589723 of IN B-PP O
49 230 237 8589723 ovarian JJ B-NP B-Disease
50 238 244 8589723 cancer NN I-NP I-Disease
51 245 247 8589723 by IN B-PP O
52 248 251 8589723 the DT B-NP O
53 252 255 8589723 age NN I-NP O
54 256 258 8589723 of IN B-PP O
55 259 261 8589723 70 CD B-NP O
56 262 263 8589723 ( ( O O
57 263 266 8589723 ref NN B-NP O
58 266 267 8589723 . . O O

1 268 269 8589723 1 LS B-LST O
2 269 270 8589723 ) ) O O
3 270 271 8589723 . . O O

1 272 275 8589723 The DT B-NP O
2 276 284 8589723 variable JJ I-NP O
3 285 295 8589723 penetrance NN I-NP O
4 296 298 8589723 of IN B-PP O
5 299 304 8589723 BRCA1 NN B-NP O
6 305 313 8589723 suggests VBZ B-VP O
7 314 318 8589723 that IN B-SBAR O
8 319 324 8589723 other JJ B-NP O
9 325 332 8589723 genetic JJ I-NP O
10 333 336 8589723 and CC I-NP O
11 337 340 8589723 non AFX I-NP O
12 340 341 8589723 - HYPH I-NP O
13 341 348 8589723 genetic JJ B-NP O
14 349 356 8589723 factors NNS I-NP O
15 357 361 8589723 play VBP B-VP O
16 362 363 8589723 a DT B-NP O
17 364 368 8589723 role NN I-NP O
18 369 371 8589723 in IN B-PP O
19 372 386 8589723 tumourigenesis NN B-NP O
20 387 389 8589723 in IN B-PP O
21 390 395 8589723 these DT B-NP O
22 396 407 8589723 individuals NNS I-NP O
23 407 408 8589723 . . O O

1 409 412 8589723 The DT B-NP O
2 413 418 8589723 HRAS1 NN I-NP O
3 419 427 8589723 variable JJ I-NP O
4 428 434 8589723 number NN I-NP O
5 435 437 8589723 of IN B-PP O
6 438 444 8589723 tandem JJ B-NP O
7 445 452 8589723 repeats NNS I-NP O
8 453 454 8589723 ( ( O O
9 454 458 8589723 VNTR NN B-NP O
10 458 459 8589723 ) ) O O
11 460 472 8589723 polymorphism NN B-NP O
12 472 473 8589723 , , O O
13 474 481 8589723 located JJ B-NP O
14 482 483 8589723 1 CD I-NP O
15 484 492 8589723 kilobase NN I-NP O
16 493 494 8589723 ( ( O O
17 494 496 8589723 kb NN B-NP O
18 496 497 8589723 ) ) O O
19 498 508 8589723 downstream RB B-ADVP O
20 509 511 8589723 of IN B-PP O
21 512 515 8589723 the DT B-NP O
22 516 521 8589723 HRAS1 NN I-NP O
23 522 527 8589723 proto AFX O O
24 527 528 8589723 - HYPH O O
25 528 536 8589723 oncogene NN B-NP O
26 537 538 8589723 ( ( O O
27 538 548 8589723 chromosome NN B-NP O
28 549 554 8589723 11p15 CD I-NP O
29 554 555 8589723 . . O O

1 556 557 8589723 5 LS B-LST O
2 557 558 8589723 ) ) O O
3 559 561 8589723 is VBZ B-VP O
4 562 565 8589723 one CD B-NP O
5 566 574 8589723 possible JJ I-NP O
6 575 582 8589723 genetic JJ I-NP O
7 583 591 8589723 modifier NN I-NP O
8 592 594 8589723 of IN B-PP O
9 595 601 8589723 cancer NN B-NP B-Disease
10 602 612 8589723 penetrance NN I-NP O
11 612 613 8589723 . . O O

1 614 625 8589723 Individuals NNS B-NP O
2 626 629 8589723 who WP B-NP O
3 630 634 8589723 have VBP B-VP O
4 635 639 8589723 rare JJ B-NP O
5 640 647 8589723 alleles NNS I-NP O
6 648 650 8589723 of IN B-PP O
7 651 654 8589723 the DT B-NP O
8 655 659 8589723 VNTR NN I-NP O
9 660 664 8589723 have VBP B-VP O
10 665 667 8589723 an DT B-NP O
11 668 677 8589723 increased VBN I-NP O
12 678 682 8589723 risk NN I-NP O
13 683 685 8589723 of IN B-PP O
14 686 693 8589723 certain JJ B-NP O
15 694 699 8589723 types NNS I-NP O
16 700 702 8589723 of IN B-PP O
17 703 710 8589723 cancers NNS B-NP B-Disease
18 710 711 8589723 , , O O
19 712 721 8589723 including VBG B-PP O
20 722 728 8589723 breast NN B-NP B-Disease
21 729 735 8589723 cancer NN I-NP I-Disease
22 736 737 8589723 ( ( O O
23 737 738 8589723 2 CD B-NP O
24 738 739 8589723 - HYPH I-NP O
25 739 740 8589723 4 CD I-NP O
26 740 741 8589723 ) ) O O
27 741 742 8589723 . . O O

1 743 745 8589723 To TO B-VP O
2 746 757 8589723 investigate VB I-VP O
3 758 765 8589723 whether IN B-SBAR O
4 766 769 8589723 the DT B-NP O
5 770 778 8589723 presence NN I-NP O
6 779 781 8589723 of IN B-PP O
7 782 786 8589723 rare JJ B-NP O
8 787 792 8589723 HRAS1 NN I-NP O
9 793 800 8589723 alleles NNS I-NP O
10 801 810 8589723 increases VBZ B-VP O
11 811 825 8589723 susceptibility NN B-NP O
12 826 828 8589723 to TO B-PP O
13 829 839 8589723 hereditary JJ B-NP B-Disease
14 840 846 8589723 breast NN I-NP I-Disease
15 847 850 8589723 and CC O I-Disease
16 851 858 8589723 ovarian JJ B-NP I-Disease
17 859 865 8589723 cancer NN I-NP I-Disease
18 865 866 8589723 , , O O
19 867 869 8589723 we PRP B-NP O
20 870 874 8589723 have VBP B-VP O
21 875 880 8589723 typed VBN I-VP O
22 881 882 8589723 a DT B-NP O
23 883 888 8589723 panel NN I-NP O
24 889 891 8589723 of IN B-PP O
25 892 895 8589723 307 CD B-NP O
26 896 902 8589723 female JJ I-NP O
27 903 908 8589723 BRCA1 NN I-NP O
28 909 917 8589723 carriers NNS I-NP O
29 918 920 8589723 at IN B-PP O
30 921 925 8589723 this DT B-NP O
31 926 931 8589723 locus NN I-NP O
32 932 937 8589723 using VBG B-VP O
33 938 939 8589723 a DT B-NP O
34 940 943 8589723 PCR NN I-NP O
35 943 944 8589723 - HYPH O O
36 944 949 8589723 based VBN B-NP O
37 950 959 8589723 technique NN I-NP O
38 959 960 8589723 . . O O

1 961 964 8589723 The DT B-NP O
2 965 969 8589723 risk NN I-NP O
3 970 973 8589723 for IN B-PP O
4 974 981 8589723 ovarian JJ B-NP B-Disease
5 982 988 8589723 cancer NN I-NP I-Disease
6 989 992 8589723 was VBD B-VP O
7 993 994 8589723 2 CD B-NP O
8 994 995 8589723 . . O O
9 996 998 8589723 11 CD B-ADJP O
10 999 1004 8589723 times NNS I-ADJP O
11 1005 1012 8589723 greater JJR I-ADJP O
12 1013 1016 8589723 for IN B-PP O
13 1017 1022 8589723 BRCA1 NN B-NP O
14 1023 1031 8589723 carriers NNS I-NP O
15 1032 1042 8589723 harbouring VBG B-VP O
16 1043 1046 8589723 one CD B-NP O
17 1047 1049 8589723 or CC I-NP O
18 1050 1053 8589723 two CD I-NP O
19 1054 1058 8589723 rare JJ I-NP O
20 1059 1064 8589723 HRAS1 NN I-NP O
21 1065 1072 8589723 alleles NNS I-NP O
22 1072 1073 8589723 , , O O
23 1074 1082 8589723 compared VBN B-PP O
24 1083 1085 8589723 to TO B-PP O
25 1086 1094 8589723 carriers NNS B-NP O
26 1095 1099 8589723 with IN B-PP O
27 1100 1104 8589723 only RB B-NP O
28 1105 1111 8589723 common JJ I-NP O
29 1112 1119 8589723 alleles NNS I-NP O
30 1120 1121 8589723 ( ( O O
31 1121 1122 8589723 P NN B-NP O
32 1123 1124 8589723 = SYM B-VP O
33 1125 1126 8589723 0 CD B-NP O
34 1126 1127 8589723 . . O O

1 1128 1131 8589723 015 CD B-NP O
2 1131 1132 8589723 ) ) O O
3 1132 1133 8589723 . . O O

1 1134 1137 8589723 The DT B-NP O
2 1138 1147 8589723 magnitude NN I-NP O
3 1148 1150 8589723 of IN B-PP O
4 1151 1154 8589723 the DT B-NP O
5 1155 1163 8589723 relative JJ I-NP O
6 1164 1168 8589723 risk NN I-NP O
7 1169 1179 8589723 associated VBN B-VP O
8 1180 1184 8589723 with IN B-PP O
9 1185 1186 8589723 a DT B-NP O
10 1187 1191 8589723 rare JJ I-NP O
11 1192 1197 8589723 HRAS1 NN I-NP O
12 1198 1204 8589723 allele NN I-NP O
13 1205 1208 8589723 was VBD B-VP O
14 1209 1212 8589723 not RB I-VP O
15 1213 1220 8589723 altered VBN I-VP O
16 1221 1223 8589723 by IN B-PP O
17 1224 1233 8589723 adjusting VBG B-VP O
18 1234 1237 8589723 for IN B-PP O
19 1238 1241 8589723 the DT B-NP O
20 1242 1247 8589723 other JJ I-NP O
21 1248 1253 8589723 known VBN I-NP O
22 1254 1258 8589723 risk NN I-NP O
23 1259 1266 8589723 factors NNS I-NP O
24 1267 1270 8589723 for IN B-PP O
25 1271 1281 8589723 hereditary JJ B-NP B-Disease
26 1282 1289 8589723 ovarian JJ I-NP I-Disease
27 1290 1296 8589723 cancer NN I-NP I-Disease
28 1297 1298 8589723 ( ( O O
29 1298 1299 8589723 5 CD B-NP O
30 1299 1300 8589723 ) ) O O
31 1300 1301 8589723 . . O O

1 1302 1316 8589723 Susceptibility NN B-NP O
2 1317 1319 8589723 to TO B-PP O
3 1320 1326 8589723 breast NN B-NP B-Disease
4 1327 1333 8589723 cancer NN I-NP I-Disease
5 1334 1337 8589723 did VBD B-VP O
6 1338 1341 8589723 not RB I-VP O
7 1342 1348 8589723 appear VB I-VP O
8 1349 1351 8589723 to TO I-VP O
9 1352 1354 8589723 be VB I-VP O
10 1355 1363 8589723 affected VBN I-VP O
11 1364 1366 8589723 by IN B-PP O
12 1367 1370 8589723 the DT B-NP O
13 1371 1379 8589723 presence NN I-NP O
14 1380 1382 8589723 of IN B-PP O
15 1383 1387 8589723 rare JJ B-NP O
16 1388 1393 8589723 HRAS1 NN I-NP O
17 1394 1401 8589723 alleles NNS I-NP O
18 1401 1402 8589723 . . O O

1 1403 1407 8589723 This DT B-NP O
2 1408 1413 8589723 study NN I-NP O
3 1414 1416 8589723 is VBZ B-VP O
4 1417 1420 8589723 the DT B-NP O
5 1421 1426 8589723 first JJ I-NP O
6 1427 1429 8589723 to TO B-VP O
7 1430 1434 8589723 show VB I-VP O
8 1435 1438 8589723 the DT B-NP O
9 1439 1445 8589723 effect NN I-NP O
10 1446 1448 8589723 of IN B-PP O
11 1449 1450 8589723 a DT B-NP O
12 1451 1460 8589723 modifying NN I-NP O
13 1461 1465 8589723 gene NN I-NP O
14 1466 1468 8589723 on IN B-PP O
15 1469 1472 8589723 the DT B-NP O
16 1473 1483 8589723 penetrance NN I-NP O
17 1484 1486 8589723 of IN B-PP O
18 1487 1489 8589723 an DT B-NP O
19 1490 1499 8589723 inherited VBN I-NP B-Disease
20 1500 1506 8589723 cancer NN I-NP I-Disease
21 1507 1515 8589723 syndrome NN I-NP I-Disease

1 0 0 8644703 -DOCSTART- -X- -X- O

1 0 5 8644703 Rapid JJ B-NP O
2 6 15 8644703 detection NN I-NP O
3 16 18 8644703 of IN B-PP O
4 19 29 8644703 regionally RB B-NP O
5 30 39 8644703 clustered VBN I-NP O
6 40 44 8644703 germ NN I-NP O
7 44 45 8644703 - HYPH I-NP O
8 45 49 8644703 line NN I-NP O
9 50 55 8644703 BRCA1 NN I-NP O
10 56 65 8644703 mutations NNS I-NP O
11 66 68 8644703 by IN B-PP O
12 69 78 8644703 multiplex JJ B-NP O
13 79 91 8644703 heteroduplex NN I-NP O
14 92 100 8644703 analysis NN I-NP O
15 100 101 8644703 . . O O

1 102 108 8644703 UKCCCR NNP B-NP O
2 109 117 8644703 Familial NNP I-NP O
3 118 125 8644703 Ovarian NNP I-NP B-Disease
4 126 132 8644703 Cancer NNP I-NP I-Disease
5 133 138 8644703 Study NNP I-NP O
6 139 144 8644703 Group NNP I-NP O
7 144 145 8644703 . . I-NP O
8 146 150 8644703 Germ NNP I-NP O
9 150 151 8644703 - : O O
10 151 155 8644703 line NN B-NP O
11 156 165 8644703 mutations NNS I-NP O
12 166 168 8644703 of IN B-PP O
13 169 172 8644703 the DT B-NP O
14 173 178 8644703 BRCA1 NN I-NP O
15 179 183 8644703 gene NN I-NP O
16 184 187 8644703 are VBP B-VP O
17 188 199 8644703 responsible JJ B-ADJP O
18 200 203 8644703 for IN B-PP O
19 204 205 8644703 a DT B-NP O
20 206 217 8644703 substantial JJ I-NP O
21 218 228 8644703 proportion NN I-NP O
22 229 231 8644703 of IN B-PP O
23 232 240 8644703 families NNS B-NP O
24 241 245 8644703 with IN B-PP O
25 246 254 8644703 multiple JJ B-NP O
26 255 260 8644703 cases NNS I-NP O
27 261 263 8644703 of IN B-PP O
28 264 269 8644703 early JJ B-NP O
29 269 270 8644703 - HYPH I-NP O
30 270 275 8644703 onset NN I-NP O
31 276 282 8644703 breast NN I-NP B-Disease
32 283 286 8644703 and CC O I-Disease
33 286 287 8644703 / SYM B-NP I-Disease
34 287 289 8644703 or CC O I-Disease
35 290 297 8644703 ovarian JJ B-NP I-Disease
36 298 304 8644703 cancer NN I-NP I-Disease
37 304 305 8644703 . . O O

1 306 311 8644703 Since IN B-SBAR O
2 312 315 8644703 the DT B-NP O
3 316 325 8644703 isolation NN I-NP O
4 326 328 8644703 of IN B-PP O
5 329 334 8644703 BRCA1 NN B-NP O
6 335 339 8644703 last JJ B-NP O
7 340 344 8644703 year NN I-NP O
8 344 345 8644703 , , O O
9 346 347 8644703 > SYM B-NP O
10 348 350 8644703 65 CD B-NP O
11 351 359 8644703 distinct JJ I-NP O
12 360 369 8644703 mutations NNS I-NP O
13 370 379 8644703 scattered VBN B-VP O
14 380 390 8644703 throughout IN B-PP O
15 391 394 8644703 the DT B-NP O
16 395 401 8644703 coding VBG I-NP O
17 402 408 8644703 region NN I-NP O
18 409 413 8644703 have VBP B-VP O
19 414 418 8644703 been VBN I-VP O
20 419 427 8644703 detected VBN I-VP O
21 427 428 8644703 , , O O
22 429 435 8644703 making VBG B-VP O
23 436 444 8644703 analysis NN B-NP O
24 445 447 8644703 of IN B-PP O
25 448 451 8644703 the DT B-NP O
26 452 456 8644703 gene NN I-NP O
27 457 461 8644703 time NN I-NP O
28 462 471 8644703 consuming NN I-NP O
29 472 475 8644703 and CC O O
30 476 487 8644703 technically RB B-ADJP O
31 488 499 8644703 challenging JJ I-ADJP O
32 499 500 8644703 . . O O

1 501 503 8644703 We PRP B-NP O
2 504 508 8644703 have VBP B-VP O
3 509 518 8644703 developed VBN I-VP O
4 519 520 8644703 a DT B-NP O
5 521 530 8644703 multiplex JJ I-NP O
6 531 543 8644703 heteroduplex NN I-NP O
7 544 552 8644703 analysis NN I-NP O
8 553 557 8644703 that WDT B-NP O
9 558 560 8644703 is VBZ B-VP O
10 561 569 8644703 designed VBN I-VP O
11 570 572 8644703 to TO I-VP O
12 573 580 8644703 analyze VB I-VP O
13 581 584 8644703 one CD B-NP O
14 584 585 8644703 - HYPH I-NP O
15 585 592 8644703 quarter NN I-NP O
16 593 595 8644703 of IN B-PP O
17 596 599 8644703 the DT B-NP O
18 600 606 8644703 coding VBG I-NP O
19 607 615 8644703 sequence NN I-NP O
20 616 618 8644703 in IN B-PP O
21 619 620 8644703 a DT B-NP O
22 621 627 8644703 single JJ I-NP O
23 627 628 8644703 - HYPH I-NP O
24 628 632 8644703 step NN I-NP O
25 633 642 8644703 screening NN I-NP O
26 643 652 8644703 procedure NN I-NP O
27 653 656 8644703 and CC O O
28 657 661 8644703 that WDT B-NP O
29 662 666 8644703 will MD B-VP O
30 667 673 8644703 detect VB I-VP O
31 674 687 8644703 approximately RB B-NP O
32 688 691 8644703 50% CD I-NP O
33 692 694 8644703 of IN B-PP O
34 695 698 8644703 all DT B-NP O
35 699 704 8644703 BRCA1 NN I-NP O
36 705 714 8644703 mutations NNS I-NP O
37 715 717 8644703 so RB B-VP O
38 718 721 8644703 far RB I-VP O
39 722 730 8644703 reported VBN I-VP O
40 731 733 8644703 in IN B-PP O
41 734 740 8644703 breast NN B-NP B-Disease
42 740 741 8644703 / SYM B-NP I-Disease
43 741 748 8644703 ovarian JJ I-NP I-Disease
44 749 755 8644703 cancer NN I-NP I-Disease
45 756 764 8644703 families NNS I-NP O
46 764 765 8644703 . . O O

1 766 768 8644703 We PRP B-NP O
2 769 773 8644703 have VBP B-VP O
3 774 778 8644703 used VBN I-VP O
4 779 783 8644703 this DT B-NP O
5 784 793 8644703 technique NN I-NP O
6 794 796 8644703 to TO B-VP O
7 797 804 8644703 analyze VB I-VP O
8 805 810 8644703 BRCA1 NN B-NP O
9 811 813 8644703 in IN B-PP O
10 814 817 8644703 162 CD B-NP O
11 818 826 8644703 families NNS I-NP O
12 827 831 8644703 with IN B-PP O
13 832 833 8644703 a DT B-NP O
14 834 841 8644703 history NN I-NP O
15 842 844 8644703 of IN B-PP O
16 845 851 8644703 breast NN B-NP B-Disease
17 852 855 8644703 and CC O I-Disease
18 855 856 8644703 / SYM B-NP I-Disease
19 856 858 8644703 or CC O I-Disease
20 859 866 8644703 ovarian JJ B-NP I-Disease
21 867 873 8644703 cancer NN I-NP I-Disease
22 874 877 8644703 and CC O O
23 878 888 8644703 identified VBD B-VP O
24 889 891 8644703 12 CD B-NP O
25 892 900 8644703 distinct JJ I-NP O
26 901 910 8644703 mutations NNS I-NP O
27 911 913 8644703 in IN B-PP O
28 914 916 8644703 35 CD B-NP O
29 917 925 8644703 families NNS I-NP O
30 925 926 8644703 . . O O
31 926 927 8644703 . . O O

1 0 0 8644702 -DOCSTART- -X- -X- O

1 0 8 8644702 Founding VBG B-VP O
2 9 14 8644702 BRCA1 NN B-NP O
3 15 24 8644702 mutations NNS I-NP O
4 25 27 8644702 in IN B-PP O
5 28 38 8644702 hereditary JJ B-NP B-Disease
6 39 45 8644702 breast NN I-NP I-Disease
7 46 49 8644702 and CC O I-Disease
8 50 57 8644702 ovarian JJ B-NP I-Disease
9 58 64 8644702 cancer NN I-NP I-Disease
10 65 67 8644702 in IN B-PP O
11 68 76 8644702 southern JJ B-NP O
12 77 83 8644702 Sweden NNP I-NP O
13 83 84 8644702 . . I-NP O
14 85 89 8644702 Nine CD I-NP O
15 90 99 8644702 different JJ I-NP O
16 100 104 8644702 germ NN I-NP O
17 104 105 8644702 - HYPH I-NP O
18 105 109 8644702 line NN I-NP O
19 110 119 8644702 mutations NNS I-NP O
20 120 122 8644702 in IN B-PP O
21 123 126 8644702 the DT B-NP O
22 127 132 8644702 BRCA1 NN I-NP O
23 133 139 8644702 breast NN I-NP B-Disease
24 140 143 8644702 and CC O I-Disease
25 144 151 8644702 ovarian JJ B-NP I-Disease
26 152 158 8644702 cancer NN I-NP I-Disease
27 159 173 8644702 susceptibility NN I-NP O
28 174 178 8644702 gene NN I-NP O
29 179 183 8644702 were VBD B-VP O
30 184 194 8644702 identified VBN I-VP O
31 195 197 8644702 in IN B-PP O
32 198 200 8644702 15 CD B-NP O
33 201 203 8644702 of IN B-PP O
34 204 206 8644702 47 CD B-NP O
35 207 215 8644702 kindreds NNS I-NP O
36 216 220 8644702 from IN B-PP O
37 221 229 8644702 southern JJ B-NP O
38 230 236 8644702 Sweden NNP I-NP O
39 236 237 8644702 , , O O
40 238 240 8644702 by IN B-PP O
41 241 244 8644702 use NN B-NP O
42 245 247 8644702 of IN B-PP O
43 248 252 8644702 SSCP NN B-NP O
44 253 256 8644702 and CC I-NP O
45 257 269 8644702 heteroduplex NN I-NP O
46 270 278 8644702 analysis NN I-NP O
47 279 281 8644702 of IN B-PP O
48 282 285 8644702 all DT B-NP O
49 286 291 8644702 exons NNS I-NP O
50 292 295 8644702 and CC O O
51 296 304 8644702 flanking VBG B-VP O
52 305 311 8644702 intron NN B-NP O
53 312 318 8644702 region NN I-NP O
54 319 322 8644702 and CC B-PP O
55 323 325 8644702 by IN B-PP O
56 326 327 8644702 a DT B-NP O
57 328 335 8644702 protein NN I-NP O
58 335 336 8644702 - HYPH B-NP O
59 336 346 8644702 truncation NN I-NP O
60 347 351 8644702 test NN I-NP O
61 352 355 8644702 for IN B-PP O
62 356 360 8644702 exon NN B-NP O
63 361 363 8644702 11 CD I-NP O
64 363 364 8644702 , , O O
65 365 373 8644702 followed VBN B-VP O
66 374 376 8644702 by IN B-PP O
67 377 383 8644702 direct JJ B-NP O
68 384 394 8644702 sequencing NN I-NP O
69 394 395 8644702 . . O O

1 396 399 8644702 All DT B-NP O
2 400 403 8644702 but IN B-PP O
3 404 407 8644702 one CD B-NP O
4 408 410 8644702 of IN B-PP O
5 411 414 8644702 the DT B-NP O
6 415 424 8644702 mutations NNS I-NP O
7 425 428 8644702 are VBP B-VP O
8 429 438 8644702 predicted VBN I-VP O
9 439 441 8644702 to TO I-VP O
10 442 446 8644702 give VB I-VP O
11 447 451 8644702 rise NN B-NP O
12 452 454 8644702 to TO B-PP O
13 455 464 8644702 premature JJ B-NP O
14 465 476 8644702 translation NN I-NP O
15 477 488 8644702 termination NN I-NP O
16 489 492 8644702 and CC O O
17 493 500 8644702 include VBP B-VP O
18 501 506 8644702 seven CD B-NP O
19 507 517 8644702 frameshift NN I-NP O
20 518 528 8644702 insertions NNS I-NP O
21 529 531 8644702 or CC I-NP O
22 532 541 8644702 deletions NNS I-NP O
23 541 542 8644702 , , O O
24 543 544 8644702 a DT B-NP O
25 545 553 8644702 nonsense JJ I-NP O
26 554 562 8644702 mutation NN I-NP O
27 562 563 8644702 , , O O
28 564 567 8644702 and CC O O
29 568 569 8644702 a DT B-NP O
30 570 576 8644702 splice NN I-NP O
31 577 585 8644702 acceptor NN I-NP O
32 586 590 8644702 site NN I-NP O
33 591 599 8644702 mutation NN I-NP O
34 599 600 8644702 . . O O

1 601 604 8644702 The DT B-NP O
2 605 614 8644702 remaining VBG I-NP O
3 615 623 8644702 mutation NN I-NP O
4 624 626 8644702 is VBZ B-VP O
5 627 628 8644702 a DT B-NP O
6 629 637 8644702 missense JJ I-NP O
7 638 646 8644702 mutation NN I-NP O
8 647 648 8644702 ( ( O O
9 648 656 8644702 Cys61Gly NN B-NP O
10 656 657 8644702 ) ) O O
11 658 660 8644702 in IN B-PP O
12 661 664 8644702 the DT B-NP O
13 665 669 8644702 zinc NN I-NP O
14 669 670 8644702 - HYPH B-VP O
15 670 677 8644702 binding VBG B-NP O
16 678 683 8644702 motif NN I-NP O
17 683 684 8644702 . . O O

1 685 689 8644702 Four CD B-NP O
2 690 695 8644702 novel JJ I-NP O
3 696 703 8644702 Swedish JJ I-NP O
4 704 712 8644702 founding NN I-NP O
5 713 722 8644702 mutations NNS I-NP O
6 723 727 8644702 were VBD B-VP O
7 728 738 8644702 identified VBN I-VP O
8 740 743 8644702 the DT B-NP O
9 744 754 8644702 nucleotide NN I-NP O
10 755 759 8644702 2595 CD I-NP O
11 760 768 8644702 deletion NN I-NP O
12 769 770 8644702 A NN I-NP O
13 771 774 8644702 was VBD B-VP O
14 775 780 8644702 found VBN I-VP O
15 781 783 8644702 in IN B-PP O
16 784 788 8644702 five CD B-NP O
17 789 797 8644702 families NNS I-NP O
18 797 798 8644702 , , O O
19 799 802 8644702 the DT B-NP O
20 803 804 8644702 C NN I-NP O
21 805 809 8644702 1806 CD I-NP O
22 810 811 8644702 T NN I-NP O
23 812 820 8644702 nonsense JJ I-NP O
24 821 829 8644702 mutation NN I-NP O
25 830 832 8644702 in IN B-PP O
26 833 838 8644702 three CD B-NP O
27 839 847 8644702 families NNS I-NP O
28 847 848 8644702 , , O O
29 849 852 8644702 the DT B-NP O
30 853 857 8644702 3166 CD I-NP O
31 858 867 8644702 insertion NN I-NP O
32 868 873 8644702 TGAGA NN I-NP O
33 874 876 8644702 in IN B-PP O
34 877 882 8644702 three CD B-NP O
35 883 891 8644702 families NNS I-NP O
36 891 892 8644702 , , O O
37 893 896 8644702 and CC O O
38 897 900 8644702 the DT B-NP O
39 901 911 8644702 nucleotide NN I-NP O
40 912 916 8644702 1201 CD I-NP O
41 917 925 8644702 deletion NN I-NP O
42 926 928 8644702 11 CD I-NP O
43 929 931 8644702 in IN B-PP O
44 932 935 8644702 two CD B-NP O
45 936 944 8644702 families NNS I-NP O
46 944 945 8644702 . . O O

1 946 954 8644702 Analysis NN B-NP O
2 955 957 8644702 of IN B-PP O
3 958 961 8644702 the DT B-NP O
4 962 972 8644702 intragenic JJ I-NP O
5 973 985 8644702 polymorphism NN I-NP O
6 986 993 8644702 D17S855 NN I-NP O
7 994 1002 8644702 supports VBZ B-VP O
8 1003 1009 8644702 common JJ B-NP O
9 1010 1017 8644702 origins NNS I-NP O
10 1018 1020 8644702 of IN B-PP O
11 1021 1024 8644702 the DT B-NP O
12 1025 1034 8644702 mutations NNS I-NP O
13 1034 1035 8644702 . . O O

1 1036 1042 8644702 Eleven CD B-NP O
2 1043 1045 8644702 of IN B-PP O
3 1046 1049 8644702 the DT B-NP O
4 1050 1052 8644702 15 CD I-NP O
5 1053 1061 8644702 kindreds NNS I-NP O
6 1062 1073 8644702 manifesting VBG B-VP O
7 1074 1079 8644702 BRCA1 NN B-NP O
8 1080 1089 8644702 mutations NNS I-NP O
9 1090 1094 8644702 were VBD B-VP O
10 1095 1101 8644702 breast NN B-NP B-Disease
11 1101 1102 8644702 - HYPH O I-Disease
12 1102 1109 8644702 ovarian JJ B-NP I-Disease
13 1110 1116 8644702 cancer NN I-NP I-Disease
14 1117 1125 8644702 families NNS I-NP O
15 1125 1126 8644702 , , O O
16 1127 1134 8644702 several JJ B-NP O
17 1135 1137 8644702 of IN B-PP O
18 1138 1142 8644702 them PRP B-NP O
19 1143 1147 8644702 with IN B-PP O
20 1148 1149 8644702 a DT B-NP O
21 1150 1161 8644702 predominant JJ I-NP O
22 1162 1169 8644702 ovarian JJ I-NP B-Disease
23 1170 1176 8644702 cancer NN I-NP I-Disease
24 1177 1186 8644702 phenotype NN I-NP O
25 1186 1187 8644702 . . O O

1 1188 1191 8644702 The DT B-NP O
2 1192 1195 8644702 set NN I-NP O
3 1196 1198 8644702 of IN B-PP O
4 1199 1201 8644702 32 CD B-NP O
5 1202 1210 8644702 families NNS I-NP O
6 1211 1213 8644702 in IN B-PP O
7 1214 1219 8644702 which WDT B-NP O
8 1220 1222 8644702 no DT B-NP O
9 1223 1228 8644702 BRCA1 NN I-NP O
10 1229 1240 8644702 alterations NNS I-NP O
11 1241 1245 8644702 were VBD B-VP O
12 1246 1254 8644702 detected VBN I-VP O
13 1255 1263 8644702 included VBN I-VP O
14 1264 1265 8644702 1 CD B-NP O
15 1266 1272 8644702 breast NN I-NP B-Disease
16 1272 1273 8644702 - HYPH B-NP I-Disease
17 1273 1280 8644702 ovarian JJ I-NP I-Disease
18 1281 1287 8644702 cancer NN I-NP I-Disease
19 1288 1295 8644702 kindred NN I-NP O
20 1296 1307 8644702 manifesting VBG B-VP O
21 1308 1313 8644702 clear JJ B-NP O
22 1314 1321 8644702 linkage NN I-NP O
23 1322 1324 8644702 to TO B-PP O
24 1325 1328 8644702 the DT B-NP O
25 1329 1334 8644702 BRCA1 NN I-NP O
26 1335 1341 8644702 region NN I-NP O
27 1342 1345 8644702 and CC I-NP O
28 1346 1350 8644702 loss NN I-NP O
29 1351 1353 8644702 of IN B-PP O
30 1354 1357 8644702 the DT B-NP O
31 1358 1362 8644702 wild JJ I-NP O
32 1362 1363 8644702 - HYPH I-NP O
33 1363 1367 8644702 type NN I-NP O
34 1368 1378 8644702 chromosome NN I-NP O
35 1379 1381 8644702 in IN B-PP O
36 1382 1392 8644702 associated VBN B-NP O
37 1393 1399 8644702 tumors NNS I-NP B-Disease
38 1399 1400 8644702 . . O O

1 1401 1406 8644702 Other JJ B-NP O
2 1407 1412 8644702 tumor NN I-NP B-Disease
3 1413 1418 8644702 types NNS I-NP O
4 1419 1424 8644702 found VBN B-VP O
5 1425 1427 8644702 in IN B-PP O
6 1428 1433 8644702 BRCA1 NN B-NP O
7 1434 1442 8644702 mutation NN I-NP O
8 1442 1443 8644702 / SYM B-NP O
9 1443 1452 8644702 haplotype NN I-NP O
10 1453 1461 8644702 carriers NNS I-NP O
11 1462 1470 8644702 included VBD B-VP O
12 1471 1480 8644702 prostatic JJ B-ADJP B-Disease
13 1480 1481 8644702 , , O I-Disease
14 1482 1490 8644702 pancreas NN B-NP I-Disease
15 1490 1491 8644702 , , O I-Disease
16 1492 1496 8644702 skin NN B-NP I-Disease
17 1496 1497 8644702 , , O I-Disease
18 1498 1501 8644702 and CC O I-Disease
19 1502 1506 8644702 lung NN B-NP I-Disease
20 1507 1513 8644702 cancer NN I-NP I-Disease
21 1513 1514 8644702 , , O O
22 1515 1516 8644702 a DT B-NP O
23 1517 1526 8644702 malignant JJ I-NP B-Disease
24 1527 1535 8644702 melanoma NN I-NP I-Disease
25 1535 1536 8644702 , , O O
26 1537 1539 8644702 an DT B-NP O
27 1540 1557 8644702 oligodendroglioma NN I-NP B-Disease
28 1557 1558 8644702 , , O O
29 1559 1562 8644702 and CC O O
30 1563 1564 8644702 a DT B-NP O
31 1565 1579 8644702 carcinosarcoma NN I-NP B-Disease
32 1579 1580 8644702 . . O O

1 1581 1583 8644702 In IN B-PP O
2 1584 1587 8644702 all DT B-NP O
3 1587 1588 8644702 , , O O
4 1589 1591 8644702 12 CD B-NP O
5 1592 1594 8644702 of IN B-PP O
6 1595 1597 8644702 16 CD B-NP O
7 1598 1606 8644702 kindreds NNS I-NP O
8 1607 1618 8644702 manifesting VBG B-VP O
9 1619 1624 8644702 BRCA1 NN B-NP O
10 1625 1633 8644702 mutation NN I-NP O
11 1634 1636 8644702 or CC O O
12 1637 1644 8644702 linkage NN B-NP O
13 1645 1654 8644702 contained VBD B-VP O
14 1655 1662 8644702 ovarian JJ B-NP B-Disease
15 1663 1669 8644702 cancer NN I-NP I-Disease
16 1669 1670 8644702 , , O O
17 1671 1673 8644702 as IN B-SBAR O
18 1674 1682 8644702 compared VBN B-PP O
19 1683 1687 8644702 with IN B-PP O
20 1688 1692 8644702 only RB B-NP O
21 1693 1694 8644702 6 CD I-NP O
22 1695 1697 8644702 of IN B-PP O
23 1698 1701 8644702 the DT B-NP O
24 1702 1711 8644702 remaining VBG I-NP O
25 1712 1714 8644702 31 CD I-NP O
26 1715 1723 8644702 families NNS I-NP O
27 1724 1725 8644702 ( ( O O
28 1725 1726 8644702 P NN B-NP O
29 1727 1728 8644702 < SYM B-ADJP O
30 1728 1729 8644702 . . O O

1 1730 1733 8644702 001 CD B-NP O
2 1733 1734 8644702 ) ) O O
3 1734 1735 8644702 . . O O

1 1736 1739 8644702 The DT B-NP O
2 1740 1747 8644702 present JJ I-NP O
3 1748 1753 8644702 study NN I-NP O
4 1754 1762 8644702 confirms VBZ B-VP O
5 1763 1766 8644702 the DT B-NP O
6 1767 1778 8644702 involvement NN I-NP O
7 1779 1781 8644702 of IN B-PP O
8 1782 1787 8644702 BRCA1 NN B-NP O
9 1788 1790 8644702 in IN B-PP O
10 1791 1798 8644702 disease NN B-NP O
11 1799 1813 8644702 predisposition NN I-NP O
12 1814 1817 8644702 for IN B-PP O
13 1818 1819 8644702 a DT B-NP O
14 1820 1826 8644702 subset NN I-NP O
15 1827 1829 8644702 of IN B-PP O
16 1830 1840 8644702 hereditary JJ B-NP B-Disease
17 1841 1847 8644702 breast NN I-NP I-Disease
18 1848 1854 8644702 cancer NN I-NP I-Disease
19 1855 1863 8644702 families NNS I-NP O
20 1864 1869 8644702 often RB B-VP O
21 1870 1883 8644702 characterized VBN I-VP O
22 1884 1886 8644702 by IN B-PP O
23 1887 1894 8644702 ovarian JJ B-NP B-Disease
24 1895 1902 8644702 cancers NNS I-NP I-Disease
25 1902 1903 8644702 . . O O

1 0 0 8843194 -DOCSTART- -X- -X- O

1 0 8 8843194 Targeted VBN B-NP O
2 9 19 8843194 disruption NN I-NP O
3 20 22 8843194 of IN B-PP O
4 23 26 8843194 ATM NN B-NP O
5 27 32 8843194 leads VBZ B-VP O
6 33 35 8843194 to TO B-PP O
7 36 42 8843194 growth NN B-NP B-Disease
8 43 54 8843194 retardation NN I-NP I-Disease
9 54 55 8843194 , , O O
10 56 67 8843194 chromosomal JJ B-NP B-Disease
11 68 81 8843194 fragmentation NN I-NP I-Disease
12 82 88 8843194 during IN B-PP I-Disease
13 89 96 8843194 meiosis NN B-NP I-Disease
14 96 97 8843194 , , O O
15 98 104 8843194 immune JJ B-NP B-Disease
16 105 112 8843194 defects NNS I-NP I-Disease
17 112 113 8843194 , , O O
18 114 117 8843194 and CC O O
19 118 124 8843194 thymic JJ B-NP B-Disease
20 125 133 8843194 lymphoma NN I-NP I-Disease
21 133 134 8843194 . . I-NP O
22 135 138 8843194 ATM NN I-NP O
23 138 139 8843194 , , O O
24 140 143 8843194 the DT B-NP O
25 144 148 8843194 gene NN I-NP O
26 149 156 8843194 mutated VBN B-VP O
27 157 159 8843194 in IN B-PP O
28 160 163 8843194 the DT B-NP O
29 164 173 8843194 inherited VBN I-NP B-Disease
30 174 179 8843194 human JJ I-NP I-Disease
31 180 187 8843194 disease NN I-NP I-Disease
32 188 194 8843194 ataxia NN I-NP B-Disease
33 194 195 8843194 - HYPH B-NP I-Disease
34 195 209 8843194 telangiectasia NN I-NP I-Disease
35 209 210 8843194 , , O O
36 211 213 8843194 is VBZ B-VP O
37 214 215 8843194 a DT B-NP O
38 216 222 8843194 member NN I-NP O
39 223 225 8843194 of IN B-PP O
40 226 227 8843194 a DT B-NP O
41 228 234 8843194 family NN I-NP O
42 235 237 8843194 of IN B-PP O
43 238 245 8843194 kinases NNS B-NP O
44 246 254 8843194 involved VBN B-VP O
45 255 257 8843194 in IN B-PP O
46 258 261 8843194 DNA NN B-NP O
47 262 272 8843194 metabolism NN I-NP O
48 273 276 8843194 and CC I-NP O
49 277 281 8843194 cell NN I-NP O
50 281 282 8843194 - HYPH B-NP O
51 282 287 8843194 cycle NN I-NP O
52 288 298 8843194 checkpoint NN I-NP O
53 299 306 8843194 control NN I-NP O
54 306 307 8843194 . . O O

1 308 310 8843194 To TO B-VP O
2 311 315 8843194 help VB I-VP O
3 316 323 8843194 clarify VB I-VP O
4 324 327 8843194 the DT B-NP O
5 328 341 8843194 physiological JJ I-NP O
6 342 347 8843194 roles NNS I-NP O
7 348 350 8843194 of IN B-PP O
8 351 354 8843194 the DT B-NP O
9 355 358 8843194 ATM NN I-NP O
10 359 366 8843194 protein NN I-NP O
11 366 367 8843194 , , O O
12 368 370 8843194 we PRP B-NP O
13 371 380 8843194 disrupted VBD B-VP O
14 381 384 8843194 the DT B-NP O
15 385 388 8843194 ATM NN I-NP O
16 389 393 8843194 gene NN I-NP O
17 394 396 8843194 in IN B-PP O
18 397 401 8843194 mice NNS B-NP O
19 402 409 8843194 through IN B-PP O
20 410 420 8843194 homologous JJ B-NP O
21 421 434 8843194 recombination NN I-NP O
22 434 435 8843194 . . O O

1 436 443 8843194 Initial JJ B-NP O
2 444 454 8843194 evaluation NN I-NP O
3 455 457 8843194 of IN B-PP O
4 458 461 8843194 the DT B-NP O
5 462 465 8843194 ATM NN I-NP O
6 466 474 8843194 knockout NN I-NP O
7 475 482 8843194 animals NNS I-NP O
8 483 492 8843194 indicates VBZ B-VP O
9 493 497 8843194 that IN B-SBAR O
10 498 510 8843194 inactivation NN B-NP O
11 511 513 8843194 of IN B-PP O
12 514 517 8843194 the DT B-NP O
13 518 523 8843194 mouse NN I-NP O
14 524 527 8843194 ATM NN I-NP O
15 528 532 8843194 gene NN I-NP O
16 533 542 8843194 recreates VBZ B-VP O
17 543 547 8843194 much JJ B-NP O
18 548 550 8843194 of IN B-PP O
19 551 554 8843194 the DT B-NP O
20 555 564 8843194 phenotype NN I-NP O
21 565 567 8843194 of IN B-PP O
22 568 574 8843194 ataxia NN B-NP B-Disease
23 574 575 8843194 - HYPH B-NP I-Disease
24 575 589 8843194 telangiectasia NN I-NP I-Disease
25 589 590 8843194 . . O O

1 591 594 8843194 The DT B-NP O
2 595 605 8843194 homozygous JJ I-NP O
3 606 612 8843194 mutant NN I-NP O
4 613 614 8843194 ( ( O O
5 614 617 8843194 ATM NN B-NP O
6 617 618 8843194 - HYPH O O
7 618 619 8843194 / SYM O O
8 619 620 8843194 - SYM O O
9 620 621 8843194 ) ) O O
10 622 626 8843194 mice NNS B-NP O
11 627 630 8843194 are VBP B-VP O
12 631 637 8843194 viable JJ B-ADJP O
13 637 638 8843194 , , O O
14 639 645 8843194 growth NN B-NP O
15 645 646 8843194 - HYPH O O
16 646 654 8843194 retarded VBN B-VP O
17 654 655 8843194 , , O O
18 656 659 8843194 and CC O O
19 660 669 8843194 infertile JJ B-ADJP O
20 669 670 8843194 . . O O

1 671 674 8843194 The DT B-NP O
2 675 686 8843194 infertility NN I-NP B-Disease
3 687 689 8843194 of IN B-PP O
4 690 693 8843194 ATM NN B-NP O
5 693 694 8843194 - HYPH B-NP O
6 694 695 8843194 / SYM I-NP O
7 695 696 8843194 - HYPH I-NP O
8 697 701 8843194 mice NNS I-NP O
9 702 709 8843194 results VBZ B-VP O
10 710 714 8843194 from IN B-PP O
11 715 722 8843194 meiotic JJ B-NP O
12 723 730 8843194 failure NN I-NP O
13 730 731 8843194 . . O O

1 732 739 8843194 Meiosis NN B-NP O
2 740 742 8843194 is VBZ B-VP O
3 743 751 8843194 arrested VBN I-VP O
4 752 754 8843194 at IN B-PP O
5 755 758 8843194 the DT B-NP O
6 759 767 8843194 zygotene NN I-NP O
7 767 768 8843194 / SYM B-NP O
8 768 777 8843194 pachytene NN I-NP O
9 778 783 8843194 stage NN I-NP O
10 784 786 8843194 of IN B-PP O
11 787 795 8843194 prophase NN B-NP O
12 796 797 8843194 I CD I-NP O
13 798 800 8843194 as IN B-PP O
14 801 802 8843194 a DT B-NP O
15 803 809 8843194 result NN I-NP O
16 810 812 8843194 of IN B-PP O
17 813 821 8843194 abnormal JJ B-NP O
18 822 833 8843194 chromosomal JJ I-NP O
19 834 842 8843194 synapsis NN I-NP O
20 843 846 8843194 and CC O O
21 847 857 8843194 subsequent JJ B-NP O
22 858 868 8843194 chromosome NN I-NP O
23 869 882 8843194 fragmentation NN I-NP O
24 882 883 8843194 . . O O

1 884 890 8843194 Immune JJ B-NP B-Disease
2 891 898 8843194 defects NNS I-NP I-Disease
3 899 903 8843194 also RB B-ADVP O
4 904 907 8843194 are VBP B-VP O
5 908 915 8843194 evident JJ B-ADJP O
6 916 918 8843194 in IN B-PP O
7 919 922 8843194 ATM NN B-NP O
8 922 923 8843194 - HYPH B-NP O
9 923 924 8843194 / SYM I-NP O
10 924 925 8843194 - HYPH I-NP O
11 926 930 8843194 mice NNS I-NP O
12 930 931 8843194 , , O O
13 932 941 8843194 including VBG B-PP O
14 942 949 8843194 reduced VBN B-NP O
15 950 957 8843194 numbers NNS I-NP O
16 958 960 8843194 of IN B-PP O
17 961 965 8843194 B220 NN B-NP O
18 966 967 8843194 + SYM B-NP O
19 968 972 8843194 CD43 NN I-NP O
20 972 973 8843194 - HYPH B-NP O
21 974 977 8843194 pre AFX I-NP O
22 977 978 8843194 - HYPH I-NP O
23 978 979 8843194 B NN I-NP O
24 980 985 8843194 cells NNS I-NP O
25 985 986 8843194 , , O O
26 987 997 8843194 thymocytes NNS B-NP O
27 997 998 8843194 , , O O
28 999 1002 8843194 and CC O O
29 1003 1013 8843194 peripheral JJ B-NP O
30 1014 1015 8843194 T NN I-NP O
31 1016 1021 8843194 cells NNS I-NP O
32 1021 1022 8843194 , , O O
33 1023 1025 8843194 as RB B-CONJP O
34 1026 1030 8843194 well RB I-CONJP O
35 1031 1033 8843194 as IN I-CONJP O
36 1034 1044 8843194 functional JJ B-NP O
37 1045 1055 8843194 impairment NN I-NP O
38 1056 1058 8843194 of IN B-PP O
39 1059 1060 8843194 T NN B-NP O
40 1060 1061 8843194 - HYPH B-NP O
41 1061 1065 8843194 cell NN I-NP O
42 1065 1066 8843194 - HYPH I-NP O
43 1066 1075 8843194 dependent JJ I-NP O
44 1076 1082 8843194 immune JJ I-NP O
45 1083 1092 8843194 responses NNS I-NP O
46 1092 1093 8843194 . . O O

1 1094 1097 8843194 The DT B-NP O
2 1098 1107 8843194 cerebella NN I-NP O
3 1108 1110 8843194 of IN B-PP O
4 1111 1114 8843194 ATM NN B-NP O
5 1114 1115 8843194 - HYPH O O
6 1115 1116 8843194 / SYM O O
7 1116 1117 8843194 - HYPH O O
8 1118 1122 8843194 mice NNS B-NP O
9 1123 1129 8843194 appear VBP B-VP O
10 1130 1136 8843194 normal JJ B-ADJP O
11 1137 1139 8843194 by IN B-PP O
12 1140 1150 8843194 histologic JJ B-NP O
13 1151 1162 8843194 examination NN I-NP O
14 1163 1165 8843194 at IN B-PP O
15 1166 1167 8843194 3 CD B-NP O
16 1168 1170 8843194 to TO I-NP O
17 1171 1172 8843194 4 CD I-NP O
18 1173 1179 8843194 months NNS I-NP O
19 1180 1183 8843194 and CC O O
20 1184 1187 8843194 the DT B-NP O
21 1188 1192 8843194 mice NNS I-NP O
22 1193 1197 8843194 have VBP B-VP O
23 1198 1200 8843194 no DT B-NP O
24 1201 1206 8843194 gross JJ I-NP O
25 1207 1217 8843194 behavioral JJ I-NP B-Disease
26 1218 1231 8843194 abnormalities NNS I-NP I-Disease
27 1231 1232 8843194 . . O O

1 1233 1236 8843194 The DT B-NP O
2 1237 1245 8843194 majority NN I-NP O
3 1246 1248 8843194 of IN B-PP O
4 1249 1255 8843194 mutant JJ B-NP O
5 1256 1260 8843194 mice NNS I-NP O
6 1261 1268 8843194 rapidly RB B-ADVP O
7 1269 1276 8843194 develop VBP B-VP O
8 1277 1283 8843194 thymic JJ B-NP B-Disease
9 1284 1293 8843194 lymphomas NNS I-NP I-Disease
10 1294 1297 8843194 and CC O O
11 1298 1301 8843194 die VB B-VP O
12 1302 1308 8843194 before IN B-PP O
13 1309 1310 8843194 4 CD B-NP O
14 1311 1317 8843194 months NNS I-NP O
15 1318 1320 8843194 of IN B-PP O
16 1321 1324 8843194 age NN B-NP O
17 1324 1325 8843194 . . O O

1 1326 1331 8843194 These DT B-NP O
2 1332 1340 8843194 findings NNS I-NP O
3 1341 1349 8843194 indicate VBP B-VP O
4 1350 1354 8843194 that IN B-SBAR O
5 1355 1358 8843194 the DT B-NP O
6 1359 1362 8843194 ATM NN I-NP O
7 1363 1367 8843194 gene NN I-NP O
8 1368 1375 8843194 product NN I-NP O
9 1376 1381 8843194 plays VBZ B-VP O
10 1382 1384 8843194 an DT B-NP O
11 1385 1394 8843194 essential JJ I-NP O
12 1395 1399 8843194 role NN I-NP O
13 1400 1402 8843194 in IN B-PP O
14 1403 1404 8843194 a DT B-NP O
15 1405 1412 8843194 diverse JJ I-NP O
16 1413 1418 8843194 group NN I-NP O
17 1419 1421 8843194 of IN B-PP O
18 1422 1430 8843194 cellular JJ B-NP O
19 1431 1440 8843194 processes NNS I-NP O
20 1440 1441 8843194 , , O O
21 1442 1451 8843194 including VBG B-PP O
22 1452 1459 8843194 meiosis NN B-NP O
23 1459 1460 8843194 , , O O
24 1461 1464 8843194 the DT B-NP O
25 1465 1471 8843194 normal JJ I-NP O
26 1472 1478 8843194 growth NN I-NP O
27 1479 1481 8843194 of IN B-PP O
28 1482 1489 8843194 somatic JJ B-NP O
29 1490 1497 8843194 tissues NNS I-NP O
30 1497 1498 8843194 , , O O
31 1499 1505 8843194 immune JJ B-NP O
32 1506 1517 8843194 development NN I-NP O
33 1517 1518 8843194 , , O O
34 1519 1522 8843194 and CC O O
35 1523 1528 8843194 tumor NN B-NP B-Disease
36 1529 1540 8843194 suppression NN I-NP O
37 1540 1541 8843194 . . O O
38 1541 1542 8843194 . . O O

1 0 0 8843193 -DOCSTART- -X- -X- O

1 0 4 8843193 Dual JJ B-NP O
2 5 10 8843193 roles NNS I-NP O
3 11 13 8843193 of IN B-PP O
4 14 17 8843193 ATM NN B-NP O
5 18 20 8843193 in IN B-PP O
6 21 24 8843193 the DT B-NP O
7 25 33 8843193 cellular JJ I-NP O
8 34 42 8843193 response NN I-NP O
9 43 45 8843193 to TO B-PP O
10 46 55 8843193 radiation NN B-NP O
11 56 59 8843193 and CC O O
12 60 62 8843193 in IN B-PP O
13 63 67 8843193 cell NN B-NP O
14 68 74 8843193 growth NN I-NP O
15 75 82 8843193 control NN I-NP O
16 82 83 8843193 . . O O
17 84 87 8843193 The DT B-NP O
18 88 92 8843193 gene NN I-NP O
19 93 100 8843193 mutated VBN B-VP O
20 101 103 8843193 in IN B-PP O
21 104 110 8843193 ataxia NN B-NP B-Disease
22 110 111 8843193 - HYPH O I-Disease
23 111 125 8843193 telangiectasia NN B-NP I-Disease
24 126 127 8843193 ( ( O O
25 127 129 8843193 AT NN B-NP B-Disease
26 129 130 8843193 ) ) O O
27 131 139 8843193 patients NNS B-NP O
28 139 140 8843193 , , O O
29 141 148 8843193 denoted VBN B-VP O
30 149 152 8843193 ATM NNP B-NP O
31 152 153 8843193 , , O O
32 154 161 8843193 encodes VBZ B-VP O
33 162 163 8843193 a DT B-NP O
34 164 172 8843193 putative JJ I-NP O
35 173 180 8843193 protein NN I-NP O
36 181 183 8843193 or CC I-NP O
37 184 189 8843193 lipid NN I-NP O
38 190 196 8843193 kinase NN I-NP O
39 196 197 8843193 . . O O

1 198 200 8843193 To TO B-VP O
2 201 210 8843193 elucidate VB I-VP O
3 211 214 8843193 the DT B-NP O
4 215 224 8843193 functions NNS I-NP O
5 225 227 8843193 of IN B-PP O
6 228 231 8843193 ATM NN B-NP O
7 231 232 8843193 , , O O
8 233 235 8843193 we PRP B-NP O
9 236 245 8843193 disrupted VBD B-VP O
10 246 249 8843193 the DT B-NP O
11 250 255 8843193 mouse NN I-NP O
12 256 259 8843193 ATM NN I-NP O
13 260 264 8843193 gene NN I-NP O
14 265 272 8843193 through IN B-PP O
15 273 283 8843193 homologous JJ B-NP O
16 284 297 8843193 recombination NN I-NP O
17 298 300 8843193 in IN B-PP O
18 301 305 8843193 mice NNS B-NP O
19 305 306 8843193 . . O O

1 307 317 8843193 Consistent JJ B-ADJP O
2 318 322 8843193 with IN B-PP O
3 323 331 8843193 cellular JJ B-NP O
4 332 339 8843193 defects NNS I-NP O
5 340 342 8843193 of IN B-PP O
6 343 345 8843193 AT NN B-NP B-Disease
7 346 354 8843193 patients NNS I-NP O
8 354 355 8843193 , , O O
9 356 359 8843193 the DT B-NP O
10 360 363 8843193 ATM NN I-NP O
11 363 364 8843193 - HYPH O O
12 364 365 8843193 / SYM O O
13 365 366 8843193 - HYPH O O
14 367 372 8843193 cells NNS B-NP O
15 373 376 8843193 are VBP B-VP O
16 377 391 8843193 hypersensitive JJ B-ADJP O
17 392 394 8843193 to TO B-PP O
18 395 400 8843193 gamma SYM O O
19 400 401 8843193 - HYPH O O
20 401 412 8843193 irradiation NN B-NP O
21 413 416 8843193 and CC O O
22 417 426 8843193 defective JJ B-ADJP O
23 427 429 8843193 in IN B-PP O
24 430 434 8843193 cell NN B-NP O
25 434 435 8843193 - HYPH B-NP O
26 435 440 8843193 cycle NN I-NP O
27 441 447 8843193 arrest NN I-NP O
28 448 457 8843193 following VBG B-PP O
29 458 467 8843193 radiation NN B-NP O
30 467 468 8843193 , , O O
31 469 480 8843193 correlating VBG B-VP O
32 481 485 8843193 with IN B-PP O
33 486 487 8843193 a DT B-NP O
34 488 497 8843193 defective JJ I-NP O
35 498 500 8843193 up RB I-NP O
36 500 501 8843193 - HYPH I-NP O
37 501 511 8843193 regulation NN B-NP O
38 512 514 8843193 of IN B-PP O
39 515 518 8843193 p53 NN B-NP O
40 518 519 8843193 . . O O

1 520 522 8843193 In IN B-PP O
2 523 531 8843193 addition NN B-NP O
3 531 532 8843193 , , O O
4 533 536 8843193 ATM NN B-NP O
5 536 537 8843193 - HYPH O O
6 537 538 8843193 / SYM O O
7 538 539 8843193 - HYPH O O
8 540 545 8843193 mouse NN B-NP O
9 546 556 8843193 thymocytes NNS I-NP O
10 557 560 8843193 are VBP B-VP O
11 561 565 8843193 more RBR B-ADJP O
12 566 575 8843193 resistant JJ I-ADJP O
13 576 578 8843193 to TO B-PP O
14 579 588 8843193 apoptosis NN B-NP O
15 589 596 8843193 induced VBN B-VP O
16 597 599 8843193 by IN B-PP O
17 600 605 8843193 gamma SYM B-NP O
18 605 606 8843193 - HYPH O O
19 606 617 8843193 irradiation NN B-NP O
20 618 622 8843193 than IN B-PP O
21 623 629 8843193 normal JJ B-NP O
22 630 640 8843193 thymocytes NNS I-NP O
23 640 641 8843193 . . O O

1 642 645 8843193 ATM NN B-NP O
2 645 646 8843193 - HYPH O O
3 646 647 8843193 / SYM O O
4 647 648 8843193 - HYPH O O
5 649 660 8843193 fibroblasts NNS B-NP O
6 661 664 8843193 are VBP B-VP O
7 665 676 8843193 inefficient JJ B-ADJP O
8 677 679 8843193 in IN B-PP O
9 680 682 8843193 G1 NN B-NP O
10 683 685 8843193 to TO B-PP O
11 686 687 8843193 S NN B-NP O
12 687 688 8843193 - HYPH B-NP O
13 688 693 8843193 phase NN I-NP O
14 694 705 8843193 progression NN I-NP O
15 706 715 8843193 following VBG B-PP O
16 716 721 8843193 serum NN B-NP O
17 722 733 8843193 stimulation NN I-NP O
18 734 737 8843193 and CC O O
19 738 745 8843193 senesce NN B-NP O
20 746 751 8843193 after IN B-PP O
21 752 756 8843193 only RB B-NP O
22 757 758 8843193 a DT I-NP O
23 759 762 8843193 few JJ I-NP O
24 763 771 8843193 passages NNS I-NP O
25 772 774 8843193 in IN B-PP O
26 775 782 8843193 culture NN B-NP O
27 782 783 8843193 . . O O

1 784 788 8843193 They PRP B-NP O
2 789 793 8843193 have VBP B-VP O
3 794 796 8843193 an DT B-NP O
4 797 806 8843193 increased VBN I-NP O
5 807 819 8843193 constitutive JJ I-NP O
6 820 825 8843193 level NN I-NP O
7 826 828 8843193 of IN B-PP O
8 829 835 8843193 p21CP1 NN B-NP O
9 835 836 8843193 / SYM B-NP O
10 836 840 8843193 WAF1 NN I-NP O
11 840 841 8843193 . . O O

1 842 845 8843193 The DT B-NP O
2 846 849 8843193 ATM NN I-NP O
3 850 857 8843193 protein NN I-NP O
4 858 860 8843193 is VBZ B-VP O
5 861 870 8843193 therefore RB B-ADVP O
6 871 879 8843193 critical JJ B-ADJP O
7 880 884 8843193 both CC B-PP O
8 885 888 8843193 for IN I-PP O
9 889 897 8843193 cellular JJ B-NP O
10 898 907 8843193 responses NNS I-NP O
11 908 910 8843193 to TO B-PP O
12 911 919 8843193 ionizing VBG B-VP O
13 920 929 8843193 radiation NN B-NP O
14 930 933 8843193 and CC B-PP O
15 934 937 8843193 for IN B-PP O
16 938 944 8843193 normal JJ B-NP O
17 945 949 8843193 cell NN I-NP O
18 949 950 8843193 - HYPH B-NP O
19 950 955 8843193 cycle NN I-NP O
20 956 967 8843193 progression NN I-NP O
21 967 968 8843193 . . O O

1 969 972 8843193 ATM NN B-NP O
2 973 974 8843193 + SYM O O
3 974 975 8843193 / SYM B-NP O
4 975 976 8843193 - HYPH B-NP O
5 977 988 8843193 fibroblasts NNS I-NP O
6 989 992 8843193 and CC I-NP O
7 993 1003 8843193 thymocytes NNS I-NP O
8 1004 1010 8843193 showed VBD B-VP O
9 1011 1025 8843193 intermediately RB B-NP O
10 1026 1035 8843193 defective JJ I-NP O
11 1036 1045 8843193 responses NNS I-NP O
12 1046 1048 8843193 to TO B-PP O
13 1049 1060 8843193 irradiation NN B-NP O
14 1061 1064 8843193 but CC O O
15 1065 1067 8843193 no DT B-NP O
16 1068 1074 8843193 growth NN I-NP O
17 1075 1081 8843193 defect NN I-NP O
18 1081 1082 8843193 , , O O
19 1083 1093 8843193 suggesting VBG B-VP O
20 1094 1098 8843193 that IN B-SBAR O
21 1099 1102 8843193 the DT B-NP O
22 1103 1112 8843193 increased VBN I-NP O
23 1113 1119 8843193 cancer NN I-NP B-Disease
24 1120 1124 8843193 risk NN I-NP O
25 1125 1127 8843193 of IN B-PP O
26 1128 1130 8843193 AT NN B-NP B-Disease
27 1131 1144 8843193 heterozygotes NNS I-NP O
28 1145 1150 8843193 could MD B-VP O
29 1151 1153 8843193 be VB I-VP O
30 1154 1166 8843193 attributable JJ B-ADJP O
31 1167 1169 8843193 to TO B-PP O
32 1170 1174 8843193 poor JJ B-NP O
33 1175 1185 8843193 checkpoint NN I-NP O
34 1186 1194 8843193 function NN I-NP O
35 1194 1195 8843193 . . O O
36 1195 1196 8843193 . . O O

1 0 0 8931695 -DOCSTART- -X- -X- O

1 0 10 8931695 Phenotypic JJ B-NP O
2 11 14 8931695 and CC I-NP O
3 15 24 8931695 genotypic JJ I-NP O
4 25 32 8931695 overlap NN I-NP O
5 33 40 8931695 between IN B-PP O
6 41 57 8931695 atelosteogenesis NN B-NP B-Disease
7 58 62 8931695 type NN I-NP I-Disease
8 63 64 8931695 2 CD I-NP I-Disease
9 65 68 8931695 and CC I-NP O
10 69 80 8931695 diastrophic JJ I-NP B-Disease
11 81 90 8931695 dysplasia NN I-NP I-Disease
12 90 91 8931695 . . I-NP O
13 92 101 8931695 Mutations NNS I-NP O
14 102 104 8931695 in IN B-PP O
15 105 108 8931695 the DT B-NP O
16 109 120 8931695 diastrophic JJ I-NP B-Disease
17 121 130 8931695 dysplasia NN I-NP I-Disease
18 131 138 8931695 sulfate NN I-NP O
19 139 150 8931695 transporter NN I-NP O
20 151 155 8931695 gene NN I-NP O
21 156 161 8931695 DTDST NN I-NP O
22 162 166 8931695 have VBP B-VP O
23 167 171 8931695 been VBN I-VP O
24 172 182 8931695 associated VBN I-VP O
25 183 187 8931695 with IN B-PP O
26 188 189 8931695 a DT B-NP O
27 190 196 8931695 family NN I-NP O
28 197 199 8931695 of IN B-PP O
29 200 217 8931695 chondrodysplasias NNS B-NP B-Disease
30 218 222 8931695 that WDT B-NP O
31 223 232 8931695 comprises VBZ B-VP O
32 232 233 8931695 , , O O
33 234 236 8931695 in IN B-PP O
34 237 242 8931695 order NN B-NP O
35 243 245 8931695 of IN B-PP O
36 246 256 8931695 increasing VBG B-NP O
37 257 265 8931695 severity NN I-NP O
38 265 266 8931695 , , O O
39 267 278 8931695 diastrophic JJ B-NP B-Disease
40 279 288 8931695 dysplasia NN I-NP I-Disease
41 289 290 8931695 ( ( O O
42 290 293 8931695 DTD NN B-NP B-Disease
43 293 294 8931695 ) ) O O
44 294 295 8931695 , , O O
45 296 312 8931695 atelosteogenesis NN B-NP B-Disease
46 313 317 8931695 type NN I-NP I-Disease
47 318 319 8931695 2 CD I-NP I-Disease
48 320 321 8931695 ( ( O O
49 321 324 8931695 AO2 NN B-NP B-Disease
50 324 325 8931695 ) ) O O
51 325 326 8931695 , , O O
52 327 330 8931695 and CC O O
53 331 346 8931695 achondrogenesis NN B-NP B-Disease
54 347 351 8931695 type NN I-NP I-Disease
55 352 354 8931695 1B NN I-NP I-Disease
56 355 356 8931695 ( ( O O
57 356 361 8931695 ACG1B NN B-NP B-Disease
58 361 362 8931695 ) ) O O
59 362 363 8931695 . . O O

1 364 366 8931695 To TO B-VP O
2 367 372 8931695 learn VB I-VP O
3 373 377 8931695 more JJR B-NP O
4 378 383 8931695 about IN B-PP O
5 384 387 8931695 the DT B-NP O
6 388 397 8931695 molecular JJ I-NP O
7 398 403 8931695 basis NN I-NP O
8 404 406 8931695 of IN B-PP O
9 407 412 8931695 DTDST NN B-NP B-Disease
10 413 430 8931695 chondrodysplasias NNS I-NP I-Disease
11 431 434 8931695 and CC O O
12 435 440 8931695 about IN B-NP O
13 441 449 8931695 genotype NN I-NP O
14 449 450 8931695 - HYPH I-NP O
15 450 459 8931695 phenotype NN I-NP O
16 460 472 8931695 correlations NNS I-NP O
17 472 473 8931695 , , O O
18 474 476 8931695 we PRP B-NP O
19 477 484 8931695 studied VBD B-VP O
20 485 495 8931695 fibroblast NN B-NP O
21 496 504 8931695 cultures NNS I-NP O
22 505 507 8931695 of IN B-PP O
23 508 513 8931695 three CD B-NP O
24 514 517 8931695 new JJ I-NP O
25 518 526 8931695 patients NNS I-NP O
26 528 531 8931695 one CD B-NP O
27 532 536 8931695 with IN B-PP O
28 537 539 8931695 AO NN B-NP B-Disease
29 539 540 8931695 - HYPH B-NP I-Disease
30 540 541 8931695 2 CD I-NP I-Disease
31 541 542 8931695 , , O O
32 543 546 8931695 one CD B-NP O
33 547 551 8931695 with IN B-PP O
34 552 555 8931695 DTD NN B-NP B-Disease
35 555 556 8931695 , , O O
36 557 560 8931695 and CC O O
37 561 564 8931695 one CD B-NP O
38 565 569 8931695 with IN B-PP O
39 570 572 8931695 an DT B-NP O
40 573 585 8931695 intermediate JJ I-NP O
41 586 595 8931695 phenotype NN I-NP O
42 596 597 8931695 ( ( O O
43 597 600 8931695 AO2 NN B-NP B-Disease
44 600 601 8931695 / SYM O O
45 601 604 8931695 DTD NN B-NP B-Disease
46 604 605 8931695 ) ) O O
47 605 606 8931695 . . O O

1 607 614 8931695 Reduced VBN B-NP O
2 615 628 8931695 incorporation NN I-NP O
3 629 631 8931695 of IN B-PP O
4 632 641 8931695 inorganic JJ B-NP O
5 642 649 8931695 sulfate NN I-NP O
6 650 654 8931695 into IN B-PP O
7 655 669 8931695 macromolecules NNS B-NP O
8 670 673 8931695 was VBD B-VP O
9 674 679 8931695 found VBN I-VP O
10 680 682 8931695 in IN B-PP O
11 683 686 8931695 all DT B-NP O
12 687 692 8931695 three CD I-NP O
13 692 693 8931695 . . O O

1 694 698 8931695 Each DT B-NP O
2 699 701 8931695 of IN B-PP O
3 702 705 8931695 the DT B-NP O
4 706 711 8931695 three CD I-NP O
5 712 720 8931695 patients NNS I-NP O
6 721 724 8931695 was VBD B-VP O
7 725 730 8931695 found VBN I-VP O
8 731 733 8931695 to TO I-VP O
9 734 736 8931695 be VB I-VP O
10 737 749 8931695 heterozygous JJ B-ADJP O
11 750 753 8931695 for IN B-PP O
12 754 755 8931695 a DT B-NP O
13 756 761 8931695 c862t NN I-NP O
14 762 772 8931695 transition NN I-NP O
15 773 783 8931695 predicting VBG B-VP O
16 784 785 8931695 a DT B-NP O
17 786 791 8931695 R279W NN I-NP O
18 792 804 8931695 substitution NN I-NP O
19 805 807 8931695 in IN B-PP O
20 808 811 8931695 the DT B-NP O
21 812 817 8931695 third JJ I-NP O
22 818 831 8931695 extracellular JJ I-NP O
23 832 836 8931695 loop NN I-NP O
24 837 839 8931695 of IN B-PP O
25 840 845 8931695 DTDST NN B-NP O
26 845 846 8931695 . . O O

1 847 849 8931695 In IN B-PP O
2 850 853 8931695 two CD B-NP O
3 854 862 8931695 patients NNS I-NP O
4 863 864 8931695 ( ( O O
5 864 867 8931695 DTD NN B-NP B-Disease
6 868 871 8931695 and CC I-NP O
7 872 875 8931695 AO2 NN I-NP B-Disease
8 875 876 8931695 / SYM B-NP O
9 876 879 8931695 DTD NN I-NP B-Disease
10 879 880 8931695 ) ) O O
11 880 881 8931695 , , O O
12 882 884 8931695 no DT B-NP O
13 885 890 8931695 other JJ I-NP O
14 891 901 8931695 structural JJ I-NP O
15 902 910 8931695 mutation NN I-NP O
16 911 914 8931695 was VBD B-VP O
17 915 920 8931695 found VBN I-VP O
18 920 921 8931695 , , O O
19 922 925 8931695 but CC O O
20 926 936 8931695 polymerase NN B-NP O
21 937 942 8931695 chain NN I-NP O
22 943 951 8931695 reaction NN I-NP O
23 952 965 8931695 amplification NN I-NP O
24 966 969 8931695 and CC O O
25 970 976 8931695 single JJ B-NP O
26 976 977 8931695 - HYPH I-NP O
27 977 983 8931695 strand NN I-NP O
28 984 996 8931695 conformation NN I-NP O
29 997 1009 8931695 polymorphism NN I-NP O
30 1010 1018 8931695 analysis NN I-NP O
31 1019 1021 8931695 of IN B-PP O
32 1022 1032 8931695 fibroblast NN B-NP O
33 1033 1037 8931695 cDNA NN I-NP O
34 1038 1044 8931695 showed VBD B-VP O
35 1045 1052 8931695 reduced VBN B-NP O
36 1053 1057 8931695 mRNA NN I-NP O
37 1058 1064 8931695 levels NNS I-NP O
38 1065 1067 8931695 of IN B-PP O
39 1068 1071 8931695 the DT B-NP O
40 1072 1076 8931695 wild JJ I-NP O
41 1076 1077 8931695 - HYPH I-NP O
42 1077 1081 8931695 type NN I-NP O
43 1082 1087 8931695 DTDST NN I-NP O
44 1088 1094 8931695 allele NN I-NP O
45 1096 1101 8931695 these DT B-NP O
46 1102 1105 8931695 two CD I-NP O
47 1106 1114 8931695 patients NNS I-NP O
48 1115 1118 8931695 may MD B-VP O
49 1119 1121 8931695 be VB I-VP O
50 1122 1130 8931695 compound JJ B-NP O
51 1131 1144 8931695 heterozygotes NNS I-NP O
52 1145 1148 8931695 for IN B-PP O
53 1149 1152 8931695 the DT B-NP O
54 1153 1154 8931695 " `` I-NP O
55 1155 1162 8931695 Finnish JJ I-NP O
56 1163 1164 8931695 " '' I-NP O
57 1165 1173 8931695 mutation NN I-NP O
58 1174 1175 8931695 ( ( O O
59 1175 1177 8931695 as IN B-PP O
60 1178 1181 8931695 yet RB B-ADJP O
61 1182 1197 8931695 uncharacterized JJ I-ADJP O
62 1198 1200 8931695 at IN B-PP O
63 1201 1204 8931695 the DT B-NP O
64 1205 1208 8931695 DNA NN I-NP O
65 1209 1214 8931695 level NN I-NP O
66 1214 1215 8931695 ) ) O O
67 1215 1216 8931695 , , O O
68 1217 1222 8931695 which WDT B-NP O
69 1223 1229 8931695 causes VBZ B-VP O
70 1230 1237 8931695 reduced VBN I-VP O
71 1238 1248 8931695 expression NN B-NP O
72 1249 1251 8931695 of IN B-PP O
73 1252 1257 8931695 DTDST NN B-NP O
74 1257 1258 8931695 . . O O

1 1259 1262 8931695 The DT B-NP O
2 1263 1268 8931695 third JJ I-NP O
3 1269 1276 8931695 patient NN I-NP O
4 1277 1278 8931695 ( ( O O
5 1278 1282 8931695 with IN B-PP O
6 1283 1286 8931695 AO2 NN B-NP B-Disease
7 1286 1287 8931695 ) ) O O
8 1288 1291 8931695 had VBD B-VP O
9 1292 1295 8931695 the DT B-NP O
10 1296 1301 8931695 R279W NN I-NP O
11 1302 1310 8931695 mutation NN I-NP O
12 1311 1321 8931695 compounded VBN B-VP O
13 1322 1326 8931695 with IN B-PP O
14 1327 1328 8931695 a DT B-NP O
15 1329 1334 8931695 novel JJ I-NP O
16 1335 1343 8931695 mutation NN I-NP O
17 1343 1344 8931695 , , O O
18 1345 1348 8931695 the DT B-NP O
19 1349 1357 8931695 deletion NN I-NP O
20 1358 1360 8931695 of IN B-PP O
21 1361 1369 8931695 cytosine NN B-NP O
22 1370 1373 8931695 418 CD I-NP O
23 1374 1375 8931695 ( ( O O
24 1375 1380 8931695 delta SYM O O
25 1381 1385 8931695 c418 NN B-NP O
26 1385 1386 8931695 ) ) O O
27 1386 1387 8931695 , , O O
28 1388 1398 8931695 predicting VBG B-VP O
29 1399 1400 8931695 a DT B-NP O
30 1401 1411 8931695 frameshift NN I-NP O
31 1412 1416 8931695 with IN B-PP O
32 1417 1426 8931695 premature JJ B-NP O
33 1427 1438 8931695 termination NN I-NP O
34 1438 1439 8931695 . . O O

1 1440 1444 8931695 Also RB B-ADVP O
2 1445 1448 8931695 the DT B-NP O
3 1449 1454 8931695 delta NN I-NP O
4 1455 1459 8931695 c418 NN I-NP O
5 1460 1466 8931695 allele NN I-NP O
6 1467 1470 8931695 was VBD B-VP O
7 1471 1487 8931695 underrepresented VBN I-VP O
8 1488 1490 8931695 in IN B-PP O
9 1491 1494 8931695 the DT B-NP O
10 1495 1499 8931695 cDNA NN I-NP O
11 1499 1500 8931695 , , O O
12 1501 1503 8931695 in IN B-PP O
13 1504 1514 8931695 accordance NN B-NP O
14 1515 1519 8931695 with IN B-PP O
15 1520 1528 8931695 previous JJ B-NP O
16 1529 1541 8931695 observations NNS I-NP O
17 1542 1546 8931695 that IN B-NP O
18 1547 1556 8931695 premature JJ B-NP O
19 1557 1561 8931695 stop NN I-NP O
20 1562 1568 8931695 codons NNS I-NP O
21 1569 1575 8931695 reduce VBP B-VP O
22 1576 1580 8931695 mRNA NN B-NP O
23 1581 1587 8931695 levels NNS I-NP O
24 1587 1588 8931695 . . O O

1 1589 1592 8931695 The DT B-NP O
2 1593 1601 8931695 presence NN I-NP O
3 1602 1604 8931695 of IN B-PP O
4 1605 1608 8931695 the DT B-NP O
5 1609 1614 8931695 DTDST NN I-NP O
6 1615 1620 8931695 R279W NN I-NP O
7 1621 1629 8931695 mutation NN I-NP O
8 1630 1632 8931695 in IN B-PP O
9 1633 1634 8931695 a DT B-NP O
10 1635 1640 8931695 total NN I-NP O
11 1641 1643 8931695 of IN B-PP O
12 1644 1646 8931695 11 CD B-NP O
13 1647 1655 8931695 patients NNS I-NP O
14 1656 1660 8931695 with IN B-PP O
15 1661 1664 8931695 AO2 NN B-NP B-Disease
16 1665 1667 8931695 or CC I-NP O
17 1668 1671 8931695 DTD NN I-NP B-Disease
18 1672 1682 8931695 emphasizes VBZ B-VP O
19 1683 1686 8931695 the DT B-NP O
20 1687 1694 8931695 overlap NN I-NP O
21 1695 1702 8931695 between IN B-PP O
22 1703 1708 8931695 these DT B-NP O
23 1709 1719 8931695 conditions NNS I-NP O
24 1719 1720 8931695 . . O O

1 1721 1725 8931695 This DT B-NP O
2 1726 1734 8931695 mutation NN I-NP O
3 1735 1738 8931695 has VBZ B-VP O
4 1739 1742 8931695 not RB I-VP O
5 1743 1747 8931695 been VBN I-VP O
6 1748 1753 8931695 found VBN I-VP O
7 1754 1756 8931695 so RB B-ADVP O
8 1757 1760 8931695 far RB I-ADVP O
9 1761 1763 8931695 in IN B-PP O
10 1764 1765 8931695 8 CD B-NP O
11 1766 1774 8931695 analyzed VBN I-NP O
12 1775 1780 8931695 ACG1B NN I-NP B-Disease
13 1781 1789 8931695 patients NNS I-NP O
14 1789 1790 8931695 , , O O
15 1791 1801 8931695 suggesting VBG B-VP O
16 1802 1806 8931695 that IN B-SBAR O
17 1807 1809 8931695 it PRP B-NP O
18 1810 1816 8931695 allows VBZ B-VP O
19 1817 1821 8931695 some DT B-NP O
20 1822 1830 8931695 residual JJ I-NP O
21 1831 1839 8931695 activity NN I-NP O
22 1840 1842 8931695 of IN B-PP O
23 1843 1846 8931695 the DT B-NP O
24 1847 1854 8931695 sulfate NN I-NP O
25 1855 1866 8931695 transporter NN I-NP O
26 1866 1867 8931695 . . O O
27 1867 1868 8931695 . . O O

1 0 0 9245987 -DOCSTART- -X- -X- O

1 0 14 9245987 Constitutively RB B-NP O
2 15 25 9245987 methylated VBN I-NP O
3 26 29 9245987 CpG NN I-NP O
4 30 43 9245987 dinucleotides NNS I-NP O
5 44 46 9245987 as IN B-PP O
6 47 55 9245987 mutation NN B-NP O
7 56 59 9245987 hot JJ I-NP O
8 60 65 9245987 spots NNS I-NP O
9 66 68 9245987 in IN B-PP O
10 69 72 9245987 the DT B-NP O
11 73 87 9245987 retinoblastoma NN I-NP B-Disease
12 88 92 9245987 gene NN I-NP O
13 93 94 9245987 ( ( O O
14 94 97 9245987 RB1 NN B-NP O
15 97 98 9245987 ) ) O O
16 98 99 9245987 . . O O
17 100 101 9245987 A DT B-NP O
18 102 106 9245987 wide JJ I-NP O
19 107 115 9245987 spectrum NN I-NP O
20 116 118 9245987 of IN B-PP O
21 119 128 9245987 mutations NNS B-NP O
22 128 129 9245987 , , O O
23 130 137 9245987 ranging VBG B-VP O
24 138 142 9245987 from IN B-PP O
25 143 148 9245987 point NN B-NP O
26 149 158 9245987 mutations NNS I-NP O
27 159 161 9245987 to TO B-PP O
28 162 167 9245987 large JJ B-NP O
29 168 177 9245987 deletions NNS I-NP O
30 177 178 9245987 , , O O
31 179 183 9245987 have VBP B-VP O
32 184 188 9245987 been VBN I-VP O
33 189 198 9245987 described VBN I-VP O
34 199 201 9245987 in IN B-PP O
35 202 205 9245987 the DT B-NP O
36 206 220 9245987 retinoblastoma NN I-NP B-Disease
37 221 225 9245987 gene NN I-NP O
38 226 227 9245987 ( ( O O
39 227 230 9245987 RB1 NN B-NP O
40 230 231 9245987 ) ) O O
41 231 232 9245987 . . O O

1 233 242 9245987 Mutations NNS B-NP O
2 243 247 9245987 have VBP B-VP O
3 248 252 9245987 been VBN I-VP O
4 253 258 9245987 found VBN I-VP O
5 259 269 9245987 throughout IN B-PP O
6 270 273 9245987 the DT B-NP O
7 274 278 9245987 gene NN I-NP O
8 278 279 9245987 ; : O O
9 280 287 9245987 however RB B-ADVP O
10 287 288 9245987 , , O O
11 289 294 9245987 these DT B-NP O
12 295 302 9245987 genetic JJ I-NP O
13 303 314 9245987 alterations NNS I-NP O
14 315 317 9245987 do VBP B-VP O
15 318 321 9245987 not RB I-VP O
16 322 328 9245987 appear VB I-VP O
17 329 331 9245987 to TO I-VP O
18 332 334 9245987 be VB I-VP O
19 335 348 9245987 homogeneously RB I-VP O
20 349 360 9245987 distributed VBN I-VP O
21 360 361 9245987 . . O O

1 362 364 9245987 In IN B-PP O
2 365 375 9245987 particular JJ B-NP O
3 375 376 9245987 , , O O
4 377 378 9245987 a DT B-NP O
5 379 390 9245987 significant JJ I-NP O
6 391 401 9245987 proportion NN I-NP O
7 402 404 9245987 of IN B-PP O
8 405 412 9245987 disease NN B-NP O
9 412 413 9245987 - HYPH O O
10 413 420 9245987 causing VBG B-VP O
11 421 430 9245987 mutations NNS B-NP O
12 431 438 9245987 results VBZ B-VP O
13 439 441 9245987 in IN B-PP O
14 442 445 9245987 the DT B-NP O
15 446 455 9245987 premature JJ I-NP O
16 456 467 9245987 termination NN I-NP O
17 468 470 9245987 of IN B-PP O
18 471 478 9245987 protein NN B-NP O
19 479 488 9245987 synthesis NN I-NP O
20 488 489 9245987 , , O O
21 490 493 9245987 and CC O O
22 494 497 9245987 the DT B-NP O
23 498 506 9245987 majority NN I-NP O
24 507 509 9245987 of IN B-PP O
25 510 515 9245987 these DT B-NP O
26 516 525 9245987 mutations NNS I-NP O
27 526 531 9245987 occur VBP B-VP O
28 532 534 9245987 as IN B-PP O
29 535 536 9245987 C NN B-NP O
30 536 537 9245987 - HYPH O O
31 537 538 9245987 - SYM B-NP O
32 539 540 9245987 > SYM I-NP O
33 541 542 9245987 T NN I-NP O
34 543 554 9245987 transitions NNS I-NP O
35 555 557 9245987 at IN B-PP O
36 558 561 9245987 CpG NN B-NP O
37 562 575 9245987 dinucleotides NNS I-NP O
38 576 577 9245987 ( ( O O
39 577 581 9245987 CpGs NNS B-NP O
40 581 582 9245987 ) ) O O
41 582 583 9245987 . . O O

1 584 588 9245987 Such JJ B-NP O
2 589 598 9245987 recurrent JJ I-NP O
3 599 602 9245987 CpG NN I-NP O
4 603 612 9245987 mutations NNS I-NP O
5 612 613 9245987 , , O O
6 614 623 9245987 including VBG B-PP O
7 624 629 9245987 those DT B-NP O
8 630 635 9245987 found VBN B-VP O
9 636 638 9245987 in IN B-PP O
10 639 642 9245987 RB1 NN B-NP O
11 642 643 9245987 , , O O
12 644 647 9245987 are VBP B-VP O
13 648 654 9245987 likely JJ B-ADJP O
14 655 658 9245987 the DT B-NP O
15 659 665 9245987 result NN I-NP O
16 666 668 9245987 of IN B-PP O
17 669 672 9245987 the DT B-NP O
18 673 684 9245987 deamination NN I-NP O
19 685 687 9245987 of IN B-PP O
20 688 689 9245987 5 CD B-NP O
21 689 690 9245987 - HYPH I-NP O
22 690 704 9245987 methylcytosine NN I-NP O
23 705 711 9245987 within IN B-PP O
24 712 717 9245987 these DT B-NP O
25 718 722 9245987 CpGs NNS I-NP O
26 722 723 9245987 . . O O

1 724 726 9245987 In IN B-PP O
2 727 730 9245987 the DT B-NP O
3 731 738 9245987 present JJ I-NP O
4 739 744 9245987 study NN I-NP O
5 744 745 9245987 , , O O
6 746 748 9245987 we PRP B-NP O
7 749 753 9245987 used VBD B-VP O
8 754 757 9245987 the DT B-NP O
9 758 773 9245987 sodiumbisulfite JJ I-NP O
10 774 784 9245987 conversion NN I-NP O
11 785 791 9245987 method NN I-NP O
12 792 794 9245987 to TO B-VP O
13 795 801 9245987 detect VB I-VP O
14 802 810 9245987 cytosine NN B-NP O
15 811 822 9245987 methylation NN I-NP O
16 823 825 9245987 in IN B-PP O
17 826 840 9245987 representative JJ B-NP O
18 841 846 9245987 exons NNS I-NP O
19 847 849 9245987 of IN B-PP O
20 850 853 9245987 RB1 NN B-NP O
21 853 854 9245987 . . O O

1 855 857 9245987 We PRP B-NP O
2 858 866 9245987 analyzed VBD B-VP O
3 867 870 9245987 DNA NN B-NP O
4 871 875 9245987 from IN B-PP O
5 876 877 9245987 a DT B-NP O
6 878 885 9245987 variety NN I-NP O
7 886 888 9245987 of IN B-PP O
8 889 896 9245987 tissues NNS B-NP O
9 897 900 9245987 and CC O O
10 901 913 9245987 specifically RB B-NP O
11 914 922 9245987 targeted VBN I-NP O
12 923 926 9245987 CGA NN I-NP O
13 927 933 9245987 codons NNS I-NP O
14 934 936 9245987 in IN B-PP O
15 937 940 9245987 RB1 NN B-NP O
16 940 941 9245987 , , O O
17 942 947 9245987 where WRB B-ADVP O
18 948 957 9245987 recurrent JJ B-NP O
19 958 967 9245987 premature JJ I-NP O
20 968 979 9245987 termination NN I-NP O
21 980 989 9245987 mutations NNS I-NP O
22 990 994 9245987 have VBP B-VP O
23 995 999 9245987 been VBN I-VP O
24 1000 1008 9245987 reported VBN I-VP O
25 1008 1009 9245987 . . O O

1 1010 1012 9245987 We PRP B-NP O
2 1013 1018 9245987 found VBD B-VP O
3 1019 1023 9245987 that IN B-SBAR O
4 1024 1027 9245987 DNA NN B-NP O
5 1028 1039 9245987 methylation NN I-NP O
6 1040 1046 9245987 within IN B-PP O
7 1047 1050 9245987 RB1 NN B-NP O
8 1051 1056 9245987 exons NNS I-NP O
9 1057 1058 9245987 8 CD B-NP O
10 1058 1059 9245987 , , I-NP O
11 1060 1062 9245987 14 CD I-NP O
12 1062 1063 9245987 , , I-NP O
13 1064 1066 9245987 25 CD I-NP O
14 1066 1067 9245987 , , O O
15 1068 1071 9245987 and CC O O
16 1072 1074 9245987 27 CD B-NP O
17 1075 1083 9245987 appeared VBD B-VP O
18 1084 1086 9245987 to TO I-VP O
19 1087 1089 9245987 be VB I-VP O
20 1090 1100 9245987 restricted VBN I-VP O
21 1101 1103 9245987 to TO B-PP O
22 1104 1108 9245987 CpGs NNS B-NP O
23 1108 1109 9245987 , , O O
24 1110 1119 9245987 including VBG B-PP O
25 1120 1123 9245987 six CD B-NP O
26 1124 1127 9245987 CGA NN I-NP O
27 1128 1134 9245987 codons NNS I-NP O
28 1134 1135 9245987 . . O O

1 1136 1141 9245987 Other JJ B-NP O
2 1142 1148 9245987 codons NNS I-NP O
3 1149 1159 9245987 containing VBG B-VP O
4 1160 1170 9245987 methylated VBN B-NP O
5 1171 1180 9245987 cytosines NNS I-NP O
6 1181 1185 9245987 have VBP B-VP O
7 1186 1189 9245987 not RB I-VP O
8 1190 1194 9245987 been VBN I-VP O
9 1195 1203 9245987 reported VBN I-VP O
10 1204 1206 9245987 to TO I-VP O
11 1207 1209 9245987 be VB I-VP O
12 1210 1217 9245987 mutated VBN I-VP O
13 1217 1218 9245987 . . O O

1 1219 1228 9245987 Therefore RB B-ADVP O
2 1228 1229 9245987 , , O O
3 1230 1237 9245987 disease NN B-NP O
4 1237 1238 9245987 - HYPH O O
5 1238 1245 9245987 causing VBG B-VP O
6 1246 1255 9245987 mutations NNS B-NP O
7 1256 1258 9245987 at IN B-PP O
8 1259 1263 9245987 CpGs NNS B-NP O
9 1264 1266 9245987 in IN B-PP O
10 1267 1270 9245987 RB1 NN B-NP O
11 1271 1277 9245987 appear VBP B-VP O
12 1278 1280 9245987 to TO I-VP O
13 1281 1283 9245987 be VB I-VP O
14 1284 1294 9245987 determined VBN I-VP O
15 1295 1297 9245987 by IN B-PP O
16 1298 1305 9245987 several JJ B-NP O
17 1306 1313 9245987 factors NNS I-NP O
18 1313 1314 9245987 , , O O
19 1315 1324 9245987 including VBG B-PP O
20 1325 1328 9245987 the DT B-NP O
21 1329 1341 9245987 constitutive JJ I-NP O
22 1342 1350 9245987 presence NN I-NP O
23 1351 1353 9245987 of IN B-PP O
24 1354 1357 9245987 DNA NN B-NP O
25 1358 1369 9245987 methylation NN I-NP O
26 1370 1372 9245987 at IN B-PP O
27 1373 1382 9245987 cytosines NNS B-NP O
28 1383 1389 9245987 within IN B-PP O
29 1390 1394 9245987 CpGs NNS B-NP O
30 1394 1395 9245987 , , O O
31 1396 1399 9245987 the DT B-NP O
32 1400 1408 9245987 specific JJ I-NP O
33 1409 1414 9245987 codon NN I-NP O
34 1415 1421 9245987 within IN B-PP O
35 1422 1427 9245987 which WDT B-NP O
36 1428 1431 9245987 the DT B-NP O
37 1432 1442 9245987 methylated VBN I-NP O
38 1443 1451 9245987 cytosine NN I-NP O
39 1452 1454 9245987 is VBZ B-VP O
40 1455 1462 9245987 located JJ B-ADJP O
41 1462 1463 9245987 , , O O
42 1464 1467 9245987 and CC O O
43 1468 1471 9245987 the DT B-NP O
44 1472 1482 9245987 particular JJ I-NP O
45 1483 1489 9245987 region NN I-NP O
46 1490 1492 9245987 of IN B-PP O
47 1493 1496 9245987 the DT B-NP O
48 1497 1501 9245987 gene NN I-NP O
49 1502 1508 9245987 within IN B-PP O
50 1509 1514 9245987 which WDT B-NP O
51 1515 1519 9245987 that DT B-NP O
52 1520 1525 9245987 codon NN I-NP O
53 1526 1533 9245987 resides VBZ B-VP O
54 1533 1534 9245987 . . O O
55 1534 1535 9245987 . . O O

1 0 0 9144439 -DOCSTART- -X- -X- O

1 0 7 9144439 Insulin NN B-NP O
2 8 12 9144439 gene NN I-NP O
3 13 19 9144439 region NN I-NP O
4 20 31 9144439 contributes VBZ B-VP O
5 32 34 9144439 to TO B-PP O
6 35 42 9144439 genetic JJ B-NP O
7 43 57 9144439 susceptibility NN I-NP O
8 58 60 9144439 to TO B-PP O
9 60 61 9144439 , , O O
10 62 65 9144439 but CC O O
11 66 69 9144439 may MD B-VP O
12 70 73 9144439 not RB O O
13 74 76 9144439 to TO B-PP O
14 77 80 9144439 low JJ B-NP O
15 81 90 9144439 incidence NN I-NP O
16 91 93 9144439 of IN B-PP O
17 93 94 9144439 , , O O
18 95 102 9144439 insulin NN B-NP B-Disease
19 102 103 9144439 - HYPH B-NP I-Disease
20 103 112 9144439 dependent JJ I-NP I-Disease
21 113 121 9144439 diabetes NN I-NP I-Disease
22 122 130 9144439 mellitus NN I-NP I-Disease
23 131 133 9144439 in IN B-PP O
24 134 142 9144439 Japanese NNPS B-NP O
25 142 143 9144439 . . O O
26 144 146 9144439 In IN B-PP O
27 147 150 9144439 the DT B-NP O
28 151 160 9144439 Caucasian JJ I-NP O
29 161 171 9144439 population NN I-NP O
30 171 172 9144439 , , O O
31 173 175 9144439 it PRP B-NP O
32 176 179 9144439 has VBZ B-VP O
33 180 184 9144439 been VBN I-VP O
34 185 197 9144439 demonstrated VBN I-VP O
35 198 202 9144439 that IN B-SBAR O
36 203 206 9144439 the DT B-NP O
37 207 214 9144439 insulin NN I-NP O
38 215 219 9144439 gene NN I-NP O
39 220 221 9144439 ( ( O O
40 221 224 9144439 INS NN B-NP O
41 224 225 9144439 ) ) O O
42 226 232 9144439 region NN B-NP O
43 233 241 9144439 contains VBZ B-VP O
44 242 245 9144439 the DT B-NP O
45 246 253 9144439 insulin NN I-NP B-Disease
46 253 254 9144439 - HYPH B-NP I-Disease
47 254 263 9144439 dependent JJ I-NP I-Disease
48 264 272 9144439 diabetes NN I-NP I-Disease
49 273 281 9144439 mellitus NN I-NP I-Disease
50 282 287 9144439 locus NN I-NP O
51 288 289 9144439 ( ( O O
52 289 294 9144439 IDDM2 NN B-NP O
53 294 295 9144439 ) ) O O
54 295 296 9144439 . . O O

1 297 299 9144439 In IN B-PP O
2 300 303 9144439 the DT B-NP O
3 304 312 9144439 Japanese JJ I-NP O
4 313 323 9144439 population NN I-NP O
5 323 324 9144439 , , O O
6 325 332 9144439 however RB B-ADVP O
7 332 333 9144439 , , O O
8 334 339 9144439 there EX B-NP O
9 340 343 9144439 has VBZ B-VP O
10 344 348 9144439 been VBN I-VP O
11 349 351 9144439 no DT B-NP O
12 352 358 9144439 report NN I-NP O
13 359 372 9144439 demonstrating VBG B-VP O
14 373 376 9144439 the DT B-NP O
15 377 389 9144439 contribution NN I-NP O
16 390 392 9144439 of IN B-PP O
17 393 398 9144439 IDDM2 NN B-NP O
18 399 401 9144439 to TO B-PP O
19 402 405 9144439 the DT B-NP O
20 406 418 9144439 pathogenesis NN I-NP O
21 419 421 9144439 of IN B-PP O
22 422 426 9144439 IDDM NN B-NP B-Disease
23 426 427 9144439 . . O O

1 428 430 9144439 We PRP B-NP O
2 431 440 9144439 conducted VBD B-VP O
3 441 443 9144439 an DT B-NP O
4 444 455 9144439 association NN I-NP O
5 456 461 9144439 study NN I-NP O
6 462 464 9144439 of IN B-PP O
7 465 469 9144439 IDDM NN B-NP B-Disease
8 470 472 9144439 in IN B-PP O
9 473 474 9144439 a DT B-NP O
10 475 480 9144439 large JJ I-NP O
11 481 487 9144439 number NN I-NP O
12 488 490 9144439 of IN B-PP O
13 491 499 9144439 Japanese JJ B-NP O
14 500 508 9144439 subjects NNS I-NP O
15 509 513 9144439 with IN B-PP O
16 514 522 9144439 multiple JJ B-NP O
17 523 536 9144439 polymorphisms NNS I-NP O
18 537 539 9144439 in IN B-PP O
19 540 543 9144439 INS NN B-NP O
20 544 550 9144439 region NN I-NP O
21 550 551 9144439 . . O O

1 552 554 9144439 We PRP B-NP O
2 555 560 9144439 found VBD B-VP O
3 561 562 9144439 a DT B-NP O
4 563 574 9144439 significant JJ I-NP O
5 575 586 9144439 association NN I-NP O
6 587 589 9144439 of IN B-PP O
7 590 593 9144439 the DT B-NP O
8 594 597 9144439 INS NN I-NP O
9 598 604 9144439 region NN I-NP O
10 605 609 9144439 with IN B-PP O
11 610 614 9144439 IDDM NN B-NP B-Disease
12 614 615 9144439 . . O O

1 616 623 9144439 Alleles NNS B-NP O
2 624 634 9144439 positively RB B-VP O
3 635 645 9144439 associated VBN I-VP O
4 646 650 9144439 with IN B-PP O
5 651 655 9144439 IDDM NN B-NP B-Disease
6 656 658 9144439 in IN B-PP O
7 659 662 9144439 INS NN B-NP O
8 663 669 9144439 region NN I-NP O
9 670 674 9144439 were VBD B-VP O
10 675 678 9144439 the DT B-NP O
11 679 683 9144439 same JJ I-NP O
12 684 686 9144439 as IN B-PP O
13 687 692 9144439 those DT B-NP O
14 693 703 9144439 positively RB B-NP O
15 703 704 9144439 - HYPH I-NP O
16 704 714 9144439 associated VBN B-VP O
17 715 719 9144439 with IN B-PP O
18 720 724 9144439 IDDM NN B-NP B-Disease
19 725 727 9144439 in IN B-PP O
20 728 737 9144439 Caucasian JJ B-NP O
21 738 748 9144439 population NN I-NP O
22 748 749 9144439 , , O O
23 750 758 9144439 although IN B-SBAR O
24 759 769 9144439 positively RB B-ADVP O
25 769 770 9144439 - HYPH O O
26 770 780 9144439 associated VBN B-NP O
27 781 788 9144439 alleles NNS I-NP O
28 789 792 9144439 are VBP B-VP O
29 793 797 9144439 very RB B-ADJP O
30 798 804 9144439 common JJ I-ADJP O
31 805 806 9144439 ( ( O O
32 806 812 9144439 allele NN B-NP O
33 813 824 9144439 frequencies NNS I-NP O
34 825 826 9144439 > SYM O O
35 827 828 9144439 0 CD B-NP O
36 828 829 9144439 . . O O

1 830 831 9144439 9 CD B-NP O
2 831 832 9144439 ) ) O O
3 833 835 9144439 in IN B-PP O
4 836 839 9144439 the DT B-NP O
5 840 848 9144439 Japanese JJ I-NP O
6 849 856 9144439 general JJ I-NP O
7 857 867 9144439 population NN I-NP O
8 867 868 9144439 . . O O

1 869 874 9144439 These DT B-NP O
2 875 879 9144439 data NNS I-NP O
3 880 887 9144439 suggest VBP B-VP O
4 888 892 9144439 that IN B-SBAR O
5 893 898 9144439 IDDM2 NN B-NP O
6 899 901 9144439 is VBZ B-VP O
7 902 910 9144439 involved VBN I-VP O
8 911 913 9144439 in IN B-PP O
9 914 917 9144439 the DT B-NP O
10 918 925 9144439 genetic JJ I-NP O
11 926 940 9144439 susceptibility NN I-NP O
12 941 943 9144439 to TO B-PP O
13 944 948 9144439 IDDM NN B-NP B-Disease
14 949 951 9144439 in IN B-PP O
15 952 960 9144439 Japanese NNPS B-NP O
16 960 961 9144439 . . O O

1 962 965 9144439 The DT B-NP O
2 966 970 9144439 high JJ I-NP O
3 971 982 9144439 frequencies NNS I-NP O
4 983 985 9144439 of IN B-PP O
5 986 993 9144439 disease NN B-NP O
6 993 994 9144439 - HYPH B-NP O
7 994 1004 9144439 associated VBN I-NP O
8 1005 1012 9144439 alleles NNS I-NP O
9 1013 1015 9144439 in IN B-PP O
10 1016 1019 9144439 the DT B-NP O
11 1020 1027 9144439 general JJ I-NP O
12 1028 1038 9144439 population NN I-NP O
13 1039 1046 9144439 suggest VBP B-VP O
14 1047 1051 9144439 that IN B-SBAR O
15 1052 1057 9144439 IDDM2 NN B-NP O
16 1058 1063 9144439 locus NN I-NP O
17 1064 1066 9144439 is VBZ B-VP O
18 1067 1070 9144439 not RB O O
19 1071 1082 9144439 responsible JJ B-ADJP O
20 1083 1086 9144439 for IN B-PP O
21 1087 1090 9144439 the DT B-NP O
22 1091 1094 9144439 low JJ I-NP O
23 1095 1104 9144439 incidence NN I-NP O
24 1105 1107 9144439 of IN B-PP O
25 1108 1112 9144439 IDDM NN B-NP B-Disease
26 1113 1115 9144439 in IN B-PP O
27 1116 1124 9144439 Japanese NNPS B-NP O
28 1124 1125 9144439 . . O O

1 0 0 8755918 -DOCSTART- -X- -X- O

1 0 9 8755918 Mutations NNS B-NP O
2 10 20 8755918 associated VBN B-VP O
3 21 25 8755918 with IN B-PP O
4 26 33 8755918 variant JJ B-NP O
5 34 44 8755918 phenotypes NNS I-NP O
6 45 47 8755918 in IN B-PP O
7 48 54 8755918 ataxia NN B-NP B-Disease
8 54 55 8755918 - HYPH B-NP I-Disease
9 55 69 8755918 telangiectasia NN I-NP I-Disease
10 69 70 8755918 . . O O
11 71 73 8755918 We PRP B-NP O
12 74 78 8755918 have VBP B-VP O
13 79 89 8755918 identified VBN I-VP O
14 90 92 8755918 14 CD B-NP O
15 93 101 8755918 families NNS I-NP O
16 102 106 8755918 with IN B-PP O
17 107 113 8755918 ataxia NN B-NP B-Disease
18 113 114 8755918 - HYPH O I-Disease
19 114 128 8755918 telangiectasia NN B-NP I-Disease
20 129 130 8755918 ( ( O O
21 130 131 8755918 A NN B-NP B-Disease
22 131 132 8755918 - HYPH I-NP I-Disease
23 132 133 8755918 T NN I-NP I-Disease
24 133 134 8755918 ) ) O O
25 135 137 8755918 in IN B-PP O
26 138 143 8755918 which WDT B-NP O
27 144 152 8755918 mutation NN B-NP O
28 153 155 8755918 of IN B-PP O
29 156 159 8755918 the DT B-NP O
30 160 163 8755918 ATM NN I-NP O
31 164 168 8755918 gene NN I-NP O
32 169 171 8755918 is VBZ B-VP O
33 172 182 8755918 associated VBN I-VP O
34 183 187 8755918 with IN B-PP O
35 188 189 8755918 a DT B-NP O
36 190 194 8755918 less RBR I-NP O
37 195 201 8755918 severe JJ I-NP O
38 202 210 8755918 clinical JJ I-NP O
39 211 214 8755918 and CC I-NP O
40 215 223 8755918 cellular JJ I-NP O
41 224 233 8755918 phenotype NN I-NP O
42 234 235 8755918 ( ( O O
43 235 248 8755918 approximately RB B-NP O
44 249 252 8755918 10% CD I-NP O
45 253 254 8755918 - HYPH I-NP O
46 254 257 8755918 15% CD I-NP O
47 258 260 8755918 of IN B-PP O
48 261 262 8755918 A NN B-NP B-Disease
49 262 263 8755918 - HYPH I-NP I-Disease
50 263 264 8755918 T NN I-NP I-Disease
51 265 273 8755918 families NNS I-NP O
52 274 284 8755918 identified VBN B-VP O
53 285 287 8755918 in IN B-PP O
54 288 291 8755918 the DT B-NP O
55 292 298 8755918 United NNP I-NP O
56 299 306 8755918 Kingdom NNP I-NP O
57 306 307 8755918 ) ) O O
58 307 308 8755918 . . O O

1 309 311 8755918 In IN B-PP O
2 312 314 8755918 10 CD B-NP O
3 315 317 8755918 of IN B-PP O
4 318 323 8755918 these DT B-NP O
5 324 332 8755918 families NNS I-NP O
6 332 333 8755918 , , O O
7 334 337 8755918 all PDT B-NP O
8 338 341 8755918 the DT I-NP O
9 342 353 8755918 homozygotes NNS I-NP O
10 354 358 8755918 have VBP B-VP O
11 359 360 8755918 a DT B-NP O
12 361 364 8755918 137 CD I-NP O
13 364 365 8755918 - HYPH I-NP O
14 365 367 8755918 bp NN I-NP O
15 368 377 8755918 insertion NN I-NP O
16 378 380 8755918 in IN B-PP O
17 381 386 8755918 their PRP$ B-NP O
18 387 391 8755918 cDNA NN I-NP O
19 392 398 8755918 caused VBN B-VP O
20 399 401 8755918 by IN B-PP O
21 402 403 8755918 a DT B-NP O
22 404 409 8755918 point NN I-NP O
23 410 418 8755918 mutation NN I-NP O
24 419 421 8755918 in IN B-PP O
25 422 423 8755918 a DT B-NP O
26 424 432 8755918 sequence NN I-NP O
27 433 443 8755918 resembling VBG B-VP O
28 444 445 8755918 a DT B-NP O
29 446 452 8755918 splice NN I-NP O
30 452 453 8755918 - HYPH B-NP O
31 453 458 8755918 donor NN I-NP O
32 459 463 8755918 site NN I-NP O
33 463 464 8755918 . . O O

1 465 468 8755918 The DT B-NP O
2 469 475 8755918 second JJ I-NP O
3 476 477 8755918 A NN I-NP B-Disease
4 477 478 8755918 - HYPH I-NP I-Disease
5 478 479 8755918 T NN I-NP I-Disease
6 480 486 8755918 allele NN I-NP O
7 487 490 8755918 has VBZ B-VP O
8 491 492 8755918 a DT B-NP O
9 493 502 8755918 different JJ I-NP O
10 503 511 8755918 mutation NN I-NP O
11 512 514 8755918 in IN B-PP O
12 515 519 8755918 each DT B-NP O
13 520 527 8755918 patient NN I-NP O
14 527 528 8755918 . . O O

1 529 531 8755918 We PRP B-NP O
2 532 536 8755918 show VBP B-VP O
3 537 541 8755918 that IN B-SBAR O
4 542 545 8755918 the DT B-NP O
5 546 550 8755918 less RBR I-NP O
6 551 557 8755918 severe JJ I-NP O
7 558 567 8755918 phenotype NN I-NP O
8 568 570 8755918 in IN B-PP O
9 571 576 8755918 these DT B-NP O
10 577 585 8755918 patients NNS I-NP O
11 586 588 8755918 is VBZ B-VP O
12 589 595 8755918 caused VBN I-VP O
13 596 598 8755918 by IN B-PP O
14 599 603 8755918 some DT B-NP O
15 604 610 8755918 degree NN I-NP O
16 611 613 8755918 of IN B-PP O
17 614 620 8755918 normal JJ B-NP O
18 621 629 8755918 splicing NN I-NP O
19 629 630 8755918 , , O O
20 631 636 8755918 which WDT B-NP O
21 637 643 8755918 occurs VBZ B-VP O
22 644 646 8755918 as IN B-PP O
23 647 649 8755918 an DT B-NP O
24 650 661 8755918 alternative JJ I-NP O
25 662 669 8755918 product NN I-NP O
26 670 674 8755918 from IN B-PP O
27 675 678 8755918 the DT B-NP O
28 679 688 8755918 insertion NN I-NP O
29 688 689 8755918 - HYPH O O
30 689 699 8755918 containing VBG B-VP O
31 700 706 8755918 allele NN B-NP O
32 706 707 8755918 . . O O

1 708 711 8755918 The DT B-NP O
2 712 717 8755918 level NN I-NP O
3 718 720 8755918 of IN B-PP O
4 721 724 8755918 the DT B-NP O
5 725 728 8755918 137 CD I-NP O
6 728 729 8755918 - HYPH I-NP O
7 729 731 8755918 bp NN I-NP O
8 732 735 8755918 PCR NN I-NP O
9 736 743 8755918 product NN I-NP O
10 744 754 8755918 containing VBG B-VP O
11 755 758 8755918 the DT B-NP O
12 759 768 8755918 insertion NN I-NP O
13 769 772 8755918 was VBD B-VP O
14 773 779 8755918 lowest JJS B-ADJP O
15 780 782 8755918 in IN B-PP O
16 783 786 8755918 two CD B-NP O
17 787 795 8755918 patients NNS I-NP O
18 796 799 8755918 who WP B-NP O
19 800 806 8755918 showed VBD B-VP O
20 807 808 8755918 a DT B-NP O
21 809 814 8755918 later JJ I-NP O
22 815 820 8755918 onset NN I-NP O
23 821 823 8755918 of IN B-PP O
24 824 834 8755918 cerebellar JJ B-NP B-Disease
25 835 841 8755918 ataxia NN I-NP I-Disease
26 841 842 8755918 . . O O

1 843 844 8755918 A DT B-NP O
2 845 852 8755918 further JJ I-NP O
3 853 857 8755918 four CD I-NP O
4 858 866 8755918 families NNS I-NP O
5 867 870 8755918 who WP B-NP O
6 871 873 8755918 do VBP B-VP O
7 874 877 8755918 not RB I-VP O
8 878 882 8755918 have VB I-VP O
9 883 887 8755918 this DT B-NP O
10 888 897 8755918 insertion NN I-NP O
11 898 902 8755918 have VBP B-VP O
12 903 907 8755918 been VBN I-VP O
13 908 918 8755918 identified VBN I-VP O
14 918 919 8755918 . . O O

1 920 929 8755918 Mutations NNS B-NP O
2 930 938 8755918 detected VBN B-VP O
3 939 941 8755918 in IN B-PP O
4 942 945 8755918 two CD B-NP O
5 946 948 8755918 of IN B-PP O
6 949 953 8755918 four CD B-NP O
7 954 956 8755918 of IN B-PP O
8 957 962 8755918 these DT B-NP O
9 963 966 8755918 are VBP B-VP O
10 967 975 8755918 missense JJ B-NP O
11 976 985 8755918 mutations NNS I-NP O
12 985 986 8755918 , , O O
13 987 995 8755918 normally RB B-ADJP O
14 996 1000 8755918 rare JJ I-ADJP O
15 1001 1003 8755918 in IN B-PP O
16 1004 1005 8755918 A NN B-NP B-Disease
17 1005 1006 8755918 - HYPH I-NP I-Disease
18 1006 1007 8755918 T NN I-NP I-Disease
19 1008 1016 8755918 patients NNS I-NP O
20 1016 1017 8755918 . . O O

1 1018 1021 8755918 The DT B-NP O
2 1022 1035 8755918 demonstration NN I-NP O
3 1036 1038 8755918 of IN B-PP O
4 1039 1048 8755918 mutations NNS B-NP O
5 1049 1055 8755918 giving VBG B-VP O
6 1056 1060 8755918 rise NN B-NP O
7 1061 1063 8755918 to TO B-PP O
8 1064 1065 8755918 a DT B-NP O
9 1066 1074 8755918 slightly RB I-NP O
10 1075 1081 8755918 milder JJR I-NP O
11 1082 1091 8755918 phenotype NN I-NP O
12 1092 1094 8755918 in IN B-PP O
13 1095 1096 8755918 A NN B-NP B-Disease
14 1096 1097 8755918 - HYPH O I-Disease
15 1097 1098 8755918 T NN B-NP I-Disease
16 1099 1105 8755918 raises VBZ B-VP O
17 1106 1109 8755918 the DT B-NP O
18 1110 1121 8755918 interesting JJ I-NP O
19 1122 1130 8755918 question NN I-NP O
20 1131 1133 8755918 of IN B-PP O
21 1134 1138 8755918 what WP B-NP O
22 1139 1144 8755918 range NN B-NP O
23 1145 1147 8755918 of IN B-PP O
24 1148 1158 8755918 phenotypes NNS B-NP O
25 1159 1164 8755918 might MD B-VP O
26 1165 1170 8755918 occur VB I-VP O
27 1171 1173 8755918 in IN B-PP O
28 1174 1185 8755918 individuals NNS B-NP O
29 1186 1188 8755918 in IN B-PP O
30 1189 1193 8755918 whom WP B-NP O
31 1194 1198 8755918 both DT B-NP O
32 1199 1208 8755918 mutations NNS I-NP O
33 1209 1212 8755918 are VBP B-VP O
34 1213 1219 8755918 milder JJR B-ADJP O
35 1219 1220 8755918 . . O O

1 1221 1224 8755918 One CD B-NP O
2 1225 1236 8755918 possibility NN I-NP O
3 1237 1242 8755918 might MD B-VP O
4 1243 1245 8755918 be VB I-VP O
5 1246 1250 8755918 that IN B-SBAR O
6 1251 1262 8755918 individuals NNS B-NP O
7 1263 1266 8755918 who WP B-NP O
8 1267 1270 8755918 are VBP B-VP O
9 1271 1279 8755918 compound JJ B-NP O
10 1280 1293 8755918 heterozygotes NNS I-NP O
11 1294 1297 8755918 for IN B-PP O
12 1298 1301 8755918 ATM NN B-NP O
13 1302 1311 8755918 mutations NNS I-NP O
14 1312 1315 8755918 are VBP B-VP O
15 1316 1320 8755918 more RBR B-ADJP O
16 1321 1327 8755918 common JJ I-ADJP O
17 1328 1332 8755918 than IN B-SBAR O
18 1333 1335 8755918 we PRP B-NP O
19 1336 1343 8755918 realize VBP B-VP O
20 1343 1344 8755918 . . O O
21 1344 1345 8755918 . . O O

1 0 0 8696339 -DOCSTART- -X- -X- O

1 0 8 8696339 Cleavage NN B-NP O
2 9 11 8696339 of IN B-PP O
3 12 22 8696339 huntingtin NN B-NP O
4 23 25 8696339 by IN B-PP O
5 26 33 8696339 apopain NN B-NP O
6 33 34 8696339 , , O O
7 35 36 8696339 a DT B-NP O
8 37 49 8696339 proapoptotic JJ I-NP O
9 50 58 8696339 cysteine NN I-NP O
10 59 67 8696339 protease NN I-NP O
11 67 68 8696339 , , O O
12 69 71 8696339 is VBZ B-VP O
13 72 81 8696339 modulated VBN I-VP O
14 82 84 8696339 by IN B-PP O
15 85 88 8696339 the DT B-NP O
16 89 102 8696339 polyglutamine NN I-NP O
17 103 108 8696339 tract NN I-NP O
18 108 109 8696339 . . I-NP O
19 110 119 8696339 Apoptosis NN I-NP O
20 120 123 8696339 has VBZ B-VP O
21 124 132 8696339 recently RB I-VP O
22 133 137 8696339 been VBN I-VP O
23 138 148 8696339 recognized VBN I-VP O
24 149 151 8696339 as IN B-PP O
25 152 153 8696339 a DT B-NP O
26 154 158 8696339 mode NN I-NP O
27 159 161 8696339 of IN B-PP O
28 162 166 8696339 cell NN B-NP O
29 167 172 8696339 death NN I-NP O
30 173 175 8696339 in IN B-PP O
31 176 186 8696339 Huntington NNP B-NP B-Disease
32 187 194 8696339 disease NN I-NP I-Disease
33 195 196 8696339 ( ( O O
34 196 198 8696339 HD NN B-NP B-Disease
35 198 199 8696339 ) ) O O
36 199 200 8696339 . . O O

1 201 208 8696339 Apopain NNP B-NP O
2 208 209 8696339 , , O O
3 210 211 8696339 a DT B-NP O
4 212 217 8696339 human JJ I-NP O
5 218 229 8696339 counterpart NN I-NP O
6 230 232 8696339 of IN B-PP O
7 233 236 8696339 the DT B-NP O
8 237 245 8696339 nematode JJ I-NP O
9 246 254 8696339 cysteine NN I-NP O
10 255 263 8696339 protease NN I-NP O
11 264 269 8696339 death NN I-NP O
12 269 270 8696339 - HYPH B-NP O
13 270 274 8696339 gene NN I-NP O
14 275 282 8696339 product NN I-NP O
15 282 283 8696339 , , O O
16 284 287 8696339 CED VBN B-VP O
17 287 288 8696339 - HYPH B-NP O
18 288 289 8696339 3 CD I-NP O
19 289 290 8696339 , , O O
20 291 294 8696339 has VBZ B-VP O
21 295 296 8696339 a DT B-NP O
22 297 300 8696339 key JJ I-NP O
23 301 305 8696339 role NN I-NP O
24 306 308 8696339 in IN B-PP O
25 309 320 8696339 proteolytic JJ B-NP O
26 321 327 8696339 events NNS I-NP O
27 328 335 8696339 leading VBG B-VP O
28 336 338 8696339 to TO B-PP O
29 339 348 8696339 apoptosis NN B-NP O
30 348 349 8696339 . . O O

1 350 354 8696339 Here RB B-ADVP O
2 355 357 8696339 we PRP B-NP O
3 358 362 8696339 show VBP B-VP O
4 363 367 8696339 that IN B-SBAR O
5 368 377 8696339 apoptotic JJ B-NP O
6 378 386 8696339 extracts NNS I-NP O
7 387 390 8696339 and CC O O
8 391 398 8696339 apopain VB B-VP O
9 399 405 8696339 itself PRP B-NP O
10 406 418 8696339 specifically RB B-ADVP O
11 419 425 8696339 cleave VBP B-VP O
12 426 429 8696339 the DT B-NP O
13 430 432 8696339 HD NN I-NP B-Disease
14 433 437 8696339 gene NN I-NP O
15 438 445 8696339 product NN I-NP O
16 445 446 8696339 , , O O
17 447 457 8696339 huntingtin NN B-NP O
18 457 458 8696339 . . O O

1 459 462 8696339 The DT B-NP O
2 463 467 8696339 rate NN I-NP O
3 468 470 8696339 of IN B-PP O
4 471 479 8696339 cleavage NN B-NP O
5 480 489 8696339 increases VBZ B-VP O
6 490 494 8696339 with IN B-PP O
7 495 498 8696339 the DT B-NP O
8 499 505 8696339 length NN I-NP O
9 506 508 8696339 of IN B-PP O
10 509 512 8696339 the DT B-NP O
11 513 523 8696339 huntingtin NN I-NP O
12 524 537 8696339 polyglutamine NN I-NP O
13 538 543 8696339 tract NN I-NP O
14 543 544 8696339 , , O O
15 545 554 8696339 providing VBG B-VP O
16 555 557 8696339 an DT B-NP O
17 558 569 8696339 explanation NN I-NP O
18 570 573 8696339 for IN B-PP O
19 574 577 8696339 the DT B-NP O
20 578 582 8696339 gain NN I-NP O
21 582 583 8696339 - HYPH B-ADJP O
22 583 585 8696339 of IN B-PP O
23 585 586 8696339 - HYPH B-NP O
24 586 594 8696339 function NN I-NP O
25 595 605 8696339 associated VBN B-VP O
26 606 610 8696339 with IN B-PP O
27 611 614 8696339 CAG NN B-NP O
28 615 624 8696339 expansion NN I-NP O
29 624 625 8696339 . . O O

1 626 629 8696339 Our PRP$ B-NP O
2 630 637 8696339 results NNS I-NP O
3 638 642 8696339 show VBP B-VP O
4 643 647 8696339 that IN B-SBAR O
5 648 658 8696339 huntingtin NN B-NP O
6 659 661 8696339 is VBZ B-VP O
7 662 669 8696339 cleaved VBN I-VP O
8 670 672 8696339 by IN B-PP O
9 673 681 8696339 cysteine NN B-NP O
10 682 691 8696339 proteases NNS I-NP O
11 692 695 8696339 and CC O O
12 696 703 8696339 suggest VBP B-VP O
13 704 708 8696339 that IN B-SBAR O
14 709 711 8696339 HD NN B-NP B-Disease
15 712 717 8696339 might MD B-VP O
16 718 720 8696339 be VB I-VP O
17 721 722 8696339 a DT B-NP O
18 723 731 8696339 disorder NN I-NP B-Disease
19 732 734 8696339 of IN B-PP I-Disease
20 735 748 8696339 inappropriate JJ B-NP I-Disease
21 749 758 8696339 apoptosis NN I-NP I-Disease
22 758 759 8696339 . . O O
23 759 760 8696339 . . O O

1 0 0 9050868 -DOCSTART- -X- -X- O

1 0 4 9050868 Type NN B-NP O
2 5 8 9050868 III CD I-NP O
3 9 17 9050868 collagen NN I-NP O
4 18 20 9050868 is VBZ B-VP O
5 21 28 9050868 crucial JJ B-ADJP O
6 29 32 9050868 for IN B-PP O
7 33 41 9050868 collagen NN B-NP O
8 42 43 9050868 I CD I-NP O
9 44 59 9050868 fibrillogenesis NN I-NP O
10 60 63 9050868 and CC B-PP O
11 64 67 9050868 for IN B-PP O
12 68 74 9050868 normal JJ B-NP O
13 75 89 9050868 cardiovascular JJ I-NP O
14 90 101 9050868 development NN I-NP O
15 101 102 9050868 . . O O
16 103 107 9050868 Type NN B-NP O
17 108 111 9050868 III CD I-NP O
18 112 120 9050868 collagen NN I-NP O
19 121 123 9050868 is VBZ B-VP O
20 124 125 9050868 a DT B-NP O
21 126 135 9050868 fibrillar JJ I-NP O
22 136 143 9050868 forming VBG I-NP O
23 144 152 9050868 collagen NN I-NP O
24 153 163 9050868 comprising VBG B-VP O
25 164 169 9050868 three CD B-NP O
26 170 176 9050868 alpha1 NN I-NP O
27 177 182 9050868 (III) NN I-NP O
28 183 189 9050868 chains NNS I-NP O
29 190 193 9050868 and CC O O
30 194 196 9050868 is VBZ B-VP O
31 197 206 9050868 expressed VBN I-VP O
32 207 209 9050868 in IN B-PP O
33 210 215 9050868 early JJ B-NP O
34 216 223 9050868 embryos NNS I-NP O
35 224 227 9050868 and CC B-PP O
36 228 238 9050868 throughout IN B-PP O
37 239 252 9050868 embryogenesis NN B-NP O
38 252 253 9050868 . . O O

1 254 256 9050868 In IN B-PP O
2 257 260 9050868 the DT B-NP O
3 261 266 9050868 adult NN I-NP O
4 266 267 9050868 , , O O
5 268 272 9050868 type NN B-NP O
6 273 276 9050868 III CD I-NP O
7 277 285 9050868 collagen NN I-NP O
8 286 288 9050868 is VBZ B-VP O
9 289 290 9050868 a DT B-NP O
10 291 296 9050868 major JJ I-NP O
11 297 306 9050868 component NN I-NP O
12 307 309 9050868 of IN B-PP O
13 310 313 9050868 the DT B-NP O
14 314 327 9050868 extracellular JJ I-NP O
15 328 334 9050868 matrix NN I-NP O
16 335 337 9050868 in IN B-PP O
17 338 339 9050868 a DT B-NP O
18 340 347 9050868 variety NN I-NP O
19 348 350 9050868 of IN B-PP O
20 351 359 9050868 internal JJ B-NP O
21 360 366 9050868 organs NNS I-NP O
22 367 370 9050868 and CC I-NP O
23 371 375 9050868 skin NN I-NP O
24 375 376 9050868 . . O O

1 377 386 9050868 Mutations NNS B-NP O
2 387 389 9050868 in IN B-PP O
3 390 393 9050868 the DT B-NP O
4 394 400 9050868 COL3A1 NN I-NP O
5 401 405 9050868 gene NN I-NP O
6 406 410 9050868 have VBP B-VP O
7 411 415 9050868 been VBN I-VP O
8 416 426 9050868 implicated VBN I-VP O
9 427 429 9050868 as IN B-PP O
10 430 431 9050868 a DT B-NP O
11 432 437 9050868 cause NN I-NP O
12 438 440 9050868 of IN B-PP O
13 441 445 9050868 type NN B-NP B-Disease
14 446 448 9050868 IV CD I-NP I-Disease
15 449 455 9050868 Ehlers NNP I-NP I-Disease
16 455 456 9050868 - HYPH I-NP I-Disease
17 456 462 9050868 Danlos NNP I-NP I-Disease
18 463 471 9050868 syndrome NN I-NP I-Disease
19 471 472 9050868 , , O O
20 473 474 9050868 a DT B-NP O
21 475 482 9050868 disease NN I-NP O
22 483 490 9050868 leading VBG B-VP O
23 491 493 9050868 to TO B-PP O
24 494 500 9050868 aortic JJ B-NP B-Disease
25 501 508 9050868 rupture NN I-NP I-Disease
26 509 511 9050868 in IN B-PP O
27 512 517 9050868 early JJ B-NP O
28 518 523 9050868 adult JJ I-NP O
29 524 528 9050868 life NN I-NP O
30 528 529 9050868 . . O O

1 530 532 9050868 To TO B-VP O
2 533 541 9050868 directly RB I-VP O
3 542 547 9050868 study VB I-VP O
4 548 551 9050868 the DT B-NP O
5 552 556 9050868 role NN I-NP O
6 557 559 9050868 of IN B-PP O
7 560 566 9050868 Col3a1 NN B-NP O
8 567 569 9050868 in IN B-PP O
9 570 581 9050868 development NN B-NP O
10 582 585 9050868 and CC I-NP O
11 586 593 9050868 disease NN I-NP O
12 593 594 9050868 , , O O
13 595 597 9050868 we PRP B-NP O
14 598 602 9050868 have VBP B-VP O
15 603 614 9050868 inactivated VBN I-VP O
16 615 618 9050868 the DT B-NP O
17 619 625 9050868 Col3a1 NN I-NP O
18 626 630 9050868 gene NN I-NP O
19 631 633 9050868 in IN B-PP O
20 634 643 9050868 embryonic JJ B-NP O
21 644 648 9050868 stem NN I-NP O
22 649 654 9050868 cells NNS I-NP O
23 655 657 9050868 by IN B-PP O
24 658 668 9050868 homologous JJ B-NP O
25 669 682 9050868 recombination NN I-NP O
26 682 683 9050868 . . O O

1 684 687 9050868 The DT B-NP O
2 688 695 9050868 mutated VBN I-NP O
3 696 702 9050868 allele NN I-NP O
4 703 706 9050868 was VBD B-VP O
5 707 718 9050868 transmitted VBN I-VP O
6 719 726 9050868 through IN B-PP O
7 727 730 9050868 the DT B-NP O
8 731 736 9050868 mouse NN I-NP O
9 737 741 9050868 germ NN I-NP O
10 742 746 9050868 line NN I-NP O
11 747 750 9050868 and CC O O
12 751 761 9050868 homozygous JJ B-NP O
13 762 768 9050868 mutant JJ I-NP O
14 769 776 9050868 animals NNS I-NP O
15 777 781 9050868 were VBD B-VP O
16 782 789 9050868 derived VBN I-VP O
17 790 794 9050868 from IN B-PP O
18 795 807 9050868 heterozygous JJ B-NP O
19 808 820 9050868 intercrosses NNS I-NP O
20 820 821 9050868 . . O O

1 822 827 9050868 About IN B-NP O
2 828 831 9050868 10% CD I-NP O
3 832 834 9050868 of IN B-PP O
4 835 838 9050868 the DT B-NP O
5 839 849 9050868 homozygous JJ I-NP O
6 850 856 9050868 mutant JJ I-NP O
7 857 864 9050868 animals NNS I-NP O
8 865 873 9050868 survived VBD B-VP O
9 874 876 9050868 to TO B-PP O
10 877 886 9050868 adulthood NN B-NP O
11 887 890 9050868 but CC O O
12 891 895 9050868 have VBP B-VP O
13 896 897 9050868 a DT B-NP O
14 898 902 9050868 much RB I-NP O
15 903 910 9050868 shorter JJR I-NP O
16 911 915 9050868 life NN I-NP O
17 916 920 9050868 span NN I-NP O
18 921 929 9050868 compared VBN B-PP O
19 930 934 9050868 with IN B-PP O
20 935 939 9050868 wild JJ B-NP O
21 939 940 9050868 - HYPH I-NP O
22 940 944 9050868 type NN I-NP O
23 945 949 9050868 mice NNS I-NP O
24 949 950 9050868 . . O O

1 951 954 9050868 The DT B-NP O
2 955 960 9050868 major JJ I-NP O
3 961 966 9050868 cause NN I-NP O
4 967 969 9050868 of IN B-PP O
5 970 975 9050868 death NN B-NP O
6 976 978 9050868 of IN B-PP O
7 979 985 9050868 mutant JJ B-NP O
8 986 990 9050868 mice NNS I-NP O
9 991 994 9050868 was VBD B-VP O
10 995 1002 9050868 rupture NN B-NP O
11 1003 1005 9050868 of IN B-PP O
12 1006 1009 9050868 the DT B-NP O
13 1010 1015 9050868 major JJ I-NP O
14 1016 1021 9050868 blood NN I-NP O
15 1022 1029 9050868 vessels NNS I-NP O
16 1029 1030 9050868 , , O O
17 1031 1038 9050868 similar JJ B-ADJP O
18 1039 1041 9050868 to TO B-PP O
19 1042 1050 9050868 patients NNS B-NP O
20 1051 1055 9050868 with IN B-PP O
21 1056 1060 9050868 type NN B-NP B-Disease
22 1061 1063 9050868 IV CD I-NP I-Disease
23 1064 1070 9050868 Ehlers NNP I-NP I-Disease
24 1070 1071 9050868 - HYPH I-NP I-Disease
25 1071 1077 9050868 Danlos NNP I-NP I-Disease
26 1078 1086 9050868 syndrome NN I-NP I-Disease
27 1086 1087 9050868 . . O O

1 1088 1103 9050868 Ultrastructural JJ B-NP O
2 1104 1112 9050868 analysis NN I-NP O
3 1113 1115 9050868 of IN B-PP O
4 1116 1123 9050868 tissues NNS B-NP O
5 1124 1128 9050868 from IN B-PP O
6 1129 1135 9050868 mutant JJ B-NP O
7 1136 1140 9050868 mice NNS I-NP O
8 1141 1149 9050868 revealed VBD B-VP O
9 1150 1154 9050868 that IN B-SBAR O
10 1155 1159 9050868 type NN B-NP O
11 1160 1163 9050868 III CD I-NP O
12 1164 1172 9050868 collagen NN I-NP O
13 1173 1175 9050868 is VBZ B-VP O
14 1176 1185 9050868 essential JJ B-ADJP O
15 1186 1189 9050868 for IN B-PP O
16 1190 1196 9050868 normal JJ B-NP O
17 1197 1205 9050868 collagen NN I-NP O
18 1206 1207 9050868 I CD I-NP O
19 1208 1223 9050868 fibrillogenesis NN I-NP O
20 1224 1226 9050868 in IN B-PP O
21 1227 1230 9050868 the DT B-NP O
22 1231 1245 9050868 cardiovascular JJ I-NP O
23 1246 1252 9050868 system NN I-NP O
24 1253 1256 9050868 and CC O O
25 1257 1262 9050868 other JJ B-NP O
26 1263 1269 9050868 organs NNS I-NP O
27 1269 1270 9050868 . . O O
28 1270 1271 9050868 . . O O

1 0 0 8833159 -DOCSTART- -X- -X- O

1 0 4 8833159 Exon NN B-NP O
2 4 5 8833159 - HYPH I-NP O
3 5 11 8833159 intron NN I-NP O
4 12 21 8833159 structure NN I-NP O
5 22 24 8833159 of IN B-PP O
6 25 28 8833159 the DT B-NP O
7 29 34 8833159 human JJ I-NP O
8 35 43 8833159 neuronal JJ I-NP O
9 44 53 8833159 nicotinic JJ I-NP O
10 54 67 8833159 acetylcholine NN I-NP O
11 68 76 8833159 receptor NN I-NP O
12 77 82 8833159 alpha NN I-NP O
13 83 84 8833159 4 CD I-NP O
14 85 92 8833159 subunit NN I-NP O
15 93 94 8833159 ( ( O O
16 94 100 8833159 CHRNA4 NN B-NP O
17 100 101 8833159 ) ) O O
18 101 102 8833159 . . O O
19 103 106 8833159 The DT B-NP O
20 107 112 8833159 human JJ I-NP O
21 113 121 8833159 neuronal JJ I-NP O
22 122 131 8833159 nicotinic JJ I-NP O
23 132 145 8833159 acetylcholine NN I-NP O
24 146 154 8833159 receptor NN I-NP O
25 155 160 8833159 alpha NN I-NP O
26 161 162 8833159 4 CD I-NP O
27 163 170 8833159 subunit NN I-NP O
28 171 175 8833159 gene NN I-NP O
29 176 177 8833159 ( ( O O
30 177 183 8833159 CHRNA4 NN B-NP O
31 183 184 8833159 ) ) O O
32 185 187 8833159 is VBZ B-VP O
33 188 195 8833159 located VBN I-VP O
34 196 198 8833159 in IN B-PP O
35 199 202 8833159 the DT B-NP O
36 203 212 8833159 candidate NN I-NP O
37 213 219 8833159 region NN I-NP O
38 220 223 8833159 for IN B-PP O
39 224 229 8833159 three CD B-NP O
40 230 239 8833159 different JJ I-NP O
41 240 250 8833159 phenotypes NNS I-NP O
42 252 258 8833159 benign JJ B-NP B-Disease
43 259 267 8833159 familial JJ I-NP I-Disease
44 268 276 8833159 neonatal JJ I-NP I-Disease
45 277 288 8833159 convulsions NNS I-NP I-Disease
46 288 289 8833159 , , O O
47 290 299 8833159 autosomal JJ B-NP B-Disease
48 300 308 8833159 dominant JJ I-NP I-Disease
49 309 318 8833159 nocturnal JJ I-NP I-Disease
50 319 326 8833159 frontal JJ I-NP I-Disease
51 327 331 8833159 lobe NN I-NP I-Disease
52 332 340 8833159 epilepsy NN I-NP I-Disease
53 340 341 8833159 , , O O
54 342 345 8833159 and CC O O
55 346 349 8833159 low JJ B-NP O
56 349 350 8833159 - HYPH I-NP O
57 350 357 8833159 voltage NN I-NP O
58 358 361 8833159 EEG NN I-NP O
59 361 362 8833159 . . O O

1 363 371 8833159 Recently RB B-ADVP O
2 371 372 8833159 , , O O
3 373 374 8833159 a DT B-NP O
4 375 383 8833159 missense JJ I-NP O
5 384 392 8833159 mutation NN I-NP O
6 393 395 8833159 in IN B-PP O
7 396 409 8833159 transmembrane NN B-NP O
8 410 416 8833159 domain NN I-NP O
9 417 418 8833159 2 CD I-NP O
10 419 421 8833159 of IN B-PP O
11 422 428 8833159 CHRNA4 NN B-NP O
12 429 432 8833159 was VBD B-VP O
13 433 438 8833159 found VBN I-VP O
14 439 441 8833159 to TO I-VP O
15 442 444 8833159 be VB I-VP O
16 445 455 8833159 associated VBN I-VP O
17 456 460 8833159 with IN B-PP O
18 461 470 8833159 autosomal JJ B-NP B-Disease
19 471 479 8833159 dominant JJ I-NP I-Disease
20 480 489 8833159 nocturnal JJ I-NP I-Disease
21 490 497 8833159 frontal JJ I-NP I-Disease
22 498 502 8833159 lobe NN I-NP I-Disease
23 503 511 8833159 epilepsy NN I-NP I-Disease
24 512 514 8833159 in IN B-PP O
25 515 518 8833159 one CD B-NP O
26 519 527 8833159 extended VBN I-NP O
27 528 536 8833159 pedigree NN I-NP O
28 536 537 8833159 . . O O

1 538 540 8833159 We PRP B-NP O
2 541 545 8833159 have VBP B-VP O
3 546 556 8833159 determined VBN I-VP O
4 557 560 8833159 the DT B-NP O
5 561 568 8833159 genomic JJ I-NP O
6 569 581 8833159 organization NN I-NP O
7 582 584 8833159 of IN B-PP O
8 585 591 8833159 CHRNA4 NN B-NP O
9 591 592 8833159 , , O O
10 593 598 8833159 which WDT B-NP O
11 599 607 8833159 consists VBZ B-VP O
12 608 610 8833159 of IN B-PP O
13 611 614 8833159 six CD B-NP O
14 615 620 8833159 exons NNS I-NP O
15 621 632 8833159 distributed VBN B-VP O
16 633 637 8833159 over IN B-PP O
17 638 651 8833159 approximately RB B-NP O
18 652 654 8833159 17 CD I-NP O
19 655 657 8833159 kb NN I-NP O
20 658 660 8833159 of IN B-PP O
21 661 668 8833159 genomic JJ B-NP O
22 669 672 8833159 DNA NN I-NP O
23 672 673 8833159 . . O O

1 674 677 8833159 The DT B-NP O
2 678 688 8833159 nucleotide NN I-NP O
3 689 697 8833159 sequence NN I-NP O
4 698 706 8833159 obtained VBN B-VP O
5 707 711 8833159 from IN B-PP O
6 712 715 8833159 the DT B-NP O
7 716 723 8833159 genomic JJ I-NP O
8 724 731 8833159 regions NNS I-NP O
9 732 740 8833159 adjacent JJ B-ADJP O
10 741 743 8833159 to TO B-PP O
11 744 747 8833159 the DT B-NP O
12 748 752 8833159 exon NN I-NP O
13 753 763 8833159 boundaries NNS I-NP O
14 764 771 8833159 enabled VBD B-VP O
15 772 774 8833159 us PRP B-NP O
16 775 777 8833159 to TO B-VP O
17 778 785 8833159 develop VB I-VP O
18 786 787 8833159 a DT B-NP O
19 788 791 8833159 set NN I-NP O
20 792 794 8833159 of IN B-PP O
21 795 801 8833159 primer NN B-NP O
22 802 807 8833159 pairs NNS I-NP O
23 808 811 8833159 for IN B-PP O
24 812 815 8833159 PCR NN B-NP O
25 816 829 8833159 amplification NN I-NP O
26 830 832 8833159 of IN B-PP O
27 833 836 8833159 the DT B-NP O
28 837 845 8833159 complete JJ I-NP O
29 846 852 8833159 coding VBG I-NP O
30 853 859 8833159 region NN I-NP O
31 859 860 8833159 . . O O

1 861 864 8833159 The DT B-NP O
2 865 873 8833159 sequence NN I-NP O
3 874 882 8833159 analysis NN I-NP O
4 883 891 8833159 provides VBZ B-VP O
5 892 895 8833159 the DT B-NP O
6 896 901 8833159 basis NN I-NP O
7 902 905 8833159 for IN B-PP O
8 906 907 8833159 a DT B-NP O
9 908 921 8833159 comprehensive JJ I-NP O
10 922 930 8833159 mutation NN I-NP O
11 931 940 8833159 screening NN I-NP O
12 941 943 8833159 of IN B-PP O
13 944 950 8833159 CHRNA4 NN B-NP O
14 951 953 8833159 in IN B-PP O
15 954 957 8833159 the DT B-NP O
16 958 963 8833159 above RB I-NP O
17 963 964 8833159 - HYPH I-NP O
18 964 973 8833159 mentioned VBN I-NP O
19 974 984 8833159 phenotypes NNS I-NP O
20 985 988 8833159 and CC O O
21 989 997 8833159 possibly RB B-ADVP O
22 998 1000 8833159 in IN B-PP O
23 1001 1006 8833159 other JJ B-NP O
24 1007 1012 8833159 types NNS I-NP O
25 1013 1015 8833159 of IN B-PP O
26 1016 1026 8833159 idiopathic JJ B-NP B-Disease
27 1027 1037 8833159 epilepsies NNS I-NP I-Disease
28 1037 1038 8833159 . . O O
29 1038 1039 8833159 . . O O

1 0 0 8595416 -DOCSTART- -X- -X- O

1 0 1 8595416 A DT B-NP O
2 2 7 8595416 novel JJ I-NP O
3 8 19 8595416 homeodomain NN I-NP O
4 19 20 8595416 - HYPH O O
5 20 28 8595416 encoding VBG B-VP O
6 29 33 8595416 gene NN B-NP O
7 34 36 8595416 is VBZ B-VP O
8 37 47 8595416 associated VBN I-VP O
9 48 52 8595416 with IN B-PP O
10 53 54 8595416 a DT B-NP O
11 55 60 8595416 large JJ I-NP O
12 61 64 8595416 CpG NN I-NP O
13 65 71 8595416 island NN I-NP O
14 72 83 8595416 interrupted VBN B-VP O
15 84 86 8595416 by IN B-PP O
16 87 90 8595416 the DT B-NP O
17 91 99 8595416 myotonic JJ I-NP B-Disease
18 100 109 8595416 dystrophy NN I-NP I-Disease
19 110 118 8595416 unstable JJ I-NP O
20 119 125 8595416 (CTG)n NN I-NP O
21 126 132 8595416 repeat NN I-NP O
22 132 133 8595416 . . O O
23 134 142 8595416 Myotonic JJ B-NP B-Disease
24 143 152 8595416 dystrophy NN I-NP I-Disease
25 153 154 8595416 ( ( O O
26 154 156 8595416 DM NN B-NP B-Disease
27 156 157 8595416 ) ) O O
28 158 160 8595416 is VBZ B-VP O
29 161 171 8595416 associated VBN I-VP O
30 172 176 8595416 with IN B-PP O
31 177 178 8595416 a DT B-NP O
32 179 180 8595416 ( ( O O
33 180 183 8595416 CTG NN O O
34 183 184 8595416 ) ) O O
35 185 186 8595416 n NN B-NP O
36 187 200 8595416 trinucleotide NN I-NP O
37 201 207 8595416 repeat NN I-NP O
38 208 217 8595416 expansion NN I-NP O
39 218 220 8595416 in IN B-PP O
40 221 224 8595416 the DT B-NP O
41 225 226 8595416 3 CD I-NP O
42 226 227 8595416 - HYPH I-NP O
43 227 239 8595416 untranslated JJ I-NP O
44 240 246 8595416 region NN I-NP O
45 247 249 8595416 of IN B-PP O
46 250 251 8595416 a DT B-NP O
47 252 259 8595416 protein NN I-NP O
48 260 266 8595416 kinase NN I-NP O
49 266 267 8595416 - HYPH O O
50 267 275 8595416 encoding VBG B-VP O
51 276 280 8595416 gene NN B-NP O
52 280 281 8595416 , , O O
53 282 286 8595416 DMPK NN B-NP O
54 286 287 8595416 , , O O
55 288 293 8595416 which WDT B-NP O
56 294 298 8595416 maps VBZ B-VP O
57 299 301 8595416 to TO B-PP O
58 302 312 8595416 chromosome NN B-NP O
59 313 318 8595416 19q13 CD I-NP O
60 318 319 8595416 . . O O

1 320 321 8595416 3 LS B-LST O
2 321 322 8595416 . . O O

1 323 339 8595416 Characterisation NN B-NP O
2 340 342 8595416 of IN B-PP O
3 343 346 8595416 the DT B-NP O
4 347 357 8595416 expression NN I-NP O
5 358 360 8595416 of IN B-PP O
6 361 365 8595416 this DT B-NP O
7 366 370 8595416 gene NN I-NP O
8 371 373 8595416 in IN B-PP O
9 374 381 8595416 patient NN B-NP O
10 382 389 8595416 tissues NNS I-NP O
11 390 393 8595416 has VBZ B-VP O
12 394 398 8595416 thus RB I-VP O
13 399 402 8595416 far RB I-VP O
14 403 412 8595416 generated VBN I-VP O
15 413 424 8595416 conflicting VBG B-VP O
16 425 429 8595416 data NNS B-NP O
17 430 432 8595416 on IN B-PP O
18 433 444 8595416 alterations NNS B-NP O
19 445 447 8595416 in IN B-PP O
20 448 451 8595416 the DT B-NP O
21 452 458 8595416 steady JJ I-NP O
22 459 464 8595416 state NN I-NP O
23 465 471 8595416 levels NNS I-NP O
24 472 474 8595416 of IN B-PP O
25 475 479 8595416 DMPK NN B-NP O
26 480 484 8595416 mRNA NN I-NP O
27 484 485 8595416 , , O O
28 486 489 8595416 and CC O O
29 490 492 8595416 on IN B-PP O
30 493 496 8595416 the DT B-NP O
31 497 502 8595416 final JJ I-NP O
32 503 507 8595416 DMPK NN I-NP O
33 508 515 8595416 protein NN I-NP O
34 516 522 8595416 levels NNS I-NP O
35 523 525 8595416 in IN B-PP O
36 526 529 8595416 the DT B-NP O
37 530 538 8595416 presence NN I-NP O
38 539 541 8595416 of IN B-PP O
39 542 545 8595416 the DT B-NP O
40 546 555 8595416 expansion NN I-NP O
41 555 556 8595416 . . O O

1 557 560 8595416 The DT B-NP O
2 561 563 8595416 DM NN I-NP B-Disease
3 564 570 8595416 region NN I-NP O
4 571 573 8595416 of IN B-PP O
5 574 584 8595416 chromosome NN B-NP O
6 585 587 8595416 19 CD I-NP O
7 588 590 8595416 is VBZ B-VP O
8 591 595 8595416 gene NN B-NP O
9 596 600 8595416 rich JJ I-NP O
10 600 601 8595416 , , O O
11 602 605 8595416 and CC O O
12 606 608 8595416 it PRP B-NP O
13 609 611 8595416 is VBZ B-VP O
14 612 620 8595416 possible JJ B-ADJP O
15 621 625 8595416 that IN B-SBAR O
16 626 629 8595416 the DT B-NP O
17 630 636 8595416 repeat NN I-NP O
18 637 646 8595416 expansion NN I-NP O
19 647 650 8595416 may MD B-VP O
20 651 655 8595416 lead VB I-VP O
21 656 658 8595416 to TO B-PP O
22 659 670 8595416 dysfunction NN B-NP O
23 671 673 8595416 of IN B-PP O
24 674 675 8595416 a DT B-NP O
25 676 682 8595416 number NN I-NP O
26 683 685 8595416 of IN B-PP O
27 686 699 8595416 transcription NN B-NP O
28 700 705 8595416 units NNS I-NP O
29 706 708 8595416 in IN B-PP O
30 709 712 8595416 the DT B-NP O
31 713 721 8595416 vicinity NN I-NP O
32 721 722 8595416 , , O O
33 723 730 8595416 perhaps RB B-ADVP O
34 731 733 8595416 as IN B-PP O
35 734 735 8595416 a DT B-NP O
36 736 747 8595416 consequence NN I-NP O
37 748 750 8595416 of IN B-PP O
38 751 760 8595416 chromatin NN B-NP O
39 761 771 8595416 disruption NN I-NP O
40 771 772 8595416 . . O O

1 773 775 8595416 We PRP B-NP O
2 776 780 8595416 have VBP B-VP O
3 781 789 8595416 searched VBN I-VP O
4 790 793 8595416 for IN B-PP O
5 794 799 8595416 genes NNS B-NP O
6 800 810 8595416 associated VBN B-VP O
7 811 815 8595416 with IN B-PP O
8 816 817 8595416 a DT B-NP O
9 818 821 8595416 CpG NN I-NP O
10 822 828 8595416 island NN I-NP O
11 829 831 8595416 at IN B-PP O
12 832 835 8595416 the DT B-NP O
13 836 837 8595416 3 CD I-NP O
14 838 841 8595416 end NN I-NP O
15 842 844 8595416 of IN B-PP O
16 845 849 8595416 DMPK NN B-NP O
17 849 850 8595416 . . O O

1 851 861 8595416 Sequencing NN B-NP O
2 862 864 8595416 of IN B-PP O
3 865 869 8595416 this DT B-NP O
4 870 876 8595416 region NN I-NP O
5 877 882 8595416 shows VBZ B-VP O
6 883 887 8595416 that IN B-SBAR O
7 888 891 8595416 the DT B-NP O
8 892 898 8595416 island NN I-NP O
9 899 906 8595416 extends VBZ B-VP O
10 907 911 8595416 over IN B-NP O
11 912 913 8595416 3 CD I-NP O
12 913 914 8595416 . . I-NP O
13 915 916 8595416 5 CD I-NP O
14 917 919 8595416 kb NN I-NP O
15 920 923 8595416 and CC O O
16 924 926 8595416 is VBZ B-VP O
17 927 938 8595416 interrupted VBN I-VP O
18 939 941 8595416 by IN B-PP O
19 942 945 8595416 the DT B-NP O
20 946 947 8595416 ( ( O O
21 947 950 8595416 CTG NN O O
22 950 951 8595416 ) ) O O
23 952 953 8595416 n NN B-NP O
24 954 960 8595416 repeat NN I-NP O
25 960 961 8595416 . . O O

1 962 972 8595416 Comparison NN B-NP O
2 973 975 8595416 of IN B-PP O
3 976 983 8595416 genomic JJ B-NP O
4 984 993 8595416 sequences NNS I-NP O
5 994 1004 8595416 downstream JJ B-ADJP O
6 1005 1006 8595416 ( ( O O
7 1006 1017 8595416 centromeric JJ B-ADJP O
8 1017 1018 8595416 ) ) O O
9 1019 1021 8595416 of IN B-PP O
10 1022 1025 8595416 the DT B-NP O
11 1026 1032 8595416 repeat NN I-NP O
12 1033 1035 8595416 in IN B-PP O
13 1036 1041 8595416 human JJ O O
14 1042 1045 8595416 and CC O O
15 1046 1051 8595416 mouse NN B-NP O
16 1052 1062 8595416 identified VBD B-VP O
17 1063 1070 8595416 regions NNS B-NP O
18 1071 1073 8595416 of IN B-PP O
19 1074 1085 8595416 significant JJ B-NP O
20 1086 1094 8595416 homology NN I-NP O
21 1094 1095 8595416 . . O O

1 1096 1101 8595416 These DT B-NP O
2 1102 1112 8595416 correspond VBP B-VP O
3 1113 1115 8595416 to TO B-PP O
4 1116 1121 8595416 exons NNS B-NP O
5 1122 1124 8595416 of IN B-PP O
6 1125 1126 8595416 a DT B-NP O
7 1127 1131 8595416 gene NN I-NP O
8 1132 1141 8595416 predicted VBN B-VP O
9 1142 1144 8595416 to TO B-VP O
10 1145 1151 8595416 encode VB I-VP O
11 1152 1153 8595416 a DT B-NP O
12 1154 1165 8595416 homeodomain NN I-NP O
13 1166 1173 8595416 protein NN I-NP O
14 1173 1174 8595416 . . O O

1 1175 1177 8595416 RT NN B-NP O
2 1177 1178 8595416 - HYPH I-NP O
3 1178 1181 8595416 PCR NN I-NP O
4 1182 1190 8595416 analysis NN I-NP O
5 1191 1196 8595416 shows VBZ B-VP O
6 1197 1201 8595416 that IN B-SBAR O
7 1202 1206 8595416 this DT B-NP O
8 1207 1211 8595416 gene NN I-NP O
9 1211 1212 8595416 , , O O
10 1213 1218 8595416 which WDT B-NP O
11 1219 1221 8595416 we PRP B-NP O
12 1222 1226 8595416 have VBP B-VP O
13 1227 1233 8595416 called VBN I-VP O
14 1234 1236 8595416 DM NN B-NP B-Disease
15 1237 1242 8595416 locus NN I-NP O
16 1242 1243 8595416 - HYPH B-VP O
17 1243 1253 8595416 associated VBN B-NP O
18 1254 1265 8595416 homeodomain NN I-NP O
19 1266 1273 8595416 protein NN I-NP O
20 1274 1275 8595416 ( ( O O
21 1275 1280 8595416 DMAHP NN B-NP O
22 1280 1281 8595416 ) ) O O
23 1281 1282 8595416 , , O O
24 1283 1285 8595416 is VBZ B-VP O
25 1286 1295 8595416 expressed VBN I-VP O
26 1296 1298 8595416 in IN B-PP O
27 1299 1300 8595416 a DT B-NP O
28 1301 1307 8595416 number NN I-NP O
29 1308 1310 8595416 of IN B-PP O
30 1311 1316 8595416 human JJ B-NP O
31 1317 1324 8595416 tissues NNS I-NP O
32 1324 1325 8595416 , , O O
33 1326 1335 8595416 including VBG B-PP O
34 1336 1344 8595416 skeletal JJ B-NP O
35 1345 1351 8595416 muscle NN I-NP O
36 1351 1352 8595416 , , I-NP O
37 1353 1358 8595416 heart NN I-NP O
38 1359 1362 8595416 and CC I-NP O
39 1363 1368 8595416 brain NN I-NP O
40 1368 1369 8595416 . . O O

1 0 0 9050866 -DOCSTART- -X- -X- O

1 0 3 9050866 The DT B-NP O
2 4 10 9050866 ataxia NN I-NP B-Disease
3 10 11 9050866 - HYPH I-NP I-Disease
4 11 25 9050866 telangiectasia NN I-NP I-Disease
5 26 30 9050866 gene NN I-NP O
6 31 38 9050866 product NN I-NP O
7 38 39 9050866 , , O O
8 40 41 9050866 a DT B-NP O
9 42 56 9050866 constitutively RB I-NP O
10 57 66 9050866 expressed VBN I-NP O
11 67 74 9050866 nuclear JJ I-NP O
12 75 82 9050866 protein NN I-NP O
13 83 87 9050866 that WDT B-NP O
14 88 90 9050866 is VBZ B-VP O
15 91 94 9050866 not RB O O
16 95 97 9050866 up RB B-ADVP O
17 97 98 9050866 - HYPH B-NP O
18 98 107 9050866 regulated VBN B-VP O
19 108 117 9050866 following VBG B-PP O
20 118 124 9050866 genome NN B-NP O
21 125 131 9050866 damage NN I-NP O
22 131 132 9050866 . . O O
23 133 136 9050866 The DT B-NP O
24 137 144 9050866 product NN I-NP O
25 145 147 9050866 of IN B-PP O
26 148 151 9050866 the DT B-NP O
27 152 158 9050866 ataxia NN I-NP B-Disease
28 158 159 9050866 - HYPH B-NP I-Disease
29 159 173 9050866 telangiectasia NN I-NP I-Disease
30 174 178 9050866 gene NN I-NP O
31 179 180 9050866 ( ( O O
32 180 183 9050866 ATM NN B-NP O
33 183 184 9050866 ) ) O O
34 185 188 9050866 was VBD B-VP O
35 189 199 9050866 identified VBN I-VP O
36 200 202 9050866 by IN B-PP O
37 203 208 9050866 using VBG B-VP O
38 209 211 9050866 an DT B-NP O
39 212 221 9050866 antiserum NN I-NP O
40 222 231 9050866 developed VBN B-VP O
41 232 234 9050866 to TO B-PP O
42 235 236 9050866 a DT B-NP O
43 237 244 9050866 peptide NN I-NP O
44 245 258 9050866 corresponding VBG B-VP O
45 259 261 9050866 to TO B-PP O
46 262 265 9050866 the DT B-NP O
47 266 273 9050866 deduced VBN I-NP O
48 274 279 9050866 amino JJ I-NP O
49 280 284 9050866 acid NN I-NP O
50 285 293 9050866 sequence NN I-NP O
51 293 294 9050866 . . O O

1 295 298 9050866 The DT B-NP O
2 299 302 9050866 ATM NN I-NP O
3 303 310 9050866 protein NN I-NP O
4 311 313 9050866 is VBZ B-VP O
5 314 315 9050866 a DT B-NP O
6 316 322 9050866 single JJ I-NP O
7 322 323 9050866 , , I-NP O
8 324 328 9050866 high JJ I-NP O
9 328 329 9050866 - HYPH I-NP O
10 329 338 9050866 molecular JJ I-NP O
11 339 345 9050866 weight NN I-NP O
12 346 353 9050866 protein NN I-NP O
13 354 367 9050866 predominantly RB B-VP O
14 368 376 9050866 confined VBN I-VP O
15 377 379 9050866 to TO B-PP O
16 380 383 9050866 the DT B-NP O
17 384 391 9050866 nucleus NN I-NP O
18 392 394 9050866 of IN B-PP O
19 395 400 9050866 human JJ B-NP O
20 401 412 9050866 fibroblasts NNS I-NP O
21 412 413 9050866 , , O O
22 414 417 9050866 but CC O O
23 418 420 9050866 is VBZ B-VP O
24 421 428 9050866 present JJ B-ADJP O
25 429 431 9050866 in IN B-PP O
26 432 436 9050866 both CC B-NP O
27 437 444 9050866 nuclear JJ I-NP O
28 445 448 9050866 and CC I-NP O
29 449 459 9050866 microsomal JJ I-NP O
30 460 469 9050866 fractions NNS I-NP O
31 470 474 9050866 from IN B-PP O
32 475 480 9050866 human JJ B-NP O
33 481 492 9050866 lymphoblast NN I-NP O
34 493 498 9050866 cells NNS I-NP O
35 499 502 9050866 and CC O O
36 503 513 9050866 peripheral JJ B-NP O
37 514 519 9050866 blood NN I-NP O
38 520 531 9050866 lymphocytes NNS I-NP O
39 531 532 9050866 . . O O

1 533 536 9050866 ATM NN B-NP O
2 537 544 9050866 protein NN I-NP O
3 545 551 9050866 levels NNS I-NP O
4 552 555 9050866 and CC O O
5 556 568 9050866 localization NN B-NP O
6 569 575 9050866 remain VBP B-VP O
7 576 584 9050866 constant JJ B-ADJP O
8 585 595 9050866 throughout IN B-PP O
9 596 599 9050866 all DT B-NP O
10 600 606 9050866 stages NNS I-NP O
11 607 609 9050866 of IN B-PP O
12 610 613 9050866 the DT B-NP O
13 614 618 9050866 cell NN I-NP O
14 619 624 9050866 cycle NN I-NP O
15 624 625 9050866 . . O O

1 626 635 9050866 Truncated VBN B-NP O
2 636 639 9050866 ATM NN I-NP O
3 640 647 9050866 protein NN I-NP O
4 648 651 9050866 was VBD B-VP O
5 652 655 9050866 not RB I-VP O
6 656 664 9050866 detected VBN I-VP O
7 665 667 9050866 in IN B-PP O
8 668 680 9050866 lymphoblasts NNS B-NP O
9 681 685 9050866 from IN B-PP O
10 686 692 9050866 ataxia NN B-NP B-Disease
11 692 693 9050866 - HYPH B-PP I-Disease
12 693 707 9050866 telangiectasia NN B-NP I-Disease
13 708 716 9050866 patients NNS I-NP O
14 717 727 9050866 homozygous JJ B-ADJP O
15 728 731 9050866 for IN B-PP O
16 732 741 9050866 mutations NNS B-NP O
17 742 749 9050866 leading VBG B-VP O
18 750 752 9050866 to TO B-PP O
19 753 762 9050866 premature JJ B-NP O
20 763 770 9050866 protein NN I-NP O
21 771 782 9050866 termination NN I-NP O
22 782 783 9050866 . . O O

1 784 792 9050866 Exposure NN B-NP O
2 793 795 9050866 of IN B-PP O
3 796 802 9050866 normal JJ B-NP O
4 803 808 9050866 human JJ I-NP O
5 809 814 9050866 cells NNS I-NP O
6 815 817 9050866 to TO B-PP O
7 818 823 9050866 gamma SYM B-NP O
8 823 824 9050866 - HYPH B-NP O
9 824 835 9050866 irradiation NN I-NP O
10 836 839 9050866 and CC O O
11 840 843 9050866 the DT B-NP O
12 844 856 9050866 radiomimetic JJ I-NP O
13 857 861 9050866 drug NN I-NP O
14 862 878 9050866 neocarzinostatin NN I-NP O
15 879 882 9050866 had VBD B-VP O
16 883 885 9050866 no DT B-NP O
17 886 892 9050866 effect NN I-NP O
18 893 895 9050866 on IN B-PP O
19 896 899 9050866 ATM NN B-NP O
20 900 907 9050866 protein NN I-NP O
21 908 914 9050866 levels NNS I-NP O
22 914 915 9050866 , , O O
23 916 918 9050866 in IN B-PP O
24 919 927 9050866 contrast NN B-NP O
25 928 930 9050866 to TO B-PP O
26 931 932 9050866 a DT B-NP O
27 933 938 9050866 noted VBN I-NP O
28 939 943 9050866 rise NN I-NP O
29 944 946 9050866 in IN B-PP O
30 947 950 9050866 p53 NN B-NP O
31 951 957 9050866 levels NNS I-NP O
32 958 962 9050866 over IN B-PP O
33 963 966 9050866 the DT B-NP O
34 967 971 9050866 same JJ I-NP O
35 972 976 9050866 time NN I-NP O
36 977 985 9050866 interval NN I-NP O
37 985 986 9050866 . . O O

1 987 992 9050866 These DT B-NP O
2 993 1001 9050866 findings NNS I-NP O
3 1002 1005 9050866 are VBP B-VP O
4 1006 1016 9050866 consistent JJ B-ADJP O
5 1017 1021 9050866 with IN B-PP O
6 1022 1023 9050866 a DT B-NP O
7 1024 1028 9050866 role NN I-NP O
8 1029 1032 9050866 for IN B-PP O
9 1033 1036 9050866 the DT B-NP O
10 1037 1040 9050866 ATM NN I-NP O
11 1041 1048 9050866 protein NN I-NP O
12 1049 1051 9050866 in IN B-PP O
13 1052 1060 9050866 ensuring VBG B-VP O
14 1061 1064 9050866 the DT B-NP O
15 1065 1073 9050866 fidelity NN I-NP O
16 1074 1076 9050866 of IN B-PP O
17 1077 1080 9050866 DNA NN B-NP O
18 1081 1087 9050866 repair NN I-NP O
19 1088 1091 9050866 and CC O O
20 1092 1096 9050866 cell NN B-NP O
21 1097 1102 9050866 cycle NN I-NP O
22 1103 1113 9050866 regulation NN I-NP O
23 1114 1123 9050866 following VBG B-PP O
24 1124 1130 9050866 genome NN B-NP O
25 1131 1137 9050866 damage NN I-NP O
26 1137 1138 9050866 . . O O
27 1138 1139 9050866 . . O O

1 0 0 8649785 -DOCSTART- -X- -X- O

1 0 1 8649785 A DT B-NP O
2 2 12 8649785 previously RB I-NP O
3 13 24 8649785 undescribed JJ I-NP O
4 25 33 8649785 mutation NN I-NP O
5 34 40 8649785 within IN B-PP O
6 41 44 8649785 the DT B-NP O
7 45 60 8649785 tetramerisation NN I-NP O
8 61 67 8649785 domain NN I-NP O
9 68 70 8649785 of IN B-PP O
10 71 75 8649785 TP53 NN B-NP O
11 76 78 8649785 in IN B-PP O
12 79 80 8649785 a DT B-NP O
13 81 87 8649785 family NN I-NP O
14 88 92 8649785 with IN B-PP O
15 93 95 8649785 Li NNP B-NP B-Disease
16 95 96 8649785 - HYPH I-NP I-Disease
17 96 104 8649785 Fraumeni NNP I-NP I-Disease
18 105 113 8649785 syndrome NN I-NP I-Disease
19 113 114 8649785 . . O O
20 115 117 8649785 We PRP B-NP O
21 118 124 8649785 report VBP B-VP O
22 125 132 8649785 details NNS B-NP O
23 133 135 8649785 of IN B-PP O
24 136 137 8649785 a DT B-NP O
25 138 144 8649785 family NN I-NP O
26 145 149 8649785 with IN B-PP O
27 150 157 8649785 classic JJ B-NP O
28 158 160 8649785 Li NNP I-NP B-Disease
29 160 161 8649785 - HYPH I-NP I-Disease
30 161 169 8649785 Fraumeni NNP I-NP I-Disease
31 170 178 8649785 syndrome NN I-NP I-Disease
32 179 181 8649785 in IN B-PP O
33 182 187 8649785 which WDT B-NP O
34 188 193 8649785 there EX B-NP O
35 194 196 8649785 is VBZ B-VP O
36 197 198 8649785 a DT B-NP O
37 199 207 8649785 mutation NN I-NP O
38 208 210 8649785 in IN B-PP O
39 211 216 8649785 codon NN B-NP O
40 217 220 8649785 344 CD I-NP O
41 221 223 8649785 of IN B-PP O
42 224 227 8649785 the DT B-NP O
43 228 234 8649785 tumour NN I-NP B-Disease
44 235 245 8649785 suppressor NN I-NP O
45 246 250 8649785 gene NN I-NP O
46 251 255 8649785 TP53 NN I-NP O
47 255 256 8649785 . . O O

1 257 262 8649785 Codon NN B-NP O
2 263 266 8649785 344 CD I-NP O
3 267 269 8649785 is VBZ B-VP O
4 270 271 8649785 a DT B-NP O
5 272 275 8649785 key JJ I-NP O
6 276 283 8649785 residue NN I-NP O
7 284 290 8649785 within IN B-PP O
8 291 294 8649785 the DT B-NP O
9 295 310 8649785 tetramerisation NN I-NP O
10 311 317 8649785 domain NN I-NP O
11 317 318 8649785 , , O O
12 319 322 8649785 and CC O O
13 323 326 8649785 the DT B-NP O
14 327 332 8649785 amino JJ I-NP O
15 333 337 8649785 acid NN I-NP O
16 338 350 8649785 substitution NN I-NP O
17 351 353 8649785 of IN B-PP O
18 354 355 8649785 a DT B-NP O
19 356 363 8649785 proline NN I-NP O
20 364 367 8649785 for IN B-PP O
21 368 369 8649785 a DT B-NP O
22 370 377 8649785 leucine NN I-NP O
23 378 380 8649785 is VBZ B-VP O
24 381 390 8649785 predicted VBN I-VP O
25 391 393 8649785 to TO I-VP O
26 394 398 8649785 have VB I-VP O
27 399 407 8649785 profound JJ B-NP O
28 408 420 8649785 implications NNS I-NP O
29 421 424 8649785 for IN B-PP O
30 425 440 8649785 tetramerisation NN B-NP O
31 441 444 8649785 and CC O O
32 445 456 8649785 potentially RB B-ADVP O
33 457 460 8649785 DNA NN B-NP O
34 461 468 8649785 binding NN I-NP O
35 468 469 8649785 . . O O

1 470 474 8649785 This DT B-NP O
2 475 477 8649785 is VBZ B-VP O
3 478 481 8649785 the DT B-NP O
4 482 487 8649785 first JJ I-NP O
5 488 494 8649785 report NN I-NP O
6 495 497 8649785 of IN B-PP O
7 498 499 8649785 a DT B-NP O
8 500 508 8649785 mutation NN I-NP O
9 509 511 8649785 at IN B-PP O
10 512 516 8649785 this DT B-NP O
11 517 524 8649785 residue NN I-NP O
12 525 527 8649785 in IN B-PP O
13 528 534 8649785 either CC B-NP O
14 535 543 8649785 sporadic JJ I-NP B-Disease
15 544 551 8649785 tumours NNS I-NP I-Disease
16 552 554 8649785 or CC B-PP O
17 555 557 8649785 in IN B-PP O
18 558 561 8649785 the DT B-NP O
19 562 570 8649785 germline NN I-NP O
20 571 574 8649785 and CC O O
21 575 578 8649785 the DT B-NP O
22 579 584 8649785 first JJ I-NP O
23 585 591 8649785 report NN I-NP O
24 592 594 8649785 of IN B-PP O
25 595 596 8649785 a DT B-NP O
26 597 605 8649785 germline NN I-NP O
27 606 614 8649785 mutation NN I-NP O
28 615 621 8649785 within IN B-PP O
29 622 625 8649785 the DT B-NP O
30 626 641 8649785 tetramerisation NN I-NP O
31 642 648 8649785 domain NN I-NP O
32 648 649 8649785 . . O O

1 650 653 8649785 The DT B-NP O
2 654 660 8649785 family NN I-NP O
3 661 665 8649785 does VBZ B-VP O
4 666 669 8649785 not RB I-VP O
5 670 676 8649785 appear VB I-VP O
6 677 679 8649785 to TO I-VP O
7 680 682 8649785 be VB I-VP O
8 683 693 8649785 remarkable JJ B-ADJP O
9 694 696 8649785 in IN B-PP O
10 697 700 8649785 the DT B-NP O
11 701 709 8649785 spectrum NN I-NP O
12 710 712 8649785 of IN B-PP O
13 713 720 8649785 tumours NNS B-NP B-Disease
14 720 721 8649785 , , O O
15 722 725 8649785 and CC O O
16 726 731 8649785 there EX B-NP O
17 732 734 8649785 is VBZ B-VP O
18 735 739 8649785 loss NN B-NP O
19 740 742 8649785 of IN B-PP O
20 743 746 8649785 the DT B-NP O
21 747 751 8649785 wild JJ I-NP O
22 751 752 8649785 - HYPH I-NP O
23 752 756 8649785 type NN I-NP O
24 757 763 8649785 allele NN I-NP O
25 764 766 8649785 in IN B-PP O
26 767 768 8649785 a DT B-NP O
27 769 783 8649785 leiomyosarcoma NN I-NP B-Disease
28 784 788 8649785 from IN B-PP O
29 789 792 8649785 the DT B-NP O
30 793 800 8649785 proband NN I-NP O
31 800 801 8649785 . . O O

1 802 803 8649785 A DT B-NP O
2 804 808 8649785 cell NN I-NP O
3 809 813 8649785 line NN I-NP O
4 814 817 8649785 has VBZ B-VP O
5 818 822 8649785 been VBN I-VP O
6 823 834 8649785 established VBN I-VP O
7 835 839 8649785 from IN B-PP O
8 840 843 8649785 the DT B-NP O
9 844 850 8649785 tumour NN I-NP B-Disease
10 851 853 8649785 of IN B-PP O
11 854 857 8649785 the DT B-NP O
12 858 865 8649785 proband NN I-NP O
13 866 869 8649785 and CC O O
14 870 881 8649785 cytogenetic JJ B-NP O
15 882 885 8649785 and CC I-NP O
16 886 895 8649785 molecular JJ I-NP O
17 896 903 8649785 studies NNS I-NP O
18 904 911 8649785 carried VBN B-VP O
19 912 915 8649785 out RP B-PRT O
20 915 916 8649785 , , O O
21 917 926 8649785 providing VBG B-VP O
22 927 929 8649785 an DT B-NP O
23 930 939 8649785 extensive JJ I-NP O
24 940 948 8649785 analysis NN I-NP O
25 949 951 8649785 in IN B-PP O
26 952 956 8649785 this DT B-NP O
27 957 963 8649785 family NN I-NP O
28 963 964 8649785 . . O O
29 964 965 8649785 . . O O

1 0 0 9028321 -DOCSTART- -X- -X- O

1 0 8 9028321 Missense JJ B-NP O
2 9 18 9028321 mutations NNS I-NP O
3 19 21 9028321 in IN B-PP O
4 22 25 9028321 the DT B-NP O
5 26 29 9028321 Fas NN I-NP O
6 30 34 9028321 gene NN I-NP O
7 35 44 9028321 resulting VBG B-VP O
8 45 47 9028321 in IN B-PP O
9 48 58 9028321 autoimmune JJ B-NP B-Disease
10 59 78 9028321 lymphoproliferative JJ I-NP I-Disease
11 79 87 9028321 syndrome NN I-NP I-Disease
12 87 88 9028321 : : O O
13 89 90 9028321 a DT B-NP O
14 91 100 9028321 molecular JJ I-NP O
15 101 104 9028321 and CC I-NP O
16 105 118 9028321 immunological JJ I-NP O
17 119 127 9028321 analysis NN I-NP O
18 127 128 9028321 . . O O
19 129 139 9028321 Programmed VBN B-NP O
20 140 144 9028321 cell NN I-NP O
21 145 150 9028321 death NN I-NP O
22 151 152 9028321 ( ( O O
23 152 154 9028321 or CC O O
24 155 164 9028321 apoptosis NN B-NP O
25 164 165 9028321 ) ) O O
26 166 168 9028321 is VBZ B-VP O
27 169 170 9028321 a DT B-NP O
28 171 184 9028321 physiological JJ I-NP O
29 185 192 9028321 process NN I-NP O
30 193 202 9028321 essential JJ B-ADJP O
31 203 205 9028321 to TO B-PP O
32 206 209 9028321 the DT B-NP O
33 210 216 9028321 normal JJ I-NP O
34 217 228 9028321 development NN I-NP O
35 229 232 9028321 and CC O O
36 233 244 9028321 homeostatic JJ B-NP O
37 245 256 9028321 maintenance NN I-NP O
38 257 259 9028321 of IN B-PP O
39 260 263 9028321 the DT B-NP O
40 264 270 9028321 immune JJ I-NP O
41 271 277 9028321 system NN I-NP O
42 277 278 9028321 . . O O

1 279 282 9028321 The DT B-NP O
2 283 286 9028321 Fas NN I-NP O
3 286 287 9028321 / SYM B-NP O
4 287 290 9028321 Apo NN I-NP O
5 290 291 9028321 - HYPH B-NP O
6 291 292 9028321 1 CD I-NP O
7 293 301 9028321 receptor NN I-NP O
8 302 307 9028321 plays VBZ B-VP O
9 308 309 9028321 a DT B-NP O
10 310 317 9028321 crucial JJ I-NP O
11 318 322 9028321 role NN I-NP O
12 323 325 9028321 in IN B-PP O
13 326 329 9028321 the DT B-NP O
14 330 340 9028321 regulation NN I-NP O
15 341 343 9028321 of IN B-PP O
16 344 353 9028321 apoptosis NN B-NP O
17 353 354 9028321 , , O O
18 355 357 9028321 as IN B-SBAR O
19 358 370 9028321 demonstrated VBN B-VP O
20 371 373 9028321 by IN B-PP O
21 374 393 9028321 lymphoproliferation NN B-NP O
22 394 396 9028321 in IN B-PP O
23 397 400 9028321 MRL NN B-NP O
24 400 401 9028321 - HYPH B-NP O
25 401 404 9028321 lpr NN I-NP O
26 404 405 9028321 / SYM B-NP O
27 405 408 9028321 lpr NN I-NP O
28 409 413 9028321 mice NNS I-NP O
29 414 417 9028321 and CC B-PP O
30 418 420 9028321 by IN B-PP O
31 421 424 9028321 the DT B-NP O
32 425 433 9028321 recently RB I-NP O
33 434 443 9028321 described VBN I-NP O
34 444 454 9028321 autoimmune JJ I-NP B-Disease
35 455 474 9028321 lymphoproliferative JJ I-NP I-Disease
36 475 483 9028321 syndrome NN I-NP I-Disease
37 484 485 9028321 ( ( O O
38 485 489 9028321 ALPS NN B-NP B-Disease
39 489 490 9028321 ) ) O O
40 491 493 9028321 in IN B-PP O
41 494 500 9028321 humans NNS B-NP O
42 500 501 9028321 , , O O
43 502 506 9028321 both DT B-NP O
44 507 509 9028321 of IN B-PP O
45 510 515 9028321 which WDT B-NP O
46 516 519 9028321 are VBP B-VP O
47 520 523 9028321 due JJ B-ADJP O
48 524 526 9028321 to TO B-PP O
49 527 536 9028321 mutations NNS B-NP O
50 537 539 9028321 in IN B-PP O
51 540 543 9028321 the DT B-NP O
52 544 547 9028321 Fas NN I-NP O
53 548 552 9028321 gene NN I-NP O
54 552 553 9028321 . . O O

1 554 556 9028321 We PRP B-NP O
2 557 565 9028321 describe VBP B-VP O
3 566 567 9028321 a DT B-NP O
4 568 573 9028321 novel JJ I-NP O
5 574 580 9028321 family NN I-NP O
6 581 585 9028321 with IN B-PP O
7 586 590 9028321 ALPS NN B-NP B-Disease
8 591 593 9028321 in IN B-PP O
9 594 599 9028321 which WDT B-NP O
10 600 605 9028321 three CD B-NP O
11 606 614 9028321 affected VBN I-NP O
12 615 623 9028321 siblings NNS I-NP O
13 624 629 9028321 carry VBP B-VP O
14 630 633 9028321 two CD B-NP O
15 634 642 9028321 distinct JJ I-NP O
16 643 651 9028321 missense JJ I-NP O
17 652 661 9028321 mutations NNS I-NP O
18 662 664 9028321 on IN B-PP O
19 665 669 9028321 both CC O O
20 670 673 9028321 the DT B-NP O
21 674 677 9028321 Fas NN I-NP O
22 678 682 9028321 gene NN I-NP O
23 683 690 9028321 alleles NNS I-NP O
24 691 694 9028321 and CC O O
25 695 699 9028321 show VBP B-VP O
26 700 704 9028321 lack NN B-NP O
27 705 707 9028321 of IN B-PP O
28 708 711 9028321 Fas NN B-NP O
29 711 712 9028321 - HYPH B-NP O
30 712 719 9028321 induced VBN I-NP O
31 720 729 9028321 apoptosis NN I-NP O
32 729 730 9028321 . . O O

1 731 734 9028321 The DT B-NP O
2 735 743 9028321 children NNS I-NP O
3 744 749 9028321 share VBP B-VP O
4 750 756 9028321 common JJ B-NP O
5 757 765 9028321 clinical JJ I-NP O
6 766 774 9028321 features NNS I-NP O
7 775 784 9028321 including VBG B-PP O
8 785 797 9028321 splenomegaly NN B-NP B-Disease
9 798 801 9028321 and CC I-NP O
10 802 817 9028321 lymphadenopathy NN I-NP B-Disease
11 817 818 9028321 , , O O
12 819 822 9028321 but CC O O
13 823 827 9028321 only RB B-NP O
14 828 831 9028321 one CD I-NP O
15 832 841 9028321 developed VBD B-VP O
16 842 848 9028321 severe JJ B-NP O
17 849 859 9028321 autoimmune JJ I-NP B-Disease
18 860 874 9028321 manifestations NNS I-NP I-Disease
19 874 875 9028321 . . O O

1 876 878 9028321 In IN B-PP O
2 879 882 9028321 all DT B-NP O
3 883 888 9028321 three CD I-NP O
4 889 897 9028321 siblings NNS I-NP O
5 897 898 9028321 , , O O
6 899 901 9028321 we PRP B-NP O
7 902 914 9028321 demonstrated VBD B-VP O
8 915 918 9028321 the DT B-NP O
9 919 927 9028321 presence NN I-NP O
10 928 930 9028321 of IN B-PP O
11 931 938 9028321 anergic JJ B-NP O
12 939 942 9028321 CD3 NN I-NP O
13 943 944 9028321 + SYM B-NP O
14 945 948 9028321 CD4 NN I-NP O
15 948 949 9028321 - SYM B-NP O
16 949 952 9028321 CD8 NN I-NP O
17 952 953 9028321 - SYM B-NP O
18 954 955 9028321 ( ( O O
19 955 961 9028321 double RB B-ADJP O
20 962 970 9028321 negative JJ I-ADJP O
21 970 971 9028321 , , O O
22 972 973 9028321 [ ( O O
23 973 975 9028321 DN NNP B-NP O
24 975 976 9028321 ] ) O O
25 976 977 9028321 ) ) O O
26 978 979 9028321 T NN B-NP O
27 980 985 9028321 cells NNS I-NP O
28 985 986 9028321 ; : O O
29 987 995 9028321 moreover RB B-ADVP O
30 995 996 9028321 , , O O
31 997 998 9028321 a DT B-NP O
32 999 1006 9028321 chronic JJ I-NP O
33 1007 1017 9028321 lymphocyte NN I-NP O
34 1018 1028 9028321 activation NN I-NP O
35 1029 1032 9028321 was VBD B-VP O
36 1033 1038 9028321 found VBN I-VP O
37 1038 1039 9028321 , , O O
38 1040 1042 9028321 as IN B-SBAR O
39 1043 1055 9028321 demonstrated VBN B-VP O
40 1056 1058 9028321 by IN B-PP O
41 1059 1062 9028321 the DT B-NP O
42 1063 1071 9028321 presence NN I-NP O
43 1072 1074 9028321 of IN B-PP O
44 1075 1079 9028321 high JJ B-NP O
45 1080 1086 9028321 levels NNS I-NP O
46 1087 1089 9028321 of IN B-PP O
47 1090 1093 9028321 HLA NN B-NP O
48 1093 1094 9028321 - HYPH B-NP O
49 1094 1096 9028321 DR NN I-NP O
50 1097 1107 9028321 expression NN I-NP O
51 1108 1110 9028321 on IN B-PP O
52 1111 1121 9028321 peripheral JJ B-NP O
53 1122 1125 9028321 CD3 NN I-NP O
54 1126 1127 9028321 + SYM B-NP O
55 1128 1133 9028321 cells NNS I-NP O
56 1134 1137 9028321 and CC B-PP O
57 1138 1140 9028321 by IN B-PP O
58 1141 1144 9028321 the DT B-NP O
59 1145 1153 9028321 presence NN I-NP O
60 1154 1156 9028321 of IN B-PP O
61 1157 1161 9028321 high JJ B-NP O
62 1162 1168 9028321 levels NNS I-NP O
63 1169 1171 9028321 of IN B-PP O
64 1172 1177 9028321 serum NN B-NP O
65 1178 1188 9028321 activation NN I-NP O
66 1189 1196 9028321 markers NNS I-NP O
67 1197 1201 9028321 such JJ B-PP O
68 1202 1204 9028321 as IN I-PP O
69 1205 1212 9028321 soluble JJ B-NP O
70 1213 1224 9028321 interleukin NN I-NP O
71 1224 1225 9028321 - HYPH O O
72 1225 1226 9028321 2 CD B-NP O
73 1227 1235 9028321 receptor NN I-NP O
74 1236 1237 9028321 ( ( O O
75 1237 1240 9028321 slL NN B-NP O
76 1240 1241 9028321 - HYPH B-NP O
77 1241 1243 9028321 2R NN I-NP O
78 1243 1244 9028321 ) ) O O
79 1245 1248 9028321 and CC O O
80 1249 1256 9028321 soluble JJ B-NP O
81 1257 1261 9028321 CD30 NN I-NP O
82 1262 1263 9028321 ( ( O O
83 1263 1268 9028321 sCD30 NN B-NP O
84 1268 1269 9028321 ) ) O O
85 1269 1270 9028321 . . O O
86 1270 1271 9028321 . . O O

1 0 0 9083764 -DOCSTART- -X- -X- O

1 0 13 9083764 Heterogeneity NN B-NP O
2 14 16 9083764 in IN B-PP O
3 17 25 9083764 Schwartz NNP B-NP B-Disease
4 25 26 9083764 - HYPH B-NP I-Disease
5 26 32 9083764 Jampel NNP I-NP I-Disease
6 33 50 9083764 chondrodystrophic JJ I-NP I-Disease
7 51 59 9083764 myotonia NN I-NP I-Disease
8 59 60 9083764 . . O O
9 61 64 9083764 The DT B-NP O
10 65 73 9083764 Schwartz NNP I-NP B-Disease
11 73 74 9083764 - HYPH I-NP I-Disease
12 74 80 9083764 Jampel NNP I-NP I-Disease
13 81 89 9083764 syndrome NN I-NP I-Disease
14 90 91 9083764 ( ( O O
15 91 94 9083764 SJS NN B-NP B-Disease
16 94 95 9083764 ; : O O
17 96 113 9083764 chondrodystrophic JJ B-NP B-Disease
18 114 122 9083764 myotonia NN I-NP I-Disease
19 122 123 9083764 ; : O O
20 124 127 9083764 McK NN B-NP O
21 128 131 9083764 255 CD I-NP O
22 131 132 9083764 , , I-NP O
23 133 136 9083764 800 CD I-NP O
24 136 137 9083764 ) ) O O
25 138 140 9083764 is VBZ B-VP O
26 141 142 9083764 a DT B-NP O
27 143 154 9083764 recessively RB I-NP B-Disease
28 155 164 9083764 inherited VBN I-NP I-Disease
29 165 174 9083764 condition NN I-NP I-Disease
30 175 182 9083764 defined VBN B-VP O
31 183 185 9083764 by IN B-PP O
32 186 194 9083764 myotonia NN B-NP B-Disease
33 194 195 9083764 , , O O
34 196 201 9083764 short JJ B-NP B-Disease
35 202 209 9083764 stature NN I-NP I-Disease
36 209 210 9083764 , , O O
37 211 214 9083764 and CC O O
38 215 219 9083764 bone NN B-NP B-Disease
39 220 229 9083764 dysplasia NN I-NP I-Disease
40 229 230 9083764 . . O O

1 231 238 9083764 Genetic JJ B-NP O
2 239 246 9083764 linkage NN I-NP O
3 247 254 9083764 between IN B-PP O
4 255 258 9083764 SJS NN B-NP B-Disease
5 259 262 9083764 and CC O O
6 263 274 9083764 chromosomal JJ B-NP O
7 275 281 9083764 region NN I-NP O
8 282 286 9083764 1q36 CD I-NP O
9 286 287 9083764 - HYPH B-NP O
10 287 289 9083764 34 CD I-NP O
11 290 293 9083764 has VBZ B-VP O
12 294 298 9083764 been VBN I-VP O
13 299 307 9083764 observed VBN I-VP O
14 308 310 9083764 in IN B-PP O
15 311 318 9083764 several JJ B-NP O
16 319 327 9083764 families NNS I-NP O
17 327 328 9083764 , , O O
18 329 332 9083764 but CC O O
19 333 336 9083764 the DT B-NP O
20 337 341 9083764 gene NN I-NP O
21 342 345 9083764 has VBZ B-VP O
22 346 349 9083764 not RB I-VP O
23 350 353 9083764 yet RB I-VP O
24 354 358 9083764 been VBN I-VP O
25 359 369 9083764 identified VBN I-VP O
26 369 370 9083764 . . O O

1 371 373 9083764 We PRP B-NP O
2 374 381 9083764 studied VBD B-VP O
3 382 385 9083764 the DT B-NP O
4 386 394 9083764 clinical JJ I-NP O
5 395 398 9083764 and CC I-NP O
6 399 411 9083764 radiological JJ I-NP O
7 412 420 9083764 features NNS I-NP O
8 421 423 9083764 in IN B-PP O
9 424 426 9083764 81 CD B-NP O
10 427 435 9083764 patients NNS I-NP O
11 436 440 9083764 from IN B-PP O
12 441 444 9083764 the DT B-NP O
13 445 455 9083764 literature NN I-NP O
14 456 459 9083764 and CC O O
15 460 461 9083764 5 CD B-NP O
16 462 465 9083764 own JJ I-NP O
17 466 474 9083764 patients NNS I-NP O
18 475 481 9083764 trying VBG B-VP O
19 482 484 9083764 to TO I-VP O
20 485 493 9083764 identify VB I-VP O
21 494 502 9083764 distinct JJ B-NP O
22 503 512 9083764 subgroups NNS I-NP O
23 512 513 9083764 . . O O

1 514 516 9083764 In IN B-PP O
2 517 525 9083764 addition NN B-NP O
3 525 526 9083764 , , O O
4 527 529 9083764 we PRP B-NP O
5 530 536 9083764 tested VBD B-VP O
6 537 544 9083764 genetic JJ B-NP O
7 545 552 9083764 linkage NN I-NP O
8 553 555 9083764 to TO B-PP O
9 556 559 9083764 the DT B-NP O
10 560 563 9083764 SJS NN I-NP B-Disease
11 564 569 9083764 locus NN I-NP O
12 570 572 9083764 on IN B-PP O
13 573 583 9083764 chromosome NN B-NP O
14 584 585 9083764 1 CD I-NP O
15 586 588 9083764 in IN B-PP O
16 589 592 9083764 one CD B-NP O
17 593 599 9083764 family NN I-NP O
18 600 604 9083764 with IN B-PP O
19 605 608 9083764 two CD B-NP O
20 609 617 9083764 affected VBN I-NP O
21 618 622 9083764 sibs NNS I-NP O
22 622 623 9083764 . . O O

1 624 626 9083764 We PRP B-NP O
2 627 632 9083764 found VBD B-VP O
3 633 637 9083764 that IN B-SBAR O
4 638 639 9083764 a DT B-NP O
5 640 645 9083764 group NN I-NP O
6 646 648 9083764 of IN B-PP O
7 649 657 9083764 patients NNS B-NP O
8 658 662 9083764 have VBP B-VP O
9 663 667 9083764 mild JJ B-NP O
10 668 676 9083764 skeletal JJ I-NP O
11 677 684 9083764 changes NNS I-NP O
12 685 690 9083764 which WDT B-NP O
13 691 694 9083764 may MD B-VP O
14 695 697 9083764 be VB I-VP O
15 698 707 9083764 secondary JJ B-NP O
16 708 720 9083764 consequences NNS I-NP O
17 721 723 9083764 of IN B-PP O
18 724 732 9083764 myotonia NN B-NP B-Disease
19 732 733 9083764 , , O O
20 734 739 9083764 while IN B-SBAR O
21 740 747 9083764 another DT B-NP O
22 748 753 9083764 group NN I-NP O
23 754 756 9083764 of IN B-PP O
24 757 765 9083764 patients NNS B-NP O
25 766 772 9083764 appear VBP B-VP O
26 773 775 9083764 to TO I-VP O
27 776 780 9083764 have VB I-VP O
28 781 788 9083764 primary JJ B-NP O
29 789 793 9083764 bone NN I-NP B-Disease
30 794 803 9083764 dysplasia NN I-NP I-Disease
31 804 808 9083764 with IN B-PP O
32 809 817 9083764 myotonia NN B-NP B-Disease
33 817 818 9083764 . . O O

1 819 825 9083764 Within IN B-PP O
2 826 830 9083764 this DT B-NP O
3 831 837 9083764 latter JJ I-NP O
4 838 843 9083764 group NN I-NP O
5 843 844 9083764 , , O O
6 845 850 9083764 there EX B-NP O
7 851 854 9083764 are VBP B-VP O
8 855 866 9083764 differences NNS B-NP O
9 867 869 9083764 in IN B-PP O
10 870 873 9083764 age NN B-NP O
11 874 876 9083764 of IN B-PP O
12 877 890 9083764 manifestation NN B-NP O
13 890 891 9083764 , , O O
14 892 900 9083764 clinical JJ B-NP O
15 901 907 9083764 course NN I-NP O
16 908 911 9083764 and CC I-NP O
17 912 919 9083764 pattern NN I-NP O
18 920 922 9083764 of IN B-PP O
19 923 927 9083764 bone NN B-NP O
20 928 935 9083764 changes NNS I-NP O
21 935 936 9083764 . . O O

1 937 939 9083764 We PRP B-NP O
2 940 951 9083764 tentatively RB B-ADVP O
3 952 959 9083764 isolate VBP B-VP O
4 960 965 9083764 three CD B-NP O
5 966 975 9083764 different JJ I-NP O
6 976 981 9083764 types NNS I-NP O
7 982 984 9083764 of IN B-PP O
8 985 988 9083764 SJS NN B-NP B-Disease
9 990 994 9083764 type NN I-NP I-Disease
10 995 997 9083764 1A NN I-NP I-Disease
11 997 998 9083764 , , O O
12 999 1006 9083764 usually RB B-VP O
13 1007 1017 9083764 recognized VBN I-VP O
14 1018 1020 9083764 in IN B-PP O
15 1021 1030 9083764 childhood NN B-NP O
16 1030 1031 9083764 , , O O
17 1032 1036 9083764 with IN B-PP O
18 1037 1045 9083764 moderate JJ B-NP O
19 1046 1050 9083764 bone NN I-NP B-Disease
20 1051 1060 9083764 dysplasia NN I-NP I-Disease
21 1060 1061 9083764 , , O O
22 1062 1075 9083764 corresponding VBG B-VP O
23 1076 1078 9083764 to TO B-PP O
24 1079 1082 9083764 the DT B-NP O
25 1083 1091 9083764 original JJ I-NP O
26 1092 1104 9083764 descriptions NNS I-NP O
27 1105 1107 9083764 of IN B-PP O
28 1108 1116 9083764 Schwartz NNP B-NP O
29 1116 1117 9083764 , , I-NP O
30 1118 1124 9083764 Jampel NNP I-NP O
31 1125 1128 9083764 and CC I-NP O
32 1129 1137 9083764 Aberfeld NNP I-NP O
33 1137 1138 9083764 ; : O O
34 1139 1143 9083764 type NN B-NP O
35 1144 1146 9083764 1B NN I-NP O
36 1146 1147 9083764 , , O O
37 1148 1155 9083764 similar JJ B-ADJP O
38 1156 1158 9083764 to TO B-PP O
39 1159 1163 9083764 type NN B-NP O
40 1164 1166 9083764 1A NN I-NP O
41 1167 1170 9083764 but CC O O
42 1171 1183 9083764 recognizable JJ B-ADJP O
43 1184 1186 9083764 at IN B-PP O
44 1187 1192 9083764 birth NN B-NP O
45 1192 1193 9083764 , , O O
46 1194 1198 9083764 with IN B-PP O
47 1199 1203 9083764 more RBR B-NP O
48 1204 1214 9083764 pronounced JJ I-NP O
49 1215 1219 9083764 bone NN I-NP B-Disease
50 1220 1229 9083764 dysplasia NN I-NP I-Disease
51 1230 1240 9083764 resembling VBG B-VP O
52 1241 1247 9083764 Kniest JJS B-NP B-Disease
53 1248 1257 9083764 dysplasia NN I-NP I-Disease
54 1257 1258 9083764 ; : O O
55 1259 1262 9083764 and CC O O
56 1263 1267 9083764 type NN B-NP O
57 1268 1269 9083764 2 CD I-NP O
58 1269 1270 9083764 , , O O
59 1271 1279 9083764 manifest JJS B-ADVP O
60 1280 1282 9083764 at IN B-PP O
61 1283 1288 9083764 birth NN B-NP O
62 1288 1289 9083764 , , O O
63 1290 1294 9083764 with IN B-PP O
64 1295 1304 9083764 increased VBN B-NP O
65 1305 1314 9083764 mortality NN I-NP O
66 1315 1318 9083764 and CC I-NP O
67 1319 1323 9083764 bone NN I-NP B-Disease
68 1324 1333 9083764 dysplasia NN I-NP I-Disease
69 1334 1344 9083764 resembling VBG B-VP O
70 1345 1349 9083764 Pyle NN B-NP B-Disease
71 1350 1357 9083764 disease NN I-NP I-Disease
72 1357 1358 9083764 . . O O

1 1359 1366 9083764 Genetic JJ B-NP O
2 1367 1375 9083764 analysis NN I-NP O
3 1376 1378 9083764 of IN B-PP O
4 1379 1382 9083764 the DT B-NP O
5 1383 1389 9083764 family NN I-NP O
6 1390 1394 9083764 with IN B-PP O
7 1395 1398 9083764 two CD B-NP O
8 1399 1403 9083764 sibs NNS I-NP O
9 1404 1412 9083764 affected VBN B-VP O
10 1413 1415 9083764 by IN B-PP O
11 1416 1419 9083764 SJS NN B-NP B-Disease
12 1420 1424 9083764 type NN I-NP I-Disease
13 1425 1426 9083764 2 CD I-NP I-Disease
14 1427 1433 9083764 showed VBD B-VP O
15 1434 1442 9083764 evidence NN B-NP O
16 1443 1450 9083764 against IN B-PP O
17 1451 1458 9083764 linkage NN B-NP O
18 1459 1461 9083764 to TO B-PP O
19 1462 1472 9083764 chromosome NN B-NP O
20 1473 1477 9083764 1p36 NN I-NP O
21 1477 1478 9083764 - HYPH B-NP O
22 1478 1480 9083764 34 CD I-NP O
23 1480 1481 9083764 . . O O

1 1482 1493 9083764 CONCLUSIONS NNS B-NP O
2 1495 1498 9083764 SJS NN I-NP B-Disease
3 1499 1501 9083764 is VBZ B-VP O
4 1502 1512 9083764 clinically RB B-ADVP O
5 1513 1516 9083764 and CC O O
6 1517 1531 9083764 radiologically RB B-ADJP O
7 1532 1545 9083764 heterogeneous JJ I-ADJP O
8 1545 1546 9083764 . . O O

1 1547 1550 9083764 The DT B-NP O
2 1551 1557 9083764 causes NNS I-NP O
3 1558 1560 9083764 of IN B-PP O
4 1561 1574 9083764 heterogeneity NN B-NP O
5 1575 1578 9083764 are VBP B-VP O
6 1579 1582 9083764 not RB I-VP O
7 1583 1588 9083764 known VBN I-VP O
8 1589 1592 9083764 yet RB B-ADVP O
9 1593 1596 9083764 but CC O O
10 1597 1600 9083764 are VBP B-VP O
11 1601 1607 9083764 likely JJ B-ADJP O
12 1608 1610 9083764 to TO B-VP O
13 1611 1618 9083764 include VB I-VP O
14 1619 1623 9083764 both CC O O
15 1624 1633 9083764 different JJ B-NP O
16 1634 1643 9083764 mutations NNS I-NP O
17 1644 1646 9083764 at IN B-PP O
18 1647 1650 9083764 the DT B-NP O
19 1651 1654 9083764 SJS NN I-NP B-Disease
20 1655 1660 9083764 locus NN I-NP O
21 1661 1663 9083764 on IN B-PP O
22 1664 1674 9083764 chromosome NN B-NP O
23 1675 1676 9083764 1 CD I-NP O
24 1677 1680 9083764 and CC O O
25 1681 1684 9083764 the DT B-NP O
26 1685 1693 9083764 presence NN I-NP O
27 1694 1696 9083764 of IN B-PP O
28 1697 1698 9083764 a DT B-NP O
29 1699 1705 9083764 second JJ I-NP O
30 1706 1709 9083764 SJS NN I-NP B-Disease
31 1710 1715 9083764 locus NN I-NP O
32 1715 1716 9083764 . . O O

1 1717 1718 9083764 A DT B-NP O
2 1719 1728 9083764 tentative JJ I-NP O
3 1729 1736 9083764 clinico AFX I-NP O
4 1736 1737 9083764 - HYPH I-NP O
5 1737 1749 9083764 radiological JJ I-NP O
6 1750 1764 9083764 classification NN I-NP O
7 1765 1768 9083764 can MD B-VP O
8 1769 1771 9083764 be VB I-VP O
9 1772 1778 9083764 useful JJ B-ADJP O
10 1779 1782 9083764 for IN B-PP O
11 1783 1786 9083764 the DT B-NP O
12 1787 1803 9083764 characterization NN I-NP O
13 1804 1806 9083764 of IN B-PP O
14 1807 1815 9083764 patients NNS B-NP O
15 1816 1819 9083764 and CC O O
16 1820 1823 9083764 the DT B-NP O
17 1824 1835 9083764 development NN I-NP O
18 1836 1838 9083764 of IN B-PP O
19 1839 1847 9083764 genotype NN B-NP O
20 1847 1848 9083764 - HYPH B-NP O
21 1848 1857 9083764 phenotype NN I-NP O
22 1858 1870 9083764 correlations NNS I-NP O
23 1870 1871 9083764 . . O O
24 1871 1872 9083764 . . O O

1 0 0 8898652 -DOCSTART- -X- -X- O

1 0 7 8898652 Somatic JJ B-NP O
2 8 19 8898652 alterations NNS I-NP O
3 20 22 8898652 of IN B-PP O
4 23 26 8898652 the DT B-NP O
5 27 31 8898652 DPC4 NN I-NP O
6 32 36 8898652 gene NN I-NP O
7 37 39 8898652 in IN B-PP O
8 40 45 8898652 human JJ B-NP O
9 46 56 8898652 colorectal JJ I-NP B-Disease
10 57 64 8898652 cancers NNS I-NP I-Disease
11 65 67 8898652 in FW B-ADVP O
12 68 72 8898652 vivo FW I-ADVP O
13 72 73 8898652 . . O O
14 74 84 8898652 BACKGROUND NN B-NP O
15 85 86 8898652 & CC I-NP O
16 87 91 8898652 AIMS NNS I-NP O
17 93 96 8898652 The DT B-NP O
18 97 107 8898652 chromosome NN I-NP O
19 108 114 8898652 region NN I-NP O
20 115 120 8898652 18q21 NN I-NP O
21 121 124 8898652 has VBZ B-VP O
22 125 129 8898652 been VBN I-VP O
23 130 135 8898652 shown VBN I-VP O
24 136 138 8898652 to TO I-VP O
25 139 141 8898652 be VB I-VP O
26 142 152 8898652 frequently RB I-VP O
27 153 160 8898652 deleted VBN I-VP O
28 161 163 8898652 in IN B-PP O
29 164 174 8898652 colorectal JJ B-NP B-Disease
30 175 182 8898652 cancers NNS I-NP I-Disease
31 182 183 8898652 , , O O
32 184 187 8898652 and CC O O
33 188 192 8898652 such JJ B-NP O
34 193 201 8898652 frequent JJ I-NP O
35 202 209 8898652 allelic JJ I-NP O
36 210 214 8898652 loss NN I-NP O
37 215 217 8898652 is VBZ B-VP O
38 218 219 8898652 a DT B-NP O
39 220 228 8898652 hallmark NN I-NP O
40 229 231 8898652 of IN B-PP O
41 232 235 8898652 the DT B-NP O
42 236 244 8898652 presence NN I-NP O
43 245 247 8898652 of IN B-PP O
44 248 249 8898652 a DT B-NP O
45 250 255 8898652 tumor NN I-NP O
46 255 256 8898652 - HYPH I-NP O
47 256 266 8898652 suppressor NN I-NP O
48 267 271 8898652 gene NN I-NP O
49 271 272 8898652 . . O O

1 273 276 8898652 The DT B-NP O
2 277 281 8898652 DPC4 NN I-NP O
3 282 286 8898652 gene NN I-NP O
4 286 287 8898652 , , O O
5 288 293 8898652 which WDT B-NP O
6 294 296 8898652 is VBZ B-VP O
7 297 304 8898652 located JJ B-ADJP O
8 305 307 8898652 at IN B-PP O
9 308 313 8898652 18q21 NN B-NP O
10 313 314 8898652 , , O O
11 315 318 8898652 has VBZ B-VP O
12 319 323 8898652 been VBN I-VP O
13 324 334 8898652 identified VBN I-VP O
14 335 337 8898652 as IN B-PP O
15 338 339 8898652 a DT B-NP O
16 340 345 8898652 tumor NN I-NP O
17 345 346 8898652 - HYPH B-NP O
18 346 356 8898652 suppressor NN I-NP O
19 357 361 8898652 gene NN I-NP O
20 362 366 8898652 from IN B-PP O
21 367 378 8898652 examination NN B-NP O
22 379 381 8898652 of IN B-PP O
23 382 392 8898652 pancreatic JJ B-NP B-Disease
24 393 400 8898652 cancers NNS I-NP I-Disease
25 400 401 8898652 . . O O

1 402 405 8898652 The DT B-NP O
2 406 409 8898652 aim NN I-NP O
3 410 412 8898652 of IN B-PP O
4 413 416 8898652 the DT B-NP O
5 417 424 8898652 present JJ I-NP O
6 425 430 8898652 study NN I-NP O
7 431 434 8898652 was VBD B-VP O
8 435 437 8898652 to TO B-VP O
9 438 447 8898652 determine VB I-VP O
10 448 450 8898652 if IN B-SBAR O
11 451 453 8898652 it PRP B-NP O
12 454 459 8898652 might MD B-VP O
13 460 464 8898652 also RB I-VP O
14 465 467 8898652 be VB I-VP O
15 468 475 8898652 altered VBN I-VP O
16 476 478 8898652 in IN B-PP O
17 479 489 8898652 colorectal JJ B-NP B-Disease
18 490 497 8898652 cancers NNS I-NP I-Disease
19 497 498 8898652 . . O O

1 499 506 8898652 METHODS NNS B-NP O
2 508 516 8898652 Mutation NN I-NP O
3 517 525 8898652 analyses NNS I-NP O
4 526 528 8898652 of IN B-PP O
5 529 532 8898652 the DT B-NP O
6 533 537 8898652 DPC4 NN I-NP O
7 538 542 8898652 gene NN I-NP O
8 543 547 8898652 were VBD B-VP O
9 548 557 8898652 performed VBN I-VP O
10 558 560 8898652 on IN B-PP O
11 561 574 8898652 complementary JJ B-NP O
12 575 578 8898652 DNA NN I-NP O
13 579 586 8898652 samples NNS I-NP O
14 587 591 8898652 from IN B-PP O
15 592 594 8898652 31 CD B-NP O
16 595 602 8898652 primary JJ I-NP O
17 603 613 8898652 colorectal JJ I-NP B-Disease
18 614 620 8898652 cancer NN I-NP I-Disease
19 621 630 8898652 specimens NNS I-NP O
20 631 636 8898652 using VBG B-VP O
21 637 638 8898652 a DT B-NP O
22 639 650 8898652 combination NN I-NP O
23 651 653 8898652 of IN B-PP O
24 654 664 8898652 polymerase NN B-NP O
25 665 670 8898652 chain NN I-NP O
26 671 679 8898652 reaction NN I-NP O
27 679 680 8898652 , , O O
28 681 687 8898652 single JJ B-NP O
29 687 688 8898652 - HYPH I-NP O
30 688 694 8898652 strand NN I-NP O
31 695 707 8898652 conformation NN I-NP O
32 708 720 8898652 polymorphism NN I-NP O
33 720 721 8898652 , , O O
34 722 725 8898652 and CC O O
35 726 729 8898652 DNA NN B-NP O
36 730 740 8898652 sequencing NN I-NP O
37 740 741 8898652 . . O O

1 742 749 8898652 RESULTS NNS B-NP O
2 751 755 8898652 Four CD B-NP O
3 756 764 8898652 missense JJ I-NP O
4 765 774 8898652 mutations NNS I-NP O
5 775 784 8898652 producing VBG B-VP O
6 785 790 8898652 amino NN B-NP O
7 791 795 8898652 acid NN I-NP O
8 796 809 8898652 substitutions NNS I-NP O
9 810 813 8898652 and CC O O
10 814 815 8898652 a DT B-NP O
11 816 823 8898652 somatic JJ I-NP O
12 824 826 8898652 12 CD I-NP O
13 826 827 8898652 - HYPH I-NP O
14 827 831 8898652 base NN I-NP O
15 832 836 8898652 pair NN I-NP O
16 837 845 8898652 deletion NN I-NP O
17 846 848 8898652 in IN B-PP O
18 849 852 8898652 the DT B-NP O
19 853 859 8898652 coding VBG I-NP O
20 860 866 8898652 region NN I-NP O
21 867 869 8898652 of IN B-PP O
22 870 873 8898652 the DT B-NP O
23 874 878 8898652 DPC4 NN I-NP O
24 879 883 8898652 gene NN I-NP O
25 884 888 8898652 were VBD B-VP O
26 889 897 8898652 detected VBN I-VP O
27 898 900 8898652 in IN B-PP O
28 901 904 8898652 the DT B-NP O
29 905 907 8898652 31 CD I-NP O
30 908 915 8898652 cancers NNS I-NP B-Disease
31 916 917 8898652 ( ( O O
32 917 920 8898652 16% CD B-NP O
33 920 921 8898652 ; : O O
34 922 923 8898652 5 CD B-NP O
35 924 926 8898652 of IN B-PP O
36 927 929 8898652 31 CD B-NP O
37 929 930 8898652 ) ) O O
38 930 931 8898652 . . O O

1 932 943 8898652 CONCLUSIONS NNS B-NP O
2 945 948 8898652 The DT B-NP O
3 949 953 8898652 DPC4 NN I-NP O
4 954 958 8898652 gene NN I-NP O
5 959 962 8898652 may MD B-VP O
6 963 967 8898652 play VB I-VP O
7 968 969 8898652 a DT B-NP O
8 970 974 8898652 role NN I-NP O
9 975 977 8898652 as IN B-PP O
10 978 979 8898652 a DT B-NP O
11 980 985 8898652 tumor NN I-NP O
12 985 986 8898652 - HYPH B-NP O
13 986 996 8898652 suppressor NN I-NP O
14 997 1001 8898652 gene NN I-NP O
15 1002 1004 8898652 in IN B-PP O
16 1005 1006 8898652 a DT B-NP O
17 1007 1015 8898652 fraction NN I-NP O
18 1016 1018 8898652 of IN B-PP O
19 1019 1029 8898652 colorectal JJ B-NP B-Disease
20 1030 1037 8898652 cancers NNS I-NP I-Disease
21 1037 1038 8898652 ; : O O
22 1039 1046 8898652 however RB B-ADVP O
23 1046 1047 8898652 , , O O
24 1048 1053 8898652 while IN B-SBAR O
25 1054 1061 8898652 allelic JJ B-NP O
26 1062 1066 8898652 loss NN I-NP O
27 1067 1069 8898652 at IN B-PP O
28 1070 1075 8898652 18q21 NN B-NP O
29 1076 1078 8898652 is VBZ B-VP O
30 1079 1083 8898652 very RB B-VP O
31 1084 1089 8898652 often RB I-VP O
32 1090 1094 8898652 seen VBN I-VP O
33 1095 1097 8898652 in IN B-PP O
34 1098 1108 8898652 colorectal JJ B-NP B-Disease
35 1109 1116 8898652 cancers NNS I-NP I-Disease
36 1116 1117 8898652 , , O O
37 1118 1122 8898652 only RB B-NP O
38 1123 1124 8898652 a DT I-NP O
39 1125 1133 8898652 minority NN I-NP O
40 1134 1138 8898652 show NN I-NP O
41 1139 1143 8898652 DPC4 NN I-NP O
42 1144 1153 8898652 mutations NNS I-NP O
43 1153 1154 8898652 , , O O
44 1155 1165 8898652 suggesting VBG B-VP O
45 1166 1170 8898652 that IN B-SBAR O
46 1171 1176 8898652 there EX B-NP O
47 1177 1182 8898652 might MD B-VP O
48 1183 1185 8898652 be VB I-VP O
49 1186 1193 8898652 another DT B-NP O
50 1194 1199 8898652 tumor NN I-NP O
51 1199 1200 8898652 - HYPH B-NP O
52 1200 1210 8898652 suppressor NN I-NP O
53 1211 1215 8898652 gene NN I-NP O
54 1216 1218 8898652 in IN B-PP O
55 1219 1223 8898652 this DT B-NP O
56 1224 1234 8898652 chromosome NN I-NP O
57 1235 1241 8898652 region NN I-NP O
58 1241 1242 8898652 . . O O
59 1242 1243 8898652 . . O O

1 0 0 9066888 -DOCSTART- -X- -X- O

1 0 6 9066888 Kniest JJS B-NP B-Disease
2 7 16 9066888 dysplasia NN I-NP I-Disease
3 16 17 9066888 : : O O
4 18 20 9066888 Dr NNP B-NP O
5 20 21 9066888 . . I-NP O
6 22 23 9066888 W NNP I-NP O
7 23 24 9066888 . . O O

1 25 31 9066888 Kniest JJS B-ADVP O
2 31 32 9066888 , , O O
3 33 36 9066888 his PRP$ B-NP O
4 37 44 9066888 patient NN I-NP O
5 44 45 9066888 , , O O
6 46 49 9066888 the DT B-NP O
7 50 59 9066888 molecular JJ I-NP O
8 60 66 9066888 defect NN I-NP O
9 66 67 9066888 . . O O
10 68 74 9066888 Kniest JJS B-NP B-Disease
11 75 84 9066888 dysplasia NN I-NP I-Disease
12 85 87 9066888 is VBZ B-VP O
13 88 89 9066888 a DT B-NP O
14 90 96 9066888 severe JJ I-NP O
15 97 113 9066888 chondrodysplasia NN I-NP B-Disease
16 114 120 9066888 caused VBN B-VP O
17 121 123 9066888 by IN B-PP O
18 124 127 9066888 the DT B-NP O
19 128 137 9066888 defective JJ I-NP B-Disease
20 138 147 9066888 formation NN I-NP I-Disease
21 148 150 9066888 of IN B-PP I-Disease
22 151 155 9066888 type NN B-NP I-Disease
23 156 158 9066888 II CD I-NP I-Disease
24 159 167 9066888 collagen NN I-NP I-Disease
25 167 168 9066888 . . O O

1 169 171 9066888 We PRP B-NP O
2 172 178 9066888 report VBP B-VP O
3 179 184 9066888 about IN B-PP O
4 185 187 9066888 Dr NNP B-NP O
5 187 188 9066888 . . I-NP O
6 189 195 9066888 Kniest NNP I-NP O
7 195 196 9066888 , , O O
8 197 200 9066888 who WP B-NP O
9 201 206 9066888 first RB B-ADVP O
10 207 216 9066888 described VBD B-VP O
11 217 220 9066888 the DT B-NP O
12 221 230 9066888 condition NN I-NP O
13 231 233 9066888 in IN B-PP O
14 234 238 9066888 1952 CD B-NP O
15 238 239 9066888 , , O O
16 240 243 9066888 and CC O O
17 244 247 9066888 his PRP$ B-NP O
18 248 255 9066888 patient NN I-NP O
19 255 256 9066888 , , O O
20 257 260 9066888 who WP B-NP O
21 260 261 9066888 , , O O
22 262 264 9066888 at IN B-PP O
23 265 268 9066888 the DT B-NP O
24 269 272 9066888 age NN I-NP O
25 273 275 9066888 of IN B-PP O
26 276 278 9066888 50 CD B-NP O
27 279 284 9066888 years NNS I-NP O
28 285 287 9066888 is VBZ B-VP O
29 288 296 9066888 severely RB I-VP B-Disease
30 297 308 9066888 handicapped VBN I-VP I-Disease
31 309 313 9066888 with IN B-PP O
32 314 319 9066888 short JJ B-NP B-Disease
33 320 327 9066888 stature NN I-NP I-Disease
34 327 328 9066888 , , O O
35 329 339 9066888 restricted JJ B-NP B-Disease
36 340 345 9066888 joint JJ I-NP I-Disease
37 346 354 9066888 mobility NN I-NP I-Disease
38 354 355 9066888 , , O O
39 356 359 9066888 and CC O O
40 360 369 9066888 blindness NN B-NP B-Disease
41 370 373 9066888 but CC O O
42 374 376 9066888 is VBZ B-VP O
43 377 385 9066888 mentally RB B-ADJP O
44 386 391 9066888 alert JJ I-ADJP O
45 392 395 9066888 and CC O O
46 396 401 9066888 leads VBZ B-VP O
47 402 404 9066888 an DT B-NP O
48 405 411 9066888 active JJ I-NP O
49 412 416 9066888 life NN I-NP O
50 416 417 9066888 . . O O

1 418 427 9066888 Molecular JJ B-NP O
2 428 436 9066888 analysis NN I-NP O
3 437 439 9066888 of IN B-PP O
4 440 443 9066888 the DT B-NP O
5 444 452 9066888 patients NNS I-NP O
6 453 456 9066888 DNA NN I-NP O
7 457 463 9066888 showed VBD B-VP O
8 464 465 9066888 a DT B-NP O
9 466 472 9066888 single JJ I-NP O
10 473 477 9066888 base NN I-NP O
11 478 479 9066888 ( ( O O
12 479 480 9066888 G NN B-NP O
13 480 481 9066888 ) ) O O
14 482 490 9066888 deletion NN B-NP O
15 491 500 9066888 involving VBG B-VP O
16 501 504 9066888 the DT B-NP O
17 505 507 9066888 GT NN I-NP O
18 508 520 9066888 dinucleotide NN I-NP O
19 521 523 9066888 at IN B-PP O
20 524 527 9066888 the DT B-NP O
21 528 533 9066888 start NN I-NP O
22 534 536 9066888 of IN B-PP O
23 537 543 9066888 intron NN B-NP O
24 544 546 9066888 18 CD I-NP O
25 547 557 9066888 destroying VBG B-VP O
26 558 559 9066888 a DT B-NP O
27 560 566 9066888 splice NN I-NP O
28 567 571 9066888 site NN I-NP O
29 572 574 9066888 of IN B-PP O
30 575 578 9066888 the DT B-NP O
31 579 585 9066888 COL2A1 NN I-NP O
32 586 590 9066888 gene NN I-NP O
33 590 591 9066888 . . O O

1 592 596 9066888 This DT B-NP O
2 597 599 9066888 is VBZ B-VP O
3 600 602 9066888 in IN B-PP O
4 603 613 9066888 accordance NN B-NP O
5 614 618 9066888 with IN B-PP O
6 619 628 9066888 molecular JJ B-NP O
7 629 637 9066888 findings NNS I-NP O
8 638 640 9066888 in IN B-PP O
9 641 646 9066888 other JJ B-NP O
10 647 655 9066888 patients NNS I-NP O
11 656 660 9066888 with IN B-PP O
12 661 667 9066888 Kniest JJS B-NP B-Disease
13 668 677 9066888 dysplasia NN I-NP I-Disease
14 678 681 9066888 and CC I-NP O
15 682 690 9066888 confirms NNS I-NP O
16 690 691 9066888 , , O O
17 692 694 9066888 in IN B-PP O
18 695 698 9066888 the DT B-NP O
19 699 707 9066888 original JJ I-NP O
20 708 715 9066888 patient NN I-NP O
21 715 716 9066888 , , O O
22 717 721 9066888 that IN B-SBAR O
23 722 725 9066888 the DT B-NP O
24 726 734 9066888 disorder NN I-NP O
25 735 737 9066888 is VBZ B-VP O
26 738 744 9066888 caused VBN I-VP O
27 745 747 9066888 by IN B-PP O
28 748 753 9066888 small JJ B-NP O
29 754 761 9066888 inframe NN I-NP O
30 762 771 9066888 deletions NNS I-NP O
31 772 777 9066888 often RB B-ADVP O
32 778 781 9066888 due JJ B-ADJP O
33 782 784 9066888 to TO B-PP O
34 785 789 9066888 exon NN B-NP O
35 790 798 9066888 skipping NN I-NP O
36 799 801 9066888 as IN B-PP O
37 802 803 9066888 a DT B-NP O
38 804 810 9066888 result NN I-NP O
39 811 813 9066888 of IN B-PP O
40 814 820 9066888 COL2A1 NN B-NP O
41 821 827 9066888 splice NN I-NP O
42 828 832 9066888 site NN I-NP O
43 833 842 9066888 mutations NNS I-NP O
44 842 843 9066888 . . O O
45 843 844 9066888 . . O O

1 0 0 8894695 -DOCSTART- -X- -X- O

1 0 4 8894695 HPRT NN B-NP B-Disease
2 4 5 8894695 - HYPH I-NP I-Disease
3 5 9 8894695 APRT NN I-NP I-Disease
4 9 10 8894695 - HYPH I-NP I-Disease
5 10 19 8894695 deficient JJ I-NP I-Disease
6 20 24 8894695 mice NNS I-NP O
7 25 28 8894695 are VBP B-VP O
8 29 32 8894695 not RB O O
9 33 34 8894695 a DT B-NP O
10 35 40 8894695 model NN I-NP O
11 41 44 8894695 for IN B-PP O
12 45 50 8894695 lesch NN B-NP B-Disease
13 50 51 8894695 - HYPH I-NP I-Disease
14 51 56 8894695 nyhan NN I-NP I-Disease
15 57 65 8894695 syndrome NN I-NP I-Disease
16 65 66 8894695 . . O O
17 67 75 8894695 Complete JJ B-NP B-Disease
18 76 88 8894695 hypoxanthine NN I-NP I-Disease
19 88 89 8894695 - HYPH O I-Disease
20 89 96 8894695 guanine NN B-NP I-Disease
21 97 111 8894695 phosphoribosyl NN I-NP I-Disease
22 111 112 8894695 - HYPH B-NP I-Disease
23 112 123 8894695 transferase NN I-NP I-Disease
24 124 125 8894695 ( ( O I-Disease
25 125 129 8894695 HPRT NN B-NP I-Disease
26 129 130 8894695 ) ) O I-Disease
27 131 141 8894695 deficiency NN B-NP I-Disease
28 142 144 8894695 in IN B-PP O
29 145 151 8894695 humans NNS B-NP O
30 152 159 8894695 results VBZ B-VP O
31 160 162 8894695 in IN B-PP O
32 163 166 8894695 the DT B-NP O
33 167 172 8894695 Lesch NNP I-NP B-Disease
34 172 173 8894695 - HYPH I-NP I-Disease
35 173 178 8894695 Nyhan NNP I-NP I-Disease
36 179 187 8894695 syndrome NN I-NP I-Disease
37 188 193 8894695 which WDT B-NP O
38 194 196 8894695 is VBZ B-VP O
39 197 210 8894695 characterized VBN I-VP O
40 210 211 8894695 , , O O
41 212 217 8894695 among IN B-PP O
42 218 223 8894695 other JJ B-NP O
43 224 232 8894695 features NNS I-NP O
44 232 233 8894695 , , O O
45 234 236 8894695 by IN B-PP O
46 237 247 8894695 compulsive JJ B-NP O
47 248 252 8894695 self AFX I-NP O
48 252 253 8894695 - HYPH I-NP O
49 253 262 8894695 injurious JJ I-NP O
50 263 271 8894695 behavior NN I-NP O
51 271 272 8894695 . . O O

1 273 277 8894695 HPRT NN B-NP B-Disease
2 277 278 8894695 - HYPH I-NP I-Disease
3 278 287 8894695 deficient JJ I-NP I-Disease
4 288 292 8894695 mice NNS I-NP O
5 293 302 8894695 generated VBN B-VP O
6 303 308 8894695 using VBG B-VP O
7 309 314 8894695 mouse NN B-NP O
8 315 324 8894695 embryonic JJ I-NP O
9 325 329 8894695 stem NN I-NP O
10 330 335 8894695 cells NNS I-NP O
11 336 343 8894695 exhibit VBP B-VP O
12 344 348 8894695 none NN B-NP O
13 349 351 8894695 of IN B-PP O
14 352 355 8894695 the DT B-NP O
15 356 366 8894695 behavioral JJ I-NP O
16 367 375 8894695 symptoms NNS I-NP O
17 376 386 8894695 associated VBN B-VP O
18 387 391 8894695 with IN B-PP O
19 392 395 8894695 the DT B-NP O
20 396 401 8894695 Lesch NNP I-NP B-Disease
21 401 402 8894695 - HYPH I-NP I-Disease
22 402 407 8894695 Nyhan NNP I-NP I-Disease
23 408 416 8894695 syndrome NN I-NP I-Disease
24 416 417 8894695 . . O O

1 418 432 8894695 Administration NN B-NP O
2 433 435 8894695 of IN B-PP O
3 436 441 8894695 drugs NNS B-NP O
4 442 446 8894695 that WDT B-NP O
5 447 454 8894695 inhibit VBP B-VP O
6 455 462 8894695 adenine NN B-NP O
7 463 488 8894695 phosphoribosyltransferase NN I-NP O
8 489 490 8894695 ( ( O O
9 490 494 8894695 APRT NN B-NP O
10 494 495 8894695 ) ) O O
11 496 498 8894695 in IN B-PP O
12 499 503 8894695 HPRT NN B-NP B-Disease
13 503 504 8894695 - HYPH B-NP I-Disease
14 504 513 8894695 deficient JJ I-NP I-Disease
15 514 518 8894695 mice NNS I-NP O
16 519 522 8894695 has VBZ B-VP O
17 523 531 8894695 produced VBN I-VP O
18 532 535 8894695 the DT B-NP O
19 536 546 8894695 suggestion NN I-NP O
20 547 551 8894695 that IN B-SBAR O
21 552 562 8894695 deficiency NN B-NP B-Disease
22 563 565 8894695 of IN B-PP I-Disease
23 566 570 8894695 APRT NN B-NP I-Disease
24 571 573 8894695 in IN B-PP O
25 574 585 8894695 combination NN B-NP O
26 586 590 8894695 with IN B-PP O
27 591 595 8894695 HPRT NN B-NP B-Disease
28 595 596 8894695 - HYPH I-NP I-Disease
29 596 606 8894695 deficiency NN I-NP I-Disease
30 607 609 8894695 in IN B-PP O
31 610 614 8894695 mice NNS B-NP O
32 615 618 8894695 may MD B-VP O
33 619 623 8894695 lead VB I-VP O
34 624 626 8894695 to TO B-PP O
35 627 631 8894695 self AFX B-NP O
36 631 632 8894695 - HYPH I-NP O
37 632 642 8894695 mutilation NN B-NP O
38 643 651 8894695 behavior NN I-NP O
39 652 653 8894695 [ ( O O
40 653 654 8894695 C NN B-NP O
41 654 655 8894695 . . O O

1 656 657 8894695 L NN B-NP O
2 657 658 8894695 . . O O

1 659 661 8894695 Wu NN B-NP O
2 662 665 8894695 and CC I-NP O
3 666 667 8894695 D NN I-NP O
4 667 668 8894695 . . O O

1 669 670 8894695 W UH B-INTJ O
2 670 671 8894695 . . O O

1 672 678 8894695 Melton NN B-NP O
2 679 680 8894695 ( ( O O
3 680 684 8894695 1993 CD B-NP O
4 684 685 8894695 ) ) O O
5 686 692 8894695 Nature NNP B-NP O
6 693 698 8894695 Genet NNP I-NP O
7 698 699 8894695 . . I-NP O
8 700 701 8894695 3 CD I-NP O
9 701 702 8894695 , , I-NP O
10 703 706 8894695 235 CD I-NP O
11 706 707 8894695 - HYPH B-NP O
12 707 710 8894695 240 CD I-NP O
13 710 711 8894695 ] ) O O
14 711 712 8894695 . . O O

1 713 715 8894695 To TO B-VP O
2 716 720 8894695 test VB I-VP O
3 721 725 8894695 this DT B-NP O
4 726 737 8894695 proposition NN I-NP O
5 737 738 8894695 , , O O
6 739 741 8894695 we PRP B-NP O
7 742 746 8894695 bred VBD B-VP O
8 747 751 8894695 HPRT NN B-NP B-Disease
9 751 752 8894695 - HYPH B-NP I-Disease
10 752 756 8894695 APRT NN I-NP I-Disease
11 756 757 8894695 - HYPH B-NP I-Disease
12 757 766 8894695 deficient JJ I-NP I-Disease
13 767 771 8894695 mice NNS I-NP O
14 771 772 8894695 . . O O

1 773 781 8894695 Although IN B-SBAR O
2 782 785 8894695 the DT B-NP O
3 786 792 8894695 doubly RB I-NP O
4 792 793 8894695 - HYPH I-NP O
5 793 802 8894695 deficient JJ I-NP O
6 803 807 8894695 mice NNS I-NP O
7 808 815 8894695 excrete VBP B-VP O
8 816 823 8894695 adenine NN B-NP O
9 824 827 8894695 and CC O O
10 828 831 8894695 its PRP$ B-NP O
11 832 838 8894695 highly RB I-NP O
12 839 848 8894695 insoluble JJ I-NP O
13 849 859 8894695 derivative NN I-NP O
14 859 860 8894695 , , O O
15 861 862 8894695 2 CD B-NP O
16 862 863 8894695 , , I-NP O
17 864 865 8894695 8 CD I-NP O
18 865 866 8894695 - HYPH I-NP O
19 866 882 8894695 dihydroxyadenine NN I-NP O
20 882 883 8894695 , , O O
21 884 889 8894695 which WDT B-NP O
22 890 893 8894695 are VBP B-VP O
23 894 898 8894695 also RB I-VP O
24 899 909 8894695 associated VBN I-VP O
25 910 914 8894695 with IN B-PP O
26 915 920 8894695 human JJ B-NP O
27 921 925 8894695 APRT NN I-NP B-Disease
28 926 936 8894695 deficiency NN I-NP I-Disease
29 936 937 8894695 , , O O
30 938 948 8894695 additional JJ B-NP O
31 949 962 8894695 abnormalities NNS I-NP O
32 963 965 8894695 or CC O O
33 966 969 8894695 any DT B-NP O
34 970 974 8894695 self AFX I-NP O
35 974 975 8894695 - HYPH I-NP O
36 975 984 8894695 injurious JJ I-NP O
37 985 993 8894695 behavior NN I-NP O
38 994 998 8894695 were VBD B-VP O
39 999 1002 8894695 not RB I-VP O
40 1003 1011 8894695 detected VBN I-VP O
41 1011 1012 8894695 . . O O

1 1013 1017 8894695 Thus RB B-ADVP O
2 1017 1018 8894695 , , O O
3 1019 1023 8894695 APRT NN B-NP B-Disease
4 1023 1024 8894695 - HYPH B-NP I-Disease
5 1024 1028 8894695 HPRT NN I-NP I-Disease
6 1028 1029 8894695 - HYPH I-NP I-Disease
7 1029 1038 8894695 deficient JJ I-NP I-Disease
8 1039 1043 8894695 mice NNS I-NP O
9 1043 1044 8894695 , , O O
10 1045 1050 8894695 which WDT B-NP O
11 1051 1054 8894695 are VBP B-VP O
12 1055 1061 8894695 devoid JJ B-ADJP O
13 1062 1064 8894695 of IN B-PP O
14 1065 1068 8894695 any DT B-NP O
15 1069 1075 8894695 purine NN I-NP O
16 1076 1083 8894695 salvage NN I-NP O
17 1084 1092 8894695 pathways NNS I-NP O
18 1092 1093 8894695 , , O O
19 1094 1098 8894695 show VBP B-VP O
20 1099 1101 8894695 no DT B-NP O
21 1102 1107 8894695 novel JJ I-NP O
22 1108 1117 8894695 phenotype NN I-NP O
23 1118 1121 8894695 and CC O O
24 1122 1125 8894695 are VBP B-VP O
25 1126 1129 8894695 not RB O O
26 1130 1131 8894695 a DT B-NP O
27 1132 1137 8894695 model NN I-NP O
28 1138 1141 8894695 for IN B-PP O
29 1142 1145 8894695 the DT B-NP O
30 1146 1156 8894695 behavioral JJ I-NP B-Disease
31 1157 1170 8894695 abnormalities NNS I-NP I-Disease
32 1171 1181 8894695 associated VBN B-VP O
33 1182 1186 8894695 with IN B-PP O
34 1187 1190 8894695 the DT B-NP O
35 1191 1196 8894695 Lesch NNP I-NP B-Disease
36 1196 1197 8894695 - HYPH I-NP I-Disease
37 1197 1202 8894695 Nyhan NNP I-NP I-Disease
38 1203 1211 8894695 syndrome NN I-NP I-Disease
39 1212 1214 8894695 as IN B-SBAR O
40 1215 1225 8894695 previously RB B-ADVP O
41 1226 1235 8894695 suggested VBN B-VP O

